



US00RE48461E

(19) **United States**
 (12) **Reissued Patent**
Macleod et al.

(10) **Patent Number:** **US RE48,461 E**
 (45) **Date of Reissued Patent:** **Mar. 9, 2021**

(54) **MODULATION OF ANDROGEN RECEPTOR EXPRESSION**

(56) **References Cited**

(71) Applicant: **Ionis Pharmaceuticals, Inc.**, Carlsbad, CA (US)

U.S. PATENT DOCUMENTS
 8,927,515 B2 * 1/2015 Brown A61P 43/00
 514/44 A
 2005/0246794 A1 * 11/2005 Khvorova et al. ... A61K 31/713
 800/286

(72) Inventors: **Robert A. Macleod**, Carlsbad, CA (US); **Youngsoo Kim**, Carlsbad, CA (US); **Tianyuan Zhou**, Carlsbad, CA (US); **Susan M. Freier**, Carlsbad, CA (US); **Punit Seth**, Carlsbad, CA (US); **Eric Swayze**, Carlsbad, CA (US); **Brett Monia**, Carlsbad, CA (US)

FOREIGN PATENT DOCUMENTS

WO WO 2002/000716 1/2002
 WO WO 2011/005765 1/2011
 WO WO 2012/012467 1/2012
 WO WO 2012006241 A2 * 1/2012 C12N 15/1138
 WO WO 2012/087983 6/2012
 WO WO 2012/120374 9/2012
 WO WO 2014/059238 4/2014

(73) Assignee: **Ionis Pharmaceuticals, Inc.**, Carlsbad, CA (US)

(21) Appl. No.: **16/275,198**

OTHER PUBLICATIONS

(22) Filed: **Feb. 13, 2019**

Related U.S. Patent Documents

Reissue of:

(64) Patent No.: **9,567,588**
 Issued: **Feb. 14, 2017**
 Appl. No.: **14/854,281**
 Filed: **Sep. 15, 2015**

U.S. Applications:

(63) Continuation of application No. 14/050,574, filed on Oct. 10, 2013, now Pat. No. 9,175,291.
 (60) Provisional application No. 61/712,756, filed on Oct. 11, 2012, provisional application No. 61/712,780, filed on Oct. 11, 2012, provisional application No. 61/723,701, filed on Nov. 7, 2012, provisional application No. 61/777,813, filed on Mar. 12, 2013, provisional application No. 61/777,851, filed on Mar. 12, 2013, provisional application No. 61/777,895, filed on Mar. 12, 2013.

(51) **Int. Cl.**
C12N 15/11 (2006.01)
C12N 15/113 (2010.01)
A61K 31/7088 (2006.01)
A61K 31/4166 (2006.01)

(52) **U.S. Cl.**
 CPC **C12N 15/1138** (2013.01); **A61K 31/4166** (2013.01); **A61K 31/7088** (2013.01); **C12N 2310/11** (2013.01); **C12N 2310/315** (2013.01); **C12N 2310/321** (2013.01); **C12N 2310/3231** (2013.01); **C12N 2310/3341** (2013.01); **C12N 2310/341** (2013.01); **C12N 2310/346** (2013.01); **C12N 2320/30** (2013.01)

(58) **Field of Classification Search**
 CPC C12N 15/1138; C12N 2310/11
 See application file for complete search history.

N Souleimanian et al. Antisense 2'-Deoxy, 2'-Fluoroarabino Nucleic Acid (2'F-ANA) Oligonucleotides: In Vitro Gymnotic Silencers of Gene Expression Whose Potency Is Enhanced by Fatty Acids Molecular Therapy—Nucleic Acids (2012) 1, e43; (Year: 2012).
 I.E. Eder et al. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides Cancer Gene Therapy, vol. 7, No. 7, 2000: pp. 997-1007 (Year: 2000).
 J. K. Watts et al. Gene silencing by siRNAs and antisense oligonucleotides in the laboratory and the clinic Pathol. Jan. 2012 ; 226(2): 365-379 (Year: 2012).
 GenBank Accession No. AL158016 (2009).
 Zhang et al., "Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer" Molecular Cancer Therapeutics (2011) 10(12): 2309-2319.
 Aartsma-Rus A "Overview on AON design" Methods Mol Biol. (2012) 867:117-29.
 Chan et al., "Antisense oligonucleotides: from design to therapeutic application" Clin Exp Pharmacol Physiol. (2006) 33(5-6):533-40.
 Hamy et al., "Specific block of androgen receptor activity by antisense oligonucleotides" Prostate Cancer Prostatic Dis. (2003) 6(1):27-33.

* cited by examiner

Primary Examiner — Bruce R Campell

(74) Attorney, Agent, or Firm — Knobbe, Martens, Olson & Bear, LLC

(57) **ABSTRACT**

Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.

50 Claims, No Drawings

Specification includes a Sequence Listing.

MODULATION OF ANDROGEN RECEPTOR EXPRESSION

Matter enclosed in heavy brackets [] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue; a claim printed with strikethrough indicates that the claim was canceled, disclaimed, or held invalid by a prior post-patent action or proceeding.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 14/050,574, filed Oct. 10, 2013, which claims the benefit of priority to U.S. Provisional Patent Application No. 61/712,780 filed Oct. 11, 2012; U.S. Provisional Patent Application No. 61/712,756 filed Oct. 11, 2012; U.S. Provisional Patent Application No. 61/723,701 filed Nov. 7, 2012; U.S. Provisional Patent Application No. 61/777,813 filed Mar. 12, 2103; U.S. Provisional Patent Application No. 61/777,851 filed Mar. 12, 2103 and U.S. Provisional Patent Application No. 61/777,895 filed Mar. 12, 2103. The entire text of the above-referenced patent applications is incorporated herein by reference in their entirety.

SEQUENCE LISTING

The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BIOL0212WOSEQ.txt created Sep. 17, 2013, which is approximately 556 KB in size. The information in the electronic format of the sequence listing is incorporated herein by reference in its entirety.

FIELD

Certain embodiments are directed to compounds and compositions targeted to human androgen receptor (AR) for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting cancer cell growth or proliferation.

BACKGROUND

Androgen receptor (AR) belongs to the superfamily of nuclear receptors and is activated by binding to its hormone ligands: androgen, testosterone, or DHT. Upon binding hormone ligand in the cytoplasm, androgen receptor translocates to the nucleus where it binds DNA and functions as a transcription factor to regulate expression of a number of target genes, such as prostate specific antigen (PSA) and TMPRSS2. Knudsen et al. (Trends Endocrinol Metab 21: 315-24, 2010) Bennett et al. (Int J Biochem Cell Biol. 42:813-827, 201).

Androgen receptor (AR) signaling is a critical survival pathway for prostate cancer cells, and androgen-deprivation therapy (ADT), also known as "chemical castration", is a first-line treatment strategy against hormone-sensitive, androgen-dependent prostate cancer that reduces circulating androgen levels and thereby inhibits AR activity. Although a majority of patients initially respond to ADT, most will eventually develop castrate resistance in which the disease progresses despite castrate levels of testosterone. This type of cancer is known as castrate-resistant prostate cancer (CRPC). There are a number of mechanisms underlying the

development of castrate (castration) resistance including an increase in the expression of AR protein which can sensitize cells to low levels of androgen, AR mutations that can alter transactivation or sensitize AR to alternative ligands and the emergence of alternatively spliced forms of AR, which lack the ligand binding domain but can nevertheless act to promote tumour growth in the absence of ligand stimulation. Additionally prostate tumors may also synthesize their own androgens thereby increasing the local intra-tumoral testosterone levels available to activate the AR.

Androgen receptor (AR) signaling is a critical survival pathway for prostate cancer cells, and androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally advanced and metastatic disease. Although a majority of patients initially respond to ADT, most will eventually develop castrate resistance in which the disease progresses despite castrate levels of testosterone. This type of cancer is known as castrate-resistant prostate cancer (CRPC) (Karantos et al., Oncogene advance online: 1-13, 2013). There are a number of mechanisms underlying the development of castration resistance including an increase in the expression of AR protein which can sensitize cells to low levels of androgen (Gregory et al., Cancer Res 61: 2892-2898, 2001; Linja et al., Cancer Res 61: 3550-3555, 2001), AR mutations that can alter transactivation or sensitize AR to alternative ligands (Scher et al., J Clin Oncol 23: 8253-8261, 2005) and the emergence of alternatively spliced forms of AR, which lack the ligand binding domain but can nevertheless act to promote tumour growth in the absence of ligand stimulation (Yingming et al., Cancer Res 73:483-489, 2013). Additionally prostate tumors may also synthesize their own androgens thereby increasing the local intratumoral testosterone levels available to activate the AR (Attard et al., Cancer Cell 16:458-462, 2009).

The fact that the androgen receptor remains active in castrate resistant prostate cancer has led to the development of new agents that inhibit the production of androgen ligands or block the actions of these ligands on the AR. These new agents include abiraterone acetate which inhibits 17- α -hydroxylase/17,20-lyase (CYP17) activity resulting in a reduction in residual androgens synthesized by the adrenals and in the prostate tumour itself deBono et al. (N Engl J Med 364: 1995-2006, 2011) and enzalutamide which prevents androgen ligand from binding to AR, translocating to the nucleus, and binding to DNA (Scher et al., N Engl J Med 367:1187-1197, 2012). A number of other androgen synthesis inhibitors or androgen receptor blockers are under development either pre-clinically or clinically and include for example, ARN509, ODM201, TOK001, VT464.

Although the activity of agents such as enzalutamide and abiraterone in CRPC is very encouraging, neither works in all patients and both are associated with the development of additional resistance through re-activation of the AR by the mechanisms described above (Yingming et al., Cancer Res 73:483-489, 2013). Thus, there is a continued need to identify alternative therapies for the treatment of CRPC, and in particular those that can either remove and/or inhibit the activity of all forms of AR including for example, wildtype, mutated and splice variant ARs.

The present invention provides antisense oligonucleotides which by virtue of their design and mode of action (base-pair with the AR RNA target and mediate its destruction by RNase H, an enzyme that destroys the RNA in a DNA/RNA duplex) are aimed at inhibiting the major forms of AR By targeting an appropriate region of the AR mRNA the antisense oligonucleotide will result in inhibition of the major forms (full length, splice variant and mutated forms) of

androgen receptor proteins and therefore be suitable for the treatment of patients with CRPC.

Aside from prostate cancer, AR is also implicated as a factor in the progression of other tumours such as breast cancer. In breast cancer AR is expressed in 70-80% of tumours which are also ER positive and in 12% cases which are known as triple negative (no expression of ER, PR and HER2) (Hickey et al., *Molecular Endocrinology* 26: 1252-1267, 2012). In pre-clinical studies, the androgen receptor antagonist bicalutamide induces anti-proliferative responses in vitro in breast cancer cells and this is potentiated by addition of a PI3K/mTOR inhibitor (Ni et al., *Cancer Cell* 20: 119-131, 2011). The 2nd generation anti-androgen, enzalutamide inhibits dihydrotestosterone (DHT) mediated proliferation in ER+/AR+ breast cancer cells and is as effective as tamoxifen at inhibiting estrogen-stimulated breast cancer tumour growth in pre-clinical models in vivo (Cochrane et al., *Cancer Res* 72(24 Supplement): P2-14-02, 2012). Enzalutamide also inhibits proliferation in HER2 + and triple-negative breast cancer cells. It appears that in situations where estrogen action is reduced (eg. long-term estrogen deprivation or absence of ER) AR levels increase and can become oncogenic. This would suggest that AR antagonists may be best positioned in triple negative or hormone resistant breast cancer settings (Hickey et al., *Molecular Endocrinology* 26: 1252-1267, 2012). AR targeted therapies are currently under investigation in clinical trials for breast cancer (NCT00468715, NCT01597193, NCT01381874, NCT00755886).

AR is also expressed in a variety of other tumours, including, but not limited to bladder, ovarian, gastric, lung and liver. Pre-clinical data support a similar role as in breast cancer, to promote tumour cell proliferation survival; thus blocking AR in these tumours could have therapeutic clinical benefit (Chang et al., *Oncogene advance online*: 1-10, 2013).

SUMMARY

Several embodiments provided herein relate to the discovery of compounds and compositions for inhibiting androgen receptor levels in a cell, which can be useful for methods of treating cancer and inhibiting proliferation or growth of cancer cells, such as prostate, breast, ovarian, gastric or bladder cancer or cancer cells.

DETAILED DESCRIPTION

It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed. Herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, the use of "or" means "and/or" unless stated otherwise. Furthermore, the use of the term "including" as well as other forms, such as "includes" and "included", is not limiting. Also, terms such as "element" or "component" encompass both elements and components comprising one unit and elements and components that comprise more than one subunit, unless specifically stated otherwise.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, and

treatises, are hereby expressly incorporated by reference for the portions of the document discussed herein, as well as in their entirety.

Definitions

Unless specific definitions are provided, the nomenclature utilized in connection with, and the procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art. Standard techniques may be used for chemical synthesis, and chemical analysis. Where permitted, all patents, applications, published applications and other publications, GENBANK Accession Numbers and associated sequence information obtainable through databases such as National Center for Biotechnology Information (NCBI) and other data referred to throughout in the disclosure herein are incorporated by reference for the portions of the document discussed herein, as well as in their entirety.

Unless otherwise indicated, the following terms have the following meanings:

"2'-O-methoxyethyl" (also 2'-MOE and 2'-O(CH₂)₂—OCH₃) refers to an O-methoxy-ethyl modification at the 2' position of a sugar ring, e.g. a furanose ring. A 2'-O-methoxyethyl modified sugar is a modified sugar.

"2'-MOE nucleoside" (also 2'-O-methoxyethyl nucleoside) means a nucleoside comprising a 2'-MOE modified sugar moiety.

"2'-substituted nucleoside" means a nucleoside comprising a substituent at the 2'-position of the furanosyl ring other than H or OH. In certain embodiments, 2' substituted nucleosides include nucleosides with bicyclic sugar modifications.

"3' target site" refers to the nucleotide of a target nucleic acid which is complementary to the 3'-most nucleotide of a particular antisense compound.

"5' target site" refers to the nucleotide of a target nucleic acid which is complementary to the 5'-most nucleotide of a particular antisense compound.

"5-methylcytosine" means a cytosine modified with a methyl group attached to the 5' position. A 5-methylcytosine is a modified nucleobase.

"About" means within $\pm 7\%$ of a value. For example, if it is stated, "the compounds affected at least about 70% inhibition of Androgen Receptor", it is implied that Androgen Receptor levels are inhibited within a range of 63% and 77%.

"Administration" or "administering" refers to routes of introducing an antisense compound provided herein to a subject to perform its intended function. An example of a route of administration that can be used includes, but is not limited to parenteral administration, such as subcutaneous, intravenous, or intramuscular injection or infusion.

"Androgen-receptor positive" with respect to breast cancer or a breast cancer cell refers to a breast cancer or a breast cancer cell that expresses androgen receptor.

"Animal" refers to a human or non-human animal, including, but not limited to, mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including, but not limited to, monkeys and chimpanzees.

"Anti-androgenic agent" refers to a therapeutic compound or drug which is an androgen synthesis inhibitor or an androgen receptor blocker.

"Antisense activity" means any detectable or measurable activity attributable to the hybridization of an antisense compound to its target nucleic acid. In certain embodiments,

antisense activity is a decrease in the amount or expression of a target nucleic acid or protein encoded by such target nucleic acid.

"Antisense compound" means an oligomeric compound that is capable of undergoing hybridization to a target nucleic acid through hydrogen bonding. Examples of antisense compounds include single-stranded and double-stranded compounds, such as, antisense oligonucleotides, siRNAs, shRNAs, ssRNAs, and occupancy-based compounds.

"Antisense inhibition" means reduction of target nucleic acid levels in the presence of an antisense compound complementary to a target nucleic acid compared to target nucleic acid levels in the absence of the antisense compound.

"Antisense mechanisms" are all those mechanisms involving hybridization of a compound with target nucleic acid, wherein the outcome or effect of the hybridization is either target degradation or target occupancy with concomitant stalling of the cellular machinery involving, for example, transcription or splicing.

"Antisense oligonucleotide" means a single-stranded oligonucleotide having a nucleobase sequence that permits hybridization to a corresponding region or segment of a target nucleic acid.

"Base complementarity" refers to the capacity for the precise base pairing of nucleobases of an antisense oligonucleotide with corresponding nucleobases in a target nucleic acid (i.e., hybridization), and is mediated by Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen binding between corresponding nucleobases.

"Bicyclic sugar moiety" means a modified sugar moiety comprising a 4 to 7 membered ring (including but not limited to a furanosyl) comprising a bridge connecting two atoms of the 4 to 7 membered ring to form a second ring, resulting in a bicyclic structure. In certain embodiments, the 4 to 7 membered ring is a sugar ring. In certain embodiments the 4 to 7 membered ring is a furanosyl. In certain such embodiments, the bridge connects the 2'-carbon and the 4'-carbon of the furanosyl.

Also included within the definition of LNA according to the invention are LNAs in which the 2'-hydroxyl group of the ribosyl sugar ring is connected to the 4' carbon atom of the sugar ring, thereby forming a methyleneoxy (4-CH₂—O-2') bridge to form the bicyclic sugar moiety. The bridge can also be a methylene (—CH₂—) group connecting the 2' oxygen atom and the 4' carbon atom, for which the term methyleneoxy (4-CH₂—O-2') LNA is used. Furthermore; in the case of the bicyclic sugar moiety having an ethylene bridging group in this position, the term ethyleneoxy (4'-CH₂CH₂—O-2') LNA is used. α -L-methyleneoxy (4-CH₂—O-2'), an isomer of methyleneoxy (4-CH₂—O-2') LNA is also encompassed within the definition of LNA, as used herein.

"Cap structure" or "terminal cap moiety" means chemical modifications, which have been incorporated at either terminus of an antisense compound.

"Castrate-resistant prostate cancer" or "Castration-resistant prostate cancer" and prostate cancer cells refer to the reduction of sensitivity of prostate cancer and prostate cancer cells to androgen deprivation therapy or an anti-androgenic agent.

"cEt" or "constrained ethyl" means a bicyclic sugar moiety comprising a bridge connecting the 4'-carbon and the 2'-carbon, wherein the bridge has the formula: 4-CH(CH₃)—O-2'.

"Constrained ethyl nucleoside" (also cEt nucleoside) means a nucleoside comprising a bicyclic sugar moiety comprising a 4'-CH(CH₃)—O-2' bridge.

"Chemically distinct region" refers to a region of an antisense compound that is in some way chemically different than another region of the same antisense compound. For example, a region having 2'-O-methoxyethyl nucleotides is chemically distinct from a region having nucleotides without 2'-O-methoxyethyl modifications.

"Chimeric antisense compounds" means antisense compounds that have at least 2 chemically distinct regions, each position having a plurality of subunits.

"Complementarity" means the capacity for pairing between nucleobases of a first nucleic acid and a second nucleic acid.

"Comprise," "comprises" and "comprising" will be understood to imply the inclusion of a stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements.

"Contiguous nucleobases" means nucleobases immediately adjacent to each other.

"Deoxyribonucleotide" means a nucleotide having a hydrogen at the 2' position of the sugar portion of the nucleotide. Deoxyribonucleotides may be modified with any of a variety of substituents.

"Designing" or "Designed to" refer to the process of designing an oligomeric compound that specifically hybridizes with a selected nucleic acid molecule.

"Downstream" refers to the relative direction toward the 3' end or C-terminal end of a nucleic acid.

"Efficacy" means the ability to produce a desired effect.

"Estrogen-receptor (ER) positive" with respect to breast cancer or a breast cancer cell refers to breast cancer or a breast cancer cell that expresses estrogen receptor (ER).

"Estrogen-receptor (ER) negative" with respect to breast cancer or a breast cancer cell refers to breast cancer or a breast cancer cell that does not express estrogen receptor (ER).

"Expression" includes all the functions by which a gene's coded information is converted into structures present and operating in a cell. Such structures include, but are not limited to the products of transcription and translation.

"Fully complementary" or "100% complementary" means each nucleobase of a first nucleic acid has a complementary nucleobase in a second nucleic acid. In certain embodiments, a first nucleic acid is an antisense compound and a target nucleic acid is a second nucleic acid.

"Gapmer" means a chimeric antisense compound in which an internal region having a plurality of nucleosides that support RNase H cleavage is positioned between external regions having one or more nucleosides, wherein the nucleosides comprising the internal region are chemically distinct from the nucleoside or nucleosides comprising the external regions. The internal region may be referred to as the "gap" and the external regions may be referred to as the "wings."

"Her2/neu negative" with respect to breast cancer or a breast cancer cell refers to breast cancer or a breast cancer cell that does not express Her2/neu.

"Hybridization" means the annealing of complementary nucleic acid molecules. In certain embodiments, complementary nucleic acid molecules include, but are not limited to, an antisense compound and a nucleic acid target. In certain embodiments, complementary nucleic acid molecules include, but are not limited to, an antisense oligonucleotide and a nucleic acid target.

"Immediately adjacent" means there are no intervening elements between the immediately adjacent elements.

"Individual" means a human or non-human animal selected for treatment or therapy.

"Induce", "inhibit", "potentiate", "elevate", "increase", "decrease", "upregulate", "downregulate", or the like, generally denote quantitative differences between two states.

"Inhibiting the expression or activity" refers to a reduction, blockade of the expression or activity and does not necessarily indicate a total elimination of expression or activity.

"Internucleoside linkage" refers to the chemical bond between nucleosides.

"Lengthened" antisense oligonucleotides are those that have one or more additional nucleosides relative to an antisense oligonucleotide disclosed herein.

"Linked deoxynucleoside" means a nucleic acid base (A, G, C, T, U) substituted by deoxyribose linked by a phosphate ester to form a nucleotide.

"Linked nucleosides" means adjacent nucleosides linked together by an internucleoside linkage.

"Mismatch" or "non-complementary nucleobase" refers to the case when a nucleobase of a first nucleic acid is not capable of pairing with the corresponding nucleobase of a second or target nucleic acid.

"Modified internucleoside linkage" refers to a substitution or any change from a naturally occurring internucleoside bond (i.e. a phosphodiester internucleoside bond).

"Modified nucleobase" means any nucleobase other than adenine, cytosine, guanine, thymidine, or uracil. An "unmodified nucleobase" means the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).

"Modified nucleoside" means a nucleoside having, independently, a modified sugar moiety and/or modified nucleobase.

"Modified nucleotide" means a nucleotide having, independently, a modified sugar moiety, modified internucleoside linkage, or modified nucleobase.

"Modified oligonucleotide" means an oligonucleotide comprising at least one modified internucleoside linkage, a modified sugar, and/or a modified nucleobase.

"Modified sugar" means substitution and/or any change from a natural sugar moiety.

"Monomer" refers to a single unit of an oligomer. Monomers include, but are not limited to, nucleosides and nucleotides, whether naturally occurring or modified.

"Motif" means the pattern of unmodified and modified nucleosides in an antisense compound.

"Natural sugar moiety" means a sugar moiety found in DNA (2'-H) or RNA (2'-OH).

"Naturally occurring internucleoside linkage" means a 3' to 5' phosphodiester linkage.

"Non-complementary nucleobase" refers to a pair of nucleobases that do not form hydrogen bonds with one another or otherwise support hybridization.

"Nucleic acid" refers to molecules composed of monomeric nucleotides. A nucleic acid includes, but is not limited to, ribonucleic acids (RNA), deoxyribonucleic acids (DNA), single-stranded nucleic acids, and double-stranded nucleic acids.

"Nucleobase" means a heterocyclic moiety capable of pairing with a base of another nucleic acid.

"Nucleobase complementarity" refers to a nucleobase that is capable of base pairing with another nucleobase. For example, in DNA, adenine (A) is complementary to thymine (T). For example, in RNA, adenine (A) is complementary to

uracil (U). In certain embodiments, complementary nucleobase refers to a nucleobase of an antisense compound that is capable of base pairing with a nucleobase of its target nucleic acid. For example, if a nucleobase at a certain position of an antisense compound is capable of hydrogen bonding with a nucleobase at a certain position of a target nucleic acid, then the position of hydrogen bonding between the oligonucleotide and the target nucleic acid is considered to be complementary at that nucleobase pair.

"Nucleobase sequence" means the order of contiguous nucleobases independent of any sugar, linkage, and/or nucleobase modification.

"Nucleoside" means a nucleobase linked to a sugar.

"Nucleoside mimetic" includes those structures used to replace the sugar or the sugar and the base and not necessarily the linkage at one or more positions of an oligomeric compound such as for example nucleoside mimetics having morpholino, cyclohexenyl, cyclohexyl, tetrahydropyranyl, bicyclo or tricyclo sugar mimetics, e.g., non furanose sugar units. Nucleotide mimetic includes those structures used to replace the nucleoside and the linkage at one or more positions of an oligomeric compound such as for example peptide nucleic acids or morpholinos (morpholinos linked by —N(H)—C(=O)—O— or other non-phosphodiester linkage). Sugar surrogate overlaps with the slightly broader term nucleoside mimetic but is intended to indicate replacement of the sugar unit (furanose ring) only. The tetrahydropyranyl rings provided herein are illustrative of an example of a sugar surrogate wherein the furanose sugar group has been replaced with a tetrahydropyranyl ring system. "Mimetic" refers to groups that are substituted for a sugar, a nucleobase, and/or internucleoside linkage. Generally, a mimetic is used in place of the sugar or sugar-internucleoside linkage combination, and the nucleobase is maintained for hybridization to a selected target.

"Nucleotide" means a nucleoside having a phosphate group covalently linked to the sugar portion of the nucleoside.

"Oligomeric compound" means a polymer of linked monomeric subunits which is capable of hybridizing to at least a region of a nucleic acid molecule.

"Oligonucleoside" means an oligonucleotide in which the internucleoside linkages do not contain a phosphorus atom.

"Oligonucleotide" means a polymer of linked nucleosides each of which can be modified or unmodified, independent one from another.

"Phosphorothioate linkage" means a linkage between nucleosides where the phosphodiester bond is modified by replacing one of the non-bridging oxygen atoms with a sulfur atom. A phosphorothioate linkage is a modified internucleoside linkage.

"Portion" means a defined number of contiguous (i.e., linked) nucleobases of a nucleic acid. In certain embodiments, a portion is a defined number of contiguous nucleobases of a target nucleic acid. In certain embodiments, a portion is a defined number of contiguous nucleobases of an antisense compound.

"Progesterone receptor (PR) negative" with respect to breast cancer or a breast cancer cell refers to breast cancer or a breast cancer cell that does not express progesterone receptor (PR).

"Region" is defined as a portion of the target nucleic acid having at least one identifiable structure, function, or characteristic.

“Ribonucleotide” means a nucleotide having a hydroxy at the 2' position of the sugar portion of the nucleotide. Ribonucleotides may be modified with any of a variety of substituents.

“Segments” are defined as smaller or sub-portions of regions within a target nucleic acid.

“Sites,” as used herein, are defined as unique nucleobase positions within a target nucleic acid.

“Specifically hybridizable” refers to an antisense compound having a sufficient degree of complementarity between an antisense oligonucleotide and a target nucleic acid to induce a desired effect, while exhibiting minimal or no effects on non-target nucleic acids under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays and therapeutic treatments. “Stringent hybridization conditions” or “stringent conditions” refer to conditions under which an oligomeric compound will hybridize to its target sequence, but to a minimal number of other sequences.

“Subject” means a human or non-human animal selected for treatment or therapy.

“Synergy” or “synergize” refers to an effect of a combination that is greater than additive of the effects of each component alone.

“Target” refers to a protein, the modulation of which is desired.

“Target gene” refers to a gene encoding a target.

“Targeting” means the process of design and selection of an antisense compound that will specifically hybridize to a target nucleic acid and induce a desired effect.

“Target nucleic acid,” “target RNA,” “target RNA transcript” and “nucleic acid target” all mean a nucleic acid capable of being targeted by antisense compounds.

“Target region” means a portion of a target nucleic acid to which one or more antisense compounds is targeted.

“Target segment” means the sequence of nucleotides of a target nucleic acid to which an antisense compound is targeted. “5' target site” refers to the 5'-most nucleotide of a target segment. “3' target site” refers to the 3'-most nucleotide of a target segment.

“Treating cancer” refers to performing actions that lead to amelioration of cancer or of the symptoms accompanied therewith. The combination of said actions is encompassed by the term “treatment.” Amelioration of cancer includes, but is not limited to, reducing the number of cancer cells in a subject or reducing the number of cancer cells in the subject. Said treatment as used herein also includes an entire restoration of the health with respect to cancer. It is to be understood that treatment as used in accordance with embodiments provided herein may not be effective in all subjects to be treated. However, a population of subjects suffering from cancer referred to herein can be successfully treated. In certain embodiments, “treating cancer” can be described by a number of different parameters including, but not limited to, reduction in the size of a tumor in a subject having cancer, reduction in the growth or proliferation of a tumor in a subject having cancer, preventing metastasis or reducing the extent of metastasis, and/or extending the survival of a subject having cancer compared to control. The cancer referred to in this definition can be any cancer including one selected from prostate cancer, breast cancer, ovarian cancer, gastric cancer and bladder cancer.

“Unmodified” nucleobases mean the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).

“Unmodified nucleotide” means a nucleotide composed of naturally occurring nucleobases, sugar moieties, and inter-

nucleoside linkages. In certain embodiments, an unmodified nucleotide is an RNA nucleotide (i.e. β -D-ribonucleosides) or a DNA nucleotide (i.e. β -D-deoxyribonucleoside).

“Upstream” refers to the relative direction toward the 5' end or N-terminal end of a nucleic acid.

Certain Embodiments

Certain embodiments provide methods, compounds, and compositions for inhibiting androgen receptor (AR) mRNA expression.

Certain embodiments provide antisense compounds or compositions targeted to an androgen receptor nucleic acid. In certain embodiments, the androgen receptor nucleic acid is the sequences set forth in GENBANK Accession No. NT_011669.17_TRUNC_5079000_5270000 (incorporated herein as SEQ ID NO: 1), GENBANK Accession No. NM_000044.3 (incorporated herein as SEQ ID NO: 2), GENBANK Accession No. NM_001011645.2 (incorporated herein as SEQ ID NO: 3), GENBANK Accession No. FJ235916.1 (incorporated herein as SEQ ID NO: 4), GENBANK Accession No. FJ235917.1 (incorporated herein as SEQ ID NO: 5), GENBANK Accession No. FJ235918.1 (incorporated herein as SEQ ID NO: 6), GENBANK Accession No. FJ235919.1 (incorporated herein as SEQ ID NO: 7), or GENBANK Accession No. FJ235920.1 (incorporated herein as SEQ ID NO: 8).

In certain embodiments, the compounds or compositions comprise a modified oligonucleotide 10 to 30 linked nucleosides in length targeted to AR. The AR target can have a sequence recited in any one of SEQ ID NOs: 1-8 or a portion thereof or a variant thereof. In certain embodiments, the AR target can have a sequence of known AR splicing variants including, but are not limited to, AR-V1, AR-V2, AR-V3, AR-V4, AR-V5, AR-V6, and AR-V7 (also referred to as AR3), which contain exons 1-3 but lack exons 4-8. AR-V1, AR-V2, AR-V3, AR-V4, AR-V5, AR-V6, AR-V7, and additional splicing variants targetable by compounds provided herein are described in Hu et al., Cancer Res 2009; 69:16-22 and US Patent Application Publication No. US 2010/0068802, each of which is incorporated herein by reference in its entirety.

In certain embodiments, the compounds or compositions comprise a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs: 12-179. In certain embodiments, one or more modified nucleosides in the wing segment have a modified sugar. In certain embodiments, the modified sugar is a bicyclic sugar. In certain embodiments, the modified nucleoside is an LNA nucleoside. In certain embodiments, the modified nucleoside is a 2'-substituted nucleoside. In certain embodiments, 2'-substituted nucleosides include nucleosides with bicyclic sugar modifications. In certain embodiments, the modified nucleoside is a 2'-MOE nucleoside. In certain embodiments, the modified nucleoside is a constrained ethyl (cEt) nucleoside.

In certain embodiments, the compounds or compositions comprise a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence consisting of a nucleobase sequence of any of SEQ ID NOs: 12-179. In certain embodiments, one or more modified nucleosides in the wing segment have a modified sugar. In certain embodiments, the modified sugar is a bicyclic sugar. In certain embodiments, the modified nucleoside is an LNA nucleoside. In certain embodiments, the modified nucleoside

is a 2'-substituted nucleoside. In certain embodiments, 2' substituted nucleosides include nucleosides with bicyclic sugar modifications. In certain embodiments, the modified nucleoside is a 2'-MOE nucleoside. In certain embodiments, the modified nucleoside is a constrained ethyl (cEt) nucleoside.

In certain embodiments, the compounds or compositions targeted to androgen receptor comprise a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175, or a pharmaceutically acceptable salt thereof. In certain embodiments, the antisense compound targeted to human AR is ISIS 560131, ISIS 569213, ISIS 569216, ISIS 569221, ISIS 569236, ISIS 579671, ISIS 586124, ISIS 583918, ISIS 584149, ISIS 584163, ISIS 584269, or ISIS 584468.

In certain embodiments, the modified oligonucleotide comprises: a) a gap segment consisting of linked deoxynucleosides; b) a 5' wing segment consisting of linked nucleosides; and c) a 3' wing segment consisting of linked nucleosides. The gap segment is positioned between the 5' wing segment and the 3' wing segment and each nucleoside of each wing segment comprises a modified sugar.

In certain embodiments, the modified oligonucleotide consists of 20 linked nucleosides, the gap segment consisting of 10 linked deoxynucleosides, the 5' wing segment consisting of five linked nucleosides, the 3' wing segment consisting of five linked nucleosides, each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 16 linked nucleosides, a gap segment consisting of 10 linked deoxynucleosides, a 5' wing segment consisting of three linked nucleosides, a 3' wing segment consisting of three linked nucleosides, each nucleoside of each wing segment comprises a constrained ethyl (cEt) sugar, each internucleoside linkage is a phosphorothioate linkage and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 16 linked nucleosides, a gap segment consisting of 9 linked deoxynucleosides, a 5' wing segment consisting of three linked nucleosides, a 3' wing segment consisting of four linked nucleosides; the three linked nucleosides of the 5' wing segment are each a constrained ethyl (cEt) sugar; the four linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 16 linked nucleosides, a gap segment consisting of 8 linked deoxynucleosides, a 5' wing segment consisting of five linked nucleosides, a 3' wing segment consisting of three linked nucleosides; the five linked nucleosides of the 5' wing segment are each a constrained ethyl (cEt) sugar; the three linked nucleosides of the 3' wing segment are each a constrained ethyl (cEt) sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 16 linked nucleosides, a gap segment consisting of 8 linked deoxynucleosides, a 5' wing segment consisting of four linked nucleosides, a 3' wing segment consisting of four linked nucleosides; the four linked nucleosides of the 5' wing segment are a 2'-O-methoxyethyl sugar, a constrained

ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a constrained ethyl (cEt) sugar in the 5' to 3' direction; the four linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 16 linked nucleosides, a gap segment consisting of 8 linked deoxynucleosides, a 5' wing segment consisting of five linked nucleosides, a 3' wing segment consisting of three linked nucleosides; the five linked nucleosides of the 5' wing segment are a 2'-O-methoxyethyl sugar, a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a constrained ethyl (cEt) sugar in the 5' to 3' direction; the three linked nucleosides of the 3' wing segment are each a constrained ethyl (cEt) sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 16 linked nucleosides, a gap segment consisting of 7 linked deoxynucleosides, a 5' wing segment consisting of seven linked nucleosides, a 3' wing segment consisting of two linked nucleosides; the seven linked nucleosides of the 5' wing segment are a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a 2'-O-methoxyethyl sugar, a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, and a constrained ethyl (cEt) sugar in the 5' to 3' direction; the two linked nucleosides of the 3' wing segment are each a constrained ethyl (cEt) sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 16 linked nucleosides, a gap segment consisting of 7 linked deoxynucleosides, a 5' wing segment consisting of six linked nucleosides, a 3' wing segment consisting of three linked nucleosides; the six linked nucleosides of the 5' wing segment are a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, and a constrained ethyl (cEt) sugar in the 5' to 3' direction; the three linked nucleosides of the 3' wing segment are each a constrained ethyl (cEt) sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 16 linked nucleosides, a gap segment consisting of 7 linked deoxynucleosides, a 5' wing segment consisting of five linked nucleosides, a 3' wing segment consisting of four linked nucleosides; the five linked nucleosides of the 5' wing segment are a 2'-O-methoxyethyl sugar, a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a constrained ethyl (cEt) sugar in the 5' to 3' direction; the four linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, the modified oligonucleotide consists of 16 linked nucleosides, a gap segment consisting of 7 linked deoxynucleosides, a 5' wing segment consisting of four linked nucleosides, a 3' wing segment consisting of five linked nucleosides; the four linked nucleosides of the 5' wing segment are a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a

constrained ethyl (cEt) sugar in the 5' to 3' direction; the five linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a 2'-O-methoxyethyl sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, the compounds or compositions targeted to androgen receptor comprise a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises a gap segment consisting of deoxynucleosides; a 5' wing segment; and a 3' wing segment, wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and each nucleoside of each wing segment comprises a modified sugar. In certain embodiments, each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage. In certain embodiments, each cytosine of the modified oligonucleotide is a 5'-methylcytosine.

In certain embodiments, a compound targeted to androgen receptor comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 35, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

- a gap segment consisting of 9 linked deoxynucleosides;
- a 5' wing segment consisting of three linked nucleosides;

- and
- a 3' wing segment consisting of four linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; the three linked nucleosides of the 5' wing segment are each a constrained ethyl (cEt) sugar; the four linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, a compound targeted to androgen receptor comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 39, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

- a gap segment consisting of 9 linked deoxynucleosides;
- a 5' wing segment consisting of three linked nucleosides;

- and
- a 3' wing segment consisting of four linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; the three linked nucleosides of the 5' wing segment are each a constrained ethyl (cEt) sugar; the four linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, a compound targeted to androgen receptor comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 39, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

- a gap segment consisting of 8 linked deoxynucleosides;
- a 5' wing segment consisting of four linked nucleosides;

- and
- a 3' wing segment consisting of four linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; the four linked nucleosides of the 5' wing segment are a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a constrained ethyl (cEt) sugar in the 5' to 3' direction; the four linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, a compound targeted to androgen receptor comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 39, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

- a gap segment consisting of 8 linked deoxynucleosides;
- a 5' wing segment consisting of five linked nucleosides;

- and
- a 3' wing segment consisting of three linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; the five linked nucleosides of the 5' wing segment are a 2'-O-methoxyethyl sugar, a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a constrained ethyl (cEt) sugar in the 5' to 3' direction; the three linked nucleosides of the 3' wing segment are each a constrained ethyl (cEt) sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, a compound targeted to androgen receptor comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 39, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

- a gap segment consisting of 7 linked deoxynucleosides;
- a 5' wing segment consisting of four linked nucleosides;

- and
- a 3' wing segment consisting of five linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; the four linked nucleosides of the 5' wing segment are a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a constrained ethyl (cEt) sugar in the 5' to 3' direction; the five linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a 2'-O-methoxyethyl sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, a compound targeted to androgen receptor comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 35, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

- a gap segment consisting of 7 linked deoxynucleosides;
- a 5' wing segment consisting of six linked nucleosides;

- and
- a 3' wing segment consisting of three linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; the six linked

15

nucleosides of the 5' wing segment are a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, and a constrained ethyl (cEt) sugar in the 5' to 3' direction; the three linked nucleosides of the 3' wing segment are each a constrained ethyl (cEt) sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, a compound targeted to androgen receptor comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 43, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

a gap segment consisting of 10 linked deoxynucleosides;
a 5' wing segment consisting of three linked nucleosides;
and

a 3' wing segment consisting of three linked nucleosides;
wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; each nucleoside of each wing segment comprises a constrained ethyl (cEt) sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, a compound targeted to androgen receptor comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 124, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

a gap segment consisting of 10 linked deoxynucleosides;
a 5' wing segment consisting of three linked nucleosides;
and

a 3' wing segment consisting of three linked nucleosides;
wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; each nucleoside of each wing segment comprises a constrained ethyl (cEt) sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, a compound targeted to androgen receptor comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 150, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

a gap segment consisting of 10 linked deoxynucleosides;
a 5' wing segment consisting of three linked nucleosides;
and

a 3' wing segment consisting of three linked nucleosides;
wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; each nucleoside of each wing segment comprises a constrained ethyl (cEt) sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, a compound targeted to androgen receptor comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 155, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

a gap segment consisting of 10 linked deoxynucleosides;
a 5' wing segment consisting of three linked nucleosides;
and

a 3' wing segment consisting of three linked nucleosides;
wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; each nucleoside of each wing segment comprises a constrained ethyl (cEt)

16

sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, a compound targeted to androgen receptor comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 169, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

a gap segment consisting of 10 linked deoxynucleosides;
a 5' wing segment consisting of three linked nucleosides;
and

a 3' wing segment consisting of three linked nucleosides;
wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; each nucleoside of each wing segment comprises a constrained ethyl (cEt) sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, a compound targeted to androgen receptor comprises a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 175, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

a gap segment consisting of 10 linked deoxynucleosides;
a 5' wing segment consisting of three linked nucleosides;
and

a 3' wing segment consisting of three linked nucleosides;
wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; each nucleoside of each wing segment comprises a constrained ethyl (cEt) sugar; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

In certain embodiments, an antisense compound or antisense oligonucleotide targeted to an androgen receptor nucleic acid is complementary within the following nucleotide regions of SEQ ID NO: 1: 2957-2972, 3079-3094, 3099-3114, 3109-3124, 3113-3128, 3120-3135, 3133-3148, 3224-3239, 3226-3241, 3351-3366, 3353-3368, 3361-3376, 3388-3403, 3513-3528, 3517-3532, 3519-3534, 3641-3656, 3735-3750, 3764-3779, 3768-3783, 3798-3813, 3799-3814, 3851-3866, 3870-3885, 3874-3889, 3876-3891, 3878-3893, 3884-3899, 3886-3901, 3888-3903, 3901-3916, 3956-3971, 3962-3977, 3964-3979, 3967-3982, 4019-4034, 4038-4053, 4049-4064, 4056-4071, 4059-4074, 4062-4077, 4066-4081, 4070-4085, 4101-4116, 4103-4118, 4105-4120, 4109-4124, 4305-4320, 4405-4420, 4532-4547, 4534-4549, 4537-4552, 4539-4554, 4555-4570, 4571-4586, 4573-4588, 4578-4593, 4597-4612, 4632-4647, 4655-4670, 4656-4671, 4662-4677, 4699-4714, 4747-4762, 4750-4765, 4752-4767, 4754-4769, 4755-4770, 4769-4784, 4798-4813, 4804-4819, 4807-4822, 4833-4848, 4837-4852, 4839-4854, 4865-4880, 4868-4883, 4872-4887, 4874-4889, 4876-4891, 4887-4902, 4889-4904, 4916-4931, 4918-4933, 4938-4953, 4942-4957, 4944-4959, 4951-4966, 5050-5065, 5052-5067, 5054-5069, 5056-5071, 5060-5075, 5061-5076, 5062-5077, 5133-5148, 5141-5156, 5155-5170, 5265-5280, 5293-5308, 5308-5323, 5392-5407, 5448-5463, 5469-5484, 5481-5496, 5483-5498, 5486-5501, 5488-5503, 5494-5509, 5521-5536, 5666-5681, 6222-6237, 6701-6716, 7543-7558, 8471-8486, 8638-8653, 9464-9479, 10217-10232, 10250-10265, 10865-10880, 11197-11212, 11855-11870, 13189-13204, 13321-13336, 13346-13361, 16555-16570, 16793-16808, 16968-16983, 17206-17221, 18865-18880, 29329-29344, 32290-32305, 33315-33330, 39055-39070, 40615-40630, 42017-42032, 56050-56065, 58719-58734, 58720-58739, 58720-58735, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58724-58739, 58725-58740, 58725-58740, 58725-58740, 58750-58769,

58750-58765, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 60902-60917, 67454-67469, 102156-102171, 114874-114889, 115272-115287, 115365-115380, 134971-134986, 139682-139697, 139762-139777, 139782-139797, 144856-144871, 144938-144953, 148406-148421, 148443-148458, 148520-148535, 181695-181710, 182958-182973, or 183049-183064.

In certain embodiments, an antisense compound or antisense oligonucleotide targeted to an androgen receptor nucleic acid target the following nucleotide regions of SEQ ID NO: 1: 2957-2972, 3079-3094, 3099-3114, 3109-3124, 3113-3128, 3120-3135, 3133-3148, 3224-3239, 3226-3241, 3351-3366, 3353-3368, 3361-3376, 3388-3403, 3513-3528, 3517-3532, 3519-3534, 3641-3656, 3735-3750, 3764-3779, 3768-3783, 3798-3813, 3799-3814, 3851-3866, 3870-3885, 3874-3889, 3876-3891, 3878-3893, 3884-3899, 3886-3901, 3888-3903, 3901-3916, 3956-3971, 3962-3977, 3964-3979, 3967-3982, 4019-4034, 4038-4053, 4049-4064, 4056-4071, 4059-4074, 4062-4077, 4066-4081, 4070-4085, 4101-4116, 4103-4118, 4105-4120, 4109-4124, 4305-4320, 4405-4420, 4532-4547, 4534-4549, 4537-4552, 4539-4554, 4555-4570, 4571-4586, 4573-4588, 4578-4593, 4597-4612, 4632-4647, 4655-4670, 4656-4671, 4662-4677, 4699-4714, 4747-4762, 4750-4765, 4752-4767, 4754-4769, 4755-4770, 4769-4784, 4798-4813, 4804-4819, 4807-4822, 4833-4848, 4837-4852, 4839-4854, 4865-4880, 4868-4883, 4872-4887, 4874-4889, 4876-4891, 4887-4902, 4889-4904, 4916-4931, 4918-4933, 4938-4953, 4942-4957, 4944-4959, 4951-4966, 5050-5065, 5052-5067, 5054-5069, 5056-5071, 5060-5075, 5061-5076, 5062-5077, 5133-5148, 5141-5156, 5155-5170, 5265-5280, 5293-5308, 5308-5323, 5392-5407, 5448-5463, 5469-5484, 5481-5496, 5483-5498, 5486-5501, 5488-5503, 5494-5509, 5521-5536, 5666-5681, 6222-6237, 6701-6716, 7543-7558, 8471-8486, 8638-8653, 9464-9479, 10217-10232, 10250-10265, 10865-10880, 11197-11212, 11855-11870, 13189-13204, 13321-13336, 13346-13361, 16555-16570, 16793-16808, 16968-16983, 17206-17221, 18865-18880, 29329-29344, 32290-32305, 33315-33330, 39055-39070, 40615-40630, 42017-42032, 56050-56065, 58719-58734, 58720-58739, 58720-58735, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58724-58739, 58725-58740, 58725-58740, 58725-58740, 58750-58769, 58750-58765, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 60902-60917, 67454-67469, 102156-102171, 114874-114889, 115272-115287, 115365-115380, 134971-134986, 139682-139697, 139762-139777, 139782-139797, 144856-144871, 144938-144953, 148406-148421, 148443-148458, 148520-148535, 181695-181710, 182958-182973, or 183049-183064.

In certain embodiments, antisense compounds or antisense oligonucleotides target a region of an androgen receptor nucleic acid. In certain embodiments, such compounds or oligonucleotides targeted to a region of an androgen receptor nucleic acid have a contiguous nucleobase portion that is complementary to an equal length nucleobase portion of the region. For example, the portion can be at least an 8, 9, 10, 11, 12, 13, 14, 15, or 16 contiguous nucleobases portion complementary to an equal length portion of a region recited herein. In certain embodiments, such compounds or oligonucleotide target the following nucleotide regions of SEQ ID NO: 1: 2957-2972, 3079-3094, 3099-3114, 3109-3124, 3113-3128, 3120-3135, 3133-3148, 3224-3239, 3226-3241, 3351-3366, 3353-3368, 3361-3376, 3388-3403, 3513-3528, 3517-3532, 3519-3534, 3641-3656, 3735-3750, 3764-3779, 3768-3783, 3798-3813, 3799-3814, 3851-3866, 3870-3885, 3874-3889, 3876-3891, 3878-3893, 3884-3899, 3886-3901, 3888-3903, 3901-3916, 3956-3971, 3962-3977, 3964-3979,

3967-3982, 4019-4034, 4038-4053, 4049-4064, 4056-4071, 4059-4074, 4062-4077, 4066-4081, 4070-4085, 4101-4116, 4103-4118, 4105-4120, 4109-4124, 4305-4320, 4405-4420, 4532-4547, 4534-4549, 4537-4552, 4539-4554, 4555-4570, 4571-4586, 4573-4588, 4578-4593, 4597-4612, 4632-4647, 4655-4670, 4656-4671, 4662-4677, 4699-4714, 4747-4762, 4750-4765, 4752-4767, 4754-4769, 4755-4770, 4769-4784, 4798-4813, 4804-4819, 4807-4822, 4833-4848, 4837-4852, 4839-4854, 4865-4880, 4868-4883, 4872-4887, 4874-4889, 4876-4891, 4887-4902, 4889-4904, 4916-4931, 4918-4933, 4938-4953, 4942-4957, 4944-4959, 4951-4966, 5050-5065, 5052-5067, 5054-5069, 5056-5071, 5060-5075, 5061-5076, 5062-5077, 5133-5148, 5141-5156, 5155-5170, 5265-5280, 5293-5308, 5308-5323, 5392-5407, 5448-5463, 5469-5484, 5481-5496, 5483-5498, 5486-5501, 5488-5503, 5494-5509, 5521-5536, 5666-5681, 6222-6237, 6701-6716, 7543-7558, 8471-8486, 8638-8653, 9464-9479, 10217-10232, 10250-10265, 10865-10880, 11197-11212, 11855-11870, 13189-13204, 13321-13336, 13346-13361, 16555-16570, 16793-16808, 16968-16983, 17206-17221, 18865-18880, 29329-29344, 32290-32305, 33315-33330, 39055-39070, 40615-40630, 42017-42032, 56050-56065, 58719-58734, 58720-58739, 58720-58735, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58724-58739, 58725-58740, 58725-58740, 58725-58740, 58750-58769, 58750-58765, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 60902-60917, 67454-67469, 102156-102171, 114874-114889, 115272-115287, 115365-115380, 134971-134986, 139682-139697, 139762-139777, 139782-139797, 144856-144871, 144938-144953, 148406-148421, 148443-148458, 148520-148535, 181695-181710, 182958-182973, or 183049-183064.

In certain embodiments, an antisense compound or antisense oligonucleotide provided herein targets AR within exon 1, for example within nucleotide regions 2863-5593 (exon 1) or 27672-27853 (exon 1B) of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to exon 1 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 2957-2972, 3079-3094, 3099-3114, 3109-3124, 3113-3128, 3120-3135, 3133-3148, 3224-3239, 3226-3241, 3351-3366, 3353-3368, 3361-3376, 3388-3403, 3513-3528, 3517-3532, 3519-3534, 3641-3656, 3735-3750, 3764-3779, 3768-3783, 3798-3813, 3799-3814, 3851-3866, 3870-3885, 3874-3889, 3876-3891, 3878-3893, 3884-3899, 3886-3901, 3888-3903, 3901-3916, 3956-3971, 3962-3977, 3964-3979, 3967-3982, 4019-4034, 4038-4053, 4047-4062, 4049-4064, 4056-4071, 4059-4074, 4062-4077, 4066-4081, 4070-4085, 4101-4116, 4103-4118, 4105-4120, 4109-4124, 4305-4320, 4405-4420, 4532-4547, 4534-4549, 4537-4552, 4539-4554, 4555-4570, 4571-4586, 4573-4588, 4578-4593, 4597-4612, 4632-4647, 4655-4670, 4656-4671, 4662-4677, 4699-4714, 4747-4762, 4750-4765, 4752-4767, 4754-4769, 4755-4770, 4769-4784, 4798-4813, 4804-4819, 4807-4822, 4833-4848, 4837-4852, 4839-4854, 4865-4880, 4868-4883, 4872-4887, 4874-4889, 4876-4891, 4887-4902, 4889-4904, 4916-4931, 4918-4933, 4938-4953, 4942-4957, 4944-4959, 4951-4966, 5050-5065, 5052-5067, 5054-5069, 5056-5071, 5060-5075, 5061-5076, 5062-5077, 5133-5148, 5141-5156, 5155-5170, 5265-5280, 5293-5308, 5308-5323, 5392-5407, 5448-5463, 5469-5484, 5481-5496, 5483-5498, 5486-5501, 5488-5503, 5494-5509, or 5521-5536.

In certain embodiments, an antisense compound or antisense oligonucleotide provided herein targets AR within exon 2, for example within nucleotide regions 102087-102238 (exon 2) or 139551-139834 (exon 2c) of SEQ ID NO: 1. In certain embodiments, an antisense compound

provided herein targeted to exon 2 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 102155-102170, 102156-102171, 139682-139697, 139762-139777, or 139782-139797.

In certain embodiments, an antisense compound or antisense oligonucleotide provided herein targets AR within exon 3, for example within nucleotide regions 144841-144957 (exon 3), 148380-148594 (exon 3b), or 153504-154908 (exon 3d) of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to exon 3 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 144856-144871, 144938-144953, 148406-148421, 148443-148458, or 148520-148535.

In certain embodiments, an antisense compound or antisense oligonucleotide provided herein targets AR within exon 7, for example within nucleotide region 181658-181815 of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to exon 7 of AR is complementary within nucleotide region 181695-181710 of SEQ ID NO: 1.

In certain embodiments, an antisense compound or antisense oligonucleotide provided herein targets AR within exon 8, for example within nucleotide region 182517-189455 of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to exon 8 of AR is complementary within nucleotide regions 182958-182973 or 183049-183064 of SEQ ID NO: 1.

In certain embodiments, an antisense compound or antisense oligonucleotide provided herein targets AR within intron 1, for example within nucleotide regions 5594-27671 or 27854-102086 of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to intron 1 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 5666-5681, 6222-6237, 6701-6716, 7543-7558, 8471-8486, 8638-8653, 9464-9479, 10217-10232, 10250-10265, 10865-10880, 11197-11212, 11855-11870, 13189-13204, 13321-13336, 13346-13361, 16555-16570, 16793-16808, 16968-16983, 17206-17221, 18865-18880, 29329-29344, 32290-32305, 33315-33330, 39055-39070, 40615-40630, 42017-42032, 56050-56065, 58719-58734, 58720-58739, 58720-58735, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58724-58739, 58725-58740, 58725-58740, 58725-58740, 58750-58769, 58750-58765, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 60902-60917, or 67454-67469.

In certain embodiments, an antisense compound or antisense oligonucleotide provided herein targets AR within intron 2, for example within nucleotide regions 102239-139550 or 139835-144840 of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to intron 2 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 114874-114889, 115272-115287, 115365-115380, or 134971-134986.

In certain embodiments, the following nucleotide regions of SEQ ID NO: 1, when targeted by antisense compounds or antisense oligonucleotides, display at least 50% inhibition: 3099-3114, 3120-3135, 3351-3366, 3353-3368, 3361-3376, 3513-3528, 3519-3534, 3768-3783, 3799-3814, 3851-3866, 3888-3903, 4059-4074, 4534-4549, 4555-4570, 4571-4586, 4578-4593, 4655-4670, 4699-4714, 4750-4765, 4755-4770, 4785-4800, 5054-5069, 5060-5075, 5061-5076, 5062-5077, 5155-5170, 5265-5280, 5392-5407, 5448-5463, 5483-5498, 7543-7558, 8471-8486, 8638-8653, 9464-9479, 10217-10232, 10250-10265, 10865-10880, 11197-11212, 11855-11870, 13189-13204, 13321-13336, 13346-13361, 16555-

16570, 16793-16808, 16968-16983, 17206-17221, 18865-18880, 29329-29344, 32290-32305, 33315-33330, 39055-39070, 40615-40630, 42017-42032, 56050-56065, 58719-58734, 58720-58735, 58720-58739, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58725-58740, 58750-58765, 58750-58769, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 60902-60917, 67454-67469, 102156-102171, 114874-114889, 114874-114889, 115272-115287, 115365-115380, 134971-134986, 144856-144871, 181695-181710, 182958-182973, and 183049-183064.

In certain embodiments, the following nucleotide regions of SEQ ID NO: 1, when targeted by antisense compounds or antisense oligonucleotides, display at least 60% inhibition: 3799-3814, 3851-3866, 3888-3903, 4059-4074, 4534-4549, 4555-4570, 4571-4586, 4578-4593, 4655-4670, 4699-4714, 4755-4770, 4865-4880, 5060-5075, 5061-5076, 5062-5077, 5155-5170, 5265-5280, 5392-5407, 5448-5463, 5483-5498, 7543-7558, 8471-8486, 8638-8653, 9464-9479, 10217-10232, 10250-10265, 10865-10880, 11197-11212, 11855-11870, 13189-13204, 13321-13336, 13346-13361, 16555-16570, 16793-16808, 16968-16983, 17206-17221, 18865-18880, 29329-29344, 32290-32305, 33315-33330, 42017-42032, 56050-56065, 58719-58734, 58720-58735, 58720-58739, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58725-58740, 58750-58765, 58750-58769, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 67454-67469, 102156-102171, 115272-115287, 115365-115380, 144856-144871, 181695-181710, 182958-182973, and 183049-183064.

In certain embodiments, the following nucleotide regions of SEQ ID NO: 1, when targeted by antisense compounds or antisense oligonucleotides, display at least 70% inhibition: 3799-3814, 3851-3866, 3888-3903, 4059-4074, 4534-4549, 4655-4670, 4699-4714, 4755-4770, 4865-4880, 5060-5075, 5062-5077, 5155-5170, 5265-5280, 5392-5407, 5448-5463, 5483-5498, 7543-7558, 8471-8486, 8638-8653, 9464-9479, 10865-10880, 11197-11212, 11855-11870, 13189-13204, 13321-13336, 13346-13361, 16555-16570, 16793-16808, 16968-16983, 17206-17221, 18865-18880, 33315-33330, 42017-42032, 58719-58734, 58720-58739, 58720-58735, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58725-58740, 58750-58769, 58750-58765, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 102156-102171, 115365-115380, 144856-144871, 181695-181710, 182958-182973, and 183049-183064.

In certain embodiments, the following nucleotide regions of SEQ ID NO: 1, when targeted by antisense compounds or antisense oligonucleotides, display at least 80% inhibition: 3799-3814, 3851-3866, 3888-3903, 4059-4074, 4534-4549, 4655-4670, 4699-4714, 4755-4770, 4865-4880, 5060-5075, 5062-5077, 5155-5170, 5265-5280, 5392-5407, 5448-5463, 5483-5498, 8471-8486, 8638-8653, 9464-9479, 10865-10880, 11197-11212, 13189-13204, 16793-16808, 58719-58734, 58720-58735, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58725-58740, 58750-58765, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 102156-102171, 144856-144871, 181695-181710, 182958-182973, and 183049-183064.

In certain embodiments, the following nucleotide regions of SEQ ID NO: 1, when targeted by antisense compounds or antisense oligonucleotides, display at least 90% inhibition: 4534-4549, 5060-5075, 5062-5077, 5155-5170, 5265-5280, 5448-5463, 58720-58735, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58725-58740, 58750-58765, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 182958-182973, and 183049-183064.

In certain embodiments, the following antisense compounds or antisense oligonucleotides target a region of an androgen receptor nucleic acid and effect at least a 50% inhibition of an androgen receptor mRNA, ISIS IDs: 549332, 549334, 549338, 549347, 549358, 549360, 549361, 549362, 549366, 549371, 549372, 549374, 549377, 549379, 549380, 549381, 549387, 549390, 549414, 549432, 549434, 549457, 549458, 549459, 560071, 560098, 560099, 560100, 560131, 560132, 560133, 560137, 569213, 569215, 569216, 569220, 569222, 569223, 569227, 569228, 569229, 569236, 569238, 583559, 583567, 583608, 583609, 583613, 583635, 583638, 583662, 583795, 583796, 583799, 583834, 583919, 584145, 584148, 584149, 584152, 584157, 584158, 584162, 584163, 584165, 584166, 584167, 584168, 584179, 584180, 584183, 584184, 584192, 584233, 584242, 584245, 584263, 584269, 584274, 584312, 584329, 584361, 584465, 584465, 584468, 584469, 584469, 584495, 584495, 585233, 585259, 585262, 585263, 585264, 585265, 585268, 585269, 585271, 585274, 586124, 586224, 586224, 586225, 586225, 586227, and 586227.

In certain embodiments, the following antisense compounds or antisense oligonucleotides target a region of an androgen receptor nucleic acid and effect at least a 50% inhibition of an androgen receptor mRNA, SEQ ID NOs: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 46, 49, 53, 54, 55, 57, 59, 63, 92, 93, 95, 101, 125, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, and 177.

In certain embodiments, the following antisense compounds or antisense oligonucleotides target a region of an androgen receptor nucleic acid and effect at least a 60% inhibition of an androgen receptor mRNA, ISIS IDs: 549332, 549334, 549338, 549347, 549358, 549360, 549361, 549362, 549366, 549371, 549372, 549374, 549377, 549379, 549380, 549381, 549387, 549390, 549414, 549432, 549434, 549457, 549458, 549459, 560071, 560098, 560099, 560100, 560131, 560137, 569213, 569216, 569222, 569228, 569236, 583795, 583796, 583799, 584145, 584148, 584149, 584152, 584157, 584158, 584162, 584163, 584165, 584166, 584167, 584168, 584179, 584180, 584183, 584184, 584192, 584233, 584242, 584245, 584274, 584312, 584361, 584468, 584469, 585233, 585259, 585262, 585263, 585264, 585265, 585268, 585269, 585274, 586124, 586224, 586225, and 586227.

In certain embodiments, the following antisense compounds or antisense oligonucleotides target a region of an androgen receptor nucleic acid and effect at least a 60% inhibition of an androgen receptor mRNA, SEQ ID NOs: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 92, 93, 95, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 170, 171, 173, 175, and 176.

In certain embodiments, the following antisense compounds or antisense oligonucleotides target a region of an androgen receptor nucleic acid and effect at least a 70% inhibition of an androgen receptor mRNA, ISIS IDs: 549332, 549334, 549338, 549347, 549358, 549360, 549361, 549362, 549366, 549371, 549372, 549374, 549377, 549379, 549380, 549381, 549387, 549390, 549414, 549432, 549434, 549457, 549458, 549459, 560071, 560098, 560099, 560100, 560131, 560137, 569222, 584145, 584148, 584149, 584152, 584162, 584163, 584165, 584166, 584167, 584168, 584179, 584180, 584183, 584184, 584192, 584245, 584274, 584469, 585259, 585262, 585268, 585269, 586124, 586224, 586225, and 586227.

In certain embodiments, the following antisense compounds or antisense oligonucleotides target a region of an androgen receptor nucleic acid and effect at least a 70% inhibition of an androgen receptor mRNA, SEQ ID NOs: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 148, 149, 150, 151, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 167, 170, and 176.

In certain embodiments, the following antisense compounds or antisense oligonucleotides target a region of an androgen receptor nucleic acid and effect at least a 80% inhibition of an androgen receptor mRNA, ISIS IDs: 549332, 549334, 549338, 549347, 549358, 549360, 549361, 549362, 549366, 549371, 549372, 549374, 549377, 549379, 549380, 549381, 549387, 549390, 549414, 549432, 549434, 549457, 549458, 549459, 560098, 560099, 560100, 560137, 584148, 584149, 584152, 584162, 584163, 584166, 584180, 586124, 586224, 586225, and 586227.

In certain embodiments, the following antisense compounds or antisense oligonucleotides target a region of an androgen receptor nucleic acid and effect at least a 80% inhibition of an androgen receptor mRNA, SEQ ID NOs: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 29, 31, 32, 33, 34, 35, 36, 37, 39, 40, 41, 43, 149, 150, 151, 154, 155, 157, and 161.

In certain embodiments, the following antisense compounds or antisense oligonucleotides target a region of an androgen receptor nucleic acid and effect at least a 90% inhibition of an androgen receptor mRNA, ISIS IDs: 549358, 549371, 549372, 549374, 549377, 549380, 549432, 549434, 549457, 549458, 549459, 560098, 560099, 560100, 560137, and 586224.

In certain embodiments, the following antisense compounds or antisense oligonucleotides target a region of an androgen receptor nucleic acid and effect at least a 90% inhibition of an androgen receptor mRNA, SEQ ID NOs: 16, 21, 22, 23, 24, 26, 33, 34, 35, 36, 37, 39, 40, and 41.

Percent inhibition of androgen receptor mRNA can be determined using standard methods known to those of skill in the art, such as described in Example 1.

It is understood that the sequence set forth in each SEQ ID NO in the examples contained herein is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase. As such, antisense compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Antisense compounds described by ISIS number (ISIS #) indicate a combination of nucleobase sequence, chemical modification, and motif.

In certain embodiments, the compounds or compositions as described herein are efficacious by virtue of having at least one of an in vitro IC_{50} of less than 250 nM, less than 200 nM, less than 150 nM, less than 100 nM, less than 90 nM, less than 80 nM, less than 70 nM, less than 65 nM, less than 60 nM, less than 55 nM, less than 50 nM, less than 45 nM, less than 40 nM, less than 35 nM, less than 30 nM, less than 25 nM, or less than 20 nM when delivered to HuVEC cells. In certain embodiments inhibition is measured with primer probe set RTS3559, as described herein.

In certain embodiments, the compounds or compositions as described herein are highly tolerable as demonstrated by having at least one of an increase an ALT or AST value of no more than 4 fold, 3 fold, or 2 fold over saline treated animals or an increase in liver, spleen, or kidney weight of no more than 30%, 20%, 15%, 12%, 10%, 5%, or 2%. In certain embodiments, the compounds or compositions as described herein are highly tolerable as demonstrated by

having no increase of ALT or AST over saline treated animals. In certain embodiments, the compounds or compositions as described herein are highly tolerable as demonstrated by having no increase in liver, spleen, or kidney weight over saline treated animals.

In certain embodiments, an antisense compound provided herein targets an AR splicing variant that includes exon 1 encoding the N-terminal domain and exons 2 and 3 encoding the DNA binding domain, but does not include at least a portion of exon 4 encoding the short hinge region or at least a portion of exons 4-8 encoding the ligand binding domain. An example of such an AR splicing variant includes, but is not limited to, AR-V7, which contains exons 1-3 but lacks exons 4-8. Additional examples of such AR splicing variants include, for example, AR3, AR4, AR4b, AR5, and AR6 (SEQ ID NOs: 4-8, respectively). In certain embodiments, an antisense compound targeted to AR upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain is capable of inhibiting androgen receptor levels to a greater extent than an antisense compound targeted to the ligand binding domain, such as EZN-4176, which is targeted to exon 4 and corresponds to SEQ ID NO: 58 described in U.S. Pat. No. 7,737,125.

In certain embodiments, an antisense compound targets an AR splicing variant that has a functional DNA binding domain, but not a functional ligand binding domain. It will be understood that in certain embodiments an antisense compound can target an AR splicing variant that includes the entire or at least a functional portion of exon 1 encoding the N-terminal domain and the entire or at least a functional portion of exons 2 and 3 encoding the DNA binding domain, but does not include at least a functional portion of exon 4 encoding the short hinge region or at least a functional portion of exons 4-8 encoding the ligand binding domain. It is contemplated that certain AR splicing variants targeted by the antisense compounds provided herein substantially consisting of exons 1-3 may also include a non-functional portion of nucleic acid sequence from a genomic region or exons 4-8. It is contemplated that the splicing process may give rise to such AR splicing variants that retain DNA binding function but not ligand binding function. In certain embodiments, an antisense compound targeted to an AR splicing variant that has a functional DNA binding domain, but not a functional ligand binding domain, is capable of inhibiting growth or proliferation of prostate cancer cells that are castrate-resistant. In certain embodiments, an antisense compound targeted to an AR splicing variant that has a functional DNA binding domain, but not a functional ligand binding domain, is capable of inhibiting growth or proliferation of a prostate cancer cell resistant to a diarylhydantoin AR inhibitor of Formula XI to a greater extent than an antisense compound targeted to the ligand binding domain, such as EZN-4176, which is targeted to exon 4 and corresponds to SEQ ID NO: 58 described in U.S. Pat. No. 7,737,125. In certain embodiments, an antisense compound provided herein targets AR within exon 1, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain. In certain embodiments, an antisense compound provided herein targets AR within exon 2, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain. In certain embodiments, an antisense compound provided herein targets AR within intron 1, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain.

In certain embodiments, an antisense compound provided herein is capable of reducing expression of both full-length AR and an AR splicing variant that includes exon 1 encoding

the N-terminal domain and exons 2 and 3 encoding the DNA binding domain, but does not include at least a portion of exon 4 encoding the short hinge region or at least a portion of any one of exons 4-8 encoding the ligand binding domain.

In certain embodiments, such an antisense compound targets human androgen receptor upstream of the ligand binding domain. In certain embodiments, such antisense compounds target human androgen receptor upstream of the 3' end of exon 3. In certain embodiments, an antisense compound provided herein targets AR within exon 1, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain. In certain embodiments, an antisense compound provided herein targets AR within exon 2, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain. In certain embodiments, an antisense compound provided herein targets AR within intron 1, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain.

In certain embodiments, an antisense compound provided herein targets an AR splicing variant that includes exon 1 encoding the N-terminal domain and exons 2 and 3 encoding the DNA binding domain, but does not include at least a portion of exon 4 encoding the short hinge region or at least a portion of exons 4-8 encoding the ligand binding domain. An example of such an AR splicing variant includes, but is not limited to, AR-V7, which contains exons 1-3 but lacks exons 4-8.

Certain embodiments are drawn to an antisense compound targeted to human androgen receptor (AR) upstream of the ligand binding domain that is capable of inhibiting growth or proliferation of the resistant prostate cancer cell to a greater extent than an antisense compound targeted to the ligand binding domain, such as EZN-4176, which is targeted to exon 4 and corresponds to SEQ ID NO: 58 described in U.S. Pat. No. 7,737,125. In certain embodiments, an antisense compound targeted to human androgen receptor (AR) upstream of the ligand binding domain is targeted to a region of AR upstream of the 3' end of exon 3. In certain embodiments, an antisense compound provided herein targets AR within exon 1, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain. In certain embodiments, an antisense compound provided herein targets AR within exon 2, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain. In certain embodiments, an antisense compound provided herein targets AR within intron 1, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain.

In certain embodiments, the nucleobase sequence of a modified oligonucleotide provided herein is at least 70%, 75%, 80%, 85%, 90%, 95% or 100% complementary to any one of SEQ ID NOs: 1-8, as measured over the entirety of the modified oligonucleotide.

In certain embodiments, an antisense compound is a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence at least 90% complementary to any of SEQ ID NOs: 1-8 as measured over the entirety of said modified oligonucleotide.

In certain embodiments, an antisense compound is a modified oligonucleotide consisting of 12 to 30 linked nucleosides and having a nucleobase sequence 100% complementary to any of SEQ ID NOs: 1-8 as measured over the entirety of said modified oligonucleotide. In certain embodiments, a compound or modified oligonucleotide provided herein is single-stranded.

In certain embodiments, a modified oligonucleotide provided herein consists of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,

18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 linked nucleosides. In certain embodiments, the modified oligonucleotide consists of 20 linked nucleosides. In certain embodiments, the modified oligonucleotide consists of 16 linked nucleosides.

In certain embodiments, at least one internucleoside linkage of a modified oligonucleotide provided herein is a modified internucleoside linkage. In certain embodiments, each internucleoside linkage is a phosphorothioate internucleoside linkage.

In certain embodiments, at least one nucleoside of the modified oligonucleotide comprises a modified sugar. In certain embodiments, at least one modified sugar comprises a 2'-O-methoxyethyl group ($2'\text{-O}(\text{CH}_2)_2\text{-OCH}_3$). In certain embodiments, the modified sugar comprises a 2'-O- CH_3 group.

In certain embodiments, at least one modified sugar is a bicyclic sugar. In certain embodiments, the bicyclic sugar comprises a 4'-(CH_2)_n-O-2' bridge, wherein n is 1 or 2. In certain embodiments, the bicyclic sugar comprises a 4'- CH_2 -O-2' bridge. In certain embodiments, the bicyclic sugar comprises a 4-CH(CH_3)-O-2' bridge.

In certain embodiments, at least one nucleoside of a modified oligonucleotide provided herein comprises a modified nucleobase. In certain embodiments, the modified nucleobase is a 5-methylcytosine.

In certain embodiments, a modified oligonucleotide provided herein consists of a single-stranded modified oligonucleotide.

In certain embodiments, compounds or compositions provided herein comprise a salt of the modified oligonucleotide. Compositions and Methods for Formulating Pharmaceutical Compositions

Antisense oligonucleotides may be admixed with pharmaceutically acceptable active or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

An antisense compound targeted to an androgen receptor nucleic acid can be utilized in pharmaceutical compositions by combining the antisense compound with a suitable pharmaceutically acceptable diluent or carrier. In certain embodiments, a pharmaceutically acceptable diluent is water, such as sterile water suitable for injection. Accordingly, in one embodiment, employed in the methods described herein is a pharmaceutical composition comprising an antisense compound targeted to an androgen receptor nucleic acid and a pharmaceutically acceptable diluent. In certain embodiments, the pharmaceutically acceptable diluent is water. In certain embodiments, the antisense compound is an antisense oligonucleotide provided herein.

Pharmaceutical compositions comprising antisense compounds encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other oligonucleotide which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of antisense compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.

A prodrug can include the incorporation of additional nucleosides at one or both ends of an antisense compound

which are cleaved by endogenous nucleases within the body, to form the active antisense compound.

In certain embodiments, the compounds or compositions further comprise a pharmaceutically acceptable carrier or diluent.

Certain Indications

Certain aspects of the invention are directed to methods of treating cancer which comprises administering an antisense compound targeted to androgen receptor as provided herein.

In certain embodiments, the cancer is AR positive. In certain embodiments, the cancer is prostate cancer, breast cancer, ovarian cancer, bladder cancer or gastric cancer. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of the nucleobase sequence of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence consisting of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175. In certain embodiments, the antisense compound is single-stranded. In certain embodiments, the antisense compound targeted to androgen receptor is ISIS 560131, ISIS 569213, ISIS 569216, ISIS 569221, ISIS 569236, ISIS 579671, ISIS 586124, ISIS 583918, ISIS 584149, ISIS 584163, ISIS 584269, or ISIS 584468.

Certain aspects are directed to an antisense compound targeted to androgen receptor provided herein for use in treating cancer. In certain embodiments, the cancer is AR positive. In certain embodiments, the cancer is prostate cancer, breast cancer, ovarian cancer, bladder cancer or gastric cancer. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of the nucleobase sequence of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence consisting of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175. In certain embodiments, the antisense compound is single-stranded. In certain embodiments, the antisense compound targeted to androgen receptor is ISIS 560131, ISIS 569213, ISIS 569216, ISIS 569221, ISIS 569236, ISIS 579671, ISIS 586124, ISIS 583918, ISIS 584149, ISIS 584163, ISIS 584269, or ISIS 584468.

Certain aspects are directed to use of an antisense compound targeted to androgen receptor provided herein for the manufacture of a medicament for treating cancer. In certain embodiments, the cancer is AR positive. In certain embodi-

ments, the cancer is prostate cancer, breast cancer, ovarian cancer, bladder cancer or gastric cancer. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of the nucleobase sequence of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence consisting of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175. In certain embodiments, the antisense compound is single-stranded. In certain embodiments, the antisense compound targeted to androgen receptor is ISIS 560131, ISIS 569213, ISIS 569216, ISIS 569221, ISIS 569236, ISIS 579671, ISIS 586124, ISIS 583918, ISIS 584149, ISIS 584163, ISIS 584269, or ISIS 584468.

Certain aspects of the invention are directed to the use of an antisense compound targeted to human androgen receptor (AR) as described herein, for treating a cancer patient whose cancer has become resistant to treatment with an anti-androgenic agent (e.g. compound or drug). In certain embodiments, said cancer is prostate cancer. In certain embodiments, said patient is one that has, or whose cancer has, developed resistance to treatment with an agent selected from: MDV3100, ARN-059, ODM-201, abiraterone acetate, TOK001, TAK700 and VT464. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of the nucleobase sequence of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence consisting of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175. In certain embodiments, the antisense compound targets AR within exon 1, for example within nucleotide regions 2863-5593 (exon 1) or 27672-27853 (exon 1B) of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to exon 1 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 2957-2972, 3079-3094, 3099-3114, 3109-3124, 3113-3128, 3120-3135, 3133-3148, 3224-3239, 3226-3241, 3351-3366, 3353-3368, 3361-3376, 3388-3403, 3513-3528, 3517-3532, 3519-3534, 3641-3656, 3735-3750, 3764-3779, 3768-3783, 3798-3813, 3799-3814, 3851-3866, 3870-3885, 3874-3889, 3876-3891, 3878-3893, 3884-3899, 3886-3901, 3888-3903, 3901-3916, 3956-3971, 3962-3977, 3964-3979, 3967-3982, 4019-4034, 4038-4053, 4049-4064, 4056-4071, 4059-4074, 4062-4077, 4066-4081, 4070-4085, 4101-4116, 4103-4118, 4105-4120,

4109-4124, 4305-4320, 4405-4420, 4532-4547, 4534-4549, 4537-4552, 4539-4554, 4555-4570, 4571-4586, 4573-4588, 4578-4593, 4597-4612, 4632-4647, 4655-4670, 4656-4671, 4662-4677, 4699-4714, 4747-4762, 4750-4765, 4752-4767, 4754-4769, 4755-4770, 4769-4784, 4798-4813, 4804-4819, 4807-4822, 4833-4848, 4837-4852, 4839-4854, 4865-4880, 4868-4883, 4872-4887, 4874-4889, 4876-4891, 4887-4902, 4889-4904, 4916-4931, 4918-4933, 4938-4953, 4942-4957, 4944-4959, 4951-4966, 5050-5065, 5052-5067, 5054-5069, 5056-5071, 5060-5075, 5061-5076, 5062-5077, 5133-5148, 5141-5156, 5155-5170, 5265-5280, 5293-5308, 5308-5323, 5392-5407, 5448-5463, 5469-5484, 5481-5496, 5483-5498, 5486-5501, 5488-5503, 5494-5509, or 5521-5536. In certain embodiments, an antisense compound provided herein targets AR within exon 2, for example within nucleotide regions 102087-102238 (exon 2) or 139551-139834 (exon 2c) of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to exon 2 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 102155-102170, 102156-102171, 139682-139697, 139762-139777, or 139782-139797. In certain embodiments, an antisense compound provided herein targets AR within exon 3, for example within nucleotide regions 144841-144957 (exon 3), 148380-148594 (exon 3b), or 153504-154908 (exon 3d) of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to exon 3 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 144856-144871, 144938-144953, 148406-148421, 148443-148458, or 148520-148535. In certain embodiments, an antisense compound provided herein targets AR within intron 1, for example within nucleotide regions 5594-27671 or 27854-102086 of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to intron 1 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 5666-5681, 6222-6237, 6701-6716, 7543-7558, 8471-8486, 8638-8653, 9464-9479, 10217-10232, 10250-10265, 10865-10880, 11197-11212, 11855-11870, 13189-13204, 13321-13336, 13346-13361, 16555-16570, 16793-16808, 16968-16983, 17206-17221, 18865-18880, 29329-29344, 32290-32305, 33315-33330, 39055-39070, 40615-40630, 42017-42032, 56050-56065, 58719-58734, 58720-58739, 58720-58735, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58724-58739, 58725-58740, 58725-58740, 58725-58740, 58750-58769, 58750-58765, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 60902-60917, or 67454-67469. In certain embodiments, an antisense compound provided herein targets AR within intron 2, for example within nucleotide regions 102239-139550 or 139835-144840 of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to intron 2 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 114874-114889, 115272-115287, 115365-115380, or 134971-134986. In certain embodiments, the antisense compound is single-stranded. In certain embodiments, the antisense compound targeted to androgen receptor is ISIS 560131, ISIS 569213, ISIS 569216, ISIS 569221, ISIS 569236, ISIS 579671, ISIS 586124, ISIS 583918, ISIS 584149, ISIS 584163, ISIS 584269, or ISIS 584468.

By resistant to treatment with a particular agent (e.g. compound or drug) is meant that the agent is less or no longer effective in halting the growth or spread of the cancer and so the patient, or their cancer, has become less responsive or sensitive to it over time. Typically such patient would be classed as resistant to said agent and would no longer be

treated with such agent. A subject having prostate cancer resistant to an agent selected from: MDV3100, ARN-059, ODM-201, abiraterone acetate, TOK001, TAK700 and VT464 can include, for example, a patient who previously received said agent but whose prostate cancer has become less sensitive or responsive to a agent. For example, prostate cancer resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone acetate, TOK001, TAK700 and VT464, can include prostate cancer that has increased in tumor volume, metastasis, or progression despite treatment with the agent. In certain embodiments, prostate cancer resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone acetate, TOK001, TAK700 and VT464, can include prostate cancer that is refractory to the agent and is not decreasing in tumor volume, metastasis, or progression despite treatment. Several embodiments relate to a method of treating prostate cancer resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone acetate, TOK001, TAK700 and VT464, in a subject comprising identifying the subject as having prostate cancer resistant to the agent and administering to the subject an antisense compound targeted to human androgen receptor (AR) upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain, as described herein. Several embodiments relate to a method of treating prostate cancer resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone acetate, TOK001, TAK700 and VT464, in a subject comprising administering to a subject identified or diagnosed as having prostate cancer resistant to said anti-androgenic agent an antisense compound targeted to human androgen receptor (AR) upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain, as described herein. In certain embodiments, prostate cancer cells resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone acetate, TOK001, TAK700 and VT464, preferentially expresses an AR splicing variant over full-length AR.

Certain aspects of the invention are directed to a method of treating a patient suffering from prostate cancer wherein the patient has, or their cancer has, developed or become resistant to treatment with an anti-androgenic agent (compound or drug) comprising administering to said patient an antisense compound targeted to human androgen receptor (AR) as described herein. In certain embodiments, said patient is one that has developed resistance to treatment with an agent selected from: MDV3100, ARN-059, ODM-201, abiraterone acetate, TOK001, TAK700 and VT464. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of the nucleobase sequence of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence consisting of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175. In certain embodiments, the antisense compound is single-stranded. In certain embodiments, the


antisense compound targeted to androgen receptor is ISIS 560131, ISIS 569213, ISIS 569216, ISIS 569221, ISIS 569236, ISIS 579671, ISIS 586124, ISIS 583918, ISIS 584149, ISIS 584163, ISIS 584269, or ISIS 584468.

A prostate cancer that has developed or become resistant to treatment with an anti-androgenic agent is referred to as castrate-resistant prostate cancer (CRPC). Thus, in several embodiments, a prostate cancer cell resistant to an anti-androgenic agent, such as MDV3100, was previously exposed to the inhibitor and has become less responsive or sensitive to it over time. For example, MDV3100 might initially inhibit prostate cancer cell growth or proliferation in the patient, but over time such inhibitory effect may be diminished when the cells become resistant to the inhibitor.

Certain aspects of the invention are directed to the use of an antisense compound targeted to androgen receptor provided herein for the manufacture of a medicament for treating cancer in a patient whose cancer has become become resistant to treatment with an anti-androgenic agent (compound or drug). In certain embodiments the cancer is prostate cancer. In certain embodiments, said patient is one that has, or whose cancer has, developed resistance to treatment with an agent selected from: MDV3100, ARN-059, ODM-201, abiraterone acetate, TOK001, TAK700 and VT464. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of the nucleobase sequence of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence consisting of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175. In certain embodiments, the antisense compound is single-stranded. In certain embodiments, the antisense compound targeted to androgen receptor is ISIS 560131, ISIS 569213, ISIS 569216, ISIS 569221, ISIS 569236, ISIS 579671, ISIS 586124, ISIS 583918, ISIS 584149, ISIS 584163, ISIS 584269, or ISIS 584468.

Enzalutamide:


MDV3100, also known as enzalutamide (Xtandi™) and by the IUPAC name 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide, is an androgen receptor ligand binding inhibitor belonging to the diarylhydantoin class of androgen receptor inhibitors represented by Formula XI. MDV3100 has the following chemical formula:



31

MDV3100 and additional diarylhydantoin androgen receptor inhibitors suitable for use in certain embodiments provided herein are described in U.S. Pat. No. 7,709,517, US Patent Application Publication No. US20100172975 and US Patent Application Publication No. US20100210665, which are incorporated herein by reference in their entireties.


ARN-509:



The compound of Formula XII, also known as ARN-509 and by the IUPAC name 4-(7-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-6,8-dioxo-5,7-diazaspiro[3.4]octan-5-yl)-2-fluoro-N-methylbenzamide, is an androgen receptor ligand binding inhibitor. ARN-509 and additional androgen receptor inhibitors suitable for use in certain embodiments provided herein are described in WO 2007126765, WO 2008119015 and US Patent Application Publication No. 2013/0116258, which are incorporated herein by reference in their entirety.

Abiraterone Acetate

The compound of Formula XIII, which is also known as Abiraterone acetate and ZYTIG-A® and by the IUPAC name [(3S,8R,9S,10R,13S,14S)-10,13-dimethyl-17-(3-pyridyl)-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-yl]acetate, is an androgen biosynthesis inhibitor and has the following chemical formula:




The structure and synthesis of Abiraterone acetate is described in Potter et al., Journal of Medicinal Chemistry (38(13), 2463-71, 1995), which is incorporated herein by reference in its entirety.

Galeterone:

The compound of Formula XIV, which is also known as TOK-001 and Galeterone, and by the IUPAC name (3S,10R,13S)-17-(1H-benzo[d]imidazol-1-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]

32


phenanthren-3-ol, has the following chemical formula:



The structure and synthesis of TOK-001 is described in Handratta et al., (Journal of Medicinal Chemistry (2005), 48(8), 2972-84, 2005), which is incorporated herein by reference in its entirety:

Orteronel:

The compound of Formula XV, which is also known as TAK-700 and Orteronel and by the IUPAC name 6-[7(S)-hydroxy-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-7-yl]-N-methylnaphthalene-2-carboxamide, is an androgen biosynthesis inhibitor and has the following chemical formula:



The structure and synthesis of TAK-700 is described in Kaku et al., Bioorganic and Medicinal Chemistry (19(21), 6383-99, 2011).

Yin et al., (Int. J. Mol. Sci., 14(7):13958-13978, 2013) discusses recent progress with various pharmaceutical therapies, including ODM-21, VT464, ARN509, TAK700 and TOK-001, for castration-resistant prostate cancer.

Certain Combinations and Combination Therapies

In certain embodiments, a first agent comprising the compound described herein is co-administered with one or more secondary agents. In certain embodiments, such second agents are designed to treat the same disease, disorder, or condition as the first agent described herein. In certain embodiments, such second agents are designed to treat a different disease, disorder, or condition as the first agent described herein. In certain embodiments, a first agent is designed to treat an undesired side effect of a second agent. In certain embodiments, second agents are co-administered with the first agent to treat an undesired effect of the first agent. In certain embodiments, such second agents are designed to treat an undesired side effect of one or more pharmaceutical compositions as described herein. In certain embodiments, second agents are co-administered with the

first agent to produce a combinational effect. In certain embodiments, second agents are co-administered with the first agent to produce a synergistic effect. In certain embodiments, the co-administration of the first and second agents permits use of lower dosages than would be required to achieve a therapeutic or prophylactic effect if the agents were administered as independent therapy.

In certain embodiments, one or more compounds or compositions provided herein are co-administered with one or more anti-androgenic agents. In certain embodiments, one or more compounds or compositions provided herein and one or more anti-androgenic agents, are administered at different times. In certain embodiments, one or more compounds or compositions provided herein and one or more anti-androgenic agents, are prepared together in a single formulation. In certain embodiments, one or more compounds or compositions provided herein and one or more anti-androgenic agents, are prepared separately. In certain embodiments, an anti-androgenic agent is selected from MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464.


Certain aspects of the invention are directed to the use of an antisense compound targeted to human androgen receptor (AR) as described herein in combination with an anti-androgenic agent. In particular embodiments such use is in a method of treating a patient suffering from cancer or in the manufacture of a medicament for treating cancer. In certain embodiments the cancer is selected from: prostate cancer, breast cancer, ovarian cancer, bladder cancer or gastric cancer. Particular classes of anti-androgenic agents are the second generation anti-hormonal agents such as: enzalutamide (MDV3100), ARN-059, ODM-201, abiraterone acetate, Galeterone (TOK001), orteronel (TAK700) and VT464 (see Yin et al. supra).

Certain aspects are drawn to a combination of an antisense compound targeted to human androgen receptor (AR) as described herein and an anti-androgenic agent, such as a second generation anti-hormonal agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464.


In certain embodiments, such a combination of an antisense compound targeted to androgen receptor (AR) as described herein and an anti-androgenic agent, such as a second generation anti-hormonal agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, is useful for inhibiting cancer cell growth or proliferation and/or treating cancer. In certain embodiments the cancer is selected from: prostate cancer, breast cancer, ovarian cancer, bladder cancer or gastric cancer. In certain embodiments the cancer is prostate cancer. In certain embodiments the cancer is breast cancer. In certain embodiments, an antisense compound targeted to AR as described herein and an anti-androgenic agent, such as a second generation anti-hormonal agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, synergize in combination to inhibit growth or proliferation of a cancer cell. In several embodiments, the cancer cell is a prostate cancer cell which is or has become castration-resistant. In various embodiments, the cancer cell is a prostate cancer cell which is or has become resistant to a second generation anti-hormonal agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or

20 contiguous nucleobases of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of the nucleobase sequence of any of SEQ ID NOs: 12-179. In certain embodiments, the antisense compound targeted to androgen receptor comprises a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence consisting of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175. In certain embodiments, the antisense compound targeted to androgen receptor is ISIS 560131, ISIS 569213, ISIS 569216, ISIS 569221, ISIS 569236, ISIS 579671, ISIS 586124, ISIS 583918, ISIS 584149, ISIS 584163, ISIS 584269, or ISIS 584468.

Several embodiments are drawn to a combination of an antisense compound targeted to human androgen receptor (AR) and a diarylhydantoin AR inhibitor of Formula XI, such as MDV3100. In several embodiments, a diarylhydantoin Androgen Receptor (AR) inhibitor is a compound of Formula XVI:



wherein X is selected from the group consisting of trifluoromethyl and iodo, wherein W is selected from the group consisting of O and NR5, wherein R5 is selected from the group consisting of H, methyl, and



wherein D is S or O and E is N or O and G is alkyl, aryl, substituted alkyl or substituted aryl; or D is S or a and E-G together are C1-C4 lower alkyl,

wherein R1 and R2 together comprise eight or fewer carbon atoms and are selected from the group consisting of alkyl, substituted alkyl including haloalkyl, and, together with the carbon to which they are linked, a cycloalkyl or substituted cycloalkyl group,


wherein R3 is selected from the group consisting of hydrogen, halogen, methyl, C1-C4 alkoxy, formyl, haloacetoxy, trifluoromethyl, cyano, nitro, hydroxyl, phenyl, amino, methylcarbamoyl, methoxycarbonyl, acetamido, methane-sulfonamino, methanesulfonyl, 4-methanesulfonyl-1-piperazinyl, piperazinyl, and C1-C6 alkyl or alkenyl optionally substituted with hydroxyl, methoxycarbonyl, cyano, amino, amido, nitro, carbamoyl, or substituted carbamoyl including methylcarbamoyl, dimethylcarbamoyl, and hydroxyethylcarbamoyl,

wherein R4 is selected from the group consisting of hydrogen, halogen, alkyl, and haloalkyl, and

35

wherein R3 is not methylaminomethyl or dimethylaminomethyl.

R5 may be



In certain embodiments, such a combination of an antisense compound targeted to androgen receptor (AR) and a diarylhydantoin AR inhibitor of Formula XVI, such as MDV3100, is useful for inhibiting prostate cancer cell growth or proliferation and/or treating prostate cancer. In certain embodiments, an antisense compound targeted to AR and a diarylhydantoin AR inhibitor of Formula XVI, such as MDV3100, synergize in combination to inhibit growth or proliferation of a prostate cancer cell. In several embodiments, the prostate cancer cell is castration-resistant. In various embodiments, the prostate cancer cell is resistant to a diarylhydantoin AR inhibitor of Formula XVI, such as MDV3100. In certain embodiments, the prostate cancer cell or castration-resistant prostate cancer cell preferentially expresses an AR splicing variant over full-length AR. In certain embodiments the antisense compound targeted to AR as described herein and the other anti-androgenic agent are used in combination treatment by administering the two agents simultaneously, separately or sequentially. In certain embodiments the two agents are formulated as a fixed dose combination product. In other embodiments the two agents are provided to the patient as separate units which can then either be taken simultaneously or serially (sequentially).

In certain embodiments, antisense compounds useful for inhibiting prostate cancer cell and/or castration-resistant prostate cancer cell growth or proliferation in combination with another anti-androgenic agent, such as a second generation anti-hormonal agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, target human androgen receptor upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain. In certain embodiments, an antisense compound provided herein targets AR within exon 1, exon 2, exon 3, intron 1, or intron 2 as described herein.

In certain embodiments, an antisense compound provided herein targets an AR splicing variant that includes exon 1 encoding the N-terminal domain and exons 2 and 3 encoding the DNA binding domain, but does not include at least a portion of exon 4 encoding the short hinge region or at least a portion of exons 4-8 encoding the ligand binding domain. An example of such an AR splicing variant includes, but is not limited to, AR-V7, which contains exons 1-3 but lacks

36

exons 4-8. Additional examples of such AR splicing variants include, for example, AR3, AR4, AR4b, AR5, and AR6 (SEQ ID NOs: 4-8, respectively). In certain embodiments, the prostate cancer cell, which may be castration-resistant, preferentially expresses an AR splicing variant over full-length AR. In particular embodiments the prostate cancer cell is castration-resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464. In certain embodiments, an antisense compound targeted to AR upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain is capable of inhibiting growth or proliferation of a prostate cancer cell, including a castration-resistant prostate cancer cell, in combination with an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, to a greater extent than an antisense compound targeted to the ligand binding domain, such as EZN-4176, which is targeted to exon 4 and corresponds to SEQ ID NO: 58 described in U.S. Pat. No. 7,737,125, in combination with the same anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464. In certain embodiments, the combination of an antisense compound as described herein and the anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, provides a synergistic (e.g. greater-than-additive) effect in inhibiting the growth or proliferation of a prostate cancer cell, such as a castration-resistant prostate cancer cell, compared to the antisense compound alone or the anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464 alone. Accordingly, in certain embodiments the amounts of either or both of the antisense compound and/or anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, when used in combination can be less than the corresponding amount of either the antisense compound alone or the anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, alone necessary to achieve an equivalent level of prostate cancer cell growth or proliferation inhibition.

In certain embodiments, an antisense compound provided herein useful for inhibiting prostate cancer cell and/or castration-resistant prostate cancer cell growth or proliferation in combination with an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, targets an AR splicing variant that has a functional DNA binding domain, but not a functional ligand binding domain. It will be understood that in certain embodiments an antisense compound can target an AR splicing variant that includes the entire or at least a functional portion of exon 1 encoding the N-terminal domain and the entire or at least a functional portion of exons 2 and 3 encoding the DNA binding domain, but does not include at least a functional portion of exon 4 encoding the short hinge region or at least a functional portion of exons 4-8 encoding the ligand binding domain. It is contemplated that certain AR splicing variants targeted by the antisense compounds provided herein substantially consisting of exons 1-3 may also include a non-functional portion of nucleic acid sequence from a genomic region or exons 4-8. It is contemplated that the splicing process may give rise to such AR splicing variants that retain DNA binding function but not ligand binding function. In certain embodiments, the prostate cancer cell, which may be castrate-resistant, preferentially expresses an AR splicing variant over full-length AR.

In certain embodiments the prostate cancer cell is castrate-resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464. In certain embodiments, an antisense compound provided herein targets AR within exon 1, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain. In certain embodiments, an antisense compound provided herein targets AR within exon 1, exon 2, exon 3, intron 1, or intron 2 as described herein.

In certain embodiments, an antisense compound targeted to an AR splicing variant that has a functional DNA binding domain, but not a functional ligand binding domain, is capable of inhibiting growth or proliferation of a prostate cancer cell, including a castration-resistant prostate cancer cell, in combination with an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, to a greater extent than an antisense compound targeted to the ligand binding domain, such as EZN-4176, which is targeted to exon 4 and corresponds to SEQ ID NO: 58 described in U.S. Pat. No. 7,737,125, in combination with a the same anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464. In certain embodiments, the combination of an antisense compound and anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, provides a synergistic (e.g. greater-than-additive) effect in inhibiting the growth or proliferation of a prostate cancer cell, such as a castration-resistant prostate cancer cell, compared to the antisense compound alone or the anti-androgenic agent alone. Accordingly, in certain embodiments the amounts of either or both of the antisense compound and/or anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, when used in combination can be less than the corresponding amount of either the antisense compound alone or anti-androgenic agent, alone necessary to achieve an equivalent level of prostate cancer cell growth or proliferation inhibition.

In certain embodiments, an antisense compound provided herein useful for inhibiting prostate cancer cell and/or castration-resistant prostate cancer cell growth or proliferation in combination with a anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464 is capable of reducing expression of both full-length AR and an AR splicing variant that includes exon 1 encoding the N-terminal domain and exons 2 and 3 encoding the DNA binding domain, but does not include at least a portion of exon 4 encoding the short hinge region or at least a portion of any one of exons 4-8 encoding the ligand binding domain. In certain embodiments, such an antisense compound targets human androgen receptor upstream of the 3' end of exon 3. In certain embodiments, an antisense compound provided herein targets AR within exon 1, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain.

In certain embodiments, there is provided a combination of an antisense compound targeted to human androgen receptor (AR) as described herein and an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, wherein the antisense compound comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous nucleobases of any

of SEQ ID NOs: 12-179. In certain embodiments, there is provided a combination of an antisense compound targeted to human androgen receptor (AR) and an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, wherein the antisense compound comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising any of SEQ ID NOs: 12-179. In certain embodiments, there is provided a combination of an antisense compound targeted to human androgen receptor (AR) and an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, wherein the antisense compound comprises a modified oligonucleotide consisting of the nucleobase sequence of any of SEQ ID NOs: 12-179. In certain embodiments, there is provided a combination of an antisense compound targeted to human androgen receptor (AR) and a diarylhydantoin AR inhibitor of Formula XI, such as MDV3100, wherein the antisense compound comprises a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence consisting of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175. In certain embodiments, there is provided a combination of an antisense compound targeted to human androgen receptor (AR) and a diarylhydantoin AR inhibitor of Formula XI, such as MDV3100, wherein the antisense compound targeted to androgen receptor is ISIS 560131, ISIS 569213, ISIS 569216, ISIS 569221, ISIS 569236, ISIS 579671, ISIS 586124, ISIS 583918, ISIS 584149, ISIS 584163, ISIS 584269, or ISIS 584468.

Several embodiments are drawn to a method of inhibiting prostate cancer cell growth or proliferation comprising contacting the prostate cancer cell with an antisense compound targeted to human androgen receptor (AR) and an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464. In certain embodiments, the antisense compound and an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, synergize in combination to inhibit the growth or proliferation of the prostate cancer cell. In several embodiments, the prostate cancer cell is castration-resistant. In various embodiments, the prostate cancer cell is castration-resistant by being resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464. In certain embodiments, the prostate cancer cell or castration-resistant prostate cancer cell preferentially expresses an AR splicing variant over full-length AR.

In certain aspects of any of the foregoing embodiments, antisense compounds useful for inhibiting prostate cancer cell growth or proliferation in combination with a diarylhydantoin AR inhibitor of Formula XVI, such as MDV3100, can target (i) human androgen receptor upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain or (ii) an AR splicing variant that has a functional DNA binding domain, but not a functional ligand binding domain; and/or is capable of (i) reducing expression of both full-length AR and an AR splicing variant that includes exon 1 encoding the N-terminal domain and exons 2 and 3 encoding the DNA binding domain, but does not include at least a portion of exon 4 encoding the short hinge region or at least a portion of any one of exons 4-8 encoding the ligand binding domain; with the proviso that the antisense compounds do not have a nucleobase sequence consisting of any of SEQ ID NOs: 194-215 identified in Table A below.

TABLE A

SEQ ID NO:	Sequence
194	GAGAACCATCCTCACC
195	GGACCAGGTAGCCTGT
196	CCCTGGACTCAGATG
197	GCACAAGGAGTGGGAC
198	GCTGTGAAGAGAGTGT
199	TTTGACACAAGTGGGA
200	GTGACACCCAGAAGCT
201	CATCCCTGCTTCATAA
202	TGGGGAGAACCATCCTCACCTGC
203	TCCAGGACCAGGTAGCCTGTGGGG
204	TGTTCCCTGGACTCAGATGCTCC
205	TGGGGCACAAGGAGTGGGACGCAC
206	TTCGGCTGTGAAGAGAGTGTGCCA
207	CGCTTTTGACACAAGTGGGACTGG
208	CATAGTGACACCCAGAAGCTTCAT
209	GAGTCATCCCTGCTTCATAACATT
210	CTGTGAAGAGAGTG
211	TGTGAAGAGAGT
212	TTGACACAAGTGGG
213	TGACACAAGTGG
214	TGACACCCAGAAGC
215	GACACCCAGAAG

In certain aspects of any of the foregoing embodiments, antisense compounds useful for inhibiting growth or proliferation of a prostate cancer cell resistant to anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, can target (i) human androgen receptor upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain or (ii) an AR splicing variant that has a functional DNA binding domain, but not a functional ligand binding domain; and/or is capable of (i) reducing expression of both full-length AR and an AR splicing variant that includes exon 1 encoding the N-terminal domain and exons 2 and 3 encoding the DNA binding domain, but does not include at least a portion of exon 4 encoding the short hinge region or at least a portion of any one of exons 4-8 encoding the ligand binding domain; or (ii) inhibiting growth or proliferation of the resistant prostate cancer cell to a greater extent than an antisense compound targeted to the ligand binding domain, such as EZN-4176; with the proviso that the antisense compounds do not have a nucleobase sequence consisting of any of SEQ ID NOs: 194-215 described in U.S. Pat. No. 7,737,125 as SEQ ID NOs: 2-9, 49-50, 52-53, 55-56, and 86-93 (herein incorporated by reference), and identified in Table A.

Certain aspects are directed to methods of treating breast cancer and methods of inhibiting breast cancer cell growth or proliferation with an antisense oligonucleotide targeted to human androgen receptor (AR) as described herein. In

certain embodiments, the breast cancer has one or more of the following characteristics: Androgen Receptor positive, dependent on androgen for growth, Estrogen Receptor (ER) negative, independent of estrogen for growth, Progesterone Receptor (PR) negative, independent of progesterone for growth, or Her2/neu negative. In certain embodiments, the breast cancer or breast cancer cell is apocrine.

Certain embodiments are drawn to a method of treating breast cancer in a subject comprising administering to the subject an antisense compound targeted to human androgen receptor (AR). Certain embodiments are drawn to a method of treating breast cancer in a subject comprising identifying a subject having breast cancer and administering to the subject an antisense compound targeted to human androgen receptor (AR), thereby treating the subject's breast cancer. Certain embodiments are directed to a method of inhibiting growth or proliferation of a breast cancer cell comprising contacting the breast cancer cell with an antisense compound targeted to human androgen receptor (AR). Certain embodiments relate to a method of inhibiting AR expression in a subject having or at risk of having breast cancer comprising identifying a subject breast cancer, and administering to the subject an antisense compound targeted to human AR, wherein the antisense compound inhibits AR expression in the subject.

In certain embodiments, the breast cancer or breast cancer cell has one or more of the following characteristics: Androgen Receptor positive, dependent on androgen for growth, Estrogen Receptor (ER) negative, independent of estrogen for growth, Progesterone Receptor (PR) negative, independent of progesterone for growth, or Her2/neu negative. In certain embodiments, the breast cancer or breast cancer cell is ER, PR, and HER2 triple negative and AR positive (ER-, PR-, HER2-, AR+). In certain embodiments, the breast cancer or breast cancer cell is ER negative and AR positive (ER-, AR+). In certain embodiments, the breast cancer or breast cancer cell is ER positive and AR positive (ER+, AR+).

In certain embodiments, the breast cancer or breast cancer cell is apocrine. Apocrine breast cancers are often "triple negative", meaning that the cells do not express ER, PR, or HER2 receptors, and usually, but not necessarily, AR positive. In certain embodiments, an apocrine breast cancer or breast cancer cell is ER, PR, and HER2 triple negative and AR positive (ER-, PR-, HER2-, AR+). In certain embodiments, an apocrine breast cancer or breast cancer cell is ER negative and AR positive (ER-, AR+). In certain embodiments, an apocrine breast cancer or breast cancer cell originates from the sweat gland of the breast. In certain embodiments, an apocrine breast cancer or breast cancer cell is a ductal cancer or cancer cell of the breast. In certain embodiments, an apocrine breast cancer can have any one or more of the following features: a large amount of eosinophilic granular cytoplasm, well-defined margins, large vesicular nuclei, a nuclear to cytoplasmic ratio of about 1:2, and/or accumulations of secreted granules in the apical cytoplasm known as apical snouts.

In certain embodiments, the breast cancer or breast cancer cell is an ER negative and AR positive (ER-, AR+) molecular apocrine breast cancer or breast cancer cell. In certain aspects, an ER negative and AR positive (ER-, AR+) molecular apocrine breast cancer or breast cancer cell can further be PR positive, PR negative, HER2 negative, or HER2 positive.

Breast cancer can be identified as positive or negative with respect to hormone receptors, such as ER, PR, or HER2 by standard histological techniques. For example, histologi-

cal breast cancer samples can be classified as “triple negative” (ER-, PR-, HER2-) when less than 1% of cells demonstrate nuclear staining for estrogen and progesterone receptors, and immunohistochemical staining for HER2 shows a 0, 1-fold, or a 2-fold positive score and a FISH ratio (HER2 gene signals to chromosome 17 signals) of less than 1.8 according to the relevant ASCO and CAP guidelines. (Meyer, P. et al., PLoS ONE 7(5): e38361 (2012)).

In certain embodiments, an antisense compound useful for treating breast cancer or inhibiting growth or proliferation of a breast cancer cell target provided herein targets AR within exon 1, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain. In certain embodiments, an antisense compound provided herein targets AR within exon 1, for example within nucleotide regions 2863-5593 (exon 1) or 27672-27853 (exon 1B) of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to exon 1 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 3353-3368, 3361-3376, 3519-3534, 3735-3750, 3768-3783, 3798-3813, 3799-3814, 3851-3866, 3870-3885, 3874-3889, 3888-3903, 4047-4062, 4062-4077, 4109-4124, 4534-4549, 4537-4552, 4555-4570, 4571-4586, 4573-4588, 4578-4593, 4655-4670, 4750-4765, 4752-4767, 4833-4848, 4837-4852, 4839-4854, 4865-4880, 4872-4887, 4874-4889, 4876-4891, 4916-4931, 4918-4933, 5052-5067, 5054-5069, 5060-5075, 5061-5076, 5061-5076, 5062-5077, 5155-5170, 5265-5280, 5293-5308, 5392-5407, 5448-5463, 5483-5498, 5486-5501, or 5494-5509.

In certain embodiments, an antisense compound provided herein targets AR within exon 2, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain. In certain embodiments, an antisense compound useful for treating breast cancer or inhibiting growth or proliferation of a breast cancer cell target provided herein targets AR within exon 2, for example within nucleotide regions 102087-102238 (exon 2) or 139551-139834 (exon 2c) of SEQ ID NO: 1. In certain embodiments, an antisense compound provided herein targeted to exon 2 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 102155-102170 or 102156-102171.

In certain aspects, an antisense compound useful for treating breast cancer or inhibiting growth or proliferation of a breast cancer cell provided herein targets AR within intron 1, which is upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain. In certain embodiments, an antisense compound provided herein targets AR within intron 1, for example within nucleotide regions 5594-27671 or 27854-102086 of SEQ ID NO: 1. In certain aspects, an antisense compound provided herein targeted to intron 1 of AR is complementary within any of the following nucleotide regions of SEQ ID NO: 1: 5666-5681, 6701-6716, 7543-7558, 8471-8486, 8638-8653, 9464-9479, 10865-10880, 11197-11212, 11855-11870, 13189-13204, 13321-13336, 13346-13361, 16793-16808, 16968-16983, 17206-17221, 18865-18880, 32290-32305, 33315-33330, 39055-39070, 40615-40630, 42017-42032, 56050-56065, 58719-58734, 58720-58735, 58721-58736, 58722-58737, 58723-58738, 58725-58740, 58750-58765, 58751-58766, 58752-58767, 58753-58768, 58754-58769, or 58755-58770.

In certain aspects of any of the foregoing embodiments, antisense compounds useful for treating breast cancer or inhibiting growth or proliferation of a breast cancer cell target human androgen receptor upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain. In certain embodiments, antisense compounds provided herein, including but not limited to those that target human andro-

gen receptor upstream of the 3' end of exon 3 and/or upstream of the ligand binding domain, can treat breast cancer or inhibiting growth or proliferation of a breast cancer cell to a greater extent than an antisense compound targeted to the ligand binding domain, such as EZN-4176; with the proviso that the antisense compounds do not have a nucleobase sequence consisting of any of SEQ ID NOs: 194-215 described in U.S. Pat. No. 7,737,125 as SEQ ID NOs: 2-9, 49-50, 52-53, 55-56, and 86-93 (herein incorporated by reference), and identified in Table A.

Antisense Compounds

Oligomeric compounds include, but are not limited to, oligonucleotides, oligonucleosides, oligonucleotide analogs, oligonucleotide mimetics, antisense compounds, antisense oligonucleotides, and siRNAs. An oligomeric compound may be “antisense” to a target nucleic acid, meaning that is is capable of undergoing hybridization to a target nucleic acid through hydrogen bonding.

In certain embodiments, an antisense compound has a nucleobase sequence that, when written in the 5' to 3' direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted. In certain such embodiments, an antisense oligonucleotide has a nucleobase sequence that, when written in the 5' to 3' direction, comprises the reverse complement of the target segment of a target nucleic acid to which it is targeted.

In certain embodiments, an antisense compound is 10-30 subunits in length. In certain embodiments, an antisense compound is 12 to 30 subunits in length. In certain embodiments, an antisense compound is 12 to 22 subunits in length. In certain embodiments, an antisense compound is 14 to 30 subunits in length. In certain embodiments, an antisense compound is 14 to 20 subunits in length. In certain embodiments, an antisense compound is 15 to 30 subunits in length. In certain embodiments, an antisense compound is 15 to 20 subunits in length. In certain embodiments, an antisense compound is 16 to 30 subunits in length. In certain embodiments, an antisense compound is 16 to 20 subunits in length. In certain embodiments, an antisense compound is 17 to 30 subunits in length. In certain embodiments, an antisense compound is 17 to 20 subunits in length. In certain embodiments, an antisense compound is 18 to 30 subunits in length. In certain embodiments, an antisense compound is 18 to 21 subunits in length. In certain embodiments, an antisense compound is 18 to 20 subunits in length. In certain embodiments, an antisense compound is 20 to 30 subunits in length. In other words, such antisense compounds are from 12 to 30 linked subunits, 14 to 30 linked subunits, 14 to 20 subunits, 15 to 30 subunits, 15 to 20 subunits, 16 to 30 subunits, 16 to 20 subunits, 17 to 30 subunits, 17 to 20 subunits, 18 to 30 subunits, 18 to 20 subunits, 18 to 21 subunits, 20 to 30 subunits, or 12 to 22 linked subunits, respectively. In certain embodiments, an antisense compound is 14 subunits in length. In certain embodiments, an antisense compound is 16 subunits in length. In certain embodiments, an antisense compound is 17 subunits in length. In certain embodiments, an antisense compound is 18 subunits in length. In certain embodiments, an antisense compound is 20 subunits in length. In other embodiments, the antisense compound is 8 to 80, 12 to 50, 13 to 30, 13 to 50, 14 to 30, 14 to 50, 15 to 30, 15 to 50, 16 to 30, 16 to 50, 17 to 30, 17 to 50, 18 to 22, 18 to 24, 18 to 30, 18 to 50, 19 to 22, 19 to 30, 19 to 50, or 20 to 30 linked subunits. In certain such embodiments, the antisense compounds are 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65,

66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, or 80 linked subunits in length, or a range defined by any two of the above values. In some embodiments the antisense compound is an antisense oligonucleotide, and the linked subunits are nucleotides.

In certain embodiments antisense oligonucleotides may be shortened or truncated. For example, a single subunit may be deleted from the 5' end (5' truncation), or alternatively from the 3' end (3' truncation). A shortened or truncated antisense compound targeted to an Androgen Receptor nucleic acid may have two subunits deleted from the 5' end, or alternatively may have two subunits deleted from the 3' end, of the antisense compound. Alternatively, the deleted nucleosides may be dispersed throughout the antisense compound, for example, in an antisense compound having one nucleoside deleted from the 5' end and one nucleoside deleted from the 3' end.

When a single additional subunit is present in a lengthened antisense compound, the additional subunit may be located at the 5' or 3' end of the antisense compound. When two or more additional subunits are present, the added subunits may be adjacent to each other, for example, in an antisense compound having two subunits added to the 5' end (5' addition), or alternatively to the 3' end (3' addition), of the antisense compound. Alternatively, the added subunits may be dispersed throughout the antisense compound, for example, in an antisense compound having one subunit added to the 5' end and one subunit added to the 3' end.

It is possible to increase or decrease the length of an antisense compound, such as an antisense oligonucleotide, and/or introduce mismatch bases without eliminating activity. For example, in Woolf et al. (Proc. Natl. Acad. Sci. USA 89:7305-7309, 1992), a series of antisense oligonucleotides 13-25 nucleobases in length were tested for their ability to induce cleavage of a target RNA in an oocyte injection model. Antisense oligonucleotides 25 nucleobases in length with 8 or 11 mismatch bases near the ends of the antisense oligonucleotides were able to direct specific cleavage of the target mRNA, albeit to a lesser extent than the antisense oligonucleotides that contained no mismatches. Similarly, target specific cleavage was achieved using 13 nucleobase antisense oligonucleotides, including those with 1 or 3 mismatches.

Gautschi et al. (J. Natl. Cancer Inst. 93:463-471, March 2001) demonstrated the ability of an oligonucleotide having 100% complementarity to the bcl-2 mRNA and having 3 mismatches to the bcl-xL mRNA to reduce the expression of both bcl-2 and bcl-xL in vitro and in vivo. Furthermore, this oligonucleotide demonstrated potent anti-tumor activity in vivo.

Maier and Dolnick (Nuc. Acid. Res. 16:3341-3358, 1988) tested a series of tandem 14 nucleobase antisense oligonucleotides, and a 28 and 42 nucleobase antisense oligonucleotides comprised of the sequence of two or three of the tandem antisense oligonucleotides, respectively, for their ability to arrest translation of human DHFR in a rabbit reticulocyte assay. Each of the three 14 nucleobase antisense oligonucleotides alone was able to inhibit translation, albeit at a more modest level than the 28 or 42 nucleobase antisense oligonucleotides.

Certain Antisense Compound Motifs and Mechanisms

In certain embodiments, antisense compounds have chemically modified subunits arranged in patterns, or motifs, to confer to the antisense compounds properties such as enhanced inhibitory activity, increased binding affinity for a target nucleic acid, or resistance to degradation by in vivo nucleases.

Chimeric antisense compounds typically contain at least one region modified so as to confer increased resistance to nuclease degradation, increased cellular uptake, increased binding affinity for the target nucleic acid, and/or increased inhibitory activity. A second region of a chimeric antisense compound may confer another desired property e.g., serve as a substrate for the cellular endonuclease RNase H, which cleaves the RNA strand of an RNA:DNA duplex.

Antisense activity may result from any mechanism involving the hybridization of the antisense compound (e.g., oligonucleotide) with a target nucleic acid, wherein the hybridization ultimately results in a biological effect. In certain embodiments, the amount and/or activity of the target nucleic acid is modulated. In certain embodiments, the amount and/or activity of the target nucleic acid is reduced. In certain embodiments, hybridization of the antisense compound to the target nucleic acid ultimately results in target nucleic acid degradation. In certain embodiments, hybridization of the antisense compound to the target nucleic acid does not result in target nucleic acid degradation. In certain such embodiments, the presence of the antisense compound hybridized with the target nucleic acid (occupancy) results in a modulation of antisense activity. In certain embodiments, antisense compounds having a particular chemical motif or pattern of chemical modifications are particularly suited to exploit one or more mechanisms. In certain embodiments, antisense compounds function through more than one mechanism and/or through mechanisms that have not been elucidated. Accordingly, the antisense compounds described herein are not limited by particular mechanism.

Antisense mechanisms include, without limitation, RNase H mediated antisense; RNAi mechanisms, which utilize the RISC pathway and include, without limitation, siRNA, ssRNA and microRNA mechanisms; and occupancy based mechanisms. Certain antisense compounds may act through more than one such mechanism and/or through additional mechanisms.

RNase H-Mediated Antisense

In certain embodiments, antisense activity results at least in part from degradation of target RNA by RNase H. RNase H is a cellular endonuclease that cleaves the RNA strand of an RNA:DNA duplex. It is known in the art that single-stranded antisense compounds which are "DNA-like" elicit RNase H activity in mammalian cells. Accordingly, antisense compounds comprising at least a portion of DNA or DNA-like nucleosides may activate RNase H, resulting in cleavage of the target nucleic acid. In certain embodiments, antisense compounds that utilize RNase H comprise one or more modified nucleosides. In certain embodiments, such antisense compounds comprise at least one block of 1-8 modified nucleosides. In certain such embodiments, the modified nucleosides do not support RNase H activity. In certain embodiments, such antisense compounds are gapmers, as described herein. In certain such embodiments, the gap of the gapmer comprises DNA nucleosides. In certain such embodiments, the gap of the gapmer comprises DNA-like nucleosides. In certain such embodiments, the gap of the gapmer comprises DNA nucleosides and DNA-like nucleosides.

Certain antisense compounds having a gapmer motif are considered chimeric antisense compounds. In a gapmer an internal region having a plurality of nucleotides that supports RNaseH cleavage is positioned between external regions having a plurality of nucleotides that are chemically distinct from the nucleosides of the internal region. In the case of an antisense oligonucleotide having a gapmer motif, the gap segment generally serves as the substrate for endo-

nuclease cleavage, while the wing segments comprise modified nucleosides. In certain embodiments, the regions of a gapmer are differentiated by the types of sugar moieties comprising each distinct region. The types of sugar moieties that are used to differentiate the regions of a gapmer may in some embodiments include β -D-ribonucleosides, β -D-deoxyribonucleosides, 2'-modified nucleosides (such 2'-modified nucleosides may include 2'-MOE and 2'-O—CH₃, among others), and bicyclic sugar modified nucleosides (such bicyclic sugar modified nucleosides may include those having a constrained ethyl). In certain embodiments, nucleosides in the wings may include several modified sugar moieties, including, for example 2'-MOE and bicyclic sugar moieties such as constrained ethyl or LNA. In certain embodiments, wings may include several modified and unmodified sugar moieties. In certain embodiments, wings may include various combinations of 2'-MOE nucleosides, bicyclic sugar moieties such as constrained ethyl nucleosides or LNA nucleosides, and 2'-deoxynucleosides.

Each distinct region may comprise uniform sugar moieties, variant, or alternating sugar moieties. The wing-gap-wing motif is frequently described as "X-Y-Z", where "X" represents the length of the 5'-wing, "Y" represents the length of the gap, and "Z" represents the length of the 3'-wing. "X" and "Z" may comprise uniform, variant, or alternating sugar moieties. In certain embodiments, "X" and "Y" may include one or more 2'-deoxynucleosides. "Y" may comprise 2'-deoxynucleosides. As used herein, a gapmer described as "X-Y-Z" has a configuration such that the gap is positioned immediately adjacent to each of the 5'-wing and the 3' wing. Thus, no intervening nucleotides exist between the 5'-wing and gap, or the gap and the 3'-wing. Any of the antisense compounds described herein can have a gapmer motif. In certain embodiments, "X" and "Z" are the same; in other embodiments they are different. In certain embodiments, "Y" is between 8 and 15 nucleosides. X, Y, or Z can be any of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30 or more nucleosides.

In certain embodiments, the antisense compound targeted to an Androgen Receptor nucleic acid has a gapmer motif in which the gap consists of 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 linked nucleosides.

In certain embodiments, the antisense oligonucleotide has a sugar motif described by Formula A as follows: (J)_m-(B)_n-(J)_p-(B)_r-(A)_t-(D)_g-(A)_v-(B)_w-(J)_x-(B)_y-(J)_z wherein:

each A is independently a 2'-substituted nucleoside; each B is independently a bicyclic nucleoside; each J is independently either a 2'-substituted nucleoside or a 2'-deoxynucleoside; each D is a 2'-deoxynucleoside; m is 0-4; n is 0-2; p is 0-2; r is 0-2; t is 0-2; v is 0-2; w is 0-4; x is 0-2; y is 0-2; z is 0-4; g is 6-14; provided that: at least one of m, n, and r is other than 0; at least one of w and y is other than 0; the sum of m, n, p, r, and t is from 2 to 5; and the sum of v, w, x, y, and z is from 2 to 5.


RNAi Compounds

In certain embodiments, antisense compounds are interfering RNA compounds (RNAi), which include double-stranded RNA compounds (also referred to as short-interfering RNA or siRNA) and single-stranded RNAi compounds (or ssRNA). Such compounds work at least in part through the RISC pathway to degrade and/or sequester a target nucleic acid (thus, include microRNA/microRNA-mimic compounds). In certain embodiments, antisense compounds comprise modifications that make them particularly suited for such mechanisms.

i. ssRNA Compounds

In certain embodiments, antisense compounds including those particularly suited for use as single-stranded RNAi compounds (ssRNA) comprise a modified 5'-terminal end. In certain such embodiments, the 5'-terminal end comprises a modified phosphate moiety. In certain embodiments, such modified phosphate is stabilized (e.g., resistant to degradation/cleavage compared to unmodified 5'-phosphate). In certain embodiments, such 5'-terminal nucleosides stabilize the 5'-phosphorous moiety. Certain modified 5'-terminal nucleosides may be found in the art, for example in WO/2011/139702.

In certain embodiments, the 5'-nucleoside of an ssRNA compound has Formula IIc:




IIc

wherein:

T₁ is an optionally protected phosphorus moiety;

T₂ is an internucleoside linking group linking the compound of Formula IIc to the oligomeric compound;

A has one of the formulas:



Q₁ and Q₂ are each, independently, H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl or N(R₃)(R₄);

Q₃ is O, S, N(R₅) or C(R₆)(R₇);

each R₃, R₄, R₅, R₆ and R₇ is, independently, H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl or C₁-C₆ alkoxy;

M₃ is O, S, NR₁₄, C(R₁₅)(R₁₆), C(R₁₅)(R₁₆)C(R₁₇)(R₁₈), C(R₁₅)=C(R₁₇), OC(R₁₅)(R₁₆) or OC(R₁₅)(Bx₂);

R₁₄ is H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆ alkynyl;

R₁₅, R₁₆, R₁₇ and R₁₈ are each, independently, H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆ alkynyl;

Bx₁ is a heterocyclic base moiety;

or if Bx₂ is present then Bx₂ is a heterocyclic base moiety and Bx₁ is H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆ alkynyl;

J₄, J₅, J₆ and J₇ are each, independently, H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted

C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆ alkynyl;

or J₄ forms a bridge with one of J₅ or J₇ wherein said bridge comprises from 1 to 3 linked biradical groups selected from O, S, NR₁₉, C(R₂₀)(R₂₁), C(R₂₀)=C(R₂₁), C[=C(R₂₀)(R₂₁)] and C(=O) and the other two of J₅, J₆ and J₇ are each, independently, H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆ alkynyl;

each R₁₉, R₂₀ and R₂₁ is, independently, H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆ alkynyl;

G is H, OH, halogen or O—[C(R₈)(R₆)]_n—[(C=O)_m—X₁]_j—Z;

each R₈ and R₉ is, independently, H, halogen, C₁-C₆ alkyl or substituted C₁-C₆ alkyl;

X₁ is O, S or N(E₁);

Z is H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl or N(E₂)(E₃);

E₁, E₂ and E₃ are each, independently, H, C₁-C₆ alkyl or substituted C₁-C₆ alkyl;

n is from 1 to about 6;

m is 0 or 1;

j is 0 or 1;

each substituted group comprises one or more optionally protected substituent groups independently selected from halogen, OJ₁, N(J₁)(J₂), =NJ₁, SJ₁, N₃, CN, OC(=X₂)J₁, OC(=X₂)N(J₁)(J₂) and C(=X₂)N(J₁)(J₂);

X₂ is O, S or NJ₃;

each J₁, J₂ and J₃ is, independently, H or C₁-C₆ alkyl;


when j is 1 then Z is other than halogen or N(E₂)(E₃); and

wherein said oligomeric compound comprises from 8 to 40 monomeric subunits and is hybridizable to at least a portion of a target nucleic acid.

In certain embodiments, M₃ is O, CH=CH, OCH₂ or OC(H)(Bx₂). In certain embodiments, M₃ is O.

In certain embodiments, J₄, J₅, J₆ and J₇ are each H. In certain embodiments, J₄ forms a bridge with one of J₅ or J₇.


In certain embodiments, A has one of the formulas:



wherein:

Q₁ and Q₂ are each, independently, H, halogen, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy or substituted C₁-C₆ alkoxy. In certain embodiments, Q₁ and Q₂ are each H. In certain embodiments, Q₁ and Q₂ are each, independently, H or halogen. In certain embodiments, Q₁ and Q₂ is H and the other of Q₁ and Q₂ is F, CH₃ or OCH₃.

In certain embodiments, T₁ has the formula:



wherein:


R_a and R_c are each, independently, protected hydroxyl, protected thiol, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₁-C₆ alkoxy, substituted C₁-C₆ alkoxy, protected amino or substituted amino; and

R_b is O or S. In certain embodiments, R_b is O and R_a and R_c are each, independently, OCH₃, OCH₂CH₃ or CH(CH₃)₂.

In certain embodiments, G is halogen, OCH₃, OCH₂F, OCHF₂, OCF₃, OCH₂CH₃, O(CH₂)₃F, OCH₂CHF₂, OCH₂CF₃, OCH₂—CH=CH₂, O(CH₂)₂—OCH₃, O(CH₂)₂—SCH₃, O(CH₂)₂—OCF₃, O(CH₂)₃—N(R₁₀)(R₁₁), O(CH₂)₂—ON(R₁₀)(R₁₁), O(CH₂)₂—O(CH₂)₂—N(R₁₀)(R₁₁), OCH₂C(=O)—N(R₁₀)(R₁₁), OCH₂C(=O)—N(R₁₂)—(CH₂)₂—N(R₁₀)(R₁₁) or O(CH₂)₂—N(R₁₂)—C(=NR₁₃)[N(R₁₀)(R₁₁)] wherein R₁₀, R₁₁, R₁₂ and R₁₃ are each, independently, H or C₁-C₆ alkyl. In certain embodiments, G is halogen, OCH₃, OCF₃, OCH₂CH₃, OCH₂CF₃, OCH₂—CH=CH₂, O(CH₂)₂—OCH₃, O(CH₂)₂—O(CH₂)₂—N(CH₃)₂, OCH₂C(=O)—N(H)CH₃, OCH₂C(=O)—N(H)—(CH₂)₂—N(CH₃)₂ or OCH₂—N(H)—C(=NH)NH₂. In certain embodiments, G is F, OCH₃ or O(CH₂)₂—OCH₃. In certain embodiments, G is O(CH₂)₂—OCH₃.

In certain embodiments, the 5'-terminal nucleoside has Formula IIc:

IIc



In certain embodiments, antisense compounds, including those particularly suitable for ssRNA comprise one or more type of modified sugar moieties and/or naturally occurring sugar moieties arranged along an oligonucleotide or region thereof in a defined pattern or sugar modification motif. Such motifs may include any of the sugar modifications discussed herein and/or other known sugar modifications.

In certain embodiments, the oligonucleotides comprise or consist of a region having uniform sugar modifications. In certain such embodiments, each nucleoside of the region comprises the same RNA-like sugar modification. In certain embodiments, each nucleoside of the region is a 2'-F nucleoside. In certain embodiments, each nucleoside of the region is a 2'-OMe nucleoside. In certain embodiments, each nucleoside of the region is a 2'-MOE nucleoside. In certain embodiments, each nucleoside of the region is a cEt nucleoside. In certain embodiments, each nucleoside of the region is an LNA nucleoside. In certain embodiments, the uniform region constitutes all or essentially all of the oligonucleotide. In certain embodiments, the region constitutes the entire oligonucleotide except for 1-4 terminal nucleosides.

In certain embodiments, oligonucleotides comprise one or more regions of alternating sugar modifications, wherein the nucleosides alternate between nucleotides having a sugar modification of a first type and nucleotides having a sugar modification of a second type. In certain embodiments, nucleosides of both types are RNA-like nucleosides. In certain embodiments the alternating nucleosides are selected from: 2'-OMe, 2'-F, 2'-MOE, LNA, and cEt. In certain embodiments, the alternating modifications are 2'-F and

2'-OMe. Such regions may be contiguous or may be interrupted by differently modified nucleosides or conjugated nucleosides.


In certain embodiments, the alternating region of alternating modifications each consist of a single nucleoside (i.e., the pattern is $(AB)_x A_y$, wherein A is a nucleoside having a sugar modification of a first type and B is a nucleoside having a sugar modification of a second type; x is 1-20 and y is 0 or 1). In certain embodiments, one or more alternating regions in an alternating motif includes more than a single nucleoside of a type. For example, oligonucleotides may include one or more regions of any of the following nucleoside motifs:

AABBAA;
 ABBABB;
 AABAAB;
 ABBABAABB;
 ABABAA;
 AABABAB;
 ABABAA;
 ABBAABBABABAA;
 BABBAAABBABABAA;
 or
 ABABBAABBABABAA;

wherein A is a nucleoside of a first type and B is a nucleoside of a second type. In certain embodiments, A and B are each selected from 2'-F, 2'-OMe, BNA, and MOE.

In certain embodiments, oligonucleotides having such an alternating motif also comprise a modified 5' terminal nucleoside, such as those of formula IIc or IIe.

In certain embodiments, oligonucleotides comprise a region having a 2-2-3 motif. Such regions comprises the following motif:



wherein: A is a first type of modified nucleoside;

B and C, are nucleosides that are differently modified than A, however, B and C may have the same or different modifications as one another;

x and y from 1 to 15.

In certain embodiments, A is a 2'-OMe modified nucleoside. In certain embodiments, B and C are both 2'-F modified nucleosides. In certain embodiments, A is a 2'-OMe modified nucleoside and B and C are both 2'-F modified nucleosides.

In certain embodiments, oligonucleosides have the following sugar motif:



wherein:

Q is a nucleoside comprising a stabilized phosphate moiety. In certain embodiments, Q is a nucleoside having Formula IIc or IIe;

A is a first type of modified nucleoside;

B is a second type of modified nucleoside;


D is a modified nucleoside comprising a modification different from the nucleoside adjacent to it. Thus, if y is 0, then D must be differently modified than B and if y is 1, then D must be differently modified than A. In certain embodiments, D differs from both A and B.

X is 5-15;

Y is 0 or 1;

Z is 0-4.

In certain embodiments, oligonucleosides have the following sugar motif:



wherein:

Q is a nucleoside comprising a stabilized phosphate moiety. In certain embodiments, Q is a nucleoside having Formula IIc or IIe;

A is a first type of modified nucleoside;

D is a modified nucleoside comprising a modification different from A.

X is 11-30;

Z is 0-4.

In certain embodiments A, B, C, and D in the above motifs are selected from: 2'-OMe, 2'-F, 2'-MOE, LNA, and cEt. In certain embodiments, D represents terminal nucleosides. In certain embodiments, such terminal nucleosides are not designed to hybridize to the target nucleic acid (though one or more might hybridize by chance). In certain embodiments, the nucleobase of each D nucleoside is adenine, regardless of the identity of the nucleobase at the corresponding position of the target nucleic acid. In certain embodiments the nucleobase of each D nucleoside is thymine.

In certain embodiments, antisense compounds, including those particularly suited for use as ssRNA comprise modified internucleoside linkages arranged along the oligonucleotide or region thereof in a defined pattern or modified internucleoside linkage motif. In certain embodiments, oligonucleotides comprise a region having an alternating internucleoside linkage motif. In certain embodiments, oligonucleotides comprise a region of uniformly modified internucleoside linkages. In certain such embodiments, the oligonucleotide comprises a region that is uniformly linked by phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide is uniformly linked by phosphorothioate internucleoside linkages. In certain embodiments, each internucleoside linkage of the oligonucleotide is selected from phosphodiester and phosphorothioate. In certain embodiments, each internucleoside linkage of the oligonucleotide is selected from phosphodiester and phosphorothioate and at least one internucleoside linkage is phosphorothioate.

In certain embodiments, the oligonucleotide comprises at least 6 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least 8 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least 10 phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 6 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 8 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 10 consecutive phosphorothioate internucleoside linkages. In certain embodiments, the oligonucleotide comprises at least one block of at least 12 consecutive phosphorothioate internucleoside linkages. In certain such embodiments, at least one such block is located at the 3' end of the oligonucleotide. In certain such embodiments, at least one such block is located within 3 nucleosides of the 3' end of the oligonucleotide.

Oligonucleotides having any of the various sugar motifs described herein, may have any linkage motif. For example, the oligonucleotides, including but not limited to those described above, may have a linkage motif selected from non-limiting the table below:

5' most linkage	Central region	3'-region
PS	Alternating PO/PS	6 PS
PS	Alternating PO/PS	7 PS
PS	Alternating PO/PS	8 PS

ii. siRNA Compounds

In certain embodiments, antisense compounds are double-stranded RNAi compounds (siRNA). In such embodiments, one or both strands may comprise any modification motif described above for ssRNA. In certain embodiments, ssRNA compounds may be unmodified RNA. In certain embodiments, siRNA compounds may comprise unmodified RNA nucleosides, but modified internucleoside linkages.

Several embodiments relate to double-stranded compositions wherein each strand comprises a motif defined by the location of one or more modified or unmodified nucleosides. In certain embodiments, compositions are provided comprising a first and a second oligomeric compound that are fully or at least partially hybridized to form a duplex region and further comprising a region that is complementary to and hybridizes to a nucleic acid target. It is suitable that such a composition comprise a first oligomeric compound that is an antisense strand having full or partial complementarity to a nucleic acid target and a second oligomeric compound that is a sense strand having one or more regions of complementarity to and forming at least one duplex region with the first oligomeric compound.

The compositions of several embodiments modulate gene expression by hybridizing to a nucleic acid target resulting in loss of its normal function. In some embodiments, the target nucleic acid is Androgen Receptor. In certain embodiment, the degradation of the targeted Androgen Receptor is facilitated by an activated RISC complex that is formed with compositions of the invention.

Several embodiments are directed to double-stranded compositions wherein one of the strands is useful in, for example, influencing the preferential loading of the opposite strand into the RISC (or cleavage) complex. The compositions are useful for targeting selected nucleic acid molecules and modulating the expression of one or more genes. In some embodiments, the compositions of the present invention hybridize to a portion of a target RNA resulting in loss of normal function of the target RNA.

Certain embodiments are drawn to double-stranded compositions wherein both the strands comprises a hemimer motif, a fully modified motif, a positionally modified motif or an alternating motif. Each strand of the compositions of the present invention can be modified to fulfil a particular role in for example the siRNA pathway. Using a different motif in each strand or the same motif with different chemical modifications in each strand permits targeting the antisense strand for the RISC complex while inhibiting the incorporation of the sense strand. Within this model, each strand can be independently modified such that it is enhanced for its particular role. The antisense strand can be modified at the 5'-end to enhance its role in one region of the RISC while the 3'-end can be modified differentially to enhance its role in a different region of the RISC.

The double-stranded oligonucleotide molecules can be a double-stranded polynucleotide molecule comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The double-stranded oligonucleotide molecules can be assembled from two separate oligonucleotides, where one strand is the sense strand and the other is the antisense strand, wherein the antisense and sense strands are self-complementary (i.e. each strand comprises nucleotide sequence that is complementary to nucleotide sequence in the other strand; such as where the antisense strand and sense strand form a duplex or double-stranded structure, for example wherein the double-stranded region is about 15 to about 30, e.g., about 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 base pairs; the antisense strand comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense strand comprises nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof (e.g., about 15 to about 25 or more nucleotides of the double-stranded oligonucleotide molecule are complementary to the target nucleic acid or a portion thereof). Alternatively, the double-stranded oligonucleotide is assembled from a single oligonucleotide, where the self-complementary sense and antisense regions of the siRNA are linked by means of a nucleic acid based or non-nucleic acid-based linker(s).

The double-stranded oligonucleotide can be a polynucleotide with a duplex, asymmetric duplex, hairpin or asymmetric hairpin secondary structure, having self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a separate target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof. The double-stranded oligonucleotide can be a circular single-stranded polynucleotide having two or more loop structures and a stem comprising self-complementary sense and antisense regions, wherein the antisense region comprises nucleotide sequence that is complementary to nucleotide sequence in a target nucleic acid molecule or a portion thereof and the sense region having nucleotide sequence corresponding to the target nucleic acid sequence or a portion thereof, and wherein the circular polynucleotide can be processed either in vivo or in vitro to generate an active siRNA molecule capable of mediating RNAi.

In certain embodiments, the double-stranded oligonucleotide comprises separate sense and antisense sequences or regions, wherein the sense and antisense regions are covalently linked by nucleotide or non-nucleotide linker molecules as is known in the art, or are alternately non-covalently linked by ionic interactions, hydrogen bonding, van der Waals interactions, hydrophobic interactions, and/or stacking interactions. In certain embodiments, the double-stranded oligonucleotide comprises nucleotide sequence that is complementary to nucleotide sequence of a target gene. In another embodiment, the double-stranded oligonucleotide interacts with nucleotide sequence of a target gene in a manner that causes inhibition of expression of the target gene.

As used herein, double-stranded oligonucleotides need not be limited to those molecules containing only RNA, but further encompasses chemically modified nucleotides and

non-nucleotides. In certain embodiments, the short interfering nucleic acid molecules lack 2'-hydroxy (2'-OH) containing nucleotides. In certain embodiments short interfering nucleic acids optionally do not include any ribonucleotides (e.g., nucleotides having a 2'-OH group). Such double-stranded oligonucleotides that do not require the presence of ribonucleotides within the molecule to support RNAi can however have an attached linker or linkers or other attached or associated groups, moieties, or chains containing one or more nucleotides with 2'-OH groups. Optionally, double-stranded oligonucleotides can comprise ribonucleotides at about 5, 10, 20, 30, 40, or 50% of the nucleotide positions. As used herein, the term siRNA is meant to be equivalent to other terms used to describe nucleic acid molecules that are capable of mediating sequence specific RNAi, for example short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically modified siRNA, post-transcriptional gene silencing RNA (ptgsRNA), and others. In addition, as used herein, the term RNAi is meant to be equivalent to other terms used to describe sequence specific RNA interference, such as post transcriptional gene silencing, translational inhibition, or epigenetics. For example, double-stranded oligonucleotides can be used to epigenetically silence genes at both the post-transcriptional level and the pre-transcriptional level. In a non-limiting example, epigenetic regulation of gene expression by siRNA molecules of the invention can result from siRNA mediated modification of chromatin structure or methylation pattern to alter gene expression (see, for example, Verdel et al., 2004, *Science*, 303, 672-676; Pal-Bhadra et al., 2004, *Science*, 303, 669-672; Allshire, 2002, *Science*, 297, 1818-1819; Volpe et al., 2002, *Science*, 297, 1833-1837; Jenuwein, 2002, *Science*, 297, 2215-2218; and Hall et al., 2002, *Science*, 297, 2232-2237).

It is contemplated that compounds and compositions of several embodiments provided herein can target Androgen Receptor by a dsRNA-mediated gene silencing or RNAi mechanism, including, e.g., "hairpin" or stem-loop double-stranded RNA effector molecules in which a single RNA strand with self-complementary sequences is capable of assuming a double-stranded conformation, or duplex dsRNA effector molecules comprising two separate strands of RNA. In various embodiments, the dsRNA consists entirely of ribonucleotides or consists of a mixture of ribonucleotides and deoxynucleotides, such as the RNA/DNA hybrids disclosed, for example, by WO 00/63364, filed Apr. 19, 2000, or U.S. Ser. No. 60/130,377, filed Apr. 21, 1999. The dsRNA or dsRNA effector molecule may be a single molecule with a region of self-complementarity such that nucleotides in one segment of the molecule base pair with nucleotides in another segment of the molecule. In various embodiments, a dsRNA that consists of a single molecule consists entirely of ribonucleotides or includes a region of ribonucleotides that is complementary to a region of deoxyribonucleotides. Alternatively, the dsRNA may include two different strands that have a region of complementarity to each other.

In various embodiments, both strands consist entirely of ribonucleotides, one strand consists entirely of ribonucleotides and one strand consists entirely of deoxyribonucleotides, or one or both strands contain a mixture of ribonucleotides and deoxyribonucleotides. In certain embodiments, the regions of complementarity are at least 70, 80, 90, 95, 98, or 100% complementary to each other and to a target nucleic acid sequence. In certain embodiments,

the region of the dsRNA that is present in a double-stranded conformation includes at least 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 50, 75, 100, 200, 500, 1000, 2000 or 5000 nucleotides or includes all of the nucleotides in a cDNA or other target nucleic acid sequence being represented in the dsRNA. In some embodiments, the dsRNA does not contain any single stranded regions, such as single stranded ends, or the dsRNA is a hairpin. In other embodiments, the dsRNA has one or more single stranded regions or overhangs. In certain embodiments, RNA/DNA hybrids include a DNA strand or region that is an antisense strand or region (e.g. has at least 70, 80, 90, 95, 98, or 100% complementarity to a target nucleic acid) and an RNA strand or region that is a sense strand or region (e.g. has at least 70, 80, 90, 95, 98, or 100% identity to a target nucleic acid), and vice versa.

In various embodiments, the RNA/DNA hybrid is made in vitro using enzymatic or chemical synthetic methods such as those described herein or those described in WO 00/63364, filed Apr. 19, 2000, or U.S. Ser. No. 60/130,377, filed Apr. 21, 1999. In other embodiments, a DNA strand synthesized in vitro is complexed with an RNA strand made in vivo or in vitro before, after, or concurrent with the transformation of the DNA strand into the cell. In yet other embodiments, the dsRNA is a single circular nucleic acid containing a sense and an antisense region, or the dsRNA includes a circular nucleic acid and either a second circular nucleic acid or a linear nucleic acid (see, for example, WO 00/63364, filed Apr. 19, 2000, or U.S. Ser. No. 60/130,377, filed Apr. 21, 1999.) Exemplary circular nucleic acids include lariat structures in which the free 5' phosphoryl group of a nucleotide becomes linked to the 2' hydroxyl group of another nucleotide in a loop back fashion.

In other embodiments, the dsRNA includes one or more modified nucleotides in which the 2' position in the sugar contains a halogen (such as fluorine group) or contains an alkoxy group (such as a methoxy group) which increases the half-life of the dsRNA in vitro or in vivo compared to the corresponding dsRNA in which the corresponding 2' position contains a hydrogen or an hydroxyl group. In yet other embodiments, the dsRNA includes one or more linkages between adjacent nucleotides other than a naturally-occurring phosphodiester linkage. Examples of such linkages include phosphoramidate, phosphorothioate, and phosphorodithioate linkages. The dsRNAs may also be chemically modified nucleic acid molecules as taught in U.S. Pat. No. 6,673,661. In other embodiments, the dsRNA contains one or two capped strands, as disclosed, for example, by WO 00/63364, filed Apr. 19, 2000, or U.S. Ser. No. 60/130,377, filed Apr. 21, 1999.

In other embodiments, the dsRNA can be any of the at least partially dsRNA molecules disclosed in WO 00/63364, as well as any of the dsRNA molecules described in U.S. Provisional Application 60/399,998; and U.S. Provisional Application 60/419,532, and PCT/US2003/033466, the teaching of which is hereby incorporated by reference. Any of the dsRNAs may be expressed in vitro or in vivo using the methods described herein or standard methods, such as those described in WO 00/63364.

Occupancy

In certain embodiments, antisense compounds are not expected to result in cleavage or the target nucleic acid via RNase H or to result in cleavage or sequestration through the RISC pathway. In certain such embodiments, antisense activity may result from occupancy, wherein the presence of the hybridized antisense compound disrupts the activity of the target nucleic acid. In certain such embodiments, the

antisense compound may be uniformly modified or may comprise a mix of modifications and/or modified and unmodified nucleosides.

Target Nucleic Acids, Target Regions and Nucleotide Sequences

Nucleotide sequences that encode human Androgen Receptor include, without limitation, the following: GENBANK Accession No. NT_011669.17_TRUNC_5079000_5270000 (incorporated herein as SEQ ID NO: 1), GENBANK Accession No. NM_000044.3 (incorporated herein as SEQ ID NO: 2), GENBANK Accession No. NM_001011645.2 (incorporated herein as SEQ ID NO: 3), GENBANK Accession No. FJ235916.1 (incorporated herein as SEQ ID NO: 4), GENBANK Accession No. FJ235917.1 (incorporated herein as SEQ ID NO: 5), GENBANK Accession No. FJ235918.1 (incorporated herein as SEQ ID NO: 6), GENBANK Accession No. FJ235919.1 (incorporated herein as SEQ ID NO: 7), and GENBANK Accession No. FJ235920.1 (incorporated herein as SEQ ID NO: 8).

Androgen Receptor mRNA encodes several functional domains. In certain embodiments, full-length Androgen Receptor mRNA includes exon 1 encoding the N-terminal domain, exons 2 and 3 encoding the DNA binding domain, exon 4 encoding the short hinge region, and exons 4-8 encoding the ligand binding domain.

In certain embodiments, Androgen Receptor splicing variants targetable by the antisense compounds provided herein include exon 1 encoding the N-terminal domain and exons 2 and 3 encoding the DNA binding domain, or functional portions thereof, but does not include at least a portion of exon 4 encoding the short hinge region or at least a portion of exons 4-8 encoding the ligand binding domain. Examples of such AR splicing variants include, but are not limited to, AR-V1, AR-V2, AR-V3, AR-V4, AR-V5, AR-V6, and AR-V7 (also referred to as AR3), which contain exons 1-3 but lack exons 4-8. AR-V1, AR-V2, AR-V3, AR-V4, AR-V5, AR-V6, AR-V7, and additional splicing variants targetable by the antisense compounds provided herein are described in Hu et al., *Cancer Res* 2009; 69:16-22 and US Patent Application Publication No. US 2010/0068802, each of which is incorporated herein by reference in its entirety. Further examples of such AR splicing variants targetable by the antisense compounds provided herein include, but are not limited to, AR3, AR4, AR4b, AR5, and AR6 (SEQ ID NOs: 4-8, respectively) as described in Guo et al., *Cancer Res.* 2009; 69: 2305-13, which is incorporated herein by reference in its entirety.

Hybridization

In some embodiments, hybridization occurs between an antisense compound disclosed herein and an Androgen Receptor. The most common mechanism of hybridization involves hydrogen bonding (e.g., Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding) between complementary nucleobases of the nucleic acid molecules.

Hybridization can occur under varying conditions. Stringent conditions are sequence-dependent and are determined by the nature and composition of the nucleic acid molecules to be hybridized.

Methods of determining whether a sequence is specifically hybridizable to a target nucleic acid are well known in the art. In certain embodiments, the antisense compounds provided herein are specifically hybridizable with Androgen Receptor.

Complementarity

An antisense compound and a target nucleic acid are complementary to each other when a sufficient number of

nucleobases of the antisense compound can hydrogen bond with the corresponding nucleobases of the target nucleic acid, such that a desired effect will occur (e.g., antisense inhibition of a target nucleic acid, such as an Androgen Receptor nucleic acid).

Non-complementary nucleobases between an antisense compound and an Androgen Receptor nucleic acid may be tolerated provided that the antisense compound remains able to specifically hybridize to a target nucleic acid. Moreover, an antisense compound may hybridize over one or more segments of an Androgen Receptor nucleic acid such that intervening or adjacent segments are not involved in the hybridization event (e.g., a loop structure, mismatch or hairpin structure).

In certain embodiments, the antisense compounds provided herein, or a specified portion thereof, are, or are at least, 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to an Androgen Receptor nucleic acid, a target region, target segment, or specified portion thereof. Percent complementarity of an antisense compound with a target nucleic acid can be determined using routine methods.

For example, an antisense compound in which 18 of 20 nucleobases of the antisense compound are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining noncomplementary nucleobases may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, an antisense compound which is 18 nucleobases in length having four non-complementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid and would thus fall within the scope of the present invention. Percent complementarity of an antisense compound with a region of a target nucleic acid can be determined routinely using BLAST programs (basic local alignment search tools) and PowerBLAST programs known in the art (Altschul et al., *J. Mol. Biol.*, 1990, 215, 403 410; Zhang and Madden, *Genome Res.*, 1997, 7, 649 656). Percent homology, sequence identity or complementarity, can be determined by, for example, the Gap program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, Madison Wis.), using default settings, which uses the algorithm of Smith and Waterman (*Adv. Appl. Math.*, 1981, 2, 482 489).

In certain embodiments, the antisense compounds provided herein, or specified portions thereof, are fully complementary (i.e. 100% complementary) to a target nucleic acid, or specified portion thereof. For example, an antisense compound may be fully complementary to an Androgen Receptor nucleic acid, or a target region, or a target segment or target sequence thereof. As used herein, "fully complementary" means each nucleobase of an antisense compound is capable of precise base pairing with the corresponding nucleobases of a target nucleic acid. For example, a 20 nucleobase antisense compound is fully complementary to a target sequence that is 400 nucleobases long, so long as there is a corresponding 20 nucleobase portion of the target nucleic acid that is fully complementary to the antisense compound. Fully complementary can also be used in reference to a specified portion of the first and/or the second nucleic acid. For example, a 20 nucleobase portion of a 30 nucleobase antisense compound can be "fully complementary" to a target sequence that is 400 nucleobases long. The 20 nucleobase portion of the 30 nucleobase oligonucleotide

is fully complementary to the target sequence if the target sequence has a corresponding 20 nucleobase portion wherein each nucleobase is complementary to the 20 nucleobase portion of the antisense compound. At the same time, the entire 30 nucleobase antisense compound may or may not be fully complementary to the target sequence, depending on whether the remaining 10 nucleobases of the antisense compound are also complementary to the target sequence.

The location of a non-complementary nucleobase may be at the 5' end or 3' end of the antisense compound. Alternatively, the non-complementary nucleobase or nucleobases may be at an internal position of the antisense compound. When two or more non-complementary nucleobases are present, they may be contiguous (i.e. linked) or non-contiguous. In one embodiment, a non-complementary nucleobase is located in the wing segment of a gapmer antisense oligonucleotide.

In certain embodiments, antisense compounds that are, or are up to 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleobases in length comprise no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as an Androgen Receptor nucleic acid, or specified portion thereof.

In certain embodiments, antisense compounds that are, or are up to 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length comprise no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, such as an Androgen Receptor nucleic acid, or specified portion thereof.

The antisense compounds provided also include those which are complementary to a portion of a target nucleic acid. As used herein, "portion" refers to a defined number of contiguous (i.e. linked) nucleobases within a region or segment of a target nucleic acid. A "portion" can also refer to a defined number of contiguous nucleobases of an antisense compound. In certain embodiments, the antisense compounds, are complementary to at least an 8 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 9 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 10 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least an 11 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 12 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 13 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 14 nucleobase portion of a target segment. In certain embodiments, the antisense compounds are complementary to at least a 15 nucleobase portion of a target segment. Also contemplated are antisense compounds that are complementary to at least a 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more nucleobase portion of a target segment, or a range defined by any two of these values.

Identity

The antisense compounds provided herein may also have a defined percent identity to a particular nucleotide sequence, SEQ ID NO, or compound represented by a specific Isis number, or portion thereof. As used herein, an antisense compound is identical to the sequence disclosed herein if it has the same nucleobase pairing ability. For

example, a RNA which contains uracil in place of thymidine in a disclosed DNA sequence would be considered identical to the DNA sequence since both uracil and thymidine pair with adenine. Shortened and lengthened versions of the antisense compounds described herein as well as compounds having non-identical bases relative to the antisense compounds provided herein also are contemplated. The non-identical bases may be adjacent to each other or dispersed throughout the antisense compound. Percent identity of an antisense compound is calculated according to the number of bases that have identical base pairing relative to the sequence to which it is being compared.

In certain embodiments, the antisense compounds, or portions thereof, are at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% identical to one or more of the antisense compounds or SEQ ID NOs, or a portion thereof, disclosed herein.

In certain embodiments, a portion of the antisense compound is compared to an equal length portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of the target nucleic acid.

In certain embodiments, a portion of the antisense oligonucleotide is compared to an equal length portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of the target nucleic acid.

Modifications

A nucleoside is a base-sugar combination. The nucleobase (also known as base) portion of the nucleoside is normally a heterocyclic base moiety. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to the 2', 3' or 5' hydroxyl moiety of the sugar. Oligonucleotides are formed through the covalent linkage of adjacent nucleosides to one another, to form a linear polymeric oligonucleotide. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside linkages of the oligonucleotide.

Modifications to antisense compounds encompass substitutions or changes to internucleoside linkages, sugar moieties, or nucleobases. Modified antisense compounds are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target, increased stability in the presence of nucleases, or increased inhibitory activity.

Chemically modified nucleosides may also be employed to increase the binding affinity of a shortened or truncated antisense oligonucleotide for its target nucleic acid. Consequently, comparable results can often be obtained with shorter antisense compounds that have such chemically modified nucleosides.

Modified Internucleoside Linkages

The naturally occurring internucleoside linkage of RNA and DNA is a 3' to 5' phosphodiester linkage. Antisense compounds having one or more modified, i.e. non-naturally occurring, internucleoside linkages are often selected over antisense compounds having naturally occurring internucleoside linkages because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases.

Oligonucleotides having modified internucleoside linkages include internucleoside linkages that retain a phospho-

rus atom as well as internucleoside linkages that do not have a phosphorus atom. Representative phosphorus containing internucleoside linkages include, but are not limited to, phosphodiester, phosphotriester, methylphosphonates, phosphoramidate, and phosphorothioates. Methods of preparation of phosphorous-containing and non-phosphorous-containing linkages are well known.

In certain embodiments, antisense compounds targeted to an Androgen Receptor nucleic acid comprise one or more modified internucleoside linkages. In certain embodiments, the modified internucleoside linkages are phosphorothioate linkages. In certain embodiments, each internucleoside linkage of an antisense compound is a phosphorothioate internucleoside linkage.

Modified Sugar Moieties

Antisense compounds can optionally contain one or more nucleosides wherein the sugar group has been modified. Such sugar modified nucleosides may impart enhanced nuclease stability, increased binding affinity, or some other beneficial biological property to the antisense compounds. In certain embodiments, nucleosides comprise chemically modified ribofuranose ring moieties. Examples of chemically modified ribofuranose rings include without limitation, addition of substituent groups (including 5' and 2' substituent groups, bridging of non-geminal ring atoms to form bicyclic nucleic acids (BNA), replacement of the ribosyl ring oxygen atom with S, N(R), or C(R₁)(R₂) (R, R₁ and R₂ are each independently H, C₁-C₁₂ alkyl or a protecting group) and combinations thereof. Examples of chemically modified sugars include 2'-F-5'-methyl substituted nucleoside (see PCT International Application WO 2008/101157 Published on Aug. 21, 2008 for other disclosed 5',2'-bis substituted nucleosides) or replacement of the ribosyl ring oxygen atom with S with further substitution at the 2'-position (see published U.S. Patent Application US2005-0130923, published on Jun. 16, 2005) or alternatively 5'-substitution of a BNA (see PCT International Application WO 2007/134181 Published on Nov. 22, 2007 wherein 4'-(CH₂)—O-2' (LNA) is substituted with for example a 5'-methyl or a 5'-vinyl group).

Examples of nucleosides having modified sugar moieties include without limitation nucleosides comprising 5'-vinyl, 5'-methyl (R or S), 4'-S, 2'-F, 2'-OCH₃, 2'-OCH₂CH₃, 2'-OCH₂CH₂F and 2'-O(CH₂)₂OCH₃ substituent groups. The substituent at the 2' position can also be selected from allyl, amino, azido, thio, O-allyl, O—C₁-C₁₀ alkyl, OCF₃, OCH₂F, O(CH₂)₂SCH₃, O(CH₂)₂—O—N(R_m)(R_n), O—CH₂—C(=O)—N(R_m)(R_n), and O—CH₂—C(=O)—N(R₁)—(CH₂)₂—N(R_m)(R_n), where each R₁, R_m and R_n is, independently, H or substituted or unsubstituted C₁-C₁₀ alkyl.

As used herein, "bicyclic nucleosides" refer to modified nucleosides comprising a bicyclic sugar moiety. Examples of bicyclic nucleosides include without limitation nucleosides comprising a bridge between the 4' and the 2' ribosyl ring atoms. In certain embodiments, antisense compounds provided herein include one or more bicyclic nucleosides comprising a 4' to 2' bridge. Examples of such 4' to 2' bridged bicyclic nucleosides, include but are not limited to one of the formulae: 4'-(CH₂)—O-2' (LNA); 4'-(CH₂)—S-2'; 4'-(CH₂)₂—O-2' (ENA); 4-CH(CH₃)—O-2' (also referred to as constrained ethyl or cEt) and 4'-CH(CH₂OCH₃)—O-2' (and analogs thereof see U.S. Pat. No. 7,399,845, issued on Jul. 15, 2008); 4'-C(CH₃)(CH₃)—O-2' (and analogs thereof see published International Application WO/2009/006478, published Jan. 8, 2009); 4-CH₂—N(OCH₃)-2' (and analogs thereof see published International Application WO/2008/

150729, published Dec. 11, 2008); 4-CH₂—O—N(CH₃)-2' (see published U.S. Patent Application US2004-0171570, published Sep. 2, 2004); 4-CH₂—N(R)—O-2', wherein R is H, C₁-C₁₂ alkyl, or a protecting group (see U.S. Pat. No. 7,427,672, issued on Sep. 23, 2008); 4-CH₂—C—(H)(CH₃)-2' (see Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134); and 4-CH₂—C(=CH₂)-2' (and analogs thereof see published International Application WO 2008/154401, published on Dec. 8, 2008).

Further reports related to bicyclic nucleosides can also be found in published literature (see for example: Singh et al., Chem. Commun., 1998, 4, 455-456; Koshkin et al., Tetrahedron, 1998, 54, 3607-3630; Wahlestedt et al., Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 5633-5638; Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222; Singh et al., J. Org. Chem., 1998, 63, 10035-10039; Srivastava et al., J. Am. Chem. Soc., 2007, 129(26) 8362-8379; Elayadi et al., Curr. Opinion Invest. Drugs, 2001, 2, 558-561; Braasch et al., Chem. Biol., 2001, 8, 1-7; and Orum et al., Curr. Opinion Mol. Ther., 2001, 3, 239-243; U.S. Pat. Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 7,034,133; 7,053,207; 7,399,845; 7,547,684; and 7,696,345; U.S. Patent Publication No. US2008-0039618; US2009-0012281; U.S. Patent Ser. Nos. 60/989,574; 61/026,995; 61/026,998; 61/056,564; 61/086,231; 61/097,787; and 61/099,844; Published PCT International applications WO 1994/014226; WO 2004/106356; WO 2005/021570; WO 2007/134181; WO 2008/150729; WO 2008/154401; and WO 2009/006478. Each of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example α-L-ribofuranose and β-D-ribofuranose (see PCT international application PCT/DK98/00393, published on Mar. 25, 1999 as WO 99/14226).

In certain embodiments, bicyclic sugar moieties of BNA nucleosides include, but are not limited to, compounds having at least one bridge between the 4' and the 2' position of the pentofuranosyl sugar moiety wherein such bridges independently comprises 1 or from 2 to 4 linked groups independently selected from —[C(R_a)(R_b)]_n—, —C(R_a)=C(R_b)—, —C(R_a)=N—, —C(=O)—, —C(=NR_a)—, —C(=S)—, —O—, —Si(R_a)₂—, —S(=O)_x—, and —N(R_a)—; wherein:

x is 0, 1, or 2;

n is 1, 2, 3, or 4;

each R_a and R_b is, independently, H, a protecting group, hydroxyl, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, heterocycle radical, substituted heterocycle radical, heteroaryl, substituted heteroaryl, C₅-C₇ alicyclic radical, substituted C₅-C₇ alicyclic radical, halogen, OJ₁, NJ₁J₂, SJ₁, N₃, COOJ₁, acyl (C(=O)—H), substituted acyl, CN, sulfonyl (S(=O)₂-J₁), or sulfoxyl (S(=O)-J₁); and

each J₁ and J₂ is, independently, H, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₅-C₂₀ aryl, substituted C₅-C₂₀ aryl, acyl (C(=O)—H), substituted acyl, a heterocycle radical, a substituted heterocycle radical, C₁-C₁₂ aminoalkyl, substituted C₁-C₁₂ aminoalkyl or a protecting group.






In certain embodiments, the bridge of a bicyclic sugar moiety is —[C(R_a)(R_b)]_n—, —[C(R_a)(R_b)]_n—O—, —C(R_aR_b)—N(R)—O— or —C(R_aR_b)—O—N(R)—. In certain embodiments, the bridge is 4-CH₂-2', 4'-(CH₂)₂-2', 4'-(CH₂)₃-2', 4-CH₂-O-2', 4'-(CH₂)₂-O-2', 4-CH₂-O—

61

N(R)-2' and 4-CH₂-N(R)-O-2'- wherein each R is, independently, H, a protecting group or C₁-C₁₂ alkyl.







In certain embodiments, bicyclic nucleosides are further defined by isomeric configuration. For example, a nucleoside comprising a 4'-2' methylene-oxy bridge, may be in the α -L configuration or in the β -D configuration. Previously, α -L-methyleneoxy (4'-CH₂-O-2') BNA's have been incorporated into antisense oligonucleotides that showed antisense activity (Frieden et al., Nucleic Acids Research, 2003, 21, 6365-6372).

In certain embodiments, bicyclic nucleosides include, but are not limited to, (A) α -L-methyleneoxy (4'-CH₂-O-2') BNA, (B) β -D-methyleneoxy (4'-CH₂-O-2') BNA, (C) ethyleneoxy (4'-(CH₂)₂-O-2') BNA, (D) aminooxy (4'-CH₂-O-N(R)-2') BNA, (E) oxyamino (4'-CH₂-N(R)-O-2') BNA, and (F) methyl(methyleneoxy) (4'-CH(CH₃)-O-2') BNA, (G) methylene-thio (4'-CH₂-S-2') BNA, (H) methylene-amino (4'-CH₂-N(R)-2') BNA, (I) methyl carbocyclic (4'-CH₂-CH(CH₃)-2') BNA, (J) propylene carbocyclic (4'-(CH₂)₃-2') BNA and (K) vinyl BNA as depicted below:



62


-continued



wherein Bx is the base moiety and R is independently H, a protecting group, C₁-C₁₂ alkyl or C₁-C₁₂ alkoxy.

In certain embodiments, bicyclic nucleosides are provided having Formula I:

63



wherein:


Bx is a heterocyclic base moiety;

$-Q_a-Q_b-Q_c-$ is $-\text{CH}_2-\text{N}(\text{R}_c)-\text{CH}_2-$, $-\text{C}(=\text{O})-\text{N}(\text{R}_c)-\text{CH}_2-$, $-\text{CH}_2-\text{O}-\text{N}(\text{R}_c)-$, $-\text{CH}_2-\text{N}(\text{R}_c)-\text{O}-$ or $-\text{N}(\text{R}_c)-\text{O}-\text{CH}_2-$;

R_c is C_1-C_{12} alkyl or an amino protecting group; and

T_a and T_b are each, independently H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety or a covalent attachment to a support medium.

In certain embodiments, bicyclic nucleosides are provided having Formula II:



wherein:


Bx is a heterocyclic base moiety;

T_a and T_b are each, independently H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety or a covalent attachment to a support medium;

Z_a is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, substituted C_1-C_6 alkyl, substituted C_2-C_6 alkenyl, substituted C_2-C_6 alkynyl, acyl, substituted acyl, substituted amide, thiol or substituted thio.

In one embodiment, each of the substituted groups is, independently, mono or poly substituted with substituent groups independently selected from halogen, oxo, hydroxyl, OJ_c , NJ_c , SJ_c , N_3 , $\text{OC}(=\text{X})\text{J}_c$, and $\text{NJ}_c\text{C}(=\text{X})\text{NJ}_c$, wherein each J_c , J_d and J_e is, independently, H, C_1-C_6 alkyl, or substituted C_1-C_6 alkyl and X is O or NJ_c .

In certain embodiments, bicyclic nucleosides are provided having Formula III:



64


wherein:

Bx is a heterocyclic base moiety;

T_a and T_b are each, independently H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety or a covalent attachment to a support medium;

Z_b is C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, substituted C_1-C_6 alkyl, substituted C_2-C_6 alkenyl, substituted C_2-C_6 alkynyl or substituted acyl ($\text{C}(=\text{O})-$).

In certain embodiments, bicyclic nucleosides are provided having Formula IV:



wherein:


Bx is a heterocyclic base moiety;

T_a and T_b are each, independently H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety or a covalent attachment to a support medium;

R_d is C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_2-C_6 alkenyl, substituted C_2-C_6 alkenyl, C_2-C_6 alkynyl or substituted C_2-C_6 alkynyl;

each q_a , q_b , q_c and q_d is, independently, H, halogen, C_1-C_6 alkyl, substituted C_1-C_6 alkyl, C_2-C_6 alkenyl, substituted C_2-C_6 alkenyl, C_2-C_6 alkynyl or substituted C_2-C_6 alkynyl, C_1-C_6 alkoxy, substituted C_1-C_6 alkoxy, acyl, substituted acyl, C_1-C_6 aminoalkyl or substituted C_1-C_6 aminoalkyl;

In certain embodiments, bicyclic nucleosides are provided having Formula V:



wherein:

Bx is a heterocyclic base moiety;

T_a and T_b are each, independently H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety or a covalent attachment to a support medium;

q_a , q_b , q_c and q_d are each, independently, hydrogen, halogen, C_1-C_{12} alkyl, substituted C_1-C_{12} alkyl, C_2-C_{12} alkenyl, substituted C_2-C_{12} alkenyl, C_2-C_{12} alkynyl, substituted C_2-C_{12} alkynyl, C_1-C_{12} alkoxy, substituted C_1-C_{12} alkoxy, OJ_j , SJ_j , SO_2J_j , NJ_jJ_k , N_3 , CN , $\text{C}(=\text{O})\text{OJ}_j$, $\text{C}(=\text{O})\text{NJ}_j\text{J}_k$, $\text{C}(=\text{O})\text{J}_j$, $\text{O}-\text{C}(=\text{O})-\text{NJ}_j\text{J}_k$, $\text{N}(\text{H})\text{C}(=\text{NH})\text{NJ}_j\text{J}_k$, $\text{N}(\text{H})\text{C}(=\text{O})\text{NJ}_j\text{J}_k$ or $\text{N}(\text{H})\text{C}(=\text{S})\text{NJ}_j\text{J}_k$;

or q_a and q_b together are $=\text{C}(q_g)(q_h)$;


q_g and q_h are each, independently, H, halogen, C_1-C_{12} alkyl or substituted C_1-C_{12} alkyl.

The synthesis and preparation of the methyleneoxy (4- $\text{CH}_2-\text{O}-2'$) BNA monomers adenine, cytosine, guanine, 5-methyl-cytosine, thymine and uracil, along with their oligomerization, and nucleic acid recognition properties

have been described (Koshkin et al., Tetrahedron, 1998, 54, 3607-3630). Bicyclic nucleic acids (BNAs) and preparation thereof are also described in WO 98/39352 and WO 99/14226.

Analogues of methyleneoxy (4-CH₂-O-2') BNA and 2'-thio-BNAs, have also been prepared (Kumar et al., Bioorg. Med. Chem. Lett., 1998, 8, 2219-2222). Preparation of locked nucleoside analogs comprising oligodeoxyribo-nucleotide duplexes as substrates for nucleic acid poly-merases has also been described (Wengel et al., WO 99/14226). Furthermore, synthesis of 2'-amino-BNA, a novel conformationally restricted high-affinity oligonucle-otide analog has been described in the art (Singh et al., J. Org. Chem., 1998, 63, 10035-10039). In addition, 2'-amino- and 2'-methylamino-BNA's have been prepared and the thermal stability of their duplexes with complementary RNA and DNA strands has been previously reported.

In certain embodiments, bicyclic nucleosides are provided having Formula VI:



wherein:

Bx is a heterocyclic base moiety;

T_a and T_b are each, independently H, a hydroxyl protecting group, a conjugate group, a reactive phosphorus group, a phosphorus moiety or a covalent attachment to a support medium;

each q_i, q_j, q_k and q_l is, independently, H, halogen, C₁-C₁₂ alkyl, substituted C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, substituted C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, substituted C₂-C₁₂ alkynyl, C₁-C₁₂ alkoxy, substituted C₁-C₁₂ alkoxy, OJ_j, SJ_j, SOJ_j, N₃, CN, C(=O)OJ_j, C(=O)NJ_j, C(=O)J_j, O-C(=O)NJ_j, N(H)C(=NH)NJ_j, N(H)C(=O)NJ_j or N(H)C(=S)NJ_j; and

q_i and q_j or q_i and q_k together are =C(q_g)(q_h), wherein q_g and q_h are each, independently, H, halogen, C₁-C₁₂ alkyl or substituted C₁-C₁₂ alkyl.


One carbocyclic bicyclic nucleoside having a 4'-(CH₂)₃-2' bridge and the alkenyl analog bridge 4'-CH=CH-CH₂-2' have been described (Freier et al., Nucleic Acids Research, 1997, 25(22), 4429-4443 and Albaek et al., J. Org. Chem., 2006, 71, 7731-7740). The synthesis and preparation of carbocyclic bicyclic nucleosides along with their oligomer-ization and biochemical studies have also been described (Srivastava et al., J. Am. Chem. Soc., 2007, 129(26), 8362-8379).

As used herein, "4'-2' bicyclic nucleoside" or "4' to 2' bicyclic nucleoside" refers to a bicyclic nucleoside compris- ing a furanose ring comprising a bridge connecting two carbon atoms of the furanose ring connects the 2' carbon atom and the 4' carbon atom of the sugar ring.

As used herein, "monocyclic nucleosides" refer to nucleo- sides comprising modified sugar moieties that are not bicy- clic sugar moieties. In certain embodiments, the sugar moiety, or sugar moiety analogue, of a nucleoside may be modified or substituted at any position.


As used herein, "2'-modified sugar" means a furanosyl sugar modified at the 2' position. In certain embodiments, such modifications include substituents selected from: a halide, including, but not limited to substituted and unsub- stituted alkoxy, substituted and unsubstituted thioalkyl, sub- stituted and unsubstituted amino alkyl, substituted and unsubstituted alkyl, substituted and unsubstituted allyl, and substituted and unsubstituted alkynyl. In certain embodi- ments, 2' modifications are selected from substituents including, but not limited to: O[(CH₂)_nO]_mCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nF, O(CH₂)_nONH₂, OCH₂C(=O)N(H)CH₃, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about 10. Other 2'- substituent groups can also be selected from: C₁-C₁₂ alkyl, substituted alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aral- kyl, SH, SCH₃, OCN, Cl, Br, CN, F, CF₃, OCF₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, hetero- cycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an interca- lator, a group for improving pharmacokinetic properties, or a group for improving the pharmacodynamic properties of an antisense compound, and other substituents having similar properties. In certain embodiments, modified nucleosides comprise a 2'-MOE side chain (Baker et al., J. Biol. Chem., 1997, 272, 11944-12000). Such 2'-MOE substitution have been described as having improved binding affinity com- pared to unmodified nucleosides and to other modified nucleosides, such as 2'-O-methyl, O-propyl, and O-amino- propyl. Oligonucleotides having the 2'-MOE substituent also have been shown to be antisense inhibitors of gene expression with promising features for in vivo use (Martin, Helv. Chim. Acta, 1995, 78, 486-504; Altmann et al., Chimia, 1996, 50, 168-176; Altmann et al., Biochem. Soc. Trans., 1996, 24, 630-637; and Altmann et al., Nucleosides Nucleotides, 1997, 16, 917-926).

As used herein, a "modified tetrahydropyran nucleoside" or "modified THP nucleoside" means a nucleoside having a six-membered tetrahydropyran "sugar" substituted in for the pentofuranosyl residue in normal nucleosides (a sugar sur-rogate). Modified THP nucleosides include, but are not limited to, what is referred to in the art as hexitol nucleic acid (HNA), anitol nucleic acid (ANA), manitol nucleic acid (MNA) (see Leumann, Bioorg. Med. Chem., 2002, 10, 841-854) or fluoro HNA (F-HNA) having a tetrahydropyran ring system as illustrated below:



In certain embodiments, sugar surrogates are selected having Formula VII:

67



wherein independently for each of said at least one tetrahydropyran nucleoside analog of Formula VII:


Bx is a heterocyclic base moiety;

T_a and T_b are each, independently, an internucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense compound or one of T_a and T_b is an internucleoside linking group linking the tetrahydropyran nucleoside analog to the antisense compound and the other of T_a and T_b is H, a hydroxyl protecting group, a linked conjugate group or a 5' or 3'-terminal group;

q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each independently, H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl or substituted C₂-C₆ alkynyl; and each of R₁ and R₂ is selected from hydrogen, hydroxyl, halogen, substituted or unsubstituted alkoxy, NJ₁J₂, SJ₁, N₃, OC(=X)J₁, OC(=X)NJ₁J₂, NJ₃C(=X)NJ₁J₂ and CN, wherein X is O, S or NJ₁ and each J₁, J₂ and J₃ is, independently, H or C₁-C₆ alkyl.

In certain embodiments, the modified THP nucleosides of Formula VII are provided wherein q₁, q₂, q₃, q₄, q₅, q₆ and q₇ are each H. In certain embodiments, at least one of q₁, q₂, q₃, q₄, q₅, q₆ and q₇ is other than H. In certain embodiments, at least one of q₁, q₂, q₃, q₄, q₅, q₆ and q₇ is methyl. In certain embodiments, THP nucleosides of Formula VII are provided wherein one of R₁ and R₂ is fluoro. In certain embodiments, R₁ is fluoro and R₂ is H; R₁ is methoxy and R₂ is H, and R₁ is methoxyethoxy and R₂ is H.

In certain embodiments, sugar surrogates comprise rings having more than 5 atoms and more than one heteroatom. For example nucleosides comprising morpholino sugar moieties and their use in oligomeric compounds has been reported (see for example: Braasch et al., *Biochemistry*, 2002, 41, 4503-4510; and U.S. Pat. Nos. 5,698,685; 5,166,315; 5,185,444; and 5,034,506). As used here, the term "morpholino" means a sugar surrogate having the following formula:



In certain embodiments, morpholinos may be modified, for example by adding or altering various substituent groups from the above morpholino structure. Such sugar surrogates are referred to herein as "modified morpholinos."

Combinations of modifications are also provided without limitation, such as 2'-F-5'-methyl substituted nucleosides (see PCT International Application WO 2008/101157 published on Aug. 21, 2008 for other disclosed 5',2'-bis substituted nucleosides) and replacement of the ribosyl ring oxy-


68

VII

gen atom with S and further substitution at the 2'-position (see published U.S. Patent Application US2005-0130923, published on Jun. 16, 2005) or alternatively 5'-substitution of a bicyclic nucleic acid (see PCT International Application WO 2007/134181, published on Nov. 22, 2007 wherein a 4-CH₂-O-2' bicyclic nucleoside is further substituted at the 5' position with a 5'-methyl or a 5'-vinyl group). The synthesis and preparation of carbocyclic bicyclic nucleosides along with their oligomerization and biochemical studies have also been described (see, e.g., Srivastava et al., *J. Am. Chem. Soc.* 2007, 129(26), 8362-8379).

In certain embodiments, antisense compounds comprise one or more modified cyclohexenyl nucleosides, which is a nucleoside having a six-membered cyclohexenyl in place of the pentofuranosyl residue in naturally occurring nucleosides. Modified cyclohexenyl nucleosides include, but are not limited to those described in the art (see for example commonly owned, published PCT Application WO 2010/036696, published on Apr. 10, 2010, Robeyns et al., *J. Am. Chem. Soc.*, 2008, 130(6), 1979-1984; Horváth et al., *Tetrahedron Letters*, 2007, 48, 3621-3623; Nauwelaerts et al., *J. Am. Chem. Soc.*, 2007, 129(30), 9340-9348; Gu et al., *Nucleosides, Nucleotides & Nucleic Acids*, 2005, 24(5-7), 993-998; Nauwelaerts et al., *Nucleic Acids Research*, 2005, 33(8), 2452-2463; Robeyns et al., *Acta Crystallographica, Section F: Structural Biology and Crystallization Communications*, 2005, F61(6), 585-586; Gu et al., *Tetrahedron*, 2004, 60(9), 2111-2123; Gu et al., *Oligonucleotides*, 2003, 13(6), 479-489; Wang et al., *J. Org. Chem.*, 2003, 68, 4499-4505; Verbeure et al., *Nucleic Acids Research*, 2001, 29(24), 4941-4947; Wang et al., *J. Org. Chem.*, 2001, 66, 8478-82; Wang et al., *Nucleosides, Nucleotides & Nucleic Acids*, 2001, 20(4-7), 785-788; Wang et al., *J. Am. Chem.*, 2000, 122, 8595-8602; Published PCT application, WO 06/047842; and Published PCT Application WO 01/049687; the text of each is incorporated by reference herein, in their entirety). Certain modified cyclohexenyl nucleosides have Formula X.

X



wherein independently for each of said at least one cyclohexenyl nucleoside analog of Formula X:

Bx is a heterocyclic base moiety;

T₃ and T₄ are each, independently, an internucleoside linking group linking the cyclohexenyl nucleoside analog to an antisense compound or one of T₃ and T₄ is an internucleoside linking group linking the tetrahydropyran nucleoside analog to an antisense compound and the other of T₃ and T₄ is H, a hydroxyl protecting group, a linked conjugate group, or a 5'- or 3'-terminal group; and

q₁, q₂, q₃, q₄, q₅, q₆, q₇, q₈ and q₉ are each, independently, H, C₁-C₆ alkyl, substituted C₁-C₆ alkyl, C₂-C₆ alkenyl, substituted C₂-C₆ alkenyl, C₂-C₆ alkynyl, substituted C₂-C₆ alkynyl or other sugar substituent group.

As used herein, "2'-modified" or "2'-substituted" refers to a nucleoside comprising a sugar comprising a substituent at

the 2' position other than H or OH. 2'-modified nucleosides, include, but are not limited to, bicyclic nucleosides wherein the bridge connecting two carbon atoms of the sugar ring connects the 2' carbon and another carbon of the sugar ring; and nucleosides with non-bridging 2'substituents, such as allyl, amino, azido, thio, O-allyl, O—C₁-C₁₀ alkyl, —OCF₃, O—(CH₂)₂—O—CH₃, 2'-O(CH₂)₂SCH₃, O—(CH₂)₂—O—N(R_m)(R_n) or O—CH₂—C(=O)—N(R_m)(R_n), where each R_m and R_n is, independently, H or substituted or unsubstituted C₁-C₁₀ alkyl. 2'-modified nucleosides may further comprise other modifications, for example at other positions of the sugar and/or at the nucleobase.

As used herein, "2'-F" refers to a nucleoside comprising a sugar comprising a fluoro group at the 2' position of the sugar ring.

As used herein, "2'-OMe" or "2'-OCH₃" or "2'-O-methyl" each refers to a nucleoside comprising a sugar comprising an —OCH₃ group at the 2' position of the sugar ring.

As used herein, "oligonucleotide" refers to a compound comprising a plurality of linked nucleosides. In certain embodiments, one or more of the plurality of nucleosides is modified. In certain embodiments, an oligonucleotide comprises one or more ribonucleosides (RNA) and/or deoxyribonucleosides (DNA).

Many other bicyclo and tricyclo sugar surrogate ring systems are also known in the art that can be used to modify nucleosides for incorporation into antisense compounds (see for example review article: Leumann, *Bioorg. Med. Chem.*, 2002, 10, 841-854). Such ring systems can undergo various additional substitutions to enhance activity.

Methods for the preparations of modified sugars are well known to those skilled in the art. Some representative U.S. patents that teach the preparation of such modified sugars include without limitation, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,670,633; 5,700,920; 5,792,847 and 6,600,032 and International Application PCT/US2005/019219, filed Jun. 2, 2005 and published as WO 2005/121371 on Dec. 22, 2005, and each of which is herein incorporated by reference in its entirety.

In nucleotides having modified sugar moieties, the nucleobase moieties (natural, modified or a combination thereof) are maintained for hybridization with an appropriate nucleic acid target.

In certain embodiments, antisense compounds comprise one or more nucleosides having modified sugar moieties. In certain embodiments, the modified sugar moiety is 2'-MOE. In certain embodiments, the 2'-MOE modified nucleosides are arranged in a gapmer motif. In certain embodiments, the modified sugar moiety is a bicyclic nucleoside having a (4'-CH(CH₃)—O-2') bridging group. In certain embodiments, the (4'-CH(CH₃)—O-2') modified nucleosides are arranged throughout the wings of a gapmer motif.

Modified Nucleobases

Nucleobase (or base) modifications or substitutions are structurally distinguishable from, yet functionally interchangeable with, naturally occurring or synthetic unmodified nucleobases. Both natural and modified nucleobases are capable of participating in hydrogen bonding. Such nucleobase modifications can impart nuclease stability, binding affinity or some other beneficial biological property to antisense compounds. Modified nucleobases include synthetic and natural nucleobases such as, for example, 5-methylcytosine (5-me-C). Certain nucleobase substitutions, including 5-methylcytosine substitutions, are particularly

useful for increasing the binding affinity of an antisense compound for a target nucleic acid. For example, 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278).

Additional modified nucleobases include 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (—C≡C—CH₃) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine.

Heterocyclic base moieties can also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Nucleobases that are particularly useful for increasing the binding affinity of antisense compounds include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2 aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.

In certain embodiments, antisense compounds targeted to an androgen receptor nucleic acid comprise one or more modified nucleobases. In certain embodiments, shortened or gap-widened antisense oligonucleotides targeted to an androgen receptor nucleic acid comprise one or more modified nucleobases. In certain embodiments, the modified nucleobase is 5-methylcytosine. In certain embodiments, each cytosine is a 5-methylcytosine.

Conjugated Antisense Compounds

Antisense compounds may be covalently linked to one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the resulting antisense oligonucleotides. Typical conjugate groups include cholesterol moieties and lipid moieties. Additional conjugate groups include carbohydrates, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone, acridine, fluoresceins, rhodamines, coumarins, and dyes.

Antisense compounds can also be modified to have one or more stabilizing groups that are generally attached to one or both termini of antisense compounds to enhance properties such as, for example, nuclease stability. Included in stabilizing groups are cap structures. These terminal modifications protect the antisense compound having terminal nucleic acid from exonuclease degradation, and can help in delivery and/or localization within a cell. The cap can be present at the 5'-terminus (5'-cap), or at the 3'-terminus (3'-cap), or can be present on both termini. Cap structures are well known in the art and include, for example, inverted deoxy abasic caps. Further 3' and 5'-stabilizing groups that can be used to cap one or both ends of an antisense compound to impart nuclease stability include those disclosed in WO 03/004602 published on Jan. 16, 2003.

In certain embodiments, antisense compounds, including, but not limited to those particularly suited for use as ssRNA, are modified by attachment of one or more conjugate groups. In general, conjugate groups modify one or more properties of the attached oligonucleotide, including but not limited to

pharmacodynamics, pharmacokinetics, stability, binding, absorption, cellular distribution, cellular uptake, charge and clearance. Conjugate groups are routinely used in the chemical arts and are linked directly or via an optional conjugate linking moiety or conjugate linking group to a parent compound such as an oligonucleotide. Conjugate groups includes without limitation, intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, thioethers, polyethers, cholesterol, thiocholesterols, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins and dyes. Certain conjugate groups have been described previously, for example: cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Lett.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., do-decan-diol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or hexylaminocarbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937).

For additional conjugates including those useful for ssRNA and their placement within antisense compounds, see e.g., PCT Publication No.; WO2013/033230.

Compositions and Methods for Formulating Pharmaceutical Compositions

Antisense oligonucleotides may be admixed with pharmaceutically acceptable active or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered.

An antisense compound targeted to an androgen receptor nucleic acid can be utilized in pharmaceutical compositions by combining the antisense compound with a suitable pharmaceutically acceptable diluent or carrier. In certain embodiments, a pharmaceutically acceptable diluent is water, such as sterile water suitable for injection. Accordingly, in one embodiment, employed in the methods described herein is a pharmaceutical composition comprising an antisense compound targeted to an androgen receptor nucleic acid and a pharmaceutically acceptable diluent. In certain embodiments, the pharmaceutically acceptable diluent is water. In certain embodiments, the antisense compound is an antisense oligonucleotide provided herein.

Pharmaceutical compositions comprising antisense compounds encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other oligonucleotide which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to pharmaceutically

acceptable salts of antisense compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts.

A prodrug can include the incorporation of additional nucleosides at one or both ends of an antisense compound which are cleaved by endogenous nucleases within the body, to form the active antisense compound.

In Vitro Testing of Antisense Oligonucleotides

Described herein are methods for treatment of cells with antisense oligonucleotides, which can be modified appropriately for treatment with other antisense compounds.

Cells may be treated with antisense oligonucleotides when the cells reach approximately 60-80% confluency in culture.

One reagent commonly used to introduce antisense oligonucleotides into cultured cells includes the cationic lipid transfection reagent LIPOFECTIN (Invitrogen, Carlsbad, Calif.). Antisense oligonucleotides may be mixed with LIPOFECTIN in OPTI-MEM 1 (Invitrogen, Carlsbad, Calif.) to achieve the desired final concentration of antisense oligonucleotide and a LIPOFECTIN concentration that may range from 2 to 12 ug/mL per 100 nM antisense oligonucleotide.

Another reagent used to introduce antisense oligonucleotides into cultured cells includes LIPOFECTAMINE (Invitrogen, Carlsbad, Calif.). Antisense oligonucleotide is mixed with LIPOFECTAMINE in OPTI-MEM 1 reduced serum medium (Invitrogen, Carlsbad, Calif.) to achieve the desired concentration of antisense oligonucleotide and a LIPOFECTAMINE concentration that may range from 2 to 12 ug/mL per 100 nM antisense oligonucleotide.

Another technique used to introduce antisense oligonucleotides into cultured cells includes electroporation.

Yet another technique used to introduce antisense oligonucleotides into cultured cells includes free uptake of the oligonucleotides by the cells.

Cells are treated with antisense oligonucleotides by routine methods. Cells may be harvested 16-24 hours after antisense oligonucleotide treatment, at which time RNA or protein levels of target nucleic acids are measured by methods known in the art and described herein. In general, when treatments are performed in multiple replicates, the data are presented as the average of the replicate treatments.

The concentration of antisense oligonucleotide used varies from cell line to cell line. Methods to determine the optimal antisense oligonucleotide concentration for a particular cell line are well known in the art. Antisense oligonucleotides are typically used at concentrations ranging from 1 nM to 300 nM when transfected with LIPOFECTAMINE. Antisense oligonucleotides are used at higher concentrations ranging from 625 to 20,000 nM when transfected using electroporation.

RNA Isolation

RNA analysis can be performed on total cellular RNA or poly(A)+mRNA. Methods of RNA isolation are well known in the art. RNA is prepared using methods well known in the art, for example, using the TRIZOL Reagent (Invitrogen, Carlsbad, Calif.) according to the manufacturer's recommended protocols.

EMBODIMENTS

E1. A compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a

nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 12-179.

E2. A compound comprising a modified oligonucleotide consisting of 16 to 30 linked nucleosides and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 12-179.

E3. A compound comprising a modified oligonucleotide consisting of the nucleobase sequence of any one of SEQ ID NOs: 12-179.

E4. A compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides and having a nucleobase sequence comprising at least 8 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175.

E5. A compound comprising a modified oligonucleotide consisting of 16 to 30 linked nucleosides and having a nucleobase sequence comprising the nucleobase sequence of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175.

E6. A compound comprising a modified oligonucleotide consisting of 16 linked nucleosides and having a nucleobase sequence consisting of the nucleobase sequence of SEQ ID NO: 35, 39, 43, 124, 150, 155, 169, or 175.

E7. A compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides complementary within nucleotides 2957-2972, 3079-3094, 3099-3114, 3109-3124, 3113-3128, 3120-3135, 3133-3148, 3224-3239, 3226-3241, 3351-3366, 3353-3368, 3361-3376, 3388-3403, 3513-3528, 3517-3532, 3519-3534, 3641-3656, 3735-3750, 3764-3779, 3768-3783, 3798-3813, 3799-3814, 3851-3866, 3870-3885, 3874-3889, 3876-3891, 3878-3893, 3884-3899, 3886-3901, 3888-3903, 3901-3916, 3956-3971, 3962-3977, 3964-3979, 3967-3982, 4019-4034, 4038-4053, 4049-4064, 4056-4071, 4059-4074, 4062-4077, 4066-4081, 4070-4085, 4101-4116, 4103-4118, 4105-4120, 4109-4124, 4305-4320, 4405-4420, 4532-4547, 4534-4549, 4537-4552, 4539-4554, 4555-4570, 4571-4586, 4573-4588, 4578-4593, 4597-4612, 4632-4647, 4655-4670, 4656-4671, 4662-4677, 4699-4714, 4747-4762, 4750-4765, 4752-4767, 4754-4769, 4755-4770, 4769-4784, 4798-4813, 4804-4819, 4807-4822, 4833-4848, 4837-4852, 4839-4854, 4865-4880, 4868-4883, 4872-4887, 4874-4889, 4876-4891, 4887-4902, 4889-4904, 4916-4931, 4918-4933, 4938-4953, 4942-4957, 4944-4959, 4951-4966, 5050-5065, 5052-5067, 5054-5069, 5056-5071, 5060-5075, 5061-5076, 5062-5077, 5133-5148, 5141-5156, 5155-5170, 5265-5280, 5293-5308, 5308-5323, 5392-5407, 5448-5463, 5469-5484, 5481-5496, 5483-5498, 5486-5501, 5488-5503, 5494-5509, 5521-5536, 5666-5681, 6222-6237, 6701-6716, 7543-7558, 8471-8486, 8638-8653, 9464-9479, 10217-10232, 10250-10265, 10865-10880, 11197-11212, 11855-11870, 13189-13204, 13321-13336, 13346-13361, 16555-16570, 16793-16808, 16968-16983, 17206-17221, 18865-18880, 29329-29344, 32290-32305, 33315-33330, 39055-39070, 40615-40630, 42017-42032, 56050-56065, 58719-58734, 58720-58739, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58725-58740, 58750-58769, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 60902-60917, 67454-67469, 114874-114889, 115272-115287, 115365-115380, 134971-134986, 102156-102171, 139682-139697, 139762-139777, 139782-139797, 144856-144871, 144938-144953, 148406-148421, 148443-148458, 148520-148535, 181695-181710, 182958-182973, or 183049-183064 of SEQ ID NO: 1, wherein said modified oligonucleotide is at least 90% complementary to SEQ ID NO: 1.

E8. A compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides having a nucle-

obase sequence comprising a portion of at least 8 contiguous nucleobases 100% complementary to an equal length portion of nucleobases 2957-2972, 3079-3094, 3099-3114, 3109-3124, 3113-3128, 3120-3135, 3133-3148, 3224-3239, 3226-3241, 3351-3366, 3353-3368, 3361-3376, 3388-3403, 3513-3528, 3517-3532, 3519-3534, 3641-3656, 3735-3750, 3764-3779, 3768-3783, 3798-3813, 3799-3814, 3851-3866, 3870-3885, 3874-3889, 3876-3891, 3878-3893, 3884-3899, 3886-3901, 3888-3903, 3901-3916, 3956-3971, 3962-3977, 3964-3979, 3967-3982, 4019-4034, 4038-4053, 4049-4064, 4056-4071, 4059-4074, 4062-4077, 4066-4081, 4070-4085, 4101-4116, 4103-4118, 4105-4120, 4109-4124, 4305-4320, 4405-4420, 4532-4547, 4534-4549, 4537-4552, 4539-4554, 4555-4570, 4571-4586, 4573-4588, 4578-4593, 4597-4612, 4632-4647, 4655-4670, 4656-4671, 4662-4677, 4699-4714, 4747-4762, 4750-4765, 4752-4767, 4754-4769, 4755-4770, 4769-4784, 4798-4813, 4804-4819, 4807-4822, 4833-4848, 4837-4852, 4839-4854, 4865-4880, 4868-4883, 4872-4887, 4874-4889, 4876-4891, 4887-4902, 4889-4904, 4916-4931, 4918-4933, 4938-4953, 4942-4957, 4944-4959, 4951-4966, 5050-5065, 5052-5067, 5054-5069, 5056-5071, 5060-5075, 5061-5076, 5062-5077, 5133-5148, 5141-5156, 5155-5170, 5265-5280, 5293-5308, 5308-5323, 5392-5407, 5448-5463, 5469-5484, 5481-5496, 5483-5498, 5486-5501, 5488-5503, 5494-5509, 5521-5536, 5666-5681, 6222-6237, 6701-6716, 7543-7558, 8471-8486, 8638-8653, 9464-9479, 10217-10232, 10250-10265, 10865-10880, 11197-11212, 11855-11870, 13189-13204, 13321-13336, 13346-13361, 16555-16570, 16793-16808, 16968-16983, 17206-17221, 18865-18880, 29329-29344, 32290-32305, 33315-33330, 39055-39070, 40615-40630, 42017-42032, 56050-56065, 58719-58734, 58720-58739, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58725-58740, 58750-58769, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 60902-60917, 67454-67469, 114874-114889, 115272-115287, 115365-115380, 134971-134986, 102156-102171, 139682-139697, 139762-139777, 139782-139797, 144856-144871, 144938-144953, 148406-148421, 148443-148458, 148520-148535, 181695-181710, 182958-182973, or 183049-183064 of SEQ ID NO: 1, wherein the nucleobase sequence of the modified oligonucleotide is complementary to SEQ ID NO: 1.

E9. The compound of any one of E1, E7, or E8, wherein the compound comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides complementary within exon 1 nucleotides 2957-2972, 3079-3094, 3099-3114, 3109-3124, 3113-3128, 3120-3135, 3133-3148, 3224-3239, 3226-3241, 3351-3366, 3353-3368, 3361-3376, 3388-3403, 3513-3528, 3517-3532, 3519-3534, 3641-3656, 3735-3750, 3764-3779, 3768-3783, 3798-3813, 3799-3814, 3851-3866, 3870-3885, 3874-3889, 3876-3891, 3878-3893, 3884-3899, 3886-3901, 3888-3903, 3901-3916, 3956-3971, 3962-3977, 3964-3979, 3967-3982, 4019-4034, 4038-4053, 4049-4064, 4056-4071, 4059-4074, 4062-4077, 4066-4081, 4070-4085, 4101-4116, 4103-4118, 4105-4120, 4109-4124, 4305-4320, 4405-4420, 4532-4547, 4534-4549, 4537-4552, 4539-4554, 4555-4570, 4571-4586, 4573-4588, 4578-4593, 4597-4612, 4632-4647, 4655-4670, 4656-4671, 4662-4677, 4699-4714, 4747-4762, 4750-4765, 4752-4767, 4754-4769, 4755-4770, 4769-4784, 4798-4813, 4804-4819, 4807-4822, 4833-4848, 4837-4852, 4839-4854, 4865-4880, 4868-4883, 4872-4887, 4874-4889, 4876-4891, 4887-4902, 4889-4904, 4916-4931, 4918-4933, 4938-4953, 4942-4957, 4944-4959, 4951-4966, 5050-5065, 5052-5067, 5054-5069, 5056-5071, 5060-5075, 5061-5076, 5062-5077, 5133-5148, 5141-5156, 5155-5170, 5265-5280, 5293-5308, 5308-5323, 5392-5407, 5448-5463,

5469-5484, 5481-5496, 5483-5498, 5486-5501, 5488-5503, 5494-5509, or 5521-5536 of SEQ ID NO:1.

E10. The compound of E9, wherein the compound comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides complementary within exon 1 nucleotides 5052-5067 of SEQ ID NO:1.

E11. The compound of any one of E1, E7, or E8, wherein the compound comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides complementary within intron 1 nucleotides 5666-5681, 6222-6237, 6701-6716, 7543-7558, 8471-8486, 8638-8653, 9464-9479, 10217-10232, 10250-10265, 10865-10880, 11197-11212, 11855-11870, 13189-13204, 13321-13336, 13346-13361, 16555-16570, 16793-16808, 16968-16983, 17206-17221, 18865-18880, 29329-29344, 32290-32305, 33315-33330, 39055-39070, 40615-40630, 42017-42032, 56050-56065, 58719-58734, 58720-58739, 58721-58736, 58722-58737, 58723-58738, 58724-58739, 58725-58740, 58750-58769, 58751-58766, 58752-58767, 58753-58768, 58754-58769, 58755-58770, 60902-60917, 67454-67469, 114874-114889, 115272-115287, 115365-115380, or 134971-134986 of SEQ ID NO:1.

E12. The compound of E11, wherein the compound comprises a modified oligonucleotide consisting of 10 to 30 linked nucleosides complementary within intron 1 nucleotides 8638-8653, 11197-11212, 40615-40630, 58719-58734, 58720-58735, or 58721-58736 of SEQ ID NO:1.

E13. The compound of any one of E1-12, wherein the modified oligonucleotide comprises at least one modified sugar.

E14. The compound of E13, wherein at least one modified sugar comprises a 2'-O-methoxyethyl group.

E15. The compound of E13, wherein the at least one modified sugar is a bicyclic sugar.

E16. The compound of E15, wherein the bicyclic sugar comprises a 4'-CH(CH₃)—O-2' group.

E17. The compound of E15, wherein the bicyclic sugar comprises a 4'-CH₂—O-2' or 4'-(CH₂)₂—O-2' group.

E18. The compound of any one of E1-17, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.

E19. The compound of E18, wherein each internucleoside linkage of the antisense oligonucleotide is a phosphorothioate internucleoside linkage.

E20. The compound of any one of E1-19, wherein the modified oligonucleotide comprises at least one modified nucleobase.

E21. The compound of E20, wherein the modified nucleobase is a 5-methylcytosine.

E22. The compound of any one of E1-21, wherein the modified oligonucleotide comprises:

- a gap segment consisting of linked deoxynucleosides;
- a 5' wing segment consisting of linked nucleosides; and
- a 3' wing segment consisting of linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

E23. The compound of E22, wherein the modified oligonucleotide comprises:

- a gap segment consisting of ten linked deoxynucleosides;
- a 5' wing segment consisting of 3 linked nucleosides; and
- a 3' wing segment consisting of 3 linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-

methoxyethyl sugar or a constrained ethyl sugar; and wherein each internucleoside linkage is a phosphorothioate linkage.

E24. A compound comprising a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 35, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

- a gap segment consisting of 9 linked deoxynucleosides;
- a 5' wing segment consisting of three linked nucleosides; and

a 3' wing segment consisting of four linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; the three linked nucleosides of the 5' wing segment are each a constrained ethyl (cEt) sugar; the four linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

E25. A compound comprising a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 39, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

- a gap segment consisting of 9 linked deoxynucleosides;
- a 5' wing segment consisting of three linked nucleosides; and

a 3' wing segment consisting of four linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; the three linked nucleosides of the 5' wing segment are each a constrained ethyl (cEt) sugar; the four linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

E26. A compound comprising a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 39, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

- a gap segment consisting of 8 linked deoxynucleosides;
- a 5' wing segment consisting of four linked nucleosides; and

a 3' wing segment consisting of four linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; the four linked nucleosides of the 5' wing segment are a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a constrained ethyl (cEt) sugar in the 5' to 3' direction; the four linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; each internucleoside linkage is a phosphorothioate linkage; and each cytosine is a 5-methylcytosine.

E27. A compound comprising a single-stranded modified oligonucleotide consisting of 16 linked nucleosides having a nucleobase sequence consisting of the sequence of SEQ ID NO: 39, or a pharmaceutically acceptable salt thereof, wherein the modified oligonucleotide comprises:

- a gap segment consisting of 8 linked deoxynucleosides;
- a 5' wing segment consisting of five linked nucleosides; and

79


E36. The compound of any one of E1-35, wherein the modified oligonucleotide is at least 90% complementary to a nucleic acid encoding androgen receptor.

E37. The compound of any one of E1-36, wherein the antisense oligonucleotide is 100% complementary to a nucleic acid encoding androgen receptor.


E38. The compound of E37, wherein the nucleic acid encoding androgen receptor comprises the nucleotide sequence of any one of SEQ ID NOs: 1-8.

E39. A composition comprising the compound of any one of E1-38, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

E40. A composition comprising the compound of any one of E1-38 and a diarylhydantoin Androgen Receptor (AR) inhibitor of Formula XVI:



wherein X is selected from the group consisting of trifluoromethyl and iodo, wherein W is selected from the group consisting of O and NR5, wherein R5 is selected from the group consisting of H, methyl, and



wherein D is S or O and E is N or O and G is alkyl, aryl, substituted alkyl or substituted aryl; or D is S or O and E-G together are C1-C4 lower alkyl,

wherein R1 and R2 together comprise eight or fewer carbon atoms and are selected from the group consisting of alkyl, substituted alkyl including haloalkyl, and, together with the carbon to which they are linked, a cycloalkyl or substituted cycloalkyl group,


wherein R3 is selected from the group consisting of hydrogen, halogen, methyl, C1-C4 alkoxy, formyl, haloacetoxy, trifluoromethyl, cyano, nitro, hydroxyl, phenyl, amino, methylcarbamoyl, methoxycarbonyl, acetamido, methanesulfonamino, methanesulfonyl, 4-methanesulfonyl-1-piperazinyl, piperazinyl, and C1-C6 alkyl or alkenyl optionally substituted with hydroxyl, methoxycarbonyl, cyano, amino, amido, nitro, carbamoyl, or substituted carbamoyl including methylcarbamoyl, dimethylcarbamoyl, and hydroxyethylcarbamoyl,

wherein R4 is selected from the group consisting of hydrogen, halogen, alkyl, and haloalkyl, and

wherein R3 is not methylaminomethyl or dimethylaminomethyl.

80

R5 may be



E41. The composition of E40, wherein the diarylhydantoin Androgen Receptor (AR) inhibitor is MDV3100.

E42. A composition comprising the compound of any one of E1-38 and an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464.

E43. A method of treating cancer comprising administering to a subject having cancer the compound of any one of E1-38 or composition of any one of E39-42, thereby treating cancer in the subject.

E44. An antisense compound of any one of E1-38 or composition of any one of E39-42 for use in treating cancer

E45. The compound or composition of E44, wherein the cancer is prostate cancer, breast cancer, ovarian cancer, gastric cancer or bladder cancer.

E46. The compound or composition of E45, wherein the cancer is castrate-resistant prostate cancer.

E47. The compound or composition of E46, wherein the castrate-resistant prostate cancer is resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464.

E48. The method of E43, wherein the cancer is prostate cancer, breast cancer, ovarian cancer, gastric cancer or bladder cancer.

E49. The method of E48, wherein the cancer is castrate-resistant prostate cancer.

E50. The method of E49, wherein the castrate-resistant prostate cancer is resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464.

E51. The compound of E44-47 or the method of E49 or E50, wherein the antisense compound targets an AR splicing variant.

E52. The compound or method of E51, wherein the AR splicing variant lacks a functional ligand binding domain.

E53. The compound of E44-47 or the method of any one of E49-52, wherein the antisense compound is capable of reducing expression of full-length AR and an AR splicing variant lacking any one of exons 4-8.

E54. The compound or method of E51, wherein the AR splicing variant consists of exons 1-3.

E55. The compound of E44-47 or the method of any one of E49-52, wherein the antisense compound is targeted to AR upstream of the 3' end of exon 3 and is capable of inhibiting growth or proliferation of the prostate cancer cell

to a greater extent than an antisense compound targeted to a region of AR downstream of the 3' end of exon 3.

E56. The compound or method of E55, wherein the antisense compound targeted to a region of AR downstream of the 3' end of exon 3 is capable of reducing levels of full-length AR but not an AR splicing variant consisting of exons 1-3.

E57. The compound or method of E56, wherein the region downstream of the 3' end of exon 3 comprises exon 4.

E58. The compound of E44-47 or the method of any one of E49-52, wherein the prostate cancer cell preferentially expresses an AR splicing variant over full-length AR.

E59. The compound or method of E58, wherein the AR splicing variant lacks a functional ligand binding domain.

E60. A method of treating prostate cancer resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464 in a subject comprising administering to the subject an antisense compound targeted to human androgen receptor (AR) upstream of the 3' end of exon 3, thereby treating the prostate cancer.

E61. The method of E60, wherein the subject is diagnosed as having prostate cancer resistant to the anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464.

E62. The method of E60 or E61, wherein the antisense compound targets an AR splicing variant.

E63. The method of E62, wherein the AR splicing variant lacks a functional ligand binding domain.

E64. The method of any one of E60-63, wherein the antisense compound is capable of reducing expression of full-length AR and an AR splicing variant lacking any one of exons 4-8.

E65. The method of E64, wherein the AR splicing variant consists of exons 1-3.

E66. The method of any one of E60-65, wherein the antisense compound is targeted to AR upstream of the 3' end of exon 3 and is capable of inhibiting growth or proliferation of a prostate cancer cell resistant to the diarylhydantoin Androgen Receptor (AR) inhibitor to a greater extent than an antisense compound targeted to a region of AR downstream of the 3' end exon 3.

E67. The method of E66, wherein the antisense compound targeted to a region of AR downstream of the 3' end of exon 3 is capable of reducing levels of full-length AR but not an AR splicing variant lacking any one of exons 4-8.

E68. The method of E67, wherein the AR splicing variant consists of exons 1-3.

E69. The method of E68, wherein the region downstream of the 3' end of exon 3 comprises exon 4.

E70. The method of any one of E60-69, wherein the prostate cancer is castration-resistant.

E71. The method of any one of E60-70, wherein the prostate cancer comprises cells that preferentially express an AR splicing variant over full-length AR.

E72. The method of E71, wherein the AR splicing variant lacks any one of exons 4-8.

E73. The method of E72, wherein the AR splicing variant consists of exons 1-3.

E74. The method of E72, wherein the AR splicing variant lacks a functional ligand binding domain.

E75. A method of inhibiting prostate cancer cell growth or proliferation comprising contacting the prostate cancer cell with an antisense compound targeted to human androgen receptor (AR) and anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464, wherein the antisense compound and

the anti-androgenic agent synergize in combination to inhibit the growth or proliferation of the prostate cancer cell.

E76. The method of E75, wherein the antisense compound is targeted to AR upstream of the 3' end of exon 3.

E77. The method of E75 or E76, wherein the prostate cancer cell is contacted with an amount of the antisense compound and an amount of anti-androgenic agent that are each or both less in combination than the amount of either the antisense compound or anti-androgenic agent alone effective in inhibiting the growth or proliferation of said prostate cancer cell.

E78. The method of any one of E75-77, wherein the antisense compound and anti-androgenic agent provide a greater-than-additive effect compared to the antisense compound alone or anti-androgenic agent alone in inhibiting the growth or proliferation of said prostate cancer cell.

E79. The method of any one of E75-78, wherein the antisense compound targets an AR splicing variant.

E80. The method of E79, wherein the AR splicing variant lacks a functional ligand binding domain.

E81. The method of any one of E75-80, wherein the antisense compound is capable of reducing expression of full-length AR and an AR splicing variant consisting of exons 1-3.

E82. A method of inhibiting growth or proliferation of an androgen receptor (AR)-positive breast cancer cell comprising contacting the breast cancer cell with an antisense compound targeted to human androgen receptor (AR) wherein the growth or proliferation of the breast cancer cell is inhibited.

E83. A method of inhibiting AR expression in a subject having or at risk of having an androgen receptor (AR)-positive breast cancer comprising:

identifying a subject having or at risk of having AR-positive breast cancer, and

administering to the subject an antisense compound targeted to human AR,

wherein the antisense compound inhibits AR expression in the subject.

E84. A method of treating AR-positive breast cancer in a subject comprising administering to the subject an antisense compound targeted to human androgen receptor (AR), thereby treating the breast cancer in the subject.

E85. The method of any one of E82-84, wherein the AR-positive breast cancer or breast cancer cell is dependent on androgen expression for growth.

E86. The method of any one of E82-85, wherein the breast cancer or breast cancer cell is estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, or Her2/neu-negative.

E87. The method of any one of E82-85, wherein the breast cancer or breast cancer cell is ER-positive and AR-positive.

E88. The method of any one of E82-85, wherein the breast cancer or breast cancer cell is ER-negative and AR-positive.

E89. The method of any one of E82-88, wherein the breast cancer or breast cancer cell is an apocrine breast cancer or breast cancer cell.

E90. The method of any one of E60-88, wherein the antisense compound is the compound of any one of E1-38, or pharmaceutically acceptable salt thereof.

E91. The method of any one of E60-88, wherein the antisense compound is the compound of any one of E24-35, or pharmaceutically acceptable salt thereof.

EXAMPLES

Non-Limiting Disclosure and Incorporation by Reference

While certain compounds, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same. Each of the references recited in the present application is incorporated herein by reference in its entirety.

Example 1

Antisense Inhibition of Human AR in HuVEC Cells

Antisense oligonucleotides were designed targeting an AR nucleic acid and were tested for their effects on AR mRNA in vitro. The antisense oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are presented in separate tables shown below. Cultured HuVEC cells at a density of 20,000 cells per well were transfected using electroporation with 500 nM antisense oligonucleotide. After a treatment period of approximately 24 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human primer probe set RTS3559 (forward sequence TCCTTCACCAATGTCAACTCC, designated herein as SEQ ID NO: 9; reverse sequence GAGC-CATCCAAACTCTTGAGA, designated herein as SEQ ID

NO: 10; probe sequence AGTACCG-CATGCACAAGTCCCG, designated herein as SEQ ID NO: 11) was used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells. A total of 155 oligonucleotides were tested. Only those oligonucleotides which were selected for further study are shown in Tables 1 and 2.

The newly designed chimeric antisense oligonucleotides in Tables 1 and 2 were designed as 3-10-3 (S)-cET gapmers. The gapmers are 16 nucleosides in length, wherein the central gap segment comprises of ten 2'-deoxynucleosides and is flanked by wing segments on both the 5' direction and on the 3' direction comprising three nucleosides. Each nucleoside in the 5' wing segment and each nucleoside in the 3' wing segment has an (S)-cEt modification. The internucleoside linkages throughout each gapmer are phosphorothioate linkages. All cytosine residues throughout each gapmer are 5-methylcytosines. "Start site" indicates the 5'-most nucleoside to which the gapmer is targeted in the human gene sequence. "Stop site" indicates the 3'-most nucleoside to which the gapmer is targeted human gene sequence. Each gapmer listed in Tables 1 and 2 is targeted to either the human AR genomic sequence, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NT_011669.17 truncated from nucleotides 5079000 to 5270000) or the human AR mRNA sequence, designated herein as SEQ ID NO: 2 (GENBANK Accession No. NM_000044.3), or both. 'n/a.' indicates that the oligonucleotide does not target that particular gene sequence.

TABLE 1

Target Start Site for SEQ ID NO: 1	Target Start Site for SEQ ID NO: 2	ISIS No	Sequence	% inhibition	SEQ ID NO
3799	937	549332	GCGCTCTGACAGCCTC	84	12
3851	989	549334	CACCTGCGGAAGCTC	83	13
3888	1026	549338	GGCTGTGATGATGCGG	83	14
4047	1185	549345	TCTGGAACAGATTCTG	82	191
4059	1197	549347	CTTCGCGCACGCTCTG	84	15
4534	1672	549358	ATGGTGCTGGCCTCGC	91	16
4655	1793	549360	GGTCGAAGTGCCCCCT	89	17
4699	1837	549361	GACACCGACACTGCCT	84	18
4755	1893	549362	CCCGAAGCTGTTCCCC	85	19
4865	2003	549366	CTTGCCTGCGCTGTCG	84	20
5060	2198	549371	GTTGTAGTAGTCGCGA	93	21
5062	2200	549372	AAGTTGTAGTAGTCGC	92	22
5155	2293	549374	GCGCTGCCGTAGTCCA	93	23
5265	2403	549377	AGGATGAGGAAGCGGC	90	24
5392	2530	549379	GCTCCCGCTCGCCGC	86	25
5448	2586	549380	CGCTTTCCTGGCCCGC	94	26
5483	2621	549381	GCCGCCAGGGTACCAC	89	27

TABLE 1-continued

Target Start Site for SEQ ID NO: 1	Target Start Site for SEQ ID NO: 2	ISIS No	Sequence	% inhibition	SEQ ID NO
n/a	2721	549383	CCAAACGCATGTCCCC	88	28
102155	2800	549386	GCTTCATCTCCACAGA	77	192
102156	2801	549387	AGCTTCATCTCCACAG	84	29
n/a	2871	549388	TCCCTTCAGCGGCTCT	88	30
144856	2801	549390	TTTCTGCTGGCGCACA	89	31

TABLE 2

Target Start Site for SEQ ID NO: 1	Target Start Site for SEQ ID NO: 2	ISIS No	Sequence	% inhibition	SEQ ID NO
181695	3602	549414	GTTCAATTCGAAGTTCA	81	32
182958	4164	549432	GAGGATCATCACAGAT	90	33
183049	4255	549434	CTAAACTTCCCGTGGC	96	34
58721 58751	n/a	549457	TTGATTTAATGGTTGC	98	35
58722 58752	n/a	549458	GTTGATTTAATGGTTG	95	36
58725 58755	n/a	549459	ATGGTTGATTTAATGG	96	37

Example 2

40

Dose-Dependent Antisense Inhibition of Human AR
in HuVEC Cells

Gapmers from the study described above exhibiting significant in vitro inhibition of AR mRNA were selected and tested at various doses in HuVEC cells. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 18.5 nM, 55.6 nM, 166.7 nM, 500.0 nM and 1500.0 nM concentrations of antisense oligonucleotide, as specified in Tables 3 and 4. After a treatment period of approximately 16 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human AR primer probe set RTS3559 was used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells. The antisense oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are presented in separate tables shown below.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotide is also presented in Tables 3 and 4. As illustrated, AR mRNA levels were reduced in a dose-dependent manner in the antisense oligonucleotide treated cells.

TABLE 3

ISIS No	18.5 nM	55.6 nM	166.7 nM	500.0 nM	1500.0 nM	IC ₅₀ (nM)
549358	0	29	63	85	95	141
549360	2	44	58	79	83	116
549361	0	12	30	52	66	525
549362	0	10	23	57	74	447
549371	0	30	52	83	88	148
549372	0	22	51	85	89	150
549374	15	40	59	83	92	108
549377	0	13	52	72	93	216
549379	9	11	51	68	88	237
549380	14	50	87	94	98	62
549381	4	14	33	71	91	261
549383	2	10	34	75	88	270
549388	0	15	42	36	86	428
549390	12	0	35	55	91	369

TABLE 4

ISIS No	18.5 nM	55.6 nM	166.7 nM	500.0 nM	1500.0 nM	IC ₅₀ (nM)
549332	24	35	57	79	79	104
549334	9	29	46	63	72	253
549338	30	32	47	67	78	154
549347	5	15	37	62	71	357
549366	8	44	58	72	91	129
549387	2	9	41	68	92	261

60

65

TABLE 4-continued

ISIS No	18.5 nM	55.6 nM	166.7 nM	500.0 nM	1500.0 nM	IC ₅₀ (nM)
549414	0	21	35	53	76	366
549432	10	15	46	80	92	179
549434	27	38	60	86	96	85
549457	50	70	95	99	99	18
549458	22	48	84	97	98	57
549459	51	61	90	94	97	18

Example 3

Antisense Inhibition of Human AR in HuVEC
Cells

Additional antisense oligonucleotides were designed targeting an AR nucleic acid and were tested for their effects on

segment and each nucleoside in the 3' wing segment has an (S)-cEt modification. The 5-10-5 MOE gapmer is 20 nucleosides in length, wherein the central gap segment comprises of ten 2'-deoxynucleosides and is flanked by wing segments on the 5' direction and the 3' direction comprising five nucleosides each. Each nucleoside in the 5' wing segment and each nucleoside in the 3' wing segment has a 2'-MOE modification. The internucleoside linkages throughout each gapmer are phosphorothioate linkages. All cytosine residues throughout each gapmer are 5-methylcytosines. "Start site" indicates the 5'-most nucleoside to which the gapmer is targeted in the human gene sequence. "Stop site" indicates the 3'-most nucleoside to which the gapmer is targeted in the human gene sequence. Each gapmer listed in Table 5 is targeted to the human AR genomic sequence, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NT_011669.17 truncated from nucleotides 5079000 to 5270000)

TABLE 5

Target Start Site	Target Stop Site	ISIS No	ISIS No	Motif	% inhibition	SEQ ID NO
58721 58751	58736 58766	549457	TTGATTTAATGGTTGC	3-10-3	98	35
58722 58752	58737 58767	549458	GTTGATTTAATGGTTG	3-10-3	94	36
58725 58755	58740 58770	549459	ATGGTTGATTTAATGG	3-10-3	92	37
58720 58750	58739 58769	560071	TGGTTGATTTAATGGTTGCA	5-10-5	73	38
58720 58750	58735 58765	560098	TGATTTAATGGTTGCA	3-10-3	99	39
58723 58753	58738 58768	560099	GGTTGATTTAATGGTT	3-10-3	95	40
58724 58754	58739 58769	560100	TGGTTGATTTAATGGT	3-10-3	91	41
58721 58751	58736 58766	560137	TTGATTTAATGGTTGC	3-10-3	95	35

AR mRNA in vitro. Cultured HuVEC cells at a density of 20,000 cells per well were transfected using electroporation with 500 nM antisense oligonucleotide. After a treatment period of approximately 24 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human primer probe set RTS3559 was used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells. A total of 82 oligonucleotides were tested. Only those oligonucleotides which were selected for further study are shown in Table 5.

The newly designed chimeric antisense oligonucleotides in Table 5 were designed as 3-10-3 (S)-cEt gapmers or 5-10-5 MOE gapmers. The 3-10-3 (S)-cEt gapmers are 16 nucleosides in length, wherein the central gap segment comprises of ten 2'-deoxynucleosides and is flanked by wing segments on both the 5' direction and on the 3' direction comprising three nucleosides. Each nucleoside in the 5' wing

Example 4

Dose-Dependent Antisense Inhibition of Human AR
in HuVEC Cells

Gapmers from the studies described above exhibiting significant in vitro inhibition of AR mRNA were selected and tested at various doses in HuVEC cells. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 31.3 nM, 62.5 nM, 125.0 nM, 250.0 nM, 500.0 nM, and 1000.0 nM concentrations of antisense oligonucleotide, as specified in Table 6. After a treatment period of approximately 16 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human AR primer probe set RTS3559 was used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells. The antisense oligonucleotides were tested in a series of experi-

ments that had similar culture conditions. The results for each experiment are presented in separate tables shown below.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotide is also presented in Table 6. As illustrated, AR mRNA levels were reduced in a dose-dependent manner in the antisense oligonucleotide treated cells.

TABLE 6

ISIS No	31.25 nM	62.5 nM	125.0 nM	250.0 nM	500.0 nM	1000.0 nM	IC ₅₀ (μ M)
549457	40	57	78	89	96	96	0.03
549458	15	25	47	70	88	93	0.1
549459	16	23	50	71	85	92	0.1
560071	7	0	19	40	57	76	0.4
560098	20	41	64	83	94	94	0.1
560099	13	29	58	72	89	94	0.1
560100	16	24	53	69	81	93	0.1
560137	27	49	61	82	91	96	0.1

Example 5

Antisense Inhibition of Human AR in HuVEC Cells

Additional antisense oligonucleotides were designed targeting an AR nucleic acid and were tested for their effects on AR mRNA in vitro. Cultured HuVEC cells at a density of 20,000 cells per well were transfected using electroporation with 250 nM antisense oligonucleotide. After a treatment period of approximately 24 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human primer probe set RTS3559 was

used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells. A total of 40 oligonucleotides were tested. Only those oligonucleotides which were selected for further study are shown in Table 7.

The newly designed chimeric antisense oligonucleotides in Table 7 were designed as 3-10-3 (S)-cET gapmers or deoxy, MOE and (S)-cEt oligonucleotides. The 3-10-3 (S)-cEt gapmers are 16 nucleosides in length, wherein the central gap segment comprises of ten 2'-deoxynucleosides and is flanked by wing segments on both the 5' direction and on the 3' direction comprising three nucleosides. Each nucleoside in the 5' wing segment and each nucleoside in the 3' wing segment has an (S)-cEt modification. The deoxy, MOE and (S)-cEt oligonucleotides are 16 nucleosides in length wherein the nucleoside have either a MOE sugar modification, an (S)-cEt sugar modification, or a deoxy modification. The 'Chemistry' column describes the sugar modifications of each oligonucleotide. 'k' indicates an (S)-cEt sugar modification; the number indicates the number of deoxynucleosides; and 'e' indicates a MOE modification. The internucleoside linkages throughout each gapmer are phosphorothioate linkages. All cytosine residues throughout each gapmer are 5-methylcytosines. The SEQ ID NO listed in the table refers to the oligonucleotide sequence. "Start site" indicates the 5'-most nucleoside to which the gapmer is targeted in the human gene sequence. "Stop site" indicates the 3'-most nucleoside to which the gapmer is targeted in the human gene sequence. Each gapmer listed in Table 7 is targeted to the human AR genomic sequence, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NT_011669.17 truncated from nucleotides 5079000 to 5270000).

TABLE 7

Target Start Site	Target Stop Site	Sequence	ISIS No	Chemistry	% inhibi- tion	SEQ ID NO
58721 58751	58736 58766	TTGATTTAATGGTTGC	549457	kkk-10-kkk	67	35
58722 58752	58737 58767	GTTGATTTAATGGTTG	549458	kkk-10-kkk	71	36
58720 58750	58735 58765	TGATTTAATGGTTGCA	560098	kkk-10-kkk	69	39
58721 58751	58736 58766	TTGATTTAATGGTTGC	560131	kkk-9-kkke	74	35
58721 58751	58736 58766	TTGATTTAATGGTTGC	560137	ekkk-8-kkke	66	35
58720 58750	58735 58765	TGATTTAATGGTTGCA	569213	kkk-9-kkke	69	39
58720 58750	58735 58765	TGATTTAATGGTTGCA	569216	ekkk-8-kkke	68	39
58721 58751	58736 58766	TTGATTTAATGGTTGC	569222	eekkk-8-kkk	74	35
58721 58751	58736 58766	TTGATTTAATGGTTGC	569228	eekkk-7-kkke	67	35
58720 58750	58735 58765	TGATTTAATGGTTGCA	569236	ekkk-7-kkkee	66	39

91

Example 6

Dose-Dependent Antisense Inhibition of Human AR
in HuVEC Cells

Gapmers from the studies described above exhibiting significant in vitro inhibition of AR mRNA were selected and tested at various doses in HuVEC cells. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 31.3 nM, 62.5 nM, 125.0 nM, 250.0 nM, 500.0 nM, and 1000.0 nM concentrations of antisense oligonucleotide, as specified in Table 8. After a treatment period of approximately 16 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human AR primer probe set RTS3559 was used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells. The antisense oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are presented in separate tables shown below.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotide is also presented in Table 8. As illustrated, AR mRNA levels were reduced in a dose-dependent manner in the antisense oligonucleotide treated cells.

TABLE 8

ISIS No	31.25 nM	62.5 nM	125.0 nM	250.0 nM	500.0 nM	1000.0 nM	IC ₅₀ (μM)
549457	34	44	75	82	93	96	0.06
549458	30	36	54	70	85	90	0.10
560098	30	54	65	78	89	97	0.07
560131	16	48	65	82	89	97	0.09

92

TABLE 8-continued

	ISIS No	31.25 nM	62.5 nM	125.0 nM	250.0 nM	500.0 nM	1000.0 nM	IC ₅₀ (μM)
5	560137	35	39	64	73	89	94	0.08
	569213	35	53	65	83	94	96	0.06
	569216	38	51	68	83	91	96	0.05
	569222	36	48	67	83	91	98	0.06
	569228	26	43	62	78	88	92	0.09
10	569236	17	39	54	79	84	92	0.11

Example 7

Dose-Dependent Antisense Inhibition of Human AR
in HuVEC Cells

Additional antisense oligonucleotides were designed as deoxy, MOE and (S)-cEt oligonucleotides targeting AR gene sequences and were tested at various doses in HuVEC cells. The oligonucleotides are 16 nucleosides in length wherein the nucleoside have either a MOE sugar modification, an (S)-cEt sugar modification, or a deoxy modification. The 'Chemistry' column describes the sugar modifications of each oligonucleotide. 'k' indicates an (S)-cEt sugar modification; the number indicates the number of deoxynucleosides; otherwise 'd' indicates deoxyribose; and 'e' indicates a MOE modification. The internucleoside linkages throughout each gapmer are phosphorothioate linkages. All cytosine residues throughout each gapmer are 5-methylcytosines. The SEQ ID NO listed in the table refers to the oligonucleotide sequence. "Start site" indicates the 5'-most nucleoside to which the gapmer is targeted in the human gene sequence. "Stop site" indicates the 3'-most nucleoside to which the gapmer is targeted human gene sequence. Each gapmer listed in Table 9 is targeted to the human AR genomic sequence, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NT_011669.17 truncated from nucleotides 5079000 to 5270000)

TABLE 9

Target Start Site	Target Stop Site	Sequence	ISIS No	Chemistry	SEQ ID NO
58720 58750	58735 58765	TGATTTAATGGTTGCA	569221	eekkk-8-kkk	39
58720 58750	58735 58765	TGATTTAATGGTTGCA	569227	eekkk-7-kkke	39
58720 58750	58735 58765	TGATTTAATGGTTGCA	569236	ekkk-7-kkkee	39
58720 58750	58735 58765	TGATTTAATGGTTGCA	579666	ekkeekk-7-kk	39
58721 58751	58736 58766	TTGATTTAATGGTTGC	579667	ekkeekk-7-kk	35
58720 58750	58735 58765	TGATTTAATGGTTGCA	579670	ekkekk-7-kkk	39
58721 58751	58736 58766	TTGATTTAATGGTTGC	579671	ekkekk-7-kkk	35
58721 58751	58736 58766	TTGATTTAATGGTTGC	569228	eekkk-7-kkke	35
58723 58753	58738 58768	GGTTGATTTAATGGTT	579669	ekkeekk-7-kk	40
58722 58752	58737 58767	GTTGATTTAATGGTTG	579672	ekkekk-7-kkk	36

TABLE 9-continued

Target Start Site	Target Stop Site	Sequence	ISIS No	Chemistry	SEQ ID NO
58722 58752	58737 58767	GTTGATTTAATGGTTG	569217	ekkk-8-kkke	36
58723 58753	58738 58768	GGTTGATTTAATGGTT	569214	kkk-9-kkke	40
58723 58753	58738 58768	GGTTGATTTAATGGTT	560099	kkk-10-kkk	40

Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 62.5 nM, 125.0 nM, 250.0 nM, 500.0 nM, and 1000.0 nM concentrations of antisense oligonucleotide, as specified in Tables 10-12. After a treatment period of approximately 16 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human AR primer probe set RTS3559 was used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells. The antisense oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are presented in separate tables shown below.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotide is also presented in Tables 10-12. As illustrated, AR mRNA levels were reduced in a dose-dependent manner in some of the antisense oligonucleotide treated cells.

TABLE 10

ISIS No	62.5 nM	125.0 nM	250.0 nM	500.0 nM	1000.0 nM	IC ₅₀ (nM)
549458	25	46	55	64	78	203
569227	8	40	33	51	73	388
569228	29	44	63	77	87	158
569236	4	35	54	68	88	252
579666	33	34	47	64	80	229
579667	30	29	44	36	76	411

TABLE 11

ISIS No	62.5 nM	125.0 nM	250.0 nM	500.0 nM	1000.0 nM	IC ₅₀ (nM)
549458	16	22	44	64	74	324
579669	24	39	45	74	91	207
579670	27	28	55	75	70	236
579671	6	40	54	57	77	288
579672	9	30	50	72	86	258

TABLE 12

ISIS No	62.5 nM	125.0 nM	250.0 nM	500.0 nM	1000.0 nM	IC ₅₀ (nM)
549458	19	22	45	38	71	470
569214	20	26	61	62	76	265
569217	34	39	49	64	64	247
569221	12	32	59	57	73	294

Example 8

Antisense Inhibition of Human AR in HuVEC Cells

Additional antisense oligonucleotides were designed targeting an AR nucleic acid and were tested for their effects on AR mRNA in vitro. Cultured HuVEC cells at a density of 20,000 cells per well were transfected using electroporation with 1,000 nM antisense oligonucleotide. After a treatment period of approximately 24 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human primer probe set RTS3559 was used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells. A total of 75 oligonucleotides were tested. Only those oligonucleotides which were selected for further study are shown in Table 13.

The newly designed chimeric antisense oligonucleotides in Table 13 were designed as 3-10-3 (S)-cEt gapmers, 3-9-4 (S)-cEt gapmers, 4-8-4 (S)-cEt gapmers, 4-9-3 (S)-cEt gapmers, 5-7-4 (S)-cEt gapmers, 5-8-3 (S)-cEt gapmers, 6-7-3 (S)-cEt gapmers, or deoxy, MOE and (S)-cEt oligonucleotides. The 3-10-3 (S)-cEt gapmers are 16 nucleosides in length, wherein the central gap segment comprises of ten 2'-deoxynucleosides and is flanked by wing segments on both the 5' direction and on the 3' direction comprising three nucleosides. The 3-9-4 (S)-cEt gapmers are 16 nucleosides in length, wherein the central gap segment comprises of nine 2'-deoxynucleosides and is flanked by a wing segment on the 5' direction comprising three nucleotides and on the 3' direction comprising four nucleosides. The 4-8-4 (S)-cEt gapmers are 16 nucleosides in length, wherein the central gap segment comprises of eight 2'-deoxynucleosides and is flanked by wing segments on both the 5' direction and on the 3' direction comprising four nucleosides. The 4-9-3 (S)-cEt gapmers are 16 nucleosides in length, wherein the central gap segment comprises of nine 2'-deoxynucleosides and is flanked by a wing segment on the 5' direction comprising four nucleotides and on the 3' direction comprising three nucleosides. The 5-7-4 (S)-cEt gapmers are 16 nucleosides in length, wherein the central gap segment comprises of seven 2'-deoxynucleosides and is flanked by a wing segment on the 5' direction comprising five nucleotides and on the 3' direction comprising four nucleotides. The 5-8-3 (S)-cEt gapmers are 16 nucleosides in length, wherein the central gap segment comprises of eight 2'-deoxynucleosides and is flanked by a wing segment on the 5' direction comprising five nucleotides and on the 3' direction comprising three nucleosides. The 6-7-3 (S)-cEt gapmers are 16 nucleosides in length, wherein the central gap segment comprises of

seven 2'-deoxynucleosides and is flanked by a wing segment on the 5' direction comprising six nucleotides and on the 3' direction comprising three nucleosides. Each nucleoside in the 5' wing segment and each nucleoside in the 3' wing segment has an (S)-cEt modification. The deoxy, MOE and (S)-cEt oligonucleotides are 16 nucleosides in length wherein the nucleoside have either a MOE sugar modification, an (S)-cEt sugar modification, or a deoxy modification. The 'Chemistry' column describes the sugar modifications of each oligonucleotide. 'k' indicates an (S)-cEt sugar modification; the number indicates the number of deoxynucleosides; otherwise 'd' indicates deoxyribose; and 'e' indicates

a MOE modification. The internucleoside linkages throughout each gapmer are phosphorothioate linkages. All cytosine residues throughout each gapmer are 5-methylcytosines.

The SEQ ID NO listed in the table refers to the oligonucleotide sequence. "Start site" indicates the 5'-most nucleoside to which the gapmer is targeted in the human gene sequence. "Stop site" indicates the 3'-most nucleoside to which the gapmer is targeted human gene sequence. Each gapmer listed in Table 13 is targeted to the human AR genomic sequence, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NT_011669.17 truncated from nucleotides 5079000 to 5270000).

TABLE 13

Target Start Site	Target Stop Site	Sequence	ISIS No	Chemistry	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	kkk-10-kkk	64	22
5061	5076	AGTTGTAGTAGTCGCG	585233	kkk-8-keeee	69	42
5062	5077	AAGTTGTAGTAGTCGC	585259	ekkk-9-kkk	71	22
5062	5077	AAGTTGTAGTAGTCGC	585262	kkk-9-kkke	77	22
5062	5077	AAGTTGTAGTAGTCGC	585263	kkk-8-kkkee	69	22
5062	5077	AAGTTGTAGTAGTCGC	585264	kkk-7-kkkeee	62	22
5062	5077	AAGTTGTAGTAGTCGC	585265	eekk-8-kkee	69	22
5062	5077	AAGTTGTAGTAGTCGC	585268	keke-8-ekek	72	22
5062	5077	AAGTTGTAGTAGTCGC	585269	ekek-8-ekek	73	22
5062	5077	AAGTTGTAGTAGTCGC	585271	ekk-10-kke	57	22
5062	5077	AAGTTGTAGTAGTCGC	585274	kkk-10-kke	65	22
58719	58734	GATTTAATGGTTGCAA	586124	kkk-10-kkk	82	43
58720 58750	58735 58765	TGATTTAATGGTTGCA	569227	eekkk-7-kkke	51	39
58722 58752	58737 58767	GTTGATTTAATGGTTG	560132	kkk-9-kkke	58	36
58722 58752	58737 58767	GTTGATTTAATGGTTG	569229	eekkk-7-kkke	57	36
58722 58752	58737 58767	GTTGATTTAATGGTTG	569238	ekkk-7-kkkee	51	36
58722 58752	58737 58767	GTTGATTTAATGGTTG	549458	kkk-10-kkk	87	36
58722 58752	58737 58767	GTTGATTTAATGGTTG	569223	eekkk-8-kkk	59	36
58724 58754	58739 58769	TGGTTGATTTAATGGT	569215	kkk-9-kkke	59	41
58725 58755	58740 58770	ATGGTTGATTTAATGG	560133	kkk-9-kkke	53	37
58725 58755	58740 58770	ATGGTTGATTTAATGG	569220	ekkk-8-kkke	58	37
58721 58751	58736 58766	TTGATTTAATGGTTGC	586224	kkkkk-8-kkk	90	35
58722 58752	58737 58767	GTTGATTTAATGGTTG	586225	kkkkk-8-kkk	88	36
58720 58750	58735 58765	TGATTTAATGGTTGCA	586227	kkkkk-8-kkk	87	39

97

Example 9

Dose-Dependent Antisense Inhibition of Human AR
in HuVEC Cells

Antisense oligonucleotides from the studies described above exhibiting significant *in vitro* inhibition of AR mRNA were selected and tested at various doses in HuVEC cells. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 31.25 nM, 62.5 nM, 125.0 nM, 250.0 nM, 500.0 nM, and 1000.0 nM concentrations of antisense oligonucleotide, as specified in Table 14. After a treatment period of approximately 16 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human AR primer probe set RTS3559 was used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells. The antisense oligonucleotides were tested in a series of experiments that had similar culture conditions. The results for each experiment are presented in separate tables shown below.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotide is also presented in Table 14. As illustrated, AR mRNA levels were reduced in a dose-dependent manner in the antisense oligonucleotide treated cells.

TABLE 14

ISIS No	31.25 nM	62.5 nM	125.0 nM	250.0 nM	500.0 nM	1000.0 nM	IC ₅₀ nM
549372	2	17	31	51	61	80	271
549458	0	19	40	63	74	90	196
560132	8	19	21	53	65	85	252
560133	17	15	24	35	58	79	336
569215	12	2	26	55	71	90	234
569220	11	29	34	43	59	78	275
569223	21	20	30	59	73	87	191
569227	13	22	45	46	61	74	255
569229	16	14	36	47	74	84	220
569238	4	32	33	54	71	88	202

Example 10

Dose-Dependent Antisense Inhibition of Human AR
in HuVEC Cells

Gapmers from Example 8 exhibiting significant *in vitro* inhibition of AR mRNA were selected and tested at various doses in HuVEC cells. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 46.9 nM, 187.5 nM, 750.0 nM, and 3000.0 nM concentrations of antisense oligonucleotide, as specified in Table 15. After a treatment period of approximately 16 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human AR primer probe set RTS3559 was used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotide is also presented in Table 15. As illustrated, AR mRNA levels were reduced in a dose-dependent manner in antisense oligonucleotide treated cells.

98

TABLE 15

ISIS No	46.9 nM	187.5 nM	750.0 nM	3000.0 nM	IC ₅₀ (μM)
549372	9	41	66	87	0.29
549458	15	50	85	96	0.19
586124	28	47	84	94	0.13
586224	39	75	93	98	0.05
586225	17	61	89	97	0.13
586227	20	60	88	96	0.13

Example 11

Antisense Inhibition of Human AR in HuVEC
Cells

Additional antisense oligonucleotides were designed targeting an AR nucleic acid and were tested for their effects on AR mRNA *in vitro*. Cultured HuVEC cells at a density of 20,000 cells per well were transfected using electroporation with 500 nM antisense oligonucleotide. After a treatment period of approximately 24 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human primer probe set RTS3559 was used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells. A total of 616 oligonucleotides were tested. Only those oligonucleotides which were selected for further study are shown in Tables 16-23.

The newly designed chimeric antisense oligonucleotides in Tables 16-23 were designed as 3-10-3 (S)-cET gapmers. The gapmers are 16 nucleosides in length, wherein the central gap segment comprises of ten 2'-deoxynucleosides and is flanked by wing segments on both the 5' direction and on the 3' direction comprising three nucleosides. Each nucleoside in the 5' wing segment and each nucleoside in the 3' wing segment has an (S)-cEt modification. The internucleoside linkages throughout each gapmer are phosphorothioate linkages. All cytosine residues throughout each gapmer are 5-methylcytosines.

The SEQ ID NO listed in the table refers to the oligonucleotide sequence. "Start site" indicates the 5'-most nucleoside to which the gapmer is targeted in the human gene sequence. "Stop site" indicates the 3'-most nucleoside to which the gapmer is targeted human gene sequence. Each gapmer listed in Tables 16-23 is targeted to either the human AR genomic sequence, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NT_011669.17 truncated from nucleotides 5079000 to 5270000) or the human AR mRNA sequence, designated herein as SEQ ID NO: 2 (GENBANK Accession No. NM_000044.3), or both. 'n/a.' indicates that the oligonucleotide does not target that particular gene sequence.

TABLE 16

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	47	22
58722 58752	58737 58767	GTTGATTTAATGGTTG	549458	60	36
2957	2972	ACAGCACTGGAGCGGC	583542	45	44
3079	3094	AACTTCACCGAAGAGG	583556	43	45
3099	3114	AGTCTTTAGCAGCTTT	583559	52	46
3109	3124	GCTTCCTCCGAGTCTT	583564	45	47
3113	3128	CCTTGCTTCCTCCGAG	583566	47	48
3120	3135	GCACTTTCCTTGCTTC	583567	52	49
3133	3148	TCAGTCCTACCAGGCA	583571	43	50
3224	3239	GACTGAGGCAGCTGCG	583583	45	51
3226	3241	CCGACTGAGGCAGCTG	583584	44	52

TABLE 17

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	40	22
58722 58752	58737 58767	GTTGATTTAATGGTTG	549458	46	36
3351	3366	GCTAGCTCGCCCGCTC	583608	51	53
3353	3368	CAGCTAGCTCGCCCGC	583609	51	54
3361	3376	GCAATGTGCAGCTAGC	583613	51	55
3388	3403	GTCGCCTGGCTCCTAA	583620	41	56
3513	3528	CTGGCTCCGCACTCGG	583635	50	57
3517	3532	ATCTCTGGCTCCGCAC	583637	43	58
3519	3534	TGATCTCTGGCTCCGC	583638	51	59
3641	3656	AGTGTCCTGAAGTA	583642	42	60
3735	3750	AGGCTCACAGTCTGTC	583649	46	61
3764	3779	GACACACGGTGGACAA	583660	44	62
3768	3783	AGAAGACACACGGTGG	583662	51	63
3798	3813	CGCTCTGACAGCCTCA	583667	42	64

TABLE 18

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	26	22
58722 58752	58737 58767	GTTGATTTAATGGTTG	549458	48	36
3870	3885	GTCGCTGCAGCTAGCT	583685	47	65

TABLE 18-continued

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
3874	3889	GGTAGTCGCTGCAGCT	583687	41	66
3876	3891	GCGGTAGTCGCTGCAG	583688	38	67
3878	3893	ATGCGGTAGTCGCTGC	583689	39	68
3884	3899	GTGATGATGCGGTAGT	583692	41	69
3886	3901	CTGTGATGATGCGGTA	583693	36	70
3901	3916	GAAGAGTTCAACAGGC	583700	36	71
3956	3971	GCTTGGCTGAATCTTC	583709	39	72
3962	3977	CCTTGAGCTTGGCTGA	583712	37	73
3964	3979	ATCCTTGAGCTTGGCT	583713	36	74
3967	3982	TCCATCCTTGAGCTTG	583714	36	75
4019	4034	GTAGGTCTTGGACGGC	583719	36	76
4038	4053	GATTCTGGAAAGCTCC	583727	40	77
4049	4064	GCTCTGGAACAGATTC	583728	45	78
4056	4071	CGCGCACGCTCTGGAA	583731	34	79
4062	4077	TCACTTCGCGCACGCT	583734	46	80
4066	4081	TGGATCACTTCGCGCA	583736	47	81
4070	4085	GTTCTGGATCACTTCG	583738	36	82
4101	4116	CGCTCGCGCCTCTGG	583745	40	83
4103	4118	TGCGCTCGCGCCTCT	583746	32	84
4105	4120	GCTGCGCTCGCGCCT	583747	35	85

TABLE 19

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	39	22
58722	58737	GTTGATTTAATGGTTG	549458	50	36
58752	58767				
4109	4124	AGGTGCTGCGCTCGCG	583749	36	86
4305	4320	GCTGTTCTCATCCAG	583759	38	87
4405	4420	TGCTGCGGCAGCCCCT	583771	40	88
4532	4547	GGTGCTGGCCTCGCTC	583787	37	89
4537	4552	TGCATGGTGCTGGCCT	583789	39	90
4539	4554	GTTGCATGGTGCTGGC	583790	39	91
4555	4570	TGCTGTTGCTGAAGGA	583795	63	92
4571	4586	GGATACTGCTTCCTGC	583796	65	93
4573	4588	TCGGATACTGCTTCCT	583797	35	94
4578	4593	TGCCTTCGGATACTGC	583799	65	95
4597	4612	CTCGCTCTCCCGCTGC	583802	37	96

TABLE 19-continued

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
4632	4647	TGTCCTTGGAGGAAGT	583809	45	97
4656	4671	TGGTCGAAGTGCCCCC	583818	42	98
4662	4677	CAGAAATGGTCGAAGT	583821	42	99

TABLE 20

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	23	22
58722 58752	58737 58767	GTTGATTTAATGGTTG	549458	54	36
4747	4762	TGTTCCCCTGGACTCA	583833	37	100
4750	4765	AGCTGTTCCCCTGGAC	583834	52	101
4752	4767	GAAGCTGTTCCCCTGG	583835	44	102
4754	4769	CCGAAGCTGTTCCCCT	583836	37	103
4769	4784	GTACATGCAATCCCCC	583843	35	104
4798	4813	ACAGCGGGTGGAACTC	583847	34	105
4804	4819	GGACGCACAGCGGGTG	583850	38	106
4807	4822	GTGGGACGCACAGCGG	583851	33	107
4833	4848	TGCATTGCGCCAATGG	583853	33	108
4837	4852	CCTTTGCATTGCGCCA	583855	44	109
4839	4854	AACCTTTGCATTGCGC	583856	45	110
4868	4883	GCTCTTGCCTGCGCTG	583862	32	111
4872	4887	CAGTGCTCTTGCCTGC	583864	46	112
4874	4889	TTCAGTGCTCTTGCCT	583865	45	113
4876	4891	TCTTCAGTGCTCTTGC	583866	32	114
4887	4902	ACTCAGCAGTATCTTC	583868	34	115
4889	4904	ATACTCAGCAGTATCT	583871	47	116
4916	4931	TTTGGTGTAACCTCCC	583880	39	117
4918	4933	CCTTTGGTGTAACCTC	583881	47	118
4938	4953	CTAGGCTCTCGCCTTC	583890	32	119
4942	4957	CAGCCTAGGCTCTCGC	583892	35	120
4944	4959	AGCAGCCTAGGCTCTC	583893	34	121
4951	4966	CTGCCAGAGCAGCCTA	583896	37	122

TABLE 21

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	37	22
58722 58752	58737 58767	GTTGATTTAATGGTTG	549458	47	36
5050	5065	TCGCGACTCTGGTACG	583917	37	123
5052	5067	AGTCGCGACTCTGGTA	583918	47	124
5054	5069	GTAGTCGCGACTCTGG	583919	55	125
5056	5071	TAGTAGTCGCGACTCT	583920	42	126
5061	5076	AGTTGTAGTAGTCGCG	583922	37	42
5133	5148	TCTCCAGCTTGATGCG	583932	39	127
5141	5156	CAGCGGGTTCTCCAGC	583933	38	128
5293	5308	CCTTCTTCGGCTGTGA	583969	44	129
5308	5323	GGTCCATACTGCG	583975	42	130

TABLE 22

Target Start Site on SEQ ID NO: 1	Target Start Site on SEQ ID NO: 2	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	2200	AAGTTGTAGTAGTCGC	549372	46	22
58722 58752	n/a n/a	GTTGATTTAATGGTTG	549458	39	36
5469	2607	ACACATCAGGTGCGGT	583990	30	131
5481	2619	CGCCAGGTACACAC	583996	33	132
5486	2624	CATGCCGCCAGGTAC	583998	45	133
5488	2626	ACCATGCCGCCAGGT	583999	29	134
5494	2632	CTGCTACCATGCCGC	584002	30	135
5521	2659	ACACAAGTGGGACTGG	584006	33	136
n/a	2870	CCCTTCAGCGCTCTT	584044	29	137

TABLE 23

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	25	22
58722 58752	58737 58767	GTTGATTTAATGGTTG	549458	51	36
144938	144953	CAGAGTCATCCCTGCT	584069	36	138
148406	148421	CACCCCTAAGATTCTT	584100	36	139
148443	148458	AAGGTAGTCTTTAAGG	584106	30	140
148520	148535	GTTTTCAAATGCAGCC	584111	33	141
139682	139697	GCCATGAGACAGCTTT	584125	35	142

TABLE 23-continued

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
139762	139777	ATTCTTGACTGTCTGA	584128	38	143
139782	139797	GCATGCCAGCTGGCTC	584130	29	144
5666	5681	CGCGCAGGTAGGAGCC	584138	35	145
6222	6237	TCTAACATGACGGTT	584139	37	146
6701	6716	ATGCAATTGCCTGCCA	584141	39	147

Example 12

Antisense Inhibition of Human AR in HuVEC Cells

Additional antisense oligonucleotides were designed targeting an AR nucleic acid and were tested for their effects on AR mRNA in vitro. Cultured HuVEC cells at a density of 20,000 cells per well were transfected using electroporation with 1,000 nM antisense oligonucleotide. After a treatment period of approximately 24 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human primer probe set RTS3559 was used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells. A total of 385 oligonucleotides were tested. Only those oligonucleotides which were selected for further study are shown in Tables 24-28.

The newly designed chimeric antisense oligonucleotides in Tables 24-28 were designed as 3-10-3 (S)-cET gapmers. The gapmers are 16 nucleosides in length, wherein the central gap segment comprises of ten 2'-deoxynucleosides and is flanked by wing segments on both the 5' direction and on the 3' direction comprising three nucleosides. Each nucleoside in the 5' wing segment and each nucleoside in the 3' wing segment has an (S)-cEt modification. The internucleoside linkages throughout each gapmer are phosphorothioate linkages. All cytosine residues throughout each gapmer are 5-methylcytosines.

The SEQ ID NO listed in the table refers to the oligonucleotide sequence. "Start site" indicates the 5'-most nucleoside to which the gapmer is targeted in the human gene sequence. "Stop site" indicates the 3'-most nucleoside to which the gapmer is targeted human gene sequence. Each gapmer listed in Tables 24-28 is targeted to the human AR genomic sequence, designated herein as SEQ ID NO: 1 (GENBANK Accession No. NT_011669.17 truncated from nucleotides 5079000 to 5270000)

TABLE 24

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	63	22
58722	58737	GTTGATTTAATGGTTG	549458	88	36
58752	58767				
7543	7558	ATGGGAGTAACTTTTG	584145	76	148
8471	8486	CATATTATTGTCTGC	584148	85	149
8638	8653	GTCAATATCAAAGCAC	584149	85	150
9464	9479	GAGTTGTGATTTCAGG	584152	88	151
10217	10232	TTGATGGAATGCTGAT	584157	69	152
10250	10265	GGTTAACTTTCTCTGA	584158	69	153
10865	10880	TGGATTGTAAATTACG	584162	82	154
11197	11212	GAACATTATTAGGCTA	584163	81	155
11855	11870	TCAATCTAGATACCAT	584165	70	156
13189	13204	CACATCAGAAGGAGTA	584166	89	157
13321	13336	GAGTGTTAATGAAGAC	584167	78	158
13346	13361	CTGATTAGCTATGACC	584168	70	159
16555	16570	ATGAGTCCTCAGAATC	584179	74	160
16793	16808	GTAGATTCTAGCTTTG	584180	81	161

TABLE 24-continued

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
16968	16983	ACAGGCTCTGACTAGG	584183	76	162
17206	17221	TGTGTGACCCTTGGAC	584184	78	163
18865	18880	AAGTATGAGCATGGTT	584192	73	164

TABLE 25

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	59	22
58722	58737	GTTGATTTAATGGTTG	549458	76	36
58752	58767				
29329	29344	GGATTCTCTACACACA	584233	62	165
32290	32305	CCATTTGTGCCAAACC	584242	62	166
33315	33330	AGGTTAGGGAGTAGGC	584245	70	167
39055	39070	TAGGGTTTGGTCAGAA	584263	56	168
40615	40630	CCTTATGGATGCTGCT	584269	57	169
42017	42032	GTTATCTTACTCTCCC	584274	70	170

TABLE 26

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	58	22
58722	58737	GTTGATTTAATGGTTG	549458	79	36
58752	58767				
56050	56065	GATTGTGTATAGCTGC	584312	65	171
60902	60917	GGTTATGGTTCTGTCT	584329	58	172
67454	67469	CTTCATTGCAGGTCTG	584361	61	173

TABLE 27

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	70	22
58722	58737	GTTGATTTAATGGTTG	549458	76	36
58752	58767				
114874	114889	TAGCCAACTTTCTTTA	584465	58	174
115272	115287	CATTGTACTATGCCAG	584468	64	175
115365	115380	TTTGGTAACATTAGGC	584469	74	176
134971	134986	ATGGTTGTCCTGTACA	584495	58	177

TABLE 28

Target Start Site	Target Stop Site	Sequence	ISIS No	% inhibition	SEQ ID NO
5062	5077	AAGTTGTAGTAGTCGC	549372	54	22
58722	58737	GTTGATTAAATGGTTG	549458	65	36
58752	58767				
114874	114889	TAGCCAACTTTCTTTA	584465	54	174
115365	115380	TTTGGTAACATTAGGC	584469	63	176
134971	134986	ATGGTTGTCCTGTACA	584495	53	177

15

Example 13

Dose-Dependent Antisense Inhibition of Human AR
in HuVEC Cells

Gapmers from the studies described above exhibiting significant in vitro inhibition of AR mRNA were selected and tested at various doses in HuVEC cells. Cells were plated at a density of 20,000 cells per well and transfected using electroporation with 46.9 nM, 187.5 nM, 750.0 nM, and 3000.0 nM concentrations of antisense oligonucleotide, as specified in Tables 29-37. After a treatment period of approximately 16 hours, RNA was isolated from the cells and AR mRNA levels were measured by quantitative real-time PCR. Human AR primer probe set RTS3559 was used to measure mRNA levels. AR mRNA levels were adjusted according to total RNA content, as measured by RIBOGREEN®. Results are presented as percent inhibition of AR, relative to untreated control cells.

The half maximal inhibitory concentration (IC₅₀) of each oligonucleotide is also presented in Tables 29-37. As illustrated, AR mRNA levels were reduced in a dose-dependent manner in some of the antisense oligonucleotide treated cells.

TABLE 29

ISIS No	46.9 nM	187.5 nM	750.0 nM	3000.0 nM	IC ₅₀ (μM)
549372	7	41	70	91	0.32
549458	21	72	91	97	0.11
583542	9	28	47	66	0.90
583556	19	47	68	66	0.34
583559	30	49	63	80	0.22
583564	16	33	55	74	0.52
583566	0	28	50	74	0.73
583567	17	34	60	79	0.43
583571	18	36	53	59	0.80
583583	21	31	49	64	0.79
583584	24	44	52	73	0.41
583608	12	46	67	76	0.35
583609	16	48	63	73	0.36
583613	24	60	70	75	0.19
583635	35	56	69	78	0.13
583638	33	64	79	85	0.11
583649	28	50	68	84	0.20
583660	21	39	61	72	0.42
583662	27	59	75	75	0.15

TABLE 30

ISIS No	46.9 nM	187.5 nM	750.0 nM	3000.0 nM	IC ₅₀ (μM)
549372	13	29	69	90	0.37
549458	22	62	92	97	0.13
583620	0	17	44	54	1.85
583637	22	32	59	75	0.45
583642	18	35	67	74	0.46
583667	35	55	73	82	0.14
583685	32	53	73	81	0.16
583687	34	67	83	81	0.08
583688	3	26	50	60	1.05
583689	20	34	62	74	0.44
583692	8	47	61	71	0.44
583709	8	50	70	84	0.29
583712	15	47	72	78	0.29
583727	18	49	70	76	0.29
583728	9	48	67	70	0.40
583734	29	60	74	75	0.12
583736	21	38	60	63	0.51
583738	16	40	56	71	0.51
583745	19	51	68	77	0.27

TABLE 31

ISIS No	46.9 nM	187.5 nM	750.0 nM	3000.0 nM	IC ₅₀ (μM)
549372	5	36	69	88	0.36
549458	24	59	92	98	0.13
583693	12	39	64	80	0.38
583700	14	34	57	71	0.55
583713	29	51	67	74	0.22
583714	22	34	59	79	0.40
583719	22	46	65	72	0.32
583731	18	24	47	58	1.31
583746	24	44	65	67	0.35
583747	13	38	50	69	0.64
583771	17	27	47	69	0.77
583789	30	49	71	85	0.19
583790	17	42	65	81	0.32
583795	37	61	83	90	0.09
583796	38	69	83	90	0.07
583799	29	60	76	85	0.14
583809	13	37	68	81	0.36
583818	9	46	71	84	0.31
583821	11	35	61	77	0.46

TABLE 32

ISIS No	46.9 nM	187.5 nM	750.0 nM	3000.0 nM	IC ₅₀ (μM)
549372	15	39	70	86	0.30
549458	19	58	89	96	0.15
583749	34	40	75	87	0.17

US RE48,461 E

113

TABLE 32-continued

ISIS No	46.9 nM	187.5 nM	750.0 nM	3000.0 nM	IC ₅₀ (μM)
583759	5	28	61	67	0.63
583787	15	31	66	74	0.43
583797	21	50	74	82	0.22
583802	17	25	47	60	1.07
583834	34	54	73	84	0.13
583835	20	55	74	88	0.19
583836	11	27	67	86	0.39
583850	9	21	54	78	0.60
583855	22	50	81	91	0.18
583856	31	55	74	89	0.14
583864	30	49	72	85	0.17
583864	0	47	62	85	0.37
583865	33	42	68	85	0.19
583871	28	30	68	87	0.28
583880	13	52	78	92	0.22
583881	28	50	85	91	0.15

114

TABLE 35

ISIS No	46.9 nM	187.5 nM	750.0 nM	3000.0 nM	IC ₅₀ (μM)
549372	0	28	64	88	0.42
549458	13	49	84	91	0.19
584106	3	13	12	32	>30
584111	22	30	59	84	0.33
584130	0	10	11	37	>30
584138	2	40	62	89	0.37
584145	6	32	63	88	0.36
584148	16	48	79	95	0.20
584149	11	37	68	89	0.31
584152	28	59	87	95	0.11
584162	24	45	80	92	0.18
584163	19	37	74	90	0.25
584166	34	52	84	92	0.10
584167	13	45	76	93	0.21
584179	1	25	62	87	0.44
584180	26	56	84	96	0.12
584183	3	41	64	87	0.31
584184	9	42	76	93	0.23
584192	1	34	73	95	0.30

TABLE 33

ISIS No	46.9 nM	187.5 nM	750.0 nM	3000.0 nM	IC ₅₀ (μM)
549372	14	33	64	90	0.34
549458	21	61	90	96	0.13
583833	26	43	70	74	0.26
583843	22	40	67	85	0.30
583847	8	30	60	84	0.46
583851	8	24	54	76	0.61
583853	24	51	70	80	0.21
583862	15	37	64	79	0.41
583866	17	48	71	91	0.24
583868	19	31	59	81	0.41
583890	0	0	17	33	>30
583892	22	38	68	83	0.27
583893	15	35	62	79	0.42
583896	13	17	49	69	0.86
583918	16	47	68	86	0.30
583919	27	60	85	91	0.14
583920	11	16	50	72	0.76
583969	12	26	66	86	0.44
583975	19	49	55	88	0.36

TABLE 36

ISIS No	46.9 nM	187.5 nM	750.0 nM	3000.0 nM	IC ₅₀ (μM)
549372	2	26	61	85	0.42
549458	1	51	83	96	0.23
584157	6	6	52	82	0.59
584158	14	37	70	89	0.26
584165	12	34	66	89	0.30
584168	5	32	70	91	0.32
584233	0	30	66	86	0.39
584242	12	38	66	93	0.27
584245	4	33	69	90	0.32
584263	9	24	67	90	0.34
584269	6	26	69	92	0.34
584274	17	36	74	93	0.23
584312	17	37	65	93	0.26
584329	0	17	67	86	0.46
584361	0	18	71	87	0.41
584465	0	0	32	51	2.5
584468	9	26	60	90	0.37
584469	13	46	73	89	0.22
584495	0	14	55	74	0.65

TABLE 34

ISIS No	46.9 nM	187.5 nM	750.0 nM	3000.0 nM	IC ₅₀ (μM)
549372	14	36	64	88	0.32
549458	14	53	84	95	0.18
583917	6	30	50	70	0.64
583922	16	43	76	92	0.23
583932	9	35	64	81	0.38
583933	22	25	56	81	0.41
583990	0	9	33	56	1.92
583996	26	12	50	70	0.71
583998	4	25	38	70	0.89
583999	13	12	30	64	1.53
584002	12	46	70	92	0.25
584006	21	26	59	88	0.35
584044	23	30	51	78	0.44
584069	18	40	63	82	0.30
584100	6	5	20	44	7.79
584125	12	12	47	76	0.72
584128	20	22	41	72	0.74
584139	13	33	56	85	0.4
584141	22	37	61	85	0.29

TABLE 37

ISIS No	46.9 nM	187.5 nM	750.0 nM	3000.0 nM	IC ₅₀ (μM)
549372	9	41	66	87	0.29
549458	15	50	85	96	0.19
586124	28	47	84	94	0.13
586195	41	62	90	95	0.07
586197	27	47	77	94	0.14
586198	39	62	89	96	0.07
586199	25	56	89	97	0.13
586200	23	44	85	95	0.15
586205	34	67	89	95	0.07
586207	0	39	79	93	0.3
586208	32	70	88	93	0.08
586212	20	60	86	94	0.13
586221	39	72	94	98	0.04
586224	39	75	93	98	0.05
586225	17	61	89	97	0.13
586227	20	60	88	96	0.13
586232	24	45	82	91	0.17
586240	14	49	83	93	0.18
586570	16	44	81	91	0.21

Selection of Antisense Oligonucleotides Targeting Human Androgen Receptor (AR) mRNA for Assays with Prostate Cancer Cell Lines

Antisense oligonucleotides from those presented in the studies above, targeting different regions of the human AR genomic sequence, were selected for further studies in prostate cancer cell lines. AR-V7 and AR-V567es are major AR splice variants detected in cancer patients as described in Hornberg, E. et al., PLoS One 2011. Vol. 6.

The following ISIS oligonucleotides were selected for further studies: ISIS 549372, which targets the human AR genomic sequence at exon 1; ISIS 549434, which targets the human AR genomic sequence at the 3'-end of exon 8 beyond the stop codon of AR; ISIS 560131, which targets the human AR genomic sequence at intron 1; and ISIS 569236, which targets the human AR genomic sequence at intron 1. Another antisense oligonucleotide, ISIS 554221 (AC-CAAGTTTCTTCAGC, designated herein as SEQ ID NO: 178), was designed as a 3-10-3 LNA gapmer with phosphorothioate backbone targeted to exon 4, (i.e. the ligand binding domain) of AR identical to an antisense oligonucleotide designated as SEQ ID NO: 58 of U.S. Pat. No. 7,737,125 for use as a benchmark.

Example 15

Effect of Antisense Inhibition of Human Androgen Receptor (AR) mRNA on Androgen Receptor Protein Levels in MDV3100-Resistant C4-2B Cells

C4-2B cells are androgen-independent human prostate adenocarcinoma cells commonly used in the field of oncology and have been established as clinically relevant cultured cells (Thalmann, G. N. et al., Cancer Res. 1994. 54: 2577). MDV3100 or Enzalutamide is an experimental androgen receptor antagonist drug developed by Medivation for the treatment of castration-resistant prostate cancer. ISIS 549372, ISIS 554221, and ISIS 549434 were tested in MDV3100-resistant (MR) C4-2B cells.

The cells were cultured in the presence of 5 μ M concentration of MDV3100 over the course of 2 months to induce MDV3100 resistance. ISIS 549372, ISIS 549434, and ISIS 554221 at 1 μ M concentration of antisense oligonucleotide were each added to the culture media at 1 μ M concentration for free uptake by the cells. After a treatment period of 2 days, cells were harvested in RIPA buffer containing protease inhibitors. The presence of bands for full-length AR, as well as the variant form, AR-V7, was detected by western blot using AR antibody (N-20, Santa Cruz). Treatment of the cells with ISIS 549372 reduced full-length AR and AR-V7 more extensively than treatment with either ISIS 554221 or ISIS 549434.

Example 16

Effect of Antisense Inhibition of Human Androgen Receptor (AR) mRNA on AR-Target Genes in MDV3100-Resistant C4-2B Cells

The effect of antisense inhibition of AR on AR target genes was analyzed. ISIS 549372, ISIS 549458, ISIS 554221, and ISIS 549434 were tested in C4-2B MR cells.

Cells were plated at a density of 40,000 cells per well in 96-well plates and cultured in RPMI1640 medium with 10%

fetal bovine serum. The cells were cultured in the presence of 5 μ M concentration of MDV3100 over the course of 2 months to induce MDV3100 resistance. ISIS 549372, ISIS 549458, ISIS 549434, and ISIS 554221 were each added at 0.04 μ M, 0.20 μ M, 1.00 μ M, and 5.00 μ M concentrations of antisense oligonucleotide to culture media for free uptake by the cells. A control oligonucleotide, ISIS 347526 (sequence TCTTATGTTTCCGAACCGTT (SEQ ID NO: 179) 5-10-5 MOE gapmer) with no known target region in human gene sequences, was included as a negative control. After a treatment period of 24 hrs, total AR mRNA levels were measured by quantitative real-time PCR using primer probe set RTS3559. Human AR primer probe set hAR_LTS00943 (forward sequence GCCCCTGGATGGATAGCTACT, designated herein as SEQ ID NO: 180; reverse sequence CCACAGATCAGGCAGGTCTTC, designated herein as SEQ ID NO: 181; probe sequence ACTGCCAGGGAC-CATGTTTGGCCC, designated herein as SEQ ID NO: 182) was used to measure AR-V7 mRNA levels. AR mRNA levels were adjusted to human actin mRNA levels. Results are presented in Table 38 as percent inhibition of total AR, relative to untreated control cells. Treatment of the cells with ISIS 549372, ISIS 549458, and ISIS 549434 reduced total AR transcript levels in a dose dependent manner more extensively than treatment with ISIS 554221.

Western analysis of full-length AR, as well as the AR-V7 variant, was also conducted in a manner similar to the assay described above. The assay demonstrated that treatment with ISIS 549372 and ISIS 549458 reduced levels of full-length AR and AR-V7. Treatment with ISIS 549434 reduced levels of full-length AR but not that of AR-V7. Treatment with ISIS 554221 reduced levels of full-length AR less extensively compared to ISIS 549372, and did not reduce levels of AR-V7. The control oligonucleotide ISIS 347526 did not reduce protein levels, as expected.

The mRNA level of the AR target gene, KLK2 was measured using the primer probe set hKLK2_LTS00963 (forward sequence CTGCGCCCCAGGAGTCT, designated herein as SEQ ID NO: 183; reverse sequence CTCAGAGTAAGCTCTAGCACACATGTC, designated herein as SEQ ID NO: 184; probe sequence AGTGTGT-GAGCCTCCATCTCCTGTCCAA, designated herein as SEQ ID NO: 185). The mRNA level of the AR target gene, KLK3 was measured using the primer probe set RTS1072 (forward sequence GCCAAGGAGGGAGGGTCTT, designated herein as SEQ ID NO: 186; reverse sequence CCCCC-CATAGTGAATCAGCTT, designated herein as SEQ ID NO: 187; probe sequence ATGAAGTAAGGAGAGGGACTGGACCCCC, designated herein as SEQ ID NO: 188). As presented in Tables 39 and 40, treatment with ISIS 549372, ISIS 549458, and ISIS 549434 reduced target gene levels in a dose dependent manner more extensively than treatment with ISIS 554221.

TABLE 38

Percent inhibition of full-length AR mRNA in C4-2B MR cells					
ISIS No	0.04 μ M	0.20 μ M	1.00 μ M	5.00 μ M	
549372	35	47	88	91	
549434	9	36	66	88	
549458	41	78	94	97	
554221	0	0	0	23	
347526	28	35	31	17	

117

TABLE 39

Percent inhibition of KLK3 mRNA in C4-2B MR cells				
ISIS No	0.04 μ M	0.20 μ M	1.00 μ M	5.00 μ M
549372	17	35	68	80
549434	10	47	42	64
549458	0	42	81	92
554221	0	0	47	56
347526	5	38	42	16

TABLE 40

Percent inhibition of KLK2 mRNA in C4-2B MR cells				
ISIS No	0.04 μ M	0.20 μ M	1.00 μ M	5.00 μ M
549372	14	16	57	87
549434	5	27	49	68
549458	35	47	87	93
554221	24	25	56	66
347526	28	29	23	22

Example 17

Effect of Antisense Inhibition of Human Androgen Receptor (AR) mRNA on the Proliferative Ability of MDV3100-Resistant C4-2B Cells

The effect of antisense inhibition of AR on the proliferative ability of cancer cells was analyzed. ISIS 549372, ISIS 549458, ISIS 554221, and ISIS 549434 were tested in C4-2B MR cells.

ISIS 549372, ISIS 549434, ISIS 549458, and ISIS 554221 were each added to the culture media at 0.04 μ M, 0.20 μ M, 1.00 μ M, and 5.00 μ M concentration of antisense oligonucleotide. ISIS 347526 was included as a negative control. After a treatment period of 6 days, the proliferative capacity of the cancer cells was measured with using CellTiter 96® AQueous One Solution Cell Proliferation kit (Promega), following the manufacturer's instructions. Results are presented in Table 41 as percent inhibition of proliferation, relative to non-treated cells. Treatment of the cells with ISIS 549372, ISIS 549434, and ISIS 549458 reduced proliferation of the cells in a dose dependent manner more extensively than treatment with ISIS 554221.

TABLE 41

Percent inhibition of C4-2B MR cell proliferation				
ISIS No	0.04 μ M	0.20 μ M	1.00 μ M	5.00 μ M
549372	0	4	25	43
549434	0	0	21	22
549458	8	16	41	56
554221	11	12	0	24
347526	11	22	7	16

Example 18

Effect of Antisense Inhibition of Human Androgen Receptor (AR) mRNA on MDV3100-Resistant LMR20 Cells

An MDV3100-resistant cell line, designated as LMR20, was created. The effect of antisense inhibition of AR on the

118

proliferative ability and AR mRNA levels of LMR20 cells was analyzed. ISIS 560131, ISIS 549458, and ISIS 569236 were tested along with the LNA gapmer, ISIS 554221.

LnCaP cells were incubated with increasing concentrations of MDV3100 for approximately 6 months. A single clone was selected after extensive culturing in the presence of 20 μ M MDV3100. The clone, LMR20, maintained the ability to allow free uptake of antisense oligonucleotides without lipid-mediated transfection, while demonstrating an approximately ten-fold increase in IC₅₀ when treated with MDV3100, compared to parental LnCaP cells.

Study 1

LMR20 cells were plated at 1,500 cells per well in phenol red-free medium with charcoal-stripped fetal bovine serum (CSS), to remove any androgens from the medium (Life Technologies). ISIS 560131, ISIS 549458, ISIS 569236, and ISIS 554221 were individually added to the culture media at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M concentration. ISIS 549148, which has no known human target sequence, was included as a control. The synthetic androgen agonist, R1881, (Takeda, A. N. et al., Mol. Pharmacol. 2007. 71: 473-82) was added on day 1 at 1 nM dose to a set of cells also treated with each of the antisense oligonucleotides. DHT was added on day 1 at a dose of 10 nM to another set of cells also treated with each of the antisense oligonucleotides. MDV3100 was added on day 1 at a dose of 10 nM to another set of cells untreated with antisense oligonucleotide, which served as a control. After a treatment period of 5 days, the proliferative ability of the cancer cells was measured by the standard MTT assay. Results are presented in Table 42 as percent inhibition of proliferation, relative to non-treated cells.

As presented in Table 42, in the presence of androgen agonists R1881 or DHT, ISIS 560131, ISIS 549458, and ISIS 569236 significantly inhibited MDV3100-resistant prostate cancer cell proliferation in a dose dependent manner more extensively than ISIS 554221. Inhibition of proliferation by the antisense oligonucleotides was also either comparable or more potent than with treatment with MDV3100.

TABLE 42

Percent inhibition of LMR20 cell proliferation						
Treatment	ASO (μ M)	ISIS 560131	ISIS 569236	ISIS 549458	ISIS 554221	MDV3100
CSS	0.04	0	0	0	0	0
	0.20	0	10	0	1	5
	1.0	9	0	0	2	0
	5.0	16	12	5	16	11
CSS + R1881	0.04	0	0	0	1	0
	0.20	13	2	22	10	5
	1.0	55	34	59	19	31
	5.0	70	61	74	54	67
CSS + DHT	0.04	0	0	0	0	0
	0.20	13	10	25	0	1
	1.0	57	32	60	10	13
	5.0	71	57	70	36	41

Study 2

LMR20 cells were plated at 1,500 cells per well in phenol red-free medium with CSS. ISIS 560131, ISIS 549458, ISIS 569236, and the LNA gapmer ISIS 554221 were individually added to the culture media at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M concentration. ISIS 549148, which has no known human target sequence, was included as a control. MDV3100 was added on day 1 at a dose of 10 nM to a set of cells, and served as a control. DHT was added on day 1 at a dose of 10 nM for 72 hrs to one set of cells also treated

with each of the antisense oligonucleotides or MDV3100. R1881 was added on day 1 at a dose of 10 nM for 72 hrs to another set of cells also treated with each of the antisense oligonucleotides or MDV3100. mRNA levels of AR, prostate-specific antigen (PSA) and TMPRSS2, an androgen-regulated gene (Lin, B., et al., Cancer Res. 1999, 59: 4180), were measured. Results are presented in Tables 43-45 as mRNA levels expressed as a percentage of the baseline values. mRNA levels may be lowered or increased after treatment.

As presented in Tables 43-45, ISIS 560131, ISIS 549458, and ISIS 569236 reduced AR mRNA levels in LMR20 cells, treated with or without either AR agonist, in a dose dependent manner relative to the baseline. Treatment with the LNA gapmer ISIS 554221 did not alter AR mRNA levels. ISIS 560131, ISIS 549458, and ISIS 569236 reduced PSA levels and TMPRSS2 more extensively than the LNA gapmer ISIS 554221 or MDV3100. Treatment with MDV3100 increased the levels of AR mRNA in cells treated with AR agonist, and did not reduce either PSA or TMPRSS2 mRNA levels.

TABLE 43

mRNA levels (% baseline value) of cells without AR agonist treatment						
Gene	ASO (μ M)	560131	569236	549458	554221	MDV3100
AR	0.04	107	104	101	124	106
	0.20	74	87	75	140	101
	1.0	29	42	30	132	99
	5.0	17	27	25	98	92
	0.04	113	122	135	106	98
PSA	0.20	83	90	85	118	93
	1.0	75	78	50	58	90
	5.0	71	73	72	87	113
	0.04	92	96	110	95	101
	0.20	67	81	85	117	119
TMPRSS2	1.0	52	59	54	77	119
	5.0	45	48	62	73	141

TABLE 44

mRNA levels (% baseline value) after treatment with DHT						
Gene	ASO (μ M)	560131	569236	549458	554221	MDV3100
AR	0.04	89	94	91	137	105
	0.20	55	77	66	135	124
	1.0	25	44	34	136	110
	5.0	20	34	31	100	143
	0.04	74	108	93	97	124
PSA	0.20	61	79	71	86	108
	1.0	35	46	47	64	95
	5.0	35	46	47	64	95
	0.04	112	113	127	121	134
	0.20	108	123	119	118	144
TMPRSS2	1.0	93	111	106	122	132
	5.0	71	110	91	114	124

TABLE 45

mRNA levels (% baseline value) after treatment with R1881						
Gene	ASO (μ M)	560131	569236	549458	554221	MDV3100
AR	0.04	87	89	88	131	94
	0.20	65	80	56	133	107

TABLE 45-continued

mRNA levels (% baseline value) after treatment with R1881						
Gene	ASO (μ M)	560131	569236	549458	554221	MDV3100
PSA	1.0	30	44	25	124	115
	5.0	26	37	32	99	136
	0.04	92	90	93	100	84
	0.20	77	90	67	93	101
	1.0	44	57	50	80	92
TMPRSS2	5.0	35	41	44	57	87
	0.04	132	126	137	136	114
	0.20	117	131	119	134	125
	1.0	88	98	96	125	133
	5.0	76	95	96	122	139

Example 19

Effect of Antisense Inhibition of Human Androgen Receptor (AR) mRNA in Combination with MDV3100 on the Proliferative Ability of C4-2B Cells

The effect of antisense inhibition of AR in combination with different doses of MDV3100 on the proliferative ability of cancer cells was analyzed. ISIS 549372, ISIS 549434, ISIS 549458, and ISIS 554221 were tested in C4-2B cells.

C4-2B cells were plated at 1,500 cells per well. ISIS 549372, ISIS 549434, ISIS 549458, or ISIS 554221 were individually added to the culture media at 0.1 μ M concentration. ISIS 347526 was included as a negative control. MDV3100 was also added on day 1 at doses of 0.25 μ M or 1.00 μ M. After a treatment period of 6 days, the proliferative capacity of the cancer cells was measured with CellTiter 96® Aqueous One Solution Cell Proliferation kit (Promega), following the manufacturer's instructions. Results are presented in Table 46 as percent inhibition of proliferation, relative to non-treated cells. Treatment of the cells with ISIS 549372 or ISIS 549458 reduced proliferation of the cells more extensively than treatment with ISIS 554221. For instance, as presented in Table 46, treatment with ISIS 549372 alone reduced cell proliferation by 59% and treatment with ISIS 549458 reduced cell proliferation by 74% compared to ISIS 554221 alone, which reduced cell proliferation by 23%.

As presented in Tables 46 and 47, ISIS 549372 or ISIS 549458 in combination with MDV3100 inhibited prostate cancer cell proliferation to a greater extent than an equal molar concentration of ISIS 554221 in combination of MDV3100.

To find out whether treatment of the cells with ISIS 549372 or ISIS 549458 was synergistic with MDV3100, the assay was repeated at 0.1 μ M ASO. As presented in Table 46, treatment with ISIS 549372 or ISIS 549458 was synergistic with MDV3100. For instance, MDV3100 alone at 0.25 μ M inhibited proliferation by 4%; ISIS 549372 alone at 0.1 μ M inhibited cell proliferation by 23%; in combination, cell proliferation was inhibited by 66%. Similarly, ISIS 549458 alone at 0.1 μ M inhibited cell proliferation by 39%; in combination, cell proliferation was inhibited by 75%. Hence, the combination of ISIS 549372 or ISIS 549458 and MDV3100 was synergistic (i.e. greater than additive) in terms of inhibition of prostate cancer cell proliferation.

121

TABLE 46

Percent inhibition of C4-2B cell proliferation with 0.1 μ M ASO

	MDV3100		
	0 μ M	0.25 μ M	1 μ M
PBS	0	9	38
ISIS 549372	23	44	66
ISIS 549458	39	59	75
ISIS 554221	9	29	59
ISIS 141923	0	4	38

TABLE 47

Percent inhibition of C4-2B cell proliferation with 0.2 μ M ASO

	MDV3100		
	0 μ M	0.25 μ M	1 μ M
PBS	0	20	46
ISIS 549372	59	69	77
ISIS 549458	74	75	79
ISIS 554221	23	45	67
ISIS 141923	0	5	50

Example 20

Effect of Antisense Inhibition of Human Androgen Receptor (AR) mRNA in Combination with MDV3100 on the Proliferative Ability of LNCaP Cells

The effect of antisense inhibition of AR in combination with different doses of MDV3100 on the proliferative ability of cancer cells was analyzed. ISIS 560131 and ISIS 569236 were tested in LNCaP cells.

LNCaP cells were plated at 1,000 cells per well. ISIS 560131 or ISIS 569236 was individually added to the culture media at 0.08 μ M, 0.04 μ M, 0.2 μ M, or 1.0 μ M concentration. ISIS 549148 was included as a negative control. MDV3100 was added to the ISIS oligonucleotide-treated cells on day 2 at doses of 0.016 μ M, 0.08 μ M, 0.4 μ M, or 2.0 μ M. After a treatment period of 5 days, the proliferative capacity of the cancer cells was measured with CellTiter 96® AQueous One or CellTiter-Glo® Solution Cell Proliferation kit (Promega), following the manufacturer's instructions. Results are presented in Tables 48-52 as percent inhibition of proliferation, relative to non-treated cells.

As presented in the Tables, treatment with ISIS 560131 or ISIS 569236 was synergistic with MDV3100. For instance, MDV3100 with control oligonucleotide, ISIS 549148, at 0.08 μ M inhibited proliferation by an average of 7%; ISIS 560131 alone at 0.04 μ M inhibited cell proliferation by 24%; in combination, cell proliferation was inhibited by 41%. Similarly, ISIS 569236 alone at 0.04 μ M inhibited cell proliferation by 9%; in combination, cell proliferation was inhibited by 26%. Hence, the combination of ISIS 560131 or ISIS 569236 and MDV3100 was synergistic (i.e. greater than additive) in terms of inhibition of prostate cancer cell proliferation.

122

TABLE 48

Proliferation (% untreated control) in LNCaP without MDV-3100

	ASO Dose			
	0.08 μ M	0.04 μ M	0.2 μ M	1.0 μ M
ISIS 560131	106	76	50	26
ISIS 569236	106	91	60	35
ISIS 549148	104	101	91	82

TABLE 49

Proliferation (% untreated control) in LNCaP with 0.016 μ M MDV-3100

	ASO Dose			
	0.08 μ M	0.04 μ M	0.2 μ M	1.0 μ M
ISIS 560131	103	71	49	25
ISIS 569236	104	92	58	29
ISIS 549148	106	86	83	59

TABLE 50

Proliferation (% untreated control) in LNCaP with 0.08 μ M MDV-3100

	ASO Dose			
	0.08 μ M	0.04 μ M	0.2 μ M	1.0 μ M
ISIS 560131	99	59	48	27
ISIS 569236	98	74	51	31
ISIS 549148	93	101	89	90

TABLE 51

Proliferation (% untreated control) in LNCaP with 0.4 μ M MDV-3100

	ASO Dose			
	0.08 μ M	0.04 μ M	0.2 μ M	1.0 μ M
ISIS 560131	68	50	40	26
ISIS 569236	61	48	41	27
ISIS 549148	65	57	50	48

TABLE 52

Proliferation (% untreated control) in LNCaP with 2.0 μ M MDV-3100

	ASO Dose			
	0.08 μ M	0.04 μ M	0.2 μ M	1.0 μ M
ISIS 560131	45	42	38	23
ISIS 569236	44	41	35	23
ISIS 549148	39	42	41	32

123

Example 21

Effect of Antisense Inhibition of Human Androgen Receptor (AR) mRNA in Combination with MDV3100 on the Proliferative Ability of C4-2B Cells

The effect of antisense inhibition of AR in combination with different doses of MDV3100 on the proliferative ability of cancer cells was analyzed. ISIS 560131 and ISIS 569236 were tested in C4-2B cells.

C4-2B cells were plated at 1,000 cells per well. ISIS 560131 or ISIS 569236 was individually added to the culture media at 0.08 μ M, 0.04 μ M, 0.2 μ M, or 1.0 μ M concentration. ISIS 549148 was included as a negative control. MDV3100 was added to the ISIS oligonucleotide-treated cells on day 2 at doses of 0.016 μ M, 0.08 μ M, 0.4 μ M, or 2.0 μ M. After a treatment period of 5 days, the proliferative capacity of the cancer cells was measured with CellTiter 96® AQueous One Solution Cell Proliferation kit (Promega), following the manufacturer's instructions. Results are presented in Tables 53-57 as percent inhibition of proliferation, relative to non-treated cells.

As presented in the Tables, treatment with ISIS 560131 or ISIS 569236 was synergistic with MDV3100. For instance, MDV3100 with control oligonucleotide, ISIS 549148, at 0.4 μ M inhibited proliferation by an average of 6%; ISIS 560131 alone at 0.08 μ M inhibited cell proliferation by 16%; in combination, cell proliferation was inhibited by 31%. Similarly, MDV3100 with control oligonucleotide, ISIS 549148, at 0.08 μ M did not inhibit proliferation (0%); ISIS 569236 alone at 0.2 μ M inhibited cell proliferation by 37%; in combination, cell proliferation was inhibited by 52%. Hence, the combination of ISIS 560131 or ISIS 569236 and MDV3100 was synergistic (i.e. greater than additive) in terms of inhibition of prostate cancer cell proliferation.

TABLE 53

Proliferation (% untreated control) in C4-2B without MDV-3100				
ASO Dose				
	0.08 μ M	0.04 μ M	0.2 μ M	1.0 μ M
ISIS 560131	84	59	47	41
ISIS 569236	100	72	63	51
ISIS 549148	111	117	118	126

TABLE 54

Proliferation (% untreated control) in C4-2B with 0.016 μ M MDV-3100				
ASO Dose				
	0.08 μ M	0.04 μ M	0.2 μ M	1.0 μ M
ISIS 560131	104	71	53	39
ISIS 569236	107	74	65	55
ISIS 549148	110	107	124	103

124

TABLE 55

Proliferation (% untreated control) in C4-2B with 0.08 μ M MDV-3100				
ASO Dose				
	0.08 μ M	0.04 μ M	0.2 μ M	1.0 μ M
ISIS 560131	66	73	56	42
ISIS 569236	89	79	51	43
ISIS 549148	84	125	123	114

TABLE 56

Proliferation (% untreated control) in C4-2B with 0.4 μ M MDV-3100				
ASO Dose				
	0.08 μ M	0.04 μ M	0.2 μ M	1.0 μ M
ISIS 560131	69	69	48	48
ISIS 569236	90	63	48	39
ISIS 549148	89	110	88	88

TABLE 57

Proliferation (% untreated control) in C4-2B with 2.0 μ M MDV-3100				
ASO Dose				
	0.08 μ M	0.04 μ M	0.2 μ M	1.0 μ M
ISIS 560131	37	42	49	43
ISIS 569236	44	45	48	46
ISIS 549148	47	40	52	59

Example 22

Effect of Antisense Inhibition of Human Androgen Receptor (AR) mRNA in Combination with MDV3100 on the Proliferative Ability of 22RV1 Cells

The effect of antisense inhibition of AR in combination with different doses of MDV3100 on the proliferative ability of cancer cells was analyzed. ISIS 560131 and ISIS 569236 were tested in 22RV1 cells.

22RV1 cells were plated at 2,000 cells per well in 5% CSS medium for 48 hours. Cells were transfected using RNAiMAX reagent with ISIS 560131 or ISIS 569236 at 0.4 nM, 1.34 nM, 4 nM, or 13.4 nM concentrations. ISIS 549148 was included as a negative control. DHT at 1 nM and/or MDV3100 at doses of 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M were added after 4 hours. After a treatment period of 3 days, the proliferative capacity of the cancer cells was measured with CellTiter 96® AQueous One Solution Cell Proliferation kit (Promega), following the manufacturer's instructions. Results are presented in Tables 58-62 as percent inhibition of proliferation, relative to non-treated cells.

As presented in the Tables, treatment with ISIS 560131 or ISIS 569236 was synergistic with MDV3100. For instance, MDV3100 with control oligonucleotide, ISIS 549148, at 1.0 μ M inhibited proliferation by an average of 5%; ISIS 560131 alone at 1.34 nM inhibited cell proliferation by 3%; in combination, cell proliferation was inhibited by 23%. Similarly, MDV3100 with control oligonucleotide, ISIS 549148, at 1.0 μ M inhibited proliferation by 5%; ISIS

125

569236 alone at 1.0 μ M inhibited cell proliferation by 17%; in combination, cell proliferation was inhibited by 30%. Hence, the combination of ISIS 560131 or ISIS 569236 and MDV3100 was synergistic (i.e. greater than additive) in terms of inhibition of prostate cancer cell proliferation.

TABLE 58

Proliferation (% untreated control) in 22RV1 without MDV-3100				
	ASO Dose			
	0.4 nM	1.34 nM	4.0 nM	13.4 nM
ISIS 560131	103	97	77	57
ISIS 569236	97	83	69	37
ISIS 549148	109	109	109	99

TABLE 59

Proliferation (% untreated control) in 22RV1 cells with 0.04 μ M MDV-3100				
	ASO Dose			
	0.4 nM	1.34 nM	4.0 nM	13.4 nM
ISIS 560131	96	80	65	39
ISIS 569236	83	70	61	24
ISIS 549148	106	106	100	85

TABLE 60

Proliferation (% untreated control) in 22RV1 cells with 0.2 μ M MDV-3100				
	ASO Dose			
	0.4 nM	1.34 nM	4.0 nM	13.4 nM
ISIS 560131	95	90	76	51
ISIS 569236	93	77	60	20
ISIS 549148	101	115	110	96

TABLE 61

Proliferation (% untreated control) in 22RV1 cells with 1.0 μ M MDV-3100				
	ASO Dose			
	0.4 nM	1.34 nM	4.0 nM	13.4 nM
ISIS 560131	96	77	63	40
ISIS 569236	79	70	52	18
ISIS 549148	106	95	98	82

TABLE 62

Proliferation (% untreated control) in 22RV1 cells with 5.0 μ M MDV-3100				
	ASO Dose			
	0.4 nM	1.34 nM	4.0 nM	13.4 nM
ISIS 560131	91	76	63	41
ISIS 569236	82	72	52	24
ISIS 549148	96	102	98	85

126

Example 23

Effect of Antisense Inhibition of Human Androgen Receptor (AR) mRNA on CWR22-RV1 Cells

The effect of antisense inhibition of AR on the proliferative ability of cancer cells was analyzed. ISIS 549372, ISIS 549434, ISIS 549458, and ISIS 554221 were tested in CWR22-RV1 cells.

CWR22-RV1 cells were plated and transfected using RNAiMax reagent (Life Technologies) with ISIS oligonucleotides at 1.7 nM, 5.0 nM, 16.7 nM, or 50 nM concentrations. ISIS 347526 was included as a negative control. After a treatment period of 6 days, the target reduction and proliferative capacity of the cancer cells was measured.

Antisense inhibition of AR full-length mRNA was measured with the RTS3559 primer probe set. The results are presented in Table 63 as percent inhibition relative to non-treated cells. The reduction in V7 splice variant of the AR mRNA was also measured by RT-PCR using SYBR Green staining (Hu, R. et al., Cancer Res. 2009. 69: 16-22). The results are presented in Table 64, as percent reduction, relative to non-treated cells. Cell proliferation was measured with CellTiter 96® AQueous One Solution Cell Proliferation kit (Promega), following the manufacturer's instructions. Results are presented in Table 65 as percent inhibition of proliferation, relative to non-treated cells.

TABLE 63

Percent inhibition of AR full-length mRNA					
Dose (nM)	ISIS 549372	ISIS 549434	ISIS 549458	ISIS 554221	ISIS 347526
1.7	24	27	28	24	0
5.0	53	46	41	41	3
16.7	64	69	61	67	4
50.0	78	86	78	72	0

TABLE 64

Percent inhibition of AR splice variant, V7					
Dose (nM)	ISIS 549372	ISIS 549434	ISIS 549458	ISIS 554221	ISIS 347526
1.7	23	0	18	25	17
5.0	35	20	34	1	0
16.7	56	4	58	7	0
50.0	82	23	82	35	10

TABLE 65

Percent inhibition of cell proliferation					
Dose (nM)	ISIS 549372	ISIS 549434	ISIS 549458	ISIS 554221	ISIS 347526
1.7	0	8	0	17	0
5.0	0	15	0	11	0
16.7	25	13	17	27	0
50.0	53	38	40	47	0

127

Example 24

Effect of Antisense Inhibition of Human Androgen Receptor (AR) mRNA by Free Uptake of Antisense Oligonucleotide by C4-2B Cells

The effect of free uptake of antisense oligonucleotides on AR mRNA levels was investigated. ISIS 549372, ISIS 549434, ISIS 549458, and ISIS 554221 were tested.

Cells were plated at a concentration of 1,000 cells/well in 96-well plates to measure cell proliferation, and at 4,000 cells/well to measure target reduction. ISIS 549458, ISIS 549372, ISIS 549434, and ISIS 554221 were added individually at 0.04 μ M, 0.20 μ M, 1.00 μ M, or 5.00 μ M. After an incubation period of 24 hrs, mRNA levels were measured using hAR_LTS00943. The data is presented in Table 66. The results indicate that ISIS 549458, ISIS 549372, and ISIS 549434 inhibited AR mRNA expression more potently than ISIS 554221.

On day 6, cells plated for measuring proliferation were incubated with MTT reagent until the development of color. Color intensity was measured using a spectrophotometer at 490 nm. The data is presented in Table 67.

TABLE 66

Percent inhibition of AR full-length mRNA				
Dose (μ M)	ISIS 549372	ISIS 549434	ISIS 549458	ISIS 554221
0.04	10	10	16	0
0.20	36	35	48	0
1.00	73	52	80	0
5.00	80	55	86	0

TABLE 67

Percent inhibition of cell proliferation				
Dose (μ M)	ISIS 549372	ISIS 549434	ISIS 549458	ISIS 554221
0.04	8	0	7	0
0.20	34	14	31	10
1.00	44	35	45	21
5.00	45	37	41	30

Example 25

Effect of Antisense Inhibition of Human Androgen Receptor (AR) mRNA by Free Uptake of Antisense Oligonucleotide by LnCaP Cells

The effect of free uptake of antisense oligonucleotides on AR mRNA levels was investigated.

Cells were plated at a concentration of 4,000 cells/well in 96-well plates. ISIS oligonucleotides, specified in Table 68, were added individually at 0.02 μ M, 0.10 μ M, 0.50 μ M, 2.50 μ M, or 10.00 μ M. After an incubation period of 24 hrs, mRNA levels were measured using primer probe set hAR_LTS00943. The data is presented in Table 68. The results indicate that most of the ISIS oligonucleotides inhibited AR mRNA expression more potently than ISIS 554221 at each concentration.

128

TABLE 68

Percent inhibition of AR mRNA						
ISIS No	0.02 μ M	0.1 μ M	0.5 μ M	2.5 μ M	10 μ M	
554221	0	0	0	0	17	
549372	0	0	21	63	78	
549458	4	14	67	86	89	
560131	0	0	13	31	57	
569213	3	0	31	59	78	
569216	15	17	49	66	82	
569221	18	31	49	78	91	
569227	0	0	4	33	55	
569236	3	2	21	43	70	
579666	0	8	30	49	68	
579667	0	0	8	12	40	
579671	15	0	19	54	71	
583918	8	0	0	0	13	
584149	0	0	0	14	39	
584163	0	0	19	41	70	
584269	0	0	0	12	23	
584468	0	0	10	44	73	
586124	0	0	19	64	82	
586227	0	0	14	44	59	

Example 26

Effect of Antisense Inhibition of Human Androgen Receptor (AR) mRNA in the Presence of DHT on the Proliferative Ability of 22RV1 Cells

Dihydrotestosterone (DHT) is an androgen hormone and AR activator. The effect of antisense inhibition of AR on the proliferative ability of cancer cells treated with DHT was analyzed. ISIS 560131 and ISIS 569236 were tested in the human prostate carcinoma cell line, 22RV1.

22RV1 cells were plated at 1,500 cells per well. ISIS 560131 and ISIS 569236 were individually transfected into the cells using RNAiMAX™ reagent (Life Technologies) at 1.34 nM, 4.00 nM, 13.4 nM, or 40.0 nM concentration. ISIS 549148, which has no known human target sequence, was included as a control. Separate sets of cells, also treated with each of the antisense oligonucleotides, were treated with DHT added on day 1 at a final concentration of 1 nM. After a treatment period of 5 days, the proliferative ability of the cancer cells was measured using the standard MTT assay. Results are presented in Table 69 as percent inhibition of proliferation, relative to non-treated cells.

As presented in Table 69, both ISIS 560131 and ISIS 569236 significantly inhibited prostate cancer cell proliferation even in the presence of AR activator, DHT, compared to the control. The control oligonucleotide did not show any effect on proliferation, as expected.

TABLE 69

Percent inhibition of 22RV1 cell proliferation				
	ASO (nM)	ISIS 560131	ISIS 569236	ISIS 549148
-DHT	1.34	0	0	0
	4.0	2	18	0
	13.4	29	47	4
	40.0	54	64	0
+DHT	1.34	0	0	0
	4.0	1	6	0
	13.4	13	32	3
	40.0	34	56	0

129

Example 27

Time-Course Study of Treatment C4-2B Cells with
ISIS Oligonucleotides Targeting AR

The effect of antisense inhibition of on C4-2B cancer cells on gene expression was analyzed. ISIS 560131 and ISIS 569236 were tested.

AR mRNA Analysis

C4-2B cells were plated at 1,000 cells per well in complete medium. ISIS 560131 or ISIS 569236 was individually added to the culture media to the final concentrations of 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M concentrations without using transfection reagent. ISIS 549148 was included as a negative control. MDV-3100 was added at dose of 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M in a separate set of cells. After a treatment period of 8 hours, 24 hours, and 48 hours, AR expression was measured with primer probe set hAR-LTS00943. Results are presented in Tables 70-72 as percent expression of AR, relative to non-treated cells. Treatment of the cells with ISIS 560131 or ISIS 569236 reduced AR expression in the cells relative to the control set. Treatment with MDV-3100 increased AR expression at the 48 hour time-point.

TABLE 70

Percent expression of AR compared to the control group in 8 hours				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	110	85	68	45
ISIS 569236	100	87	84	58
ISIS 549148	116	105	111	110
MDV-3100	99	100	92	103

TABLE 71

Percent expression of AR compared to the control group in 24 hours				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	47	18	5	4
ISIS 569236	103	35	15	5
ISIS 549148	87	85	87	107
MDV-3100	88	99	96	84

TABLE 72

Percent expression of AR compared to the control group in 48 hours				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	33	5	6	4
ISIS 569236	80	19	7	2
ISIS 549148	98	90	87	99
MDV-3100	94	94	113	126

AR Protein Analysis

Protein levels in the cells were also analyzed. The cells were harvested in RIPA buffer containing protease inhibitors. The presence of bands for full-length AR was detected by western blot using AR antibody (N-20, SC-816, Santa Cruz Biotechnology). Full-length AR was significantly reduced in cells treated with ISIS 560131 or ISIS 569236 for 24 hours and 48 hours, normalized to the levels of the house-keeping gene, GAPDH.

mRNA Expression Analysis of Downstream Genes

Expression analysis of prostate-specific antigen (PSA) and TMPRSS2 were also analyzed. Results are presented in

130

Tables 73-75 as percent inhibition of PSA expression and Tables 76-78 as percent inhibition of TMPRSS2 expression, relative to non-treated cells. Treatment of the cells with ISIS 560131 or ISIS 569236 reduced PSA and TMPRSS2 expression in the cells relative to the control set at the 24 hr and 48 hr time points. Treatment with MDV-3100 also reduced downstream gene expressions but not as potently as that with the ISIS oligonucleotides.

TABLE 73

Percent inhibition of PSA expression compared to the control group in 8 hours				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	12	0	3	1
ISIS 569236	18	3	0	0
ISIS 549148	1	8	8	0
MDV-3100	0	3	23	33

TABLE 74

Percent inhibition of PSA expression compared to the control group in 24 hours				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	27	46	56	60
ISIS 569236	10	34	44	54
ISIS 549148	22	13	16	6
MDV-3100	24	24	53	65

TABLE 75

Percent inhibition of PSA expression compared to the control group in 48 hours				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	20	61	71	80
ISIS 569236	4	45	68	76
ISIS 549148	2	0	18	10
MDV-3100	5	5	32	63

TABLE 76

Percent inhibition of TMPRSS2 expression compared to the control group in 8 hours				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	0	0	6	0
ISIS 569236	0	0	0	0
ISIS 549148	5	0	0	0
MDV-3100	0	6	45	52

TABLE 77

Percent inhibition of TMPRSS2 expression compared to the control group in 24 hours				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	35	57	66	67
ISIS 569236	10	32	57	66
ISIS 549148	29	10	29	10
MDV-3100	23	31	63	72

131

TABLE 78

	Percent inhibition of TMPRSS2 expression compared to the control group in 48 hours			
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	46	71	77	76
ISIS 569236	22	57	70	75
ISIS 549148	0	4	0	0
MDV-3100	5	16	46	59

Example 28

Antisense Inhibition of AR mRNA in LNCaP Cells
Cultured in Complete Media and CSS Media

The effect of antisense inhibition of AR in LNCaP cells cultured in complete medium, as well as CSS medium with DHT, was investigated.

Gene Expression in Complete Medium

Cells were plated at 1,000 cells per well. ISIS 560131 or ISIS 569236 was added individually at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M. ISIS 549148 was included as a negative control. MDV3100 was added a dose of 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M. μ M in a separate set of cells. After an incubation period of 48 hours, RNA levels of AR, PSA and TMPRSS2 were measured. The data is presented in Tables 79-81.

Protein analysis of full-length AR also demonstrated a dose-dependent decrease of expression, normalized to levels of the house-keeping gene, GAPDH.

TABLE 79

	Percent expression of AR in LNCaP cells cultured in complete medium			
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	101	53	17	7
ISIS 569236	98	90	47	20
ISIS 549148	102	111	109	109
MDV-3100	111	133	121	139

TABLE 80

	Percent inhibition of PSA expression in LNCaP cells cultured in complete medium			
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	0	60	87	90
ISIS 569236	0	19	63	81
ISIS 549148	0	0	0	0
MDV-3100	0	35	84	87

TABLE 81

	Percent inhibition of TMPRSS2 expression in LNCaP cells cultured in complete medium			
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	0	25	50	51
ISIS 569236	0	5	40	48
ISIS 549148	0	0	0	0
MDV-3100	0	0	34	39

Gene Expression in CSS Medium and CSS+DHT Media

Cells were plated at 2,000 cells per well and cultured in phenol red-free RPMI supplemented with 5% charcoal

132

stripped serum (Gibco) media for 16 hours. ISIS 560131 or ISIS 569236 was added individually at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M to each cell set. ISIS 549148 was included as a negative control. MDV3100 was added at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M in a separate set of cells. After an incubation period of 4 hrs, DHT was added to the medium to a final concentration of 1 nM as indicated. RNAs were collected 48 hrs later and levels of AR, PSA and TMPRSS2 were measured. The data is presented in Table 82-85. In the absence of DHT, AR expression in LNCaP cells was 95%, PSA expression was 7% and TMPRSS2 expression was 24% compared to the untreated control.

TABLE 82

	Percent expression of AR in LNCaP cells cultured in CSS medium			
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	81	46	16	5
ISIS 569236	94	66	35	13
ISIS 549148	106	97	96	104
MDV-3100	91	67	64	77

TABLE 83

	Percent expression of AR in LNCaP cells cultured in CSS + DHT medium			
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	101	71	27	10
ISIS 569236	104	86	55	21
ISIS 549148	98	102	96	111
MDV-3100	107	121	110	113

TABLE 84

	Percent inhibition of PSA expression in LNCaP cells cultured in CSS + DHT medium			
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	10	21	21	72
ISIS 569236	4	11	45	59
ISIS 549148	0	8	0	9
MDV-3100	15	38	81	82

TABLE 85

	Percent inhibition of TMPRSS2 expression in LNCaP cells cultured in CSS + DHT medium			
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	6	11	26	64
ISIS 569236	6	8	40	50
ISIS 549148	0	0	1	10
MDV-3100	8	24	60	69

Effect on Proliferation in CSS Medium and CSS+DHT Media

After a treatment period of 5 days in complete medium or CSS+1 nM DHT medium, the proliferative capacity of the cancer cells was measured with using CellTiter 96® Aqueous One Solution or CellTiter-Glo® solution Cell Proliferation kit (Promega), following the manufacturer's instructions. Results are presented in Tables 86 and 87 as percent inhibition of proliferation, relative to non-treated cells. Treatment of the cells with ISIS 560131, ISIS 569236, and MDV-3100 reduced proliferation of the cells in a dose

133

dependent compared to the control. Treatment with ISIS oligonucleotides in CSS+DHT medium reduced the proliferative capacity to a greater extent than treatment with MVD-3100. The proliferative capacity of cells cultured in CSS medium without DHT is 17% of untreated control levels.

TABLE 86

Proliferation (% untreated control) in LNCaP cells cultured in complete medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	96	70	48	45
ISIS 569236	100	85	68	54
ISIS 549148	101	95	94	110
MDV-3100	107	88	65	45

TABLE 87

Proliferation (% untreated control) in LNCaP cells cultured in CSS + DHT medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	97	81	46	8
ISIS 569236	95	99	54	17
ISIS 549148	112	96	95	89
MDV-3100	112	95	74	33

Example 29

Antisense Inhibition of AR mRNA in C4-2 Cells Cultured in Complete Media and CSS Media

The effect of antisense inhibition of AR mRNA levels in C4-2 cells cultured in complete medium, as well as CSS medium with DHT, was investigated.

Gene Expression in Complete Medium

Cells were plated at 1,000 cells per well. ISIS 560131 or ISIS 569236 was added individually at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M. ISIS 549148 was included as a negative control. MDV3100 was added at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M in a separate set of cells. After an incubation period of 48 hrs, RNA levels of AR, PSA and TMPRSS2 were measured. The data is presented in Tables 88-90. Treatment with ISIS oligonucleotide inhibited AR expression, whereas treatment with MDV-3100 increased AR expression in the cells.

Protein analysis of full-length AR and PSA also demonstrated a dose-dependent decrease of expression, normalized to levels of the house-keeping gene, GAPDH.

TABLE 88

Percent expression of AR in C4-2 cells cultured in complete medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	48	13	8	8
ISIS 569236	72	27	11	9
ISIS 549148	89	90	84	86
MDV-3100	95	99	132	137

134

TABLE 89

Percent inhibition of PSA expression in C4-2 cells cultured in complete medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	48	78	88	89
ISIS 569236	35	62	83	88
ISIS 549148	15	24	24	23
MDV-3100	28	40	72	89

TABLE 90

Percent inhibition of TMPRSS2 expression in C4-2 cells cultured in complete medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	29	62	76	71
ISIS 569236	17	54	67	67
ISIS 549148	2	7	10	0
MDV-3100	10	20	44	67

Gene Expression in CSS+DHT Media

Cells were plated at 2,000 cells per well and cultured in CSS media with 1 nM DHT. ISIS 560131 or ISIS 569236 was added individually at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M to each cell set. ISIS 549148 was included as a negative control. MDV3100 was added at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M in a separate set of cells. After an incubation period of 48 hrs, RNA levels of AR, PSA and TMPRSS2 were measured. The data is presented in Table 91-93. In the absence of DHT, AR expression in C4-2 cells was 153%, PSA expression was 42% and TMPRSS2 expression was 23% compared to the untreated control. Treatment with ISIS oligonucleotide inhibited AR expression, whereas treatment with MDV-3100 increased AR expression in the cells.

TABLE 91

Percent expression of AR in C4-2 cells cultured in CSS + DHT medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	88	57	20	15
ISIS 569236	89	82	52	23
ISIS 549148	101	101	118	111
MDV-3100	101	109	156	148

TABLE 92

Percent inhibition of PSA expression in C4-2 cells cultured in CSS + DHT medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	10	24	49	74
ISIS 569236	0	4	57	64
ISIS 549148	0	8	21	22
MDV-3100	9	8	51	73

135

TABLE 93

Percent inhibition of TMPRSS2 expression in C4-2 cells cultured in CSS + DHT medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	10	17	51	78
ISIS 569236	0	11	61	67
ISIS 549148	3	0	22	28
MDV-3100	9	0	44	78

Effect on Proliferation in CSS Medium and CSS+DHT Media

After a treatment period of 5 days in complete medium or CSS+1 nM DHT medium, the proliferative capacity of the cancer cells was measured with using CellTiter 96® AQueous One Solution or CellTiter-Glo® Cell Proliferation kit (Promega), following the manufacturer's instructions. Results are presented in Tables 94 and 95 as percent inhibition of proliferation, relative to non-treated cells. Treatment of the cells with ISIS 560131, ISIS 569236, and MDV-3100 reduced proliferation of the cells in a dose dependent manner compared to the control. The proliferative capacity of cells cultured in CSS medium without DHT is 17% of untreated control levels.

TABLE 94

Proliferation (% untreated control) in C4-2 cells cultured in complete medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	104	82	70	51
ISIS 569236	103	81	57	58
ISIS 549148	106	112	91	94
MDV-3100	105	108	71	67

TABLE 95

Proliferation (% untreated control) in C4-2 cells cultured in CSS + DHT medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	106	94	47	31
ISIS 569236	99	99	88	51
ISIS 549148	102	82	82	91
MDV-3100	122	124	87	22

Example 30

Antisense Inhibition of AR mRNA in C4-2B Cells Cultured in Complete Media and CSS Media

The effect of antisense inhibition of AR mRNA levels in C4-2B cells cultured in complete medium, as well as CSS medium with DHT, was investigated.

Gene Expression in Complete Medium

Cells were plated at 1,000 cells per well. ISIS 560131 or ISIS 569236 was added individually at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M. ISIS 549148 was included as a negative control. MDV3100 was added at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M in a separate set of cells. After an incubation period of 48 hrs, RNA levels of AR, PSA and TMPRSS2 were measured. The data is presented in Tables 96-98. Treatment with ISIS oligonucleotide inhibited AR expression, whereas treatment with MDV-3100 increased AR expression in the cells.

136

Protein analysis of full-length AR also demonstrated a dose-dependent decrease of expression, normalized to levels of the house-keeping gene, GAPDH.

TABLE 96

Percent expression of AR in C4-2B cells cultured in complete medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	34	15	14	14
ISIS 569236	61	23	20	16
ISIS 549148	101	91	88	87
MDV-3100	108	121	157	182

TABLE 97

Percent inhibition of PSA expression in C4-2B cells cultured in complete medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	56	84	89	92
ISIS 569236	30	72	81	89
ISIS 549148	3	11	18	14
MDV-3100	8	27	73	88

TABLE 98

Percent inhibition of TMPRSS2 expression in C4-2B cells cultured in complete medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	46	71	72	75
ISIS 569236	33	59	69	73
ISIS 549148	0	2	4	0
MDV-3100	3	24	55	71

Gene Expression in CSS+DHT Media

Cells were plated at 2,000 cells per well and cultured in CSS media with 1 nM DHT. ISIS 560131 or ISIS 569236 was added individually at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M to each cell set. ISIS 549148 was included as a negative control. MDV3100 was added at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M in a separate set of cells. After an incubation period of 48 hrs, RNA levels of AR, PSA and TMPRSS2 were measured. The data is presented in Tables 99-101. In the absence of DHT, AR expression in C4-2 cells was 188%, PSA expression was 43% and TMPRSS2 expression was 27% compared to the untreated control. Treatment with ISIS oligonucleotide inhibited AR expression, whereas treatment with MDV-3100 increased AR expression in the cells.

TABLE 99

Percent expression of AR in C4-2B cells cultured in CSS + DHT medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	55	31	15	13
ISIS 569236	67	49	24	19
ISIS 549148	91	104	101	95
MDV-3100	112	144	165	173

137

TABLE 100

Percent inhibition of PSA expression in C4-2B cells cultured in CSS + DHT medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	0	17	50	61
ISIS 569236	0	5	33	46
ISIS 549148	0	0	0	0
MDV-3100	0	0	37	45

TABLE 101

Percent inhibition of TMPRSS2 expression in C4-2B cells cultured in CSS + DHT medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	0	34	60	76
ISIS 569236	0	6	43	59
ISIS 549148	0	0	0	3
MDV-3100	0	11	48	66

Effect on Proliferation in CSS Medium and CSS+DHT Media

After a treatment period of 5 days in complete medium or CSS+1 nM DHT medium, the proliferative capacity of the cancer cells was measured with using CellTiter 96® Aqueous One or CellTiter-Glo® Solution Cell Proliferation kit (Promega), following the manufacturer's instructions. Results are presented in Tables 102 and 103 as percent inhibition of proliferation, relative to non-treated cells. Treatment of the cells with ISIS 560131, ISIS 569236, and MDV-3100 reduced proliferation of the cells in a dose dependent compared to the control. Treatment with ISIS oligonucleotides in CSS+DHT medium reduced the proliferative capacity to a greater extent than treatment with MVD-3100. The proliferative capacity of cells cultured in CSS medium without DHT is 12% of untreated control levels.

TABLE 102

Proliferation (% untreated control) in C4-2B cells cultured in complete medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	93	50	50	41
ISIS 569236	98	64	55	48
ISIS 549148	119	97	103	98
MDV-3100	131	105	72	60

TABLE 103

Proliferation (% untreated control) in C4-2B cells cultured in CSS + DHT medium				
	0.04 μ M	0.2 μ M	1 μ M	5.0 μ M
ISIS 560131	111	75	49	40
ISIS 569236	109	109	67	39
ISIS 549148	109	131	119	114
MDV-3100	125	100	83	17

138

Example 31

Antisense Inhibition of AR mRNA in VCaP Cells Cultured in Complete Media and CSS Media

The effect of antisense inhibition of AR in VCaP prostate cancer cells (Korenychuk, S. et al., In Vivo. 2001. 15: 163-168) cultured in complete medium, as well as CSS medium with DHT, was investigated. VCaP cells express both full length AR, as well as the V7 variant.

Gene Expression in Complete Medium

Cells were plated at 10,000 cells per well. ISIS 560131 or ISIS 569236 was added individually at 1.34 nM, 4 nM, 13.4 nM, or 40 nM using RNAiMax transfection reagent. ISIS 549148 was included as a negative control. After an incubation period of 48 hrs, RNA levels of full length AR, the V7 variant, PSA and TMPRSS2 were measured. The data is presented in Tables 104-107.

Protein analysis of full-length AR and the V7 variant also demonstrated a dose-dependent decrease of expression of both compared to levels of the house-keeping gene, GAPDH.

TABLE 104

Percent inhibition of full-length AR in VCaP cells cultured in complete medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	0	59	77	84
ISIS 569236	0	41	49	74
ISIS 549148	0	8	5	17

TABLE 105

Percent inhibition of AR V7 variant in VCaP cells cultured in complete medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	0	57	78	84
ISIS 569236	0	40	53	80
ISIS 549148	0	8	0	14

TABLE 106

Percent inhibition of PSA expression in VCaP cells cultured in complete medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	2	24	35	46
ISIS 569236	7	19	40	52
ISIS 549148	2	0	0	20

TABLE 107

Percent inhibition of TMPRSS2 expression in VCaP cells cultured in complete medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	0	0	0	4
ISIS 569236	0	0	0	36
ISIS 549148	0	0	0	0

A separate set of cells was treated with MDV-3100 at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M. After an incubation period

139

of 48 hrs, RNA levels of full length AR, the V7 variant, PSA and TMPRSS2 were measured. The data is presented in Tables 108 expressed as percent expression of gene levels compared to the untreated control.

TABLE 108

Percent of gene expression in VCaP cells treated with MDV-3100 and cultured in complete medium				
	0.04 μ M	0.2 μ M	1.0 μ M	5.0 μ M
Full length AR	136	135	160	178
AR V7 variant	172	179	244	237
PSA	105	76	75	61
TMPRSS2	131	121	135	141

Gene Expression in CSS+DHT Media

Cells were plated at 15,000 cells per well and cultured in CSS media for 16 hours. Cells were then transfected using RNAiMax reagent with ISIS 560131 or ISIS 569236 at 1.34 nM, 4 nM, 13.4 nM, or 40 nM to each cell set. ISIS 549148 was included as a negative control. After 4 hrs, 1 nM DHT was added. MDV3100 was added in a separate set of cells at doses of 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M. After an incubation period of 48 hrs, RNA levels of AR, PSA and TMPRSS2 were measured. The data is presented in Tables 109-113. In the absence of DHT, AR expression in VCaP cells was 555%, V7 variant expression was 656%, PSA expression was 11%, and TMPRSS2 expression was 22% compared to the untreated control.

TABLE 109

Percent inhibition of full-length AR in VCaP cells cultured in CSS medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	12	16	37	38
ISIS 569236	23	21	38	35
ISIS 549148	0	0	0	0

TABLE 110

Percent inhibition of AR V7 variant in VCaP cells cultured in CSS + DHT medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	27	31	39	41
ISIS 569236	37	33	48	39
ISIS 549148	12	0	0	5

TABLE 111

Percent inhibition of PSA expression in VCaP cells cultured in CSS + DHT medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	0	35	69	73
ISIS 569236	8	25	62	74
ISIS 549148	0	3	9	0

140

TABLE 112

Percent inhibition of TMPRSS2 expression in VCaP cells cultured in CSS + DHT medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	0	21	49	57
ISIS 569236	6	19	40	54
ISIS 549148	0	0	0	0

TABLE 113

Percent of gene expression in VCaP cells treated with MDV-3100 and cultured in CSS + DHT medium				
	0.04 μ M	0.2 μ M	1.0 μ M	5.0 μ M
Full length AR	114	94	142	233
AR V7 variant	82	65	101	181
PSA	90	72	57	30
TMPRSS2	115	96	70	42

Effect on Proliferation

After a treatment period of 5 days in complete medium or CSS+1 nM DHT medium, the proliferative capacity of the cancer cells was measured with using CellTiter 96® Aqueous One or CellTiter-Glo® Solution Cell Proliferation kit (Promega), following the manufacturer's instructions. Results are presented in Tables 114-116 as percent inhibition of proliferation, relative to non-treated cells. Treatment of the cells with ISIS 560131, ISIS 569236, and MDV-3100 reduced proliferation of the cells in a dose dependent compared to the control. Treatment with ISIS oligonucleotides in CSS+DHT medium reduced the proliferative capacity to a greater extent than treatment with MVD-3100. The proliferative capacity of cells cultured in CSS medium without DHT is 12% of untreated control levels.

TABLE 114

Proliferation (% untreated control) in VCaP cells cultured in complete medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	98	66	53	48
ISIS 569236	98	76	68	59
ISIS 549148	98	98	113	106

TABLE 115

Proliferation (% untreated control) in VCaP cells cultured in CSS + DHT medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	95	65	42	37
ISIS 569236	83	68	61	45
ISIS 549148	114	123	104	92

TABLE 116

Proliferation (% untreated control) in VCaP cells treated with MDV-3100		
	Complete medium	CSS + DHT medium
0.04 μ M	49	117
0.2 μ M	44	119

141

TABLE 116-continued

Proliferation (% untreated control) in VCaP cells treated with MDV-3100		
	Complete medium	CSS + DHT medium
1.0 μ M	27	71
5.0 μ M	17	65

Effect on Apoptosis

After a treatment period of 72 hours in complete medium, apoptosis of the cancer cells was measured with Caspase-Glo 3/7 assay (Promega). Results are presented in Tables 117 and 118 as percent apoptosis of the cells, relative to non-treated cells. Treatment of the cells with ISIS 560131, ISIS 569236, and MDV-3100 increased apoptosis of the cells in a dose dependent compared to the control.

Apoptosis was also measured by protein western blot analysis of cleaved PARP levels, which were shown to be increased in a dose-dependent manner in cells treated with ISIS 560131, ISIS 569236, and MDV-3100.

TABLE 117

Apoptosis (% untreated control) in VCaP cells cultured in complete medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	189	253	356	262
ISIS 569236	176	293	402	581
ISIS 549148	131	108	103	146

TABLE 118

Apoptosis (% untreated control) in VCaP cells treated with MDV-3100	
	%
0.04 μ M	186
0.2 μ M	210
1.0 μ M	612
5.0 nM	528

Example 32

Antisense Inhibition of AR mRNA in 22RV1 Cells Cultured in Complete Media and CSS Media

The effect of antisense inhibition of AR in 22RV1 cells cultured in complete medium, as well as CSS medium with DHT, was investigated.

Gene Expression in Complete Medium

Cells were plated at 1,000 cells per well. ISIS 560131 or ISIS 569236 was added individually at 1.34 nM, 4 nM, 13.4 nM, or 40 nM using RNAiMax transfection reagent. ISIS 549148 was included as a negative control. After an incubation period of 48 hrs, RNA levels of full length AR, the V7 variant, PSA and TMPRSS2 were measured. The data is presented in Tables 119-122.

Protein analysis of full-length AR and the V7 variant also demonstrated a dose-dependent decrease of expression compared to levels of the house-keeping gene, GAPDH.

142

TABLE 119

Percent inhibition of full-length AR in 22RV1 cells cultured in complete medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	7	19	49	76
ISIS 569236	17	15	37	71
ISIS 549148	6	0	11	17

TABLE 120

Percent inhibition of AR V7 variant in 22RV1 cells cultured in complete medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	12	29	57	81
ISIS 569236	30	2	46	81
ISIS 549148	0	0	22	26

TABLE 121

Percent inhibition of PSA expression in 22RV1 cells cultured in complete medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	10	20	27	36
ISIS 569236	0	17	25	7
ISIS 549148	9	11	17	27

TABLE 122

Percent inhibition of TMPRSS2 expression in 22RV1 cells cultured in complete medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	7	3	19	32
ISIS 569236	0	13	21	36
ISIS 549148	15	9	14	4

A separate set of cells was treated with MDV-3100 at 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M. After an incubation period of 48 hrs, RNA levels of full length AR, the V7 variant, PSA and TMPRSS2 were measured. The data is presented in Tables 123 expressed as percent expression of gene levels compared to the untreated control.

TABLE 123

Percent of gene expression in 22RV1 cells treated with MDV-3100 and cultured in complete medium				
	0.04 μ M	0.2 μ M	1.0 μ M	5.0 μ M
Full length AR	103	93	81	83
AR V7 variant	106	98	87	77
PSA	83	70	71	86
TMPRSS2	101	80	82	93

Gene Expression in CSS+DHT Media

Cells were plated at 2,000 cells per well and cultured in CSS media for 16 hours. Cells were then transfected using RNAiMax reagent with ISIS 560131 or ISIS 569236 at 1.34 nM, 4 nM, or 13.4 nM to each cell set. ISIS 549148 was included as a negative control. After 4 hrs, 1 nM DHT was added. MDV3100 was added in a separate set of cells at doses of 0.04 μ M, 0.2 μ M, 1.0 μ M, or 5.0 μ M. After an

143

incubation period of 48 hrs, RNA levels of AR, AR V7 variant, PSA and TMPRSS2 were measured. The data is presented in Tables 124-128. In the absence of DHT, AR expression in VCaP cells was 555%, V7 variant expression was 656%, PSA expression was 11%, and TMPRSS2 expression was 22% compared to the untreated control.

Treatment with ISIS oligonucleotides resulted in significant inhibition of full length AR and the V7 variant, as well as downstream gene expression. Treatment with ISIS oligonucleotides resulted in inhibition of gene expression to a greater extent than treatment with MVD-3100.

TABLE 124

Percent inhibition of full-length AR in 22RV1 cells cultured in CSS + DHT medium			
	1.34 nM	4.0 nM	13.4 nM
ISIS 560131	65	85	93
ISIS 569236	59	89	97
ISIS 549148	2	13	22

TABLE 125

Percent inhibition of AR V7 variant in 22RV1 cells cultured in CSS + DHT medium			
	1.34 nM	4.0 nM	13.4 nM
ISIS 560131	63	83	93
ISIS 569236	54	88	97
ISIS 549148	19	19	32

TABLE 126

Percent inhibition of PSA expression in 22RV1 cells cultured in CSS + DHT medium			
	1.34 nM	4.0 nM	13.4 nM
ISIS 560131	3	50	66
ISIS 569236	28	49	70
ISIS 549148	8	23	29

TABLE 127

Percent inhibition of TMPRSS2 expression in 22RV1 cells cultured in CSS + DHT medium			
	1.34 nM	4.0 nM	13.4 nM
ISIS 560131	39	50	59
ISIS 569236	27	50	75
ISIS 549148	0	3	1

TABLE 128

Percent of gene expression in 22RV1 cells treated with MDV-3100 and cultured in CSS + DHT medium				
	0.04 μ M	0.2 μ M	1.0 μ M	5.0 μ M
Full length AR	5	11	6	18
AR V7 variant	16	17	19	12
PSA	15	19	18	16
TMPRSS2	17	9	26	18

144

Effect on Proliferation

After a treatment period of 5 days in complete medium, the proliferative capacity of the cancer cells was measured with using CellTiter 96® Aqueous One or CellTiter-Glo® Solution Cell Proliferation kit (Promega), following the manufacturer's instructions. Results are presented in Tables 129 and 130 as percent inhibition of proliferation, relative to non-treated cells. Treatment of the cells with ISIS 560131, ISIS 569236, and MDV-3100 reduced proliferation of the cells in a dose dependent compared to the control. Treatment with ISIS oligonucleotides in CSS+DHT medium reduced the proliferative capacity to a greater extent than treatment with MVD-3100. The proliferative capacity of cells cultured in CSS medium without DHT is 12% of untreated control levels.

TABLE 129

Proliferation (% untreated control) in 22RV1 cells cultured in complete medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	94	72	50	17
ISIS 569236	92	53	20	7
ISIS 549148	97	97	101	83

TABLE 130

Proliferation (% untreated control) in 22RV1 cells treated with MDV-3100			
		%	
0.04 μ M		87	
0.2 μ M		83	
1.0 μ M		81	
5.0 μ M		74	

Effect on Apoptosis

After a treatment period of 72 hours in complete medium or CSS+DHT medium, apoptosis of the cancer cells was measured with Caspase-glo 3/7 assay kit (Promega). Results are presented in Tables 131 and 132 as percent apoptosis of the cells, relative to non-treated cells. Treatment of the cells with ISIS 560131 and ISIS 569236 increased apoptosis of the cells in a dose dependent compared to the control.

TABLE 131

Apoptosis (% untreated control) in 22RV1 cells cultured in complete medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	99	127	131	566
ISIS 569236	91	141	333	1452
ISIS 549148	81	76	72	123

TABLE 132

Apoptosis (% untreated control) in 22RV1 cells cultured in CSS + DHT medium				
	1.34 nM	4.0 nM	13.4 nM	40 nM
ISIS 560131	121	113	172	518
ISIS 569236	127	106	257	1136
ISIS 549148	113	94	102	108

145

Example 33

Effect of ISIS Antisense Oligonucleotides Targeting
Human Androgen Receptor in Cynomolgus
Monkeys

Cynomolgus monkeys were treated with ISIS antisense oligonucleotides selected from studies described above. Antisense oligonucleotide efficacy and tolerability were evaluated. The human antisense oligonucleotides tested are cross-reactive with the rhesus genomic sequence (GEN-
BANK Accession No. NW_001218131.1 truncated from
nucleotides 134001 to 308000 and designated herein as SEQ
ID NO: 189). The target start site and target region of each
oligonucleotide to SEQ ID NO: 189, as well as the details of
their chemistry and sequence, is presented in Table 133.

TABLE 133

Antisense oligonucleotides complementary to SEQ ID NO: 189					
ISIS No	Target Start Site	Target Region	Sequence	Chemistry	SEQ ID NO
560131	59450	Intron	TTGATTTAATGGTTGC	Deoxy, MOE, and (S)-cEt	35
569213	59449 59479	Intron	TGATTTAATGGTTGCA TGATTTAATGGTTGCA	Deoxy, MOE, and (S)-cEt	39 39
569216	59449 59479	Intron	TGATTTAATGGTTGCA TGATTTAATGGTTGCA	Deoxy, MOE, and (S)-cEt	39 39
569221	59449 59479	Intron	TGATTTAATGGTTGCA TGATTTAATGGTTGCA	Deoxy, MOE, and (S)-cEt	39 39
569236	59449 59479	Intron	TGATTTAATGGTTGCA TGATTTAATGGTTGCA	Deoxy, MOE, and (S)-cEt	39 39
579671	59450	Intron	TTGATTTAATGGTTGC	Deoxy, MOE, and (S)-cEt	35
586124	59448	Intron	GATTTAATGGTTGCAA	3-10-3 (S)-cEt	43
583918	3754	Exon	AGTCGCGACTCTGGTA	3-10-3 (S)-cEt	124
584149	7260	Intron	GTCAATATCAAAGCAC	3-10-3 (S)-cEt	150
584163	9811	Intron	GAACATTATTAGGCTA	3-10-3 (S)-cEt	155
584269	41322	Intron	CCTTATGGATGCTGCT	3-10-3 (S)-cEt	169
584468	109552	Intron	CATTGTACTATGCCAG	3-10-3 (S)-cEt	175

Treatment

Prior to the study, the monkeys were kept in quarantine for a 30-day period, during which the animals were observed daily for general health. The monkeys were 2-4 years old and weighed between 2 and 4 kg. Thirteen groups of four randomly assigned male cynomolgus monkeys each were injected subcutaneously with ISIS oligonucleotide or PBS. PBS solution or ISIS oligonucleotides, at a dose of 40 mg/kg, were administered with a loading regimen consisting of four doses on the first week of the study (days 1, 3, 5, and 7), followed by a maintenance regimen consisting of once weekly administration starting on Day 14 (weeks 2 to 6). Subcutaneous injections were performed in clock-wise rotations at 4 sites on the back; one site per dose. The injection sites were delineated by tattoo, while sedated using ketamine, and were separated by a minimum of 3 cm.

During the study period, the monkeys were observed a minimum of once daily for signs of illness or distress. The

146

protocols described in the Example were approved by the Institutional Animal Care and Use Committee (IACUC).

Target Reduction

5 RNA Analysis

RNA was extracted from liver, heart, skeletal muscle, kidney, and prostate tissues for real-time PCR analysis of AR using primer probe set RTS3559. The results were normalized to RIBOGREEN®. Results are presented as percent inhibition of AR mRNA, relative to PBS control. As shown in Table 134, treatment with ISIS antisense oligonucleotides resulted in significant reduction of AR mRNA, relative to the PBS control. 'n/a' indicates that mRNA levels were not measured in that organ.

TABLE 134

Percent Inhibition of AR mRNA in the cynomolgus monkey relative to the PBS control					
ISIS No	Heart	Skeletal Muscle	Kidney	Liver	Prostate
560131	32	30	19	65	27
569221	52	35	31	60	n/a
569236	42	47	42	33	32
579671	24	31	53	33	n/a
583918	76	74	73	88	58
584149	33	63	77	93	45
584163	53	73	90	98	58
584269	72	76	92	96	41
584468	33	53	88	97	50

Protein Analysis

Serum testosterone protein levels were measured in the plasma with an ELISA kit (Enzo Life Sciences), following the manufacturer's instructions. The results are presented in

147

Table 135, expressed in ng/mL. The results indicate that some of the ISIS oligonucleotides reduced testosterone protein levels.

TABLE 135

Testosterone protein levels in the cynomolgus monkey	
	ng/mL
PBS	12.6
ISIS 560131	14.7
ISIS 569221	8.8
ISIS 569236	12.7
ISIS 579671	7.3
ISIS 584269	14.1
ISIS 584468	13.6

Tolerability Studies

Body and Organ Weight Measurements

To evaluate the effect of ISIS oligonucleotides on the overall health of the animals, body and organ weights were measured. Body weights were measured on day 42 and are presented in Table 136. Organ weights were measured at the time of euthanasia and the data is also presented in Table 136. Specifically, treatment with ISIS 560131 was well tolerated in terms of the body and organ weights of the monkeys.

TABLE 136

Final body and organ weights in cynomolgus monkeys						
Treatment	Body Wt (kg)	Spleen (g)	Heart (g)	Kidney (g)	Mesenteric lymph nodes (g)	Liver (g)
PBS	2.5	2.6	8.5	13	1.4	58
ISIS 560131	2.4	2.5	9.8	12	2.0	58
ISIS 569213	2.4	5.3	8.3	16	2.4	69
ISIS 569216	2.6	4.9	9.3	15	2.7	71
ISIS 569221	2.5	3.3	8.5	14	3.5	68
ISIS 569236	2.4	3.2	8.4	12	2.4	56
ISIS 579671	2.4	3.2	8.8	14	2.5	62
ISIS 586124	2.5	3.3	9.4	14	2.8	58
ISIS 583918	2.5	4.6	8.9	12	3.5	60
ISIS 584149	2.5	2.2	9.3	13	2.1	60
ISIS 584163	2.5	3.2	8.4	15	3.3	54
ISIS 584269	2.5	4.7	8.7	13	3.6	60
ISIS 584468	2.5	4.1	8.3	13	3.8	60

Liver Function

To evaluate the effect of ISIS oligonucleotides on hepatic function, the monkeys were fasted overnight. Approximately, 1.5 mL of blood samples were collected on day 44 from all the study groups. Blood was collected in tubes without anticoagulant for serum separation. The tubes were kept at room temperature for a minimum of 90 min and then centrifuged at 3,000 rpm for 10 min. Levels of various liver function markers were measured using a Toshiba 120FR NEO chemistry analyzer (Toshiba Co., Japan). The results are presented in Table 137. Specifically, treatment with ISIS 560131 was well tolerated in terms of the liver function markers.

148

TABLE 137

Liver function markers in cynomolgus monkey plasma			
Treatment	Albumin (g/dL)	AST (IU/L)	ALT (IU/L)
PBS	4.2	37	39
ISIS 560131	4.0	87	68
ISIS 569213	3.7	80	47
ISIS 569216	3.7	93	75
ISIS 569221	4.0	73	48
ISIS 569236	4.1	45	35
ISIS 579671	4.0	53	56
ISIS 586124	3.9	94	56
ISIS 583918	4.1	73	75
ISIS 584149	4.5	58	57
ISIS 584163	4.2	68	50
ISIS 584269	4.0	81	75
ISIS 584468	4.0	52	46

Hematology

To evaluate any effect of ISIS oligonucleotides in cynomolgus monkeys on hematologic parameters, blood samples of approximately 0.5 mL of blood was collected day 44 from each of the available study animals in tubes containing K₂-EDTA. Samples were analyzed for red blood cell (RBC) count, white blood cells (WBC) count, platelet count, hemoglobin content and hematocrit, using an ADVIA2120i hematology analyzer (SIEMENS, USA). The data is presented in Table 138.

The data indicate treatment with most of the oligonucleotides did not cause any changes in hematologic parameters outside the expected range for antisense oligonucleotides at this dose. Specifically, treatment with ISIS 560131 was well tolerated in terms of the hematology of the monkeys.

TABLE 138

Hematological parameters in cynomolgus monkeys					
Treatment	RBC ($\times 10^6$ μ L)	Platelets ($\times 10^3$ μ L)	WBC ($\times 10^3$ μ L)	Hemo- globin (g/dL)	HCT (%)
PBS	5.3	426	13.6	13.2	43
ISIS 560131	5.8	392	11.3	13.1	44
ISIS 569213	5.6	426	12.9	12.5	42
ISIS 569216	5.6	504	12.2	12.8	43
ISIS 569221	5.6	406	11.1	12.9	45
ISIS 569236	5.7	358	14.4	13.1	44
ISIS 579671	5.4	438	10.0	12.5	42
ISIS 586124	5.8	391	10.4	13.6	45
ISIS 583918	5.8	435	12.7	13.3	46
ISIS 584149	5.7	478	11.3	13.7	45
ISIS 584163	5.5	461	9.1	12.8	44
ISIS 584269	5.2	522	9.8	12.4	41
ISIS 584468	5.9	408	11.1	13.5	45

Kidney Function

To evaluate the effect of ISIS oligonucleotides on kidney function, the monkeys were fasted overnight. Approximately, 1.5 mL of blood samples were collected from all the study groups on day 44. Blood was collected in tubes without anticoagulant for serum separation. The tubes were kept at room temperature for a minimum of 90 min and then centrifuged at 3,000 rpm for 10 min. Levels of BUN and creatinine were measured using a Toshiba 120FR NEO chemistry analyzer (Toshiba Co., Japan). Results are presented in Table 139, expressed in mg/dL. The plasma chemistry data indicate that most of the ISIS oligonucleotides did not have any effect on the kidney function outside the expected range for antisense oligonucleotides. Specifici-

149

cally, treatment with ISIS 560131 was well tolerated in terms of the kidney function of the monkeys.

Kidney function was also assessed by urinalysis. Fresh urine from all animals was collected on day 44 using a clean cage pan on wet ice. Food was removed overnight the day before fresh urine collection was done but water was supplied. The total protein and creatinine levels were measured using a Toshiba 120FR NEO automated chemistry analyzer (Toshiba Co., Japan) and the protein to creatinine ratio was calculated. The results are presented in Table 140.

TABLE 139

Plasma BUN and creatinine levels (mg/dL) in cynomolgus monkeys		
Treatment	BUN	Creatinine
PBS	30.5	0.78
ISIS 560131	23.7	0.84
ISIS 569213	29.4	0.91
ISIS 569216	28.4	0.81
ISIS 569221	20.2	0.86
ISIS 569236	24.9	0.87
ISIS 579671	22.7	0.74
ISIS 586124	23.8	0.87
ISIS 583918	24.5	0.87
ISIS 584149	26.4	0.85
ISIS 584163	22.4	0.82
ISIS 584269	21.8	0.89
ISIS 584468	22.2	0.78

TABLE 140

Urine protein/creatinine ratio in cynomolgus monkeys	
Treatment	Ratio
PBS	0.00
ISIS 560131	0.02
ISIS 569213	0.02
ISIS 569216	0.08
ISIS 569221	0.00
ISIS 569236	0.02
ISIS 579671	0.00
ISIS 586124	0.01
ISIS 583918	0.01
ISIS 584149	0.01
ISIS 584163	0.01
ISIS 584269	0.00
ISIS 584468	0.00

C-Reactive Protein Level Analysis

To evaluate any inflammatory effect of ISIS oligonucleotides in cynomolgus monkeys, the monkeys were fasted overnight. Approximately, 1.5 mL of blood samples were collected from all the study groups on day 44. Blood was collected in tubes without anticoagulant for serum separation. The tubes were kept at room temperature for a minimum of 90 min and then centrifuged at 3,000 rpm for 10 min. C-reactive protein (CRP), which is synthesized in the liver and which serves as a marker of inflammation, was measured on day 43 using a Toshiba 120FR NEO chemistry analyzer (Toshiba Co., Japan). Complement C3 was also measured similarly, and the data is presented as a percentage of baseline values. The results are presented in Table 141 and indicate that treatment with most of the ISIS oligonucleotides did not cause any inflammation in monkeys.

150

TABLE 141

C-reactive protein and C3 levels in cynomolgus monkey plasma		
Treatment	CRP (mg/dL)	C3 (% of baseline)
PBS	2.5	118
ISIS 560131	1.7	100
ISIS 569213	2.8	60
ISIS 569216	3.6	94
ISIS 569221	4.9	91
ISIS 569236	2.6	103
ISIS 579671	4.5	101
ISIS 586124	4.0	93
ISIS 583918	3.5	89
ISIS 584149	1.7	110
ISIS 584163	1.0	102
ISIS 584269	4.9	102
ISIS 584468	1.3	111

Pharmacokinetics Studies

The concentrations of the full-length oligonucleotide in the kidney and the liver of select treatment groups were measured. The method used is a modification of previously published methods (Leeds et al., 1996; Geary et al., 1999) which consist of a phenol-chloroform (liquid-liquid) extraction followed by a solid phase extraction. An internal standard (ISIS 355868, a 27-mer 2'-O-methoxyethyl modified phosphorothioate oligonucleotide, GCGTTTGCTCTCTCTCTTGCGTTTTT, designated herein as SEQ ID NO: 190) was added prior to extraction. Tissue sample concentrations were calculated using calibration curves, with a lower limit of quantitation (LLOQ) of approximately 1.14 µg/g.

The results are presented in Table 142, expressed as µg/g tissue. The kidney to liver ratio was also calculated and is presented in Table 142.

TABLE 142

Oligonucleotide concentration of in cynomolgus monkeys			
Treatment	Liver	Kidney	K/L ratio
ISIS 560131	793	2029	2.6
ISIS 569221	966	1372	1.4
ISIS 569236	898	1282	1.4
ISIS 579671	871	2576	3.0
ISIS 584269	698	2823	4.0
ISIS 584468	474	2441	5.2

Example 34

Effect of Antisense Inhibition of Androgen Receptor (AR) on an Androgen Receptor-Dependent Breast Cancer Orthotopic Model

MDA-MB-453 cells express AR in the absence of estrogen receptors and progesterone receptor (Hall, R. E. et al., Eur. J. Cancer 1994. 30: 484-490). The effect of inhibition of AR mRNA expression with antisense oligonucleotides was examined in MDA-MB-453 tumor-bearing mice. Study 1

ISIS 569216 (TGATTTAATGGTTGCA; SEQ ID NO: 39), which is the antisense oligonucleotide tested in the assay, was designed as a deoxy, MOE and (S)cEt oligonucleotide, and is 16 nucleosides in length. The chemistry of

the oligonucleotide is 5'-Te Gk Ak Tk Td Td Ad Ad Td Gd Gd Td Tk Gk Ck A, where 'e' denotes a 2'-O-methoxyethyl ribose; 'k' denotes an (S)-cEt; 'd' denotes a 2'-deoxyribose. The internucleoside linkages throughout the oligonucleotide are phosphorothioate (P=S) linkages. All cytosine residues throughout the oligonucleotide are 5-methylcytosines. ISIS 569216 has two target start sites, 58720 and 58750, on the human AR genomic sequence (GENBANK Accession No. NT_011669.17 truncated from nucleosides 5079000 to 5270000, SEQ ID NO: 1).

Treatment

MDA-MB-453 breast carcinoma cells (5×10^6), mixed with 50% Matrigel, were injected into the mammary fat pad of 10 female NSG mice. Dihydrotestosterone (DHT) pellets, the active form of the major circulating androgen, testosterone, were implanted subcutaneously at the same time. Once the tumor reached a size of 100 mm³, the mice were randomly divided into two treatment groups. The first treatment group was injected with ISIS 569216 administered by subcutaneous injection at a dose of 50 mg/kg five times a week for 4 weeks. The second treatment group was injected with vehicle only, administered by subcutaneous injection five times a week for 4 weeks, and served as the control group. Tumor growth was monitored once a week and mice were sacrificed on day 32 after treatment. Tumor tissue and TB-interface samples were collected and processed for further analysis.

RNA Analysis

Tumors were excised and the tissue was processed for RNA extraction and qPCR analyses. AR mRNA expression was assessed at the TB-interface and normalized to actin mRNA expression. AR mRNA expression in mice treated with ISIS 569216 was inhibited by 48% compared to the control group.

Measurement of Tumor Volume

Tumor volumes were measured on a regular basis throughout the study period, using Vernier calipers. As shown in Table 143, tumor volumes were significantly decreased in mice treated with ISIS 569216 compared to the control group.

TABLE 143

Tumor volume on different days in the MDA-MB-453 cancer orthotopic model						
	Day 16	Day 23	Day 30	Day 37	Day 44	Day 51
ISIS 569216	134	142	173	125	92	73
Control	111	141	155	195	287	347

Study 2.

Treatment

MDA-MB-453 cells obtained from ATCC were maintained in Leibovitz's L-15 media with 10% FBS. Female NSG mice (Jackson Laboratories) were implanted in the mammary fat pad with 5×10^6 tumor cells in growth-factor-reduced matrigel (1:1). DHT pellets were also implanted at the same time in the mice between the shoulder blades.

After 20 days, the mice were then randomly divided into treatment groups. Groups of mice were injected with 50 mg/kg of ISIS 569236 or ISIS 560131 administered subcutaneously 5 days per week for 2 weeks. A group of mice were similarly treated with control oligonucleotide, ISIS 549148 (a 3-10-3 (S)-cEt gapmer with sequence GGCTAC-TACGCCGTCA, designated herein as SEQ ID NO: 193, with no known human sequence). Another control group of mice was similarly treated with PBS.

Measurement of Tumor Growth

Tumor volumes were measured on a regular basis throughout the study period, using Vernier calipers. As shown in Table 144, tumor volumes were decreased in mice treated with antisense oligonucleotides targeting AR compared to the control group.

TABLE 144

Tumor volumes in the MDA-MB-453 model							
	Day 0	Day 8	Day 13	Day 20	Day 23	Day 27	Day 29
PBS	136	336	331	358	338	417	481
ISIS 549148	148	303	312	365	413	490	550
ISIS 560131	144	261	243	204	232	233	258
ISIS 569236	134	283	260	230	264	329	323

RNA Analysis

RNA extraction was performed using an RNA extraction kit from Qiagen. AR RNA expression was measured using primer probe set LTS00943 and normalized to human actin mRNA expression.

Human AR RNA expression was assessed in tumor tissue. AR RNA expression in mice treated with ISIS 560131 was inhibited by 35% and AR expression in mice treated with ISIS 569236 was inhibited by 19% compared to the control group.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 215

<210> SEQ ID NO 1

<211> LENGTH: 191001

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

ctgacagaaa gcagatcatt ggttgacctga ggaggaggag tataggagag gtggagggaa 60

aatgtacaaa gtggcacaat aaaaactttt ggaatcatag atatattcac tatcttgatt 120

gagtgatgat ttcattgagt caccggtgtg tcaaaaatga tcaatttatg caactttaaa 180

-continued

tatgtgcagt	ttattgtata	tatcaattat	acctcagtac	ggctattaaa	aagaaaccct	240
ctggctgcac	aatgcagaac	tgattctagg	aaagagtggg	gggaggatga	ccatttacag	300
tgctccaggt	ggaagagaac	ggcgccttct	ggaagtgaac	taggttggca	acaacagaga	360
tgaaataaat	gggcagatgt	gtgagatact	taggaaataa	aacccgatgg	tcaccathtt	420
ccaaaggtea	gctcatcctg	gctttccaga	gcaaagagct	aggggaagact	ttattaataa	480
atccctcttg	aagttgcaga	ggaagcttat	agcagaaact	tactctcaac	ctgactaatc	540
tgagagaaca	cctctgggtc	catttgatta	ctaaaaaact	gcaaagaaca	ggaggagaaa	600
gaagaagaaa	gctggtacaa	acagtgaact	tatataatat	taatcaataa	ttgtctcttg	660
ttcttaaaag	caatgggaag	aaaatgagat	ttgagctgga	agatcagagt	tcaaaatcca	720
aataaagtat	atggccctaa	tatgcttata	gtagttaacc	tttctgata	atgatataat	780
tgttgacagc	accatcttta	aaaataaaaa	taacatagta	atccttcaga	ttttagaat	840
gctttcctgt	ttacaagttt	gttctatata	cattatgtct	tttaaatgac	acactagcct	900
tctgagggta	acttatattg	gcaacagttt	tcagatgtgg	aaactgtgaa	gacaatgttg	960
gtgatgtgga	agcaacataa	actttggagt	ctttcagacc	caggtttgaa	tgtcagactg	1020
ctttttatct	agagtaactt	cagagcatta	tttctcacct	taattttttt	tcaggcctct	1080
ttgtgtctat	gtgtcctctt	cactcctgtc	cattgttcat	tcagtgatth	ttgcaccttc	1140
cttcactgtt	agtgtgtaga	cacatagtct	tcctggctct	gagacctatg	ttaattccat	1200
tctaccatcc	tgccagccca	ctcaattcct	attgagcaat	gctagttgaa	agttgtgggtg	1260
ggattaaatg	ttgcaatgag	tattcaaatg	aggttgaaat	atctacgcat	tctacttaca	1320
tatggtgagg	tatattcaag	gaaggctgta	gccattaaaa	tctcaggaaa	taatttttca	1380
cctctcagg	tgaagggtc	ttcaggcctt	tgtgttctgg	aaggttcatt	tatagccatt	1440
tcccaaatga	caatgcgatt	gatgagtcta	gagtctagct	caaatagcaa	tggaactggaa	1500
gactagttta	ggttttacta	atgtggaaca	tagaacaact	tatgtccttg	tttcagcctg	1560
ttcatctgtg	aaatagagcc	tatcatatcc	agtcttcctt	gccttttaggt	ttgagttacc	1620
ttctttggtc	aaggtaaagta	aatgcctatg	atgtttggct	gtgcacaaga	taaagctaca	1680
acaaagctac	aacctatctt	ttctctgtag	aagactgcaa	aaagcaaaag	agaccagggc	1740
aaaaatctcg	gaatgacttt	tggaacagag	agcctcccca	gaatcagaag	tcaaaaggaat	1800
ttaaaacata	gggaggccca	gggtctctac	tgacataaag	gaaagatggt	ttccttatag	1860
gtttacgttt	acattttctc	tctctttcca	ttcccacttg	catctccacc	tttacacagg	1920
gcttatggga	cctcctccac	aaaagagcag	ttgcagtaac	ccacatcacc	ctctacgcct	1980
ggctgtccat	caagaggcga	aaagcagccc	tatataggtt	ctatccttgg	atagttccag	2040
ttgtaaagtt	taaaatatgc	gaaggcaact	tggaagaaag	agcggctgca	tacaaagcaa	2100
acgtttacag	agctctggac	aaaattgagc	gcctatgtgt	acatggcaag	tgtttttagt	2160
gtttgtgtgt	ttacctgctt	gtctgggtga	ttttgccttt	gagagtctgg	atgagaaatg	2220
catggttaaa	ggcaattcca	gacaggaaga	aaggcagaga	agagggtaga	aatgacctct	2280
gattcttggg	gctgagggtt	cctagagcaa	atggcacaat	gccacgaggc	ccgatctatc	2340
cctatgacgg	aatctaaggt	ttcagcaagt	atctgctggc	ttggtcatgg	cttgctctct	2400
agtttttagg	agactctccc	actctcccat	ctgcgcgctc	ttatcagtc	tgaaagaaac	2460
ccctggcagc	caggagcagg	tattcctatc	gtccttttcc	tcctcctctc	gcctccaccc	2520

-continued

tggttggttt	ttagattggg	ctttggaacc	aaatttggtg	agtgetggcc	tccaggaaat	2580
ctggagccct	ggcgccctaaa	ccttggttta	ggaaagcagg	agctattcag	gaagcagggg	2640
tcctccaggg	ctagagctag	cctctcctgc	cctcgcccac	gctgcgccag	cacttgtttc	2700
tccaaagcca	ctaggcaggc	gttagcgcgc	ggtgagggga	ggggagaaaa	ggaaagggga	2760
ggggagggaa	aaggaggtgg	gaaggcaagg	aggccggccc	ggtggggcg	ggaccgact	2820
cgcaactgt	tgcatttgc	ctccacctcc	cagcgcccc	tccgagatcc	cggggagcca	2880
gcttgctggg	agagcgggac	ggtccggagc	aagcccagag	gcagaggagg	cgacagaggg	2940
aaaaagggcc	gagctagccg	ctccagtgc	gtacaggagc	cgaagggacg	caccacgcca	3000
gccccagccc	ggctccagcg	acagccaacg	cctcttgacg	cgcgggcggt	tcgaagccgc	3060
cgcccgagc	tgccctttcc	tcttcggtga	agtttttaaa	agctgctaaa	gactcggagg	3120
aagcaaggaa	agtgcctgg	aggactgacg	gctgcctttg	tcctcctcct	ctccaccccg	3180
cctcccccca	ccctgccttc	ccccctccc	cgtcttctc	tccgcagct	gcctcagtcg	3240
gctactctca	gccaaccccc	ctcaccaccc	ttctccccac	ccgccccccc	gcccccgctg	3300
gcccagcgct	gccagcccca	gtttgcagag	aggtaactcc	ctttggctgc	gagcgggcga	3360
gctagctgca	cattgcaaag	aaggetctta	ggagccaggc	gactggggag	cggtctcagc	3420
actgcagcca	cgacccgct	ggttaggctg	cacgcggaga	gaacctctg	ttttcccca	3480
ctctctctcc	acctcctcct	gccttcccca	ccccgagtcg	ggagccagag	atcaaaagat	3540
gaaaaggcag	tcaggctctc	agtagccaaa	aaacaaaaca	aacaaaaaca	aaaaagccga	3600
aataaaagaa	aaagataata	actcagttct	tatttgcacc	tacttcagtg	gacactgaat	3660
tggaagggtg	gaggattttg	ttttttctct	ttaagatctg	ggcatctttt	gaatctaccc	3720
ttcaagtatt	aagagacaga	ctgtgagcct	agcagggcag	atcttgccca	ccgtgtgtct	3780
tcttctgcac	gagactttga	ggctgtcaga	gcgctttttg	cgtgggtgct	cccgcaagtt	3840
tccttctctg	gagcttcccg	cagggtggga	gctagctgca	gcgactaccg	catcatcaca	3900
gcctgttgaa	ctcttctgag	caagagaagg	ggaggcgggg	taagggaagt	aggtggaaga	3960
ttcagccaag	ctcaaggatg	gaagtgcagt	tagggctggg	aagggtctac	cctcggccgc	4020
cgtccaagac	ctaccgagga	gctttccaga	atctgttcca	gagcgtgcgc	gaagtgatcc	4080
agaacccggg	ccccaggcac	ccagaggccg	cgagcgagc	acctcccgcc	gccagtttgc	4140
tgctgctgca	gcagcagcag	cagcagcagc	agcagcagca	gcagcagcag	cagcagcagc	4200
agcagcagca	gcagcaagag	actagcccca	ggcagcagca	gcagcagcag	ggtgaggatg	4260
gttctcccca	agcccatcgt	agaggcccca	caggctacct	ggtcctggat	gagggaacagc	4320
aaccttcaca	gccgcagtcg	gccctggagt	gccaccccca	gagagggtgc	gtcccagagc	4380
ctggagccgc	cgtggccgcc	agcaaggggc	tgccgcagca	gctgccagca	cctccggacg	4440
aggatgactc	agctgcccc	tccacgttgt	ccctgctggg	ccccactttc	cccggcttaa	4500
gcagctgctc	cgtgacctt	aaagacatcc	tgagcgaggc	cagcaccatg	caactccttc	4560
agcaacagca	gcaggaagca	gtatccgaag	gcagcagcag	cgggagagcg	agggaggcct	4620
cgggggctcc	cacttctctc	aaggacaatt	acttaggggg	cacttcgacc	atttctgaca	4680
acgccaagga	gttgtgtaag	gcagtgtcgg	tgtccatggg	cctgggtgtg	gaggcggttg	4740
agcatctgag	tccaggggaa	cagcttcggg	gggattgcat	gtacgcccc	cttttgggag	4800
ttccaccgcg	tgtgcgtccc	actccttggt	ccccattggc	cgaatgcaaa	ggttctctgc	4860
tagacgacag	cgcaggcaag	agcactgaag	atactgctga	gtattccctc	ttcaagggag	4920

-continued

gttacaccaa	agggctagaa	ggcgagagcc	taggctgctc	tggcagcgct	gcagcagga	4980
gctccgggac	acttgaactg	ccgtctaccc	tgtctctcta	caagtccgga	gcactggacg	5040
aggcagctgc	gtaccagagt	cgcgactact	acaactttcc	actggctctg	gccggaccgc	5100
cgccccctcc	gccgcctccc	catceccacg	ctcgcaccaa	gctggagaac	ccgctggact	5160
acggcagcgc	ctgggcggct	gcggcggcgc	agtgcgccta	tggggacctg	gcgagcctgc	5220
atggcgcggg	tgcagcggga	cccggttctg	ggtcacccctc	agccgcgcgt	tcctcatcct	5280
ggcacactct	cttcacagcc	gaagaaggcc	agttgtatgg	accgtgtggg	ggtggtgggg	5340
gtggtggcgg	cggcgggcggc	ggcgggcggcg	gcggcgggcgg	cggcgggcggc	ggcgggcgagg	5400
cgggagctgt	agccccctac	ggctacactc	ggccccctca	ggggctggcg	ggccaggaaa	5460
gcgacttcac	cgcacctgat	gtgtggtacc	ctggcggcat	ggtgagcaga	gtgccctatc	5520
ccagtcaccac	ttgtgtcaaa	agcgaaatgg	gcccttgat	ggatagctac	tccggacctt	5580
acggggacat	gcggtaaagt	tttccttcca	gaaatgtcgc	ctttcgcccc	agggcagagt	5640
cactctgtgt	tctggggtat	ctagcggctc	ctacctgcgc	gaacactcag	attgccccctg	5700
ggagagctca	gcagggtaaa	cctagagctc	tcccgtggac	tcccggcctg	ccagaggttt	5760
aacctgagct	ctcctaattt	ctgctgcgtg	ccttgggtgc	tgattcctgc	cctcccagat	5820
tcttcaactc	cccccaaccgc	cccaaattct	cactacctcc	tggtactcga	ggtcccaaac	5880
agaaatccta	ttgcacgggc	caccttcaga	gataaagctc	ccaagccctc	cactcttcct	5940
ttcctcctgt	cctcaaagtc	tgagaacctc	aacaggaatt	tgggcaattt	ctcctcttca	6000
ggtctgttag	gatttcactt	tcagcctgcg	cagattagag	tcaaaaagac	cggcccaata	6060
gcttctcagc	gggtatcctc	cagagaggta	aagtgaatt	ctcggttagg	gaaagaaagt	6120
ggtctctggg	tgctgaggtc	tgctgtgtga	aagggtgaac	ttctttctcc	tgaagcaact	6180
ggggacttgc	tccagggctg	gaggtcagta	gagataatcc	aaaccgtcat	gttttagagta	6240
ggcagagggg	caactttctt	ggtaaagact	tcacaggatt	tgcactcaca	gtttctcaac	6300
gttggttgac	tatgttgaaa	gtagtgtctt	gggtcggttt	tctcttgtaa	agtgtttatt	6360
ttctctgtgg	attataacag	atccacagcc	ccctacttca	ggtttgcatc	agatctataa	6420
agaggagaa	attcttttaa	tgtacaattt	aattaggctt	gactctgact	tacaaaactg	6480
ttggaaaaca	tttttttgta	aagcatttcc	tgctatttca	gtgtgctcca	aaatctccac	6540
tggggagggt	ggagttaggt	tttttattat	attcctttat	ttttaggaca	tgtttgcaat	6600
ttagaataatg	tgcagttagc	tctaacaat	tgagtaagaa	ctcttaatga	cctatgagcc	6660
gtaatcttac	cccaaagt	taattagcat	atgagaaaag	tggcaggcaa	ttgcacgtg	6720
cttattaaaa	attattctc	acgcagttg	ttgagcttct	tggagaccat	gctgaagatt	6780
ttctcccca	gcaaattaag	atattagttt	atctgctgag	ggaggacaga	ctgaattggg	6840
gaattaactc	ctcaggtagg	ccaggtgctg	atgtccctgt	ggacttttgt	cttattcttt	6900
gtttctatgg	ctgttttctt	ttacctgtga	cttctccgaa	atttctttgt	tagccttaac	6960
atctttgttt	ggggacttaa	atccagcaat	ttgccttctt	tactgatgc	tttcttctt	7020
acaaggtaga	tagcacagt	ttagtaaaga	aagaaagagg	agggtaggat	ttcatattat	7080
ttcgtgggct	gttgaagaaa	cagcttctta	ccaggttcta	cattccatta	ggtttttaat	7140
gtttgactta	caagattttc	agagggttca	tttgatattg	tcaaagtctt	ttccagttaa	7200
tttagactct	tcatttttgt	aatgggttta	tgctatggga	caaaaaagt	attcttcatt	7260

-continued

ttataagaac aaatttactt ggtagggtta attttttttc tagggctgtc actagacggt	7320
ggagccctc ttctactgta aacttttctt gggggaaaat gtctaagggt cattttgacc	7380
tgccatgata ctaaaccag acactggaac ctccatctt ctgcatgct cccccacaac	7440
ttacttactt aacagggaaa aaactgatgg ttccacatat ttgctaaaa atgtgtgcct	7500
tcaaagacaa aacaaaaatt tttagggaat aactatagag agcaaaagtt actcccatca	7560
agtagacaac gagcttggtg attttatttc aggtcttaat gaaaaaagct tctttatgag	7620
gaaggttatc atatcttggg gctccttga cagtcgctt aaattaatga cataaactaa	7680
tgagaattta gcagttctcg cagaaagtac aagtttattt ttttttctg gtttgtgatt	7740
gctgcactga atagaggag tctagttaa gggacaactg gtgttctgt cttgtgagtt	7800
gacgaagact ttccatttct aggatataga aaatccttaa gccggtttat tgaaaattaa	7860
tcaatttaat cagaatgcaa tcaattocaa taaaaagtt agtattttct tcttttttat	7920
tgaaaattaa tttaatcaga atacaatcaa ttccaatcca aaagttgata tttcttact	7980
ttctcttttt ttccctcatt ttgtaggat acaatttggg gaaaggcaag agatttctta	8040
agccaaagca agagtgtctt cctctctgt gttgcatgca ttatgtgcca tgtttgagct	8100
aaaaatctca aaattgggca ggttccaat gacctgttg gtccctcctt ttaccattca	8160
tgtgtgtgtt tatgtacata attttgtgga ggggttttt taaaccttag taacatctgc	8220
actcactctg tgttcttata catttacagt gtttctgctg agaggaggga agatgcaaa	8280
gtggtctctt ttacttaatt tagcatgtgg tttgaacaga aggaaaaata aaaagtgtg	8340
gggcttgtgt gcaacctga tgatatttta tggagctgtc tgtcttctct ctgagatcaa	8400
acaggactac aactttgtta attgaccact ggctcccttg gcaaaagtag ggcttcttat	8460
attccagcaa gcagcacaat aatatgacaa aaattttatc ttgggagttg ggttctaaga	8520
gagtgcagtc cagaattaga gtttggggt tagagaaatt atccagatgc caaaagaaca	8580
ttttaatttt tctcttggtt atttgttctg gtctccatag taggtagtat tttagtagtg	8640
ctttgatatt gacaagtctt gctcccttc tctattagat ttttcaaat aaggcatttt	8700
attaattcct ctttcttct cctctctcct ctcagttctc aagcattttt atgactatct	8760
tacaagcaac agtttgtctt gtaagcaga attttcttt gaaaccaaga cagattattt	8820
ctgcccatag gcttcaggaa ccaatatattt ggcaagaagc atcttttctt tgtggtcagc	8880
aaataggtgg tgagtctgt ctggatocca acaatcaaca cctgaggacc aaatagccac	8940
actgggtggc acccattctg gaagtataca caggaagtag ccctcttctg tgttcacagc	9000
tcaagtcagc caaagattaa cactggtgag agatattttc aaagaagttt gcaggcttcc	9060
aattgcaggg tcattttggg gtgctttctt gcctgtacta attttatctc atcaagcttc	9120
cattctttga gctgtaaact ttgaaataat atactggatt tgctggtagc ttttaattttc	9180
tttgtttaagt gttttcattc ccatagtaat ttttcatcta gtgtacatat atgcatttaa	9240
aacaaaaatt ctttggcttc cttatgcgta tatgcactgc ggcttgtaca cgtacaagct	9300
acttggtggg attatgtgaa ctggagttag aaatgtggac aattttatta tgattatttt	9360
taatggtgat atcaagatca ccagtttcat tcggaacctt gcataagcag ggagcagaat	9420
gcggtactgg tgtggcaag caagggttta ttttatagcc aaacctgaaa tcacaactct	9480
gaaaaataaa aaaaaaaaa accaaacaaa aaaatcaagt tttgtgagct tggtcagaga	9540
aggaaaagga aatctctccc tccccccac ctccaccatt ttctctttgt ctgcagcttc	9600
ctcaagtgc gctgtcccc gattttcttt tattccactc ctttcatgtt tttgacattg	9660

-continued

aaatacagac	tcttctttcc	acttctcagg	gtatttttct	tattacacct	gtggcatgct	9720
cctaagaat	ttctttttta	aaaaaatct	gtagagtagt	agattagatt	aacccagta	9780
tctctccctt	aagactagat	gacatgagg	gattgcaaaa	tgaatagctg	ggtttttttt	9840
tttttttttt	tttttacctt	gaggttaaag	cctggttcaa	cagttgctga	gagagttaac	9900
tagattgctt	gaggacttgg	caatttcata	aagtattttg	tcttatgctg	tctctgtctc	9960
tgtcttgatc	tctgtctctc	tctgtctact	gtaatgttgg	ctactttctc	tcagagcctg	10020
agagacagct	ctgagacact	tcccaggctc	gttcggttca	gacctcagta	gctggatcac	10080
aagcagtacc	caatatgcac	atgagggtgc	gtgctgcaag	tgtccggctg	ggctaactctg	10140
cttaagcttc	ataaaaaatta	atcatttgaa	aacaagaaa	gatattaaag	aaattattct	10200
atctccgact	tcccctatca	gcattccatc	aagttctggg	atgttaaatt	cagagaaagt	10260
taaccttatc	ttaaacacaa	agttgacttt	taacaaaaat	tgcttataaa	gttctgtaca	10320
gttaccagca	ttgggtgccc	tttgtcgtac	ggaagagaat	tatgaaatct	catatttaca	10380
tagcattctt	ccaaaaaaag	agacgggtgt	ttccagttaa	ttcactgcac	tcgtgtaagt	10440
gtgagtaggc	caggaggggt	gcttagtgat	tacccttttg	ctaggtaaca	aagtagaaag	10500
ttagattttc	tatgatattt	gtttaccacg	taggggaacc	tctctagagc	aatactccca	10560
agctttttct	tcttgaaatt	tcccacctga	cagataatac	tttagattgt	tgctcttaag	10620
gacttctctc	agtagctgct	acatagagat	gattgtccgt	gaattattgc	ttgcacactc	10680
atgggtgatg	ctactccctc	tctctcatgg	caattcttgc	tgccaacctg	caggccacac	10740
caggattgag	ggcagctcat	ctcgataaat	ttatagcatt	aaagtgctgg	gtcatttgag	10800
aatgttgtea	atttaggtta	cttagtacct	aagttttatt	ctttaataaa	cagctttatt	10860
gagacgtaat	ttacaatcca	tacaattcac	tcactctaaag	tgtacagttt	catgcttttt	10920
agaatattca	gagttgtgca	accattattg	caatcaattt	tagaacattt	taatcaccce	10980
caaaggaaac	cctatgcacc	tttgtgttca	tccccctata	ttccctcagt	ccttagcaac	11040
caataatcta	cttctatcta	tggtgtgtct	tattctaaca	ttttgtatga	atgaaatcat	11100
gtaatatgtg	gtcttttgtg	actagcttct	ttcacataaa	atatgttttc	aagggtcatcc	11160
atgttgaaag	acatatcagt	acttcactat	tttttatagc	ctaataatgt	tccactatat	11220
ggatatacca	cattctatct	atccatttat	cagggtgatga	gcattacggg	tgtttccacc	11280
ttttggctat	tatgaataat	actgctgtga	acattcacgt	gcaagtttat	tgtggacata	11340
ttcagtcac	atattttgga	cattttcagt	tcttttggat	acatacatag	gattgaaatc	11400
tctgagtcac	atgataccct	tgtgtttatc	cttttgaaag	actgtcaaac	tgttttctaa	11460
agtgtctgca	ctgtttttaca	atcccatcag	caacctatgg	gggtccattt	cttccacatc	11520
cttgccaaca	cttgttattc	tctgtctttt	tcattatagc	tatattagtg	ggtgtgaagt	11580
ggtacctcat	tgtggctttt	atttccattt	ccctaataac	aaataatgtt	cagtatccat	11640
gttcttattg	gccatttgta	tatctctttt	tttgagaaat	atctatttgg	atcctttgct	11700
cagtttttag	ttgggttttt	tattattgag	ttttaagatt	tttaaaaaat	atattctgga	11760
tacatgtcct	ttaatagatt	gtgatttgta	gatatttttt	cacattctgt	gagttgtctt	11820
ttttactttc	cttttttttc	tttttaagtt	cttaaatggta	tctagattga	agcacaaaaa	11880
tgtttttaag	tttgatgaag	tccaattcat	ctatttattt	tctgttttgg	cttatgattt	11940
tggcgtcgta	tctaagaagt	ctttgcctaa	tccaagatca	caaagattta	catatgtttc	12000

-continued

cttctaagag	ttttatagtt	ttcgctattt	acatttaggt	ctttcatcag	tttgatgta	12060
atgtttatat	atgactgagg	taggggtcca	acttcattct	tttgcattga	gatattcagt	12120
tctcacaata	ttgttggtga	atctttctct	acttaactgt	cttggcaccc	tttggtgtaa	12180
atcagttgac	cgtaaatgtg	agggtttaat	tgtggactct	caactatatt	cagttgatct	12240
atatgtttat	tcctatgccc	gtaccacgtt	atcttgatta	ttgtaggttt	ttagtgagtt	12300
ttgaaattag	gaattttgaa	ctcttcaact	ttggtcttct	ttttcaagat	tgccttggtc	12360
cttggtgggc	ccttgaattt	tcaaatgaat	tgggataagc	ttgtcaattt	ctacgaagaa	12420
gtcagctagg	attctcagag	gaactatatt	aaatctgtaa	accaatttgg	ggagcattgt	12480
catctcaaca	acgttaagtt	atcttcatcc	ataaatatgc	gatgtcttcc	catttattta	12540
ggctctcctt	ttgtcaacaa	ttttatttgt	tttcagatta	taagttttgc	agttcttttt	12600
aaaattttatt	cctaagtgat	ttattttttg	atactataaa	ttgaactgtc	ttattgattt	12660
tattttcaga	ttattcgtcg	ccaatgtatg	gaaatataat	tgttttgtat	attgatcttg	12720
tatcctgcaa	ccttgctgaa	aatacctgag	ttttgaatgc	ttctgggact	tatggggaag	12780
agggcttctg	ctgctgcact	gaaagttaaa	gcttacttca	tttcatcctg	tatgaaggct	12840
gcatggggac	attcttctca	gttttactca	gctataaatt	cgaactggta	atcccatccc	12900
ctttcgggat	gaataggaga	gtgtttttta	atgttcatct	ctttagagaa	cagcaggaaa	12960
gaagcctagt	aaggtttggg	tagttttata	tccctttttt	agaatttggg	tttgggaact	13020
attagcaagg	cagttagtaa	taataataat	ttctatatag	aaaactaaca	tgtagaggtg	13080
acaaatgaaa	tcactagcta	tattaggctt	atgtttaggt	tatcgttaag	agctaaaatc	13140
ataattttat	gtttttatat	gttgctcctt	ggacaaagta	aattccagta	ctccttctga	13200
tgtgcatttc	tagatgggga	aaggattcat	ttactctcat	ataatttaag	cttcttttta	13260
gggatgtact	ccatagccat	gaagcaaaga	taaaattcat	ctatacacag	actgaacttt	13320
gtcttcatta	acactctagg	ctaagggtca	tagctaatac	gctacaactg	taatgtcctg	13380
ataattgtga	attaactgca	gggcacccag	caaaagggtt	agttataatc	taatagctgt	13440
ctgtagagat	tagcctaata	aagggaattt	ttaaaaaaga	atctggccgg	gcatggtggc	13500
tcaatcctgt	aatcccagca	ctttggggag	ccgagggtgg	tggatcacct	gagatcggga	13560
gtccaagacc	agcctggcca	acatggtgaa	accccatgtc	tactaaaaat	acaaaaatta	13620
tccaggcggt	ttggtgagca	cccacaatcc	cagctacttg	tgaggctgag	gcaggaggat	13680
cacttaagcc	taaggaggag	agggtgcagt	gagccgagat	catgccactg	cactccaggc	13740
tccgtcaaaa	aaaaaaaaaa	aaaagaatct	atcaatcaac	cacttttcat	taagcacctg	13800
ctatgtgccc	agcatgtgct	aggaagagat	aagggtgaaag	gggacacaat	tcagacagaa	13860
tcttcttgag	gtaactgctt	acgaggagct	tatagccact	aaaaacaaaa	acaaacaaaa	13920
accaaacaac	caaaaaccaa	acagaaatgc	agtatcatca	tgccatgatg	cctgtatgag	13980
atcctggatt	gtacggtatg	gatttcttaa	aatgtagata	ttttaaaaaa	aaagaggaat	14040
gaatcaatag	aggctgaagt	ggtcagcaat	gttacctgtg	gctgctttta	atccttcgtg	14100
gaagtaagta	ggagcatgtc	taaactcaag	caatagatta	aagatcttga	tgtatatattt	14160
aaataacaga	agtttagtacc	actggaagaa	atgaactgga	ggaatgggtt	gaaatctatt	14220
tctgcttatt	caatagtcca	ccccagtcac	gttagttgcc	aatttcttct	tcagtttctt	14280
tggtatatcc	attgcacttg	gtgggtacat	gtttatgatg	tctttatctg	aacaagtccg	14340
caataatatg	agtaataaat	taaaattgaa	ggtgattaat	ggctctgaat	ttgacataag	14400

-continued

```

agttgttttc ctgccttcta agtttccatt gatcctgatg aattgcacaa accaaacaat 14460
tcggggagta agggggcaca tgatgatctt ataagagctt tgctgtatta gacaacgtaa 14520
cattctgaaa tggcctacca cctaacatgg gctctgttct ctgcaggttg agtaggttcc 14580
ttgcttgtagg aactgtagtc ccgctatttg gccgctaggg ggactgcaag tgccccgtgg 14640
caggatttcc ctgggaatgg tgagcctcca ttgatggttt caacacacag ccaaggccct 14700
atcgaggat aacttgaacc agaactgcct agcaccagac aataaataag ctactatggt 14760
acttactgtt tcatttgga tgtgttttct cgaagtggca agcatttttt agtaatat 14820
tgacttttta atacctttct ttgcatatgg agcagaaaac agtgacactg gatataattca 14880
agtagcactg tccagtttat agagaagttt catattccat tattgcattt cattcttgtt 14940
tctacctttt acaagtaact agagtttga gtattataat agtattcata ctattacagt 15000
actattattc ccattataaa aattgtgcaa agagtggta agttacatgt ttacaatcaa 15060
acagcttcaa agtgactgat ctggaatttc agtccattc tttcttctcc agatcatgtg 15120
ttccctgctt ttacttcaca gctcttttta cttatagat gggaaacatg agagtcagag 15180
aggcaaaaga accacaagtg gtatcaatac tagaaattta tgaatttctt aaggcttcta 15240
ggtttggtac ccattcccca gactgatgga ttggttggtg tgagagttct gggtgccaat 15300
aaccttgcca ttctacttta cagactgcat atattcaata aatgcttatt aagcatctac 15360
tatatgcaa attctgtact aggcaccaat gatgtagtgg tgaacagaac agacaaaaat 15420
ctcttcgtgg agcagacagt ttaatgagag gagacatgta gtgtacatct gagcatgaaa 15480
agtgccatgc agaataaact cacagagtgt agggatataga gattgatggg gagaggggat 15540
atthttatatt tgctggccag ggaaaacctt actggaaaag taaattttga gtagtgacct 15600
gaaggaaatt aggaatgag ctgctatttg gacatctgga gttagaatat tccaggccca 15660
gggaaccaca ggcgcaaagg gcctgaggca ggagcacact tgctgtgatg gaggacaaag 15720
aggcccatat ggctggttta aataagtga ggatggtaga caatgagatc agagttaatg 15780
agggtgcatg gtaggtcttc cttaggactt tgaattttac tcctaagcag gttgtattgg 15840
acggttttga gcagggtaac atgacctgac ttacatttta acaggctccc tctcttcat 15900
aacatctgtc actctgatat attatacgtt tgtttgttta cttactgtat gtggggggaa 15960
gagactgtgg gagcaagggg ggaagcaggg aaacaagtac actgcagtga tctgggtgag 16020
agggtgacct gtctcagact aagggtggtat tgggtggagaa ggtaggaagt ggctgaattc 16080
tggatgagtt ttgatggat agccaacagc atttactgac agattggata ttcactgtga 16140
aaaaaataga gatgaggatg attgccagt ttttggtctg agtaactgga aaaatgagat 16200
tgccatttac tgaatagggtg aagactgtat gtagagcagg tgcatgggca gggtagaaat 16260
caagagtttg atttttgact tataaagttt gaattatctg atgaacatcc tgatggcttc 16320
ttctcagtta gttctcatgc agtgccttca gctttgctgt tctcaagaa aattaaaaag 16380
gaacttagag atgcctagg ctgtaggtag cctctccctt ctttctttt actttataga 16440
ggctataga agggtaggga cttatccaag gtgaaacagt gagctggcga cagaactagg 16500
gcacaaaccc agttctcttg aattctgaat cagtagattt tcttttttta gtgtgattct 16560
gaggactcat ttgggcaaga gtgagttttt tgttattgtt ttttgttgtt ttctttgcc 16620
aaacctaaaa ccaggtaatt aaactaaata gtgaataaaa ctgggaaact atacaaattg 16680
gttgctctcc ccaatcacac tgaatatatta ttatttttac tgaaccacat accaaaatat 16740

```

-continued

ttttcctgta	aaaacacagt	aagtgaactt	ttaaaggcaa	ttgagctttt	aacaaagcta	16800
gaatctacag	aggacctgga	cagaaatggc	cttaaatcct	aggaaattag	agttcatgga	16860
acctgggaga	ccatcttgtc	cagctagctc	attttatggg	tgaggtgcct	gaggcaccaa	16920
gatggaaagg	gacctggcta	agctcataca	gcaagctagt	gcctgagcct	agtcagagcc	16980
tgttttaagg	gttagtcgta	tgttgttttc	ttgaaaaaag	ttacattgga	aaagtgaaaa	17040
ttctttggtc	catactgaga	acaagaatt	atacataatc	atatataata	ataatgatag	17100
cacttcctga	atgtttgctg	tgtaaacttt	ggcaccttgc	atgaattgat	tcatttaatt	17160
ctcatgtcaa	ctttaggaag	caggcctaga	gagggttaagg	aacatgtcca	agggtcacac	17220
agctaggaag	tagcagaact	tgtgtgcact	cccaggaagt	ctggcttcta	accacaaggt	17280
tctaactact	gtgcaatacc	aggagcttct	cagattaccc	ttcaccttta	ccaacccaaa	17340
tgactggtga	cgtagggtgac	ttcattatgc	tctgccccta	ttatagtcca	ctgatcctca	17400
ccaaataggt	gggtggccta	gagggttaaag	tagaggcaga	gtgatggaaa	gggggtggta	17460
gaagaagttg	atgactcatg	atagggattg	gaaaacagga	ctacaggaat	tattgaaaag	17520
ggcctagaga	tcccaaggag	gttgatctcc	gactgctaca	aacctgggca	attcaatgcc	17580
tgcttaaata	ggagagttaa	gataagaaaa	ataaaattgc	caatttttac	agtcagacat	17640
tgttttat	attttacatg	tattaattca	tttaatcctc	aaaatactcc	atgaggtagc	17700
tacaattatc	atttctatgt	tgtagatgaa	gaaacaggca	cagagcaatt	aaataacatg	17760
cacaagatta	gagaacaagt	aagtgggaagt	gccaatatta	gaatctaggt	agttcagctc	17820
cacaacttat	gttattttcc	actatattta	tggaaatgagg	taattttctt	ataacagaaa	17880
gtttttaaaa	tgcaaaaaaca	ttgtgcctga	acttcaaaca	ctgaacaact	catatcctta	17940
atatgcacca	gtttctttta	agcactctta	gaaggaagga	tacttaacct	aatgtcacat	18000
ggtagagtaag	tagcagaacc	ggaacttgaa	tttgagactc	cggactgcca	gacctctttc	18060
cactctatca	cttgggctcc	cttctaacat	tgacttgtct	ccctccatcc	ctcctccgta	18120
ttgttctgcc	cttcaccttt	taattacctg	tctccatcaa	caagattgga	cagagaattg	18180
ggagagttag	cagagtccat	ttccttcacg	agactggaca	aaaggaacaa	aatgttagga	18240
aaaaatgtca	gcattgtgga	tttgtgggat	ttacactaaa	taagaaggga	cacttcccag	18300
gactgacaag	atgtacctc	cgtccctcta	ggccccaatg	tggtgtgcag	gatcccatag	18360
gaagtcatga	atgtggttgt	cagataacct	ttttgttact	gtggaaatgg	aagcaggcta	18420
ctgcaaaaat	ctgtctctcc	agggtttctt	ttaaagaagg	tagtcttgct	aaatgataac	18480
tatttcagca	tttatttgaa	aatgggcagt	gcaggagaga	aagaattttt	ccaagcttgt	18540
cacattgggc	cacctctctg	aagcattgtc	caacttctaa	ttagatgagg	agactgcata	18600
aaccaagagt	tgagagtaaa	gatggaacaa	cttgatgttt	gggtgttggg	tgacagaaag	18660
attccagaac	atgttttggg	tctctttact	ctgtccatcc	ctccttccct	ttcatctttg	18720
tttaaaaacc	acagtttagca	aatgtgtagt	ctgtttgcaa	ttgttcatct	gaaaaatttg	18780
tttgatcagc	cttttgaaata	aaaagacca	aattagactg	agatatttca	gtcaccaact	18840
atctaataat	agacaaaaaa	ttttaacat	gctcatactt	tcatatggta	tgtagtgtgc	18900
tttagacatt	ttctgggctt	cagtggggtg	ctagattgac	tcaaaatatg	gcaggtcaga	18960
tgtgggattg	agcagggtgg	actcttctct	acccttccca	attcagagtt	ccccatcaaa	19020
gatgatctca	tagtgtttga	aaaaccaagc	tgaaggcttt	gggaattagg	gtgctgaagg	19080
gatatgctgt	ttcccaaaagc	cttctcagtc	attccttctc	ccccagttc	agattcttaa	19140

-continued

cacctctttc	caggattagt	gcagtgatcc	cacgtccttt	ctctctagct	ctctctgcta	19200
ctctctaatt	cctattgtat	ttgtgccacc	agatctttcc	aaagtttagc	tccaatcttg	19260
tctgtatact	gctttaaatg	tctattagtc	tttaagctcc	ttaagggtag	gagtcctgtc	19320
ttatTTTTc	cctattcttc	gtgcttaatg	caaaggaagc	cttgctgtat	agttgtgtaa	19380
tgcattgatta	caatttcagc	ttctcccat	tggttatagg	gttaaagtc	aaattattta	19440
aatctgggtg	tcaagtcctt	ttatgatctg	cttatTTTTc	cagcctgaat	tcctggagtt	19500
cccttacaaa	actcttaaaa	cccagccaaa	aggatctagt	cactgtcact	ttaaaccatc	19560
ctcactctct	tgtTTTTtga	acatgttatt	tttcttataa	tccttttgac	cttgaaggct	19620
atcccaattt	caatactatc	cattcttcta	tgacagcccc	ctacaaaatg	aatattctca	19680
acctcccaac	ccaaggagaa	gtgatctata	tgacacaata	tggttgaaag	aatgttggtc	19740
tcacttcttt	atctgtaaac	caggggctag	aaatctctag	tttataagat	tttgtggaga	19800
ggggatcata	tgtgattatg	gatgttaggc	acaagtcaag	agtgcataag	accttttgga	19860
tttatccctt	ttttctttct	ccatcaatat	ggtacttagt	cccttaaatc	agaagtactt	19920
gtgttaatgt	ctgataacgt	ccttctaaat	atacctctaa	acatctgtct	ctctttaggg	19980
caaaggttgg	atatatctgc	aaagattctc	tttgatata	agatatccac	agcacataac	20040
ttaacagtgg	tgtacacagt	aggatttcca	taagtatttc	tttatgaaat	gattcagagt	20100
caatagtagt	aagtaactgc	caaaaacaac	tgatggattg	taagttccat	taacataaat	20160
acagtcagcc	ctccatatcc	atggattcca	tatccacaga	tttaagcaac	tgcatagga	20220
aaatatatTT	tagagacaca	gtaaaaataa	caattcgaca	gtaaaaaaat	acaaataaaa	20280
ttatgtaaaa	caactattta	cataacattg	tattagctat	tacaagtaat	ctagatataa	20340
atgaaatata	tgggggatgt	atatagggtt	aatacaaaat	tgacaccatt	ttatatgttt	20400
tagttaagga	acatgaatat	ttttggattt	tggtattcat	gggagtgggg	gaatggaacc	20460
atgccccctc	aaataccaag	ggactattat	atgggacaca	gaataaagga	gttgattgtc	20520
ttgctctggt	aaattctggt	cagacacatt	tgcaatgtat	tgctcagccc	cagtattcat	20580
ggagcatctc	cttttgtaaa	gcattggagg	gctgtgagag	agacatggag	cagtgaacat	20640
aactattggt	tcaacgtacc	tgaaggatta	tcatggaata	aagaagttag	atgtttttct	20700
gtagtacccc	aaagggcaaa	agcaatgagg	acagattaca	gttcagtaaa	cgaagagagt	20760
tttttttttt	tttttttttt	ttttttgaga	tgggagtctt	cactcttgct	gcccaggctg	20820
gagtgcattg	gcgcaatctt	ggctcactgc	aacctcgctt	cccgggttca	agtgattctc	20880
ctgccttagc	ctctggagta	gctgggatta	caggtgtata	ccaccactcc	tgggtaattt	20940
tatttattat	ttatttattt	ctttatttat	tttagtagag	acggagattt	catcatgttg	21000
gccaaagtgg	tctcaaacct	ctgactgcag	gtgatccgcc	tgctcggccc	tcccaaatg	21060
ttgagattac	aggcgtgaat	caatgtgccc	agcctgaaag	atattttctt	agaatagctt	21120
ctttcacctt	tcatcagaag	ttgtcaacat	ggaccatatg	agttttgttt	ggtctatatg	21180
gtgtatatgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	gtgtgtatgt	gtgtgtgttt	21240
attgaattac	ttgctaacat	ttacttcaa	aattcagatt	tccaccatag	ggaatgaaga	21300
tctggcaata	caggactttc	attcctacat	ggtaatgacc	agctgtaggt	gaaaagcagc	21360
tgatcctctg	gatgggccat	gcactttgca	gtttgccag	gcagcactga	tcgcttttat	21420
tcatttaagt	tacctgcttg	actcttctag	tcattcgagt	atgcatcccc	catcagatca	21480

-continued

gagacctaag	caaactcttg	gtcccttgct	tactccaagg	gctttcactc	ctcgtatagg	21540
aggagctaaa	gaaatgtaca	agcagcacca	caataggatc	agacctggct	ttcaattcta	21600
gcacggccac	ataacatagt	tggatgacct	caggacagta	acataacccc	tctgagcctc	21660
tagatcttca	ttatctgtag	agcactcttc	ttatagagtt	attataagaa	tgaaataaaa	21720
caactaggat	aaagggcatg	gcacttagta	ggtgctgaaa	tattagtccc	cttctcttaa	21780
ttcaccacac	catactgtgc	tatctattgg	ctgaatcaca	taaatagtaa	attcacattc	21840
actgaagaca	ttcaagaaga	gtctggaccc	tttggaacc	atgtataggg	caaaggtttg	21900
aactcatagt	agatgatttt	tacagtcact	ttttaacaat	ttaaagcct	atagatgact	21960
ccaaaatgcc	catttgatg	atatgaggca	tactttgtgt	agttaaggat	tttaaataca	22020
taacagagag	gctgaagggc	cttcgggaaa	gaagctggg	taagagtcaa	agtgtagtat	22080
gttgaccgat	gttcaggaat	aggctttggc	atctgacaga	ttttgtttta	aatactggct	22140
ctgggtctta	ctagcttcca	gttctgggct	gcttcacctc	tcttgagttt	cagtttcttc	22200
atttctaaaa	tgaagatact	aatgcttctc	ttgttgggtt	tttgtgaata	taagtgagat	22260
aataaatgta	aatatctagc	ccagggcctg	gtgcatagta	caagcttcat	aaattgtacc	22320
tattattatt	agtagtagta	gtagtccaga	caaacagagc	ttgggaaaac	gctagactct	22380
ggctgacata	catgggcttt	tcccaggcc	actgctgcct	ggcttcccct	tccacaaagc	22440
tttgagtctc	caaaatgctt	tggtctggaat	gtaagcgtga	ggtcattgca	gataacaggg	22500
gagcatgatt	tgcttcggta	atgcaagtta	ttaagttact	tcctcagcc	cagctgaaat	22560
ctcttattgg	ttgatgtgtg	cttcaaagtg	tgagacagag	ctagtctgag	gagagaggga	22620
gagtgagaag	attcctcttc	ttggccagag	gtcatggctc	tccacaagga	acagaatgac	22680
tcaatgcaaa	ttatgggacc	tctttgagtt	tggggcccct	acatttaaac	tagtaactcc	22740
gttgcacata	ttggcaccct	tcccccaaca	aaattactgg	gcaggaattt	tcttgaatcc	22800
ttcctgggcc	tggaatgatc	tcctctctca	tccttgatg	ccacacagct	ggcaaatggc	22860
aggcagcaga	acaaaaacaa	gcctcttagc	atataggggg	agaaagagtc	acagcagtac	22920
tgaatttgct	tgggaacctc	atgttaacaa	aggaccttcc	tctcaacacc	ccaaacagat	22980
taaaacattt	ttttaacagc	aagttgtgtc	tgggagcagc	tctttgcttg	ggtataattta	23040
aagatctgct	gagtcattta	agagcaggct	ggcatatcct	aagaggcaag	gactataccc	23100
cagtctatgg	gggagtaagt	tgagagggtga	aatctgtttg	gctttctccc	atggaaacaa	23160
acaagggtgat	ccacttccat	ctcccacgac	tctggagagc	atctactaag	ccttcttatt	23220
ctatcaactt	tgaactcttc	agtgtataat	agagtaaggg	tgagagggaa	ggagcagtcg	23280
taccagtgtc	attattggta	tgttcaggag	ttcaatttct	tcctgattca	gtcttggcgg	23340
gatgtatttg	tttgggaatt	tatccatttt	ttctagattt	ttctagtttg	tgtgcataga	23400
ggtgttcata	atacctctctg	atagttattt	ttatttctgt	ggtgtcagtg	gtaataaccc	23460
ctgctgtctg	aaattgtaat	ggccctgcta	ttggtagctg	agagtagcat	ggaagtgtca	23520
ggttgatggg	ttcatttaat	tcttttcttt	tcagtttcag	tcacatgcat	tgttaccatg	23580
gcatatgaca	gttgctagaa	agtgaataaa	ttttttttct	actttattct	ccactgcact	23640
tctaaattta	ttagtggaga	aattagcagt	taccaactgt	tcattatagg	tacacattgg	23700
ggtttcctta	gagccaattt	tccccctgg	tttcatcttg	taaactctga	atcctaaaaa	23760
ttagcaaaac	ctagagcttc	tctttgggtc	tggtctgttt	gaacctgtgt	ccacagaccc	23820
caatcttctt	tcttgtttga	ggcaactatc	cttctctttg	cccaccgcca	ttttccttca	23880

-continued

tctacttttc	ccttctctag	cacctcagac	tgtcttccca	cagtggcaca	gcctcccact	23940
ccactttcac	tgtgccatct	ccttgccatc	aaaaccatcc	tcacagaccc	ttctgaaacc	24000
acttctagga	agggaaatca	caatggatcc	atgaaggatg	ctttctggat	gactttaaaa	24060
gattgggtatt	aagatatttt	atcagtggta	gcaacactga	cttattcagg	cagccatgcc	24120
ccggatctat	aagaaatcag	gtaagctaaa	agttgcttga	gctggcagga	gacctagttc	24180
tcttttttcc	tttccctctt	gcattttgtt	tatcgatggt	tttcaaagga	cttagaggct	24240
ggctttgtta	tagttagttg	gtaagagaaa	tggtggagga	ccggaaaatg	ggagtggaaac	24300
gaatgagcat	gtttgagact	aagttattac	aattcctagg	atgtataaat	tgcttgaaat	24360
ctaccaagta	ctttcagaca	cattatcttt	tttactcttc	aaaatcaact	tgagggtagg	24420
cacaacaggg	atcaaatcct	tagttcacag	atgagtaaac	tgagactgga	ggaaattaaa	24480
ggagattcca	aggtaaactca	gacaataagc	aacagaacca	ggatttggtg	aatttttttg	24540
ggggtgggag	gtacagagtc	tcactcaggc	tgagtgagc	tggaaggctc	tcgtctcact	24600
gcaacctctg	cctcctgagt	tcaagtgatt	ctcgtgcctc	aacctcctga	gtagctggga	24660
ttacagacat	gtgtacaat	gcctggctaa	tttttgatt	tttagtagag	atgaggtttt	24720
gtcatgttgc	ccaggccggt	cctgaattct	tggtctcaag	tgatccacct	ccattggcct	24780
tccaaagtgc	agggtattata	agcatgagcc	actgctccca	gcccagacc	attaattttt	24840
gacagtaagt	ccaacttttt	tcaagttcac	agctcagatt	tgctattgaa	tgaatgagta	24900
tatatgtcat	ttgggaacat	tctttccaac	ttttggttga	agatttggtt	tatcacttgt	24960
gaaaattttt	tttcattctt	agcaatgtca	gtttagttaa	atgagcattt	catttgcgaa	25020
ttcactaatt	aattatttta	ttcatcaata	catttctga	gtaccaactt	tctatcaaac	25080
cctgtgctgg	attctgaggc	tacaaagaga	aataagatac	catctcaggc	ctctaaaatc	25140
tcacagactg	gggactgaca	tctcagtagt	aaacatatga	acagcaactt	gtgaaacgcc	25200
attagcaaaa	tctcaagtta	tattcttcag	tgactatggc	catcctaaaa	atggggtgtc	25260
ttttatttgg	ggtaaatgaa	gatgaagcct	tatgagaaat	tgcattttaa	tctaactctg	25320
tcttgctaag	aacagaagtg	gaatgtttca	gcctctgtgt	gtgtatttgt	gtgtgtgaag	25380
gttgagtgtg	tgatgatgga	tggggctgcg	agattgttaa	gtaggatcta	tggggggcct	25440
taaatggtcc	tggtgagtcc	caactttctg	gttatgtatt	tgagtagagt	atgggggtga	25500
caaagattgt	tgtttaagag	ttgattttag	attttttcca	agtaaatggt	cagctgactt	25560
ggagcatcat	cattccactt	gctttgaaaa	cctgccactt	aaggtctcct	ccagtcatag	25620
gttaactctt	tctggccaag	tattactctt	tttgagcatt	tacctgtcag	tgacaggta	25680
aatgttagat	gttgctctct	tgttttcttg	tttaactctt	actttgatcc	taggtagctc	25740
ttattagtcc	cactttatag	gtaagaaact	gaatttcaga	gacttgaatg	acttgttcaa	25800
gatcacatag	tatagtaact	tggtagtgtg	ggacttgaat	tttgattgtt	cagttttttg	25860
tttgtttgtt	tcctggcctc	cctgctgttt	tcactattcc	acaccacttc	agctttattt	25920
ttcatagagg	ccattaaatg	tacctcccat	cagccaaaagc	ctcttgccct	ccttcaacgt	25980
aactcttctc	tagcgtctct	ttaataatct	tctgaaaagg	ttttacagcc	tttctgggta	26040
ctgggaccca	gagtcttaat	ccaggctctt	aagtgcctta	tttaactgta	atatggaaaa	26100
tcaaagtcac	agctaattca	ggaaaaatga	gtttgggatg	tgaatttctc	aggcaacttg	26160
tcactctctt	tttacttctt	tagcttcata	aacttaccca	caatgttccc	tgaggactaa	26220

-continued

gagtaatgga	gggtgatgag	gaaaggettt	cctcccttcc	tttccgagag	tcctttagcc	26280
aatgccaca	cctcctcctg	tttccctagt	ctccgtgcag	agatggaagt	gggagataga	26340
catgggttcc	tttcagccct	gagttcatgc	cagggttttc	tttccctcta	gctggactga	26400
ggtaggagga	gaggttgaag	tcaccaata	agaccatgag	tgaagaagac	taaagtactt	26460
gaaagagcag	cagacctacg	cttaaaatac	tagggtttgt	gtccagactt	tgtgggttac	26520
tatctgtata	atthttggca	agtcaacagt	tctgagtcag	agttccctta	tcagcagatt	26580
ggaagataaa	ttctaattat	atagatgaaa	cattaagtct	agaagtaatt	tgtaaattca	26640
gaaagggcct	atagatttaa	agtgtagccg	ttttgattac	cacaaactaa	atcctatact	26700
tcagggataa	aatcttctcc	tgttttttct	aaaagcctgt	gcatgtgtgg	tgtagggggt	26760
gggttttccc	ttgtaccagc	aacttagcaa	ttgtagtaac	ggggtgagg	gcagtggcat	26820
gcttcttcat	tgagcaagt	tgaagagg	gttatgcatt	cagggttcag	cagatggcag	26880
gcagagtagc	ccctccaaat	ctccctccca	taccacaaag	ccctcttatt	tattcaaact	26940
taacattaga	agctcatttc	aagtaggcac	gtctgtgtct	gggcgtctat	ttccttctt	27000
tgtatatagc	aggcatttgt	caacttggtg	aaaagcatta	ctcttcttcc	catttctgag	27060
gactaattgt	gcttcttcgc	tagacacgag	ttcaaacacg	tgggttgaaa	gagggaaggt	27120
ttatgccaaa	gaatcagaaa	tagtcataat	ttagagagaa	ttctagaggt	cagttccctt	27180
tcgtatggac	tgggcaactg	aaaccagac	agggaaggga	attagaccaa	gttcacaagc	27240
acaaacactt	tactggcaca	ttcagattgg	aaatcgagg	cttctgctcc	cagggtcagaa	27300
ctaaatgccc	tttctagcta	gggtgttctt	tgatctcagt	gattttgact	ctttctactg	27360
cactctgggg	acagtggggt	ctgcggtacc	aactccaatt	aaagtgggaa	tatgtaccag	27420
ccccctccct	tgggttttat	ttttcagagg	cctggcagtc	agagggtatc	tgatctctat	27480
atgcaatatt	ttcacactac	tgtacttatt	gaaatcacat	ttgaatcttg	gcaattaaca	27540
aggcagtaat	tggcatcagg	agggtatgtt	agtttgctta	tctgcgcctg	ccctcctctt	27600
ccccaccac	tgtgtattgc	agaatgtttt	atcagctctg	atttgccaag	ttgctctctt	27660
ctccagtagg	tgtctcgagc	agagagggat	tcctcggagg	tcattctgtt	catcttcttg	27720
cctatgcaaa	tgcttgcttg	aagctgcttg	aggctggcct	tgtaccggac	ttgttacagg	27780
gaaccaggga	aacgaatgca	gagtgtctct	gacattgcct	gtcacttttt	cccatgatac	27840
tctggcttca	cagggtgggag	gttcttcaat	tgaaaactta	gaactcagtt	tctagggtag	27900
tgagtgttgt	aaggtttgga	ctgtgacctt	atattacgca	gccatgacat	tatctattag	27960
gcattctagc	tagcttgctt	gaatatctta	gcattgtgac	taatttgggg	cagaatatag	28020
tgtgggtggg	ggattttgtg	tgtggggggg	ggttgggggt	tgagcaattc	attattatta	28080
aatgcaaaa	agcacttaat	tcgctatgat	aagattgcct	ttttcatgca	tactggccta	28140
cctgcaagac	ccctagagac	agtaagcagc	atacatgggt	tcttccagtt	ttcagccttt	28200
gtgcaaggaa	caactgtggg	tttctgcaca	tgtgttgtgg	tttgatgttt	gtatgtgatt	28260
gtgtaccagg	gtatgtgtgt	ctgttattgt	gagttcattt	ctgagcagtt	gtgacacaca	28320
gagatccaga	aacagtgtct	taccctgtgt	gctttgctag	tgggaacgtg	tcttttcttt	28380
tgtgctcgta	tctctgtgta	atcgagtgtc	ttgctaagtc	aatgtgcctc	tgtctctttt	28440
taccagttct	gtctttgtgt	ctctgtgcct	tcattgtattt	tttccctga	gtttgcacgt	28500
ctctgtctat	gtggatatct	ctcactccag	gccactgtat	cactgtgtct	gtattacagc	28560
tgtttatttc	tgtcggtgtg	tggatttcta	tgtctgtttt	catcttaatt	tgtgtgtcta	28620

-continued

```

agcaagactg ttttgggggtg actatttcag tttatgtcat agccattcct tgtgtgactg 28680
cttctaggta tgtctttttc tatgcccta ttgtcccat ctccatgtgt ctctgtgtgt 28740
atatgttcta atgtatctgc ctacttatct tagtttgtat ttctctgggt gtatatccct 28800
ctcttgcaagt tctgggcctt tgcagttttt ggcttatgtt tttgtatata tccactagaa 28860
ttggcttctt atcttttttg tgcagtttt agtttgtatg agtgagcata tccaactctg 28920
tctttgagaa gcagaactgt ctgtgtttgc agtcagttgt gttggctgtc cctgtgtttg 28980
tccctgtgtg tgcatttcat tgtatgtgta cgcacccatg tatctttctg cttctctgtg 29040
accagatatt tctgtgtagc tgtctatgta tattggcttc tgtctgtgtc tgtgtgtgtg 29100
gctctacgtc tgtgcatatg caccaccgg gtccataaaa agctcacctg ctctccaagg 29160
aatctaccag attattttgt gaaataactc acgtttcgtt tttttacttg ccagctgcta 29220
tggtaacttaa aagtgtgttg gtacgtaggt gtgcataatt tattcatgta ggatgtcaaa 29280
agagtcagtt aaaaattatg cacagtgtgt ctttattaac aggacacttg tgtgtagaga 29340
atccttgaga aatgagtggt tagatgataa atcttttcat attaatcca tgatgtcagt 29400
gaagtaaatt tgcaagatat gggctgcata agaactatgt tctttttaa actcagcata 29460
ttgatggtgg agaaagcatt tatttgtact gcaaagctct atttctgata agacatcaca 29520
aataagaatt attgtgatga gacttatcac aaataagaat tattgtgata attcttattt 29580
gtgataagaa ttactgggtt agaagtggtt acttttctgg tttgttttg gtttttgtt 29640
tgaagtgtta ctacagatgg tgtcttaggg acaaagagct ctgaggttga cttagaacac 29700
atggagtaca gataaaaagg agaatgaaaa gtaacagaga gatgggcata ttcttgttt 29760
gaatggagtc atccaggggc tcaggatgga gtgcacagga aatggagagg tgaaggtcat 29820
agagagaagt ttagcaggac cagatcttct cttgtcctgg gctgctgtga ccatataagg 29880
aaggcagtaa ggggaggggt agggatgagg aagagaccag ctctcctctt tctttctgat 29940
ggaaggttac cacctctatt taaaacttct gttcttttgg tttctcttct tttctttgat 30000
tatattattt tctggacttg ttctgccaaa gcaagaagga aattcccat gtggctcact 30060
catttattat acttgtttct ttgcacgata ttaaagacag cttgttaagt gtcactgcaa 30120
acatcataca cactgatcca ctgatatggg caggggggtc tttatgccag ttctgtctct 30180
ttcccagtgt atctgtgggt cctaattggc gcaaccatga ttttctgat gtcagctctg 30240
gatgtcagtt gtccagtgtg tatgcaggct gcttaagagt acatacagtt ccttcacaat 30300
tatggtagtc cctgagaagg aagtggctat taataaaga ctaggttcag tagaaacatg 30360
taagttgtct aggtgttga aattaataca gtactgtgct aagggaacat atatctagaa 30420
gttaactgaa ttatgtctaa taaaagagt acaaatgtt cataaatatt ttgacctaat 30480
cctcctgtaa gattaggaga gggatatttc cgatattcaa ataattttt taattggcaa 30540
acaccttaga catactattt acataaaatt gacatgacaa aattaagtca ttgtgtctgt 30600
tttatgataa aacaggctct ttgtatttag ttagaattat tgaatgtaa ataataaaaa 30660
ttaaaaaaaa aacaaggagg aggaatctat cctattttat aattcagacc gttgaattga 30720
gtttttcttt tgttgtattg atttaaatgc agagaagtct atgatgtgg attccagtca 30780
gaagataaac atttgtatgt gggctctaca ttgcagccaa ccttgataat ttcaaacctc 30840
gattttctca tctgtataat ggtaataata aagcctgtct cagtagctac caaatgattg 30900
catatgacaa acttctcact tatttaaggg aaaaaataag aaaaagaagg acaatagggt 30960

```

-continued

```

ggatttttca tatagtaaaa ttatttcagt tagggtaata ttctgagatt gtcttctgaa 31020
gcaaaccctg caaaccctgg ccattctggt ttgttttaga aagaattcat cagttctgat 31080
tctgcctttt ctggggaggg aggctgagta ttggattgaa gaggagtcac tacttttctg 31140
agatgatata tccgtggtaa aaattattaa tgctttgcac atgcaacata gagtgttcaa 31200
ttttgttagt caacaaatat ttaagtggca gctgttatga cctcaggggt gtagtgactt 31260
ccttattgtc ctttaattat taaaaagaa atctatatca gaatatcagg taaactotta 31320
ttacatcaaa tattataata aagatacttt ttatatcttc taaacaaagt agagatctca 31380
gatgttggtt catttatcaa tataatatta gatttgaaaa ttccagtata caaaaggaaa 31440
aggacagctt cttaaagttt atagtgtttt tctatgaact atcaattccg ttttttctg 31500
ttttactggt atgatggaaa ctaaatttcg agttgtaagt agtagataat tagactgcag 31560
ggtaagcctt gagattactt cttttcaggt aggaaactct actgtgtatt tggctagttc 31620
aacctatcat gggtagtcaa aaatagttac atatacaagt cagcattttt taaattgttc 31680
agttgtgctt aagattgggt ctttcagga acaatccagc tttatcaaaa aattattgct 31740
tacatgtaaa gtgttctgac attttaatgc tcacaatagc cgaatgacgt gggtaagaat 31800
cttcgtcttc attttataga tgaagaaatg aagacacaga gacataaatt aactgggcca 31860
gggtcctacc actagaatgt gatagatgat aatttgagct cagcacatag ttatttcct 31920
ataatatttg ttttatgatt gtatagatgt ctgctgacca accttaactt ctgctcccta 31980
agattaacca ttctacaaag cagaaactgg aggtcattca aatgaaagct ctacactttt 32040
agagggccat taacaatgct caagttaaag aaaagcaatc aaagacaact aaaatactgg 32100
taccttcaaa cagtacttat gaattattta accttagata atttggtttt gaggtagaaa 32160
gatagagtaa gatggaggaa ccaattcttc cctgggttga tatttattta tcttgcctt 32220
ttgaagtcta ggccaatcat cctatttatt ctgaatggcc cgtaacgtt tatccattta 32280
gggacagcag gtttggcaca aatggattgg ttttctgagg tcttatgtag agggctgcac 32340
tgactgactt ctgaaagtcc cccctaacc cttcaaatctc agggctcatct ggtctcaagc 32400
cttcaattat gaatacatth ctattgcctt tttagtaac agcacaacac tgcaagetga 32460
cccactgggt ggatggaatg gggctcttgc cctaccaccc tttggcaaac aatttgaggg 32520
tggcattgtc actacctcat tgtatatagg gtctcttgag gcccagaatg gcaaaataat 32580
tttcccagtg tcacacagcg agttattgtc agagtaaata tcaattttga attttagac 32640
cacgtggttt tacctcatca tttctgtttg ttatgaaagt tttacaaata attagaagta 32700
gaaataatga ttaaaataaa gcataactac taaaaaatag tttattgcag caccacctaa 32760
attcatctca ccactctacc agtagcatac atttcacaat tgggttaaca ttgctctgga 32820
tcttatagct gttgaagaag acaaaattct ttccattctc cagcttatat ttccccatt 32880
tgtaaaacat aatggaagtg tacggaaaat aggagttgat aatttttaag gcccttgcca 32940
gcacattagt acataggatt cttgcaagtg gtggtttact tcaactcaac tatagaaggc 33000
ctatgcgaca ccccatag agggtagttt gaaagaaaat gctagtgact acgtgtgttt 33060
ccttcctgac atattttata gaaggatgag agttccagca ttttttcaga cttggatctg 33120
gctttcatct ccttctctct cccacctctt aaaaacaacag aggcagcaac catttacaca 33180
ctttccagaa gtaagtaagt aagactgtat tccagaaaca ccctatatca aaatggaaat 33240
atactcaagt gcccacatga cccattgggc tagtttgaac gtgtgcagtc tctgtgctcc 33300
cgttttagc ttaagcctac tccctaacct gtcatatgtc accagccat ggagcctagg 33360

```

-continued

gcaatgactg	ccatcatatc	tgactttatg	gcctctcagc	tttcaatgac	tagctttgta	33420
gcagaagttt	agcctctcat	ccccataact	ttggaagtag	tggtgagata	aagaaacgtt	33480
gaattgaagg	ttgtgttttc	tagatttctt	tcaattgctc	cttaggcttt	agaagataaa	33540
ttctcctaaa	agagagggtg	tacaattaat	ccaagcaaag	ggaaagatgt	cagtaaaact	33600
gccccctttc	atagagggtg	ggcaactgct	gggaagggaag	aaattagcct	gaggccatgt	33660
gattactaat	aaactcaaag	cggcattttt	ttactttctc	atatgagggt	gaaactataa	33720
gcttaaatg	ctgactttct	ggcagcacca	aacagtaagg	aaaccacaaa	gataaaccca	33780
aataatagag	ccaattttct	ttttttccgg	gggggatgac	ttctaactag	tgatatgagg	33840
aaggataaga	aaatgtttct	ttgtaggaca	tatgatcttt	gctaagtgca	ctgaatgtat	33900
gtagaggaga	caagtctgct	gagggtagga	gaattgggccc	aagatttaac	acattttcaa	33960
agctccatga	agaagcctac	tgagcagtg	gagtgaggca	ggttggggat	agtgaagtat	34020
ttgtaattca	tttttaaaaa	ggagagggag	agagaaaagg	aaaaactggg	ccacccatcc	34080
tttgaaga	aaccttgaaa	gaggtccaaa	tatccttaga	aatccttgac	ttcttaaaag	34140
tgatgtttgt	tttttcccc	tgacaattat	agaggtcaga	gagtttttct	ttctattac	34200
aaaacattga	gagtgtgtag	aaataattgt	aggtagctta	gccttggtctg	tagtcagaac	34260
ttttgtactg	tgactttagg	atctgtatgg	aatcgtatga	tatgcgata	cacccaaaaac	34320
tctatgggtt	atcaaatgg	gatagcatta	aaagaaatag	tgcttttgtt	tagaagaaga	34380
aatgaaatgc	ttgtgtccag	atgccttaaag	gaaggcagtg	cagactttca	gaaactagac	34440
tttaagagct	gtactcagat	actgagaagg	gctgatggct	gaaggaggaa	caatttaaaa	34500
gaataaccgt	ctctcctctc	cctgtatatt	ggacataaaa	gaatatccca	ttcttttcag	34560
aatgtaata	caacagttta	gcttgctagt	aacttcacat	gctatttccct	ttacctctta	34620
tatttgaggt	gtctatttgg	agtggtgtgt	gtttctagct	attctgttta	tctggtttgt	34680
ttttgttggt	gtaggaaact	ggtataaatt	ttatttggtt	aaatatcacc	tcaattttca	34740
actaaagctt	tatttaagtt	tcacatgaaa	aagacaaatg	aggcaaagga	agagaaaaat	34800
gcattgtcag	aatcagaatt	atgagaaaaa	aagtcaaaac	aacatatttg	aatgtccag	34860
aaaacctgtg	agtttttatg	tatactatac	aggaaagata	ttctgtcatc	tggttgccaa	34920
actatggagg	gtgggagact	tcgaattttt	gtcaaaaagt	attctttcat	tagaaagata	34980
catgggtgtg	cttccatgtc	agcaacatga	ctgcagacca	ggaagtcctc	acggagagct	35040
ggaatatggg	tattttggac	tctctgggta	gatgcagctt	ttacttcaca	tcctcagtg	35100
tactactgta	aattttcatt	ttcctgtgga	ataccctatt	tggttccatt	gtatatagtt	35160
gacaactaga	attcgttcgc	tgttgcttga	gcccactat	aaacttcttg	cactatacct	35220
atcttctgat	gtgcctgtgg	aagagctacc	ataatgaatg	tgtacatgga	caaaaaaaaa	35280
gagagagaga	gagagaatta	aatcatgagt	ttgtgccttg	ggagctacag	tttaaacatt	35340
tgctgttttt	ctcacttaat	gaaaaattta	tttgaataa	acagcacaga	aaggaagaaa	35400
gacaggctgg	caagcatcct	cctcctaata	cacttatcca	cgtttgata	ccttggtctc	35460
agcctcagag	gtcatatttt	tagtaaaatg	gccaccagaa	ataaaggatt	ttattttcca	35520
gactttgggt	tttgagctg	gtgtgctgag	agctagcaga	gaaagcccta	ctcaggtaga	35580
tgtaccagag	caggatgggt	gctggtggat	atggtggaat	accttttatg	tggttatctc	35640
ctccttgtaa	ctcttggtg	cataaccctt	attttctttt	ctatttttat	tctctctctt	35700

-continued

```

ggaaaaaaaa ttggtggttaa attttcatgt gagccatatt gtctttttaa atagttttat 35760
taataataaaa tgtacgtacc ataaagcata cccattttaa ctgtaaatgt caatgggttt 35820
ctctctctct ctctcttttt tttttttttt ttggatgctc agagtgtgc aacaattatc 35880
aaaatcaatt ttggaacaat ttcattgcc caaaaggaaa ccctctgcc attagcagtt 35940
actccccatt tccccaccc cctgaccctt caaccctagg caagcacaaa tgtactttct 36000
gtctctatag atttagccat tctggacatt tcatgtaaac agaatcatgc aatatgtcac 36060
cctttgtatc tggcttcttt cacttagcat gatgtttcca aggttcatct gcattgtagc 36120
atctgccaat acttcattcc ttatttatgg ctgaataata ttccattgta ttaatgtatc 36180
atatttgttt ttccaatca tcagttgatg gacatttggg ttgttttcat ctttttttta 36240
gctattttaa ataatgctgc tatgaacgtt cgtgtacaag tttttgtatg aacatctgtt 36300
tttatttctc cttggtatac acctaggagt ggaattgctg ggtaatatgg tagcttaaca 36360
tttaatcttt tgaggaaactg ccagattttt ccaaagcagc agaatcattt tacattttga 36420
ccagaagtat atgagagttt tagtttctcc acatcctcaa caacactcat tattgtcatt 36480
gtccttttca gcttttttga taatagtaat ctcaatgggt gtgaattggg accccatcat 36540
gcttttgatt tgcatttctc tgaagagtaa ggatattgat catcttttca tgtgcttatt 36600
ggccgtttgt atattttttg atcctttgct catttccaaa ttgggttatt tgtctttgca 36660
ttattgagtt gtaagatctt acaatatatt ttggatgttt gtcattttag ggatgatact 36720
tcacagttat atgatgtttt ctgcaagca ttgctgtgt tctactgggt ttacatatct 36780
tagctgcatt agccactttg ctgggtatga atgccagcag aatctaagtg accttggctt 36840
cactactgag aatgcaaccc aagaacagaa atttgtcaga aatttagcac tgaagcccc 36900
cacttcccaa acttatctgg gacaaggaga atctacattt aaagctctat actttgtgtt 36960
gtgttttttt tacttttagct tggttggatt taggatcttt tctttttgtt ttgcttatg 37020
catacctaag cagaggcaag ggaggaaagg gatatgaacc tggtagaaaa gtaagtaagc 37080
tttattcaga ttggcatatc catcttaata tggttcaatt ggctgaagaa gtatctcaac 37140
taaaaactctg gaatactttg aagtaccagc aatatgtacc aaatgtactt tttatttatg 37200
tttggctctc atgtacttgt gtgtgaaaca atgagcaca ataataccct ccttgttttt 37260
aagcaattta tattggtgat ttaaaaaata aataaactca agtgggaaat catgaaaccc 37320
catgtaaaaa caataagagc atgtttttaa atcccacaga ctttagtttc aaatagtgg 37380
tttgctatct cttagctgtg tgtcactgtg caagtactt tgtttctctg agtctttatt 37440
gggtatatat gtaaaaaacc accttctcaa attattgtga ggacaaaatg aagtaattaa 37500
cataaagttc ctggtgtata ataagtgtc atattttgta ttgagcaca gggaactgg 37560
gtttttgaaa ctgcacatta ctgttgcagt caaatctggc atgaaattag tgcatagaca 37620
gaatgggctg ggaatatgaa aggactttga acatttatat tctgctttat ttaggcataa 37680
gtgcttaata attattgata gtttctctg gttatctgac attttgaaga tactattacc 37740
tagcagaaat ttcttgaat aataatctct tactttata tactgttttg tgcctttaga 37800
agtacttaat gctctttatt tcactatctg ttcataaaca ttctctgaag caagcataca 37860
gtcagtatga attccatttt tcagatgaga cagctgaggg tgaagacat agagtactt 37920
gtctcaattc acaagtaaaa gtgccagagt ttgaaccaga gccaggtct tctctctcaa 37980
cgtagctctt tttctcttc attatatcag gcatagtagc aacgtattct tttactagct 38040
ttttatcttg aatatccttt tagcagcttg ccttgggtgt tagtgtgctt ataacattgt 38100

```

-continued

cgttgaatat	cttaatacat	ttagtgggtct	tggaagcag	ttttgtcttc	agaaggacac	38160
tgaaatctgt	ggaaaggact	gcagaagatt	gggtgggcag	acacctatca	ctttcggggc	38220
tggtagactt	tctattgaag	caatttgcaa	ggctactttg	tattgtctaa	aagcactact	38280
tcagaaaagg	gttgtgatgt	caaaataggc	actttgagtg	aagaaagggc	tgtaagcatg	38340
gggtgaaaaat	gtggtagatg	attgtcttga	gttattttct	ttaatgtcaa	acaggcagtc	38400
cttggaatgc	tacttcaaaa	agtgttgat	aatgttgaag	atacagttac	agatttccaa	38460
cacgaaactc	ataaatatgc	aattccctgt	cctcctaggc	acatgaagga	aaatttatga	38520
gcttcaggtt	tctatgcagc	tattaaagca	tatttaactc	gctttgagct	caagctcact	38580
ctcgttggtc	ctcttcgttt	cttcctctta	catgagcaaa	ctgcctttct	ttttgtttaa	38640
aaatagtaag	taggtttgtt	ttcctccagg	tgatcatgaat	gcaaacattg	taattttctca	38700
tctgttcagc	ctttttgcac	aacaaaatgg	cagcaccag	gaggttgaaa	gggttaaatt	38760
gttccttctc	tgagtagtac	cataagttgt	tagtctgcta	ctctttctcc	cagttggcac	38820
atgaccttaa	catccaatcg	ctagtgggtg	ggccattttt	tggtcttatt	ttggcctttc	38880
ctcagccacc	actcatcagt	tctcatgcgt	atttgtcaga	tcctgctccc	caactccaca	38940
gttcttagtt	catcttaagc	atatggctgt	ctgtcttttc	tctaaagatc	ctcaagggaa	39000
aaaaaaaaaa	gcactctccag	ggggaattta	ctgectcata	gcctgacag	agattttctga	39060
ccaaacccta	acgaaaaaat	ttcttccctc	catttgtctt	ttattgtttt	tacaggggag	39120
atatgtaaca	taataacaat	tatatgcac	ataataatta	cttctacaaa	taataatctg	39180
ttgtcaaaaa	tatacacagc	tttgatttcc	cttattatgg	cccttcatta	agttgtgggt	39240
taagaatagc	tatgattatt	acttttgtga	taattataat	ccataatatg	gaaacttata	39300
aaattacctt	taaagtgtta	ctattattct	ggccacagga	tggaagttg	ttcgctagtt	39360
actcatttat	aacctgaatg	tactttttac	tgaatctaaa	ggatcatctc	ttgcttgga	39420
attcccatga	cttgtcttcc	tgactcttca	gatctcagct	taaaagctct	cccttcaaag	39480
aagccttccc	tgaccactct	ggttttttct	tcttttttta	cctctactcc	ttttccatt	39540
acttgctgtc	atagcattct	gtttgtttcc	tttgaagtgc	ctattccaat	ttgtcattat	39600
gaatgagttt	ttttgtctg	ttgcttatta	tccattttcc	ccactagatt	gtcaactctg	39660
tgagggcaga	gaccatgata	ctctgttcac	tcctatatac	attcccagca	ctatcagact	39720
ttttggcaca	tagaagatac	tcagtaaata	tttgttgaat	gaataagtca	taaagaagag	39780
tttatatttt	aactcttagt	tgaataatct	aagccaagaa	ttatcaacct	gggttggacg	39840
tgagaatcat	taatgaatct	ttaaaacaat	gacaaggcaa	tctatttatt	aattatctcc	39900
aggtctaaac	tttagcacgt	atatacat	taaaagccca	taagtgtatc	ttacgtatag	39960
ccagtgcctat	ctgtctcttc	tcctgtcctt	ccccctcctc	tccttactcc	tctctcatag	40020
ttttaggatt	agcatggccc	cacaacaaat	ctttaattca	catggcaatt	tctaggattt	40080
atcatggaaa	atgagccaaa	ttgccttcaa	gaagttttta	cgtacctctt	atatagaatg	40140
tgatgtttta	tatgtacctc	ttatagaatg	tgagctttta	agaggcatat	cttattgcaa	40200
gaaatttcaa	tggtgaaaaa	aatattgaat	atttataaag	tcaaaaatgc	aaacttttat	40260
atgattttca	aacctatgaa	gttatatcat	gttcaggcct	tctttccagc	atgtggetct	40320
cagccctggg	actgtcctta	accataaacc	tcacttttgc	cctctatagg	gagaggttta	40380
tggttataat	tactcatttt	aaatagtgtg	tattagtaat	gtacactatt	tgtatatattg	40440

-continued

ttgactgcct	cctatatgcc	aaccactatg	ctagaaattt	tgtaatatcc	ttcacgatat	40500
tcaagatatt	aacatatccg	cattttataa	atgaggaaac	tgctctcaaa	gagggttagtt	40560
tacacagcca	gtaagccgct	aagcctagat	tgatggaag	gtatgtgaga	aaaaagcagc	40620
atccataagg	ttttcattct	cctaccctgt	acgacagagg	taatagaaat	tattagttaa	40680
agaaataata	gaattttaca	agactctagg	aagggagaat	gtgaaggata	cagttctcag	40740
ttactggaat	gagtgccaga	gtaccagtac	atggcttgcc	ttggggtttg	gactacctat	40800
cttaactcct	ttgctctccc	caatcttgat	ctcatttggt	tgaaagatca	tctgcccac	40860
ataaaaatgc	atttctaatt	ctgtaattta	agtcagtgcc	aagatcagat	tcagttaaag	40920
tttactttcc	tgacagcttt	ttagtatcat	atctattttg	caaaactcta	gtgataaatg	40980
tatgcacatt	tacacatata	gcactctctc	tgattctgac	taagatatta	ctgggttggtg	41040
tagaagtgat	gggctcctta	gaagaaaggt	ttgatatact	actaatctaa	ggactgaatt	41100
ttctcatctt	tgtctttgcc	ccttttgact	gatgaccaga	gcaggagcac	ataacattct	41160
tttgtgctaa	cagtatctct	gcacacatt	gatcaggaga	attggcatct	ccagagccct	41220
gggatggtaa	cttctctggt	gattttcagg	aaagattagg	tgatattttc	tccatgggaa	41280
gaggatgttt	gatgtgtggt	ggcttttagca	aaaggaagct	tgtggagtca	actgtaagta	41340
gacagaattg	cctttgactt	aatctgtttc	agtcgttggt	catactcagg	tcctccagag	41400
gacctttaag	catttttatt	gactttgtgg	tctattcac	gaaactaaag	atactgattc	41460
tcagtcatga	gtctgtccca	aaattgccta	gggaatcaaa	aataattgta	ccagttccca	41520
ttcctggaca	ttatgattca	tttggctcgg	tatgaaggcc	aggaatctgt	atttttaaaa	41580
ttcactcaag	caattttcat	atatagctat	aattgaaaat	ctgtggctga	acttctccac	41640
tcccgtatcc	atcgcaatac	tcccccaagg	tggcatttaa	gatgggccta	gagggttata	41700
taagatttca	atattaaaac	atggattaaa	agtgaagact	tttcacatgg	agataatttg	41760
gaagaaaaac	ttgcaaaaat	gtgagagcat	tgagaacttt	tctttcccaa	ggaaagaagt	41820
ggcagcttca	tttttggtca	ttgcaaacag	cagtgcata	catgaaagga	aagtgggtgt	41880
gctcatcaac	tttgaataac	ttgtacaga	acccttgaga	ctcctctctg	cttataaaga	41940
aaaagtgtca	actgtaaagt	tgatttatct	atgaaccata	ggctactatg	aaatctctgt	42000
tcccagctag	aggcctggga	gagtaagata	actacttggt	tattccacgg	agccacttat	42060
tagctttttc	tatagcacat	acctcaaagt	aagcatttca	ataaaagaac	cacattctat	42120
tcacatgctt	cattttatcc	tgatttatgt	aaaaattccc	aaactcctca	agcagtgttt	42180
ctttgtaagg	caataatctt	cagttctggt	gcaaagggtca	ggagtgatag	aatgaaaatg	42240
gtactagata	caacagctct	ttggtatttg	catggccatt	acattgccat	ggggctgcaa	42300
gacttgtag	tgcttgatat	ttgcttggt	gatgaatgag	tctgtgtttg	tgctaatgga	42360
gtgatttgag	aggtagttct	ccactgtcag	tcaagagggt	ggttttgaaa	gctgattgcc	42420
aatggtcatt	ctgctaacca	ctctggttct	ccttttagata	gagacttatt	cagattcaag	42480
tcttcattga	ctttgtggca	taaacattgt	acacaccaga	tgtattcaac	aaccataaaa	42540
aaaaacaatt	aggactcaag	tagtatgtca	gagtgtagtc	actgatgata	tataattctc	42600
cactaccaag	aagatggaag	cacactgttg	agtagctaca	tcctacatat	gttggccaga	42660
atttaggaat	acacatgtga	tctatacatt	ttgaggattt	gtctgacccc	tagaaaaatcc	42720
tggtgaagtt	tttctggtgt	cagtttggtc	ttaatgttta	ggaaatgccc	acagactact	42780
cctgctttct	gcttattcac	atagtaaacy	caaagcacag	gactagtgtg	tcattctggat	42840

-continued

caaggagaaa	tgagttagca	gatataaaat	aatcagaaa	ggaggtagtt	ctcaaatatt	42900
tactccatga	atagttgctg	gatgttcatt	aactctatag	catttggtac	tacttattgg	42960
ggatcctgga	aagaaaatat	attgtctata	tccactgttc	actgaggccc	tctccctacc	43020
cagaaactcc	ctgtctccat	cactcactct	ccacattcat	tgaccaggg	gaacagtcca	43080
tggatgagtg	aacttgagct	ctatcttaaa	ggatggagtt	cgatttcaag	gcaagaggta	43140
taagagaaag	ttcagagaca	acactggcta	tggctcttgt	gaagaaaagt	gaattgaata	43200
ggctcctgtg	gagatcttaa	gtaagtactt	ctggagataa	ggttgaggaa	aagtaggttt	43260
gaatcttcat	ccagaggtag	cccctaaatg	tgttgagttt	attgaaagag	tacttgactt	43320
ggattcagac	agatctgcat	ttgactcctg	ttttgccatt	tataagaatt	tgagtaatta	43380
ttgtttctaa	ataagagttt	attgagccaa	gcactcagta	aatgtttgaa	tgggaaaatt	43440
aactgccctg	tttttctatt	gtcagatgg	cctcttcgtt	ggataacttg	gtaactgttg	43500
ataacctttt	ctcaggaatc	agaaggtaga	aagggtggga	aaatataaga	aacaaaaag	43560
catatttcta	tttttatttt	catattgtct	tccaactctc	ccaggettct	ttgtttgcaa	43620
ggctgacttt	tataatactt	tttgggtaga	gcaggtcctt	ctttggtttg	gggttaaacc	43680
gtgagtaacc	ttattttcta	ggtctcagcc	aactttgaag	ggcatgaact	cacagtagcc	43740
tcactaggat	cacttcagca	gtgagaattt	atctttcttg	tataaaagtg	taagagttga	43800
tggcggccag	gcgcagtggc	tcacgactgt	aatcccagca	ctttaggagg	ttgagatggg	43860
tggatcacct	gaggtcagga	gttcaagacc	agcctgacca	acatggtgaa	accccatgtc	43920
tactaaaaat	acaaaaatta	gttgggtgtg	gtggcacatg	cctgtaatcc	cagctactca	43980
ggaggctgag	acagaagaat	tgcttgaacc	tggaaagcag	aggttgagga	ttgcagtga	44040
ccgagattgc	accactgcac	tccagcctgg	gtgacagagt	gagactgtca	aaaaaaaaa	44100
aaaaaaagag	ttgatagcaa	aataactatc	tgtagcataa	acctcagtat	tctttatcat	44160
tcagtatcaa	cattattact	gaaaacaata	agcaatatgg	actgagtttc	tgtggggtgg	44220
aatgtgaag	tggatcatag	catgatataa	cttgtcattt	ggcttccttt	ataaacatta	44280
tcaactacct	cagctctatc	aatcacttgg	cagtccttag	tgaacattat	aactcaaag	44340
actagtcagg	tctgttcatt	gcccattgaa	aggcatatac	ctgaagtga	aagtctgagg	44400
taacttagca	ataagcttgc	agtacagtgt	ttagtgaagc	cgagggaattc	aaggatttga	44460
gtcatgccag	attgctccat	aaccatagcc	tatctttgtc	acaagtaaga	aggtttaaaa	44520
atcaccatag	cattattgg	cacaacgttt	ggagataggg	aagagtttgt	ggatggatca	44580
tggcagtgca	tggacagtga	ttagcccata	acacaaccag	tgaacactgt	tgtaccctaa	44640
gcacataaat	caccacatat	actattaata	tattttatgga	tgacaacaga	cactataatt	44700
ttatgtcagt	gctttctgct	gtgaaaaaca	aagaaagtta	aggttacctt	ttttatattt	44760
gcacatatac	tccagacctt	ttcctttatc	tctctcttgc	aagttcttct	ttctttcagc	44820
tgactatctg	ctgttctctg	tatggctccc	agtggctttt	caagagggtta	cttggttttt	44880
aagagaagac	ccttgaagga	cagagagagc	ctgaatcatt	caaaataatg	aattactcag	44940
gatgaaattt	caataatttg	caagtgtgtg	gagatagata	ttttgaggaa	gcataatttt	45000
ctatgtaccc	ctcaaatcgt	ggctggagat	gacagcctct	tccacctcca	tataagacca	45060
tttcatttcc	ttctactttt	ttctccctcc	ttcccccaaa	cacacaaaca	tacacatatc	45120
ctgtgcttca	gtcacacaga	acttcttact	atttcatttc	aattctctat	ggctttgcat	45180

-continued

```

gttctgctcc ttctgcctag aatgctcctt tccttttttc acctggaac atcccaattc 45240
aatgtcacc tcccttattt ataccaactt tgtctgtaac tcctttatca cacttccttc 45300
tgtgattagt caattcactt gttctgtgtt acacctctat gagagatgaa aattccttct 45360
ccatctctgg aactcatgcc ctctgcataat agtaggcaat ctgtaaatgt ttgaagggtg 45420
agtgaattaa tgaatgacct tcaacctttc aggcttccaa tttctctctt gaaaaggaca 45480
gccaaatgaa aactcataat tttagaagat gaggttagac ggttggttag tgcatgcaga 45540
gaccagttat tatttaggta ttatggaagt ttatagttct tgtatgttga gttcagtgtg 45600
agagtggccc caaacatagt taatgaccac tccagaccca gttgttatag agttggcccc 45660
agctgtattg cttctattta agactaggat aagaaatgac actttcctac tttttacctt 45720
attgaaaggg tagaggctca ctgttatcaa tctcagttca cttgttgatt gcactggctt 45780
gccaaagtgag aatattagca cctctgcaca tttctatagc tctgccactt atgagatcct 45840
tccttcccat tgtcatattt aataatcagg atagccctat aaaatatgca ttctcatttc 45900
ccagatgagg atactaaggc tcaagtagga gaacttactt gtttagtaag atcatacagc 45960
taggaagtgg gagaggcaag agttgaacct agatcttctt agctcctagt ccattgttct 46020
gtctactggg tcacactgga ccagccagga ggcaggaaaa tcagctgggg aatgtggtgc 46080
caacgtgtga tgtttgccta aatgtgtgca tccttgctgg aagccagcca tgattcatgc 46140
tgcataagta ttcattaatg ttcatttcat ttatttggtt atccatatgc tttccagggc 46200
gaaggcaagc taggacaagg gcagacaagc agccttaaag tttgggtgct ttccttcgaa 46260
gttgagctgc ctgtttgaaa atcacacttt ttggtgatag aagatggttc cagtacagat 46320
tttattttatt actgcatcta catggataga cattttccaa agcatagctg aaaaatgtg 46380
taagtccag aatattttct gatttagaca cagactttga gcatgataac cacatttagc 46440
atgttaggaa attctgtcag aatgcttctg gaaaggctac cttccagaa tgaaatgaaa 46500
aaagaaaagg atggactttg aaactggcta gatttgggtt atacttactc atagtgtgac 46560
cctggcaaat gatttaactt ctccgaattt cacttttctt attctttgaa gtgaaatttt 46620
aaaatgccat cttgcctgat ttttgtaga atgaaaatga gatccacac caggaattta 46680
gaagctactc agtaaatatt gcttctctcc tttcccttc cccagtcctg tccccgaga 46740
cattcagtag ttattcacag gcatgcattc tgaagtctgc ctactgctcc atgttgaaat 46800
gcactgctct tgcaaggact gattatctat ttttctgtct tccaaggccc cctgtgttcc 46860
actccacct cccaattctg ggggcttcca aagtgggcag gtacagaatg ttctgtggag 46920
catcgagggc tgttactcaa tatcttgccc agcactctca actgctcttt gcacacactc 46980
catatgaagg caaactccag atcttgagc ccatgtgtgt gtcatgcatt gtactgcttc 47040
ttgtacccaa atccatctca agggtagta gaccaggctc agacttgctc tgggagcaga 47100
tttctcaagc tgcccatgtc ccacactgt ttgattaaaa ggaggtgctt caaactcttt 47160
ggctttatat agactagaat cagaatgatt ggtggtgcct ctgttctcaa ggtatcccaa 47220
agcactttgt aaggaaatat gacaagcgt gaggcocatg aggcagctac aacagccgcc 47280
accagcact tcacaattag tcatgccag cctgggatca tcaagcctgt ttttattgga 47340
agagcaagag agagagggaa tgctagctgg caatttcccc aggtacctt tatgaaagtg 47400
cccttggtc ttccaatttc atctgaataa ccagctcagg caaatttttc tctatcaaaa 47460
agcagaatgt gatagtgaca agctgatgcc cggctgatgc cccaggacat tgactaaata 47520
gacttggcct cacaattggg ttttattctc tatctccttt cttccctttt gttctttttc 47580

```

-continued

tggtgtttctt	tccccattgc	catctgcaga	gtgtttctcag	tcagaagtca	gctgtggggt	47640
ggacagtttg	tcattttaag	atcatcccta	ttctgtctac	ctttcttata	cctcatatca	47700
ttgcttttag	agcaaggaca	attctggaag	tgaaactaca	ataacactct	gggctccttt	47760
ccctctagta	gtactcaaca	cacttgtaat	tacatgttca	aatttgctct	tcttatttct	47820
acttaggttc	atgaaggcaa	gggacatgcc	tgtgttgctt	actttctctt	ggcaggcaca	47880
tacagcaagt	cttcaaaaaa	tgcttggtta	ctacaaatta	agtggttaag	aagtccactg	47940
ttaattagcc	gggcgcgggtg	gcgggcgccct	gtagtcccag	ctactcgga	ggctgaggca	48000
ggagaatggc	gtgaaccogg	gaagcggagc	ttgcagtgag	ccgagattgc	gccactgcag	48060
tccgcagtec	ggcctggggc	acagagcgag	actccgtctc	aaaaaaaaa	aaaaaaaaa	48120
agtccactgt	tagtatcttt	tccccgcct	agtttgtaag	caactggcct	cttctatttg	48180
taagttacct	gttttcattt	ccatatgcc	caaagcaaac	tttagctcac	ggccttacag	48240
agtgtgtatg	ttagtatgtt	aaaatgaaat	caactttcct	ctcccaggcc	ttctaattga	48300
catgaatttg	ggagtagact	tgcatgggcc	ttgtctctga	cagccaacag	agtcctcttc	48360
tgttgatttc	actgttgcc	tccatgagga	tcccatggag	aaagtgtgtc	attgatatac	48420
attttgaggg	cagactcaac	ttgagtaaac	ctgattgagc	tttccccatc	tgccctccag	48480
agatcactgc	ctgtgctttg	ttaaaaagag	aattatagga	gtcctctcaa	ggcagagagg	48540
cctaaaatta	gacatggcag	ccatgccttt	ggtgtgcatg	gaggttggat	acaggcagcc	48600
agtttccctc	ctgtttcttc	ccttgcttac	acagccaagg	agtgagacca	agcctcaagg	48660
ggaggagctg	tatactcgag	catgcctgt	ggttctctgg	cctgactgag	ggactatttt	48720
atataatcca	atagagaagc	gtggaagaca	tctaggttgc	cactgtcatt	tgaaattgga	48780
atttttaaaa	gagaacctcg	aagacttgaa	gaaagcttcc	ttttgcctcc	ccttacagtt	48840
gatttttgag	cttcttaaa	ctacctagtc	caaagtaccc	acactcttat	tcttttgtct	48900
ttcctactgg	ttttattttt	ttttcatctt	cccagggtgt	tgatgatcac	taagagcttc	48960
aacattgctc	accctgacca	ggtatgaagc	caagagtgtg	gtttagggca	taaaagaatg	49020
tcggaactca	aggactaggt	tgagggtggg	aagggggatg	aaggcttctt	ttttcttggt	49080
gttaagcaga	aataacttag	atctcagagt	gaaagccttg	aattatcaca	tatatcactg	49140
gaaaagacta	gttctttgct	atgataacaa	ttgttcatca	tctctccctc	gaggatttgg	49200
ggtcaaggcc	tggtacaccc	ttttaatgat	ttcagtcatg	tgacttaacc	tctttaaaact	49260
tggattttct	tcctctttac	aatggaaatg	atgacaataa	tactacctc	acagatattg	49320
ataataatga	tatctcacta	ggaagagaat	taagtaatat	gagggataaa	aaggcatttg	49380
taaatggtaa	aatgagatta	tgattttgaa	agctattatt	attttccttt	cactgtctat	49440
tatctcaact	cttctatttt	cttgcctttt	gtacagcatg	gataatttag	atgtgactct	49500
ggacagaggg	atggatcaga	tgacttctta	agttatcttc	cagtttagga	gttcgtaaac	49560
tatactttct	cctttccaga	ctatcctagt	aagaaaattc	tcttttaaga	cagagtagaa	49620
ctctggaatt	catcagtttt	gatgtttctt	aaagtgtaat	ctaagatagt	gctcctgtat	49680
taagttctga	tgtctgacca	ttgttcaaat	aaagagtaaa	atgcaaatga	caggaaattg	49740
gctgcgttct	gaatcctatt	tttatttggg	ataacaataa	gcctgtatgg	tactgtgac	49800
ctttgatttg	ctgtttctgc	aacctcacac	ttgtctcagg	attcttcttc	cacttctgca	49860
ctttatattg	ggtttcttcc	aggcatcata	ttaacttta	agccagggat	gtgtatatgc	49920

-continued

atgggctgtg	ggcctgaaaa	aaattagccc	gagagagaaa	aaaatttaag	tagtgggcta	49980
gaagtaagca	tgctactaga	aacagaattt	gggaacacag	ctctgggcct	agaaaagcga	50040
cctgtcaact	tgttacagtt	aacatcaata	actataggat	gggtttgggtg	gaaaattatg	50100
ctgaccaaca	gggtgggaga	gaatagggtc	agaatatata	tcgctgtaag	gttgagaaaa	50160
aaagaagtga	aaaaaaaaaga	aatgcataga	gagaaaaagg	agtttagagg	taacatgtta	50220
aagtgtaga	aataaactgg	agagcttgac	ttctcttgaa	tatattttta	aataaagtac	50280
tcctttcaac	tccaaatgca	gcaggcttgg	ttcccttctc	ctacctccat	tgcggatgaa	50340
agcttaatct	ttaagatggg	cttgggtggg	tagagtacgc	cccttggtga	gcactgtgct	50400
ctctgcaacc	ccaataaggc	ccaacagggc	tctccaagga	ggcaaaattc	tgatgataca	50460
tttctgttta	gtggaaaatg	ggtagggaaa	attatgtctt	agaatcaatt	aaccaaacat	50520
aaaatccctc	aaggggcttg	gtaggatgcc	tagggaagag	ccacgagata	aaaatccag	50580
gctggaaggg	cattgttgca	gcactgtcat	tctccagttt	ctcttgagtg	tgaccacc	50640
ctctcctttg	ttctcactgc	tgacatcatt	tgtaaaataa	tttcttccct	taaataaaca	50700
agacatacaa	tcctctaact	gactaaagaa	cagttaccta	gaagaaacct	tagtggaaag	50760
tattttcttc	atctaacgga	tgattgtctt	tacagaggtg	gagtaaagga	tgtgcgaggg	50820
agcataatca	agctaagaga	tgcatgctga	cttaaaaggc	atgatatatg	tgaaactaag	50880
ataatgtgtt	caagagtgat	gctttgttga	tgcagaacca	ctgaattcct	tactattatg	50940
tttgctgac	tatcgccctc	ttaataaaga	acttggtgtt	tgagtgttca	ttgaaattag	51000
ccatattagg	tttatgtggg	gatgtgagga	tctatgtcta	ccaattgcag	cctctgctgc	51060
aaattggagg	cagaaatctg	ggctgaacaa	taggtaagag	tgtcaactct	acagatctct	51120
cacatgctaa	gcaagcacia	tataggggca	tccagggtta	cacaaaggat	taatttggga	51180
acaattatcc	tcattttcac	ttcctaaaaa	gattttgaat	aagatgtctt	ttaagtaaga	51240
agctccctga	atgcatttaa	aatatgattt	gattatgtac	atttcagatt	tttctacctt	51300
tctaggagta	tctctgttgt	ataaaaacac	aaaattctgg	aacttttgaa	aggaagatgt	51360
gcctctcttc	atacatttgt	cattcttgaa	cgattgtaaa	atgaagtgc	tgcatatcac	51420
gtcatgtgcc	ctattgattt	cttttcttgt	tttaggaata	ttcccagaaa	aaaaaaaaac	51480
tttttttttt	ttaaaatcta	ctaagcatgc	taggtaagac	tgaagatgaa	tctattttaag	51540
ttatgtcaat	atctatttat	aaagattttt	gtgatattct	tttctactga	gaacttcaag	51600
catatcccaa	aaggaaagggt	tagataacct	tacaaactgt	ggcaatgact	tactgagtaa	51660
ttgctggcaa	ctgatttttg	gtgctctctg	ttttgatagt	atagcagtc	gagtaggttt	51720
cagaagagca	aaactaagac	aatccaggga	aatgccattt	gagaatttct	aactttaaaa	51780
aaacaagtaa	aatagtcca	agaatattat	ctaactaacc	ccaaagtcta	caatgtaact	51840
cttttatttt	gataatgctg	ttctaaccct	atctacttca	gtcctttccc	acccagctgg	51900
tttaggaatc	aaattcccaa	tgtttcatca	ctgttaacat	tactgtttta	ctcttcaact	51960
tagttcttaa	atggcatagt	gtcttaaaat	ccctcagcct	ctttcacatt	tgattttctt	52020
ggaaactttt	taccttttca	ttgaagccca	tatgatcttt	tccgaaacag	acccttatct	52080
ttacctcctt	ctttggagtc	tttctcctac	ttgaatttct	gaacttctta	aaatggccgc	52140
tttggtgttg	tgtagtaaat	tcagtaataa	gttttctttt	cttttttttt	ttttcttttt	52200
ttttgagaca	gagctctgct	ctgtcaccag	gctgcaggct	gtagtgcagt	ggagtgatct	52260
tggctcactg	caacctccac	ctcccgggtt	caagcgattc	ccttgctca	gactcccaag	52320

-continued

tagcaagtag	cagcaccatg	cccagcta	gtttgtattt	ttagtagagt	cggggtttcg	52380
ccatgttggc	caggatgggc	tcgatctctt	gacctcatga	tctgcccgcc	ttgccctccc	52440
aaagtgcctg	gattacaggc	gtgtgccagt	atgccccagc	agtaataagt	tttcttaagt	52500
gctttcttaa	tattctgata	tttttaaaaa	agatctggac	tattttgtca	tacaggcaac	52560
agaatgttaa	accatttcat	aaaacaatga	caaataatac	tgaatttttc	atcagttata	52620
aatgcatttc	ctttataaca	ttgaacatgt	ttttgcaact	gaaataagta	cggttttcat	52680
ttttagaagg	cacatgataa	agttaaggca	gtggttaatt	aattttttca	gattaatttt	52740
tcagaaaagt	gactgtttct	gtctattgtc	ttaaccccag	gcatcaaagg	attttaatca	52800
gaaagaaccg	aggaataatt	tggttatttt	agtgcctttt	tttgagacaa	agtcttattc	52860
tgtctcccag	gctggagtac	agtagtgcgc	tcatggctta	ctacagcctc	gatctcctgg	52920
ttcaagtgat	cctccaactt	cactttccca	gctaactggg	accacaagtg	ggcaccacac	52980
tctctgcaat	ttattttaat	ttttcataga	aatggggctc	cactatgttg	ccctggctgg	53040
tctcagaatc	ctagggtcaa	gcaatccttc	cacctcagcc	tcctaaagtg	ctgtgatttc	53100
aggcataagc	cactacactc	accctatttt	agagctttgt	caagctttgg	aaagaaaacc	53160
atttataata	taatagataa	attatggata	tttgaggcag	tttttatcat	agtatacatg	53220
gtaaaccaca	gccccctttt	ataatatgtg	tatttaataa	aaatgaaaat	attactttta	53280
tcttaaacat	gttttaacaa	agcaagcata	tgtagattag	cactaattaa	aacaaaaacc	53340
tttgtaatga	tagctgtttt	ttatatgatt	acaaaaaatt	tactatacaa	atttttatcc	53400
taatcagtgt	gaaaaactgc	aaatattagc	ttatagggct	agtcttcaga	gtcctcttcc	53460
tacctactac	tgctaataag	ccaatgaaaa	actctctgat	gtgtgtgggtg	gctcaggcct	53520
gtaatcccag	cactttggga	ggccaagggtg	ggtggatcac	ttgcactcag	gagtttaaga	53580
ccagcctggg	caacatgggtg	aaacctgtgc	tctactaaaa	atacaaaaaa	ttagctaggc	53640
gttgtgttac	gcacctgtag	tcccagctac	tcaggaggct	gagggtgggag	gatcacttga	53700
gcccgaggag	ttgaggttgc	agtgaagcaa	gatcacagga	ctgcactcca	gcctgagcta	53760
caaagtgaag	ccttgtcaaa	aagaaagaaa	gaagagagag	agagagagac	aggctcctcc	53820
gctttttcag	ttcctaaata	attttccaat	ctagaatgca	aaagattctg	aaggaagaca	53880
gttaccattt	cagatcgcca	gaagtgtgtg	ctttaatcta	gactogaata	tgttttacat	53940
caaagggttg	cctcaacagt	gctcaaacct	gcctctctga	aaacatgctg	agcacgaagg	54000
ttacttgaag	tcttagcttg	agtacttaag	agagtgtctat	ggagggattg	ttgatgagag	54060
ctgtgtcaca	gctaattttt	cttttagta	taaagggtta	taaaaatctt	acactgtata	54120
ttgacaaatt	tagcaacaaa	atgagcttga	gaaaaaaatc	aaggcctgcc	atggcatctt	54180
tgcttttttt	tcttaaaaaa	aaaacttttt	agaaagatta	tgcgactgta	ttatctgtaa	54240
ctactgcaat	gggtgaaatc	ctgatgggtat	aatttgcttt	ttaaagctat	ctttacttca	54300
gtataactta	gattaaattt	attttaaatt	taaagtatat	ttttctcttt	gtttattatt	54360
ttataatgtt	tcccatagaa	ttcacaaaat	tcattagaaa	gatttttttt	tacttcctta	54420
ggtcattaag	attctgattt	gtcaatggat	ttcacataaa	ccctgtcttt	ccaaaaatat	54480
acaaaaaaaa	aaaaaatagc	caggcgtgat	ggtgcgtgcc	tatagtccca	gctactcaga	54540
aggccgagtt	gggaggattg	cttgaaccca	ggaagtatat	gctgcagtga	gctatggtca	54600
caccactgca	ctccagcctg	ggcaacaaa	tgagacccca	tctccaataa	ataaataaac	54660

-continued

aaataagtaa	ataattttca	ccttgaaaag	cttataaatg	tatgaaatca	caatgagggg	54720
cgctgatata	gtttggatgt	gtgtccctgc	ccaaatttgg	ttttgaattg	taatccccag	54780
tgttggagat	ggggcctgga	gggaggtgat	tggtatcatga	gggcagtttt	ttcatgaatg	54840
gctcagcacc	atcccccttg	tgctgttgtg	gtgatagtaa	gttctcatga	gatctggttg	54900
tatagcacct	ccccccctgc	tctcttggtc	ctgctttcac	catgtgacat	gcctgctccc	54960
ccttcacctt	ctgccataat	tttaagttgc	ctgaggcctc	accagaagcc	gaacagatgc	55020
cggcaccatg	ctttctgcac	agcttgcaaa	gccatgagcc	aattaaacct	cttttttttt	55080
tttttataaa	ttaccagtc	tcaagtattc	tttatagcaa	ggcaagaatg	gacttacaca	55140
gtctcttttg	tatcagggag	agggctctct	tggtgactcc	acttcttttc	ttgttttatg	55200
tatccttcca	gatgatgtat	ttatttccct	tgtttttcaa	ttgatattta	ctcttaaatt	55260
aaactaatta	tttaaaaaag	catttttaaag	tctcatttta	gattattttg	actatctgat	55320
ttttaaaatg	gtttaaaaaa	tctatcttgg	cctccatatg	caatcaaata	agaaacacat	55380
tttaagcata	ttattttacct	tgtggattct	gccttctctc	gtgtgttcag	tctgtgtata	55440
ttcattttctc	ccacactgta	agaagctagt	cagatgtata	attggattat	catgctacat	55500
aatcttagca	cactcatttt	aagcatacat	agactagtga	gcaccactca	ttacatgtca	55560
tttctctaga	gaaactagtt	gggccatggc	tgccaggactc	tcacttgaaa	agacatgtgt	55620
gggtgatgtt	tctcaggcag	ttaagcaata	aagtgtaccc	tgatttgcac	tgaaaataaa	55680
gattccttta	aagggagcag	ttctagtatt	ctctctcttt	aggtaccata	tgtggaacgt	55740
ttttctatgc	actaaaacag	caactaggtt	ttatactctg	ccttacagcc	tacttcacac	55800
ccatttcaca	gggagaggaa	cagagaggta	agtgatttgc	cccaaattac	ataactagga	55860
agttatttgc	tcagtgtgga	aacttgttca	gaaggtcatt	tcattgaaat	gtaggaagag	55920
tttctggcac	ttctcttgag	caggagtcaa	aaaccttttt	ttgcactagc	ccagatagta	55980
aacatttttag	gctttgtggg	ccatatgac	tctgtcaaaa	ctcctctact	tcgttgttgt	56040
agtgcaaaa	gagctataca	caatctgaa	atgaatgggt	gtggccgtgt	tccagtacaa	56100
ccttacagaa	aaggcaatag	gctggatttg	gctctgagac	tgtagtttgc	tgacctcagc	56160
tcttgaactg	agctctttta	ctgacctcag	ctcttgaact	atggtacaag	atcccatggt	56220
cctgttttgt	acctccattt	gcctctcttt	tcactctctg	ggagcatagc	taagttcaaa	56280
attgaattag	gtacttgtag	taagagcata	cttataatcc	tgggatcttc	atgttgccag	56340
atattaacct	cttgaagttt	ttcaccacaa	cctgggcact	tttctgattt	gctcacttct	56400
agccccacct	ttggggccct	tcataagcaa	acatgcagggt	tttccagaga	gctgtatgct	56460
actgaatgca	gaaaatttgg	ctcatactgg	cctatggact	atctgctcac	tgccctgata	56520
actattttcc	aagggagtg	gtgccctacc	tttctacat	gaagtttttt	gctagtcttg	56580
ccctaaaaat	tctaggtatc	ccttgctttt	aggataaata	tgtttcactg	ggaccagctg	56640
gaaaacgaaa	aatagaatta	tccaactacc	actttaaaat	tggacaaaga	cttttgttgt	56700
tgttgttgga	gggggtggta	aacatcattt	tagcagacca	aataactttt	tggtgaaagg	56760
cagcctgttg	caaagacaca	acacttgga	aagattttga	agccctgggt	gcctttacta	56820
ctgacttaac	tacagtattt	gcggacttga	gcaagtgtct	tcccttctgt	gagcctcagg	56880
ttattcatct	ttgaaatgag	tataatacct	gtgattataa	ttacttatct	ggattctgca	56940
gagaattgaa	ggagataatg	ggtgtaaaag	tacttttagcg	cccagcactg	ctccttatga	57000
aatgagggaa	ataattgaga	tgagtgaagc	attgaggcaa	cagtacaaaa	agtgtgtaaa	57060

-continued

actcactgct	taaataagca	cctcttactg	cttttgtggc	actttgtagc	aatgtttttt	57120
ttttttttt	tgagacggag	tcttgetgtc	ttgcccaggc	tggaggttcag	tggcacgac	57180
tcggctcact	gcaacctccg	cctcacaggt	tcaagcattc	tctgacttca	gcctcctgaa	57240
tagctggatt	agaggtgcgt	gccaccacgc	ccagctaatt	tttgtatttt	tagtagagac	57300
gggggttcac	catgttgatc	aggttgggtc	cgaactcctg	acctcatgat	ctgcccgcct	57360
tggcctccca	aaatgctagg	attacagatg	tgagccacgc	caccccacct	cagcaatgtg	57420
tttttattct	gactagaaaa	gtaatgtttg	gttttgtttg	gctctttgct	taatataccc	57480
ataataagg	tacctatttg	cctttggacc	attagttcaa	atattatttt	attaatatgg	57540
aattactggg	ctccagaagc	catagtcttc	ttagctgctc	cctatcccca	ctctcacctc	57600
aatttttttt	tttcactttt	gtttttcttc	tcagggaag	gtttgaggca	aagaatgtct	57660
tcttatgatc	caaaaccaag	catggtggtg	atttattcac	caagagattc	ctaagtacct	57720
gtgtgatgga	catggtagaa	tctttgtcct	gagggagcta	tctagatcca	ttccttctga	57780
tatgcagcca	gtagccactt	gtggtaatgg	agcaatagaa	acaacactag	ttcaagtgga	57840
aacgtgagat	gagaagtagg	aggtggagag	aactaaccag	aagaggggtac	ccaaataaac	57900
cagaaatatg	tatgtgttag	agaagggggc	tattgagcgg	gtggcagtgg	catgtgtggc	57960
attacttgct	cctgtattct	ctgcttttta	cttagttgtg	gctttggtgg	tatagtctca	58020
aatctaagtt	acgtaggtaa	tattgttatg	tatcatgttt	tggcaatgta	gactaaatac	58080
tgctcataa	gagtacagga	caatgaggat	agtttggttt	tgtttactgc	atggaaaatg	58140
caggatgttt	agtaaataga	ttcatggcgt	agtgagtcca	ctactaaaat	cagactctga	58200
gaatgggttt	gatttaaatg	gctagttag	aagactgaat	ttaggccact	tgattgagaa	58260
aggccatttt	gggtaattat	aaaccaccaa	cattgtgttt	tgaatgttaa	agcttatatt	58320
tgtctccag	ttaccagaat	gtaagcttct	tgaggaggga	gagaggagtt	ttcttaattct	58380
ctgaacctgc	acctttcttc	tgtgcctagc	ccagtgcctg	gcaccaaaca	ggtgctcaat	58440
caatgttgat	tctatgttac	caacaaaaat	gagtcacatg	tgtttactat	tcaacaaatg	58500
aatacaattt	tagagtaaat	ttttactgct	tacactacat	gtagattttc	tttttagaga	58560
tttcgcaatg	ctgatttatt	tcaaaataag	cttgaagcta	agcgacaaag	ctgaatgatg	58620
atttgttttt	tatttatttt	taaatccaaa	cttacaattt	tacatgtcat	tgccagaaaa	58680
atcattaaat	aaattatgat	atgcgcatat	ggaatacttt	gcaaccatta	aatcaaccat	58740
taaatactat	gcaaccatta	aatcaaccat	taaatatgtt	ggtatatgca	aatgtgcata	58800
taccaacata	ttatatagtt	gagtaagaaa	agctagtttc	aaatgagtat	gttaatatca	58860
tctgactctt	gcaaaaggaa	aaccatacat	ttgaatgtac	atatatgcac	atgtttatat	58920
gtgcatagaa	aaagctatga	ggggatatac	ctcaagttgc	taaaagtggc	tccacctgga	58980
gagggacatg	gaaaggagtt	ggctaataac	tgaggtttgt	tatgggtatac	acccctgcac	59040
agtttgattt	tttaaaaaa	atgattataa	attactttta	ttattttataa	aaatattatt	59100
taaaattttg	gtactaaaaa	cagagctcca	tcaacaggtc	aatggataaa	gaaaatgtgg	59160
tacatatata	caaccgagta	ctattcgtca	taaaaaaatg	agaccctgtc	atttttgcaa	59220
caaaatggat	ggaactggaa	attattatat	taagtgaat	aaggcaggca	cagaaaggca	59280
aacattgcat	gttctcattt	aatctgtgga	atctaaaaat	caaaacaatt	gaactaatgg	59340
atatagaaag	tagaaggatg	gtaaccaaag	gctagaaaag	atagttgggtg	gggcagggga	59400

-continued

```

gggtgaggtg agcatgttta atgggcacaa aaaaatagaa acaatgaata agacctatta 59460
tgtgatagca caataaggtg actatagtta ataataattt aattgtacat tttaaaaata 59520
ctaaagaggt ataataggat tgattgtaac acaaagaata aatgcttgag ggatgtatac 59580
ctcattctct ataatgtgat tagtacacat tgcattgctc tatcaaaaat ttccatatac 59640
cccataaata tatacatcca ttgtgtactc acaaaattaa aaaaaactgt gcattaaaga 59700
aaaacaaaaa taaaaccat agttcaagtt ataaacaaaa taaaggtaat ttggaggaaa 59760
actgtcttca gttatattgg atatttgggg gacatttttg tatgttagtt agcaaagatc 59820
acttgaaaaa gaagattctt ccttctatga ttcaaggagg cctagcaaaa aataaatgaa 59880
atgaaataaa ataatacaaa gagaaaagat tattccataa attctgctta cttatttctg 59940
gcaaaacttg tgacagcaca tgtgaccttt tggtaaaaag acatttttat atttttagtt 60000
aagtttcaaa tataaattgt ttgtgttttt aaaataaatt aaatggatga ttccagccag 60060
atcattatga aaacacatga gatattgggt tatgcaatga ctaacagtgt gtaccttttc 60120
ttgatattta ttcataaaact ggggaataaa agtacatttt ggccatttta ctccttaaat 60180
aattttatgt ctcccaagga gagttgtaag ttgcttgata gtaaagtcta tgtattttgt 60240
accttagtgt atatattatg ggatttcagc gttagaagag ctcttaaatg ccgtgttcat 60300
agtccaacct gtcttctgat gcttgaaatc cccttgcatg aggaaatgca aagtagagag 60360
cagacactca ataatgtagt tagtgaatta tttagaaaga ggcattttga gcccataatg 60420
tatgataggt acttctacat ttattatttt attcttttga gacctgcaga aaactgtaag 60480
aaaaaagttt atttcagatt catgtgttta ttgattaat ctcttcatag gtttcatttt 60540
tcagctcctg tcagaaaaata cagattctta taaggttcac cttttaccca taagaataat 60600
agtataaagg ggataatgtg aaatacaatc acttcacaga ctgtttcaat taaataagag 60660
ctcgtagata attcagtcga ccacaccca ttttacagat gttgaaattg aagccccac 60720
caaaaggaaa agacttgctc aaagtcacac agcaagtcag tggtgaaacct aattaggccc 60780
cctgccttcc atttttagtg gattcctgtg ctgatagtca taccatatac aaatcctctt 60840
tggcagttat agcttgccca cagtaatgtg tcctgaaaaa tatgacaatt aattaagttg 60900
gagacagaac cataacctct ttataaaaat ttctggaaa gtttacatga cagtaagtaa 60960
tatataatta gaaaggataa ttcttatttc atatttatct ttttgtttca gaataataaa 61020
ctaagctatc tctactcagt ccattttaat acaaaaatat ttttaccgg actgagtttt 61080
tatgcttttt aggaactttg tatctgcctc acttagttaa aatcctagct gcactaatca 61140
cttactgtgg tgggcagaat tctagaatga ccctgaatac cttgtccttg tatgattcct 61200
tcctctttaa gtaaggataa aaactgtgaa tatgatatac ctcccttgat taggctttgt 61260
tatatggcac agttaacttt aagaaaggac caatcacaca agccatttga aagcagaggg 61320
tttgggtatt ttttaactgg tggcagaaaag ccacgcagag atttgaacat tgaggggaat 61380
ttgaatttga tgtgccagta ctaactgaa gatagaggag gctgcatgga aagtggcctt 61440
taggagtgat ccctggctga cagccagtaa gaaaatgagg gcctcagacc tacagccata 61500
aagaattctg tcagtgaact tgaacttga agtggtattc tcctctagaa cttocatata 61560
agagtccagc ctgattgaca ccttgatttt ggacttgtga gacctgagc agagaatcca 61620
gttgacttct gacctaaaaa aaaagtcaga taataaatga gtattgtttt aaactgctaa 61680
ttttgtgata atttgttatg cagcaataaa aaactaatat atttaccatg caaggcaagg 61740
catttatcct ctcattgatt agttttcttt tacctgacat aatggaatta atttatactg 61800

```

-continued

ctgtgaagtt	gtagttgaga	aacatgactt	ctaaagtaat	agaggacatg	tattattaat	61860
tttagtagta	ttaatagtaa	tgatactgat	tctcccaggc	ctatacaaat	cctttgatac	61920
acaaatgaat	agtaaaggaa	cataaattgt	ctctaggtag	actttcccac	aatgcaattt	61980
taggatacag	aggtcatatg	cctgttattc	tactgtggca	gagaaaatat	ggagcctgga	62040
aaactgttca	tttgcacac	atacatcttg	ggagctcact	ctgaacctgg	taccataata	62100
agctctgtag	acagtataaa	gaggaaagga	atcagacatg	gtgtctgacc	tcaagtgtct	62160
cataacgtag	tagaagaggt	aaaatatggg	tcacactaac	tctactgcaa	agtaggaagt	62220
gcttgtcgcc	ttgagattga	caaaatttgg	taagagtcca	gaggagattg	tctgtgaact	62280
gggccttgaa	gaatagttag	gatttgaata	ggagaaggtg	aagaaggaa	gcattccagc	62340
tagggagaag	agcacaaaca	aaagcataga	taaccttgaa	catcatcata	tgggataatt	62400
caatagttca	gtataatgga	agtataagat	gcataaaaat	aagtgtagta	ggaaacaagt	62460
ttaaagtat	agattgggg	tagtcataca	aggccttgaa	tttcaggcta	aggagttag	62520
acattaacat	ttgtttttga	acaaaggggt	gaactgatca	catctgtgat	ttagaaagaa	62580
aattctagca	atagtgtaga	taagggttga	tggtaaagtt	tggaaaggtg	tgaggcagag	62640
gctggagaca	gggagccat	ttaggataga	aagatgataa	agagatgatt	tagaagagtt	62700
gttttgaaa	aggagaagac	agaaaatgtt	ttagaggtgt	catagagata	aaattggcat	62760
ggcatggtgc	aaggaggtaa	agcccaatag	ctttgtaagg	tgctgagata	gattgaaatc	62820
acagagttag	gaagtttttag	agtcaggatt	agtaccaaga	cagcttggct	ctagatctca	62880
tacttaacac	ttacagtata	attctgagag	ggtgggtaac	agcaatagtc	agaggaaaga	62940
acccttttat	acatgatggt	acaggaacaa	cactggcttc	caacccaca	gctgctcttt	63000
aacagaaggt	cagaagctgg	ggagaaatat	gtgtgtgtgt	gtgtgtgtgt	gtgtgtgtgt	63060
gtgtgtgtgt	gtgtgtatgt	gccattttctg	ggactaagga	tgggaagtag	attagttgag	63120
gccactgcag	tggggtctgc	aagttgctag	cactcaccgc	ttccaagagg	ccttaaaggt	63180
gttgatctgt	tccttgggca	tcaccacatt	ccacaaatta	atgttcctct	gagagaatag	63240
ggtgattcaa	tttcaactgtg	cccgaagggt	acttttgggg	ttcatgtttg	ttctaagtct	63300
atgctaata	tctgccaact	gtctgtttgt	cactttctct	aacccttagc	atgtataaac	63360
tgatctgttg	ggaaatgtgt	agcatttata	ggatggtagg	atttgaaca	tcgatacaca	63420
ggactgttta	tatagagtcc	ctgggaaggg	gagagaagag	tatttctgtt	acaaatgtgg	63480
attctttggc	ccctcctcaa	acttactgag	gttcaagaat	tgacatttat	aataagcaca	63540
tatccatttt	caataaacat	gaaagtttca	taccctcttt	taatgtttga	aatcctcaaa	63600
taaattagtc	attggtgcc	gagtatcaaa	taattatggt	acagaatgta	tttctctgaa	63660
tgacaccttc	tcccagagat	tctgatatat	attcctctgc	actcaccctg	tttgataatt	63720
accagtatat	ggaccattta	cctgaagaat	aagagtaggg	tttcctactg	ttgttgaaaa	63780
tttgcttgac	tcttaacaac	ttgtgtgtga	ctgtaacaag	atcacacagg	gtaacaata	63840
ttagcttatt	caaccactgg	ctgaagaaat	ttaggaaagt	gaacacattt	ttctttacat	63900
ttctctttgt	tctgtgagcc	ttttatgctg	gaatagtttt	cactgcaggc	tgttattgtc	63960
tgccctcaga	ggagggaggt	gacctagcag	tggttaactgg	agagtgtttt	tgaaacctc	64020
tttccaaggt	tagttgcaa	tggcatcttt	ggaacagtg	ccttcacttt	tgtccctcag	64080
ggaccagtgt	gagaatggga	actttatgat	ctggagctgg	ttaagtgaag	tccaaaaata	64140

-continued

attaagaaag	tgtttccttc	cctgggaatg	agttcagtag	gaatctcaat	gtattgtaga	64200
gcactaagga	ctcagcctca	ggcatttgca	aaggattctt	ccagttgcct	gtgttacaga	64260
ggacacagtt	ggcatttctt	tttgggtgtg	aggggagatg	tgtacatggt	tgtgagatga	64320
ctcacccttt	ttgcttagat	agttccactt	tcattgtgga	cagactcttt	ggagggccag	64380
tttggcatgc	acgtgtgtgt	tcattccatc	ctggagcatt	ctttatgaga	aagccatttg	64440
ttgagtgggt	tgccattttg	ttttacagcc	actctgtggg	ctatgaaatg	gtcatccggc	64500
cgctttattt	gtccctaaaa	aaagcagttt	ttccctttct	tatcttcatg	gctgccaagc	64560
agcagaaaga	gtaactcagg	gaagccatgt	gatagccttt	tatctgtctg	ttcagaaact	64620
gatgatgtat	tggatttgat	aattcatcaa	atctgagggt	tactggtttg	tatttgcttc	64680
aaaatgggca	tataatat	ttgtcaggtaa	cataatagac	agatcattgg	cattgcttta	64740
ttgaagtga	ttaattcaat	aagcctgtaa	gtgcctgaca	tgtgccaggc	actgtgctag	64800
gcattctgtt	aacagatgag	acaaatctct	gtcttttagg	tgttttcagt	cgaacagggg	64860
agacaaatat	atgagcaaat	tgctattttt	tttaaatttc	atagtgtaca	tgagtataag	64920
gtgctgaata	tgtgattgat	tctgagggaa	aagagagata	agggaaagt	ctcagagaaa	64980
gtcaagctga	gggaagaaaa	gcaccccgaga	cagagggact	agcatagagc	tatgctagta	65040
cattgagttt	aagggaatgg	cacatacttc	actgttgctt	cagcagacag	caggcctgtt	65100
aggttacaaa	gggccttgga	tgacatgctg	aggggtttta	aaattttatt	taaattttaa	65160
ttgacaaaat	ataattgtat	atttctgtga	ggtacaatgt	gacgttatga	tatatgtatg	65220
caatgtagaa	tgattaaatc	aagctaattt	gtatatctac	cacctcacat	acttattttt	65280
tgggttagaac	atttaaaatt	tattctctta	acaactttga	aatagacaac	acattattat	65340
caactgtagt	caccatgttg	tgcatatctc	aaaaacttct	aacaaaaact	ttttaccctt	65400
tgaagatatt	gaactgtttt	atgaacacaa	tcttagaagg	atttaaaaaa	taatttgcta	65460
ttcaccaagt	acttcttacg	tacactgtgc	atgaaatgat	tattactttt	tctaataatta	65520
gttttcttga	ttgaggcttg	gcaattatta	gtttgtatgc	ctttagaagg	atcataagca	65580
gaggtttatc	ccagtaggat	ttgcatttta	gaatgatgac	tttgggagta	aaatacagag	65640
aagtgaiaacc	agagatagtg	ggatcattct	ggagtctgtt	gcctacactg	aacagtagtt	65700
gagcgaaaaa	ggatgggcag	aatgtgttgg	ttctgggtat	tgcaaatcca	tggcacttga	65760
gtgaaaaagt	ttaagccttc	tattggtctc	ttgtgaatat	cttcaacatg	catgactaca	65820
aatagaacac	atggttttgt	tgttattgtt	gttgtgtttt	tgtttttttt	tttatttgag	65880
atggagtttt	gctcttcttg	cccagactgg	agtgcaatgg	cacgaatttg	gctcaccaca	65940
acctccgcct	cccaggttca	agcgattctc	ctgcctcagc	ctcctgagta	gctgggatta	66000
gaatcatgcg	ccaccacacc	cggctaattt	tgtattttta	gtagaaacag	ggtttctcca	66060
tgttgggtcag	gctgtcttga	actcccgacc	tcagatgato	ctccacctc	ggcctcccaa	66120
agtactgaga	ttacgggcat	gagccaccgc	gcccggccca	cacggtattt	ttgaaagaac	66180
agtgagcttg	gattagaaca	ctagtgtcca	ggcctgtctg	ctactacata	agtaattatg	66240
aatccatagc	catcttggtg	ctcttcttct	ctgagccttg	gtttctttag	ctataaaatg	66300
ggaagttaga	actttctagc	tacttctttg	agttatgagt	aacaagttag	gtaatacact	66360
taaaagagaa	tgtgctatac	aaatactggg	tcttaagaca	gctgttggtta	atgtactgag	66420
tattatgctt	acctcacagg	gttattgtga	gcatcaaatg	ggataatgga	tttgaagca	66480
ttttgtttaa	agtgtgatcc	aatgtttaag	aattagtaaa	aatagtaaaa	gaacaattca	66540

-continued

```

ttctccatcc agatgtttctg tccccactgt gacttatgtg ctcattcaga gttgtacaga 66600
aaaaacctcca cttaattttc acaagctgga gttccacatg taacagaatc atatgggacc 66660
aaaaaattctc ctgtattggc ttcttccctg ccgtattttg gctctgggac caacaagaca 66720
cccatTTTTgc atgagctgcc tgccaccaac ttgcgctca catctagttc tgttgcccat 66780
gtgcaagctg aatttgggccc cgggccccc gatctaacaat gaaactcaag ttcccttctg 66840
ttcaaaactgt ccaggcataa tagtcttaaa gtccgatgcc cagcagagcc gtagattttt 66900
cactggccaa aaatcaacat gaaaccagat gtatctgtaa atctagtttc ataacacttt 66960
gtagtcaatg gaaatacagt agcaggcaga ccagaccaga gtttactatt tgcagtggaa 67020
ttaataacca catggaaact ttgccttttg tatctgcgag atggaagata aagggtcgaa 67080
ttcaaagcag ttcccacott accctctaaa ttccaacata aagaggcctt gaatgtcctt 67140
ctatcttatt gtatatttca ttaacagaag tatgttcta gctacttagt cattctatct 67200
ctattctcct ttgttttaac ttcagtgggtg ccagcttaag atgctctggc ttccagcttt 67260
catggagcac gtcagtgttt taaacttacc tttagggaca gaaatgttag gaagatccta 67320
gttctcatc tcttctgctc tgacaaggaa atttagaatt gcctaaagaa aggatgtatt 67380
ggccaaccta ataataaatc agtatttagt aatctaaagc atatttgaaa aatttgtaac 67440
atgagttgaa attcagacct gcaatgaagt gtttttaaaa gatttaaaat cgaaataata 67500
taaaagaatg taaaaacaa gtaaaacata tcactagtta atcactctac caaaattcat 67560
ttttatgttt gcatatttaa ccatttttat ttctatatt tgtccatgaa catgtgtttt 67620
tatatattgt ttatattaaa catggtttta atcatggctt atttctttta tgttttactt 67680
cttttccttt gacataaaat attgtatttt ttaaatttta attgcttctt ggcataccct 67740
tccaatattg gtggctatat agattgaagt taaaactaat tacaatcaga gaaaattaac 67800
aattcatccc ttcaatctca ttagtcacaa gttaaaact caatagccac atctatctag 67860
ttgctactgt tttgaatagt acagatataa gacattttca tcaacacaga aaattcactt 67920
ggaaagcatt gccttgaggt aatgtgcc aactgtacta tatcattttt ctcttgttgg 67980
acatctaagt tatttcttat tttttaaata ttttatataa cttgacgggtg aatataccta 68040
tgtacatagc tatttgcctt ggctgaatta tttcttagaa tcaatttcaa aagtggagtt 68100
attaggtcaa agagcatgag aagatttttt ggaacctgca gtgtattgcc atagtccctc 68160
caaaaaagt ttatgtcaact taaagtactt ctagcagcat atgattgtac taatttcgct 68220
gcaatctcaa caacactgga cattataagt ttttattcta ccctattttc cattaaaaga 68280
tagcttatgc ttgattgact ttgcatttta ttttattatt aataatgatg tggtttcctt 68340
ttttctagat tttattttta ttaaggcat cctttgattt taacctgatt tttttctct 68400
aaaaattatt ctaagaaaag acaaagggtga tacgaaatat atcctgagtt tttattttt 68460
tcttgcatgg gatttgtata ttgacacctt tgcccattta tactatgatt tcttagtgtc 68520
ttccctggca attttaatga agacttcatg tatatcaatt tttccacaaa tataatcttt 68580
ctaaaaatat gttttttcca caatataatt cagacgtatt ctccgaaatg ttggaaaaac 68640
ttaagtaggc atcaaagcat ttgaagattt gtttaaagggt gtgttttata ccagttttaa 68700
attgtaattt aagggtcata aaatagggtga aaattaaatc atttttcagt aagggggcaa 68760
gaccacttaa ctcttggaat atacaggaaa cgtagatttc tagaggccaa gaaggaggt 68820
gggattattt tgtaactgcc cccaaccttc taacctgtaa tgaaacaaac actgaaggcc 68880

```

-continued

cttaaacatt	tttaggctta	attggetgtc	cttgacttta	gggcacatct	aaaaatcctg	68940
aggcaaccac	tcaagagaac	atgcttttgt	taattcaaag	ggagctgtcc	tacgagtgtc	69000
cagaatcctc	tgtagtcttg	ggcctggtgc	ttgagagacc	caaaggaaaag	gtcaatggaa	69060
ttacagctta	gtgtagagc	tttcatgcat	cacactaatt	aattaatgtc	ataaaggtct	69120
ctctcctggt	atgggaaaaa	gcagcaata	ggaacttctg	gtaggggtgc	taaagttggt	69180
ttgatatttt	ttattagcat	ttttaactaa	tacaagtaat	acatgcttat	ggtagaatga	69240
taaaactgaa	aaaaaaggta	tgaaaattta	gaagttctcc	tactcatgac	ctcaccctt	69300
ctttcactcc	cagtttctact	cctcagaggg	taaccacagt	gactagcttc	ttgtgtttgg	69360
ttcctgagat	tttctatgta	tatataattgt	tagatataatg	catgggtatgt	tttcaaaatt	69420
cctgttacac	tataattact	gttctacaac	ttaatttttt	cacttaatta	atagacctta	69480
tatatgcttt	tccatategg	tatatataga	tctatataag	ttttcttaaa	gggtgcacaa	69540
ctttcaattg	tatggtgtgc	ttgtaattta	ctttttgttt	cccttactaa	tggatatttc	69600
atgtttccct	aactcttttg	atattaagag	tagtgtgtgca	attaacatcc	ttgagaggca	69660
gtatatatgg	tgtttaagat	gaatggttct	ggagccagac	tactttggat	tgaatattgg	69720
tgccaccaat	tccttctgtg	atgaccttag	gcaagttgct	taatttcttt	gcctcagtgt	69780
ccttgtgtga	aaaaatggag	gcaataatgg	tcactatcca	gtagggcttt	tatgaggatt	69840
tagtaagtta	ataatgcact	ttaagaactt	agttattttt	agattaagta	gtgaaggact	69900
atataattgt	tagtataatt	gtataccttt	attatcatac	ttttgcatgt	atagcaataa	69960
gacaaattct	tagatgttta	accattggac	ataaggaatg	tacgcatttt	aagtactggt	70020
agatattacc	ttttccctgc	caaaaattgc	aaatattgga	tattaacttt	ttaaacttta	70080
gtaaatctga	taagtataaa	taacagttta	tcatcatttt	aagttgccta	tcttaatttt	70140
gtgtgaaaat	gattatcttt	tcacatgttt	ttttggccat	ttatgtttct	ttccatgtga	70200
actaactggt	cctggccatt	gcctatttgt	tgttgcgtgt	actatatggc	ttttcatctg	70260
tttcttattg	gtttatggag	ctctttgtat	atacaggaat	ttagcctcta	tttatatgtg	70320
tgacaaatc	tttttccaat	ttatctttaa	aatttggtta	tgttttccta	ttcatcagtc	70380
taaaattatg	tagttaaatt	catcattgtt	ttttcttatg	acttttagagt	ttggagatca	70440
tgttcaaaag	gtctttctag	gtggggatga	tttaaatcat	gtactggaag	tatttttgcc	70500
aaaaagactc	acgaattatg	gatgttagag	ctaaaaggga	ccttagagat	ttcctagttc	70560
aaccaccttt	tcttcatacc	tttttaattt	ttctctgcag	atgaaaagaa	gtttagtctc	70620
aaagaaagaa	aagagtctaa	aggttctcca	gtaagcta	ggcaaaaatg	tagactggaa	70680
cttctagctc	ctgatgtgta	tttcagtgtg	cattcaattt	aaccagatgg	tttcacaaaa	70740
agagctttct	actaaaaaat	aaaatacata	cttaagcaac	tcagagaatt	ttttttttat	70800
ttttcagatt	aattttcact	tagagattca	tcagcatatg	tactatacat	gtacaaatca	70860
cctgtgtggt	ttggatattt	agttaaacaa	atgtgcaaat	attttaacca	aaggagcata	70920
ttcatttgtg	ttttattttc	ttaatgggtt	tcgttatgaa	tgtgaaatgt	gtatttacct	70980
taacagaaat	taagtatatt	tttggctctga	catatatgag	aactgaaaag	cattggccttg	71040
gctgctaact	gcattctcat	ctttctttct	ctgctttggc	aaagtctggg	attaaatcta	71100
atacctttta	aactgttttg	gacttcagcc	agagtgcact	gtcttgaatt	cagaactgcg	71160
cagatcattc	cccattctaa	ggccctctca	tgcctctca	ttgcctgtag	gatgagatcc	71220
aagtacctta	gcatagctta	tgcactgtag	tcacttgacc	tctagcacct	atgcagtctt	71280

-continued

ccagtcttat	ttacacattc	ctttgcacat	gctgtttccc	cgtgtggggc	aacttttttc	71340
ttgcctgtct	gcctgcctaa	gccaacttaa	ataaacatca	tttctgtaac	ttctgtgaag	71400
ccttttccaa	tctctccact	ccaagacgaa	ggtgtttcta	taggcatgac	ttctggaatg	71460
gcagatcaag	gatctggtgg	accctctact	cagtgaatac	accgtttaac	tagtaaaat	71520
gatcaatcaa	ccatttaaaa	tcttcagaaa	atatacctaag	ggcacatagc	aaaaagagaa	71580
acatttatct	aagaaaagct	attaagcctc	agtaaaaaa	gcaagagtct	atggcatttg	71640
agtcatgacc	tgttcctaata	ccttcctcta	tctccattct	tcaggcaagt	gcaaccaaga	71700
agatggaggc	ttcctctctc	tcaaaatctt	actccatagt	tataatttca	cccacaatgg	71760
ggcagaccac	aagcatctct	tttttttccc	ccagccctat	attacagaat	cactgttcta	71820
ggaaggcata	gcttagagga	ttggagattc	cttcacaccc	cactttctac	gtatgagggc	71880
tttgccccag	ggatggtaag	tcaagaatac	agggatcctg	cttgtgcctg	cctcagctca	71940
tatataaggt	aaagcttcca	cactaggaaa	ggcaaatata	gaggactagg	gaatataccg	72000
ttatccccag	gggtccacttg	tagaacaggg	gtgtcattct	gggagaagca	ggtcactgcc	72060
ccacttgtag	aacaggggag	tcactcgtca	ctgtccctgg	ttcaaattct	attgcagtga	72120
cagaggttct	gtcccagggg	aaggcagggt	gttaggatgg	agaactccac	agttctccct	72180
gaggtgactg	actttatttg	gaacagagca	tgaagaagtt	catgcctaag	ggcactgtca	72240
aaaataatgg	agatcttggt	ggtgagcaat	taagagtggg	ttggtagctc	catgatacta	72300
gtaacaacaa	gcaaacagc	agaccagcat	ggaggatacc	agagaaccag	acaaaggaat	72360
cactaagaag	agcccttggt	gaattgcact	cactgctggg	tgtgtggaaa	gttatgcatg	72420
tgtgctttac	tgtaccctct	caaaagcaac	ctaaacagga	tgtgggtag	gctctaaagc	72480
attctctaag	ccacacatgg	atccatcagt	aaaatgtgga	gggcttaagg	ataaaaaggc	72540
ttaagtacaa	tctctggccc	tacattttct	aaatgttatg	ccacctgac	caaggggcaa	72600
ctcctacaaa	gccaggcaaa	ataataaaat	catatttgtc	tctagtggaa	tgataacta	72660
tgcctaaaac	tgtgcccttt	gaaaagcaac	tagagagata	atttctgaag	tgtttgtccc	72720
tacctgaatg	tgtggcaaaa	ttctaaactc	cctgaagtgt	gaaagtgggt	tccaagccac	72780
atgcacatcc	agtagtggtg	aagggtgaaa	atctaactgg	ctaagagggc	ttcatagcaa	72840
cattaaccaa	aaagtgggtt	atgtagtctt	tgcctgcttc	ataattccct	aggcatttca	72900
tgtctattctg	tactcagaag	gcttaaagtc	agggttaggg	aaggaggcct	atgaggttac	72960
tgtgcagagg	cagtgtctgg	aaataaatga	agttaaataa	atttaggcca	tcgtggttta	73020
aagaatggat	tgtggagata	agaaggataa	aggaaaccca	gagtcaagaa	aaataaaact	73080
tttcattggt	gccatgccaa	cccatatccg	agcctgaggg	aaaaggaaaa	atgtgtctcc	73140
tgatatacac	ttatacaaaa	tatcaactaa	ttttatttgt	tggaactgaat	agaaaaagtc	73200
aacaaaaatt	aaaaataaaa	aaatcatgac	tatattttta	ataagtgggt	tatgtaaacc	73260
cagagttgac	caatgggatg	ccagtctcaa	ccataaaaac	aaacaaaaca	ttgtgagtaa	73320
caacaccaga	agtctcaaa	gtgcagggaa	accaatttca	cagaagcagt	tcagccaagt	73380
cactaaacaa	acaaacgact	aagcaaaaaa	caagaatgag	tctcagaaa	ggtaagtca	73440
gtatccagag	ttgttacaat	atagtatcta	aaatatttgt	ttgaactaaa	aattttgagg	73500
catgcaaaga	atgaggaaag	tatgactcat	acatggtatt	atatgaaaaa	atcaacaaaa	73560
aactatccat	gaggaaacaa	agatgttgaa	attcactagg	gaaagacttt	aaaaaccagc	73620

-continued

tatttaaata	tattcaaaga	actgaaggaa	ctatgtctaa	aataactaaaa	taaagtataa	73680
taacaatttc	ttgtcaagta	gagaatgcc	ataaagagat	agaagttata	aaaaaagaaa	73740
aaaatggaaa	atctggagtt	gaaaattata	ataactgaaa	tgaaaaattc	actagaaaag	73800
gtcacaagaa	gatataactt	ggcagaagaa	acaatcagca	aattagaaca	tagatcaata	73860
tagattattc	attttgaagg	gtagaagaa	aaaaagaatg	aagaaaactg	aagattccca	73920
aagaaatgta	ggacatctta	aagacacatc	attaggagaa	gaaaagaagg	gaaagaaaag	73980
agcagaaaga	atatttttta	aaaaatggat	aaaatcttcc	aaaatttaat	gaaaaacatc	74040
aacctacaca	tcaaagaaaa	ttttttttaa	acttcaagca	ggaaaatgta	acgatattga	74100
tacttagata	catcatagtc	aaaatattgg	agtcaaatat	aaagagaaaa	ttttgaaatt	74160
agcaagagaa	aatgaaatg	gaaccacaat	aagattaaca	gctgattctc	atcagaaata	74220
acagagagca	gaaggcagtg	caatcccata	ttctaaacgt	tgaagaata	aaaaaactgt	74280
cagtcaagaa	tcatatattc	aacaaaacta	tctttaaagg	taaaaatgaa	atgaagacat	74340
tcttaggtaa	acaaggctg	agagaathtt	tcattagctg	acatgccttg	caagaaatac	74400
taaaagcttc	ctagacagta	gctttaatct	gcatgaaaaa	aaattccaat	aaagggaaat	74460
ttgtaataaa	taaaaataca	tcattatata	ttcttttcca	cttaacttat	ttaaaatcaa	74520
tttcttaaag	cactatctgt	aaaattgtat	tgttatttga	caataaaatg	taaaagaggg	74580
gagtgggaat	taagctaaat	tggagtaagg	aaatggatc	acatggtaaa	ttgaatttac	74640
agaaagaaat	gaaaaaatta	agtggcaaat	atgaagagta	acattaaaaa	cttctataaa	74700
ttaattgtgg	cctcctttct	tcccttagct	tctgtaaaag	acataagact	attaaaaatg	74760
acaataatta	taaacacatt	gttttattag	taataaacat	agacaaatta	tctacaacaa	74820
ttattattat	acaaggagag	ggaatggagc	tgtagaggag	taaagttttt	ataacctact	74880
ggaactaagt	cagtataaat	atgatgtcga	ttctgttaat	ttgagatata	tgtagaagc	74940
cccaaagtaa	tacttgagaa	aatgatgcaa	aaatacagtt	ttaaaaagtt	aaaaacatag	75000
tttagcttat	gtgtgcctag	tactccatta	ttattttttt	attatatttt	aagttctggg	75060
gtacatgtgc	agaatgtgca	ggtttggtac	ataggcatat	atgtgcatg	gtggtttgct	75120
gcacccatca	atccgtcata	tacattaggt	atttctccta	atactatccc	tccccctgtc	75180
ccctaacccc	ctcaacaggc	cctgggtgtg	gatgttcccc	tccctgtgtc	catgtgttct	75240
cattgttcaa	ctccactta	tgagtgagaa	catgcggtgt	ttcgttttct	gttcttgtgt	75300
tagtttgctg	agaatgatgg	tttccagctt	catccatgtc	cttgacagagg	acatgaactc	75360
atccttttta	tggctgcata	gtagtccatc	gtgtatatgt	gccacatttt	ctttctgctt	75420
gttcccagga	gaaagtggct	gaagattcca	gagagaagct	gaatgcagtt	taattctttt	75480
tgccataaac	acgacaaccc	attttcctgc	aagctgtgtt	agtttgctct	cttcttggtt	75540
cattcattca	tttattcata	gcttcataa	atatttaaca	aacactaatt	aggggccaag	75600
ccatgtgcta	ggcacagggg	ataaaactgt	gaacaaaaca	agccccagct	actcttaagg	75660
aactgataga	caaatggacc	agcaaacacg	ctggctcctg	tttgaaggca	aagcgccctg	75720
tgctcctgat	ctcatgagca	cagagcattt	agcctaagtc	tcatcctcct	aaggcctcag	75780
aaataaggcc	ttattttta	aatgtcaagt	cagtcatttg	aagactaaat	catagaatcc	75840
tagaaaaact	gtaccgggag	caaggcaaaa	gaatgggatg	agcatgaaac	atatattcag	75900
aagttgtggg	gtgtaggtat	ataagccaag	ctcttttctt	cacttgcttg	ctaagtcact	75960
tagcttttct	gcctttttgt	ttgctctgtc	tggaaatgga	gttaatgaaa	tatatctaca	76020

-continued

tgataggat	attgagaaga	ttaaataaga	tgctgctgct	accagtatg	cccttaccct	76080
gctgtactta	gaagtatatg	aaattcattt	tctaaatfff	tgtatgagtg	tttcatgcat	76140
gcccaccacc	atggaagcta	ccttaagaca	gtgagggact	ttgtttaact	tgtttgact	76200
acatcctcag	tctaattggg	tctggcttat	ggtaggcacc	aaatataatt	ttattgacag	76260
aaaggatgat	aatgaatgtg	aaggcatttt	taagtttatg	aagtgttggtg	catattgttg	76320
ttaattttta	gctgttaoct	taaagaaccc	ctaatacaac	tctcttgagt	tttatagata	76380
tcatagaaga	tatatcttcc	cttgacatag	aagcttccct	tgaaggttcc	cttgactcat	76440
gtatttgct	cacagtgatt	gtgcagatcc	cacaagataa	atttatgtga	atgtgcttta	76500
tgtgcttgaa	gtgctccaca	aatatgggtt	ttataagatg	agaaaataga	gtcagggaga	76560
aagggtgactg	atccaagggtc	atgcaaagag	ttagtgtcag	aatttataat	ggaatttcag	76620
gtcccaact	cccactccag	tatactaagg	cagattccag	agaagaaaca	gtggagagca	76680
ggcactgatg	agggacaaag	aaaagcaggc	tccgtctggc	tgcaacttgt	ctcttcatgg	76740
caaaaagaaa	ctaggaaagt	gctatgccag	agacgacatg	ataactttgc	agaatggaaa	76800
gagcttggtt	accacattga	atactttatc	tgtgtttatc	taacgacagt	tccaccagct	76860
ctttaccact	tgacttttgc	ctaattcaaa	aatataccaa	ctatgaaaca	ttttccttct	76920
cagtttttat	tctagattac	attttgttca	actttatctt	aatgtgtagt	gtagaaagag	76980
taaggtaaga	gtatagcaag	tggttatfff	ccatttctac	tgaggacaga	gaaataatct	77040
aagggtattg	tattagagat	gaagaagtgc	atggccagga	catgagagat	actgtgatag	77100
aatggatatt	gtgaagtctt	tggtagtfff	tgaggggaaa	aaagagaagg	ttttctttgt	77160
ctgatatagt	ttagcaacgt	cttaatttag	gattcaaaaag	ttgttcaggg	tccatcttgg	77220
ccttcaaatt	aagatgcctt	ttgagagata	acattgttgt	tttcaaactc	tgttctgtga	77280
cttaagaatg	agaggagaag	gaagaaaaga	ggagaaaatt	tgagggaaaa	gtgcccaagc	77340
agcgtcaagg	ctagacactg	gaaattttatc	aatgaaagcc	acatggtgga	tggaatcag	77400
atatgtgcat	caattatttg	tgttccaatc	catatagaag	taccgtataa	tgaccaagc	77460
taataagggtc	tttgaagaa	gaccatacaa	gtggagatgt	gttccatttc	tatctagggg	77520
tagagttagg	aagggttca	ttgaataagt	ggtagcctct	tggtgtgaga	cctgagttat	77580
gagatgatgt	ggcaaaggag	acagatggct	gggggcaagg	tggtgtcatt	gaaattggag	77640
gcagtagcaa	tataagcaaa	gctacagggg	catgaaaaag	caagggttaga	ttagtgaatt	77700
gcaacagggt	ggtactgctg	gaaggtcaca	tggaagagat	tgtgaaggta	ttgagataag	77760
aagctagaaa	taagctttga	atgccatcct	agtactttga	atttgcattg	tgtaagccaa	77820
gtggttttca	cttggtcatt	taataaaaatt	acagattctc	aggtctcacc	tgtaacttca	77880
gattcagaag	agtctgctaa	ctgaagggtg	aatcagtggt	ccatattgct	aattagctcc	77940
tcagaggatt	ctaataatc	agtgaattat	gaccactgct	gtaagccata	ggtagttatt	78000
gaaagctgct	atggagagga	gccacagaag	cagatgtttt	agataggatt	cctctggggg	78060
cctgtgtaat	ttatggactg	gagaggatca	gacagggaagc	agaaagactt	gaataagaca	78120
gttgtagtta	ttttggaggc	aaagattctc	tctctctctc	tctgtgtgtg	tgtgtgtgtg	78180
tgtaattgta	ggaactatff	aggcagtaaa	attaacagat	attagtcact	gattgactga	78240
gtggatggca	gtgatagggtg	gggtgcgttg	agggaaggtg	attacattaa	gtccaggatg	78300
actcatgggt	ttctaagttg	agtcattggg	gattgccatc	caatgtgaga	aactatatag	78360

-continued

tcttatcata	ggtgatcttg	gaggtagact	tgaattaaaa	tcttgaagcc	atcaattgct	78420
gtatgtgggt	cttgggcaga	acacttaagg	tttctggacc	tcagttatct	cttctgtaaa	78480
atgaggaaaa	taatgcatac	ctcatgcatt	tgttgtaaag	actaaatgag	gttaaagtat	78540
gtagagtgtg	gttagtaaac	tgggacgtat	agtggccag	taaacatcag	ctgttattat	78600
tgtgctatat	gttgatgagt	gtactggagt	gagatgggg	aggggatttt	ttagtctctg	78660
ccaatgactc	ctctcccat	gatcaaaac	agaaaatcag	tctcttatgt	gttgaggagt	78720
gagacacttc	tccaagtgt	ttaaggctaa	taccttgcc	tgttttgcc	tgggcccag	78780
ctcactacac	atctgtttaa	gagatcagg	taagctctgt	tcttggtgag	tatctcaatg	78840
gggctgtttt	tctagtctct	gtagtctct	tgggccaaca	tgaatgtct	aacctgggt	78900
tcttggttgt	ggattctctg	caacatttca	ctgctaccca	agttgtgtct	gcttacatga	78960
tgctatcttc	cttcttttgg	gtttctgaag	ccctcagaca	cttggtgaa	cattttttcac	79020
atttcttaag	ctatatcatc	tgtgttttcc	ctgccacaga	caaagtcaca	aaaggacttt	79080
aagataggtt	tgggtttttt	ttttcccag	ggtttttata	cattttgggt	aagggaagt	79140
ggtaaatgct	gcttttctgc	cttaaccagt	agtgtctgac	agaggaggta	gcatgatgat	79200
tgcagagctc	actggactga	aagtcagatg	ctttaccgc	ctagactcta	gtaccaagg	79260
gaagatggag	tgagatggg	taaatggga	gaaattacca	tttatttga	gtgtgccagg	79320
ccttttctca	tgtattgtct	aatgcatttg	tcacaattct	ctttgggtt	gaaatgtgat	79380
tttcttcatt	ttatagataa	ggaaacttat	gggaaggag	gttaggttca	tcttgtgcc	79440
aactttacat	ggctagtgat	caataatagt	gagattcaaa	ctcagatttc	tctgcccaca	79500
agcctttgct	tttctctct	ttgacactgt	aactaatgag	aagatgtatt	taactctgag	79560
tctcatctgc	ctcaactgta	aaatggagct	ctgtaactct	tgtctgtgat	gacagtaaat	79620
ctcctcagac	cagacttatg	ataggggata	aggatatttg	tatctttggg	cccctaattg	79680
attgaaagt	cttctaagt	cctggcacat	agaagggcac	tcaataaata	tttaccacat	79740
tttcagaaaa	gagggtagct	ccataatgg	tgagatacat	tttgggtgg	actgtagtgt	79800
ttaatgcttt	taccatctgt	taaaatgatt	ttggagtata	gctagataac	tgatgatggt	79860
tgttatatag	attttttcat	agggttgcct	ttccaaattc	tatgccgtgg	aagaagttaa	79920
atatccagaa	tttgacagga	aatattattc	tacaacagat	ccctggcgta	agaatgataa	79980
cacctgtgtt	ctagtctcag	acttgccct	gaataactgt	ttctctggt	caattctctg	80040
tctctatcta	ggcttgaat	ttccccaaa	tgatgaagga	gttggactag	tttagtggg	80100
ttcagcctcg	agtggccatt	aaaattatct	ggggatcttt	gaaaaaaatt	agatgccag	80160
atttttgcg	ttgttgtgt	tgtttttgt	tgtttgttt	ttaattatac	tttaagtct	80220
gggatacatg	tgcagaacat	gcaggtttgt	tacataggt	tacacgtgcc	atgggtgtt	80280
gctgcaccca	tcaaccgctc	atctacatta	ggtattttct	ctaattgtat	ccctccctag	80340
tcccctaacc	ccagacaggc	cctggtgtgt	gatgttcccc	tcctgtgtc	tatgtgtct	80400
cattgttcag	ctccccctta	tgagtgagaa	cgtgcagtgt	ttggttttct	gttctgtgt	80460
tagtttgcg	agaatgatgg	ttccagttt	catccatgtt	ctttcaaagg	acatgaacct	80520
atcctttttt	atggtggcct	gatattccat	ggtgtattga	actgctcact	ccagtccaat	80580
taaatcagaa	tacagaatgt	tgagaggagc	atcagtattt	taagaaggcc	ccctagttaa	80640
gttcaatgtg	cagccaagg	tgagaaacac	tggactagat	gattgataag	ggccatccaa	80700
ctttgatagt	caacaagaga	caatgctata	gagtatggtg	gacagagcat	gggctttaga	80760

-continued

gttagccagg	tatgcattca	gacctgggt	ctgttactta	ctagttgtgt	gatcttgaag	80820
aaatcaaaat	ggagatacac	tatgtacctg	gcagtaatag	ttgtggggat	taagcacctt	80880
caccagagct	taggacataa	taagcccca	gtaaatagct	tctttaatat	cagaagttca	80940
gatggaagat	gtgagaaaa	tattggttca	gtaagattta	acaggtaaat	taaaatcaag	81000
tatttgaaaa	cattttcctg	tttctttagc	aatggattcc	agaaacataa	tgtggaaata	81060
gctctcagtc	cttagatttg	atgacattgc	agaaagaaat	ctggctagtc	gtcccatggc	81120
tgattggcta	tgatggctag	aaagccattg	gaaaaaaaa	attggctcac	agaagacagc	81180
agatgtggct	tgggaaatgc	aaggacatga	ctgtaataag	gatttgtcta	tccagcccca	81240
tttatgagag	tgattccagg	agaaaaggac	agatttgtat	tgtcagtggt	atcgctgtt	81300
aaaaaacact	tttctacta	ccactccagc	tgtcttgcca	tgttgttggt	tgatgtaagc	81360
tacagaaaa	ggaaatcacc	aatagggcta	tagcaacctg	atgcatagtg	acaagtaatt	81420
gttctattca	tggttatgtg	ttgtacagag	cacttgctgc	atgtcagggt	tgagacttga	81480
gtatgcatta	gggccatgga	cacccccatc	ttatctttaa	gtagatttca	aagtaaatat	81540
ttgatgaata	tgtaaaatat	ttagtttggt	cagtcatagg	gctgagaaca	tggtggcagt	81600
tacctcctag	tatctgcaag	caaaaaaagt	ttttctctcc	tatagcaatt	gccatctcag	81660
ccacttttgc	agcattttct	tttctacac	tttgcattaa	ccatttgtgc	acttgtctta	81720
gcctcaaaac	ggccatgaaa	gctccttgag	gataggggct	atgtcttttt	catctttata	81780
tatgcatcat	ttagcagagc	tgtcccttta	taatgtacta	attactgaat	gaagggatgc	81840
atagatgaat	aaatgaatga	aaagtaggag	tgacctgtct	tctctctttc	ttcacgatgg	81900
ggactagtgt	gtgtatataa	ggggataatt	tttgtgtcac	ataaaatata	accttactta	81960
gaaggaaga	cttcacgaat	ggtggaatga	gaaccacccc	cccgcccca	taaatccgcc	82020
ctttcatgaa	agcagtga	acgctagcaa	acgttgtgaa	aattaacttt	tccagaactc	82080
tggaaaggaa	acagaggctt	ccaacaatct	gagaagaatg	tattcaagaa	aaacttcggt	82140
aagctctctg	atcacagtgg	aaataataaa	caattagtaa	tagaaggata	gttgggaaat	82200
tcaccatttg	tgggatataa	acagtggatc	aaagaagaaa	tcataaggga	aatgagaaaa	82260
tactttgaga	ttaatgaaaa	tgaaaataca	ttgttccaaa	acttacagga	tacagccaag	82320
ctaaagcagt	acttaaaggg	aaatttgtaa	ctgcgaaggg	ctatatcaac	aaagacaaat	82380
gatctcaaat	caagaacctc	accttcacc	ttagactagg	aaaggaacag	caaaactaca	82440
agaaagcagg	aagaaagact	aataaagact	aaaagggaaa	taaatgaaat	aatagagtag	82500
aaaaacacta	gaatcaatga	aattaacat	tgattctttg	aagagatcaa	caaaactgaa	82560
aaaaacttta	gtcagattga	ataagaaaa	aagagagaaa	attcaaatta	tcaaatgag	82620
caatgaaat	ggggccatca	ctacctacct	taaaagaat	tttcaaagga	ttaaagaaa	82680
atgccattgc	attagtctcat	tctcacacaa	ctataaaaa	gctacctgag	atggggtagt	82740
ttatgaagaa	aagcgttcta	attgactcac	agttccacag	tctgtacagc	aggcatggat	82800
catgaggcct	taggaaat	acatcaggtg	aaaggctaag	gggcatggaa	gacatgtctt	82860
cacacggcag	caggagagag	agcaaagagg	gaagtgccac	acacttttaa	accatcagct	82920
ctcatgacaa	ctcactcact	atcatgagaa	cagcaagggg	aaaatctgcc	ctcatgatcc	82980
aattacttcc	taccaggctc	cttccccaac	actggaaatt	acaattcaac	gtgcgatttg	83040
gatggtgtga	cacagagcaa	aaccatatca	accatactgt	atgccaaaa	attagatgac	83100

-continued

ctagatgaaa	tggaacaaata	ctcagaaaaa	cacaaactat	ctaaagtgc	cagtgaagaa	83160
acagaaaatc	tgagtagtcc	tgtaacaagt	cctgtaacaa	aactggatta	gtaattaaga	83220
aacttccac	aaagaaaagc	ccaggttcag	tcttcactgg	tgaatactat	caaatattta	83280
aggaagattt	aatccttcac	aaattatttc	aaaacttgga	agaggctgga	accctttcca	83340
actaattctg	caaagtcagc	attaccctga	tgccaaaacc	aaagatatga	cacaaaaata	83400
aaactgcagg	ctaataatc	atttgaatat	agataacttt	ctaaaaatct	caacaaaatg	83460
ctagcaaaac	gaattcagca	acaaataaaa	agggttataa	agggtgacca	agtaggattt	83520
atctctggaa	tgtaaattaa	cattcaaaaa	cctaagaata	ggaggaaact	ttcttaactt	83580
tgtaatggac	atctctgaaa	aacacacagc	taacatcata	ctaaataggg	aaagattgaa	83640
atttttcctt	gtaagatcag	gaacaagaca	aggatgactg	ttctcaccat	ttcaatttac	83700
cattgtattg	tagattcaag	tcaaggcaat	taggcacaaa	aaaaaaaaa	aaaaaaaaa	83760
aaaaagaaa	aggtaaaagg	cacccatatt	ggaaaggaag	agggtgaaa	atctatattc	83820
acagatgaca	tgatcttata	caaagaaaac	cttaaggaat	ccatgataaa	ctattaaaac	83880
gagtaaacga	gttcagcaag	gtttcagaat	acaagattaa	tgtgcacaaa	tcaattgtat	83940
ttctgtacac	tagcaatgag	caatctgaaa	atgagattaa	gaaaacagtt	cactcacaat	84000
ataatcaaaa	taccagaata	cttaaaaaata	aatttaacaa	agaagcgta	agacttgat	84060
gctgcacaa	acaaaacact	gtggaaagta	attaaaaatc	taataaata	gaaaaacatc	84120
ccttgttcac	gtactagagg	actcaatatt	gtcaagatgg	aaatactccc	caaagattga	84180
aggaaatccc	tatcaaaata	ctggctgttt	tcttagcaga	aatgaaaat	ctgaccctaa	84240
aattaatatt	taaatacatg	gaacctagga	taaccacaa	aatattgaga	aagaaaaaca	84300
aagtcggcgt	acccatgctt	cctgattcca	aaccttatta	caaagcagtg	gtaatcaaga	84360
gtgtatggta	ttggcataag	gacaaacaga	tcaataaatg	gaatactatt	gagaatccaa	84420
aagttaactc	ttacatttaa	gaccaattga	ctttcaaaag	tggtgctaag	acatttcaat	84480
gaggaaagaa	tagtcttttc	aataaattgt	actggaaaa	ttggatatcc	acatgaaaat	84540
aaaagatttt	ggaccacttc	aaacctgcaa	aaaaaataaa	atgatctcat	ggtgtatcat	84600
ggatctaata	gctatagagc	taagatgata	aatctcagaa	gaaaatatca	aagtaaatct	84660
ttatgacctt	gaagtaggca	atgggttttt	ggctataaca	ccaaaagcac	aagcaataag	84720
agaaaaaaa	ttttttttaa	aaaacccttg	attattttat	taaaattttg	ttgtgggtac	84780
aaagtaggtg	tgtatattta	tgggggtatat	gagatatttt	gatacaggca	tacaatgttc	84840
aatgatcata	ttaggataaa	tgaagtatcc	agtaacctca	gcattttatca	tttgtgttac	84900
aaacaatcca	attatactct	tttagttatt	tttaaatgta	cagtacatta	ttattgtagt	84960
cattcccttg	tgctatcaaa	tactatatgt	tattcattct	atctaactat	attattgtac	85020
ccattaacca	tccccactcc	cctgcctccc	agctacactt	cgtagcatct	ggtaaccatg	85080
atttcctctt	atctccatga	gttcagtagt	ttcagctcat	ggagatagac	agaactaatt	85140
ttattagctc	ccacaaatta	gtccccatgt	cagaacatgt	aaagtttgtc	tttctgtgcc	85200
aggtttattt	cacataacat	aacgaactct	agttccaacc	atgttggtgc	aaatgacag	85260
ctctctcttt	tttttttttt	tttttttttt	tgagatggag	tctggctgtc	tcccaggctg	85320
gactgcagtg	gtgcaatctc	agctcactgc	aagctccgcc	tcccagggtc	atgccattct	85380
cctgcctcag	cctcctgagt	agctgggact	acaggcacco	gccaccatgc	ccgactaatt	85440
ttatatatat	atatatatat	atatatttat	tattattata	ctttaagttt	tagggtacat	85500

-continued

gtgcacaatg	tgacaggttag	ttacatatgt	atacatgtgc	catgcaggtg	cgctgcaccc	85560
actaactcat	catctageat	taggtatata	tcccacatgct	atccctcccc	cctccccccac	85620
cccacaacat	tccccagagt	gtgatgttcc	ccttcctctg	tccatgtgtt	ctcattgttc	85680
aattcccacc	tatgagttag	aacatgcggt	gtttggtttt	ttgttcttgc	gatagtttac	85740
tgagaatgat	gatttccaat	ttcatccatg	tccctacaaa	ggacatgaac	tcacctcttt	85800
ttatggctgc	atagtattcc	atgggtgtata	tgtgccacat	tttcttaatc	cagtctatca	85860
ttgttgagca	tttgggttgg	ttccaagtct	ttgctattgt	gaataatgcc	gcaatgaaca	85920
tacgtgtgca	tgtgtcttta	tagcagcatg	atttatagtc	ctttgggtat	atacccagta	85980
atgggatggc	tggttcaaat	ggtatttcta	gttctagatc	cctgaggaat	caccacactg	86040
acttccacaa	gggttgaact	agtttacagt	cccaccaaca	gtgtcaaagt	gttctatttt	86100
ctccacatcc	tctccagcac	ctgttggttc	ctgacttttt	aatgattgcc	attctaactg	86160
gcgtgagatg	atatctcatt	gtgggtttga	tttgcatttc	tctgatggcc	agtgatgggtg	86220
agcatttttt	catgtgtttt	ttgggtgcat	aaatgtcttc	tttttagaag	tgtctgttca	86280
tatccttcgc	ccactttttg	atggggtcgt	ttgttttttt	cttgtaaatt	tgtttgagtt	86340
cattgtagat	tctggatatt	agccctttgt	cagatgagta	cgttgcgaaa	attttctctc	86400
attttgtagg	ttgcctgttc	aatctgatgg	tagtttcttt	tgtctgtcag	aagctcttta	86460
gttgaaatag	atcccatttg	tcaattttga	cttttggtgt	tttagacatg	cttttggtgt	86520
tttagacatg	aagtccttgc	ccatgcctat	gtcctgaatg	gtaatgccta	ggttttcttc	86580
taggggtttt	atgggttttag	gtctaacgtt	taagtcttta	atccatctcg	aattgatttt	86640
tgtataaggt	gtaaggaagg	gatccagttt	cagctttcta	catatggcta	gccagttttt	86700
ccagcaccat	ttattaaata	gggaatcctt	gccccattgc	ttatttttgt	cagggtttgtc	86760
aaagatcaga	tagttgtaga	tatgcggcat	tatttctgag	ggctctgttc	tgtttcattg	86820
atctatatct	ctcttttggg	accagtagca	tgtctgtttg	attactgtag	ccttgtagta	86880
tagttagaag	tcagggtgag	tgatgcctcc	agctttgttc	ttttggctta	ggattgactt	86940
ggggatgtgg	gctctttttt	ggttccatat	gaactttaaa	gtagtttttt	ccaattctgt	87000
gaagaaagtc	atcagtagct	tgatggggat	ggcattgaat	ctataaatta	ccttgggcag	87060
tatggccatt	ttcacgatat	tgattcttcc	tacccatgag	catggaatgt	tcttccattt	87120
gtttgtatcc	tcttttatat	ccttgagcag	tgggtttgtg	ttctccttga	agaggctcct	87180
cacatccctt	gaaagttgga	ttcctaggta	ttttattctc	tttgaagcaa	ttgtgaatgg	87240
gagttcactc	atgatttggc	tctctgtttg	tctgttattg	gtgtataaga	atgctgtgat	87300
ttttgtacat	tgattttgta	tcctgagact	ttgctgaagt	tgcttatcag	cttaaggaga	87360
ttttgggctg	agacaacggg	gttttctaga	tatacaatca	tgtcatctgc	aaacagggac	87420
aatttgactt	cctcttttcc	taattgaata	ccctttattt	ccttctctctg	cctaattgcc	87480
ctggccagaa	cttccaacac	tatgttgaat	aggagtgggtg	agagagggca	tccctgtcct	87540
gtgccagttt	tcaaagagaa	tgettccagt	ttttgaccat	tcagtatgtt	attggctgtg	87600
ggtttgcatt	agatagctct	tattatttta	aaatacggcc	catcaatacc	taatttattg	87660
agagttttta	gcatgaagcg	ttattgaatt	ttgtcaaagg	ccttttctgc	atctattgag	87720
ataatcatgt	ggtttttctg	tttggttctg	tttatatgct	ggattacatt	tattgatttg	87780
cgtatattga	accagccttg	catcccaagg	atgaagccca	cttgatcatg	gtggataagc	87840

-continued

tttttgatgt	gctgctggat	tccgtttgcc	agtattttat	tgaggatttt	tgcatcaatg	87900
ttcatcaagc	atattgggtct	aaaattctct	tttttggttg	tgtctctgcc	cgtcttttgt	87960
atcaggatga	tgtcggcctc	ataaaatgag	ttagggagga	ttccctcttt	ttctattgat	88020
tggaaatagt	tcagaaggaa	tgttaccagt	tcctccttgt	acctctgata	gaattcggct	88080
gtgaatccat	ctggctctgg	actctttttg	gttggttaagc	tattgattat	tgccacaatt	88140
tcagatcctg	ttattgggtct	attcagagat	tcaacttctt	cctgggttag	tcttgggag	88200
gtgtatgtgt	caaggaaatt	atccatttct	tctagatttt	ctagtattat	tgcttagagg	88260
tgtttgtagt	attctctgat	ggtagtttgt	atttctgtgg	gatcgggtgt	gatatcccct	88320
ttatcatttt	ttattgtgtc	tatttgatc	ttctctcttt	tttcttttat	tagtcttget	88380
agcagtctat	caattttgtt	gaccccttca	aaaaaccacc	tcctggattc	attaattttt	88440
tgaaggggtt	tttgtgtctc	tatttccttt	agttctgtct	tgattttagt	tatttcttgc	88500
cttctgctag	cttttgatg	tgtttgtctc	tgcttttcta	gttcttttaa	ttgtgatgtt	88560
aggggtgtcaa	ttttggatct	ttcctgcttt	ctcttgctgg	catttagtgc	tataaatttc	88620
cctctacaca	ctgctttgaa	tgtgtcccag	agattctggt	atgttgtgtc	tttgttctct	88680
ttggtttcaa	agaacatctt	tatttctgcc	ttcatttctg	tatgtaccca	gtagtcattc	88740
aggagcaggt	tgttcagttt	ccatgtagtt	gagcggtttt	gagtgcagatt	cttaatactg	88800
agttctagtt	tgattgtcac	gtggctctgag	agatagtttg	ttataatttc	tgttctttta	88860
catttgctga	ggagagcttt	acttccaaact	atgtgggtcaa	ttttggaata	ggtgtgggtgt	88920
ggtgctgaaa	aaaatgtata	ttctgttgat	ttggggtaga	gagttctgta	gatgtctatt	88980
aggtctgctt	ggtgcagagc	tgagttcaat	tcctgggtat	ccttggttaac	tttctgtctc	89040
gttgatctgt	ctaagtgtga	cagtgggggtg	ttaaagtctc	ccattattaa	tgtgtgagag	89100
tctaagtctc	tttgtaggtc	actaaggact	tgctttatga	atctgggtgc	tcctgtattg	89160
ggtgcatata	tatttaggat	acttagctct	tcttggtgaa	tgatccctt	taccattatg	89220
taatggcctt	ctttgtctct	tttgatcttt	gttggtttaa	agtctgtttt	atcagagact	89280
agaattgtaa	cccctgcctt	ttttttgttt	tcattttgct	tggtagatct	tcctccatcc	89340
ttttattttg	agcctatgtg	tgtctctgca	tatgagatgg	gtttcctgaa	tacagcacac	89400
tgatgggtct	tgactcttta	tccaatttgc	cagtctgtgt	cttttaattg	gagcatttag	89460
tccatttaca	tttaaagtta	atattgttat	gtgtgaattt	tatcctgtca	ttatgatatt	89520
agctgggtat	tttgctcgtt	agttgatgca	gtttcttctt	agtcctgatg	gtctttacat	89580
tttgcatga	ttttgcagcg	gctgggtacc	gtcgttctct	tcctgtttta	gtgcttctct	89640
caggacctct	tttagggcag	gcctgggtgt	gacaaaatct	ctcggcattt	gcttgtctgt	89700
aaaggatttt	atttctcctt	cacttatgaa	gcttagtttg	gctggatatg	aaattctggg	89760
ttgaaaaatc	ttttctttat	gaatgttgaa	tattggcccc	tactctcttc	tggtctgtaa	89820
agtttctgcc	gagagatctg	ctgttagtct	gatgggcttc	cctttgaggg	taacctgacc	89880
tttctctctg	gctgccctta	acattttttc	cttcatttca	acttttttga	atctgacaa	89940
tatgtgtctt	ggagtgtctc	ttctcaagga	gtatctttgt	ggcattctct	gtatttctct	90000
aatctgaatg	ttggcctgcc	ttgctagact	ggggagggttc	tcctggataa	tatcctgcag	90060
agtgttttcc	aacttggttc	cattctcccc	gtcaatttca	ggtacaccaa	tcagacatag	90120
atttggtctt	ttcccatagt	cccataattc	ttggaggctt	tgctcgtttc	ttttattctt	90180
ttttctctca	aagttccctt	ctcacttcat	ttcattcatt	tcattctcca	tcgctgatac	90240

-continued

```

cctttcttcc agttgatgc attggctcct gaggtttctg cattcttcac gtagttctcg 90300
agccttagtt ttcagctcca tcagctcctt taagcacttc tctgtattgg ttattctagt 90360
tatacattct tctaaatttt ttccaagtgt ttcaacttct ttgcctttgg ttggaatgtc 90420
ctcccatagc ttggagtaat ttgattgtct gaagccttct tctctcatct catcaaagtc 90480
attctctgtc cagctttgtt ccgttgtctg tgaggaactg cgttcctttg gaggaggaga 90540
ggcgtctctc ttttttagtgt ttccagtttt tctgtctctg ttttcccat ctttgtggtt 90600
ttatctactt ttggtgtttg atgatggtga tgtacagatg gggttttggg gtggatgtcc 90660
tttctgtttt ttagttttcc ttctaagaga caggaccctc agctgcagggt ctgttgagggt 90720
acccggccgt gtgagggtgc agtctgcccc tgctgggggg tgccctccag ttaggctgct 90780
caggggctag gggtcaggga cccacttgag gaggcagtct gccattctc agatctccag 90840
ctgcgtgctg ggagaaccac tgctctcttc aaagctgtcc aacagggaca tttaagtctg 90900
cagagggtac tgctgtcttt ttgtttgtct atgccctgcc ccagagggtg aagcctatag 90960
aggcaggcag gccctcttga gctgtgggtg gctccacca gttcgagctt ccagctgct 91020
ttgtttacct aagcaagcct gggcaatggc aggtgccct cccccagcct cgctgccacc 91080
ttgcagtttg atctcagact gctgtgctag caataagcaa gactccatgg gcgtaggacc 91140
ctctgagcca tgtgcgggat ataatctct ggtgcgccgt tttttaagcc cgtcagaaaa 91200
acgcagtatt tgggtgggag tgacccaatt ttccagggtc cgtctgtcac ccctttcttt 91260
gactaggaat gggaaactcc tgacccttg cgttcccgga gtgaggcaat gcctcgccct 91320
gcttcggctc acacacgggt cgtgcaccc actgaactgc gccactgtc tggcactccc 91380
tagtgagatg agcccgtac ctcatagga aatgcagaaa tcaccgtct tctgcttcgc 91440
tcctgctggg agctgtagac ctgagctgtt cctattcgcc catcttggtt ccagaaaaaa 91500
aaattgttaa attggacttc atcaaatgtt aaattttgt gctgcaaat ataccatcaa 91560
gaaagtgaat atctaccca cagaatgaga gaaagtattt gcaaatcata tatctgataa 91620
gggtattgaa tttagaatat ataagaact cttgcaactc aatataaaaa gacaacccaa 91680
ttttaaaatg ggcaagtat ttgaatagaa atttcttgat agaagatata caaatttaaa 91740
aatgctcaac atcattagtc attagggaaa tgcagatcaa aaccaaattg agataccggt 91800
ttacacctat taagatggct atagaataaa agaacaata acaagtattg gctttaatgt 91860
ggaggagcca gaacccttat atattgctgg taaaatgtaa agtcatgcag ccctttgaaa 91920
tacagtctgc aagtctttaa aaaattacta tttgttattt gggttttctt cacttttaat 91980
ttaggttcag aggtacatat gcaggtttgc tatatagcta aattgtgtgt cacaggagtt 92040
tagtgtacac attatttcat caccaggta ataagcatgg tacccaatag gtagtttttc 92100
tatcctcacc ctctctctac cctccaccat caagtaggcc ctggtgcctc ttgttctttt 92160
ctttgtgttc atatgtactc aatatttagc ttccacttat cagtgagaac atgtggtatt 92220
tggttttctg ttctgtctt agtttgctta ggatactggc ctccagattc atccacgttg 92280
ctgcaaagga catgatctca ttctttttgc atagtatact atggtgtaca tgtatcaaaa 92340
atgttactgt ttgacctagt aattctattc caaggtaaat actcaagaga aatgaaaaca 92400
tgtccacaca aatacttgta cacaaatgtt cattgcagca ttatttataa tagccaaaga 92460
gtggacgaca aatgtcttcc aaatgtgggc tccaaatgtc caccaactga taaatggaaa 92520
aacaaaatgt ggtatatoca tgccatgggt tatctgtcaa taataagaaa tgaagtactc 92580

```

-continued

atacatgctc	caacatggat	gaaccttgaa	aacattatgc	taggtgaaaa	aagcaactca	92640
caaaagacta	cactgtatga	ttttatattgt	attaaatgtc	cataaaagaa	aaatattttag	92700
agatagaaag	gaaattagtt	tttccagggt	ctgggaggag	acagtatgag	gagtggctgc	92760
taatgggtac	aggatttctt	tttgagtgga	tataattgct	ctaaaattag	tttgcagtaa	92820
tagatgtgag	tatgctaaaa	tgggtgaatt	ttatagtatg	tgaaatataa	ctcagtaagc	92880
ccattaaaaa	caaccttaatt	aaattaaaac	caagctataa	cagaaatatt	atatggcttt	92940
ggcagtttag	aatagtggga	aaatatggag	taagggtggg	gaaatagtcc	caagtataat	93000
tctggttttg	tcactactag	tgtatggact	tggacaagtc	atttgctttc	tctaagtatc	93060
agtttgcata	tatgcaaaat	agaggtaatg	atacctacct	cagtgggtacc	ttttcaaac	93120
cttgttcttc	ctcatctctc	ctctaccact	ttctcataat	attattacag	taataaccat	93180
ttattaagca	ctgtgtccgc	agtgggtggg	ggctgcttta	cctccacaac	ttcactgaat	93240
cctcactgca	gtcttgtggg	atcttttattt	ctttgcccat	tttcatgta	aataaattga	93300
agtcaaatga	gttgttcaag	gtccttctgt	tagcaagtgg	cagagatgga	catgaaaact	93360
agatcttcta	cctatgtgtc	tttccacttc	aactaaagaa	tttattaaag	agaattgaaa	93420
agctatgaac	taaatttcgg	taatactttt	aatagtaaac	attgctgccc	tcgtgaatga	93480
acacacacta	aatttcaaat	ctcacggtgg	cagggataaa	agatgctacc	tatcttaagc	93540
cattacttca	ccaactcttc	caccaaata	ttccttgtta	ccacaaataa	gtaagcacia	93600
tagatctata	aggagagaat	aattgtgaac	tctgatttta	tcttaaaaag	tcatgtaggg	93660
atgtcatgtt	ccacaatgtg	attaataaaa	tatatattgt	tactaaacac	aaggaaaaat	93720
attatgttcc	ataaagatgt	ttgggtggtg	cctcgacctc	ttttagtttg	aaaagtaggt	93780
atgtatgaga	aagatatgtg	tttacctgtt	taccttgccc	ttctctctgt	ctcttcccc	93840
ctctctccct	ccctcccca	cccctatgcc	ctacaccccc	gcaaccccca	catgtattta	93900
cctttctcta	aaagctctgc	atagccaaga	aaagtgcctc	tttttatttt	taggatatta	93960
gatatttcat	tttcttatgg	taagacaaaa	gattaaggca	accaagactt	acaatgtgcc	94020
taccatgtgg	caggcacaga	ggcaagggtc	tttacctgtt	atttaagtga	attgtaattc	94080
tcacaaaagc	cgtctagagt	tgaatatatt	tccaactcta	aatgaggcaa	atggagcaca	94140
gagagcctta	attatttccac	ccaaagtcca	gtggtagagg	caggattcca	acccaggctc	94200
ggtagggctc	aatccttgt	tgggttgcca	ttcctcttgc	taacaaataa	aactggtctg	94260
tgacttttgc	atttcacccc	gcttccacag	tcaactgggtg	gacttactta	agttaatcag	94320
attcttcaaa	gtatcccca	gtcctccttt	gaaaagaaag	ttgggggaca	ggaggaggag	94380
cagaggagag	gagataaaaa	ggaaggaggt	caggagagag	gagagagaga	gagaaacctg	94440
gtgatctcag	ctgggtgcca	aggtttcccta	agcccaagtt	ccccatgggt	gagcctgtat	94500
tgtcaggcca	acagcttcta	gtaatccact	tttatttaat	taatagtga	actgttgaa	94560
aattgcaagt	ggtgttctgg	ttcagaaacc	ttccgttcta	tggggcactg	cttttgcttc	94620
agattcataa	aaccaaagtc	tctgcctcaa	gataataagt	gaacgtgtaa	ccctcgggag	94680
gtaagaaaaa	acacaatgtc	acgtgcaaat	tctgcacttg	ttctcaaagc	aaacctctcc	94740
tgtgtttgca	attaggatgt	tatctaggag	catattcaaa	acttttgagg	tttttatttt	94800
agtttttctt	tcattatgtg	ctgttttagt	aatatcaaag	aatacatgta	atatataatt	94860
tatatgtcat	aacaataaaa	ttaatgttga	tgagcccaga	ttaaagaatc	aacaacatta	94920
acatcatgat	tgcacaaacc	ctattagaat	ggaagctctg	tgaaggcatg	gatttttctc	94980

-continued

cattttgttc	actgctatat	ccccaggacc	tagaggagtg	tcagccacat	aataggagct	95040
tagtcaatat	tttaaaaaata	agagcataaa	tctacttata	tectetttec	tettaccatc	95100
actcccagcc	tcccctcaga	ggtaaccact	atcctatat	tgggctttat	tattcccttg	95160
cattttgata	agttttcaca	tgtatatcc	caaataatat	attgcttgct	tttgcttctt	95220
tttaaacctt	atataatgga	atcatattgt	atgtatccta	ttgtgaatta	tgtcttttac	95280
acaacattag	tatttgagat	tcaactatgt	gtagctcgat	tccattcctt	ttcattgctg	95340
attgtagttt	attggatatg	tgtgccataa	attatttttc	tctgtcagtg	taatgtttat	95400
catttatgct	ttaataaaca	aaactgctat	gactgttcct	gcattgtgct	cctagtacat	95460
atgtgaccaa	ctttctctag	gatataagcc	tgagagaggg	actgcagttg	gaattttacat	95520
ttccaaagcc	caaagttag	ctcatgagtc	agagctgcaa	tgtgcccttt	gtccacacta	95580
ggtcaggatc	agtgggagtg	ctacccaaaa	tattttgcta	gctggggagt	cagggagaag	95640
cagagactga	cctagttagg	ccaggaggca	ctatctcagg	tctctagtca	aaatgggttg	95700
caattagtaa	aagtcagat	tctgaatccc	cttcactatt	tatcttcctc	ttcctccttt	95760
acagttat	ttgttcaagg	tgcactttat	taaactcatg	cctaacaaac	aaaactctaa	95820
tgaatat	gtctttcatt	gattgtaaat	tcaattaatt	agattgcttg	aaaaaatttt	95880
aactgtat	tcactttagt	atggatgaaa	atttcgattt	ctttaaaaaa	catttttttaa	95940
taataacaca	acataaagtc	taccctcata	acaaaattta	agggcacaac	accatattgt	96000
ttttttttta	ttttattatt	attatacttt	aagtttttagg	gtacatgtgc	acaacgtgca	96060
ggtttggtgc	atatgtatac	atgtgccatg	ttgggtgtgt	gcacccatta	actcgtcatt	96120
tagcattagg	tatatctcct	aatgctatcc	ctccccctc	ccccacccc	acaacagtcc	96180
ccagtgtgtg	atgttcccct	tctgtgtgcc	atgtgttctc	aatgttcagt	tcccacctat	96240
gagtgagaac	atgtgggtgt	tggttttttg	tccttgccat	agtttgctga	ggatgatggg	96300
ttccagcttc	atccatgtcc	ctacaaagga	catgaactca	tcctttttta	tggtgcata	96360
gtattccacg	gtgtatatgt	gccacatttt	cttaatccag	tctatcattg	ttggacattt	96420
gggttggttc	caagtctttg	ctattgtgaa	tagtgccgca	ataaacatac	gtgtgcatga	96480
caacaccata	ttgttaactg	taggcacaat	gtgtacagc	agacgtctag	aactttttct	96540
tcaggcttaa	ctgaaacttt	atagccattg	aacagcaaca	ctccatttcc	gtttcttaaa	96600
ggtcctttac	aaaatgagct	ttctgcgtgt	ttccattttg	tttatctgat	aacttttttt	96660
tcttttttta	ttatacttta	agttctgggg	tacatgtgca	gaatgtacag	gtttgttaca	96720
taggtacaca	catgccaggg	tgtttggctg	cacctatcaa	cctgtcatct	acattagata	96780
tttctcttaa	tgetattccc	tccttgccc	ctcacccctc	actggcccca	gtgtgtgatg	96840
ttccctagcc	tgtgtccaag	tgttctcatt	gttcaactcc	cacttttgag	tgagaacatg	96900
cagtgtttga	ttttcttttc	ttgtgttagt	ttgtgagaa	tgatggtttc	cagcttcctc	96960
catgtccctg	caaaggacat	gaactcttcc	ttttatatgg	ctgcacaata	ttccatgggtg	97020
tatatgtgcc	acaatttctt	tatccaatct	atcattgatg	ggcatttcag	ttgttccaag	97080
tctttgctat	tgtgaatagt	gccacagtag	acataagtg	gcattgtgtc	ttatggtaga	97140
atgatttata	atcctttggt	tatataccca	gtaatagaaa	tgcttggtca	aatgggtatt	97200
ctagttctag	atccttgagg	aattgccaca	ctgtcttcca	caatgggtga	actaatttac	97260
actcccacca	acaatgtaaa	agcgttccca	tttcttcaca	tcctctccag	cacctgttgt	97320

-continued

ttcctgactt	tttaatgac	acgattctaa	ctggcgtgag	atggatattc	attgtgggtt	97380
tgatttgc	ttctotaatg	accagtgatg	atgagctttt	tttcatgttt	gttgaccgca	97440
taaatgtctt	cttttgagaa	gtgcctgttc	atttccttca	cccacttttt	gatgggggtg	97500
tttgtctttt	tcttgtaa	ttgtttaagt	tcattgcaca	ttctggatat	taattaacct	97560
ttcgtcagat	ggatagactg	cagaaaattt	ctcccattct	gtaggttgct	tgttcactct	97620
gatgatcggt	tcttttgctg	tcagaaagct	cttgagttaa	attagatcac	atttgtcaat	97680
cttggtctct	gttgccattg	cttttggtgt	tttagtcatg	tagtctttgc	ccatgcctat	97740
gtcctgaatg	gtattgccta	ggttttcttc	tagggttttc	atggtttttag	gtcttacgtg	97800
actcatcttg	atttaatttt	tgtgtaaggt	gtaaggaagg	gggccagttt	cagttttctg	97860
catatggcta	gctagttttc	ccaacacccat	ttattaaata	gggaatcctt	tccccattgc	97920
ttgtctttgt	caggtttgtc	aaagattaga	tggttgtaga	tggttggtat	tatttctgag	97980
acctctgttc	tgttccattg	gtctatatat	ctgttttggg	accagtaccg	tgctattttg	98040
gttactgtag	ccttgtagta	tagtttgaag	tcaggtagca	tgatgcctcc	agctttgtgc	98100
ttttggctta	gaattgcctt	ggctatgcag	gctctttatt	ggttccatat	gaaatttaaa	98160
gtagtttttt	tataattctg	cgaagaaagt	cattggcagc	ttgatggggg	tagtattgaa	98220
tctgtaaaac	actttgggca	gtttggccat	tttcatgata	atgattcttc	ctatccatga	98280
gcatggaatg	gttttccatt	tatttttgtc	ttctcttatt	tccttgagca	gtggtttgta	98340
attctccttg	aagaggtoct	tcacatccct	tgtaagttgg	attcctacat	attttattct	98400
gtttgtagca	attgtgaatg	ggagttoact	catgatttgg	ctctctgttt	gtctgttatt	98460
gggtgtatagg	aatgcttggtg	attttcgcac	actgattttg	tatcctgaga	ctttgctgaa	98520
gttgcttgtc	agcttaaggt	gattttgggc	tgagagaatg	gggttttctg	aatatacatt	98580
catgtcatct	gcaaacagag	acaatttgac	ttcctgtttt	cctatttgaa	tatcctttat	98640
tgctttctct	ttcctgattg	ccttgccag	aacttccaat	actatgttga	ataggggtgg	98700
tgagagacgg	catccttgtc	ttgttctggg	tttcaaaggg	agtgcttcca	gtttttgacc	98760
attcagtatg	atattgggtg	tgggtttgtc	ataaatagct	cttattattt	tgagatatat	98820
tccatcaata	cctagtttat	tgagagtttg	agcatgaagc	agtgttgtat	tttgtcgaag	98880
gccttttctg	catctattga	gataatcata	tggttttgtc	attgggtctg	ttgatgtgat	98940
ggattatggt	tattgatttg	tgtatgttga	accagccttg	catcccaggg	gtgaagcgga	99000
cttgatcggt	gtggataagc	tttttgatgt	gctgctggat	tggttttgcc	agtatttttt	99060
tattgaggat	ttttgcactg	atgttcatca	gggttattgg	cctgacgttt	tctttttttg	99120
ttgtgtctct	gccagggttt	ggatcagga	tgatgctggc	ccataaaatg	agttaggagg	99180
gattccttct	ttttctgttg	tttggaatag	tttcggaagg	aatggtacca	gctcctcttt	99240
gtacatctgg	tagaattcat	ctgtgaatcc	ttctgggtct	ggactttttt	tggttggtag	99300
gctattaatt	acttcctcaa	tttcagaact	tgttatagtt	ctattcaggt	atttgacttc	99360
ctgctttagg	cttgggaggg	tatatgcgtt	caggaattta	tctatttctt	ctagattttc	99420
tattttattt	gccccagagg	tgtttatagt	attctctgat	ggtaatttgt	atttctgtgg	99480
gatccgtggg	gatatccctt	ttatcatttt	ttattgcac	tggtattctt	ctctcttttc	99540
ttctttagta	gtctggctag	tggtctatct	acaaaataga	ctgtttatct	gatattttat	99600
ttgtaattat	ctaataataa	ccatcattat	catcatcagc	attatcatta	tcatctcctt	99660
taccataaca	tacatttggt	tctttcaaat	aataatccca	tctttgaagt	gcatcctcat	99720

-continued

```

cttttagcagt ctgcactctg ctttcttata tcatttatta tcttatttta taattattta 99780
tttccagtec ttcttctcta acagatagta gtttcttagg gccaaaggaaa tatctcgatc 99840
accactatat cccagcacc taacctgtg cctgggccat agggccagat gctaagagtt 99900
gagttgaacc attgtaccta atcttaacct tcattagcac aacatggttt gtcagtgggt 99960
aagaatctac actttggagt cagactcacc caggatggaa tcctggcatt gccacttatt 100020
attaatagat gcgtgatctt gaacaagttt acttaattgt tctgagcatc agtttcctct 100080
tctgcaatat agggatgata cacagctacc tggtaggttg ttgggaaaaa taaatgggat 100140
gatatgtatg aaatggcctg gcataatagag tgcctaaata catgttcttc tgattctatt 100200
tggacagttt gtgttagtaa cagaagtaa aaaggtggag aaaggagaaa ggtacttgtg 100260
aaaattttct atttctctc catgtttcat tcaggactga ggaagggggc acagttttta 100320
cccaaggaaa tgacattttt agccaaaaga aatgatctta gcatttagct gaattatata 100380
ttggaagtaa gctcctcca tgtggaactt atggccttgc tagccttggg ttgttggaag 100440
tgctcttgct ggctttctag ttagggtagg gaaaggaagg cttgtgggga atgaagatag 100500
gccatgatat caagccactg ggtttgcaaa tcagtagaat tttttattgc tttctgttgt 100560
acttgggact tgaataaagg ctgatatttg tgtcttgctg gtaaagtgtc tgtaaagtga 100620
gtgaaagttt tctttgtctt tgtcctgaca tagctgttca cttggggttg aggggaggat 100680
aacctttcat gttttttttt tttcttcatt ctgatgactg tgctgaacat tcaaaccaaa 100740
aggccattgg tggaaagtaa aggtgagtggt tgagaagaca atagggtaat ggaaactgtg 100800
ttggacttgt aatcaaattg tcctgcactt cccctctcca agtcttaacg tttttcatct 100860
gtacagtgga tattaaaatg agaaaataag cttgtcttca cagagtttcc gttaggtgtt 100920
gacacaacaa acaggctccc attagggtcc attttccttc attccttagt aaggaagaag 100980
tgcttataaa atatagcagt tgtgctcttg tgaatgatag catgggcagt tgtcatctcc 101040
ctgaagcaga tgaacccag aatgtcactt gagttttgtt taatgcttag gcataagaca 101100
taggaatgac aaaagctgac ctttgggtag tgagaacaat gttccatttt gttcaaacct 101160
gaatttttta ctataggaga ctgagaatta accttcocatg aaggttttag gattggcttt 101220
ctggcccttc tccttcatat ccacctgaaa gagcttgggc gcagaagttc ttgcagaaag 101280
gcagttagac aaggtgactt ctgaagctcc agtggccaag tattttgatg gtagcctaaa 101340
agatgtccag aatcattgta catcattttt tcaacagaag cttcaggcat agggattatg 101400
cttggtactt tatgttgttg aatggaatct gccggatgtc catgtgatct atagaaacac 101460
ctaaggaaag tgaagaaatg agggaaaaaa aagaacaaga cttttatgat aatactaata 101520
acgatccttg tgtatttatt ccaatggcat tttatccatt atctgattta tattaccact 101580
cacagcagca gctcaatagg atgggagata ttatctctat tttatagatg agatttgagg 101640
ctcacgaagc taaagcaagg aacatcaaat cactttgata tttggctctg ttttgttata 101700
ggctctccct tggatgaggt aaagttacaa acctgggttc atatcattta attagtctga 101760
aaatgttgcc tggacaccac ctccagttag atatcttaac ctcaggcttc ctgccttcat 101820
tgctcccgea tatagacata gactatgaga ttggctaata ccagagaact tccctaatacc 101880
cttggaaga tccaaaaagg ctcaagcaca ccctacaacc atcatcttta ggagaagtct 101940
cagaaaaatc agcttcacac taactaactt gagcaatgaa taatagtcac ttatgcctgc 102000
aggttaatgc tgaagacctg agacttccact tgcctatttc tgccattcag tgacatgtgt 102060

```

-continued

```

tgcattggtt ttttgtgtct ttccagtttg gagactgcc a gggaccatgt tttgcccatt 102120
gactattact ttccacccca gaagacctgc ctgatctgtg gagatgaagc ttctgggtgt 102180
cactatggag ctctcacatg tggaagctgc aaggctctct tcaaaagagc cgctgaaggt 102240
aaagggtctt gcacatgcac ttctctttcc ctttctcctt taccttccag agagagacac 102300
taacctttca gggcccagga ttttatcatc tcagaaatag agtcattggc aaggccctat 102360
caaataactt aggagcctaa ggaagcaaat ttttgtactt gctagtctcc tggtttcagc 102420
agccttggtt gtacaggcaa ttaggcaggt gaaggtgggc ccagctgggg cttggggctc 102480
agtgggtcct agaaatgaaa gaaaaattaa tgatttgaaa agatttaatt tcctcccttc 102540
ttgttttcta ctctgctggc tagtaaagga aaaatttgtc cttattagag aggttagaag 102600
tggagaaaacc ccaactgagt ccccgactg ttccttgga tgaatatgag actgttctt 102660
agcaaaggct tcctggctc gggcccagaa agggagtgtt ctactcttc agcagactat 102720
cagtctctgc acctgtctcc tctgtttg gctccttgg gacctgtctt tgcattaata 102780
gttcttaggt aggtagaac tcagagtga gaaacacatt tattctctc tccagagacc 102840
tgatctcaa gcctgtccat tagtcctaa ccttaacta aggtagctc ttatatctgg 102900
ctaaattggc tcaagcccta gctccttagt tttatttagc ttagaacaac tcatgtctgc 102960
tcaacctcta gaggcgtca gccacattc tgcagtagaa actcccttt tcaggcctct 103020
tatatacggg aatgtctct tcctctaacc acccagggt taagcttct gcttatccac 103080
ttcacctgt attgagggt ttcttctcaa agagacattg atgaggagc cctagagaga 103140
gatgtctgct tctgggacca gaccttgt taaacaccag tattcacctc tgcccact 103200
ttcccaaaag aggtacttcc tgccaaggcc tttctcttcc ctctcactgg ctggaagtgt 103260
tgagtccac ttcagaacca gaacagagaa ccttctctc tataagagct ataaacctg 103320
agaacagtct taaaacatag gtatgtaggc cacaccattc accacgaatg tactgatact 103380
catcagaata tggaagaagc accagagagt ttgaagctc tagagaaaag gtagaaaag 103440
aatgcccttt aactgacctc ctcaagtata gccaatcaca atgatgagtg ttgattctc 103500
atthttggcta ggtggcagaa atatctataa aacagaagct gccatgtgt tttctccag 103560
tcctcagggc ctacaagaag gcagctatca tttggtatta ctgaaaacat gcccctgtt 103620
cagctcctac ccccaatta cccattgcta ctgtttatgc tgggctaata tgaagcccag 103680
ggcctaagt tctaggtcta ggcagtaagg cctagagcag tgcctaaga gcctgagagc 103740
agtgccttcc tttcttcaga gtactcatga aaggatggct gtcagaaaag gaaatgagga 103800
tgggttccag agacttcaga ccaccccaac tccccagtg agacctggc acctcccat 103860
acctctcac ctacggggcc ctgtctatag agcagagaat gaaacagagc actcatctag 103920
aggtagtgtg tcagcaagcc caggcactgc accacagtaa tagcagccat atcagatggg 103980
aaaggagtcc aagtgaacaa acaagcaaat tcaatagtca gatagattag attatacttg 104040
atgcttctc tgagttttac aaatatgggt cactaaattg ttattttcag aaaacagggg 104100
aatgctcaa tcacattgtg aaaggaaga ttttctgtc atatcatata tcccacatgg 104160
gagctttctg cagaagttag agctgaagga gggaggcagg cagaaggga actggcaggg 104220
ctgctggga ggagctctgc aatgaggtgg atcctgtgcc atttgagaac agggaagaaa 104280
agaaatgagg ttttggggag ggaatcccc aactcacaga acacacagaa atccagcaag 104340
gtttcaaac gctctacacc ttagagtctg ttaagttagg gaaactctgt gagctcatag 104400
ggccaaatgc acttgctgc ttgaaatag aaaaatcagc aatggattcc ttgaaaaa 104460

```

-continued

atgaaaaggg aaccttctga gcccttgggt tattttgaca tatggaccat agatttcagt 104520
cctgagccct ttgaaggttag gagaagggtgg tttagaaaac acacacacac acgcacacaa 104580
acacacacca gaatgaagca aaaaaaaat tactgggtgtt ttctttctcc tcccatctgt 104640
gaagctgttg gattgatttt actgccatca ttatccctgt ttgaaggcag ggggctgtct 104700
tattacccaa agaggacatt tattgatttg gttttctttt tccattttta caatgcactc 104760
ttatcgccca tatggccttt ctggagggtgg ttttcagtct ggcttgttga aacatcaaat 104820
tatacctgtc tttagaaaa tagaaacaaa aatctttctc ttcttactt gcttgttga 104880
gtcagttaac tcggactgag tattcagagt ctgattatc acttaattca tagtttcata 104940
aatctctgga atgggcatag gtacaggact taaaagcctg gcactctaga cagaaatatg 105000
tttttagctt tgggtgttta taacagatgg gacttttagg ctgtcattgg tgcagggtc 105060
agcacagagt cagttgtaat ctggacaggt tttgtgttg aggaagagtg ggaagaggga 105120
gtcctacatt ttctcctgt cagtaatgtt ggagaattgg ggtgagggtg aggctgggca 105180
gggagggtct gcataaaaa aagggtgcgg tgagaaaaa taatgctact aagccatgag 105240
ggtaaaatga ccaaattctg gttgagagaa acttgggtcaa agtgtgtatg gggagagaaa 105300
gttgggtcaa gtctgtgtct gagtgcttg tgggatgaac tctgggttag aaacaggcat 105360
ggagggaat agttggttta tggagtgggt aggatgagtg ggggtgtgaa agggaaggca 105420
ttttggatgc taagagacca ggaagtcaaa gcaaggcaat acacataaac agaggtaagg 105480
gtcagagag gtttttagtg ttagacttg gataagaaat ttccctttt ggacctcagt 105540
ttctctgtt tgtaaaaaa cggacttgaa ctatgattt taaaatgtgc ttccagctta 105600
gacattttgt gaccgttcta caaattacaa acataatcat catcatttca gcaaactcac 105660
atgtatttat acctgcataa gtttttggtc ttgctttcct agaagggtgac taatcccaga 105720
tcctaataca ttaagaagc aatcttcaga tggggataga gccagctgag agagtgtact 105780
atggatggag tgagttaaaa ctcaggactc agattttctc cttgtgatca ttgctgggtg 105840
acttccttct tttctatatt tctcatctgg aaaatcagga tatgaatccc catctctacc 105900
tcattatgtt tcaaagaggg ttaattaatc catcatgtgc attatgtgct caagaattta 105960
ctatttttca gacattttct agtaaaacat tgaagattat atgtccattt gttttgtaca 106020
catggagtgc tgtttggtac acatcataaa attgaaactg tagtttacat tctgaactca 106080
aagaattaca ccactctcac tgatgtttac aatagggtccc aatttagttt ctttagcaaa 106140
ttttatgtaa gtatggcttt gattctctct ctcactccag gttttgtta ggaagaaat 106200
gcaagtgaac cctcattgaa ctctttctgt cctttaaatc cattctttcc cactcaact 106260
catgtggaat tgaatgttg ctctagtttg gagtctagca gagagtttt ggtgcatatc 106320
agtgccctc tcactccctg acttttcaag taacatttcc cagaggcaaa ttaactctgc 106380
taagaggatc tgcttgacgc ttcaacagag ccttcacag gtatcttttg ccaaggagtt 106440
gactgatcct gactttgcga gtccatagaga tcttttcaca aagctcctct catgtttctg 106500
cctctgattt tcttaaatgt cacagacaga ctttagattt aggggttgggt taactttttt 106560
tgtaaagggc catgtagtaa atattttagg cttttagat catatggtct ctgtgtcaac 106620
tactcaactc tgcctttgta ggatgaaagc agccatagac aatactggaa ctaatgggag 106680
tagctgtgtt ccaataaaac tttatgggca ctgaaatttg aatttcactt aattttcaca 106740
tgtcgtttaa tattattttt cttttttacc atttaaaat ttagaaatca ttcttagctc 106800

-continued

```

tttgggcctc acaaaaacag atggtagagt ggatttggtt tatgggctgc agtttggtga 106860
cctgtgcttt agctaatac tctgtactt ataaatctgc ataggtttta tgtttttcca 106920
tctcttggtt tcttagtagg ccagtc aaag tttgaacaac ttgttagcac agaatacctg 106980
gcctagtggc ttcttggtcc tgagcttatt tactaaacaa gagaaaaaat aaataagtct 107040
agaaatgcta gaagaggata cttttttggt ttaatgatct agtagatcac tcctccttgc 107100
aatacccaga ggagaaactg aaaatatctc aaacattttc tagacttctg tgttgtaaat 107160
ttgtggataa ctatgaacta tatatgaatg aacttttctg gatgacacat atattccaga 107220
tggtaaaaag gaagggcttt ggggactctc tggtagcaag tgtcatggaa aaactgtgtg 107280
tctcatagaa agtagatccc aggaggccag cagagttgtg gatctgccat atattacctc 107340
atgattctgt cttcgacac tcaccggctt aattctgggc ctcccataa cagactaga 107400
ccacaggctt gcagaagaaa taatttagct ctgtaactca ttgaagttgg tgcccaccca 107460
agtctctgtc agtgcccaat tcgggagcca tgccaagaat ttgccattgc tgcctcatgg 107520
tggccttggt cctgcttatt tatagcctgt gcattttatg aaacagggat taataagaag 107580
ttgccatagc acttgacca ttatgtaaat atctgtaatg cttacataac ttttgcact 107640
tgcaagacct tttgagtcca ttgccttctg ctaccatgcc ttaccaattt cctagtccct 107700
tattattatt tttcaattca ttatatttaa cttctgtgat acacgttcag aatatgcagg 107760
tttcttatat aggtatacac gtgccgtggt ggtgtgctgc aaccaacaac ccgtcatcta 107820
cattagggtat ttctccta at gctatccctc cactagccca ccaccccta ataagcccca 107880
gtgtgtgatg tccccctccc tgtgtccatg tgttctcatt gttcaactcc cacttatgag 107940
tgagaacatg cagtgtttgg ttttctgttc ctgtgtttgt tttctgagaa tgatggttc 108000
cagcttcac cgtgtccctg caaaggacat gaactcatcc ttttttatga ctgcatagta 108060
ttccatgggt tatatgtgcc acattttctt tatccagtat atcattgatg ggcatttcgg 108120
ttggttccaa gtctgtgcta ttgtgaatag tgctgcaata aacatacgtg tgcatgcgtc 108180
tttatagaag aatgacttat aatcctttgg gtatataccc agtaaatggga tggctgggtc 108240
aaatggcatt tcagggttcta gatccttgag gaatctccac actgtcttcc acaatgggtg 108300
aactgattta cacccccacc aacaatgtaa aagtgttcct attctccat attctctcca 108360
gcctctgttg tttcctgact ttttaatgat cgccattcta actggcattg acatggtatc 108420
tcactgtggt tttgatttgc atttccctaa tgaccagtga tgataagctt ttttcatat 108480
gtttgttggc cgcataaatg tcttcttttg agaagtgtct gttcatatcc ttcacccact 108540
ttctgggtgtg gttggttatt ttttcttctg aaatttgttt aagttccttg tagattctgg 108600
atattagccc tttgtcagat gtagatattg cgaaaatttt ctctcattct gtaggttgg 108660
tgttcactct gatgatagtt tcttttctg tgcagaagct ctttagttta attagatttc 108720
atttgtcaat tttggctttt gttgccattg cttttggtgt tttagccatg aagactttgc 108780
ccattcacia ttgctacaaa gagaataaaa tacctaggaa tacaactcac aagggatgtg 108840
aaggacctct tcaaggagaa ctacaacca ctgctcaagg caataagaga ggacacaaac 108900
aaaaggagaa acattccatg ctcatggata ggaacaatca atatcgtgaa aattgccata 108960
ctgccc aaag taaattatag attcaatgct atccccatta agctaccatt gactttcttc 109020
acagaattag aaaatactac tttaaatttc atatggaacc aaaaagagcc catataccca 109080
agacaattct aagcaaaaag aataaagctg gaggtatcaa gctacctgac ttcaaactat 109140
actacaaggc tacagtaacc cttatcaatt ttttatgtgc ctctccatat tctgcagtca 109200

```

-continued

gaagcttctt cagtcctttc agggaattgc tgggtgacta tcaaactctg gtagttcatt 109260
tttgcagttg gctgctgttg tgaggataag agtttagactc actttctctt cagagataga 109320
aattatgtat taattctctg ggttcttagac ccacagcaag gagcatactg ctctcaaaa 109380
taactgaatt ctgcgagaag ccatcattgt aaaacaacaa tatcttcagt tatagtagcc 109440
atgtgtgcaa cttctggaaa ctgttattca gattttcatg ttccttccct gtctcttcat 109500
agctaggcag ctgctttcag cctgttacag atgctagtga gctttctacc tacaaacctg 109560
cagaaaaattg aactgagatt tggaggtgaa agactcttga taaagggaac aagggtttaga 109620
attctcagtc cctttgtctc caggctgtgt tgtgactact gaggcactcc agtgaaatca 109680
ctattcctcc tatctagact aatgcctgtc tctgcagagc acctcataag aacaggcctg 109740
gtagtaatat cctcatgcat tcagtcagta aatatttaca gagtgcctac tacatatagg 109800
gtattgggct gacatatgca agatacaggg cctgcttcca ggaggttata gcttattgat 109860
cataaatgtg gcattttttt tttttgagac ggagtcttgc tctgtctgtc acccaggctg 109920
gagtgccagt gcacgatctc ggctcactgc aacctccacc tcccaggttc atgtgatttt 109980
cctgcctcac cctcctgagc agctgagact acaggggctc atcaccacac ccagcttttt 110040
tttttttttc tgtattttta gttagagacag ggtttcacca tattggccag gctggctctg 110100
aactcctgac ctgctgctcc acccacctca gcttccaaa gtgctgggat tacaggcgtg 110160
aaaatgtggc aatctttaa gctcttcagt ggatgaaagg ccacctatc tgctgtcctt 110220
tgaaacttgc caactttctt ggtacagagt gagagggtat tctcttggtt ttccatataa 110280
gtaaactgag gcttttgccag ttcacacaa ggtagtaaat aatatatttg gaatttgaac 110340
ccaagtcttc tggggtcaaa ggcagcattc actctgctct gtcacagcag ctctcaaat 110400
aagccaacat agaaaccaag tactatgcct aggcacaag aaaggcagca atgaagagca 110460
acagcagagt caaatatgag agaaggaagt taagaaagat gttaagtact gtggggagta 110520
actgagaaac caccaagtat cgctaaccac acagggaact tgtcttccta agaaaattcc 110580
aagcacttaa aaccgctggt agttcatcag caactctctt cattagatgt gcgagggaca 110640
tgtggggcat agtccttcta ctaacttata ttcttcaggg gaaagttctg attctgatga 110700
gaccagcat ggtagctctt aattcactgt tgtcacacga ctatagaaca ggaagcaca 110760
cttaacacct gtgctcatga gaattttgct ccttatgacc aagctaaaga aagagcttag 110820
acaggatgtg tgggtataaa tgtagattaa tgggtccttg gctctttggt ttgagccttc 110880
tcagcagagc atcccacgga gtgttttcca tggggccacg agcaagagaa atccacttcc 110940
ctcctcctca atgtcagaaa atagagaata ttgtcttcca ggatagaatt aaaaagtcac 111000
agaggcagca acttgtttcc ctatattagg gttttaaaat tctgttttcc ctctctctcc 111060
tgggtcagat cattgtgtgg atggaccttg atttcattgt ggtatctgta tgtggacctt 111120
gaagaccatg gacttctaac aattccttaa gttacataag cacattccta cagggtcaca 111180
gtctatttac ttacaggatg gttgatttgg tcacaggtta tttcatgaaa atacttaaaa 111240
gatttgagcgt gttcaaaact gcagtatctt taaacactaa aacttgaagg aagggaattt 111300
agaaatcaaa aaatctggtc aaaccatttc atggaaaagg aaagtgaagg tcagagagag 111360
gaaattactt tcctgggttt gtatagccta taaatggcag aaatgagagc ctccctgcca 111420
tttctagttt tctgtctgag agactctcct gcctaatagc taattagcag agtcacagag 111480
gtcattacct tgcaattctc aagaattatg tgaggcagca tagtaagcat ttatggccct 111540

-continued

tggttectag aaggagctta gtccttgata gtcctctctg cctttgccat tgtgtgagac 111600
tgtcttctgt aactgtatgt ctctctccct agtaagttaa tgagtaataa aggtattcta 111660
tagtgagagg actctgtaag acatttcttg gtgtgaggat tgtccaagg ttgttttgtg 111720
tgtatgtgca tgtataaact ttttaggga gcatattcat agcttttaca tggatctcag 111780
aggctctata acccagagaa gattacagaa taccagtctt gtctttggta aggattttat 111840
agacccatcc tgactacagt gatatccaac atggctatgt aatgactggc actttcccca 111900
cataacatat atttattcca cactcagtgc ctactgtgta catgagacct ataccgggca 111960
ctgggataag agacatgaaa taacagctaa aattgtttat tgagcagtca gtatgcatta 112020
gatgtttgt agtcattttc ttattcaatc tgtataccct caatttaca atgaggaaac 112080
tgaggcacag aagagttgag tgatttgccc aaagtcatac aaatagtcag tggctatgtg 112140
atgaatagtt accaacataa aagagtgaga ttactgctgt actaaaagta ggtacataat 112200
cccctgagca gacagtatga gagaatgatt tattttacct ggaaagtta ggaaggcttc 112260
acagaggagt taagggttga tctgggtctt gagggatgga taagagtttg ccagatacaa 112320
aaagtagga agagaacttc aggaggaggg aacaggctga gcaaagacac ggcatgtga 112380
aagtgggagg cttgtttggg gaacattatg gaatctggag gttattgtgg ggaatctcat 112440
cagatgcagc aagctgtttg acaggccttc agttggctct ttgtacctg ctccctccgc 112500
atgctgagct gtccatagct gccctaggct ggtgtctggg attttcggaa gaaggttact 112560
atccaggtag tgtaacaaga tgcagtgcaa aagcaccaga ttggggctct ggctctgctg 112620
ctgacttacc acctggcctt aagcatgtct agttccctct ttgtacatta aaatctccat 112680
tggaacagta acatggttgt attaaatgat cttgaagatt ttacctgcac gttttgcaca 112740
tgtaccttaa aacttaaaagt ataataaaaa aattaaaata aaaaataaaa atataacaat 112800
ataaatcttt aacaataatt ttagtagtaa atctctacaa ttttacagat aatccagatg 112860
catccattgg ccaatgggtc actttgtatg cataaatatt gggaaacagg cagacccaat 112920
ttcaatcctt agttgtaaga cttaatacat atgtgatctc gagcaaatca cttttgtatg 112980
cctctataag gataataata gctcacagaa ttattttaag aactaaatga tgtgtaataa 113040
agctactggg actcagtaag ttttgtatcc ttttctaga gtgagtcttg gtcataggca 113100
tgcgataact tgcagcgtcc ctgggtaggc cgaaagagca aataagagat ggtatctatg 113160
gtattcccca ggtaaaggag gccttggggt ggcataagat ttcacttctc tttagagtta 113220
cttaattagg gaccagaaag gccatcagca tttgtatgag aatatacaa aggtcaatct 113280
cttctctttt actttttacc tccagttaca ctgtgagtaa cattccccag ccagcccagc 113340
cagcacgtgt tcattgcctc tcttgacttc cagactttgg acttgaagg gtcagagctc 113400
tctgtgtatc tttgtcccca acaagataag tctgacctcc ccagcaaatt caagtcccaa 113460
gccactgtcc aggagaaaag ctagcaaggc cataaattat tctccatatt ttccagccat 113520
tggtttcctt tgtccagcca gaggtgtgtc tcaaagtatg ctgaggccag attcaataga 113580
aacctgagcc agcacctgtg taaataattt ttaaagctcc ttttctgaa gctggatgaa 113640
tatttttaaa aactaagctg gattgtcttt tatctagcat gccgtctcct acattcctag 113700
tgctatggac ctcttgaggg aatgtgggtt gggttatagt gtattgtctt gtctgttgtg 113760
ggggaggagg acatttcttt cagaagcaag gtaatacttt ggtctggctt atgactctat 113820
tttgtttaaa atgaaactat ggcagtatag tggattcat tctgctccc ataggttaac 113880
tttacatccc tctgtcttca cccactcttc agttctgatt cttttaaaag cagccaacca 113940

-continued

```

aaaccagcaa gtacatactg cttatctctg acttccacca gaatcaactt cagatcttgt 114000
ccaaagctcc atctgaagag aggggaataa caccagcca agagccctca gggcccatca 114060
gtaagtagac atcctgtcct tgaggttcct taactctgct cagcttcaga atacagaagg 114120
ggttggttct tcatttgtgt tgtttataac taaaagcctc ctactcccca cttttttgca 114180
tagcttcttc tgccatccca cctgtgtagc ctcttcaact ccccaaaaac tcctctgtag 114240
cccatgtcac ttggaaagag ttttctttgt ctcttttgca acttgacaat gactagccag 114300
caagtttaag ttcaaattat tgttccatgg gagcagagat agatatagga aacaaaaaaa 114360
agggatatgg aggtatagag tgatttccca cctacctagt gagcactact gagatattca 114420
agtactctct acccaagaat tctattgata taaaggtaaa aaacttgatc ttaggtctaa 114480
tatccgtag tagtgtgacc ttgggaaaat gataccaccc ccaaaggctt agttttctta 114540
actgtaaaat aggcatacag atgaccaccc ccagaggatt cataaggata acatgagata 114600
aggcaacttg aaatttctta gcatagtgat agactttcga aaataaaatg aatcaaacac 114660
tgataacagt acttcttagt acacaaatga gaaatcagtc cctcatcaaa ttacagcaca 114720
ttttcaatgc tccaattatg tcaactgtag aatgctaagtg tggattaaat aatttgtctg 114780
ttgctattta tacggataat ttgatagtag ttatttttgg acatggatag ctttgaagcc 114840
ttacagatga gtccatcccc aagtacccaa aactaaagaa agttggctag agtgatgaca 114900
aggtggcagc acagagctcc ctgctgtctg ggccctgtcc cctagctaga gagaactcca 114960
ggctataagc atttgtattc tcatagtcca atggcagggg agaagggctg gaggtgagta 115020
gttttcactc atttattttt tcaacaagca tgtatgggtat caggccttgt atgcattccag 115080
agacaaatgt gaactagccg tgcctcaag gagattccag tctggtgggc ctgccttcca 115140
aggtcagttg cagctttagc actataaaga gcacctacct gcggcagata caatgtgatg 115200
ggacatgaca gagaaaaaat ctataagcag agcctcccca ttcccaggca ttgaaacaat 115260
cctaaccaag actggcatag tacaatgagc ctgtccctat cagcaggttt ggaagcctta 115320
acaacaacaa caaaaacaat aataatggtg atgataatca tagagcctaa tgttaccaaa 115380
cattttccat gtgttaagta ctatactaag tgcatactta atcctcaca caatgctata 115440
agatagtaga tactcttact actaccctga ttttaccaat gtggaaactg aggcacagaa 115500
gactaagaga acaggaatac acctaatcca cctcagttca acaaacatca agcatctgtt 115560
ttatgtcagg cctcgtgctg gatggcaggg agagagagat gagtaaaagca tagtttcagt 115620
ccagtgggag caaatgacag cacacagtgg ggcaggtata ttgcagccct tctgcttgat 115680
gctaagaact cagtgtcagt gatgaatgaa acacagtcac tctctcaaag atcttaagc 115740
ttagtaggag atatctgtgt ggaaacaaaa attaaatact gctgtgataa gtgtcataag 115800
agataagtgg aaaatgagag agagagatca ctgtagcaat tgattggttt aaatcaaagc 115860
ccccaaaaa atgttattga gaattataa acaactaatt gatttaaatc aaagcccaaa 115920
cagaagtgtt tgctaatttt atttcaattt ggttgataat ttggttgaaa tgaatttatt 115980
tcatttttta ttccatcctt acaatggaag attagtgtt gtttccacc caaggatacc 116040
aggatatttc aggggctgta ttacaatata gttaaattat tcctttatct caaagcacat 116100
ccacacttct ccctatcctt acctttactc agggtatctc ttctgcctca ggtgcttttt 116160
ctccacattt ccatattctt aagtcctacc ttcttcagg gcctcactca aatgcctcct 116220
cctccatgaa gcattcacc gactgaaagg taccocgccc tctcctgtac tccacatcac 116280

```

-continued

ttcatgggtg tctccacttc ctgctttatc tttcagtaat acacttacag ttctctttcc 116340
tccactagac tgagctcttc agaggaagac tcaacttggt gaaacctga ttttacttta 116400
aacacattga aaacctctac tggagtgcac tgtgtctggt gggcttcaac cttaattctt 116460
aagtatgtga aaacacatca cctatctgga ggtttacact ttctgctaata gactttattt 116520
ttaagcccac caccctaaca caacaaatac ttaaaacttg tcttcatttc ctttaggtct 116580
ggccctcatg catgcatata atttatagag tcaactgttt gctcggttgt cctcatgcct 116640
ctatatattt ggaggttttag attgtttcca tatactcagg ttgtattcat gtcctttttt 116700
tctttttaaa tttccttagc atccatttcc accattggaa attcagggtc aaaacagggg 116760
tttgggattg gagcatgtct atcacagata accaatcatg tgttatgact taagaattta 116820
tgaaagggcc ctctacctga agatatcttg ctactgatgc tgtctcacag tgtctgaaac 116880
tcccacata tgtggaattg ttttggaagg ctttgccctc tgggacacat tcagccataa 116940
tcaagaaata gtattgagca ttagactgtc agtatgtcca ttagcaagac tgtggaggaa 117000
tggaatcacc aatattatat tttatagggg atacagaata caagagaagt tctgaagaga 117060
aaattcttat gtagaatagg aaggcttaga tacagcatga aagctgcagg ctttgaggag 117120
ccagaggtea aatgaaagca ttgagtattt gtttagatga aagaacagaa agggaaaaag 117180
aagcagagga agggatagta gagagaaatg tataagtttt atccatttaa cttgtaattg 117240
tgtttggtc tgggcacaat agaagcagtg agatcacttt attttatttt attctttata 117300
gacagggtct tgctatgttg ccaggtgtc agtgtgcagc tcttcacaag tgtgatcata 117360
gcgtactaca cctcaaaact cctggactca agcaatctc ccatctcagc ctctgagta 117420
gctgggacta caagtgcaca ccaccagcc cagtgcagtc acttgaaact agggagagat 117480
gtgtgagttc tgggcaacca gtagtgggt ttacatagaa ctgtaggggt caaggccaaa 117540
ggggacgtcc tgttccaagt cacctctttt ggacattaga aaaccacgag gggtttgaa 117600
atcagaaaac cagcagaggc aggaaaactc agggcagcat gggagattca gtatatataa 117660
aaaggttcac accagtaac aaacagaatt ttaactgctg atgtggagta gaggcagctt 117720
tgtctgctgt gtgataacca aacctttacg aatagtaggt gtatatggg aattggaggg 117780
agatagggtg ctgtgttttag taattggttg acttcactga gatgggttg ggattgtggc 117840
ttccagatga tcagattttc ttttttaggt agagactcca acatcattac agaactataa 117900
attacatgtg gaaaagaaag gcctcctatg ttagaataga aaataaaatg ctgtggggtt 117960
gagggacaga ggtgctgtct aggaagtcag atagcgtttt ccagtctgt cctcagagt 118020
tccttgctct cattgagact caattctct tacttttttt ttatacttt aagtttttag 118080
gtacatgtgc acaacatgca ggtttggtac atatgtatac atgtgccatg ttggtgtgct 118140
gcaccattta actcatcatt taacattagg tatatctcct aatgctatcc tccccctc 118200
ccctctcccc accacaggcc ctagtgtgtg atgttccct tcctgtgtcc atgtgttctc 118260
attgttcaat tctcacctgt gagtgagaac atgcggtgtt tggttttttg tccttgatg 118320
agtttgctga gaatgatggt ttccagcttc atccatgtcc ctacaaagga catgaactct 118380
tcatttttta tggctgcgta gtattccatg gtatatatgt gccacatttt cttaatccag 118440
tttatcattg atggacattt ggggttggtc caaggctttg ctattgtgaa tagtgccatg 118500
ataaacatag gtgtgcattg gtctttatag cagcatgatt tataatcctt agggatatata 118560
cccagtaatg ggatggctgg gtcaaatggt atttctagtt ctagatccct gaggaatgc 118620
cacactgact tccacaatgg ttcaactagt ttacagtccc accaacagtg taaaagggtt 118680

-continued

cctattttctc cacgtectct ccagcacctg ttgtttctctg actttttaat gatcaccatt 118740
ctaattgggtg tgagatggta tctcgtgggt ttgatttgca tttctctgat ggccagtgat 118800
gatgagcatt ttttcattgtg tctgttggct gtgtaaagt cttctttgag acgtgtctgt 118860
tcatactctt tgcccacttt ttgatagggt tgtttgtttt tttcttgtaa atttgtttga 118920
gttctttgta gattctggat attacccttt gtcagatgag tagattgcaa aagttttctc 118980
ccattctgta ggttgccctgt tcaactctgat ggtagtttct tttgctatgc agaagtctct 119040
tagttgaatt agatcccatt tgtcaatttt ggcttttgtt gccattgctt ttggtgtttt 119100
agacatgaag tccttgccca tgcctatgtc ctgaatggta ttgcgtaggt tttcttctag 119160
ggtttttatg gtttttaggtc taacatgtaa gtctttaatc catcttgaat taattttagt 119220
ataagggtga aggaagggtt ccagtttcag ctgtctacat atggctagcc agttttccca 119280
acaccattta ttaaataggg aatcccttcc ccatttcttg tttttgtcag gtttgtcaaa 119340
gatcagatgg ttgtatatat gcggcattat ttctcagggc tctgttctgt tccattggtc 119400
tatatctctg ttttggtaacc agtaccatgc tgttttggct actgtagcct tgtagtatag 119460
tttgaagtc gatagcgtga tgcctccagc tctgttcttt tggcttaggg ttgactggc 119520
gattcaggct cttttttggt tccatatgaa ctttaaagta gttttttcca tttctgtgaa 119580
gaaagtcatg ggtagcttga tgaggatggc attgaatcta taaattacct tgggcagtat 119640
ggccattttc acaatattga ttcttcctac ccatgagcat ggaatgttct tccatttgtt 119700
tgtatcttct tttatttcoat tgagcagtggt tttgtagtcc tccttgaaga ggtccttcaa 119760
gtcccttgta agttggattc ctaggatatt tattctctta gaagcaattg caaatgggag 119820
ttcactcatg atttggctct ctgttttctg ttattgggtc ataagaatgc ttgtgatttt 119880
tgcacattga ttttgtatcc tgagactttg ctgaagttgc ttatcagctt aaggagattt 119940
tgggttgaga cgatgggggt ttctagggtat acaatcatgt catctgcaa cagagacaat 120000
ttgaattcct cttttcctaa ttgaatgcc tttatttctt tctcctgcct gattgcctctg 120060
gccagaactt ccaacagtat gttgaatagg agtggtgaga gagggcatcc ctgtcttctg 120120
ccagttttca aagggatgc ttccagtttt tgcccattca gtatgatatt ggctgtgggt 120180
ttgtcataga tagctcttat tattttgaga tacgtcccat caataactaa tttattgaga 120240
gttttttagca tgaagcgtg ttgaattttg ttaaaggcct tttctgcac tattgagata 120300
atcatgtggt ttttgtcgtt ggttctgttt atatgctgga ttatgtttat tgatttgcgt 120360
atattgaacc agccttgcac ccagggtatg aagcccactt gatcatagt gatacgttt 120420
ttgctggtat tttattgagg atttttgcac caatgtttat cagggatatc ggtctaaaa 120480
tctctttttt gttgtgtctc tgcttggctt tggatcagg atgatgttg cctctaaaa 120540
tgagttaggg aggattccct ctttttctat ttattggaat agtttcagaa ggaagggtac 120600
cagctcctcc ttgtacctct ggtaggatcc agctgtgaat ccatctggtt ctggactttt 120660
tttgattggt aagctattag ttatatctc aatttcagag cctgttattg gtctattcag 120720
agattcaact tcttctcgtt ttagtcttgg gatggtgtat gtgtcgagga atttatccat 120780
ttcttctaga ttttctagtt tatttgcata cagggtgtta tagtatgctc tgatggtagt 120840
ttgtacttct gtgggatcgg tgattatata ccttttatca tttttattg cgtctatttg 120900
attcttctcc cttttcttct ttattagtct tgctagtgggt ctatcaattt tgttgatctt 120960
ttcaaaaaac cagttcctgg attcattgat tttttgaagg gttttttaca tctctatttc 121020

-continued

cttcagttct gctctgatct tagttatttc ttgccttctg ctagectttg aatgtgtttg 121080
cccttgcttc tctagttctt ttaattgtga tgttaggggt tcaattttgg atctttctcg 121140
ctttctcttg tgggcattta gtgctataaa ttccctctc cacactgctt tgaatgtgtc 121200
ccagagattc tggtagttg tgtctttgtt ctcatgtgtt tcaaagaaca tctttatttc 121260
tgccttcatt tcattatgta cctagtagtc attaaggagt aggttgttca gtttccatgt 121320
agttgagcgg ttttgagtga gtttcttaat cctgagttct agtttgattg cactgtagtc 121380
tgagagacag tttgttataa tttctgttct ttacatttg ctgaggagtg ctttacttcc 121440
aactatgtgg tcaattttgg aatagggtgt gtgtgggtgc gaaaagaatg tatattctgt 121500
tgatttgggg tggagagttc tgtagatgtc tgttaggtct gcttgacagt ggagtgttaa 121560
agtctcccat tattattgtg tgggagtcta agtctctttg taggtctcta aggacttgct 121620
ttatgaatct ggggtgctct gtattgggtg catatatatt taggatagtt agctcttctt 121680
gttgaattga tccctttacc attatgtaat ggccttcttt gtctcttttg atctttgttg 121740
gtttaaagtc tgttttatct gagactagga ttgcaatccc tgcctttttg tgttttccgt 121800
tgcttgata aatcttcttc catcccttta ttttgagcct atgtgtgtct ctgcagtgtt 121860
gacgggttcc ctgaatacag cacactgatg ggtcttgtct ctttatccaa tttgccagtc 121920
tgtgtctttt aattggagca tttagcccat ttacatttaa ggtaaatatt gttatgtgtg 121980
aatttgatcc tgtcattatg atgttagctg gttattttgc tcgttagttg atgcagtttc 122040
ttctagcct cgaaggctct tacaatttgg tatgttttg cagtggctgg taccggttgt 122100
tcctttccat gtttagtgct tccttcagga gctcctgcag tgcaggcctg gtggtgacaa 122160
aatttctcag catttgcttg tctgtaaagg attttatttc tccttcacct atgaaggtta 122220
gtttggctgg atatgaaatt ctgggtttta aattcttttc tttagaatg ttgaatattg 122280
gccccactc tctctggct tgtagagttt ctgctgagag atcagctctt aatctgatgg 122340
gcttcccttt gtggggaacc tgacctgtt ctctggctgc ctttaacatt ttttccctca 122400
tttcaacttt ggtgaatctg acaattatgt gtcttgaggt tgcctctc aaggagtatc 122460
tttgtggtgt tctctgtatt tcctgaattt gaatattggc ctgccttgct agattgggga 122520
agttgtctg gataatatcc tacagagtgt tttccaactt gggtccattc tccccatcac 122580
tttcaggta accaatcaga catagatttg gtcttttcac atagtcccat atttcttgga 122640
ggctttgttc atttcttttt attcttttct ctctgaactt ctgccttcatt ttcattcatt 122700
tgatcttcaa tcaactgata cctttcttcc agttgatcta atcggtact gaggttgtg 122760
catttgtcac gtagttctcg tgetgtgtt ttcagctcca tcaggctcct taaggacttc 122820
tctgcattgg ttattctagt tagccatttg tctaattttt tttcaagggt tttacttct 122880
tgccatgctg ttcgaacttc ctctttagc tcagagtagt ttgattgtct gaagccttct 122940
tctctcaact cgtcaaagtc attctccatc cagctttgtt ccattgctgg tgaggagctg 123000
cattccttg gaggaagaaa ggcactctga ttttttaggt ttccggtttt tctgctctgt 123060
tttttccca tctttgtgggt tttatctccc ttgtgtctt gaagatgggt atgtacagat 123120
gagcgtttgg tgtggatgtc ctttctgtt gttagttttc cttctgtcag gacctcagc 123180
tgcaggctg ttggagtttg ctgcaggctc actccagacc ctgtttgcct gggtatcagc 123240
agcagaggct gcagaacagt ggatatttgt gaacagaaaa tgttgctgggt tgatcattcc 123300
tctggaagtt ttgtctcaga ggaatacccg gatgtgtgag gtgtcagctc gccctactt 123360
gggggtgcct ccagttagg ctactcgggg ttcagggaac cacttgagga ggcagctctgt 123420

-continued

cogttctcag atctccagct gcatactggg agaaccacta ctctcttcaa agctgtcaga 123480
cagggacatt taagtctgca gaggtttctg ctgccttttg ttcggctatg ccttgcccc 123540
agaggtggag tctacagagg caggcaggcc tccttgagct gtggtgggct ccaccagtt 123600
cgagcttccc agctgctttg tttaacctact caagcttcag caatggcggg caccctccc 123660
ccagcctcgc tctgccttg cagtttggtc tcagactgct atactagcaa tgagcgaggc 123720
tctgtgggag taggacctc tgagccaggc acaggatata atctcctggt gtgcggtttg 123780
tgaagacat tgaaaaagt cagtattatg gtgggagtga cccgatttcc cagggtgcat 123840
ctgtcacccc tttctttgac taggaaagg aattctctga tccttctgct ttcctgggtg 123900
aggcgatgct tcgccctgct ttggctcatg ctccgtgcgc tgcaccact gtctgcacc 123960
caccatttga cactccccg tgagatgaac ccggtacctc agttggaaat gcagaaatca 124020
cccatcttct gtgttgctca cgctgggagc tgtagactgg agctgttctt attcgccat 124080
cttcacaaaa atcttacttt ggtttctagt gttaccacct actgttcttt ctcatctcaa 124140
ccttgagtat aagtacagat cacattcctt gggttcttag aaaataatag aaatgaactc 124200
tcattcatca aaatgcccac tagtaaacac tgaggagaga caaactagaa atccagtata 124260
gaaaaataaa ataggattat attccttgga atctcagaaa aaaacaatga agagctttct 124320
ttgggcatta gacactttcc cataagggtg ctgactctct tttagtcagt tcagcttggc 124380
ccaatcttca cttggtagcc cttctttctt cttcattaat ccatctccta tgctcctatg 124440
gggtcctaga gaaatgccca tcactgtacac acacatctaa taacacaaag atcactctcg 124500
actagcaagc ccttttatga tgggttgagc atttgacacc cttgttgcta gtaacatcag 124560
tgagtgcct gaccttttt tggaacagaa tatgatcagt atgttgcctc aaggaggccc 124620
tcactgttct aggaaatata attccagagt ttgctgactc acaccatgga atatatgcat 124680
aaaatggatc ctgcagataa gcccttctct gactagtctc agacattttt tctctggtaa 124740
ttttaagtt attttttatt tttgtgggtc caaagtaggt gtatatatgt atgaggtacc 124800
tgaggcattt tgatacaagc atacagtgtc taataatcac cagagttaat ggggtatccc 124860
tcaccacaag catttactct tcttttggtg tacaaacaat ccaattatat tcttttagtt 124920
attttaagat gtataataaa ttattgttga ctgcagtcac cctgttgagc tatcaaacac 124980
tagatcttat tcattctaac tatacttttg taccagtag ccatccact tcctccctc 125040
ccactacct tcccagctc tgataacct cattccactc tctatctcta tgagctcaat 125100
tgttttaagt tttagctccc acaaatatgt gagaaaatgc caagtttgct tttctgtgct 125160
tggttattt cacataatat aatgtcctct agttccatcc atgttattgc aaatgacagg 125220
atctctttct tttttatggc ttaatagtac tttattgtat gtatgtacca cattttcttc 125280
atccatttgt ctgttgatag acaagagttg cttccaaata ttgactattg tgaatagtgc 125340
tgcaataaac gtgggaatgc agatctcttt gatatactga tttctttctt ttagggtgta 125400
taccagcag tgggattgct gggctcatat atagctctat ttttagtatt ttgtggaacc 125460
tcaaactctat tctacataat ggttttactg acttacatat ccaccaacag tgtatgagga 125520
tactcttttc tcacactct caccagcatt cattactgcc tgttctttgg atgaaagcca 125580
ttttaactgt ggtgaaatga gatctcattg ttgttttgat gtgcacttct ctgatgatca 125640
gtgaggttga ggacctgtc atatatctgt ttgtcatttg tatgtttat tttgagagat 125700
gtctaccag atcttttgcc cattttttaa tcagattggt agattttttt ttctctacag 125760

-continued

```

agtgccttgag ctctttatat gccctagtta ctagtcctcg gtcagatggg tagtttgcaa 125820
atagttgctc tcattctgtg ggttgtctct tcactttgtt gatcgaaatca cttgctgtgc 125880
agaagggttt taacttgatg tgacctcatt tgteccattt tagttgcctg tgctgggtgcg 125940
gtattactca agaaattttt gccagatta atgttctgga gagtttcccc aatgttttct 126000
tgaagtagtt tcatggattg atgtcttaga tttaagtctt taatatgttt tgattttatt 126060
tttgtatttg ctgagagata gggctctagt ttccttctgc atatggatat ccagtttttc 126120
tagcaccttt tgttaaagag actattcatt ctctaataa cgttcttggc acctttgttg 126180
aaaataagtt cactgtagat gtatggactt gtttctgggt tctctgttct gttccattgg 126240
tctatgtgtc tgcttttatg tgaataccat gttgttttgg ttgcaaaagc tctgtagtat 126300
aatttgaaat caggtaatgt gattcttcca gttttgctct gttctttttc ctcaagatag 126360
ctttgcctat cctgggtctc ttgtggttct atataaattt taggattatt ttttctattt 126420
atgtcaagaa tgcattgat attttgatat aaattgcgtt gaatctgtag atagcttcag 126480
gtagtgtgga cattttaaca atatcaattc ttgaaatcca cgaacatgga atatccttct 126540
attatttgga tgtcttcttc aatttcttat attaattttt ttttagtttt cattgtagag 126600
atatttcatt tatttgacta agtttattgc taggtatttt attttatttt tacctattga 126660
caatgggatt gcttcttga tttctttttt agattgttca ctgttggcat acagaaatgc 126720
tactgatttt tatgtgatga ttttgtatcc cgcaacttta ctgaatttgt ttatcagttc 126780
taataggctt ttggtgcaga ctttaggctt ttccaaatat aagatcatat tatctgcaaa 126840
caagaataat ttgacttctt tcttttcaat ttggatgcct ttcatttctt tctcttgtct 126900
gattgctcta actaggactt ccagttactt gttgaataac agtggggaaa gttaacatcc 126960
ttgttttgtt tcagatctta tagccaaggc cttcagtttt tctgaattta gtatgatact 127020
agctatgggt ctgcatata tggcttttat tatgttgaag tatgttccct agttttttga 127080
aggtttttat attttaagga agataaaaat tgaactttat caaatgcttt tcatgcaaca 127140
attgaaatga tcaagtgcct tttgtcttcc attctgttga tacgatgtat cacactgatt 127200
gacttgtgta tttagaacca tccttgcac ccgtggtaaa tcccacttag tcatggtgaa 127260
tgaacttttt aatgtgttgt tgaattcagt ttgctagtat tttgttgggg atttttgcac 127320
cagtgtttat cagggatatt ggctatagt tttccttttt tttatgtgtc ttttgggttt 127380
tgttatcagg gtaatactgg cctttagtaa tgagtttggga atgattctct cctctatttt 127440
ttgaaatact ttgaatagga ttgatgttac ttccttaaat gtttggtaaa attctgcact 127500
gaagccattg ggtcctgggc tttttactgc tggggagact tttcattaca gcttcaatct 127560
tattacttgt tattggtctg ttcaggcttt agattttttt catgaatcaa tcttcacaag 127620
ttgtctgttt ctcaaaattt atcaatttct tctaggtttt ccaatgtatt gtcacccagt 127680
tgctcataat gccctctaatt gatgccttga atttttgcag taaccactgt aatgtttcct 127740
tttttaactc ctgattttat ttgagcttcc tcttttttcc ttagtctagc taaatatttg 127800
tcaatgttgt ttgttcaccc acaaaaccaa cttttcattt cactgatctt ttgtattatt 127860
ttttcctttt aattttattt atttctattc tgatatttat catttcattt cttocagtta 127920
tttgagtttg gtttgcctt gcttttccag ttctttaaga tgcattgtta gggtatttat 127980
ttgaactttt ttgatatagg tgcatttgc tataaacttt caccataata ttgcttttgc 128040
tgtatcccat aggttttagt atgttgttta gtatgtttcc aatttggtag atttcaataa 128100
atttttaaat tttcttcttt atttattgac atagtcattc cagagtatac tgtttaattt 128160

```

-continued

ccatgtgggt tgtatagttt ccaaaattcc tcttggtatt gatttctagt tttattccat 128220
tgtgtgcaga gaagaagctt gatatgaatg caattgtaa taattttttt aaaacttggt 128280
ttgtgacctt agatatgatc tgcattgag aatgatccat atgctgagga aagaatgtat 128340
attctgcagc cattggataa aattgtcttt aaatatctat taggtccatt taagacataa 128400
tgcagattaa agccgatggt tcattgttca tttttctgtc tggatgatct ctccagtgtc 128460
gaaagtgggt tgttaaaatc tctaaatatt attgttttgg gatctttctc ttctttcaac 128520
tctgataata tttgcttttag atacctgggt gctccagtgt tgggtgcata tatacttaaa 128580
attgttgtat cctcctgatg aattgacccc tttatcatta tataatgacc ttctttttct 128640
ctttgtgtag tgtttgtctt gaaatctatt ttgtcggata ttagtattgc tgctaatttt 128700
tttggtttcc atttgcataa aatatctttt tcattccttt attttcaggc agcgtgtttc 128760
tttatattta ataggtgaaa tatgtttctt gtaaataaaa attattattt taaaatattt 128820
ttaaataaat actatttttt aataagaaca attattattt ttaaaaaat ttcattagtt 128880
ttggggggcac aagtggattt tgggttaaag ggtgagttct ttagtagtgg attttgagat 128940
tttagtgcag cagccacctg agaagtgtac attaccata tattatatat atactatata 129000
tgctttatat atatagtgtg tatatataat atatatacaa ctacatattg ggtaatgtac 129060
acttctcagg tgactgtgc actaaaatct caaaatccac tactaaagaa ctcaccctt 129120
taacaaaaat ccacttgtgc ccccaaaact aatgaaattt ttaaaaaat aataattgtt 129180
cttattaaaa aatagtatta ttttaaaaat attttaaaat aataattttt atttacaaga 129240
aacataatc accattataa tataaagaaa cagctgcct gaaagtaaag gaatgaaaa 129300
gatatttcac gcaaatggaa accaaaaaaa ttagcagcta tactaatata ttatatatat 129360
actacataaa gcataatat agtatagtat atatataata catttataaa gcataatat 129420
agtatgtaga taatatatgt ttatatactt taagttctgg gatacatgtg cagaacgtgc 129480
aggtttctta cataggtata ctctgtccat ggtggtttgc tgcaccctc aacctgccat 129540
atacatatag tatttctcct aatgctatct ttccctcagc cctacccac tccctgacag 129600
gccctgggtg atgatgttcc cctccctgtg tccatgtgtt ctcatgttc aactgccact 129660
tatgagttag aacatgtggt gtttggtttt ctgttctgt gttttagttt gctgaggatg 129720
atggtttcca gcttcacca tgcctctgca aaggacatga actcatcctt tttgatggct 129780
gcatagtatt ccattggtga tatgtgccac gttttcttta tccagtatat cattgatggg 129840
cattttgggt ggttccaagt ctttgcattt gtgaatagtg ctgcaataaa catacgtgtg 129900
catttgcctt tatagaagaa tgatttataa tcttttgggt atataccag taatgggatt 129960
gctgagtcaa atgatatttc tggttctaga tctttaatga attgccacac tgtcttccac 130020
aatggttgaa ctaatttatg ctcccaccaa cagtgtaaaa gcgttcctat ttcttcaaat 130080
cctcaccagc atctgttggt tcttgacttt ttaatcgcca ttctaactgg catgagatgg 130140
tatctcattg tggttttgat ttgcatttct ctaatgacca gtgatgatga gctttttttc 130200
atgtttgttg gcagcataaa tgtcttcttt tgagaagtgt ctgttcatat tcttcacca 130260
ctttttgatg gagttatttg ttttcttctt gtaaatgtt ttaagttcct tgtcgattct 130320
ggatattagc tctttgtcag atgaatagat tgcaaaaatt ttctccatt ctgtaagttg 130380
cctgttcctt ctgctgatag tttctctgct tgtgcagaag ctcttttagt taattagatc 130440
ccatttgca attttggtt ttgttgccat tgcctctggt gttttagtca tgaagtctct 130500

-continued

acccatgcct atgtectgga tggatttgcc ttggttttct tctacagttt ttatggtttt 130560
aggctcttga ttttaagtctt taatccatct tgagttaatt ttgtataacg tgtaaggaaag 130620
aggteccactt tcagttttct gcatgaggct aacgagtttt cccaacacca tttattaaat 130680
agggaatcct tccccattg tttgtttttg tcaagtttgt caaagatcag gtggttgtag 130740
atgtgtgggtg ttattttctga ggctctgct ctgttccacg tgtctatctc tctgttttgg 130800
taccagtacc atgtgttttt gggactgta ccaactgatt ggtgagagag ggaatccttg 130860
tcttgcactg gttttcaaag ggaatgcttc agcttttgcc tatcagtat gaccaatatg 130920
tagtctttta ttctcacc cctctcaaca ccccccccc acggagtcct caaagtcct 130980
tatatcactc tgtatgtttt tgcgtctca tagcttagct cccactata aatgagaaaa 131040
tacagtattt gggttttcoat tctttggta cttaattagt ataatggcct ccagctccat 131100
ccaggtgtct tgtttttcoat ccattcagcc agtctataac ttttgcttg agagtctctg 131160
ccatttagat tcagcgttat gattgataac taagggtta ctcctgccat ttggtgtgtt 131220
tctggttatt ctgtggtctt ctcttcctt tttctctctt tctgtctcc cttttagtga 131280
aagtggtttt ctctgggtgt gtattttatt ttcttcctt ttattttttt ttgtgtgtat 131340
ttgttgcatg ttattgattt gaggttacca tgaggctgt acataatatt ttctaactca 131400
ttatttcaaa ctgatgacaa cactctatcg cataaaaaa catggaaaga gaaaactaat 131460
aaaaactcta cattttaact tcactctctt gcttggtgct accttgctgt ttctatttac 131520
atcttattgt actgtttatg tcttgaaaag tagtttcagt tattactttt gattggttca 131580
tctcatagtc tttctactca agatatgagt agttcacaca ccacaattac agtggtacaa 131640
tattctgtgt tttctgtgt accttcaatt acccatgagt ttgtatttt cagataattt 131700
gttattgctc actaacatcc tattctttca gattaagag ctcccttag catttcttgt 131760
aggaaaagtc tgggtgtaat gaattcctc agctcttgt gatctgtgaa agtctttatt 131820
ttctctcat gtttcaagga tattttcact ggatagtcta ttctagggtta aaagttttt 131880
ttttttttt cttcagccct tcaggtaagt catgccactc tctcctggc tataaggcta 131940
ccactgaaaa gtctgctgcc agacatatat gagtccatt ctatgttact tgtttatttt 132000
ctcttggtac ttttaggatc ctttctttat ctttgacct tgggagtttg attattaaat 132060
gccttgaggt ggtctttttt ggattaaac ttctctgtgt tcttgactt ggatattaat 132120
atctttctct aggtttggga agttctctgt tattatccct ttgaataaac tttctaccaa 132180
gatctctctt tctctctctg tctctctctc tctctctctc tcttcttaa ggccaataac 132240
ttttagattt gcccttttga ggtgttttc tagatctctg aggtgtgctt cattgtttgc 132300
tattttttt tttttttgt ctctctgac tacattttca aatagcctgt tttaaaactc 132360
actaattctt tcttttgctt ggtcaattat gctgttaaga gactctgagg cattcttcag 132420
tgtgtcagtt gcatttttca gcaccagaat gtctgcttat ttttttttag attatttcca 132480
tctctttgtt aaatatatct gatagaattc tgaattctt cttagtgtta tctttaattt 132540
ccttgaattt cctcaacaca actattttga attatctgtc tgaagggtca catatctcta 132600
ttttccagg attgctatct ggtgctttat ttagttcatt ttgtgaggtc atgttttctt 132660
ggatgggtgtt aatgctagta gatgttttct agtgtctgag cattgaaaag ttagatgttt 132720
attgtagtct tcacagtctg ggcctgttca tacctgccct ccttgggaga ctttccaagt 132780
attcgaaggg atttgatgc tgtgatctta gtctttggtc actgcagcca tatctgcttt 132840
atggagcatc ccatgctcag taatgctgtg gctcttccag actcatagag ttactgctg 132900

-continued

catgctcttg ggtaagagcc aggaaaattc cctggattac caagcagaga ctcttggtct 132960
cttctctcac tttcccccaa acaaatagag tctctctctc tctctctctt tctctctctc 133020
tctctccctc tcattctctg ccgacctgcc tgaatctggg gtagggatga cacaatcaca 133080
ttttagtgca acaccattgg gactgtgcta ggtcagaccc aaagctggca cagcactgag 133140
tctcgcccaa cgccacaga gacctctcc tgggtaatgt ctgtgtttgc tcaaagccta 133200
agggctatac aatcagtcag tgggtaagcc agcctgtctt atgtccttcc cttcagggtg 133260
atgagttcct caagcaggtc cagggatggg gtccaggagc caaggcctcg agctgtgact 133320
gagctggcac ccaatccata agacaaagat tttttccaca ctttcttcc ttgtcctcaa 133380
gcaaaggagt ctctcctgt ggccaccacc acccccatgt tcatggcaag tattgtctgg 133440
ctaccaccaa tcttcaacta aggccagggt gttcttttag tagcttatgg tgaatgtac 133500
caaggctgag tctctccctt caaggaagtg ggctcctctc tggcccagggt caggccgga 133560
aatactatcc aagagccaag gcttggaatc agtttcccca agagtccatt tgggtgctcta 133620
caccactgt ggcagaacca gtaccaagc tgcaagacaa agtcctcttt actcttctct 133680
ctcctttaca gagactctcc ctatagccac cacagctggg aatatgtctg gtcactcttg 133740
aagcaagaac agctctgagt ctcaactcaa actcctggca agtactgcct ggctatcaca 133800
ctgattatct agggcccaag ggctcttttag tcagcaggag atgaatcctg ccagtactga 133860
ttccttccct tcaaggcagc cggtttcttt ctggcccagt gtgtatctag aaatatcatt 133920
tgggagctag ggctggcat ggtgacctca ggactctgcc tgggtgccctg ttctactgtg 133980
gctgatgtag tatccaaatt gcaagaccaa gtctcttcta ctctccctc tctgtcttc 134040
aagcagaagg aatgagtcg ccttgaggtt gggagctgca ttgcctggga ttggaggagg 134100
gggtggcaca gcactctctt ggtcaccaca gctggtgtct tactaggctg catgttcccc 134160
aagtccactg gctctgaggc tagcacacca ggatttgacc aagaattgca attctgtgtg 134220
cttcaactgc ctttcaagtt tatttgagat ccagagcac tttagccac agtgacagggt 134280
cttgccagaa tttagttctt gactgtctgag atggacaatt tgctgtctgat tagggctggt 134340
ctaagtgtct cttctgtggg cactggctga gttctgtctc atgttgcttt ctgctgtgac 134400
agggcaacat tgagtttcaa tgcaagtccc acagtcactg caatcttctt ctccaagcc 134460
tgctctgaac accatgtggt tgctgtctgg ggctggggga gggatgtgt aggcaattca 134520
agaatgtctt tctaccctt ttgggtgctt ctttcttgg tatgatatta aaaccagtta 134580
ctgtgattgc tcacctgatt tttggttctt atgaaggctc tttttgtgt ggatcactgt 134640
tcaattttgt cctgcaagcg gggatggggg acaattgctg gaggtctctc tttggccatc 134700
ttgtccacc tctaccctag tattagcaat ttcaaagcag ttgggatgga ggtagaagga 134760
aagggcgctt ggaatcagaa aatccatgtc ttagctttga gccttagaaa attcatttga 134820
cccttgtaag cctcagttgc ttcactgtga aaagagaaat aatataatgg ctgaaaagat 134880
caaagggtgat aatgcttttg aaaacactat agaaaatgac aaaatatcac atgagtatta 134940
ttttctagtt tctaggagtc tcttaccat tgtacaggac aacctgtct atttttaaat 135000
aaattattat ttgcctctga gcaaccctgc aaagagttgc ctgtaggaga aacagcttta 135060
cttgcaaatc actccactgt tttctttgtg cacagcttat taatacataa ggcacatgtc 135120
ctccagcctg cagtaacatt ggaatcatta cctctttgga gtacctacca gagcttctca 135180
aagtgaattt tgtttatcac cacaaaaaat agtctgttgc agagataacc tccaaattca 135240

-continued

atgacaatat ttccaatcac ttttgcata tgcagaaata gacaaatata taattttgct 135300
 tatagagaca attattgtct cccaacaagt gatcagtagt cagaaaatgg ccaagaaata 135360
 ccatggggtg tgccttccca taacagctta tctttgtgtt ttagttgcaa gggtactaaa 135420
 agcctgtgca gggtttatgg caaaagtaaa acttgcctca ggagcaagcc cttgtttcat 135480
 tgtctaattg tcttaatccc cagcagacag gatttggatc tggcatttgg taacagggca 135540
 gtttccaaag ttgctgtacg caacttgagg aagagaggtg atattatcgg aatgaatttc 135600
 tttgttgtaa gttataaatg tatgggcttt tccaatccca tcaccttaa aactttattt 135660
 gttttctgca gtgagggtgt ctccgttgtc tttaatatgc ttgctttgag ttcattggatg 135720
 aacattctcg cctggctgac atgtggactc tctgaaattg ttataaggtc tttttctttg 135780
 tttttttctt gatgcccaag ctgccaaagg tagtactggc agtgggtggc agacaaggag 135840
 gtgatagcaa actttgtcct ctggcctccc ttgacctatt ccattcatta tctaagggac 135900
 tccaagccag cattccacag agtgccctca ccaaactcac taagactgaa ggcgaaaccg 135960
 gattccaaac agccattatg aaaggaaaga gagagagact tagggtttgc aaaataagat 136020
 accctgttga ttctttttat tccatacaga tactactatt ctttaggaaa acgttaaaat 136080
 cacatgatct tccaggacct gggctgcttc tttaagaagc atgttacaga aagctttatt 136140
 ggccaacaac atattgaaag atagattaat caatcattca ttcaaataag gtatattcag 136200
 aattgaggta tattgtagcc agacagttag actacaaaaa aagaatgcac cgtacctta 136260
 tctcttgca aatctaagc gggagataac cactctttca atttatagtg acctataaca 136320
 tttcgtacac tgctgaatat ctttacatgg taataacaca atggaaagct tgcaaaatag 136380
 acagaggcta ggggaagaag gattgagtgt gaatatagcc tcttataaat cgagaggaat 136440
 ggtctgtgtc ttctgatcat acagagataa taaatatgga aatgatttca aactaacaaa 136500
 gcaaatgtgc agaaaatact gagaatatag tgggcaggat acctgagttt tggttccatc 136560
 tctgttattg actcattgtg taactctgag caggctctgt ctgctctctg gatctcacc 136620
 tttctatct gtaaaatgag attgttggat tagatgatct ccatagaggt tctcacctat 136680
 tctgacattc aaaaggactc ctaatttttc ttatataata ataatatata tgatctgtag 136740
 agtgctttac actttatatg atatttttgc atctgttacc tcatgtgaga aaagcactgg 136800
 actgtggac tggcaatgag gacacctgga ttcttgtctc tgttttgaca ctgattcatg 136860
 gtgtgatctt caagcaaatt ctctgagttt cagtttctca atctgtaaaa taggggggta 136920
 tgaagattgg actaaatcag taggtctcta aaatgttcca caaagccctg ggggtggggg 136980
 ctctacaga gtttcgctaa ggcaaacac aacgctaagc ctgcatggaa gaggagaaaa 137040
 agagtggcct gacaagagaa gttccagtt tccatgcca acccaggca gattacattt 137100
 aattttatct gatttatata gagagtttct atgtaattgt ttattcttaa aaatagttaa 137160
 ctataaaaaa ctcaactggt ttgattttta aagattgcac atataagtga gatcatgcag 137220
 tcagtatttg tctttctatg cctggcttat ttcacttagc ataattgtct ccagcatcat 137280
 ctatgttgc gcaaatgaca gacttttctt ttcattaaag gctatatagt attccatcgt 137340
 gtatgtacac cacattttct cttttgtaac tttcatttta gggtcagggg ttcattgtga 137400
 tgtttgatat ataggtaaac tgcattgcag agaggtttct tgtacagatt atttcatcac 137460
 ccagtaata agcatagtat ctaatcaatt tttttctgat cctctccctt cctccacct 137520
 acaacctcaa gtaggcctg gtgtctattg tccccctt tgtgtccatt acaccacatt 137580
 tcttttatcc acttatccat ccatggacac ttagtttgct tccatattgt ggctattgtg 137640

-continued

```

aataatgctg aaaaaagtca aactcataga agcagagagt agaattggtg ttaccaggga 137700
ctgggaggca gttgactgag ctaggaaaag agagataata aaagggtaca atgtgtcagt 137760
tatatagaag gaataagtta tattgaacta ttgcacagca tggtgaccat agttaataat 137820
aatgtattat atgtctcagt attgctaaaa gagtaaat tttaattcta accacaaaaa 137880
attattagta ggcaagggtga tggatatgtt aatttgcttg atttaattct tctagaatgc 137940
atacatatat caaacatcc cactgtaccc cataaatata tacaattatt atttgcatt 138000
ttagaaattt aaaaacttga tttagatgag ctctaaggcc ttaagtatta aagtattaa 138060
tattaaagt atagttaacc aagtatttg tttgtaact tcatttttgt tattatttta 138120
acaaaccaat atattgtgaa tatacttcca agtgaaaaga aaaaagacat tgcagtcac 138180
actaataact gcaaacatt cctttgcaag aatatggaat aattcattta atcattcccc 138240
taatgttaga cattcaaatg tttccaactt tttctattta aataatgcta caataaactt 138300
ctattttgtg cttattgtat tattttctta caacacatcc ctagaagtgg aattcctaga 138360
agtttataca catttccaat ttttttccaa atatatggca aaatttctct ctaaagtatt 138420
tttattccta ccagaaatac ctcttcacca acacgtagta tttaatctgt accaatctgg 138480
cttaagacaa tgatatttaa tttgtatttc tgtgatttct agctaaatta aataatcttc 138540
atatgcttat tggctcattg tacttctaac tgccttctcc tgtctgttgc ccatttttct 138600
attgtgctgt ttatttttat atatcgaata tattgaccat tggttttaca tacttgatgc 138660
taataattat tcttagttta tggtttgtct ttgagtttta taatggtgtt tatttcacat 138720
aagaaattat aaatgttttc taatgaaatt tatcaagtct gtcttcactt atgttttctt 138780
cattgtcaat aacttaaaat gaccttttct accttataaa attttgaaat tttcctctgt 138840
attgtctaata agtacttaca tgatttcttc ttttaaatg acatatttaa tccatttgga 138900
atttatattg attttaacta gtaatttaac tttattttct tctccaaatg attcactagt 138960
tgctctgaca ttatttagtg aataattcat cctttcttca ctgaattgga atggcatatt 139020
ccatatactg tgtctggttt tggcctttct gatctcttcc actgatcaac ctaagctgga 139080
gccagtatca aactgttgta atcattatgc ctttagatac tttaaatgta cagcagggaa 139140
tgtcttatta ctctattttt tcacaaatat cttggcattg tctcatgttt tattccttca 139200
gataaatttt gggattatth tgcaagatt ttggttgagt tgttttaaat ttttagattt 139260
cattgggaaa gaactgaaat ccttgaata ttgcttcttc ttagccagga atatggtaca 139320
actttgcatt taattcagtt ctttctttaa ataccaccat gaagtttttt gttttgttca 139380
tataggctct gcattaacac catatatata aagtgtgaga aatactacat tcttcaggat 139440
tctctgtagg ttaacaatga agatgatgac tcaacctttt ctttgtttgc ataattgtat 139500
gccactaata gtgggttaact tctctgcctt acctcctctg ttccaaacag gatttttcag 139560
aatgaacaaa ttaaaagaat cataatcaga cactaacccc aagccatact gcatggcagc 139620
accaatggga ctgacagaaa acaacagaaa taggaagaaa tcctacagag aaacaaactt 139680
gaaagctgtc tcatggcctt tgaatcatc ttaagtttta tgatggaagg atacgactat 139740
gaagaaagac acagagcaac atcagacagt caagaatttc agagccagct ggcatgcagt 139800
ggacctcatg ccagccatt ttatgactat ttaggtagtc aagggtttta gatttttcta 139860
ataagacagt tattatgcat ttcaatgagt gatttctttg cagctctaga gtgtggcctt 139920
acctacttca acatgagaag atttttgtat tttgtcagtc atttcacaat gacttttagt 139980

```

-continued

```

gagcccttca ttatagactg tggatacaac tttgctgttg gaaattaaca gtgtcaaaca 140040
actgggtata atgtttgtaa tatctgagga gggggagctg cctaggaagt tgtattccct 140100
gtgttaattht ttcagtctct taggttatag aggaccttct agaaccacct tacagcagga 140160
ttacatccca tttacacagt tctctgtcac ttgaatacag agaagggatc cacaaggcca 140220
tatgcttctc agacaaagag aaaagatttc tgccacactc agaacgcttt gtcttcagac 140280
tataatcacc cacaccatat ttcctttgga tccactttcc agatttttgt gctggcacta 140340
acaccaactt gctgtggctt ggggcatgta atttcaatac tttgtgcccc ttttcataag 140400
tgaagtgtca ggcatacat tggacatttt aagattcttt acagcccaat gattctgtgt 140460
ttctaattag gcccaatggg tttagagctaa aaggaaacag tgagtctctt ggaaggaaa 140520
gacatataac acagtccaga ggtaaaatgg gctgtattca agaaaagata ggacaatact 140580
ttgcagggat gctgcagaga ggattcaagc cttgtatgga ggaatggatg tgatacaacc 140640
aaaaagtctt taaaaattct tccaactaa tctgagattt gtaaccttat ggactgtgat 140700
ttgcagcaaa ccaaggatgt gataaagact agtattgttt ctagaatgca aggatggttc 140760
aacatatgca aatcaatagt attaacagaa tgaaggacaa aaactatatg atcatctcaa 140820
tagatgcaga aaaataattht gacaaaattc aacatcattt tatgataaaa tctttcaaga 140880
aattgggtat tagaaggaat gtttctcaac acaataaagg ccatatcaga caagcccaca 140940
gctaacatta tattcaatga ccaggaaatga gataaggatg ctactctca ccactctctg 141000
ttaacatagt actggaagtc ctageccaatt tcatattaat gagcctcatt ttcttcatca 141060
tagaatgaag tatataataa tcctgtttat acttaacttg cacagattat tattattatt 141120
taattattat tttgagacag ggtctcactc tgtcaccacg gctggagtgc agtaccacaa 141180
tcacagctta cttcagccac gacctcccag gcataaagga tccatgcccc tcagcctcct 141240
gagtagctgg gagtacaggt gcacaccacc acacctagct aatttttttt ttccattttt 141300
ttatagagac ggagtctcac tatgtgccc aggtgggtct caaactcctg tgctcaagca 141360
atctttccac cttggccttc caaagtgtg ggattacagg agtgagccac tgcacctggc 141420
cttgacagatt attattaaac tttgtaaact aatcaaataga gagtgattat tgttactgtt 141480
aagaactctg atagcctcat ccatatattt ggagaaattg aataaataat aggaaagaaa 141540
taatagcatc ccaatgattht taccttggct ctaccatcat ttggggaagt gataattcag 141600
ataggagaag tgacttgga gcagtcttga gagattgcct gttccatccc ctatctttgt 141660
ccttaaacca aattgtacag ataaataagg tcttattttt aggacttaca gaaaaagat 141720
tcctttcata tccatctttg caatctcaa ccacttctgt cactattatg tgctatttca 141780
aacattaaat tcctcattct gctttgaagg aacacatgtg tcatgtgtac ccatttgtat 141840
gttttggtgt gttttatgct ttatgtgac acccacatat gcacagataa ttccaaaatc 141900
cagtgtgtgg gtgtgtgatt ccctgtgtta attattcagt cacactcaaa cacctatgca 141960
ctcacacata catgaatata cacatgtaca ttagcatgtt tatgcttatg ttgcattgtga 142020
ctggcaacat cagtgccttt ctaaggcaat gttaactacc ttgagttttg ggagagcttt 142080
agagaacaaa gacaagagac taaatgattc tagatgtaag agacaatgtt gcaataagtt 142140
actatcctaa aaagacagaa tacagggaca agagactatt attttgata gtttcttgct 142200
taccagtaat acttaagtcc tttacattaa aaaaaaaaaa ctctgtaaat atattgcaga 142260
agaaatccag acatccttca agattcttag agctggaaaa gattttaatg actttccagt 142320
ccaatctatc tcatgtaatc aatggggccc agagaggcaa aaggtcttgt ccaaggtcat 142380

```

-continued

atagtgaatt agtgataagg ctgaacaagg attcagatgt tggggcttcc agccactgc 142440
tctttctctc atctgggatt tgtgtatatt tgttcattag agattttcct ctgtaacctc 142500
aatatccaat gcagggcctt gcacataata gattatcagt aaatgttaaa ttaatatgtc 142560
atggctttgg ttgtactggg cttttgcact tactcctgag taaattgtaa agaatatcta 142620
cgtttttagt tgccttgttt tagaccaaga ggtacccaga gaaaagggtg gaactatgct 142680
aaggaaatta tccaggttcc aaattgaaaa aaaaaaaaaa tcatgctttt ccgctataac 142740
ctctctcatt cacagagtga ttctctttca gaagggaat ctagaactat tatgggagcc 142800
atattccatt ggtggtgcaa ccatttcttg acaactagg gtccaagaaa gtattttcct 142860
ggggaagatg agatttttca aagaaggcac gcactttcta acctaagctt atttcagtaa 142920
tcaatgtaac aagctggtct tgatgattgc agcagtacca atactgtggg agtgaccag 142980
ttctagaaca gctacaacat tggaattgaa cgcactagaa ttggatacag gacctgtttt 143040
tgaggagcta acacccaaag gctgaacagc actcgtagca ccgtccttcc tgtgcacata 143100
tggtagtctc cagtttgcaa cagaaataaa gctgttagca aattatgtgt tctatttatg 143160
caaataaaat cttgtggtat gctagaaaga gcactggcct ggagacctta gttttctcat 143220
atgttaaaaa cccctaacac aggcctggtt catagtaggc acccaataaa tagtagtttt 143280
cttcttttgg gggcctccga ttcagtgtgc ttcttcagggt aagtcacttc cctggaactc 143340
ctccttgtaa tgagagtgt actgttgtga tttttaacag ttcttcaag ccaagcattt 143400
tggaatcctt tcataaaggg agaagggaag gaaagaagaa aggaaaatta aaggaaaaag 143460
aacaataaaa acgttaaaaa ggaggaaagg aaaaaggatc ctttactaca ataaaactaa 143520
tcttatgttc ttgcaagtag cactttaagt aaaagaagtt ctttgcgtac ctggttacta 143580
ctgaacctac tacataaaat agcctactat aatagatgca tttatgtgcc taatcttcac 143640
tttttaggct tagtaaaggg agaggaaagc tgatgtatag ttaaatttat gtttttagtt 143700
gttttttttt ctactctcaa atatcaatca ctcttttagt tctctttctt ttccgacca 143760
caagcattct tcctctgctt aaagaagctt ccctaaaac ccagtctatc cagtaagcca 143820
aagcacagca ataaatttga ggaataaata ccagggaact agagacagaa aggagtgagg 143880
ggatgcagaa gctgaagctg gagcacggtt gcaagcatga gaagtctgc gtgtttcaga 143940
gcagccaagg atgtattttt gcctattcct gctggtgact ctgtgtgtct atgcattcat 144000
ctgctatatt tacatgttta gtcagtcaat ccacgtttgc tgagagcctg ctgtgtgcca 144060
ggattgtgct agcgtaaagg agcaaagtat tgagcaaaat atgtttgagc agctgtaatt 144120
ctgaggatct ctaggctga gcatgtgtat gtgtgtgcgc ttctatgtat ctgtgacaac 144180
tccagggtgt catgacagt atctttgtta ctctgttggc ttcatcgaac ttctttttac 144240
ttgctgtgat tcactacata gagtgggctt tatctctgat tttataaac tgcaagactg 144300
ggggtatgat caccagcaat ctaaaaacag ttagaaatcc catggagtta tctttttagt 144360
aaattttcct ctactaatat tatgaaaaat aagcatctta ttagctcgag tgtaattcta 144420
tgcatgatta caggtatcaa taggaagaaa cattgactga gttcaaatct cttctacgcc 144480
atgctaaagg ggtgacaagt tccacaatgg atcattttct catgggcatt tctgactttt 144540
ggtaaaagta gagcacctta ttttaaaac cattgagtag tcctaagtag ggagatatca 144600
tcaggatctg aattgttcat ccctaaaaa aacaccaatg gaaatcaaac aatatagtgc 144660
caaattaaac tgtttgaata tttaggttct gtatgatcaa attgtttggt gccatactct 144720

-continued

```

gtccactttt ttcattgtgtt aggatataat ttcatatctt ttctgttcta gaaatacccg 144780
aagaaagaga ctctggaac tcattatcag gtctatcaac tcttgatatt gttctcccag 144840
ggaaacagaa gtacctgtgc gccagcagaa atgattgcac tattgataaa ttccgaagga 144900
aaaattgtcc atcttgtcgt ctccggaat gttatgaagc agggatgact ctgggaggta 144960
agatactttt cttctctctc ctctctctc ctctctctcc cttctctctc attttctagt 145020
ctctcttttag accagatttt ctctctttgat gcttccaagg ggaccagcca tgccttagac 145080
acaggctgac cctttcatag gcaacgtggc catcagccag ctggtgcctt ttttttaac 145140
cttatctata ccaatcccca ttccggggct cagcattaga gcaggcgggtg tgaagcaggg 145200
atcaggagcc aacagaaggt gattgaggat gcattctgact gggcagggcc cccaggggac 145260
ttaatgatac tggcctgatg ttgttcagtg gtagctagga tgagagaact aagaaatcca 145320
gaacagtcag aggtgcagga tgaccaggc ataggcgag gatgaccag gcacaggctg 145380
atcctgaaca cctgggaata tcccttagct aactgctgcc tatgtttagt ggccagccac 145440
ctcgaatgag aagctacttc tctttggagc ctgtgactag gctgccacac agagccaatt 145500
tcctatccta tctctcccaa agatgagcag gtgttttaac aatttccttt tctttgcaa 145560
gctattgacc atttccaaaa gcatTTTTTT tcagtagcac agtaacgtga tagatggaag 145620
atacagctct ttcaaggcg ttctctatc ataaggctct ctgtccaca aacctgtcta 145680
ccatgagtgt tgtcaccatt ccagaaaggc ttgacatcag ttgattgaga cttatatatt 145740
ccctctccaa actcccccat ctctctcatgt ttacatctgc ccaatgccag ggtctctgct 145800
gctgcctgct acttccaaaa agatgtgtct ttcattgaga aaacaagatc attaatccac 145860
ttcgatttgg aaatggaatt tgaagaaagg caagcctatt tctgagtgc tgcaactgta 145920
gcctcatacc caattattca ttattagcct ggaaaaacca agtgcttaga atccaacct 145980
ctccctctc ctcttaagtc taatttagac cagttgtcta tctctggctt tctgtgaggt 146040
gttcaatacc ttgtctgcct atgtgcacat ttatagacaa caactagtct tcttatcctg 146100
gagcagggcc atgtgtggat ctctatatag ataactatat cctcccatc ctccagggc 146160
agtagtatta tttaaacaga acaagtacc tcacatgaat tgaccaggc tggatgagag 146220
acaatttcaa aagaatcatc tcaagtagcg tccagtactc ccaaacatca caggtagatg 146280
ttctgtgagt ggtcttccaa gcatccacat caaatgagac tcagatatct gagaaaaact 146340
aaccttgttt tggtttgctt ggtgcacccc aaagaaatcc acaattgag gtctacagtg 146400
gagaagaagt aggactgggg tcaggagta caggagcaa ggcagggaagg gtgacaaagt 146460
gattgacaag aaaaaatgtt ctccatatga atgttgacgc ccatgttga gggttcttat 146520
acactcaact gtcaattatt tagcctctctg tgaattatgt atagtataaa agataggagc 146580
tctcaagtag ggaacctctt ggcttgccat ctggcaatat gaattgcaag tccactttga 146640
tgagggtaaa gtttaatggt aacaaaagtc ctcataacat ttggatgcaa atcttaacat 146700
taattccatg tctcagccaa cattctccat tattaagcag cctgtgatgt gattacagtg 146760
aaccactttt gaaaggagc ctgtgtataa cagatagttt cactatacta tataaccgtc 146820
agatgcaggc ttgtaaatta atttgttggg gacaatgttt cagtacattt tcaaattgat 146880
tcattggtat agtactcaaa tttgagtggg ctggtgaac acaatgaaga caagctgaga 146940
agtgtgtga ctggccttca tttcagttgc aggccatga tatttttagt gtcttccatg 147000
tacaaggcac catgctaggc attagagctt gaggtggca aacttcagga agtggtcaca 147060
agataccagg attcttgatg ttgtgtaaat ggccttgctt ttagagtcag gcagatctag 147120

```

-continued

```

tttaaaggct cagctccttt atttactgtg tgcccctctg agcctcaatt tctcatctc 147180
tgatttagaa ataccatcct catagagtta taatgagtat cagatgacat gatgaatgtg 147240
aacatccttg ataaatagca aaatgctaga caaatatggg ggcttaatat gacattgagg 147300
tcactagtaa tttagctgga aagtctgtaa cacagcactt cccgatggct tttaccctaa 147360
gtaacttggt atgcatata atatgtaca gcaccaacag gcagagaatc gccagaaaa 147420
actcttgatt acctcaaacg aaaaagtacc accaggatcc tgttcagaag ctaattttag 147480
taattaaggg aatcatatgc tatgttcaaa taccatgccg gtaaaaaccc aattgtttac 147540
cttcttaaat cactgcttga agagcaaate tttccatttt gctgaatgaa cttatctcca 147600
cgttccctgc cctactgaca caacccctc ccaagtttat tggttaactta cacattcaat 147660
gcacagcaca cctttactca aacaatggaa aagaagaaa gtgtcaattc aaagtggccc 147720
ttgtctattc cttaaggagt agacttccat tttcatcaga tttggattta gcatagacat 147780
attgattacc ttgaagaaga attcatataa ttttatcttc tgattcccat cactcaaate 147840
aaaattacat aatatattcc aaaatggcaa cttagaatgt ggcttgggc aagtccttc 147900
tctcctctga tgcttggttt tcccatcata gaactggaat tgtggcttca ccgaggacct 147960
ttctgggtct aacattttgt gattctatgt aaaaagccac acagaaagga ttgtttttca 148020
gccctttctt agattgtctg tccctgctc ccagaagtat agatagttag acttgagtgc 148080
tttgatacat cgtaattgta tctacctcca ttcacaccta cttaagatat ctgtctaaaa 148140
gtagactaga cagattattc agagagtggg gggcagaagg gctgtctctg tatcttaaag 148200
aagctggcac tcttcagctg atggctgctt ggtcttgagg cctcaagatc tttaatctgg 148260
ctttctctat agtgtttcat tcaactgttg gtgatggaat ctcttcagtt cagagatact 148320
taatagatat agctttttct ttcctgcttc caggcctacc tacctgttcc ttgctttttt 148380
ttctagcagc tgttgttgtt tctgaagaa tcttgagggt gtttgaggtc tcagaatggc 148440
ttccttaaag actaccttca gactctcagc tgctcatcca caacagagat cagcctttct 148500
ttgtagatga ttcattcctg gctgcatttg aaaaccacat attgttaatt gcttgacgaa 148560
tttaaatccc ttgactactt ttcatttcag aaaacactta caaaaaaagt ccaaagagg 148620
accttccctc cagtgaatta gctgtggctt tctcacagtc catagttagg ataaatgtaa 148680
agccatttct catttttctc cgcactttcc aagggtacac tccttgtttc caagatggaa 148740
tgagaaataa agaagtgcc ttcctgccat cttctccctt gaccttttc tccttccac 148800
tttctccta ttcctccca aacatgattt atttctgctt tttgcaactc ttgagttctc 148860
agcatttagt aaatgggtgt ggtccctgtt gattccttcc tctcctggac catggaaggt 148920
agtaggcctt tcagaaatct caggtagcag ccaaacccca gaagaagaga aggaacacag 148980
agacctagac catgtgagaa cctgaggtgt gcagcattta cttcacagat tcgtctagca 149040
tatttgagag gtgtctttcc tactaggaga ctgaactctg catctgagaa taaaaactta 149100
acatatctac aggttttgac aacctctgtg aattatctag ttgagaggat ggctcaagga 149160
gcctattgcc atggtctgat gtcgttatgg acgctatgaa catccttgca gtttccattg 149220
ttgaagacag cctgatgcc agctgtctca tcattcccca tgttcaagag catcccagca 149280
ttgctacctc aggatcccat gtcctgaatg caacagagtg atttgcctgc tgaattacta 149340
ttcatggcat ggctcttcac agcatttatt catccatgta tctatccatt catccttcca 149400
gccagccaag aagttcacgc tttcatcttt tcatccattt actcacctat ttattcattt 149460

```

-continued

```

agcaaatatt tattgagtac caactatgtg ccagacactc tgctaggcat tttggggaag 149520
cagaactgaa taagatacta ttcttctcct caaaaatttg agcaagagga gaaaggaagt 149580
aatgaggaat attccttagc cataaaggaa aaataagaaa tcacttgga gaagttaggt 149640
gagatggaag gaaaaggaca tctaaggtaa agcgtacagt ttgaataaag gcacagagac 149700
atgaacaaaa tgcattgagg gtttgaggaa cagcaattgg tttaacatgg ccagagctgg 149760
ggaaatggta agggcaagct gaaaccacat tgaaagcaaa cttgggtatt atactaggta 149820
gtttagactt caagcagttg aaaatctttg agcatgggat aggcagatg acattgtgtt 149880
tatttgcatg tttctttaaa gaaaactggc agcagcacia atgttttgtt gatgagggtt 149940
taaattgtag aaagttagac aatttttagga aggcagcta gagagaaatt tctagcatca 150000
aattttgcta aacacctagg attttagtatt acctccattt gggttgttac ctgcaagtac 150060
tgaccacgta tatgaagaag tactggttta gaccaaggca attggcttgt ataagaggcc 150120
tacctcata ccaaaagcca gtttcttggt tctaggccag tgtttactgg tatgtgtcct 150180
gagaaaacta gttccatgac atgttccatg aaaaatatga tttctattgt caaataagtg 150240
agggaaaact gcatatcatg gtctctgctc ggaagattta caatccttat tagcatatca 150300
caggctctgg tgaatactgc ggtaaagtaa ccgaggagct ttgtaactca ggattcccga 150360
agttgattca accacaggac ctcatattt cacataacac ctgttatcct acaaaaccac 150420
tgttctctgg aatacacttt cgaaaacatg ggtatagaca aaaactctat cctataggca 150480
gagaatacct atacctctag ctccaggtcat cattttgcag atgtgtgtgt cattaagaat 150540
cagtcaataa tgcattaatg atcaaaagca gaccatcctt accacatggt gcataagatt 150600
atgctattat gctattagct actaatgcca cttaaagtaa ttatgttggg tctgcaacgt 150660
tgtcatcac aaaggatagg atgcaaaact gtcttagggc aaagcatggt tattgcccc 150720
gttatctaata gtctgcaggt acatattcct ggcctaagga ttgtgctaaa gaagttattt 150780
ctaagaaata tagtgacttc cagcatcatg cagaatgacc atttaatat ttgaatatct 150840
agacattctg ctgtagaatt taatagtcct tttatacact gtctgaccaa cattttgaca 150900
tttactcaga accccatcac agtgctacca cataacctca ttgctaaagt gggaggccta 150960
gaaatcacag attttagaag accatccaat gattgaatcc cctctacttc ctgttcagca 151020
ggcagcagag tgtcataaag aattaacaac gtggaactca gttactggga tttcttccat 151080
tctcctttga ttctctagac tagaattcca aagacctca ggctggtgat gcaagtggga 151140
agtctcattt ctgagaagtg ctgcttcta cccacaattc tttgatagct gagtgtctta 151200
gctgatctgc ataactgagg tgtgcaccaa ggagcagaat tactctataa attttggcat 151260
caacatgtgc aacttgtgac tcagactttt gaaactctgg ggattttttt gtttggttgg 151320
tttttgtttt aagatgtcct gtggatatag ggaaatagta caatagactc agatacagag 151380
aggccttggt tctagtcttg gttctgtcac ttactatctt gatgtccttg cacaatcac 151440
cagacctctc tgagcctcag tttctccaac cactgttg gaataataaa atctttttta 151500
cggcattgtt gtaagtatgt agaaaaactg gtacacagta ggcacacaa caatgtcacc 151560
gtacccttca gcccttcttt tgtggatgaa aaatggtctt tgtgtctcca gtcaccactg 151620
gggtctgttc tctctctctc tctgtttaca gtgtggcttt tggttcttgt tctttgttc 151680
tttggtctgt aaattacct tgaacaacc cttgaaattt cactccatg acctaaatcg 151740
tcacccctaa attggttaca tacatatatt gtgacacttt ggaggggaaa agctttatgt 151800
ctctctaact gtagttctta agggaatttg catatggaaa aaacagagac tgcgtctctt 151860

```

-continued

aattcctcca aaccaaatta tctgggatag cacatatatg ttgtactctg tctctgagca 151920
tttgctctta gagaactatg gttagagcga agtaaat tctaatcata aaaattaatg 151980
ataccgcata tctgatactt gaatgagtac ctccttgtaa aatttatact taaatccttg 152040
agttttttaa gtgtaatagc aatagaaaga ttttattgtt gtttactttt actgtgagt 152100
ctccaaaatc cctcagttgc tcttgaaaga gcaagatgat gccataggca atattttcca 152160
aaggtagtag gcagaaaact gagtacacag cacacaatag gccatatata caaaagcaag 152220
tattttgcaa ataataataa ttcaggaaaa aagcttcact ttcgttgga acctgtttgt 152280
ttaaaacat tttattattt attatttaa aagagtgtca cttgttacag attgtgggat 152340
gtgttcctta agatcacaaa aatgtaaaat attttctttt tatactgaac acatgcatag 152400
acaacttacc tgagcaagct gctttttgga gacatttgca catcttttgg gatcacgttg 152460
ttaagaagta gaactaaggg aaaaacacgc agccaccag aaatcggtag agccttcagc 152520
tcatctgtta ttaatat tctgtgacaaca gatctctagg aagtaaacag gaaattgcat 152580
cgctatctg catcaccttt tttggaatca ggttccattc ttctcagtc agttcaacct 152640
tgtgatactt tttagatctc aaccaaggca tagaaatata tttcccttg cttaataccc 152700
catggaacca atgcccctgt ggttgaagta aaaattgatt gttgagggac atttcagccc 152760
tctagcagtc aacaattaaa aacatgtaag caccgagcac ctgcagaaaa cttggactgg 152820
catttgatc taagaagaaa atctgcatct tgaccaagat gaaaagtcac cagcccaagc 152880
ttgtgcagtg aagtgtcatg ttggccacaa tgaaactgaa agagactgat gactctctc 152940
aggggtgaaa atgaggcatg gaagctttga ttagtgagct gttaggcaca cagacattaa 153000
tttcaaagca ttctcatctc cagtctgagt aataatgctt atagtattat gcaattgttt 153060
ggctgctgca agaaattcag cagactccaa caagtagtct ttcttggtct ctgagtgact 153120
gtaacttaaa ttctacctc cttctcttct cctacatctt ctactcccc accccacccc 153180
cacatacaca caattcttgt ccactatgtt cagagagatg caccgacaca tatatatgta 153240
tatatatagt atatttgta ataaagcaga aaagaagaaa aaactccaag taaacaattt 153300
tccatttccc catctcaatt ctgtcttaca agtggtatagg aaaagaaaaa ccccagtaa 153360
aaaatggcaa ccgcccacct ccccaacttt acatgctgct tcctatgtta gaggatctgt 153420
cttaggcac tgattatgga gctgctaga tacaagcccg tatttagact gctacagtca 153480
acaatgtctc tctttcatc tagaaaaatt ccgggttggc aattgcaagc atctcaaat 153540
gaccagacc tgaagaaagg ctgacttgcc tcattcaaaa tgagggtctc agagggtctc 153600
agtggatagt ctggagaaac ctggcgtctg aggccttaga gcttaggtt ttgctcctca 153660
acacagactt tgacgttggg gttgggggct actctcttga ttgctgactc cctccagcgg 153720
gaccaatagt gttttctac ctcacaggga tgtgtgagg acgggctgta gaagtaatag 153780
tggttaccat tcatgtagt gtgagtatca tgattattgt ttctgtaat gtggcttggc 153840
attggcaag tgctttttga ttgttcttga tcacatatga tggggggcag gcaactgactc 153900
aggcggatgc agtgaagctc tggctcagtc gcttgctttt cgtgggtgtgc tgccaggaag 153960
aaactttgct gatgggactc aagggtgtc cttggacaag aagcaactgt gtctgtctga 154020
ggttcctgtg gccatcttta tttgtgtatt aggcattcg tatttcccc ttaggttcta 154080
gccttctgga tccagccag tgacctagat cttagcctca ggccctgtca ctgagctgaa 154140
ggtagtagct gatccacaga agttcagtaa acaaggacca gatttctgct tctccaggag 154200

-continued

```

aagaagccag ccaacccctc tcttcaaaca cactgagaga ctacagtccg actttccctc 154260
ttacatctag ccttactgta gccacactcc ttgattgctc tctcacatca catgcttctc 154320
ttcatcagtt gtaagcctct cattcttctc ccaagccaga ctcaaatatt gtattgatgt 154380
caaagaagaa tcaacttagag ttggaatat cttgttctct ctctgtccca tagcttccat 154440
attgacacca gtttcttctc agtggagaag tggagtctgt gaagccaggg aaacacacat 154500
gtgagagtca gaaggactct cctgacttg cctggggcct gtctttccca ccttctccag 154560
tctgtctaaa cacacacaca cacacacaca cacacacaca cacgtctctc ctctctctcc 154620
cccccaaca cacacacact ctctctctct ctcacacaca cacacatata cacacacttc 154680
tttctcttct ccctgactca gcaacattct ggagaaaagc caaggaagga cttcaggagg 154740
ggagtttccc cttctcagg gcagaatttt aatctccaga ccaacaagaa gttccctaata 154800
gtggattgaa aggctaataa ggtttatttt taactacttt ctatttgttt gaatgttgca 154860
tatttctact agtgaaattt tcccttaata aagcattaa tacaccaate gtattttctt 154920
atttacaaca gactgagaga attaatgctg ttaacattgg atcttttttc tttttttttt 154980
ttcctttttt ttctctctcg ttgcttttcc aggtcatgct gacctgttca gcttgagctg 155040
tttcacattt gtttttaaat tcagtttaaa tgtaattgta aaagcatgta tgctctaaaa 155100
tcatgtagtt acttttttca gtggaaaagc ctggtattcg aaagcatttc caggctctgc 155160
aatttcatat gagcaggttt ttggtaaaat cttttgtccc tcaactcagg tggtatctgg 155220
acagtgagcc cttttcttct ggctcagtag tcagagagag gagacttgga gacagtttct 155280
gctggatcct gtgctttggc aaggatgtgc agcattgcat atcattctat cattaattat 155340
gtttactcct ccatgaacta aaaaccatta gactaaatag tccaacataa acctgaaag 155400
ataaaatttg atattctttt gcctggccat ttctctgacc cagaattggg gctgggaggg 155460
gattggagac ttgggggaaa gaatcaagga gccttcttgc ctgggggaat ttggcatgca 155520
cttattaate ccatttggtt gcactcccta ctaatccctc actccatacc tgccaaggat 155580
tggtctgctc cctgcttctc catccctgct ctagttcttc ctcacctatc tccatttccc 155640
actactgac cttctctcca gtaagatgct attcaacccg atgaaatata aagagtagca 155700
ccacctgga agtcaggata ccttagtttt agctcctgct ctaccattat ctactgtgtg 155760
gacctggggc atgacttaac ctttgcctct cagtctgaac agtctttaag aattggtttg 155820
gaggaggaag gaagggatag acaagatcca aggcctttga actctttttt ggaaatgggt 155880
ccttttcttc aaacaaaatt tgatgcagag tcccaaattt acctacagaa taaaatactg 155940
ctgttcttgt ttgaaaggaa gtgggggtgct tggagccaca tgctcaggcc cactttgccc 156000
cctctcagga accctcgaaa aaacttatag gacttatagg actgttgggg atctgccaag 156060
tctctcttat gttacatttc agtccttggt aaactctata tgtttcatca gttcactttt 156120
tcagaaagt cacctgcttg gggtaaagg catgaagtgg agaattgggg gctcagtaac 156180
tagcaatagt aaaaaacatc attgattggc ttgcagaatt tactctgttc taagcatctt 156240
acacacatac tcattccgaaa actcacaaca accttgtagg gtagatctgt tattatctta 156300
agattctgaa acctgccagc atgactctca atctttgact tgagaccagt tgccaacat 156360
ggaagggttat acttttcaca gtttaccacc ataagcagtc tttcagagtg atttctagct 156420
agagatccat tcttagaaaa agtcagaacc tgcccattag catacactgt cacatgggtg 156480
agagtacett cactgggttc atctcatttc ctctaaaaa tagtcctatg cagtagtcca 156540
gtcatatcat caccattata tagatgagaa aaactgaggt gtaggagaaa tcaagagatc 156600

```

-continued

tgttcaaggt cacacattcc ataagactct gaataccacc atcaagaata ataaaccttt 156660
tatgtgaaaa gcattttaga acttcagtgt cattattgca ttctgcctcc tggagttcag 156720
tgcacttttt caccatgctt taatcttgga gtccctgggg tacagaatct gccttctact 156780
ctcagacaac accacagtgt ctttatccct cataacaaac ttatgaatta agtaatgata 156840
ttatcccat tttacaaatt agttaactga gataccaaga ggctaagtct tgcccaaagt 156900
cacacagcta gtcagtgata gagccggagt tacaatgag gcacccctgac tccagaatat 156960
ttgctcttaa ctactactct ttatacatat gtaaggaaac taaaagcaaa agagggaag 157020
atgtccctga gggccacag tgagctccc tgactcaca tccagtattc ctctgacctt 157080
ctaactctaa agttatacag taaggctcct tgactcctaat cctagtagat ggaagatgg 157140
ctggcatgat ttaagccaga gggccaaaac tggttcccc agagccagaa ttcacctgca 157200
gaattctgtt tgtccagcac agtggttgtt tagaaaattg acgtagactg cccctaggca 157260
gggcatcaat cactgtcatt gtccccagcc ctcccttatt atgtttgccg ggctttttta 157320
ctcatttatg tgtctgcctg acttggaag gtatttgagt ttatgacttt tagatttaag 157380
cattgcaata tataagcact gcacacatgc attcacaaaa gtatagccta gtctagcttc 157440
acaaagaatt tgtagcccta caccaaacac acctttatgt ttacttagtg tttagaatta 157500
gatttaagat cagaatttag tttcacaggc attcatgtgt ggaagaacct cagtatttgt 157560
tttttgttc atactgtct acccttgcct tccctgctgt gtctggacc ctgtcaatcc 157620
tgctttctgc cattcttcat gctgagttta gggccctgc aagccattca ctgggtaatc 157680
tttaggaatg aatggagagt gaaaaccagt ttggagggtt cactgtgtcc caagcctcct 157740
ctcatttagt tctcataagt gtccaaagac acaggtagca gcacattcgt ttataaatg 157800
aggaaactaa atctcagaga agctgaacaa agacctcaa gtcattaagg tagtaattaa 157860
cggagccggg atttgaacgc aagactgttg gactccagag cctattcttt tgcctacac 157920
cacagtctct tacaaggaag atgtattcat tttctattac tgcataacac attgccacaa 157980
atttagcagc ttcaaacatt tatcagctca ctgttttgta agtcagaagt ctggcacagc 158040
atggctagat tctcagttca ggtctctga aggatgaaac tgatgtgttt accaggatgc 158100
attctaactc gaagctcagg gttctcttcc aagctcatgt aattattgca ggattcagtt 158160
atttggtggt gtaggactaa ggctccctct tcccttctgg ctaccagcca agggccattc 158220
tcagctcttg gaggtgccc tctttcctta tcatgtggac cccaacgcct tcaaagccaa 158280
caacagagac tcttcttgt gttgaatgtt tctcactcta cggatgtctt tccctggagga 158340
tcccagctcc gtaagggtc acctgatgag gtcagggtaca tcaagaatag ccacccttca 158400
aattcaactg aattagcacc ttcattacat ctacctagcc tttttacaac agcatctagg 158460
ttagtgcttg actgaatgac tggaaactaa ggtctcagaa tctcggggac cgtcttagaa 158520
gtcagcctac tacagatggt gattcttttc atgtgtcaaa tttcatagtg agataggag 158580
aacagaaaca tcacatcctt gaccttaggt aaagggttc aaacttcta agactttgga 158640
aaactcacgc cactttcacc ttttcttaa tcatggttga gaaggcctat atcttgaggt 158700
ggccaggagt gagactggaa cagtacctaa aggttaagga cgctaaagaa gttacagatt 158760
ggttacatct gctcctccct aggaatgatc catggaacct gatttgaaat tttttctct 158820
ggtgctatag atagctccca caggggtcta atgccccagg gctgaaaagt tagttcccca 158880
taggatccat ccaggcatga tatcaggcca ggtgttaca tctcctaaag aggaggtatg 158940

-continued

gactggaaag ccccttgcca atggcccttt cttgtcactg ctctgaccca agactaacag 159000
 ggcagagata gtgaactcac atactattaa aactatccac ttatacttcc ccctttctct 159060
 ttgctttatc actccattta agtaaacc aa tgagtctctg ccttgacaca gtggcaagct 159120
 gacctgtatc ttatatgaaa gaattagatt tgactctggg gctcaggtgc agagggcagg 159180
 aggggcataa ggatggcctt catggaagaa aagaagtcc tggatactga gtaacagctg 159240
 agactagcaa gcctcattgt ccaggattcc aagtcgtcta gcaacatcct ggtctctgct 159300
 gcagacagaa cagaggatcc cccggcagaa tgaatggagt ctgatttcaa ttacgttcag 159360
 tatagtcact ctcttttaggc agagaagcca gaacacctgg tgcagctagg gccactgtgg 159420
 tcacagggac aagcacacta cctgggtcct ggaggcaagt gggaatgcag tttttcttcc 159480
 ttaagcagat gccatatagg cctggggagg aggatgtgag aataccagcc aagttctcat 159540
 tggcactata cagagaaagg ggaattattt catcttgatg gattctcccc acagtctctg 159600
 cacatattga tcttacttgt aatgagtttg cttagggtca cgagtcacca tcccagggag 159660
 atctgagtca ttggtgggaa agtcgaggcg acagattata tctcactgat ctactgtca 159720
 ccaattgtct tgtgtgtccc tccacctttt gaaaagtcc atggattcat ttgtgtgtaa 159780
 ttcatttgga tttatttctt ctttatcaat agcttttagtg gggtattgca aatgggaaag 159840
 ttgcccaga gaacagtgtta cattcacagc attattcagt agaactttct gagatgatga 159900
 aaatcttcta tatcttatgt tgtacaatat aatacagcca ctaactacat gtagcttttg 159960
 aacactggaa atgtggcagg tgagactgag ggattatatt ttttaatttt taatgttgta 160020
 attaatttaa ttttttaaaa tttttgcttt ctattttata gttaataat taaactaac 160080
 ttacgtagcc cacatgtggc tagttggcta ctatactgga cagtacaagt ctagaaggat 160140
 ctgagagaga cacatgtgta gatacagcag gaataagtca aaaagagagc caatgtaaca 160200
 tagggaattc tggattggga attagagccc tggctctaata ctgagctctg ccactagggtg 160260
 acctgcctct ctctggcttc agcctcccca tctttgactt gaaagggtta actaactaac 160320
 gtcgaaagtc ccaaaatggt ggctatggac tgaattcaat tttgggatac acaagtttca 160380
 ggaatttttt aaaaatctat taatgccttc taggtgtgtg tatgcacgt tgcagacatg 160440
 tgcccatgca caagcatggg aaggcagtaa ggcattcatt tcaattcacc agtgactata 160500
 ccattcacac acacacacac acacacacac atgcacacac acctactgt 160560
 attgcctatg tagagcctga agatctttta atctgtcacc attggataag ataatttcta 160620
 aggacccttc ctgttttgtc atgctgaaaa tctttaagcc actatagtgt cccaaatcta 160680
 ttccagtttg ggcagatgac tggagtattc tcatagctc ctgtctattc ccttctggat 160740
 ttgatactag ttatgaagtt tggagtcaag ggtgaagaag ggaggcagg atgatataac 160800
 cccagcccca ctctcaact ctgcttttga gttagaagta gggttcaggg cttcagattc 160860
 cttggggagg cagtagagag aatatgggct ttataatcag aagatgaggt tcagatgatt 160920
 gggttctcac cttttttata gctgtgttac ctgagtttat tcatttgtaa aatagggata 160980
 agaaatatct ttaacctcct aagatcatgt ggaattaagt gatgtaagt gatgaagcga 161040
 ggcacgcaga aggccctgaa aaaattagta gttaccctta aggggactaa atggctctgc 161100
 aactcccgag ctcaaagcta gaaaggcca gtaatgggga agatgggggc tttctgtagg 161160
 aactgtagca ggggagcaga tctgttaggc caccagtctg tggagctgtg tccaagaact 161220
 catgtttgca ataagcccac caaatgacaa gttattgtgg ggttcaggcc tctaactcaa 161280
 gaagatggtc ttggcccaga tcataccttg cagcctgtgc ctttgggtgg atgtgggtgt 161340

-continued

tggcagtggc tatgcataac tccttattac tggetgtgcc aaagccccgc agaaatgatt 161400
gttggacaaa gtcatactgc actcagggtc ggttttccag gcttccttgt tattttcccc 161460
tgagttcttc tgtgttcctc ttgcaacacc aaccccacta ttttcctctt ccctacccta 161520
gttgttggtc caaacatgta atccattctt gcagtgtatt attgggtgac accatgactg 161580
gagtttgcac tgaaggactt ctttttctaa ttagaactaa aagtcagttc caggctgggt 161640
gtggtgggtc acgcctataa tcccagcact ttgggaggcc gagatgggag gattgcttaa 161700
ggccaggagt ttgagtccag cctggacaac atagtggagt cccatctcta caaaaatgt 161760
taaccaggag tggtagtgta caactctggt cccagctact tgggagactg aggagggaga 161820
attgcttgag cccaggaagt tgaggctaca gtgagctttg atcgtgccac tgctctccag 161880
ctgggtgaca gaggaagatc ctccctcaaa aaataaataa aaactaaaaa aaaagtcagt 161940
tccaggttgt atcttttttc acagggggca gacacagatg agagcagggt ttgttgattt 162000
tatccattta aattgagcaa taaaattctc tctttgggtt ctacctttct tatttattat 162060
tattatgtta aagggattaa agtggttcat ggtctttctc agtgcaactg cttatgctag 162120
acctcagaat tatgaccttt tcaattattt atatttctgt ctatataaat actggaaaaa 162180
atagtacaaa gtaagcatcg gaatgcctaa ggacctctaa attgtgtgtg tgagcacatg 162240
gggaagatgg ttcttaaggt ttgagttttg gattattgtg gttgtcttaa ataagtgtat 162300
ttctatcatt ctttccaatg actgtctcct agcatagttc ccattttaca gactgatggc 162360
agaggcagaa agattctctc acttctttga tactattgag gacttcagcc ttccaccgct 162420
cttctccctt ttgctaaaaa agaaaaaat caatatgtat gttacagtgc atttttttaa 162480
atatttttta ttatacttta agttctaggg tacgtgtgca caacttgag gtttgttaca 162540
tatgtataca tgtgccaagt tgggtgtgtg caccatttaa ctcttattt acattaagta 162600
tatctcttaa tgctatccct ccacccttc ccaacccac aacaggcccc agtgtgtgat 162660
gttcccttc ctgtgtccag gtgttctcat tgttcaattc ccacotgtga gtgagaacat 162720
gcagtgtttg gctttttgtc cttgagatag ttgtctgaga atgatgggtt ccagcttcat 162780
ccatgtccct acaaaggaca tgaactcctc attttttatg gctgcagatg attccatggt 162840
gtatatatgc cacattttct taatccagtc tatcattgat ggacatttg gttggttcca 162900
aggctttgct attgtgaata gtgccacaat aaacatatgt gtgcatgtac ctttagagca 162960
gcatgacata taatcctttg ggtatatacc caataatggg atggctgggt gcaatgggtat 163020
ttctagtctc agatccctga ggaatcacca cactgacttc cacaatggtt gaactagtgt 163080
acagtcctac caacagtgtg aaagtgttcc tatttctcca catcctttcc agcacctgtt 163140
gtttcctgac tttttaatga tcgccattct aactgggtgt agatgggtatc tcattgtggt 163200
tttgatttgc atttctctga tggccagtga tgatgagcat ttttcatgt gtctgttggc 163260
tgcataaatg tctttttttg agaagtatct gttaatatcc tctgcccact ttttgatggg 163320
gttgtttgtt ttttcttgt aaatttgtt gagttctttg tagattctgg gtatttgccc 163380
tttgtcagat gagtagatgg aaaaaattt ctcccattct gtaggttgcc tgttcaactc 163440
gatggtagtt tcttttctg tgtagaagct ctttagttta attagatccc atttgtcaat 163500
tttgctttt gttgccattg cttttgggtt tttagacatg aagtccttgc cgggtgcctat 163560
gtcatgaatg gtattgccta ggttttcttc tagggtttta tggttttagg tctaacattt 163620
aagctctgaa tccatcttga attaatTTTT ctataagggt taaggaaggg atccagtttc 163680

-continued

```

agctttctac atatggctaa ccagttttca cagcaccatt tgttaaataag ggaatctttt 163740
cccaatttct tgtttttgtc aggtttgtca aagatcagat ggtagtagat acgcagcatt 163800
atctctgagg gctctgttct gttccattga tctatatctc tgttttgga ccagtatcat 163860
gctgttttgg ttactgtagc cttgtagtag agtttgaagt caggtagcgt gatacctcca 163920
gctttgttct tttggcttag gattgtcttg gcaatgcagg ctcttttttg gttccatatg 163980
aactttaaag tagttttctc caattctgtg gagaaagtca ttgatagctt gatgggggatg 164040
gcattgaatc tatgaattac cttgggcagt atggccattt tcacgatatt gattcttcct 164100
acccatgagc atggaatggt cttccatttc tttgtatcct cttttatttc attgagcagt 164160
ggttttagt tctcctgaa gaggtccttc acgtcccttg taagttggat tctagggtat 164220
tttattctct tagaagcagt tgtgaatggg agttcactca tgatttggct tctgtttgtg 164280
tgttattggt gtataagaat gcttgtgatt tttgcacatt gattttgtat cctgagacct 164340
tgctgaagtt gcttatcagc ttaaggagat tttgggctga gacaatgggg ttttctagat 164400
atacaatcat gtcacgga aacagggaca atttgacttc ctcttttctt aattgaatac 164460
cctttatttc tttctgtgct ctgattgtcc tagccagaac ttccaacact atgttgaata 164520
ggaatgggtg gagagggcat cctgtcttg tgcagtttt caaaggaggt gcttccagtt 164580
tttgccatt cagtatgata ttggctgtgg gtttgcata aatagctctt attattttga 164640
gatacgtccc atcaatacct aatttattga gagtttttag catgaagggc tgttgaattt 164700
tgtcaaggc cttttctgca tctattgaga taatcatgtg gtttttgtct ttgggtctgt 164760
ttgtatgtc aattacattt attgatttgc atatgtggaa ccagtcttgc atcccaggga 164820
tgaagccac ttgatcatgg tgataagct ttttgatgtg ctgctggatt cagtttgcca 164880
gtattgtatt gaggtttttt gcatcgatat tcatcaggga tattggtgta aaattctctt 164940
tttttgtgt gtctctgcca ggcttttgta tcaggatgat gctggcctca taaaatgagt 165000
tagggaggat tccctctttt tctagtgatt ggaatggttt cagaaggaaat ggtaccagct 165060
cctccttgta cctctggtag aattcagctg tgaaatccat ctagtccctg actttttttg 165120
gctggtaagc tattaattat tgcctcaatt tcagaacctg ttattggtct attaagagat 165180
tcaacttct cctagttag tcttgggagg gtgtatgtg cgaggaattt atccatttct 165240
tctagatttt ctagtattt tgcatagagg tatttatagt attctctgat ggtagtttgt 165300
atttctgtgg gatcggtggt gatctccctt ttatcatttt ttattgcac tatttgattt 165360
ttctctcttt tctctcttat tagtcttgcc agcagtctat caattttgtt gatcttttca 165420
aaaaaccagc tctcgattc attgattttt tgaagggttt ccatgtctc tatctcttcc 165480
agttcttctc tgatcttggg tatttcttgc cttctgctag cttttgaatg tgtttgtctt 165540
tcctctctta gttcttttaa ttgtgatgtt aggggtgtca ttttagatct tcctgcttt 165600
ctcttggtgg aatttggtgc tataaatttc cctctacaca ctactttaaa tgtgtcccag 165660
agattctggt atgttgtgtc tttgttctca ttggtttcaa ggaacatctt tatttctgcc 165720
ttcatttcat tatgtacca gtatcattc aggagcaggt tggtcagttt ccatgtagta 165780
gagtggtttt gagtgagttt cttaatcctg agttccagtt tgattgcact gtggtctgag 165840
agacagtttg ttataatttc tgttctttta catttgctga ggagtgtttt acttccaact 165900
cagtggtcaa ttttgaata ggtgtggtgt ggtgctgaga agaattgata ttctgttgat 165960
ttggggtgga gagttctgta taagtctatt aggtccactt ggtacagagc tgagttcaat 166020
tctgggatat cttttgtgtc ttgttgatct gtctaagtgt gacagtgggg tgttaaagtc 166080

```

-continued

tcccttgatt attgtgtggg agtctaagtc tctttgtagg tctctaagta atcactttat 166140
gaatctgggt gttccctgtat tgggtgcata atatttagga tagttagttc ttcttggtga 166200
actgatccct ttaccattat gtaatggcct tctttgtctc ttttgatctt tgttggttta 166260
aagtctgttt taccagagac tagcattgca atccctgcct cttttggttt tccatttgct 166320
tggtagatct tccctcatcc ctttgttttg agcctatatg tgtctctgca catgagatgg 166380
gtttcctgaa tacagcacac tgatgggtct tgactcttta tccaatttgc cagtctgtgt 166440
cttttaattg gagcatttag gtaaatattt acgtttaagg ttaaatattg tatatgtgaa 166500
tttgatcctg tcattgtgat gtagctgggt tcttttgcct gttgggtgat gcagtttctt 166560
cctagcctcg atggtcttta caatttggca tgtttttgca gtggctggta ccggttggtc 166620
ctttccatgt ttagtgcttc cttcaggagc tccctgtagg caggcctggg ggtgacaaaa 166680
tctctcagca tttgcttggt tttaaagtat tttatttctc cttcacttat gaagcttagt 166740
ttggctggat atgaattctt ggggtgaaaa tctctttctt taagaatgat gaatattggc 166800
ccccactctc ttctggcttg tagagtttct gccaaagaaat ccactgttag tctgatggct 166860
tccctttgtg ggtaaccoga cctttctctc tggctgccct taacattgta tccttcattt 166920
caactttggc gaatctgata attatgtgtc ttggagtgc tctctcagag gagtatcttt 166980
gtggcgttct ctgtatttcc tgaatgtgaa tgttggcctg tcttgctagg ttgggtaagt 167040
tctcctgggg aatatcctgc agagtgtttt ccaacttggg tccattctcc ctgtcacttt 167100
caggtaaccc aatcagatgt agatttgggc ttttcacata gtcccatatt tcttgagggc 167160
tttggtcgtt tctttttact ctttttttct ctaaacttct cttctcgtt catttcattc 167220
atttgatctt caatcactga tacccttttt tccagttgat cgaatcagct actgaagctt 167280
gtgcattcgt catatagtct tcgtgccatg gttttcagct ccatcagggc atttaaggcc 167340
gtctctacat tgattattct agttagccat tcgtctaate ttttttcaag gtttttaact 167400
tctttgcgat ggggtcaaac ttctcctttt agcttggaga aatttggta tctgaagcct 167460
tctctcaact catcaaagtc attctcctgc caggtttgtt ctgttgctgg tgaggagctg 167520
tgttcctttg gaggagaaga ggggctctga tttttagaat gtttcagttt ttctgctctg 167580
ttttttcccc atctttgtgg ttttatctac ctttggctct tgatgatggg gacatacaga 167640
tgggattttg gtgtggatgt cctttctgtt tgtagtttt ccttctaaca gtcaggaccc 167700
tcagctgcag gtctgttgga gtttctgga ggtccactct agacctgtt tgctgggtg 167760
tcggcagcag aggtcagaa cagcgaatat tgctgaacag caaatgtgc tgctactca 167820
ttctctgga agtttctct cagaggggta cctagccatg tgaggatca gtctgcccct 167880
actgtgggt gtctcccagt taggctactc gggggtcagg gagccacttg aggaggcagt 167940
ctgtccgttc tcagatctcc agctgtgtgc tgggagaacc actactctct tcaaagctgt 168000
cagacaggga catttaagtc tgcagagggt tctgctgcct tttgttcggc tatgcctgc 168060
ccccagaggt ggagtctaca gaggcattga ggcctccttg agttgcggta ggctccacc 168120
agttcagct tcccagctgc tttgtttacc tactcaagcc tcagcaatgg cgggtgcccc 168180
tccccagcc tcaactgtgc cttgcagtc gatttcagac tgctctgcta gcagtgagcg 168240
atgtccatg ggcgtgggac cctccagcc aggtgtggga tataatctcc tgggtgtgccg 168300
tttgctaaga ccattgaaa agtgcagtat taggtggga gtgaccaat tttccaggtg 168360
ccatctgtca cagctttgct tggctaggaa agggaatttc ctgaccttt gcacttccc 168420

-continued

```

ggtgaggcga tgcctctccc tgccttggct cacacttggc gcactgcacc cactgtcctg 168480
taccactgt ccaacaagcc ccagtggat gaaccggga cctcagtcgg aaatgcagaa 168540
atcactcatc ttctgcgtca ctcaagctgg gagctgtaga ctggagctgt tctatttcg 168600
ccatcttatg aatcatgcac gttcaactat gagcaactat gtgtattcaa tgggaaatgg 168660
aataccataa aattgtcata tgttgagccc aaaatgatag gatagaattt gatagtctga 168720
ggatggaaag gaccttcaag gccactttta aaaaccccat tcccatatga tgcctgaatt 168780
cttaaccact gtgtgtctag tattttctca tttccagtga tatgtgtgcc tgccaacctt 168840
tccgtctcca agagctttaa ctatcaaaat gtatgtgtgt gtgttttgt gtgtgcattg 168900
gtgtgtgagt gtgcgtgtgt gtgtgtgtgt gtttagagag agagagagag acagaaagag 168960
aaggagagac taaaatccaa ttcactgttc tttctgggac ccaaagaaca agtctagtca 169020
ttctccattt ctagtctctt tccctagcaa tcggctagac atgctagaca tagacacatg 169080
tacatcactc ctttgaatta caacattcag tatttgcata tcaattatat gataaaatac 169140
aaacttagct tttattttta tttttttaga gacagtgttt tactatgtca cccaggctag 169200
agcatcagtg gcacaatcat agcccactgc agcctggaac ccctgggctc aaggaatcct 169260
tccacctctg cctcctgagt agcagagact acagatgtgc accaccagac ccagctaatt 169320
tggtttttta ctattttttg tggagatggg gtattgtctt gtgtgtgtgc tcaggctgat 169380
cttgagctcc tggcctcaag cactcctccc atctcagcct ccaaaatgc tgggattaca 169440
ggcatgaacc acctaccaca gccaaatttc ttaatatgat atacatgtct ctttaaaatc 169500
aagcaccatc tttgctttca acctcattat taaccacttt cccatatatg caacatatgt 169560
ttcagccata ctagtgtcta gtttttccct gaacactcct tgggtgcttt gtttatgccc 169620
tttctgcccc ctttgcctg gtgaaatcct catcaatctt caaattctat caaatactat 169680
cttccatata aagcattttc taaaccacc tatgtaaaaa gattagtgtt ttcctatttt 169740
gttgatgcct ccattgcagc attttccagt ccaacgtttt ctagaattga ttgtggccag 169800
gctaccagac tgggccaggg cctgtgtctt ttctgtcacc cagaagcaaa ggtctaaca 169860
tggatatctg ctgaatgaat gaacgaaaat gaatcattaa tatattagta aatacgttaa 169920
ttaaagtcc aggtatgaat actgaaggct gcattcagc agagctggat ccaaggatat 169980
gctaggttg tctagcacia gaatcagagt tttcctctgc aagctatgaa aaatttgggt 170040
ttagcaggta tttgggatga tgaattatac atttaaccag tgttgaatga gcactgtctc 170100
ttaaggagtt tagagtctgt gaccaggagg aatggtgatt ttcttagcta gggcagtttt 170160
tctaaaaagg tagttgcatt gtgtgttttt gaccactgat gataaattca agtctctctt 170220
ccttcccaat agcccggaag ctgaagaaac ttggaatct gaaactacag gaggaaggag 170280
aggcttcag caccaccagc cccactgagg agacaaccca gaagctgaca gtgtcacaca 170340
ttgaaggcta tgaatgtcag cccatcttct tgaatgtctt ggaagccatt gagccagggtg 170400
tagtgtgtgc tggacacgac aacaaccagc ccgactcctt tgcagccttg ctctctagcc 170460
tcaatgaact gggagagaga cagctgttac acgtgggtcaa gtgggccaag gccttgctg 170520
gtaaggaaaa ggggaagtggt agcatgagat aagggggatc atatttagtg aacgctccta 170580
tggaccagcc accatgtctg gtgcttttct gcccataac tcaggcagtc ttcatacata 170640
ccctgtggga gagggattgt tacaagtctc aatttaaaac tacagggtac gaaactcaga 170700
aagcaaagag aaagatagta ttatcgggtg tcttatgtgg cccacattga tgcacagcag 170760
tcatgcttct atattcaact cacaaaaatg gtcagcaaat tttccattaa tcacaaatca 170820

```

-continued

catagacata cccatatatg ccttaggatg ctcttctata tttgcacaca caggctcacc 170880
ccaaagataa tctctagttt gactgacatt ctgtcttcaa tgtcatcttt aggagctata 170940
tcatgggaac tctcataata tggtaggtg gaaagaacat gaggttggga atcagaacac 171000
ttcgggtctg ctcttagctc tgctagtaac ttattgtgtg atcccttccc cttctgggtc 171060
tcaatttctc tatctgtata atgtataaag cgtggtttgt atcaaattga tggtttccag 171120
tttttgaaaa aaggaacgct ttttgcacct taaactacct aaggaatcat aatgagagga 171180
aagattaggt aatagtgaag gaattaccaa gtgttgggtc aacagaagtt ggataacaga 171240
agttcctcag tgatggggaa ctcacttctt tcttatgtca tctgttgttt aaacaagtct 171300
ggttattaaa atattacagc ttaaggaatt cttagagatc ctctatccaa tgattcacia 171360
actttccttt agcagccaag tgccttattt ctcaaaagaa ttgtacacag atacaagtgg 171420
agctagttta tttaaagcca gagcctgtag cttgggcctc accagttcag cctctttctc 171480
tctatcccag ggaagcccta ggtcactctt gcaaaatctt agggctccaa ggaacacagt 171540
ttgaaaacca gtgaagtata tgccttttaa aggttctcct aatcctgcaa ttatgattca 171600
aagattcttt tgaaataaca acaaccaaac cttctcttgt ggagtcaaag attaacctgc 171660
ctttcaataa taactgccat tcaggtagaa atttatagtg aacagagcaa ttttgtatgt 171720
attacctgaa ttgattctta taggaatcct ataacatgag attctttctc ttattttaca 171780
gaccaaatag ggaagctgtg agaatgatgt gattggccta tagttacata gtcagaaaat 171840
agcaggacca gaacttgagc ccagggtctc tcttgattec aaattctctc tattccactc 171900
cacctgtagg ctgtagcacc actgcagttc tgtagctctg ggctttacag tgagggggcca 171960
aggcttcatt gaaggccact tgggtcatag tatgggcttg ttgcatttga agacatttca 172020
tgttggctgt caagtcttag atttgtattt ccaactcaca gggcctgggtc acagccctaa 172080
ccatctctta taccttctca gcttgggaag ctgaggtcga ctagccaata agaacttg 172140
gaaggaaacc caaggactct gactggatat gctctgtgcc aaaacagagg gttoactcag 172200
agaggaaaaa tataaaaaag aaaaaggaga aggttgcttt aattcttctc actttttcat 172260
ctggatattt tgatatcatg tgtttgacag agattcaaag tttaatcttc ccaagcagtt 172320
tccaaacact tatctcattt tataggtac agagcttttt catatatatg atccactta 172380
atctttacaa caattctatg aatcatagag actattattt ccatttcaca tgccaaggct 172440
caaagaggtt aactaacttg ctccatttgg tcacttaaca catggaacca gaacttgacc 172500
tagaccttgc ggtttctaaa ttggttatct tgacaataac ctagtgcaa acactatagc 172560
agaatttcta tgacttggga tcaactgggc ttctcttggc ccaaccacca agatggaaag 172620
ccccctcccc ttacattaac aaatctgcaa gccaatatca gttcaccatc tagcttgcca 172680
gactaaatga tttctgacct caagtctttt aaaagaatag cttcaaaaga aagccaatta 172740
ccacattcac aagaactggt cttcatatta tctataatta cctacaagta caagtaattt 172800
gctaattcaa tagattgagt tcttgacctg taagatgaac tgtgctaggc cctaataag 172860
ataaattttg ttttaagttt tctgtgacag taaagatgta tgaaaattgc ctagtagagt 172920
acctggcaca ttaataaatg ataactgtta atttggagtg ggtgagtaga ctgggtgtgc 172980
acagtatatt tagaatcaaa tttatctggt ttggaatcct agctatggac tagttctgtg 173040
accttgagca aatcacatgt cttctctgtg cttctgtgtc ctcatcttga agatgataga 173100
ataatcacta cctttcaaat tgtgtgcaac aaaaagatta tgtataaaga gcacctagta 173160

-continued

acgtagcctg aaacatagtc aatgctctgt aaatggtggt ttattattat gagacttgaa 173220
 tgctaagcca ctgctttcac gaaactcaat tttagctacc acttgccctg cctagaagct 173280
 catgcatgga ccccaagggtg aaattgtgtt ctctgaagac ctcggctggc agatgtacta 173340
 cagcagcaaa gatttccaaa ctggcctttc tttagagcca ttctcccaga ctagacagga 173400
 gactacaagt ttctgctgca catgaaaaaa atatgatgtc aatcggattc tagtgagaaa 173460
 acagagtctc aaagaaactg cttctgctcc ctagecgtgtt taatgtgttt cagaacctga 173520
 gaatgactcc tctctgtttc tccagaacag cctaacacag tggcaaatgg gtgttgagtg 173580
 aatgcatact taaggaaatc tgtagggttg cagctactct ttctcaagt aatcccttga 173640
 tagtcatgta ggctacttca gagattgggc attagagaac agagtcaggt attataatca 173700
 gattagactc tagggaggtt agccagccat attgctgata tgtgcacagt tactgggttt 173760
 gagtgctaag cagctctcat taaggacggt taattaatat tatggccaaa ttaagctttc 173820
 ccttttctct cctctttgtt agttcgggtg catttttagg agaaaaaat aagcatcagt 173880
 atggacaatt tgcttgatac ctgtacaatt taattctcat ccttccatgt gccttcacat 173940
 tcacacattc caccagaaga ccaaggttca ccagccaaaa gcttttcttg ctcccactg 174000
 cctctacccc aagatattca ggtgcaacct ccaggcctc ttctctaaga gatccttgg 174060
 tgctacatgc ttagaccctg cttcttattt cctgctgaga agggtcagtc caaggcattc 174120
 tgtgctacag aagggttcca agcaggaaact actctgggat ctgaggctcc agccggtctg 174180
 tcagcgtgtc attacagtga aggtgggaag cacaggcctg ggagctaaga ctgctaagat 174240
 gagggactct agaatccctg atacctggaa ggcctaggat ctaaaagaaa agaacaggga 174300
 aatggggcta tatgagtgga cagggaccaa ccaagcagaa caatgtgtct ggataatgta 174360
 gacttcagac ctgactctat ggtgacaaaa agctgggtgac cttggtagtt cctgagctgt 174420
 aaccttcatt agtgagtag aaaaaacact ggagaagaga atcagaacac ctgggttcta 174480
 gtattagtct agccacatat aaaccatatg acctgggta agtcagttta tttctctggc 174540
 cctcatgttc cttgttggtg aaataagtgc cacatcacct aacctctggg attattgtga 174600
 gagttaaat aggtcatcaa caggaaagtg agaagtttga tctaaatttg gggaagcatt 174660
 cctaataagg tatgatgaca aaatttcaga taattctgga tttgttggtg agaagagaga 174720
 gtgttggtag ggaagagctc tgagggtgat cctttataac tttaagcatc caactgtttc 174780
 aaaaactcca ggagaacatg gccatgtctg ttctacctgt gtattattgt agacgtagct 174840
 tctgggagcc tctgctctct gagcttaagg gaggtaatth ggagatcatt taattctcat 174900
 tttacaaaag gaaaaaaat tgagggtctt taggccattt gtttaggtaa tatttcttaa 174960
 gtgcccactc aaatacgtgg actgtactaa gtactaggga ggtaaagata aataagaaga 175020
 tatggtccct gtcttcaaga agctccaagt cttgtggggg agacagacat gtatatacat 175080
 agacttcaat gctgtgtaat gactgctata attgggtgag gctacacaag gtgcaatgag 175140
 aatgtaaaag aagaatcttt aagccttctt cttggatgag ttgggaaagc cttcacagaa 175200
 gaggtagcct ttgagtgaag acttgaaaga tgagtgtgt ttaccgatg aaaggcctga 175260
 gaaggaggaa tgcattctag gcaaaagtaa ctgcctgtgc agagataaca gagatataga 175320
 ggcattgtgag agcgcaagtg gcaagagatc agtctaggta ggcaggctcat aaagggccta 175380
 ttcatgtata atgatggcag taagatgagg atggcagtag ggtgggaaat tagtagggcc 175440
 agggtagcta ttgagttaga aagaatggag aggaaatgcc aggcagaaag aggatggacg 175500
 caagagaggg aacatgaaag tggatgaacag gtggcagtgg ctgtcaagac atctctccat 175560

-continued

```

accctgtaca ctgtatgtaa tatccatctc ccagggttgt tagaagggtc aaaccagatc 175620
gtagctggaa aacagctttg tgaagtgaaa actgctgttt atgtggggga aatgattgtt 175680
aaactgcac cttggaaagg tgaagtgatc aagagcacag accttggaat ctgactgctt 175740
tgctttgtaa cttggtctgc caattactag ctgtatgatc ttggacaagt tccttaacct 175800
ctctctgact cacttgactt ggttcacaga atggagataa taatagtact taccttactc 175860
attgttgta atgttaaatg agataatata agtaaagtc ttagaaaaga gttaaatgta 175920
ccccataaat acatacaact atcatgtacc caaaattatt ttttaattttt ttaaaaaaga 175980
gcaatccaat agcaaaagaa aaaaagagtt cactcatata agcagtcaat aagtgttaga 176040
ttatttttct cttacaactg acaatgccct ttttgtctcc atcatcatct catttgagca 176100
gctcagggaa gtaggaggga taaggaatat tatcctcacc atatagtttg tgcttttccc 176160
caccaccctc taatggccag cctggatggt ccctggggat ccttagggga tgcccgaata 176220
ccagagcatc tctgcccaac agggactcag acttagctca acccgctcagt acccagactg 176280
accactgcct ctgcctcttc ttctccaggc ttccgcaact tacacgtgga cgaccagatg 176340
gctgtcattc agtactcctg gatggggctc atgggtgttg ccatgggctg gcgatccttc 176400
accaatgtca actccaggat gctctacttc gccctgatc tggttttcaa tgagtaagt 176460
ctcctggggc ccagacctca ctaaaataca gcagcttggc cagacctggt tgggtggtgat 176520
ggtgatgggg tgacagtga gcttagctca ttgatctgc agttgtcgca gcggatgcc 176580
cagccagcca atccagtatg aggcggcttt gccctggctt tcagccaact ggaggagcc 176640
caggaggatg gtgctgagac caccctttc acaccaaga accaatccta gtcataattc 176700
tggcttgctt tgcagcttat ctcaaaacca catggaaaga ttctccctc tcacatataa 176760
aagaggcaga aagactctgg ctttaagggc tggagtctct tgggttcttt tgctaccacc 176820
aaaggctact tctagtccac atttgtgag caactagttt gtgccaagac tatgctagat 176880
actttctaaa tcctagctca ttgagtctc atggtgacct gacctcacct ttttatagat 176940
aacactattt ttttatggat ggggaaaatc aggcctcagca aaataaagtg actcacccaa 177000
agtcacagag ctagtgcctg ttggagacaa gattcaaacg tatgtccctg tcgatctcag 177060
ctcttctgct tcatggtggt aactgatggg aaggagtacc tctaccgctc tctggctgtg 177120
tgacctgggt actgccatth tccttccctt aaacagcttt aattaatacc tgccctgcc 177180
ccagctccat ataacatcat gaatttgccc agtggtctcag attttggaat tacatttttc 177240
tccactaaaa tctcagttct actattttct tagtcagcat ctttgggaaa gacctttaac 177300
ttttccgacc ctcaatttct tcatccatta atgataacag aaccttcata agtaatttct 177360
tatgataact aaatgggaat tgacagatgt ggaatgtctg gcccatagta ggcaagaagg 177420
aaaaaaaaag tccctttctg attcaccctt tccctaatag tgatacatth tttttcccg 177480
agatgggggt ttgctctgcc acccaggctg gagggcagtg gcgcaatgat ctcagcccag 177540
tgcaacctcc acctccctgg ttcaagcaat tctctgcct cagcttcccg agtagctggg 177600
attatagatg cccgccaccg tgtccatcta atttttgtat ttttggtaga gacgggattt 177660
caccatgtta gccaggctgg tctcaaaact ctgacctcat gatctgcccg cctcagccgg 177720
gcatgataat cttttctatg tctgctgtat gaggtccctc gatggcattg tgaatggagc 177780
tggccagaga aatcttccca aggaccttga gctagtctca ccacagagaa tccttccagt 177840
caggacagga attgacctc cccctcttc agccctctaa ccagaagag tcttaaaata 177900

```

-continued

aaatctacag gccaatgggt ccttcagta cagcactgca atgcgaggga gagtgagcgt 177960
ccccagctgc cctctcccaa ccttgccagc ctggtagcca aaagctaaga ataaccacta 178020
ggcttttggc acaaaactgct ttgtggtttt cagatctccg caaagttgcc tatgatgcca 178080
tcttctgggg caggccttga aaagccccct aactgttcat ctcccatcct taaacccctg 178140
ctgcccttaa gcagttgaat caactccatg agcacctgct ctaccttccc cagagccctg 178200
agacctttgg agctttgaaa agtgataatt ggttggtctc taaatcctca ttctcttctc 178260
tgcctctaag taagcatgtg gcaccccacc tcggcttcct ggtccagtct tgttcatctt 178320
ataaaaaggc ctccctacgg ggtcagaggc cttagcccat caaaccagg gctcctgaaa 178380
caataggacc cctattcttc ctgtaggaag ccaactgtgtt agagctctca ggggtgtctac 178440
aaacatctag ataagtgttt ctcaacatgg attctgttga catattggga aaaataattt 178500
tgtcattatg tagaatatgg ttaacatacc tggcaccagc ctactctata ccaaatagga 178560
ttccagtcct tctgacagcc caaactgtc ccacacattt ctgacaccca ctgaagaggc 178620
agtactctcc agttgagtgc aactaatccc tgccagcctt cctaaggtgc taatggggag 178680
cctcagaccc aaagagagag agaagaactt gtccaatgta ggtcaacca tttgctgac 178740
tcttcaaac caagctctat taccagcctt gttttttctt ttctttctct cttttagag 178800
atcacatgtt gtgaggataa tgagcttgaa ccttagctgt gtgaccttg gcaaattact 178860
gaacttctat gtgccgcaaa ttttatctgg agactgtga agagtattat aatagcacct 178920
ttctatatgt catttattga acacctgcta tgtgtcaggc actgtgctca gtgttttcca 178980
atcttcattt ctctcttctt tttctctctt gcactccac caacctgtt ctcttcctaa 179040
attccattcc tgctcattt ttctaccctc cattctctc tctcttctt cctttaactg 179100
tctccctagt atttttcccc ttttccccct ttcttttccc ctcccccat gaatttcttc 179160
tctttccttt ccccttctct ttctccatt ccccactttt tctgccctg aggctgcag 179220
caatgttaaa ggaatctca ttccagcatt gtgatttcaa tggtaaaaag attgcagcat 179280
tgtcatcaac agagggtggga aagtacattg gagactggag cagagccaga cctcagggtc 179340
agccaatctt actaaaaaat tctctacagt gaaagagctt ggagcaaac tgttctgctc 179400
aattgatttg tgataccatc taaacacttc ctctttctag ttgggcttca gcttgagttg 179460
aataattcta caccatctgc cctcttctct ctttctccag gacagccaag atctctctga 179520
gataggatgc tgagcttcca ccagacaat accaggcctg ctcatcctat ggagtaggct 179580
agtggcttgg aaacaaaaat gtcaaacat agcctttagg tccatctgg gaggtctttg 179640
tctcaccac ttaagtgggt gtcaaatctt ctctcttctc tgcacacgct gcacaatcaa 179700
tttctgtctt acacacacac acacacacac acacacacac gatttttgaa gtgctgaaa 179760
ctggaaggcc tactagcatg aggatgctgt gtcttctctt agaggatgc catggtcagc 179820
catggaaccg agagggtgct ctctcttgaa aagctggcca agcattggcc acttccccat 179880
ataatttata ggtgataatg tggtagctg ttcagaagtg actataataa atgcaactca 179940
catatgtcta cagtttccaa actgtggtaa ggagcagcca gcatatgagg gaatgggctc 180000
cccttcagca ggggacattt aaactagaca ttcaaaaaca ctccctggca gatttaacat 180060
tggaactcgt tttgaaagaa caatgtggaa tctccttcac tgggagtttt tgaataagta 180120
tgaaatttct agtattccag gccagaggca aaggggtcaa caggatgacc aaacacttcg 180180
ggtcatttgc aaatcttgat gtcttgatgt taagagctga ctactggggc ttctcctaaa 180240
aatcttcat gttgagctgc ctggaaggca ggttctcatt ctggctgtag ctgagatgtt 180300

-continued

agaactgtag tcagggagac catgtgcctc cccattgtg ttcatttggt taggctttcc 180360
tgtccctgac tcagaaaaca gaaggggcac agagacctgg aaattccatg tgctaacca 180420
tatcctggcc agagaagatg agtagttatc aggggtgcag gattttggaa aacagagaga 180480
gaaaaaaaaa aaacaaacag acaacaaaac aaaaaaacct tttcctggtc cctggagcac 180540
cagcaggaga aacagcaagc tcttcttgga aaacctggcg agggatggca atcagagaca 180600
ttccctctgg gcttattgta aacttcccct cattcctttt tccctgtgtg atctccttcc 180660
caggtaaccg atgcacaagt cccggatgta cagccagtgt gtccgaatga ggcacctctc 180720
tcaagagttt ggatggctcc aaatcacccc ccaggaattc ctgtgcatga aagcaactgct 180780
actcttcagc attagtaagt gcctagaagt gcagggaatg ccccttgagg gcacagagat 180840
tcagagagga ccacttttgc cattaaaaca ttattaggga aaagccagct cctggacatt 180900
tcccttcttc attccccctc cccatcccca ctctactctc tctcagcatc attttcctaa 180960
caagaaacaa tttcatgact agaagccaat ttatttgcta gaagtcaacc tccatcagat 181020
tccccaccta tccccagtct gtctttggga caaggccttt ttgactgggt acagcaggtc 181080
tctgaatttt tccatagctt ctgctataga aacagacatg ggccaccttg tattctttgc 181140
agggcagtag agcaggaggc atttccctct ggaaagattt cctcttctgc caacaggagg 181200
agatctatgt aagcaactca gataggattt gtatggcagc caaggaaactt ttctttaata 181260
tcttttctaa gagccctctc tttagcccta cggagggaga agggcaaat ttgatattca 181320
aagctatgtg ttttggttat ctaaatcagg gttttactgt gaatgacata aaagcttagg 181380
tcctaaaaaa tgagtatctg agaagagtag aaaaagaaaa gggtcaggaa atttgattta 181440
cttgactcct ttcagatcgg atccagctat cctttcccct gagatctccc tgacagactg 181500
aaggccccaa gcacacagac ttcaactaac aggaagccaa gtagatgggt cctgtggggg 181560
gtgggggtca agtctgtggt cagaaaaactt ggtgctttgt ctaatgctcc ttcgtgggca 181620
tgcttccctc cccattctg tcttcatccc acatcagttc cagtggatgg gctgaaaaat 181680
caaaaattct ttgatgaact tcgaatgaac tacatcaagg aactcgatcg tatcattgca 181740
tgcaaaagaa aaaatcccac atcctgctca agacgcttct accagctcac caagctcctg 181800
gactccgtgc agcctgtaag caaacgatgg aggggtgcttt atcagggaga acagcctgat 181860
agagccaatg ataatatgct tctctagagt ctggcaccac ctgttgggag gtgcttccat 181920
tccctctggt ctttgagtgt ggtccaggaa gaaaatgtgg tgaagaaaag aacacgggtc 181980
acagtgtccc agctggatat tgtgaaaggg gtggaggagt tgagaacaga gcagttggga 182040
ctcagggaag ggacttgtag cagatgaatt ctctaggcag acaaaacaga cctggatggt 182100
tttcccctct tctttgagtc atgttcatgt gagtttgtct gtctgtgtgt gtgtgtgtgt 182160
gtgtgtgtgt gtgtgtgtgt gtgtcagaga gagagagaga gagagagaga tggagtgcgg 182220
aggcttgggt gagagcacia gctggagaag tcttgagtc gagagcttac aatggataa 182280
gacatctctt gggagccctc agtgactcca tggagaccat ttctttctct ctctctcgct 182340
gtctctctct aacacacaca cacacacaca cgacctcatg ggggaggacc aagggaagtac 182400
ggggaagggg gaggaacaa aaggctgaaa gacaaaaaat cagaggttgg ggaagaggct 182460
agcagaggcc acctccttgt caaccctgtt tttctccctc ttattgttcc ctacagattg 182520
cgagagagct gcacagttc acttttgacc tgctaataca gtcacacatg gtgagcgtgg 182580
actttccgga aatgatggca gagatcatct ctgtgcaagt gccaagatc ctttctggga 182640

-continued

aagtcaagcc catctatttc cacaccagc gaagcattgg aaacctatt tccccacccc 182700
agctcatgcc ccccttcaga tgtctctgc ctgttataac tctgcactac tcctctgcag 182760
tgccttgggg aatttctctc attgatgtac agtctgtcat gaacatgttc ctgaattcta 182820
tttgcctgggc ttttttttc tctttctctc ctttcttttt cttcttccct ccctatctaa 182880
ccctcccatg gcaccttcag actttgcttc ccattgtggc tcctatctgt gttttgaatg 182940
gtgttgatg cctttaaatc tgtgatgac ctcatatggc ccagtgtcaa gttgtgcttg 183000
tttacagcac tactctgtgc cagccacaca aacgtttact tatcttatgc cacgggaagt 183060
ttagagagct aagattatct ggggaaatca aaacaaaaac aagcaacaa aaaaaaaag 183120
caaaaaaaa acaaaaaata agccaaaaaa ccttgctagt gtttttctct caaaaaataa 183180
taataaata aataaatagc tacatacata cacacataca tacaacata tagaatccc 183240
caaagaggcc aatagtgcg agaaggtgaa aattgcaggc ccatggggag ttactgattt 183300
tttcatctcc tcctccacg ggagacttta ttttctgcc atggctattg ccattagagg 183360
gcagagtgc cccagagctg agttgggcag gggggtggac agagaggaga ggacaaggag 183420
ggcaatggag catcagtacc tgcccacagc ctgggtccct gggggctaga ctgctcaact 183480
gtggagcaat tcattatact gaaaaatgtc ttgttggtga aaatttgtct gcatgttaat 183540
gctcaccccc caaaccttt tctctctcac tctctgctc caacttcaga ttgactttca 183600
atagtttttc taagacctt gaactgaatg ttctcttcag ccaaaacttg gcgacttcca 183660
cagaaaagtc tgaccactga gaagaaggag agcagagatt taacctttg taaggcccca 183720
tttgatcca ggtctgctt ctcagtgtg agtcaggag gagctggagc cagaggagaa 183780
gaaaatgata gcttggctgt tctcctgctt aggacactga ctgaatagtt aaactctcac 183840
tgccactacc ttttccccac ctttaaaaga cctgaatgaa gttttctgcc aaactccgtg 183900
aagccacaag caccttatgt cctcccttca gtgttttggt ggctgaatt tcatcacact 183960
gcatttcagc catggctac aagcctggtt gcttcttttg ggcatgttca cagattctct 184020
gttaagagcc cccaccacca agaaggttag caggccaaca gctctgacat ctatctgtag 184080
atgccagtag tcacaaagat ttcttaccac ctctcagatc gctggagccc ttagacaaac 184140
tggaagaag gcacaaagg gatcaggcaa gctgggcgtc ttgcccttgt cccccagaga 184200
tgataccctc ccagcaagtg gagaagtctc cacttcttc tttagagcag ctaaaagggc 184260
taccagatc aggggtgaag agaaaactca attaccaggg tgggaagaat gaaggcacta 184320
gaaccagaaa ccttgcaaat gctctctctg tcaccacgca tatccacctg cagaagtcat 184380
gagaagagag aaggaacaaa gaggagactc tgactactga attaaaatct tcagcggcaa 184440
agcctaaagc cagatggaca ccactctggt agtttactca tcctcctct ctgctgctga 184500
ttctgggctc tgacattgcc catactcact cagattcccc acctttgttg ctgcctctta 184560
gtcagaggga gggccaaaca ttgagacttt ctacagaacc atggcttctt tcggaaagg 184620
ctggttggtg tggctccaat actttgccac ccatgaactc aggggtgtgc ctgggacact 184680
ggttttatat agtcttttg cacacctgtg ttctgttgac ttcgttcttc aagcccaagt 184740
gcaagggaaa atgtccacct actttctcat cttggcctct gcctccttac ttagctctta 184800
atctcatctg ttgaactcaa gaaatcaagg gccagtcac aagctgcccc ttttaattga 184860
ttcactctgt ttgttgagag gatagtttct gagtgacatg atatgatcca caagggttct 184920
cttccctgat ttctgcattg atattaatag ccaaacgaac ttcaaacag ctttaataa 184980
caaggagag gggaaactaa gatgagtaat atgccaatcc aagactgctg gagaaaacta 185040

-continued

aagctgacag gttccctttt tggggtggga tagacatggt ctggttttct ttattattac 185100
acaatctggc tcatgtacag gatcactttt agctgtttta aacagaaaaa aatatccacc 185160
actcttttca gttacactag gttacatttt aataggctct ttacatctgt ttgggaatga 185220
ttttcatctt ttgtgataca cagattgaat tatatcattt tcatatctct cettgtaaat 185280
actagaagct ctcttttaca tttctctatc aaatttttca tctttatggg ttcccaatt 185340
gtgactcttg tcttcatgaa tatatgtttt tcatttgcaa aagccaaaaa tcagtgaaac 185400
agcagtgtaa ttaaaagcaa caactggatt actccaaatt tccaaatgac aaaactaggg 185460
aaaaatagcc tacacaagcc tttaggccta ctctttctgt gcttgggttt gagtgaacaa 185520
aggagatttt agcttggtct tgttctccca tggatgaaag gaggaggatt ttttttttct 185580
tttgccatt gatgttctag ccaatgtaat tgacagaagt ctcattttgc atgcgctctg 185640
ctctacaaac agagttggta tggttggtat actgtactca cctgtgaggg actggccact 185700
cagaccct tagctggtga gctagaagat gaggatcact cactggaaaa gtcacaagga 185760
ccatctccaa acaagttggc agtgcctgat gtggacgaag agtgaggaa agaaaaagaa 185820
ggagcaccag ggagaaggct ccgtctgtgc tgggcagcag acagctgcca ggatcacgaa 185880
ctctgtagtc aaagaaaaga gtcgtgtggc agtttcagct ctcgttcatt gggcagctcg 185940
cctaggccca gcctctgagc tgacatggga gttgttggt tctttgttcc atagcttttt 186000
ctatgccata ggcaatatg ttgttcttgg aaagtattt atttttttaa ctcccttact 186060
ctgagaaagg gatattttga aggactgtca tatatctttg aaaaaagaaa atctgtaata 186120
catatatttt tatgtatgtt cactggcact aaaaaatata gagagcttca ttctgtcctt 186180
tgggtagttg ctgaggtaat tgtccagggt gaaaaataat gtgctgatgc tagagtcctt 186240
ctctgtccat actctacttc taaatacata taggcataca tagcaagttt tatttgactt 186300
gtactttaag agaaaaatag tccaccatcc acatgatgca caaatgagct aacattgagc 186360
ttcaagtagc ttctaagtggt ttgtttcatt aggcacagca cagatgtggc ctttcccccc 186420
ttctctccct tgatatctgg cagggcataa aggccaggc cacttcctct gcccttccc 186480
agccctgcac caaagctgca tttcaggaga ctctctccag acagcccagt aactaccgca 186540
gcatggcccc tgcatagcc tggaaaaata agaggctgac tgtctacgaa ttatcttgtg 186600
ccagttgccc aggtgagagg gcactgggcc aaggagtggt ttttcatgtt tgaccacta 186660
caaggggtca tgggaatcag gaatgccaaa gcaccagatc aaatccaaaa cttaaagtca 186720
aaataagcca ttcagcatgt tcagtttctt ggaaaaggaa gtttctaccc ctgatgcctt 186780
tgtaggcaga tctgttttca ccattaatct ttttgaaaat cttttaagc agtttttaa 186840
aagagagatg aaagcatcac attatataac caaagattac attgtacctg ctaagatacc 186900
aaaattcata agggcagggg gggagcaagc attagtgcct ctttgataag ctgtccaaag 186960
acagactaaa ggactctgct ggtgactgac ttataagagc tttgtgggtt tttttttccc 187020
taataatata catgtttaga agaattgaaa ataatttcgg gaaaatggga ttatgggtcc 187080
ttcactaagt gattttataa gcagaactgg ctttctttt ctctagtagt tgctgagcaa 187140
attgttgaag ctccatcatt gcatggttgg aaatggagct gttcttagcc actgtgtttg 187200
ctagtccca tgttagctta tctgaagatg tgaaaccctt gctgataagg gagcatttaa 187260
agtactagat tttgcactag agggacagca ggcagaaatc cttatttctg cccacttttg 187320
atggcacaaa aagttatctg cagttgaagg cagaaagttg aaatacatg taaatgaata 187380

-continued

```

tttgtatcca tgtttcaaaa ttgaaatata tatatatata tatatatata tatatatata 187440
tatatagtgt gtgtgtgtgt tctgatagct ttaactttct ctgcatcttt atatttggtt 187500
ccagatcaca cctgatgcca tgtacttgtg agagaggatg cagttttggt ttggaagctc 187560
tctcagaaca aacaagacac ctggattgat cagttaacta aaagttttct cccctattgg 187620
gtttgaccca caggctctgt gaaggagcag agggataaaa agagtagagg acatgataca 187680
ttgtacttta ctagtccaag acagatgaat gtggaagca taaaaactca atggaactga 187740
ctgagattta ccacagggaa ggcccaaact tggggccaaa agcctacca agtgattgac 187800
cagtggtccc ctaatgggac ctgagctgtt ggaagaagag aactgttctt tggctctcac 187860
catccttggt agagaagggc agtttctctg attggaacct ggagcaagcg ctctatcttt 187920
cacacaaatt ccctcacctg agattgaggt gctcttggtt ctgggtgtct gtgtgctgta 187980
attctggttt tggatatggt ctgtaagat ttgacaaat gaaaatgtgt ttttctctgt 188040
taaaacttgt cagagtacta gaagttgtat ctctgtaggt gcagggtccat ttctgcccac 188100
aggtaggggt ttttctttg attaagagat tgacacttct gttgctagg acctcccaac 188160
tcaaccattt ctagggtgaag gcagaaaaat ccacattagt tactcctctt cagacatttc 188220
agctgagata acaaatcttt tggaaatfff tcacccatag aaagagtggg agatatttga 188280
atttagcagg tggagtttca tagtaaaac agcttttgac tcagctttga tttatcctca 188340
tttgatttgg ccagaaagta ggtaatatgc attgattggc ttctgattcc aattcagtat 188400
agcaaggtgc taggtttttt ctttcccca cctgtctctt agcctgggga attaaatgag 188460
aagccttaga atgggtggcc cttgtgacct gaaacacttc ccacataagc tacttaacaa 188520
gattgtcatg gagctgcaga ttccattgcc caccaaagac tagaacacac acatatccat 188580
acaccaaagg aaagacaatt ctgaaatgct gtttctctgg tggttccctc tctggtgctt 188640
gcctcacagt atgggaacct gtactctgca gaggtgacag gccagatttg cattatctca 188700
caaccttagc ccttgggtgt aactgtccta cagtgaagtg cctggggggg tgtcctatcc 188760
cataagccac ttggatgctg acagcagcca ccatcagaat gaccacgca aaaaaagaa 188820
aaaaaaatt aaaaagtccc ctcaaaccc agtgacacct ttctgcttct ctctagactg 188880
gaacattgat tagggagtgc ctgagacatg acattcttgt gctgtccttg gaattaatct 188940
ggcagcagga gggagcagac tatgtaaca gagataaaa ttaattttca atattgaagg 189000
aaaaaagaaa taagaagaga gagagaaaga aagcatcaca caaagatttt cttaaagaa 189060
acaattttgc ttgaaatctc tttagatggg gctcatttct cagggtggca cttggcctcc 189120
actgggcagc aggaccagct ccaagcgta gtgttctgtt ctctttttgt aatcttgga 189180
tcttttgttg ctctaaatac aattaaat ggcagaaact tgtttgttg actacatgtg 189240
tgactttggg tctgtctctg cctctgcttt cagaaatgct atccattgtg taaaatattg 189300
gcttactggg ctgccagcta aaacttggtc acatcccttg ttatggctgc aggatcgagt 189360
tattgttaac aaagagacc aagaaaagct gctaagtctc tcttatcatt gttgttaatt 189420
tgtaaaaca taaagaaatc taaaatttca gatgaatgct atcagagttc tttaattag 189480
ctctttttat tggctgtttt tattgaagtc aagagtgggt atcatgccc gttgcgtttt 189540
atgctatttt gattttcata tatttttaaa agtctttgca caagggttac aaatttgccc 189600
tgtgtgggcc ttagcataag ctgacctggg accacaaaa taacaaggaa tttgggctag 189660
aaagcacaga tggacctggt tgacctatca caacttctct tgaaaaacc caaacttgct 189720
agctggggaa aagccacaca aagccagct gccaccttc acatccttat cctttagga 189780

```

-continued

```
gcataaaatg gtgtcatcac tgcccagttc taaccaagct tcagttaaag aatgggtacc 189840
ttcacatctt cactattttt caggggcctt accgtccttg accaccaag taaaatctaa 189900
atcagccttc ttttgggttc ttcagttcaa gcaaggcctc ttcttgtggc ctctcagtat 189960
taatatattat gaggttgacg attgaatttt tgggcctgag atacaagcca tcaatgaggt 190020
gtgacaaagc atgtcaatga ataataagaa aattatctat tcttccatat cctcccctgt 190080
aataagggtt gtcagaatgc cttctttctg ggctgggttg aggattcagt gagaacatat 190140
gtgacacagc tgggtgggcta ttaagctctg gctttgtctc ctgttaaaat gccagaaccc 190200
ttgagaggga tcccacattg agccatgttt atcactgacc accttagaat ggatggattt 190260
ctcagatttt tcctgagatc aatgcttgat ggagaggaga ggagaacaat agattcttgg 190320
gatgtgtgtt atgcatgtgt ttaagtaaga gacagagagt atgtttatct gcaggttgtg 190380
tgtgtaaagt cagagcctgc ctccagagga tcttctctaa ccaccattgc ttaggtcctg 190440
ttcgtttgca tctacagcga atgaccttac agccatctga cttggcttca ctcaccactc 190500
agctcctgcc taaacagacg aggtgggttag catccaccat aagttttcca aggagtagca 190560
aagcaciaag gacacctatt gggttgaaaa gaggctagag gcatgagtcc tgtgtgtgac 190620
ttgttcatag tcatgcagct agtgtatagc taggattctc ccctgctgat ttactatgtg 190680
acactaggca gcaatctgcc cttgctggac ctcggttttc taatctgtaa aatgtgtgga 190740
gtaaaactac atgagatggg aagtcccttc tagtgcagat gccatgggta ttgaaaactg 190800
cagcaacatc tttcttaatc gtaaggggaa agaaaaagac catttactac tcctagaaca 190860
gttttggagc tagaatattc acatttgac tcaataatta tttacaaaac aactagtgtg 190920
gagaggggtc aaacaacagc tgagtcctgt gtaatagata ttgtcaaccc cttgatggat 190980
gaggaagggg ctcaaaggga a 191001
```

```
<210> SEQ ID NO 2
<211> LENGTH: 10661
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1116)...(3878)
```

```
<400> SEQUENCE: 2
```

```
cgagatcccg gggagccagc ttgctgggag agcgggacgg tccggagcaa gccagaggc 60
agaggaggcg acagagggaa aaagggccga gctagccgct ccagtgtgtg acaggaggcg 120
aagggaagca ccacgccagc cccagcccgg ctccagcgac agccaacgcc tcttgacgag 180
cggcggtctc gaagccgccg cccggagctg ccctttctc ttcggtgaag tttttaaag 240
ctgctaaaga ctcgagggaa gcaaggaaaag tgcctggtag gactgacggc tgctttgtc 300
ctcctctctc ccaccccgcc tccccccacc ctgccttccc cccctcccc gtcttctctc 360
ccgcagctgc ctcagtcggc tactctcagc caacccccct caccaccctt ctccccacc 420
gccccccgcg ccccgctggc ccagcgtgc cagcccgagt ttgcagagag gtaactccct 480
ttggctgcga gcggggcagc tagctgcaca ttgcaaagaa ggctcttagg agccaggcga 540
ctggggagcg gcttcagcac tgcagccacg acccgctgg ttaggtgcga cgcggagaga 600
accctctgtt tcccccaact ctctctccac ctctctctgc ctccccacc ccgagtgcgg 660
agccagagat caaaagatga aaaggcagtc aggtcttcag tagccaaaaa acaaaacaaa 720
caaaaacaaa aaagccgaaa taaaagaaaa agataataac tcagttctta ttgcacctc 780
```

-continued

cttcagtgga cactgaattt ggaaggtgga ggattttgtt tttttctttt aagatctggg	840
catcttttga atctaccctt caagtattaa gagacagact gtgagcctag cagggcagat	900
cttgccacc gtgtgtcttc ttctgcacga gactttgagg ctgtcagagc gctttttgcg	960
tggttgcctc cgcaagtttc cttctctgga gcttcccgca ggtgggcagc tagctgcagc	1020
gactaccgca tcacacagc ctgttgaact cttctgagca agagaagggg aggcggggta	1080
agggaaagtag gtggaagatt cagccaagct caagg atg gaa gtg cag tta ggg	1133
Met Glu Val Gln Leu Gly	1 5
ctg gga agg gtc tac cct cgg ccg ccg tcc aag acc tac cga gga gct	1181
Leu Gly Arg Val Tyr Pro Arg Pro Pro Ser Lys Thr Tyr Arg Gly Ala	10 15 20
ttc cag aat ctg ttc cag agc gtg cgc gaa gtg atc cag aac ccg ggc	1229
Phe Gln Asn Leu Phe Gln Ser Val Arg Glu Val Ile Gln Asn Pro Gly	25 30 35
ccc agg cac cca gag gcc gcg agc gca gca cct ccc ggc gcc agt ttg	1277
Pro Arg His Pro Glu Ala Ala Ser Ala Ala Pro Pro Gly Ala Ser Leu	40 45 50
ctg ctg ctg cag cag cag cag cag cag cag cag cag cag cag cag	1325
Leu Leu Leu Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln	55 60 65 70
cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag	1373
Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln	75 80 85
cag cag cag cag cag ggt gag gat ggt tct ccc caa gcc cat cgt aga	1421
Gln Gln Gln Gln Gln Gly Glu Asp Gly Ser Pro Gln Ala His Arg Arg	90 95 100
ggc ccc aca ggc tac ctg gtc ctg gat gag gaa cag caa cct tca cag	1469
Gly Pro Thr Gly Tyr Leu Val Leu Asp Glu Glu Gln Gln Pro Ser Gln	105 110 115
ccg cag tcg gcc ctg gag tgc cac ccc gag aga ggt tgc gtc cca gag	1517
Pro Gln Ser Ala Leu Glu Cys His Pro Glu Arg Gly Cys Val Pro Glu	120 125 130
cct gga gcc gcc gtg gcc gcc agc aag ggg ctg ccg cag cag ctg cca	1565
Pro Gly Ala Ala Val Ala Ala Ser Lys Gly Leu Pro Gln Gln Leu Pro	135 140 145 150
gca cct ccg gac gag gat gac tca gct gcc cca tcc acg ttg tcc ctg	1613
Ala Pro Pro Asp Glu Asp Asp Ser Ala Ala Pro Ser Thr Leu Ser Leu	155 160 165
ctg ggc ccc act ttc ccc ggc tta agc agc tgc tcc gct gac ctt aaa	1661
Leu Gly Pro Thr Phe Pro Gly Leu Ser Ser Cys Ser Ala Asp Leu Lys	170 175 180
gac atc ctg agc gag gcc agc acc atg caa ctc ctt cag caa cag cag	1709
Asp Ile Leu Ser Glu Ala Ser Thr Met Gln Leu Leu Gln Gln Gln	185 190 195
cag gaa gca gta tcc gaa ggc agc agc agc ggg aga gcg agg gag gcc	1757
Gln Glu Ala Val Ser Glu Gly Ser Ser Ser Gly Arg Ala Arg Glu Ala	200 205 210
tcg ggg gct ccc act tcc tcc aag gac aat tac tta ggg ggc act tcg	1805
Ser Gly Ala Pro Thr Ser Ser Lys Asp Asn Tyr Leu Gly Gly Thr Ser	215 220 225 230
acc att tct gac aac gcc aag gag ttg tgt aag gca gtg tcg gtg tcc	1853
Thr Ile Ser Asp Asn Ala Lys Glu Leu Cys Lys Ala Val Ser Val Ser	235 240 245
atg ggc ctg ggt gtg gag gcg ttg gag cat ctg agt cca ggg gaa cag	1901
Met Gly Leu Gly Val Glu Ala Leu Glu His Leu Ser Pro Gly Glu Gln	250 255 260

-continued

ctt	cgg	ggg	gat	tgc	atg	tac	gcc	cca	ctt	ttg	gga	gtt	cca	ccc	gct	1949
Leu	Arg	Gly	Asp	Cys	Met	Tyr	Ala	Pro	Leu	Leu	Gly	Val	Pro	Pro	Ala	
	265						270					275				
gtg	cgt	ccc	act	cct	tgt	gcc	cca	ttg	gcc	gaa	tgc	aaa	ggg	tct	ctg	1997
Val	Arg	Pro	Thr	Pro	Cys	Ala	Pro	Leu	Ala	Glu	Cys	Lys	Gly	Ser	Leu	
	280					285				290						
cta	gac	gac	agc	gca	ggc	aag	agc	act	gaa	gat	act	gct	gag	tat	tcc	2045
Leu	Asp	Asp	Ser	Ala	Gly	Lys	Ser	Thr	Glu	Asp	Thr	Ala	Glu	Tyr	Ser	
	295				300				305					310		
cct	ttc	aag	gga	ggg	tac	acc	aaa	ggg	cta	gaa	ggc	gag	agc	cta	ggc	2093
Pro	Phe	Lys	Gly	Gly	Tyr	Thr	Lys	Gly	Leu	Glu	Gly	Glu	Ser	Leu	Gly	
			315						320					325		
tgc	tct	ggc	agc	gct	gca	gca	ggg	agc	tcc	ggg	aca	ctt	gaa	ctg	ccg	2141
Cys	Ser	Gly	Ser	Ala	Ala	Ala	Gly	Ser	Ser	Gly	Thr	Leu	Glu	Leu	Pro	
			330					335					340			
tct	acc	ctg	tct	ctc	tac	aag	tcc	gga	gca	ctg	gac	gag	gca	gct	gcg	2189
Ser	Thr		Leu	Ser	Leu	Tyr	Lys	Ser	Gly	Ala	Leu	Asp	Glu	Ala	Ala	
	345						350					355				
tac	cag	agt	cgc	gac	tac	tac	aac	ttt	cca	ctg	gct	ctg	gcc	gga	ccg	2237
Tyr	Gln	Ser	Arg	Asp	Tyr	Tyr	Asn	Phe	Pro	Leu	Ala	Leu	Ala	Gly	Pro	
	360						365				370					
ccg	ccc	cct	ccg	ccg	cct	ccc	cat	ccc	cac	gct	cgc	atc	aag	ctg	gag	2285
Pro	Pro	Pro	Pro	Pro	Pro	Pro	His	Pro	His	Ala	Arg	Ile	Lys	Leu	Glu	
	375				380					385				390		
aac	ccg	ctg	gac	tac	ggc	agc	gcc	tgg	gcg	gct	gcg	gcg	gcg	cag	tgc	2333
Asn	Pro	Leu	Asp	Tyr	Gly	Ser	Ala	Trp	Ala	Ala	Ala	Ala	Ala	Gln	Cys	
			395					400						405		
cgc	tat	ggg	gac	ctg	gcg	agc	ctg	cat	ggc	gcg	ggg	gca	gcg	gga	ccc	2381
Arg	Tyr	Gly	Asp	Leu	Ala	Ser	Leu	His	Gly	Ala	Gly	Ala	Ala	Gly	Pro	
		410						415				420				
ggg	tct	ggg	tca	ccc	tca	gcc	gcc	gct	tcc	tca	tcc	tgg	cac	act	ctc	2429
Gly	Ser	Gly	Ser	Pro	Ser	Ala	Ala	Ala	Ser	Ser	Ser	Trp	His	Thr	Leu	
		425					430					435				
ttc	aca	gcc	gaa	gaa	ggc	cag	ttg	tat	gga	ccg	tgt	ggg	ggg	ggg	ggg	2477
Phe	Thr	Ala	Glu	Glu	Gly	Gln	Leu	Tyr	Gly	Pro	Cys	Gly	Gly	Gly	Gly	
	440					445					450					
ggg	ggg	ggc	ggc	ggc	ggc	ggc	ggc	ggc	ggc	ggc	ggc	ggc	ggc	ggc	ggc	2525
Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	
	455				460					465				470		
ggc	ggc	ggc	gag	gcg	gga	gct	gta	gcc	ccc	tac	ggc	tac	act	cgg	ccc	2573
Gly	Gly	Gly	Glu	Ala	Gly	Ala	Val	Ala	Pro	Tyr	Gly	Tyr	Thr	Arg	Pro	
			475					480						485		
cct	cag	ggg	ctg	gcg	ggc	cag	gaa	agc	gac	ttc	acc	gca	cct	gat	gtg	2621
Pro	Gln	Gly	Leu	Ala	Gly	Gln	Glu	Ser	Asp	Phe	Thr	Ala	Pro	Asp	Val	
		490						495					500			
tgg	tac	cct	ggc	ggc	atg	gtg	agc	aga	gtg	ccc	tat	ccc	agt	ccc	act	2669
Trp	Tyr	Pro	Gly	Gly	Met	Val	Ser	Arg	Val	Pro	Tyr	Pro	Ser	Pro	Thr	
		505						510					515			
tgt	gtc	aaa	agc	gaa	atg	ggc	ccc	tgg	atg	gat	agc	tac	tcc	gga	cct	2717
Cys	Val	Lys	Ser	Glu	Met	Gly	Pro	Trp	Met	Asp	Ser	Tyr	Ser	Gly	Pro	
	520					525				530						
tac	ggg	gac	atg	cgt	ttg	gag	act	gcc	agg	gac	cat	gtt	ttg	ccc	att	2765
Tyr	Gly	Asp	Met	Arg	Leu	Glu	Thr	Ala	Arg	Asp	His	Val	Leu	Pro	Ile	
	535				540					545				550		
gac	tat	tac	ttt	cca	ccc	cag	aag	acc	tgc	ctg	atc	tgt	gga	gat	gaa	2813
Asp	Tyr	Tyr	Phe	Pro	Pro	Gln	Lys	Thr	Cys	Leu	Ile	Cys	Gly	Asp	Glu	
			555						560					565		
gct	tct	ggg	tgt	cac	tat	gga	gct	ctc	aca	tgt	gga	agc	tgc	aag	gtc	2861
Ala	Ser	Gly	Cys	His	Tyr	Gly	Ala	Leu	Thr	Cys	Gly	Ser	Cys	Lys	Val	
		570						575					580			

-continued

ttc ttc aaa aga gcc gct gaa ggg aaa cag aag tac ctg tgc gcc agc Phe Phe Lys Arg Ala Ala Glu Gly Lys Gln Lys Tyr Leu Cys Ala Ser 585 590 595	2909
aga aat gat tgc act att gat aaa ttc cga agg aaa aat tgt cca tct Arg Asn Asp Cys Thr Ile Asp Lys Phe Arg Arg Lys Asn Cys Pro Ser 600 605 610	2957
tgt cgt ctt cgg aaa tgt tat gaa gca ggg atg act ctg gga gcc cgg Cys Arg Leu Arg Lys Cys Tyr Glu Ala Gly Met Thr Leu Gly Ala Arg 615 620 625 630	3005
aag ctg aag aaa ctt ggt aat ctg aaa cta cag gag gaa gga gag gct Lys Leu Lys Lys Leu Gly Asn Leu Lys Leu Gln Glu Glu Gly Glu Ala 635 640 645	3053
tcc agc acc acc agc ccc act gag gag aca acc cag aag ctg aca gtg Ser Ser Thr Thr Ser Pro Thr Glu Glu Thr Thr Gln Lys Leu Thr Val 650 655 660	3101
tca cac att gaa gcc tat gaa tgt cag ccc atc ttt ctg aat gtc ctg Ser His Ile Glu Gly Tyr Glu Cys Gln Pro Ile Phe Leu Asn Val Leu 665 670 675	3149
gaa gcc att gag cca ggt gta gtg tgt gct gga cac gac aac aac cag Glu Ala Ile Glu Pro Gly Val Val Cys Ala Gly His Asp Asn Asn Gln 680 685 690	3197
ccc gac tcc ttt gca gcc ttg ctc tct agc ctc aat gaa ctg gga gag Pro Asp Ser Phe Ala Leu Leu Ser Ser Leu Asn Glu Leu Gly Glu 695 700 705 710	3245
aga cag ctt gta cac gtg gtc aag tgg gcc aag gcc ttg cct ggc ttc Arg Gln Leu Val His Val Val Lys Trp Ala Lys Ala Leu Pro Gly Phe 715 720 725	3293
cgc aac tta cac gtg gac gac cag atg gct gtc att cag tac tcc tgg Arg Asn Leu His Val Asp Asp Gln Met Ala Val Ile Gln Tyr Ser Trp 730 735 740	3341
atg ggg ctc atg gtg ttt gcc atg ggc tgg cga tcc ttc acc aat gtc Met Gly Leu Met Val Phe Ala Met Gly Trp Arg Ser Phe Thr Asn Val 745 750 755	3389
aac tcc agg atg ctc tac ttc gcc cct gat ctg gtt ttc aat gag tac Asn Ser Arg Met Leu Tyr Phe Ala Pro Asp Leu Val Phe Asn Glu Tyr 760 765 770	3437
cgc atg cac aag tcc cgg atg tac agc cag tgt gtc cga atg agg cac Arg Met His Lys Ser Arg Met Tyr Ser Gln Cys Val Arg Met Arg His 775 780 785 790	3485
ctc tct caa gag ttt gga tgg ctc caa atc acc ccc cag gaa ttc ctg Leu Ser Gln Glu Phe Gly Trp Leu Gln Ile Thr Pro Gln Glu Phe Leu 795 800 805	3533
tgc atg aaa gca ctg cta ctc ttc agc att att cca gtg gat ggg ctg Cys Met Lys Ala Leu Leu Leu Phe Ser Ile Ile Pro Val Asp Gly Leu 810 815 820	3581
aaa aat caa aaa ttc ttt gat gaa ctt cga atg aac tac atc aag gaa Lys Asn Gln Lys Phe Phe Asp Glu Leu Arg Met Asn Tyr Ile Lys Glu 825 830 835	3629
ctc gat cgt atc att gca tgc aaa aga aaa aat ccc aca tcc tgc tca Leu Asp Arg Ile Ile Ala Cys Lys Arg Lys Asn Pro Thr Ser Cys Ser 840 845 850	3677
aga cgc ttc tac cag ctc acc aag ctc ctg gac tcc gtg cag cct att Arg Arg Phe Tyr Gln Leu Thr Lys Leu Leu Asp Ser Val Gln Pro Ile 855 860 865 870	3725
gcg aga gag ctg cat cag ttc act ttt gac ctg cta atc aag tca cac Ala Arg Glu Leu His Gln Phe Thr Phe Asp Leu Leu Ile Lys Ser His 875 880 885	3773
atg gtg agc gtg gac ttt ccg gaa atg atg gca gag atc atc tct gtg Met Val Ser Val Asp Phe Pro Glu Met Met Ala Glu Ile Ile Ser Val 885 890 895	3821

-continued

890	895	900	
caa gtg ccc aag atc ctt tct ggg aaa gtc aag ccc atc tat ttc cac			3869
Gln Val Pro Lys Ile Leu Ser Gly Lys Val Lys Pro Ile Tyr Phe His			
905	910	915	
acc cag tga agcattggaa accctatttc cccaccccag ctcatgcccc			3918
Thr Gln			
920			
ctttcagatg tcttctgctt gttataactc tgcactactc ctctgcagtg ccttggggaa			3978
tttctcttat tgatgtacag tctgtcatga acatgttcct gaattctatt tgctgggctt			4038
ttttttttctc tttctctcct tcttttttct tcttccctcc ctatctaacc ctcccatggc			4098
accttcagac tttgcttccc attgtggctc ctatctgtgt tttgaatggg gttgtatgcc			4158
tttaaatctg tgatgatcct catatggccc agtgtcaagt tgtgcttgtt tacagcacta			4218
ctctgtgccca gccacacaaa cgtttactta tcttatgccca cgggagagttt agagagctaa			4278
gattatctgg ggaaatcaaa acaaaaacaa gcaaacaaaa aaaaaagca aaaacaaaac			4338
aaaaaataag ccaaaaaacc ttgctagtgt ttttctctca aaaataaata aataaataaa			4398
taaatacgta catacataca cacatacata caaacatata gaaatcccca aagaggccaa			4458
tagtgacgag aaggtgaaaa ttgcaggccc atggggagtt actgattttt tcatctctc			4518
cctccacggg agactttatt tcttgccaat ggctattgcc attagagggc agagtgaccc			4578
cagagctgag ttgggcaggg ggggtggacag agaggagagg acaaggaggg caatggagca			4638
tcagtacctg cccacagcct tggteccctg gggetagact gctcaactgt ggagcaattc			4698
attatactga aaatgtgctt gttgttgaat atttgtctgc atgttaatgc ctcaccccca			4758
aaccttttct tctctcactc tctgctccca acttcagatt gactttcaat agtttttcta			4818
agacctttga actgaatgtt ctcttcagcc aaaacttggc gacttccaca gaaaagtctg			4878
accactgaga agaaggagag cagagattta acccttttga agggcccatc tggatccagg			4938
tctgctttct catgtgtgag tcaggggagga gctggagcca gaggagaaga aaatgatagc			4998
ttggtgttct tctgcttag gacactgact gaatagttaa actctcactg ccactacctt			5058
ttccccacct ttaaaagacc tgaatgaagt tttctgcca actccgtgaa gccacaagca			5118
ccttatgtcc tcccttcagt gttttgtggg cctgaatttc atcacactgc atttcagcca			5178
tggtcatcaa gctgttttgc tttttttggg catgttcaca gattctctgt taagagcccc			5238
caccaccaag aaggttagca ggccaacagc tctgacatct atctgtagat gccagtagtc			5298
acaaagattt cttaccaact ctgagatcgc tggagccctt agacaaactg gaaagaaggc			5358
atcaaaggga tcaggcaagc tgggcgtctt gcccttgtcc cccagagatg ataccctccc			5418
agcaagtgga gaagtcttca cttccttctt tagagcagct aaaggggcta cccagatcag			5478
ggttgaagag aaaactcaat taccaggggtg ggaagaatga aggcactaga accagaaacc			5538
ctgcaaatgc tcttcttgtc acccagcata tccacctgca gaagtcatga gaagagagaa			5598
ggaacaaaga ggagactctg actactgaat taaaatcttc agcggcaaag cctaaagcca			5658
gatggacacc atctgggtgag ttactcatc atcctcctct gctgctgatt ctgggctctg			5718
acattgcccc tactcactca gattccccac ctttgttgcct gcctcttagt cagagggagg			5778
ccaaaccatt gagactttct acagaacctt ggcttcttcc ggaaaggctt ggttggtgtg			5838
gctccaatac tttgccaccc atgaactcag ggtgtgccct gggacactgg ttttatatag			5898
tcttttggca cacctgtgtt ctgttgactt cgttcttcaa gccaagtgc aagggaaaat			5958
gtccacctac tttctcatct tggcctctgc ctccttactt agctcttaat ctcatctgtt			6018

-continued

gaactcaaga aatcaagggc cagtcacaa gctgccatt ttaattgatt cactctgttt	6078
gttgagagga tagtttctga gtgacatgat atgatccaca agggtttcct tccctgattt	6138
ctgcattgat attaatagcc aaacgaactt caaacacagt ttaaataaca agggagaggg	6198
gaacctaaga tgagtaatat gccaatccaa gactgctgga gaaaactaaa gctgacaggt	6258
tccctttttg ggggtgggata gacatgttct ggttttcttt attattacac aatctggctc	6318
atgtacagga tcacttttag ctgtttttaa cagaaaaaaa tatccaccac tcttttcagt	6378
tacactaggt tacattttta taggtccttt acatctgttt tggaatgatt ttcacttttt	6438
gtgatacaca gattgaatta tatcattttc atatctctcc ttgtaaatac tagaagctct	6498
cctttacatt tctctatcaa atttttcac tttatggggt tccaattgt gactcttgct	6558
tctatgaata tatgtttttc atttgcaaaa gccaaaaatc agtgaaacag cagtgttaatt	6618
aaaagcaaca actggattac tccaaatttc caaatgacaa aactagggaa aaatagccta	6678
cacaagcctt taggcctact ctttctgtgc ttgggtttga gtgaacaaag gagattttag	6738
cttggtctcg ttctcccatg gatgaaagga ggaggttttt tttttctttt tggccattga	6798
tgttctagcc aatgtaattg acagaagtct cttttgcat gcgctctgct ctacaaacag	6858
agttgggatg gttggtatc tgtactcacc tgtgagggac tggccactca gaccactta	6918
gctgtgagc tagaagatga ggatcactca ctggaaaagt cacaaggacc atctccaaac	6978
aagttggcag tgctcgatgt ggacgaagag tgaggaagag aaaaagaagg agcaccagg	7038
agaaggctcc gtctgtgctg ggcagcagac agctgccagg atcacgaact ctgtagtcaa	7098
agaaaagagt cgtgtggcag ttccagctct cgttcattgg gcagctcgcc taggccccagc	7158
ctctgagctg acatgggagt tgttggattc tttgtttcat agctttttct atgccatagg	7218
caatattgtt gttcttgga agttttattat ttttttaact cccttactct gagaaagga	7278
tattttgaag gactgtcata tatctttgaa aaaagaaat ctgtaataca tatattttta	7338
tgtatgttca ctggcactaa aaaatataga gagcttcatt ctgtcctttg ggtagttgct	7398
gaggttaattg tccaggttga aaaataatgt gctgatgcta ggtccctct ctgtccatac	7458
tctacttcta aatacatata ggcatacata gcaagtttta ttgacttgt actttaagag	7518
aaaatatgtc caccatccac atgatgcaca aatgagctaa cattgagctt caagtagctt	7578
ctaagtgttt gtttcattag gcacagcaca gatgtggcct tccccctt ctctcccttg	7638
atatctggca gggcataaag gccaggcca cttctctgc ccctcccag ccctgcacca	7698
aagctgcatt tcaggagact ctctccagac agcccagtaa ctaccgagc atggccctg	7758
catagccctg gaaaaataag aggctgactg tctacgaatt atcttggtgc agttgccag	7818
gtgagagggc actgggcca gggagtgggt ttcattgttg acccactaca aggggtcatg	7878
ggaatcagga atgccaaagc accagatcaa atccaaaact taaagtcaaa ataagccatt	7938
cagcatgttc agtttcttgg aaaaggaagt ttctaccct gatgcctttg taggcagatc	7998
tgttctcacc attaatcttt ttgaaaatct tttaaagcag tttttaaaaa gagagatgaa	8058
agcatcacat tatataacca aagattacat tgtacctgct aagataccaa aattcataag	8118
ggcagggggg gagcaagcat tagtgcctct ttgataagct gtccaaagac agactaaagg	8178
actctgctgg tgactgactt ataagagctt tgtgggtttt tttttcccta ataataaca	8238
tgtttagaag aattgaaat aatttcggga aaatgggatt atgggtcctt cactaagtga	8298
ttttataagc agaactggct ttctttttct ctagtgttg ctgagcaaat tgttgaagct	8358

-continued

ccatcattgc atggttgga atggagctgt tcttagccac tgtgtttgct agtgcccatg	8418
ttagcttata tgaagatgtg aaacccttgc tgataaggga gcatttaaag tactagattt	8478
tgactagag ggacagcagg cagaaatcct tatttctgcc cactttggat ggacacaaaa	8538
gttatctgca gttgaaggca gaaagtgaa atacattgta aatgaatatt tgtatccatg	8598
tttcaaaatt gaaatatata tatatatata tatatatata tatagtgtgt	8658
gtgtgtgttc tgatagcttt aactttctct gcacttttat atttggttcc agatcacacc	8718
tgatgccatg tacttgtgag agaggatgca gttttgtttt ggaagctctc tcagaacaaa	8778
caagacacct ggattgatca gttaactaaa agttttctcc cctattgggt ttgaccacac	8838
ggtcctgtga aggagcagag ggataaaaag agtagaggac atgatacatt gtactttact	8898
agttcaagac agatgaatgt ggaaagcata aaaactcaat ggaactgact gagatttacc	8958
acagggaagg cccaaacttg gggccaaaag cctaccacag tgattgacca gtggccccct	9018
aatgggacct gagctgttgg aagaagagaa ctgttccttg gtcttcacca tcttgtgag	9078
agaagggcag tttcctgcat tggaacctgg agcaagcgtc ctatctttca cacaaattcc	9138
ctcacctgag attgaggtgc tcttgttact ggggtgtctgt gtgtgtaat tctggttttg	9198
gatatgttct gtaagattt tgacaaatga aaatgtgttt ttctctgtta aaactgtca	9258
gagtactaga agttgtatct ctgtaggtgc aggtccattt ctgccacag gtaggggtgt	9318
tttctttgat taagagattg acacttctgt tgcctaggac ctcccaactc aaccatttct	9378
agggtgaaggc agaaaaatcc acattagtta ctctcttca gacatttcag ctgagataac	9438
aaatcttttg gaattttttc acccatagaa agagtggtag atatttgaat ttagcagggtg	9498
gagtttcata gtaaaacag cttttgactc agctttgatt tatcctcatt tgatttggcc	9558
agaaagtagg taatatgcat tgattggctt ctgattccaa ttcagtatag caagggtgta	9618
ggttttttcc tttcccacc tgtctcttag cctggggaat taaatgagaa gccttagaat	9678
gggtggccct tgtgacctga aacacttccc acataagcta cttaacaaga ttgtcatgga	9738
gctgcagatt ccattgccc ccaagacta gaacacacac atatccatac accaaaggaa	9798
agacaattct gaaatgctgt ttctctggtg gtccctctc tggctgctgc ctacagtat	9858
gggaacctgt actctgcaga ggtgacaggc cagatttgca ttatctcaca accttagccc	9918
ttggtgctaa ctgtcttaca gtgaagtgcc tggggggttg tctatccca taagccactt	9978
ggatgctgac agcagccacc atcagaatga cccacgcaaa aaaaagaaa aaaaaattaa	10038
aaagtcacct cacaccacag tgacacctt ctgctttcct ctgactgga acattgatta	10098
gggagtgcct cagacatgac attcttgtgc tgtccttgga attaatctgg cagcaggagg	10158
gagcagacta tgtaaacaga gataaaaatt aattttcaat attgaaggaa aaaagaaata	10218
agaagagaga gagaagaaa gcatacacaca aagattttct taaaagaaac aattttgctt	10278
gaaatctctt tagatggggc tcatcttca cgggtggcact tggcctccac tgggcagcag	10338
gaccagctcc aagcgctagt gttctgttct ctttttgtaa tcttggaaac tttgttgc	10398
ctaaatacaa ttaaaaatgg cagaaacttg tttgttgac tacatgtgtg actttgggtc	10458
tgtctctgcc tctgcttca gaaatgtcat ccattgtgta aaatattggc ttactggtct	10518
gccagctaaa acttggccac atccccgtt atggctgcag gatcgagtta ttgttaacaa	10578
agagacccaa gaaaagctgc taatgtctc ttatcattgt tggttaattg ttaaacata	10638
aagaaatcta aaatttcaaa aaa	10661

-continued

```

<210> SEQ ID NO 3
<211> LENGTH: 8112
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (163)...(1329)

<400> SEQUENCE: 3

gctgcgagca gagagggatt cctcgagggt catctgttcc atcttcttgc ctatgcaaat      60
gctgcctga agctgctgga ggctggcttt gtaccggact ttgtacaggg aaccagggaa      120
acgaatgcag agtgctcctg acattgcctg tcactttttc cc atg ata ctc tgg      174
                                     Met Ile Leu Trp
                                     1

ctt cac agt ttg gag act gcc agg gac cat gtt ttg ccc att gac tat      222
Leu His Ser Leu Glu Thr Ala Arg Asp His Val Leu Pro Ile Asp Tyr
  5              10              15              20

tac ttt cca ccc cag aag acc tgc ctg atc tgt gga gat gaa gct tct      270
Tyr Phe Pro Pro Gln Lys Thr Cys Leu Ile Cys Gly Asp Glu Ala Ser
              25              30              35

ggg tgt cac tat gga gct ctc aca tgt gga agc tgc aag gtc ttc ttc      318
Gly Cys His Tyr Gly Ala Leu Thr Cys Gly Ser Cys Lys Val Phe Phe
  40              45              50

aaa aga gcc gct gaa ggg aaa cag aag tac ctg tgc gcc agc aga aat      366
Lys Arg Ala Ala Glu Gly Lys Gln Lys Tyr Leu Cys Ala Ser Arg Asn
  55              60              65

gat tgc act att gat aaa ttc cga agg aaa aat tgt cca tct tgt cgt      414
Asp Cys Thr Ile Asp Lys Phe Arg Arg Lys Asn Cys Pro Ser Cys Arg
  70              75              80

ctt cgg aaa tgt tat gaa gca ggg atg act ctg gga gcc cgg aag ctg      462
Leu Arg Lys Cys Tyr Glu Ala Gly Met Thr Leu Gly Ala Arg Lys Leu
  85              90              95              100

aag aaa ctt ggt aat ctg aaa cta cag gag gaa gga gag gct tcc agc      510
Lys Lys Leu Gly Asn Leu Lys Leu Gln Glu Glu Gly Glu Ala Ser Ser
              105              110              115

acc acc agc ccc act gag gag aca acc cag aag ctg aca gtg tca cac      558
Thr Thr Ser Pro Thr Glu Glu Thr Thr Gln Lys Leu Thr Val Ser His
              120              125              130

att gaa ggc tat gaa tgt cag ccc atc ttt ctg aat gtc ctg gaa gcc      606
Ile Glu Gly Tyr Glu Cys Gln Pro Ile Phe Leu Asn Val Leu Glu Ala
              135              140              145

att gag cca ggt gta gtg tgt gct gga cac gac aac aac cag ccc gac      654
Ile Glu Pro Gly Val Val Cys Ala Gly His Asp Asn Asn Gln Pro Asp
              150              155              160

tcc ttt gca gcc ttg ctc tct agc ctc aat gaa ctg gga gag aga cag      702
Ser Phe Ala Ala Leu Leu Ser Ser Leu Asn Glu Leu Gly Glu Arg Gln
              165              170              175              180

ctt gta cac gtg gtc aag tgg gcc aag gcc ttg cct ggc ttc cgc aac      750
Leu Val His Val Val Lys Trp Ala Lys Ala Leu Pro Gly Phe Arg Asn
              185              190              195

tta cac gtg gac gac cag atg gct gtc att cag tac tcc tgg atg ggg      798
Leu His Val Asp Asp Gln Met Ala Val Ile Gln Tyr Ser Trp Met Gly
              200              205              210

ctc atg gtg ttt gcc atg ggc tgg cga tcc ttc acc aat gtc aac tcc      846
Leu Met Val Phe Ala Met Gly Trp Arg Ser Phe Thr Asn Val Asn Ser
              215              220              225

agg atg ctc tac ttc gcc cct gat ctg gtt ttc aat gag tac cgc atg      894
Arg Met Leu Tyr Phe Ala Pro Asp Leu Val Phe Asn Glu Tyr Arg Met
              230              235              240

cac aag tcc cgg atg tac agc cag tgt gtc cga atg agg cac ctc tct      942

```

His 245	Lys	Ser	Arg	Met	Tyr 250	Ser	Gln	Cys	Val	Arg 255	Met	Arg	His	Leu	Ser 260	
caa	gag	ttt	gga	tgg	ctc	caa	atc	acc	ccc	cag	gaa	ttc	ctg	tgc	atg	990
Gln	Glu	Phe	Gly	Trp	Leu	Gln	Ile	Thr	Pro	Gln	Glu	Phe	Leu	Cys	Met	
				265					270					275		
aaa	gca	ctg	cta	ctc	ttc	agc	att	att	cca	gtg	gat	ggg	ctg	aaa	aat	1038
Lys	Ala	Leu	Leu	Leu	Phe	Ser	Ile	Ile	Pro	Val	Asp	Gly	Leu	Lys	Asn	
				280				285					290			
caa	aaa	ttc	ttt	gat	gaa	ctt	cga	atg	aac	tac	atc	aag	gaa	ctc	gat	1086
Gln	Lys	Phe	Phe	Asp	Glu	Leu	Arg	Met	Asn	Tyr	Ile	Lys	Glu	Leu	Asp	
				295			300					305				
cgt	atc	att	gca	tgc	aaa	aga	aaa	aat	ccc	aca	tcc	tgc	tca	aga	cgc	1134
Arg	Ile	Ile	Ala	Cys	Lys	Arg	Lys	Asn	Pro	Thr	Ser	Cys	Ser	Arg	Arg	
				310		315					320					
ttc	tac	cag	ctc	acc	aag	ctc	ctg	gac	tcc	gtg	cag	cct	att	gcg	aga	1182
Phe	Tyr	Gln	Leu	Thr	Lys	Leu	Leu	Asp	Ser	Val	Gln	Pro	Ile	Ala	Arg	
				325		330				335					340	
gag	ctg	cat	cag	ttc	act	ttt	gac	ctg	cta	atc	aag	tca	cac	atg	gtg	1230
Glu	Leu	His	Gln	Phe	Thr	Phe	Asp	Leu	Leu	Ile	Lys	Ser	His	Met	Val	
				345					350					355		
agc	gtg	gac	ttt	ccg	gaa	atg	atg	gca	gag	atc	atc	tct	gtg	caa	gtg	1278
Ser	Val	Asp	Phe	Pro	Glu	Met	Met	Ala	Glu	Ile	Ile	Ser	Val	Gln	Val	
				360				365					370			
ccc	aag	atc	ctt	tct	ggg	aaa	gtc	aag	ccc	atc	tat	ttc	cac	acc	cag	1326
Pro	Lys	Ile	Leu	Ser	Gly	Lys	Val	Lys	Pro	Ile	Tyr	Phe	His	Thr	Gln	
				375			380					385				
tga	agcattggaa	accctatttc	cccaccccag	ctc	atgcccc	ctttcagatg										1379
tcttctgcct	gttataa	ctc	tgcactactc	ctctgcagtg	ccttggggaa	tttctctat										1439
tgatgtacag	tctgtcatga	acatgttctc	gaattctatt	tgtctgggett	tttttttctc											1499
tttctctcct	ttctttttct	tcttccctcc	ctatctaa	acc	ctcccatggc	accttcagac										1559
tttgcttccc	attgtggctc	ctatctgtgt	tttgaatggt	gttgatgccc	tttaa	atctg										1619
tgatgatcct	catatggccc	agtgta	caagt	tgtgcttgtt	tacagcacta	ctctgtgcca										1679
gccacacaaa	cgtttactta	tcttatgcca	cgggaagttt	agagagctaa	gattatctg											1739
ggaaatcaaa	acaaaaacaa	gcaaacaaaa	aaaaaaagca	aaaacaaaac	aaaaaataag											1799
ccaaaaaacc	ttgctagtgt	tttttctcca	aaaataaata	aataaataaa	taaatac	gtta										1859
catacataca	cacatacata	caaacatata	gaaatcccc	aagaggccaa	tagtgacgag											1919
aagggtgaaaa	ttgcaggccc	atggggagtt	actgattttt	tcatctcctc	cctccacggg											1979
agactttatt	ttctgccaat	ggctattgcc	attagagggc	agagtgaccc	cagagctgag											2039
ttgggcaggg	gggtggacag	agaggagagg	acaaggaggg	caatggagca	tcagtacctg											2099
cccacagcct	tggtcctc	gggctagact	gctcaactgt	ggagcaattc	attatactga</											

-continued

gcctgtttgc	ttcttttggg	catgttcaca	gattctctgt	taagagcccc	caccaccaag	2699
aaggttagca	ggccaacagc	tctgacatct	atctgtagat	gccagtagtc	acaaagattt	2759
cttaccaact	ctcagatcgc	tggagccctt	agacaaaactg	gaaagaaggc	atcaaaggga	2819
tcaggcaagc	tgggcgtctt	gcccttgctc	cccagagatg	ataccctccc	agcaagtgga	2879
gaagttctca	cttccttctt	tagagcagct	aaaggggcta	cccagatcag	ggttgaagag	2939
aaaactcaat	taccagggtg	ggaagaatga	aggcactaga	accagaaacc	ctgcaaatgc	2999
tcttcttgtc	accagcata	tccacctgca	gaagtcatga	gaagagagaa	ggaacaaaga	3059
ggagactctg	actactgaat	taaaatcttc	agcggcaaaag	cctaaagcca	gatggacacc	3119
atctggtag	tttactcctc	atcctcctct	gctgctgatt	ctgggctctg	acattgcccc	3179
tactcactca	gattccccac	ctttgttgct	gcctcttagt	cagagggagg	ccaaaccatt	3239
gagactttct	acagaaccat	ggcttctttc	ggaaaggctc	ggttgggtg	gctccaatac	3299
tttgccccc	atgaactcag	ggtgtgccct	gggacactgg	ttttatatag	tcttttggca	3359
cacctgtgtt	ctgttgactt	cgttcttcaa	gcccagtgcc	aagggaat	gtccacctac	3419
tttctcatct	tggcctctgc	ctccttactt	agctcttaat	ctcatctggt	gaactcaaga	3479
aatcaagggc	cagtcaccaa	gctgccctt	ttaattgatt	cactctgttt	gttgagagga	3539
tagtttctga	gtgacatgat	atgatccaca	agggtttcct	tccctgattt	ctgcattgat	3599
attaatagcc	aaacgaactt	caaaacagct	ttaaataaca	agggagagg	gaacctaa	3659
tgagtaatat	gccaatccaa	gactgctgga	gaaaactaaa	gctgacaggt	tccctttttg	3719
gggtgggata	gacatgttct	ggttttcttt	attattacac	aatctggctc	atgtacagga	3779
tcacttttag	ctgttttaaa	cagaaaaaaa	tatccaccac	tcttttcagt	tacactaggt	3839
tacattttaa	taggtccttt	acatctgttt	tggaatgatt	ttcatctttt	gtgatacaca	3899
gattgaatta	tatcattttc	atatctctcc	ttgtaaatac	tagaagctct	cctttacatt	3959
tctctatcaa	atttttctac	tttatgggtt	tcccaattgt	gactcttgct	ttcatgaata	4019
tatgtttttc	atttgcaaaa	gccaaaaatc	agtgaacag	cagtgttaatt	aaaagcaaca	4079
actggattac	tccaaatttc	caaatgacaa	aactagggaa	aaatagccta	cacaagcctt	4139
taggcctact	ctttctgtgc	ttgggtttga	gtgaacaaag	gagatttttag	cttggctctg	4199
ttctcccatg	gatgaaagga	ggaggatttt	ttttttcttt	tggccattga	tgttctagcc	4259
aatgtaattg	acagaagtct	cattttgcat	gcgctctgct	ctacaaacag	agttggtatg	4319
gttggtatgc	tgtactcacc	tgtgagggac	tggccactca	gaccactta	gctggtgagc	4379
tagaagatga	ggatcactca	ctggaaaagt	cacaaggacc	atctccaaac	aagttggcag	4439
tgctcgatgt	ggacgaagag	tgaggaagag	aaaaagaagg	agcaccagg	agaaggctcc	4499
gtctgtgctg	ggcagcagac	agctgccagg	atcacgaact	ctgtagctca	agaaaagagt	4559
cgtgtggcag	tttcagctct	cgttcattgg	gcagctcgcc	taggccagc	ctctgagctg	4619
acatgggagt	tgttggtatc	ttgtttcat	agctttttct	atgccatagg	caatattgtt	4679
gttcttgga	agtttattat	ttttttaact	cccttactct	gagaaaggga	tattttgaag	4739
gactgtcata	tatctttgaa	aaaagaaaat	ctgtaataca	tatattttta	tgtatgttca	4799
ctggcactaa	aaaatataga	gagcttcatt	ctgtcctttg	ggtagttgct	gaggtaattg	4859
tccagggtga	aaaataatgt	gctgatgcta	gagtcctct	ctgtccatac	tctacttcta	4919
aatacatata	ggcatacata	gcaagtttta	tttgacttgt	actttaagag	aaaatatgtc	4979
caccatccac	atgatgcaca	aatgagctaa	cattgagctt	caagtagctt	ctaagtgttt	5039

-continued

gtttcattag gcacagcaca gatgtggcct ttccccctt ctctcccttg atatctggca	5099
gggcataaag gcccaggcca ctctctctgc cccttcccag ccctgcacca aagctgcatt	5159
tcaggagact ctctccagac agcccagtaa ctacccgagc atggcccctg catagccctg	5219
gaaaaataag aggctgactg tctacgaatt atcttgtgcc agttgcccag gtgagagggc	5279
actgggcca gggagtgggt ttcattgttg acccactaca aggggtcatg ggaatcagga	5339
atgccaaagc accagatcaa atccaaaact taaagtcaaa ataagccatt cagcatgttc	5399
agtttcttgg aaaaggaagt ttctaccctt gatgccttgg taggcagatc tgttctcacc	5459
attaatcttt ttgaaaatct tttaaagcag tttttaaaa gagagatgaa agcatcacat	5519
tatataacca aagattacat tgtacctgct aagataccaa aattcataag ggcagggggg	5579
gagcaagcat tagtgctctt ttgataagct gtccaaagac agactaaagg actctgctgg	5639
tgactgactt ataagagctt tgtgggtttt tttttcccta ataatatata tgtttagaag	5699
aattgaaaat aatttcggga aaatgggatt atgggtcctt cactaagtga ttttataagc	5759
agaactggct ttctttttct ctagttagtg ctgagcaaat tgttgaagct ccatcattgc	5819
atggttgga atggagctgt tcttagccac tgtgtttgct agtgcccatg ttagcttatc	5879
tgaagatgtg aaacccttgc tgataaggga gcatttaaag tactagattt tgcactagag	5939
ggacagcagg cagaaatcct tatttctgcc cactttggat ggcacaaaaa gttatctgca	5999
gttgaaggca gaaagttgaa atacattgta aatgaatatt tgtatccatg tttcaaaatt	6059
gaaatatata tatatatata tatatatata tatatatata tatagtgtgt gtgtgtgttc	6119
tgatagcttt aactttctct gcacttttat atttggttcc agatcacacc tgatgccatg	6179
tacttgtgag agaggatgca gttttgtttt ggaagctctc tcagaacaaa caagacacct	6239
ggattgatca gttaactaaa agttttctcc cctattgggt ttgaccacaa ggtcctgtga	6299
aggagcagag ggataaaaag agtagaggac atgatacatt gtactttact agttcaagac	6359
agatgaatgt ggaaagcata aaaactcaat ggaactgact gagatttacc acagggaagg	6419
cccaacttg gggccaaaag cctaccaag tgattgacca gtggccccct aatgggacct	6479
gagctgttgg aagaagagaa ctgttccctg gtcttcacca tccttgtgag agaagggcag	6539
tttcctgcat tggaaacctg agcaagcgt ctatctttca cacaatttc ctcacctgag	6599
attgaggtgc tcttgttact ggggtgtctgt gtgctgtaat tctggttttg gatatgttct	6659
gtaaagattt tgacaaatga aaatgtgttt ttctctgtta aaacttgtca gagtactaga	6719
agttgtatct ctgtaggtgc aggtccattt ctgcccacag gtagggtgtt tttctttgat	6779
taagagattg acacttctgt tgccataggac ctcccaactc aaccatttct aggtgaaggc	6839
agaaaaatcc acattagtta ctctcttcca gacatttcag ctgagataac aaatcttttg	6899
gaattttttc acccatagaa agagtggtag atatttgaat ttagcagggt gagtttcata	6959
gtaaaaacag cttttgactc agctttgatt tatcctcatt tgatttggcc agaaagtagg	7019
taatatgcat tgattggctt ctgattccaa ttcagtatag caagggtgcta ggttttttcc	7079
tttccccacc tgtctcttag cctggggaat taaatgagaa gccttagaat ggggtggcct	7139
tgtgacctga aacacttccc acataagcta cttaacaaga ttgtcatgga gctgcagatt	7199
ccattgcca ccaaagacta gaacacacac atatccatc accaaaggaa agacaattct	7259
gaaatgctgt ttctctgggt gtccctctc ttggtgctgc ctcacagtat gggaaacctgt	7319
actctgcaga ggtgacaggc cagatttgca ttatctcaca accttagccc ttggtgctaa	7379

-continued

```

ctgtccctaca gtgaagtgcc tgggggggtg tcctatccca taagccactt ggatgctgac 7439
agcagccacc atcagaatga cccacgcaaa aaaaagaaaa aaaaattaa aaagtcacct 7499
cacaaccag tgacacctt ctgctttcct ctagactgga acattgatta gggagtgctt 7559
cagacatgac attcttgtgc tgccttgga attaatctgg cagcaggagg gagcagacta 7619
tgtaaacaga gataaaaatt aattttcaat attgaaggaa aaaagaaata agaagagaga 7679
gagaaagaaa gcatcacaca aagattttct taaaagaaac aattttgctt gaaatctctt 7739
tagatggggc tcattttctca cgggtggcact tggcctccac tgggcagcag gaccagctcc 7799
aagcgctagt gttctgttct ctttttgtaa tcttggaatc tttgttgct ctaaatacaa 7859
ttaaaatgg cagaaacttg tttgttgac tacatgtgtg actttgggtc tgtctctgcc 7919
tctgctttca gaaatgtcat ccattgtgta aaatattggc ttactggtct gccagctaaa 7979
acttggccac atcccctgtt atggctgcag gatcgagtta ttgttaacaa agagacccaa 8039
gaaaagctgc taatgtctc ttatcattgt tgtaatttg ttaaacata aagaaatcta 8099
aaatttcaaa aaa 8112

```

```

<210> SEQ ID NO 4
<211> LENGTH: 3641
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (328)...(2265)

```

```

<400> SEQUENCE: 4

```

```

gacactgaat ttggaagggtg gaggattttg tttttttctt ttaagatctg ggcacttttt 60
gaatctaccc ttcaagtatt aagagacaga ctgtgagcct agcagggcag atcttgtcca 120
ccgtgtgtct tcttctgcac gagactttga ggctgtcaga gcgctttttg cgtgggtgct 180
cccgcaagtt tccttctctg gagcttcccg caggtgggca gctagctgca gcgactaccg 240
catcatcaca gcctgttgaa ctcttctgag caagagaagg ggaggcgggg taagggaagt 300
aggtggaaga ttcagccaag ctcaagg atg gaa gtg cag tta ggg ctg gga agg 354
          Met Glu Val Gln Leu Gly Leu Gly Arg
          1                      5

gtc tac cct cgg ccg ccg tcc aag acc tac cga gga gct ttc cag aat 402
Val Tyr Pro Arg Pro Pro Ser Lys Thr Tyr Arg Gly Ala Phe Gln Asn
  10                      15                      20                      25

ctg ttc cag agc gtg cgc gaa gtg atc cag aac ccg ggc ccc agg cac 450
Leu Phe Gln Ser Val Arg Glu Val Ile Gln Asn Pro Gly Pro Arg His
          30                      35                      40

cca gag gcc gcg agc gca gca cct ccc ggc gcc agt ttg ctg ctg cag 498
Pro Glu Ala Ala Ser Ala Ala Pro Pro Gly Ala Ser Leu Leu Leu Gln
          45                      50                      55

cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag 546
Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln
          60                      65                      70

cag cag cag cag cag cag cag cag cag cag cag caa gag act agc ccc 594
Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Glu Thr Ser Pro
          75                      80                      85

agg cag cag cag cag cag cag ggt gag gat ggt tct ccc caa gcc cat 642
Arg Gln Gln Gln Gln Gln Gln Gly Glu Asp Gly Ser Pro Gln Ala His
          90                      95                      100                      105

cgt aga ggc ccc aca ggc tac ctg gtc ctg gat gag gaa cag caa cct 690
Arg Arg Gly Pro Thr Gly Tyr Leu Val Leu Asp Glu Glu Gln Gln Pro
          110                      115                      120

```

-continued

tca cag ccg cag tcg gcc ctg gag tgc cac ccc gag aga ggt tgc gtc	738
Ser Gln Pro Gln Ser Ala Leu Glu Cys His Pro Glu Arg Gly Cys Val	
125 130 135	
cca gag cct gga gcc gcc gtg gcc gcc agc aag ggg ctg ccg cag cag	786
Pro Glu Pro Gly Ala Ala Val Ala Ala Ser Lys Gly Leu Pro Gln Gln	
140 145 150	
ctg cca gca cct ccg gac gag gat gac tca gct gcc cca tcc acg ttg	834
Leu Pro Ala Pro Pro Asp Glu Asp Asp Ser Ala Ala Pro Ser Thr Leu	
155 160 165	
tcc ctg ctg ggc ccc act ttc ccc ggc tta agc agc tgc tcc gct gac	882
Ser Leu Leu Gly Pro Thr Phe Pro Gly Leu Ser Ser Cys Ser Ala Asp	
170 175 180 185	
ctt aaa gac atc ctg agc gag gcc agc acc atg caa ctc ctt cag caa	930
Leu Lys Asp Ile Leu Ser Glu Ala Ser Thr Met Gln Leu Leu Gln Gln	
190 195 200	
cag cag cag gaa gca gta tcc gaa ggc agc agc agc ggg aga gcg agg	978
Gln Gln Gln Glu Ala Val Ser Glu Gly Ser Ser Ser Gly Arg Ala Arg	
205 210 215	
gag gcc tcg ggg gct ccc act tcc tcc aag gac aat tac tta ggg ggc	1026
Glu Ala Ser Gly Ala Pro Thr Ser Ser Lys Asp Asn Tyr Leu Gly Gly	
220 225 230	
act tcg acc att tct gac aac gcc aag gag ttg tgt aag gca gtg tcg	1074
Thr Ser Thr Ile Ser Asp Asn Ala Lys Glu Leu Cys Lys Ala Val Ser	
235 240 245	
gtg tcc atg ggc ctg ggt gtg gag gcg ttg gag cat ctg agt cca ggg	1122
Val Ser Met Gly Leu Gly Val Glu Ala Leu Glu His Leu Ser Pro Gly	
250 255 260 265	
gaa cag ctt cgg ggg gat tgc atg tac gcc cca ctt ttg gga gtt cca	1170
Glu Gln Leu Arg Gly Asp Cys Met Tyr Ala Pro Leu Leu Gly Val Pro	
270 275 280	
ccc gct gtg cgt ccc act cct tgt gcc cca ttg gcc gaa tgc aaa ggt	1218
Pro Ala Val Arg Pro Thr Pro Cys Ala Pro Leu Ala Glu Cys Lys Gly	
285 290 295	
tct ctg cta gac gac agc gca ggc aag agc act gaa gat act gct gag	1266
Ser Leu Leu Asp Asp Ser Ala Gly Lys Ser Thr Glu Asp Thr Ala Glu	
300 305 310	
tat tcc cct ttc aag gga ggt tac acc aaa ggg cta gaa ggc gag agc	1314
Tyr Ser Pro Phe Lys Gly Gly Tyr Thr Lys Gly Leu Glu Gly Glu Ser	
315 320 325	
cta ggc tgc tct ggc agc gct gca gca ggg agc tcc ggg aca ctt gaa	1362
Leu Gly Cys Ser Gly Ser Ala Ala Ala Gly Ser Ser Gly Thr Leu Glu	
330 335 340 345	
ctg ccg tct acc ctg tct ctc tac aag tcc gga gca ctg gac gag gca	1410
Leu Pro Ser Thr Leu Ser Leu Tyr Lys Ser Gly Ala Leu Asp Glu Ala	
350 355 360	
gct gcg tac cag agt cgc gac tac tac aac ttt cca ctg gct ctg gcc	1458
Ala Ala Tyr Gln Ser Arg Asp Tyr Tyr Asn Phe Pro Leu Ala Leu Ala	
365 370 375	
gga ccg ccg ccc cct ccg ccg cct ccc cat ccc cac gct cgc atc aag	1506
Gly Pro Pro Pro Pro Pro Pro Pro Pro His Pro His Ala Arg Ile Lys	
380 385 390	
ctg gag aac ccg ctg gac tac ggc agc gcc tgg gcg gct gcg gcg gcg	1554
Leu Glu Asn Pro Leu Asp Tyr Gly Ser Ala Trp Ala Ala Ala Ala Ala	
395 400 405	
cag tgc cgc tat ggg gac ctg gcg agc ctg cat ggc gcg ggt gca gcg	1602
Gln Cys Arg Tyr Gly Asp Leu Ala Ser Leu His Gly Ala Gly Ala Ala	
410 415 420 425	
gga ccc ggt tct ggg tca ccc tca gcc gcc gct tcc tca tcc tgg cac	1650
Gly Pro Gly Ser Gly Ser Pro Ser Ala Ala Ala Ser Ser Ser Trp His	
430 435 440	

-continued

act ctc ttc aca gcc gaa gaa ggc cag ttg tat gga ccg tgt ggt ggt	1698
Thr Leu Phe Thr Ala Glu Glu Gly Gln Leu Tyr Gly Pro Cys Gly Gly	
445 450 455	
ggt ggg ggt ggt ggc ggc ggc ggc ggc ggc ggc ggc ggc ggc ggc	1746
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly	
460 465 470	
ggc gag gcg gga gct gta gcc ccc tac ggc tac act ccg ccc cct cag	1794
Gly Glu Ala Gly Ala Val Ala Pro Tyr Gly Tyr Thr Arg Pro Pro Gln	
475 480 485	
ggg ctg gcg ggc cag gaa agc gac ttc acc gca cct gat gtg tgg tac	1842
Gly Leu Ala Gly Gln Glu Ser Asp Phe Thr Ala Pro Asp Val Trp Tyr	
490 495 500 505	
cct ggc ggc atg gtg agc aga gtg ccc tat ccc agt ccc act tgt gtc	1890
Pro Gly Gly Met Val Ser Arg Val Pro Tyr Pro Ser Pro Thr Cys Val	
510 515 520	
aaa agc gaa atg ggc ccc tgg atg gat agc tac tcc gga cct tac ggg	1938
Lys Ser Glu Met Gly Pro Trp Met Asp Ser Tyr Ser Gly Pro Tyr Gly	
525 530 535	
gac atg cgt ttg gag act gcc agg gac cat gtt ttg ccc att gac tat	1986
Asp Met Arg Leu Glu Thr Ala Arg Asp His Val Leu Pro Ile Asp Tyr	
540 545 550	
tac ttt cca ccc cag aag acc tgc ctg atc tgt gga gat gaa gct tct	2034
Tyr Phe Pro Pro Gln Lys Thr Cys Leu Ile Cys Gly Asp Glu Ala Ser	
555 560 565	
ggg tgt cac tat gga gct ctc aca tgt gga agc tgc aag gtc ttc ttc	2082
Gly Cys His Tyr Gly Ala Leu Thr Cys Gly Ser Cys Lys Val Phe Phe	
570 575 580 585	
aaa aga gcc gct gaa ggg aaa cag aag tac ctg tgc gcc agc aga aat	2130
Lys Arg Ala Ala Glu Gly Lys Gln Lys Tyr Leu Cys Ala Ser Arg Asn	
590 595 600	
gat tgc act att gat aaa ttc cga agg aaa aat tgt cca tct tgt cgt	2178
Asp Cys Thr Ile Asp Lys Phe Arg Arg Lys Asn Cys Pro Ser Cys Arg	
605 610 615	
ctt ccg aaa tgt tat gaa gca ggg atg act ctg gga gaa aaa ttc ccg	2226
Leu Arg Lys Cys Tyr Glu Ala Gly Met Thr Leu Gly Glu Lys Phe Arg	
620 625 630	
gtt ggc aat tgc aag cat ctc aaa atg acc aga ccc tga agaaaggctg	2275
Val Gly Asn Cys Lys His Leu Lys Met Thr Arg Pro	
635 640 645	
acttgccctca ttcaaaatga gggctctaga gggctctagt ggatagtctg gagaaacctg	2335
gcgtctgagg cttaggagct taggtttttg ctccctcaaca cagactttga cgttgggggt	2395
gggggctact ctcttgattg ctgactccct ccagcgggac caatagtgtt ttctacctc	2455
acagggatgt tgtgaggacg ggctgtagaa gtaaataggg ttaccactca tgtagtgtg	2515
agtatcatga ttattgtttc ctgtaatgtg gcttgccatt ggcaaagtgc tttttgattg	2575
ttcttgatca catatgatgg gggccaggca ctgactcagg cggatgcagt gaagctctgg	2635
ctcagtcgct tgcttttctg ggtgtgctgc caggaagaaa ctttgctgat gggactcaag	2695
gtgtcacctt ggacaagaag caactgtgtc tgtctgaggt tcctgtggcc atctttattt	2755
gtgtattagg caattcgtat tccccctta ggttctagcc ttctggatcc cagccagtga	2815
cctagatctt agcctcaggc cctgtcactg agctgaagggt agtagctgat ccacagaagt	2875
tcagtaaaca aggaccagat ttctgcttct ccaggagaag aagccagcca acccctctct	2935
tcaaacacac tgagagacta cagtccgact ttccctctta catctagcct tactgtagcc	2995
acactccttg attgctctct cacatcacat gcttctcttc atcagttgta agcctctcat	3055

-continued

tcttctccca agccagactc aaatattgta ttgatgtcaa agaagaatca cttagagttt	3115
ggaatatctt gttctctctc tgctccatag cttccatatt gacaccagtt tctttctagt	3175
ggagaagtgg agtctgtgaa gccagggaaa cacacatgtg agagtcagaa ggactctccc	3235
tgacttgctt ggggcctgtc tttcccacct tctccagtct gtctaaacac acacacacac	3295
acacacacac acacacacac acacacacac gctctctctc tctctccccc cccaacacac	3355
acacactctc tctctcacac acacacacat acacacacac ttctttctct tccccctgac	3415
tcagcaacat tctggagaaa agccaaggaa ggacttcagg aggggagttt ccccttctc	3475
agggcagaat tttaatctcc agaccaacaa gaagttccct aatgtggatt gaaaggttaa	3535
tgaggtttat ttttaactac tttctatttg ttggaatgtt gcatatttct actagtgaaa	3595
ttttccctta ataaagccat taatacacc aaaaaaaaaa aaaaaa	3641

<210> SEQ ID NO 5
 <211> LENGTH: 2430
 <212> TYPE: DNA
 <213> ORGANISM: Homo sapiens
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (328)...(2274)

<400> SEQUENCE: 5

gacactgaat ttggaagggtg gaggattttg tttttttctt ttaagatctg ggcattttt	60
gaatctaccc ttcaagtatt aagagacaga ctgtgagcct agcagggcag atcttgtcca	120
ccgtgtgtct tctctgcac gagactttga ggctgtcaga gcgctttttg cgtggttgct	180
cccgcaagtt tccttctctg gagcttcccg caggtgggca gctagctgca gcgactaccg	240
catcatcaca gcctgttgaa ctcttctgag caagagaagg ggaggcgggg taagggaagt	300
aggtggaaga ttcagccaag ctcaagg atg gaa gtg cag tta ggg ctg gga agg	354
Met Glu Val Gln Leu Gly Leu Gly Arg	
1 5	
gtc tac cct cgg ccg ccg tcc aag acc tac cga gga gct ttc cag aat	402
Val Tyr Pro Arg Pro Pro Ser Lys Thr Tyr Arg Gly Ala Phe Gln Asn	
10 15 20 25	
ctg ttc cag agc gtg cgc gaa gtg atc cag aac ccg ggc ccc agg cac	450
Leu Phe Gln Ser Val Arg Glu Val Ile Gln Asn Pro Gly Pro Arg His	
30 35 40	
cca gag gcc gcg agc gca gca cct ccc ggc gcc agt ttg ctg ctg cag	498
Pro Glu Ala Ala Ser Ala Ala Pro Pro Gly Ala Ser Leu Leu Leu Gln	
45 50 55	
cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag	546
Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln	
60 65 70	
cag cag cag cag cag cag cag cag cag cag caa gag act agc ccc agg	594
Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Glu Thr Ser Pro Arg	
75 80 85	
cag cag cag cag cag cag ggt gag gat ggt tct ccc caa gcc cat cgt	642
Gln Gln Gln Gln Gln Gln Gly Glu Asp Gly Ser Pro Gln Ala His Arg	
90 95 100 105	
aga ggc ccc aca ggc tac ctg gtc ctg gat gag gaa cag caa cct tca	690
Arg Gly Pro Thr Gly Tyr Leu Val Leu Asp Glu Glu Gln Gln Pro Ser	
110 115 120	
cag ccg cag tcg gcc ctg gag tgc cac ccc gag aga ggt tgc gtc cca	738
Gln Pro Gln Ser Ala Leu Glu Cys His Pro Glu Arg Gly Cys Val Pro	
125 130 135	
gag cct gga gcc gcc gtg gcc gcc agc aag ggg ctg ccg cag cag ctg	786
Glu Pro Gly Ala Ala Val Ala Ala Ser Lys Gly Leu Pro Gln Gln Leu	

-continued

140	145	150	
cca gca cct ccg gac gag gat gac tca gct gcc cca tcc acg ttg tcc Pro Ala Pro Pro Asp Glu Asp Asp Ser Ala Ala Pro Ser Thr Leu Ser 155 160 165			834
ctg ctg ggc ccc act ttc ccc ggc tta agc agc tgc tcc gct gac ctt Leu Leu Gly Pro Thr Phe Pro Gly Leu Ser Ser Cys Ser Ala Asp Leu 170 175 180 185			882
aaa gac atc ctg agc gag gcc agc acc atg caa ctc ctt cag caa cag Lys Asp Ile Leu Ser Glu Ala Ser Thr Met Gln Leu Leu Gln Gln Gln 190 195 200			930
cag cag gaa gca gta tcc gaa ggc agc agc agc ggg aga gcg agg gag Gln Gln Glu Ala Val Ser Glu Gly Ser Ser Ser Gly Arg Ala Arg Glu 205 210 215			978
gcc tcg ggg gct ccc act tcc tcc aag gac aat tac tta ggg ggc act Ala Ser Gly Ala Pro Thr Ser Ser Lys Asp Asn Tyr Leu Gly Gly Thr 220 225 230			1026
tcg acc att tct gac aac gcc aag gag ttg tgt aag gca gtg tcg gtg Ser Thr Ile Ser Asp Asn Ala Lys Glu Leu Cys Lys Ala Val Ser Val 235 240 245			1074
tcc atg ggc ctg ggt gtg gag gcg ttg gag cat ctg agt cca ggg gaa Ser Met Gly Leu Gly Val Glu Ala Leu Glu His Leu Ser Pro Gly Glu 250 255 260 265			1122
cag ctt cgg ggg gat tgc atg tac gcc cca ctt ttg gga gtt cca ccc Gln Leu Arg Gly Asp Cys Met Tyr Ala Pro Leu Leu Gly Val Pro Pro 270 275 280			1170
gct gtg cgt ccc act cct tgt gcc cca ttg gcc gaa tgc aaa ggt tct Ala Val Arg Pro Thr Pro Cys Ala Pro Leu Ala Glu Cys Lys Gly Ser 285 290 295			1218
ctg cta gac gac agc gca ggc aag agc act gaa gat act gct gag tat Leu Leu Asp Asp Ser Ala Gly Lys Ser Thr Glu Asp Thr Ala Glu Tyr 300 305 310			1266
tcc cct ttc aag gga ggt tac acc aaa ggg cta gaa ggc gag agc cta Ser Pro Phe Lys Gly Gly Tyr Thr Lys Gly Leu Glu Gly Glu Ser Leu 315 320 325			1314
ggc tgc tct ggc agc gct gca gca ggg agc tcc ggg aca ctt gaa ctg Gly Cys Ser Gly Ser Ala Ala Ala Gly Ser Ser Gly Thr Leu Glu Leu 330 335 340 345			1362
ccg tct acc ctg tct ctc tac aag tcc gga gca ctg gac gag gca gct Pro Ser Thr Leu Ser Leu Tyr Lys Ser Gly Ala Leu Asp Glu Ala Ala 350 355 360			1410
gcg tac cag agt cgc gac tac tac aac ttt cca ctg gct ctg gcc gga Ala Tyr Gln Ser Arg Asp Tyr Tyr Asn Phe Pro Leu Ala Leu Ala Gly 365 370 375			1458
ccg ccg ccc cct ccg ccg cct ccc cat ccc cac gct cgc atc aag ctg Pro Pro Pro Pro Pro Pro Pro Pro His Pro His Ala Arg Ile Lys Leu 380 385 390			1506
gag aac ccg ctg gac tac ggc agc gcc tgg gcg gct gcg gcg gcg cag Glu Asn Pro Leu Asp Tyr Gly Ser Ala Trp Ala Ala Ala Ala Gln 395 400 405			1554
tgc cgc tat ggg gac ctg gcg agc ctg cat ggc gcg ggt gca gcg gga Cys Arg Tyr Gly Asp Leu Ala Ser Leu His Gly Ala Gly Ala Ala Gly 410 415 420 425			1602
ccc ggt tct ggg tca ccc tca gcc gcc gct tcc tca tcc tgg cac act Pro Gly Ser Gly Ser Pro Ser Ala Ala Ala Ser Ser Ser Trp His Thr 430 435 440			1650
ctc ttc aca gcc gaa gaa ggc cag ttg tat gga ccg tgt ggt ggt ggt Leu Phe Thr Ala Glu Glu Gly Gln Leu Tyr Gly Pro Cys Gly Gly Gly 445 450 455			1698
ggg ggt ggt ggc ggc ggc ggc ggc ggc ggc ggc ggc ggc ggc ggc			1746

[illegible]

<400> SEQUENCE: 6

gacactgaat ttggaaggtg gaggattttt tttttttctt ttaagatctg ggcattcttt	60
gaatctaccc ttcaagtatt aagagacaga ctgtgagcct agcagggcag atcttgtcca	120
ccgtgtgtct tcttctgcac gagactttga ggctgtcaga gcgctttttg cgtggttgct	180
cccgaagtt tccttctctg gagcttcccc cagggtggga gctagctgca gcgactaccg	240
catcatcaca gcctgttgaa ctcttctgag caagagaagg ggaggcgggg taagggaagt	300
aggtggaaga ttcagccaag ctcaagg atg gaa gtg cag tta ggg ctg gga agg	354
Met Glu Val Gln Leu Gly Leu Gly Arg	
1 5	
gtc tac cct ccg ccg ccg tcc aag acc tac cga gga gct ttc cag aat	402

-continued

Val	Tyr	Pro	Arg	Pro	Pro	Ser	Lys	Thr	Tyr	Arg	Gly	Ala	Phe	Gln	Asn	
10					15					20					25	
ctg	ttc	cag	agc	gtg	cgc	gaa	gtg	atc	cag	aac	ccg	ggc	ccc	agg	cac	450
Leu	Phe	Gln	Ser	Val	Arg	Glu	Val	Ile	Gln	Asn	Pro	Gly	Pro	Arg	His	
				30					35					40		
cca	gag	gcc	gcg	agc	gca	gca	cct	ccc	ggc	gcc	agt	ttg	ctg	ctg	cag	498
Pro	Glu	Ala	Ala	Ser	Ala	Ala	Pro	Pro	Gly	Ala	Ser	Leu	Leu	Leu	Gln	
				45				50						55		
cag	cag	cag	cag	cag	cag	cag	cag	cag	cag	cag	cag	cag	cag	cag	cag	546
Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	
				60				65						70		
cag	cag	cag	cag	cag	cag	cag	cag	cag	cag	caa	gag	act	agc	ccc	agg	594
Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Gln	Glu	Thr	Ser	Pro	Arg	
				75				80						85		
cag	cag	cag	cag	cag	cag	ggc	gat	ggc	tct	ccc	caa	gcc	cat	cgt		642
Gln	Gln	Gln	Gln	Gln	Gln	Gly	Glu	Asp	Gly	Ser	Pro	Gln	Ala	His	Arg	
				90		95			100					105		
aga	ggc	ccc	aca	ggc	tac	ctg	gtc	ctg	gat	gag	gaa	cag	caa	cct	tca	690
Arg	Gly	Pro	Thr	Gly	Tyr	Leu	Val	Leu	Asp	Glu	Glu	Gln	Gln	Pro	Ser	
				110					115					120		
cag	ccg	cag	tcg	gcc	ctg	gag	tgc	cac	ccc	gag	aga	ggc	tgc	gtc	cca	738
Gln	Pro	Gln	Ser	Ala	Leu	Glu	Cys	His	Pro	Glu	Arg	Gly	Cys	Val	Pro	
				125				130						135		
gag	cct	gga	gcc	gcc	gtg	gcc	gcc	agc	aag	ggg	ctg	ccg	cag	cag	ctg	786
Glu	Pro	Gly	Ala	Ala	Val	Ala	Ala	Ser	Lys	Gly	Leu	Pro	Gln	Gln	Leu	
				140				145						150		
cca	gca	cct	ccg	gac	gag	gat	gac	tca	gct	gcc	cca	tcc	acg	ttg	tcc	834
Pro	Ala	Pro	Pro	Asp	Glu	Asp	Asp	Ser	Ala	Ala	Pro	Ser	Thr	Leu	Ser	
				155				160						165		
ctg	ctg	ggc	ccc	act	ttc	ccc	ggc	tta	agc	agc	tgc	tcc	gct	gac	ctt	882
Leu	Leu	Gly	Pro	Thr	Phe	Pro	Gly	Leu	Ser	Ser	Cys	Ser	Ala	Asp	Leu	
					175						180			185		
aaa	gac	atc	ctg	agc	gag	gcc	agc	acc	atg	caa	ctc	ctt	cag	caa	cag	930
Lys	Asp	Ile	Leu	Ser	Glu	Ala	Ser	Thr	Met	Gln	Leu	Leu	Gln	Gln	Gln	
				190					195					200		
cag	cag	gaa	gca	gta	tcc	gaa	ggc	agc	agc	agc	ggg	aga	gcg	agg	gag	978
Gln	Gln	Glu	Ala	Val	Ser	Glu	Gly	Ser	Ser	Ser	Gly	Arg	Ala	Arg	Glu	
				205				210						215		
gcc	tcg	ggg	gct	ccc	act	tcc	tcc	aag	gac	aat	tac	tta	ggg	ggc	act	1026
Ala	Ser	Gly	Ala	Pro	Thr	Ser	Ser	Lys	Asp	Asn	Tyr	Leu	Gly	Gly	Thr	
				220				225						230		
tcg	acc	att	tct	gac	aac	gcc	aag	gag	ttg	tgt	aag	gca	gtg	tcg	gtg	1074
Ser	Thr	Ile	Ser	Asp	Asn	Ala	Lys	Glu	Leu	Cys	Lys	Ala	Val	Ser	Val	
				235				240						245		
tcc	atg	ggc	ctg	ggc	gtg	gag	gcg	ttg	gag	cat	ctg	agt	cca	ggg	gaa	1122
Ser	Met	Gly	Leu	Gly	Val	Glu	Ala	Leu	Glu	His	Leu	Ser	Pro	Gly	Glu	
				250				255						260		265
cag	ctt	cgg	ggg	gat	tgc	atg	tac	gcc	cca	ctt	ttg	gga	gtt	cca	ccc	1170
Gln	Leu	Arg	Gly	Asp	Cys	Met	Tyr	Ala	Pro	Leu	Leu	Gly	Val	Pro	Pro	
				270					275					280		
gct	gtg	cgt	ccc	act	cct	tgt	gcc	cca	ttg	gcc	gaa	tgc	aaa	ggc	tct	1218
Ala	Val	Arg	Pro	Thr	Pro	Cys	Ala	Pro	Leu	Ala	Glu	Cys	Lys	Gly	Ser	
				285				290						295		
ctg	cta	gac	gac	agc	gca	ggc	aag	agc	act	gaa	gat	act	gct	gag	tat	1266
Leu	Leu	Asp	Asp	Ser	Ala	Gly	Lys	Ser	Thr	Glu	Asp	Thr	Ala	Glu	Tyr	
				300				305						310		
tcc	cct	ttc	aag	gga	ggc	tac	acc	aaa	ggg	cta	gaa	ggc	gag	agc	cta	1314
Ser	Pro	Phe	Lys	Gly	Gly	Tyr	Thr	Lys	Gly	Leu	Glu	Gly	Glu	Ser	Leu	
				315				320						325		

-continued

ggc tgc tct ggc agc gct gca gca ggg agc tcc ggg aca ctt gaa ctg	1362
Gly Cys Ser Gly Ser Ala Ala Ala Gly Ser Ser Gly Thr Leu Glu Leu	
330 335 340 345	
ccg tct acc ctg tct ctc tac aag tcc gga gca ctg gac gag gca gct	1410
Pro Ser Thr Leu Ser Leu Tyr Lys Ser Gly Ala Leu Asp Glu Ala Ala	
350 355 360	
gcg tac cag agt cgc gac tac tac aac ttt cca ctg gct ctg gcc gga	1458
Ala Tyr Gln Ser Arg Asp Tyr Tyr Asn Phe Pro Leu Ala Leu Ala Gly	
365 370 375	
ccg ccg ccc cct ccg ccg cct ccc cat ccc cac gct cgc atc aag ctg	1506
Pro Pro Pro Pro Pro Pro Pro Pro His Pro His Ala Arg Ile Lys Leu	
380 385 390	
gag aac ccg ctg gac tac ggc agc gcc tgg gcg gct gcg gcg gcg cag	1554
Glu Asn Pro Leu Asp Tyr Gly Ser Ala Trp Ala Ala Ala Ala Ala Gln	
395 400 405	
tgc cgc tat ggg gac ctg gcg agc ctg cat ggc gcg ggt gca gcg gga	1602
Cys Arg Tyr Gly Asp Leu Ala Ser Leu His Gly Ala Gly Ala Ala Gly	
410 415 420 425	
ccc ggt tct ggg tca ccc tca gcc gcc gct tcc tca tcc tgg cac act	1650
Pro Gly Ser Gly Ser Pro Ser Ala Ala Ala Ser Ser Ser Trp His Thr	
430 435 440	
ctc ttc aca gcc gaa gaa ggc cag ttg tat gga ccg tgt ggt ggt ggt	1698
Leu Phe Thr Ala Glu Glu Gly Gln Leu Tyr Gly Pro Cys Gly Gly Gly	
445 450 455	
ggg ggt ggt ggc ggc ggc ggc ggc ggc ggc ggc ggc ggc ggc ggc	1746
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly	
460 465 470	
gag gcg gga gct gta gcc ccc tac ggc tac act ccg ccc cct cag ggg	1794
Glu Ala Gly Ala Val Ala Pro Tyr Gly Tyr Thr Arg Pro Pro Gln Gly	
475 480 485	
ctg gcg ggc cag gaa agc gac ttc acc gca cct gat gtg tgg tac cct	1842
Leu Ala Gly Gln Glu Ser Asp Phe Thr Ala Pro Asp Val Trp Tyr Pro	
490 495 500 505	
ggc ggc atg gtg agc aga gtg ccc tat ccc agt ccc act tgt gtc aaa	1890
Gly Gly Met Val Ser Arg Val Pro Tyr Pro Ser Pro Thr Cys Val Lys	
510 515 520	
agc gaa atg ggc ccc tgg atg gat agc tac tcc gga cct tac ggg gac	1938
Ser Glu Met Gly Pro Trp Met Asp Ser Tyr Ser Gly Pro Tyr Gly Asp	
525 530 535	
atg cgt ttg gag act gcc agg gac cat gtt ttg ccc att gac tat tac	1986
Met Arg Leu Glu Thr Ala Arg Asp His Val Leu Pro Ile Asp Tyr Tyr	
540 545 550	
ttt cca ccc cag aag acc tgc ctg atc tgt gga gat gaa gct tct ggg	2034
Phe Pro Pro Gln Lys Thr Cys Leu Ile Cys Gly Asp Glu Ala Ser Gly	
555 560 565	
tgt cac tat gga gct ctc aca tgt gga agc tgc aag gtc ttc ttc aaa	2082
Cys His Tyr Gly Ala Leu Thr Cys Gly Ser Cys Lys Val Phe Phe Lys	
570 575 580 585	
aga gcc gct gaa ggg aaa cag aag tac ctg tgc gcc agc aga aat gat	2130
Arg Ala Ala Glu Gly Lys Gln Lys Tyr Leu Cys Ala Ser Arg Asn Asp	
590 595 600	
tgc act att gat aaa ttc cga agg aaa aat tgt cca tct tgt cgt ctt	2178
Cys Thr Ile Asp Lys Phe Arg Arg Lys Asn Cys Pro Ser Cys Arg Leu	
605 610 615	
cgg aaa tgt tat gaa gca ggg att ctg gga gca gct gtt gtt gtt tct	2226
Arg Lys Cys Tyr Glu Ala Gly Ile Leu Gly Ala Ala Val Val Val Ser	
620 625 630	
gaa aga atc ttg agg gtg ttt gga gtc tca gaa tgg ctt cct taa	2271
Glu Arg Ile Leu Arg Val Phe Gly Val Ser Glu Trp Leu Pro	
635 640 645	

-continued

```

agactacctt cagactctca gctgctcacc cacaacagag atcagccctt cttttagat 2331
gattcattcc tggctgcatt tgaaaaccac atattgttaa ttgcttgacg aatttaaacc 2391
ccttgactac ttttcatttc aaaaaaaaaa aaaaaa 2427

<210> SEQ ID NO 7
<211> LENGTH: 4039
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (328) ... (2376)

<400> SEQUENCE: 7

gacactgaat ttggaagggtg gaggattttg tttttttctt ttaagatctg ggcattcttt 60
gaatctaccc ttcaagtatt aagagacaga ctgtgagcct agcagggcag atcttgtcca 120
ccgtgtgtct tcttctgcac gagactttga ggctgtcaga gcgctttttg cgtggttgct 180
cccgaagtt tccttctctg gagcttcccg caggtgggca gctagctgca gcgactaccg 240
catcatcaca gcctgttgaa ctcttctgag caagagaagg ggagggcggg taagggaagt 300
aggtggaaga ttcagccaag ctcaagg atg gaa gtg cag tta ggg ctg gga agg 354
          Met Glu Val Gln Leu Gly Leu Gly Arg
          1              5

gtc tac cct cgg ccg ccg tcc aag acc tac cga gga gct ttc cag aat 402
Val Tyr Pro Arg Pro Pro Ser Lys Thr Tyr Arg Gly Ala Phe Gln Asn
  10              15              20              25

ctg ttc cag agc gtg cgc gaa gtg atc cag aac ccg ggc ccc agg cac 450
Leu Phe Gln Ser Val Arg Glu Val Ile Gln Asn Pro Gly Pro Arg His
          30              35              40

cca gag gcc gcg agc gca gca cct ccc ggc gcc agt ttg ctg ctg cag 498
Pro Glu Ala Ala Ser Ala Ala Pro Pro Gly Ala Ser Leu Leu Leu Gln
  45              50              55

cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag 546
Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln
  60              65              70

cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag 594
Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln
  75              80              85

agg cag cag cag cag cag cag ggt gag gat ggt tct ccc caa gcc cat 642
Arg Gln Gln Gln Gln Gln Gln Gly Glu Asp Gly Ser Pro Gln Ala His
  90              95              100              105

cgt aga ggc ccc aca ggc tac ctg gtc ctg gat gag gaa cag caa cct 690
Arg Arg Gly Pro Thr Gly Tyr Leu Val Leu Asp Glu Glu Gln Gln Pro
  110              115              120

tca cag ccg cag tgc gcc ctg gag tgc cac ccc gag aga ggt tgc gtc 738
Ser Gln Pro Gln Ser Ala Leu Glu Cys His Pro Glu Arg Gly Cys Val
  125              130              135

cca gag cct gga gcc gcc gtg gcc gcc agc aag ggg ctg ccg cag cag 786
Pro Glu Pro Gly Ala Ala Val Ala Ala Ser Lys Gly Leu Pro Gln Gln
  140              145              150

ctg cca gca cct ccg gac gag gat gac tca gct gcc cca tcc acg ttg 834
Leu Pro Ala Pro Pro Asp Glu Asp Asp Ser Ala Ala Pro Ser Thr Leu
  155              160              165

tcc ctg ctg ggc ccc act ttc ccc ggc tta agc agc tgc tcc gct gac 882
Ser Leu Leu Gly Pro Thr Phe Pro Gly Leu Ser Ser Cys Ser Ala Asp
  170              175              180              185

ctt aaa gac atc ctg agc gag gcc agc acc atg caa ctc ctt cag caa 930
Leu Lys Asp Ile Leu Ser Glu Ala Ser Thr Met Gln Leu Leu Gln Gln
  190              195              200

```

-continued

cag cag cag gaa gca gta tcc gaa ggc agc agc agc ggg aga gcg agg Gln Gln Gln Glu Ala Val Ser Glu Gly Ser Ser Ser Gly Arg Ala Arg 205 210 215	978
gag gcc tcg ggg gct ccc act tcc tcc aag gac aat tac tta ggg ggc Glu Ala Ser Gly Ala Pro Thr Ser Ser Lys Asp Asn Tyr Leu Gly Gly 220 225 230	1026
act tcg acc att tct gac aac gcc aag gag ttg tgt aag gca gtg tcg Thr Ser Thr Ile Ser Asp Asn Ala Lys Glu Leu Cys Lys Ala Val Ser 235 240 245	1074
gtg tcc atg ggc ctg ggt gtg gag gcg ttg gag cat ctg agt cca ggg Val Ser Met Gly Leu Gly Val Glu Ala Leu Glu His Leu Ser Pro Gly 250 255 260 265	1122
gaa cag ctt cgg ggg gat tgc atg tac gcc cca ctt ttg gga gtt cca Glu Gln Leu Arg Gly Asp Cys Met Tyr Ala Pro Leu Leu Gly Val Pro 270 275 280	1170
ccc gct gtg cgt ccc act cct tgt gcc cca ttg gcc gaa tgc aaa ggt Pro Ala Val Arg Pro Thr Pro Cys Ala Pro Leu Ala Glu Cys Lys Gly 285 290 295	1218
tct ctg cta gac gac agc gca ggc aag agc act gaa gat act gct gag Ser Leu Leu Asp Asp Ser Ala Gly Lys Ser Thr Glu Asp Thr Ala Glu 300 305 310	1266
tat tcc cct ttc aag gga ggt tac acc aaa ggg cta gaa ggc gag agc Tyr Ser Pro Phe Lys Gly Gly Tyr Thr Lys Gly Leu Glu Gly Glu Ser 315 320 325	1314
cta ggc tgc tct ggc agc gct gca gca ggg agc tcc ggg aca ctt gaa Leu Gly Cys Ser Gly Ser Ala Ala Ala Gly Ser Ser Gly Thr Leu Glu 330 335 340 345	1362
ctg ccg tct acc ctg tct ctc tac aag tcc gga gca ctg gac gag gca Leu Pro Ser Thr Leu Ser Leu Tyr Lys Ser Gly Ala Leu Asp Glu Ala 350 355 360	1410
gct gcg tac cag agt cgc gac tac tac aac ttt cca ctg gct ctg gcc Ala Ala Tyr Gln Ser Arg Asp Tyr Tyr Asn Phe Pro Leu Ala Leu Ala 365 370 375	1458
gga ccg ccg ccc cct ccg ccg cct ccc cat ccc cac gct cgc atc aag Gly Pro Pro Pro Pro Pro Pro Pro Pro His Pro His Ala Arg Ile Lys 380 385 390	1506
ctg gag aac ccg ctg gac tac ggc agc gcc tgg gcg gct gcg gcg gcg Leu Glu Asn Pro Leu Asp Tyr Gly Ser Ala Trp Ala Ala Ala Ala Ala 395 400 405	1554
cag tgc cgc tat ggg gac ctg gcg agc ctg cat ggc gcg ggt gca gcg Gln Cys Arg Tyr Gly Asp Leu Ala Ser Leu His Gly Ala Gly Ala Ala 410 415 420 425	1602
gga ccc ggt tct ggg tca ccc tca gcc gcc gct tcc tca tcc tgg cac Gly Pro Gly Ser Gly Ser Pro Ser Ala Ala Ala Ser Ser Ser Trp His 430 435 440	1650
act ctc ttc aca gcc gaa gaa ggc cag ttg tat gga ccg tgt ggt ggt Thr Leu Phe Thr Ala Glu Glu Gly Gln Leu Tyr Gly Pro Cys Gly Gly 445 450 455	1698
ggt ggg ggt ggt ggc ggc ggc ggc ggc ggc ggc ggc ggc ggc ggc Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly 460 465 470	1746
ggc gag gcg gga gct gta gcc ccc tac ggc tac act cgg ccc cct cag Gly Glu Ala Gly Ala Val Ala Pro Tyr Gly Tyr Thr Arg Pro Pro Gln 475 480 485	1794
ggg ctg gcg ggc cag gaa agc gac ttc acc gca cct gat gtg tgg tac Gly Leu Ala Gly Gln Glu Ser Asp Phe Thr Ala Pro Asp Val Trp Tyr 490 495 500 505	1842
cct ggc ggc atg gtg agc aga gtg ccc tat ccc agt ccc act tgt gtc Pro Gly Gly Met Val Ser Arg Val Pro Tyr Pro Ser Pro Thr Cys Val	1890

-continued

510	515	520	
aaa agc gaa atg ggc ccc tgg atg gat agc tac tcc gga cct tac ggg Lys Ser Glu Met Gly Pro Trp Met Asp Ser Tyr Ser Gly Pro Tyr Gly 525 530 535			1938
gac atg cgt ttg gag act gcc agg gac cat gtt ttg ccc att gac tat Asp Met Arg Leu Glu Thr Ala Arg Asp His Val Leu Pro Ile Asp Tyr 540 545 550			1986
tac ttt cca ccc cag aag acc tgc ctg atc tgt gga gat gaa gct tct Tyr Phe Pro Pro Gln Lys Thr Cys Leu Ile Cys Gly Asp Glu Ala Ser 555 560 565			2034
ggg tgt cac tat gga gct ctc aca tgt gga agc tgc aag gtc ttc ttc Gly Cys His Tyr Gly Ala Leu Thr Cys Gly Ser Cys Lys Val Phe Phe 570 575 580 585			2082
aaa aga gcc gct gaa ggg aaa cag aag tac ctg tgc gcc agc aga aat Lys Arg Ala Ala Glu Gly Lys Gln Lys Tyr Leu Cys Ala Ser Arg Asn 590 595 600			2130
gat tgc act att gat aaa ttc cga agg aaa aat tgt cca tct tgt cgt Asp Cys Thr Ile Asp Lys Phe Arg Arg Lys Asn Cys Pro Ser Cys Arg 605 610 615			2178
ctt cgg aaa tgt tat gaa gca ggg atg act ctg gga gga ttt ttc aga Leu Arg Lys Cys Tyr Glu Ala Gly Met Thr Leu Gly Gly Phe Phe Arg 620 625 630			2226
atg aac aaa tta aaa gaa tca tca gac act aac ccc aag cca tac tgc Met Asn Lys Leu Lys Glu Ser Ser Asp Thr Asn Pro Lys Pro Tyr Cys 635 640 645			2274
atg gca gca cca atg gga ctg aca gaa aac aac aga aat agg aag aaa Met Ala Ala Pro Met Gly Leu Thr Glu Asn Asn Arg Asn Arg Lys Lys 650 655 660 665			2322
tcc tac aga gaa aca aac ttg aaa gct gtc tca tgg cct ttg aat cat Ser Tyr Arg Glu Thr Asn Leu Lys Ala Val Ser Trp Pro Leu Asn His 670 675 680			2370
act taa gttttatgat ggaaggatac gactatgaag aaagacacag agcaacatca Thr			2426
gacagtcaag aatttcagag ccagctggca tgcagtggac ctcatgccag cccattttat			2486
gactatttag ggaacacagaa gtacctgtgc gccagcagaa atgattgcac tattgataaa			2546
ttccgaagga aaaattgtcc atcttgtcgt ctccggaaat gttatgaagc agggatgact			2606
ctgggagaaa aattccgggt tggcaattgc aagcatctca aaatgaccag acctgaaga			2666
aaggctgact tgccctcattc aaaatgaggg ctctagaggg ctctagtgga tagtctggag			2726
aaacctggcg tctgaggctt aggagcttag gtttttgcct ctcaacacag actttgacgt			2786
tggggttggg ggctactctc ttgattgctg actccctcca gcgggaccaa tagtgttttc			2846
ctacctcaca gggatgttgt gaggacgggc tgtagaagta atagtggta ccactcatgt			2906
agttgtgagt atcatgatta ttgtttctcg taatgtggct tggcattggc aaagtgcctt			2966
ttgattgttc ttgatcacat atgatggggg ccaggcactg actcaggcgg atgcagtga			3026
gctctggctc agtcgcttgc ttttcgtggt gtgctgccag gaagaaactt tgctgatggg			3086
actcaaggtg tcaccttgga caagaagcaa ctgtgtctgt ctgaggttcc tgtggccatc			3146
tttatttctg tattaggcaa ttctgtattc ccccttaggt tctagccttc tggatcccag			3206
ccagtgcctt agatcttagc ctacagccct gtcactgagc tgaaggtagt agctgatcca			3266
cagaagttca gtaacaagg accagatttc tgctttctcca ggagaagaag ccagccaacc			3326
cctctcttca aacacactga gagactacag tccgactttc cctcttacat ctagccttac			3386
tgtagccaca ctcttggatt gctctctcac atcacatgct tctcttcatc agttgtaagc			3446

-continued

```

ctctcattct tctcccaagc cagactcaaa tattgtattg atgtcaaaga agaatacatt 3506
agagtttggg atatcttggt ctctctctgc tccatagctt ccatattgac accagtttct 3566
ttctagtggg gaagtggagt ctgtgaagcc agggaaacac acatgtgaga gtcagaagga 3626
ctctccctga cttgcctggg gctgtctttt cccaccttct ccagtctgtc taaacacaca 3686
cacacacaca cacacacaca cacacacaca cacacacgct ctctctctct cteccccccc 3746
aacacacaca cactctctct ctccacacaca cacacatata cacacacttc tttctctttc 3806
ccctgactca gcaacattct ggagaaaagc caaggaagga cttcaggagg ggagtttccc 3866
ccttctcagg gcagaatttt aatctccaga ccaacaagaa gttcccta atgtggattgaa 3926
aggctaata ggtttatttt taactacttt ctatttggtt gaatgttgca ttttctact 3986
agtgaatttt tcccttaata aagccattaa tacacccaaa aaaaaaaaaa aaa 4039

```

```

<210> SEQ ID NO 8
<211> LENGTH: 3922
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (328)...(2259)

```

```

<400> SEQUENCE: 8

```

```

gacactgaat ttggaagggt gaggattttg tttttttctt ttaagatctg ggcatttttt 60
gaatctaccc ttcaagtatt aagagacaga ctgtgagcct agcagggcag atcttgtcca 120
ccgtgtgtct tcttctgcac gagactttga ggctgtcaga gcgctttttg cgtggttgct 180
cccgcaagtt tccttctctg gagcttcccg caggtgggca gctagctgca gcgactaccg 240
catcatcaca gcctgttgaa ctcttctgag caagagaagg ggaggcgggg taagggaagt 300
aggtggaaga ttcagccaag ctcaagg atg gaa gtg cag tta ggg ctg gga agg 354
      Met Glu Val Gln Leu Gly Leu Gly Arg
      1 5

gtc tac cct cgg ccg ccg tcc aag acc tac cga gga gct ttc cag aat 402
Val Tyr Pro Arg Pro Pro Ser Lys Thr Tyr Arg Gly Ala Phe Gln Asn
  10 15 20 25

ctg ttc cag agc gtg cgc gaa gtg atc cag aac ccg ggc ccc agg cac 450
Leu Phe Gln Ser Val Arg Glu Val Ile Gln Asn Pro Gly Pro Arg His
  30 35 40

cca gag gcc gcg agc gca gca cct ccc ggc gcc agt ttg ctg ctg cag 498
Pro Glu Ala Ala Ser Ala Ala Pro Gly Ala Ser Leu Leu Leu Gln
  45 50 55

cag cag cag cag cag cag cag cag cag cag cag cag cag cag cag 546
Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln
  60 65 70

cag cag cag cag cag cag cag cag cag cag cag caa gag act agc ccc 594
Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Glu Thr Ser Pro
  75 80 85

agg cag cag cag cag cag cag ggt gag gat ggt tct ccc caa gcc cat 642
Arg Gln Gln Gln Gln Gln Gln Gly Glu Asp Gly Ser Pro Gln Ala His
  90 95 100 105

cgt aga ggc ccc aca ggc tac ctg gtc ctg gat gag gaa cag caa cct 690
Arg Arg Gly Pro Thr Gly Tyr Leu Val Leu Asp Glu Glu Gln Gln Pro
  110 115 120

tca cag ccg cag tcg gcc ctg gag tgc cac ccc gag aga ggt tgc gtc 738
Ser Gln Pro Gln Ser Ala Leu Glu Cys His Pro Glu Arg Gly Cys Val
  125 130 135

cca gag cct gga gcc gcc gtg gcc gcc agc aag ggg ctg ccg cag cag 786
Pro Glu Pro Gly Ala Ala Val Ala Ala Ser Lys Gly Leu Pro Gln Gln

```

-continued

140					145					150							
ctg	cca	gca	cct	ccg	gac	gag	gat	gac	tca	gct	gcc	cca	tcc	acg	ttg	834	
Leu	Pro	Ala	Pro	Pro	Asp	Glu	Asp	Asp	Ser	Ala	Ala	Pro	Ser	Thr	Leu		
155					160					165							
tcc	ctg	ctg	ggc	ccc	act	ttc	ccc	ggc	tta	agc	agc	tgc	tcc	gct	gac	882	
Ser	Leu	Leu	Gly	Pro	Thr	Phe	Pro	Gly	Leu	Ser	Ser	Cys	Ser	Ala	Asp		
170					175					180					185		
ctt	aaa	gac	atc	ctg	agc	gag	gcc	agc	acc	atg	caa	ctc	ctt	cag	caa	930	
Leu	Lys	Asp	Ile	Leu	Ser	Glu	Ala	Ser	Thr	Met	Gln	Leu	Leu	Gln	Gln		
190					195					200							
cag	cag	cag	gaa	gca	gta	tcc	gaa	ggc	agc	agc	agc	ggg	aga	gcg	agg	978	
Gln	Gln	Gln	205	Ala	Val	Ser	Glu	Gly	Ser	Ser	Ser	Gly	Arg	Ala	Arg		
210					215					220							
gag	gcc	tcg	ggg	gct	ccc	act	tcc	tcc	aag	gac	aat	tac	tta	ggg	ggc	1026	
Glu	Ala	Ser	Gly	Ala	Pro	Thr	Ser	Ser	Lys	Asp	Asn	Tyr	Leu	Gly	Gly		
220					225					230							
act	tcg	acc	att	tct	gac	aac	gcc	aag	gag	ttg	tgt	aag	gca	gtg	tcg	1074	
Thr	Ser	Thr	Ile	Ser	Asp	Asn	Ala	Lys	Glu	Leu	Cys	Lys	Ala	Val	Ser		
235					240					245							
gtg	tcc	atg	ggc	ctg	ggt	gtg	gag	gcg	ttg	gag	cat	ctg	agt	cca	ggg	1122	
Val	Ser	Met	Gly	Leu	Gly	Val	Glu	Ala	Leu	Glu	His	Leu	Ser	Pro	Gly		
250					255					260					265		
gaa	cag	ctt	cgg	ggg	gat	tgc	atg	tac	gcc	cca	ctt	ttg	gga	gtt	cca	1170	
Glu	Gln	Leu	Arg	Gly	Asp	Cys	Met	Tyr	Ala	Pro	Leu	Leu	Gly	Val	Pro		
270					275					280							
ccc	gct	gtg	cgt	ccc	act	cct	tgt	gcc	cca	ttg	gcc	gaa	tgc	aaa	ggt	1218	
Pro	Ala	Val	Arg	Pro	Thr	Pro	Cys	Ala	Pro	Leu	Ala	Glu	Cys	Lys	Gly		
285					290					295							
tct	ctg	cta	gac	gac	agc	gca	ggc	aag	agc	act	gaa	gat	act	gct	gag	1266	
Ser	Leu	Leu	Asp	Asp	Ser	Ala	Gly	Lys	Ser	Thr	Glu	Asp	Thr	Ala	Glu		
300					305					310							
tat	tcc	cct	ttc	aag	gga	ggt	tac	acc	aaa	ggg	cta	gaa	ggc	gag	agc	1314	
Tyr	Ser	Pro	Phe	Lys	Gly	Gly	Tyr	Thr	Lys	Gly	Leu	Glu	Gly	Glu	Ser		
315					320					325							
cta	ggc	tgc	tct	ggc	agc	gct	gca	gca	ggg	agc	tcc	ggg	aca	ctt	gaa	1362	
Leu	Gly	Cys	Ser	Gly	Ser	Ala	Ala	Ala	Gly	Ser	Ser	Gly	Thr	Leu	Glu		
330					335					340					345		
ctg	ccg	tct	acc	ctg	tct	ctc	tac	aag	tcc	gga	gca	ctg	gac	gag	gca	1410	
Leu	Pro	Ser	Thr	Leu	Ser	Leu	Tyr	Lys	Ser	Gly	Ala	Leu	Asp	Glu	Ala		
350					355					360							
gct	gcg	tac	cag	agt	cgc	gac	tac	tac	aac	ttt	cca	ctg	gct	ctg	gcc	1458	
Ala	Ala	Tyr	Gln	Ser	Arg	Asp	Tyr	Tyr	Asn	Phe	Pro	Leu	Ala	Leu	Ala		
365					370					375							
gga	ccg	ccg	ccc	cct	ccg	ccg	cct	ccc	cat	ccc	cac	gct	cgc	atc	aag	1506	
Gly	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	His	Pro	His	Ala	Arg	Ile	Lys		
380					385					390							
ctg	gag	aac	ccg	ctg	gac	tac	ggc	agc	gcc	tgg	gcg	gct	gcg	gcg	gcg	1554	
Leu	Glu	Asn	Pro	Leu	Asp	Tyr	Gly	Ser	Ala	Trp	Ala	Ala	Ala	Ala	Ala		
395					400					405							
cag	tgc	cgc	tat	ggg	gac	ctg	gcg	agc	ctg	cat	ggc	gcg	ggt	gca	gcg	1602	
Gln	Cys	Arg	Tyr	Gly	Asp	Leu	Ala	Ser	Leu	His	Gly	Ala	Gly	Ala	Ala		
410					415					420					425		
gga	ccc	ggt	tct	ggg	tca	ccc	tca	gcc	gcc	gct	tcc	tca	tcc	tgg	cac	1650	
Gly	Pro	Gly	Ser	Gly	Ser	Pro	Ser	Ala	Ala	Ala	Ser	Ser	Ser	Trp	His		
430					435					440							
act	ctc	ttc	aca	gcc	gaa	gaa	ggc	cag	ttg	tat	gga	ccg	tgt	ggt	ggt	1698	
Thr	Leu	Phe	Thr	Ala	Glu	Glu	Gly	Gln	Leu	Tyr	Gly	Pro	Cys	Gly	Gly		
445					450					455							
ggg	ggg	ggg	ggg	ggc	ggc	ggc	ggc	ggc	ggc	ggc	ggc	ggc	ggc	ggc	ggc	1746	

-continued

Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Gly	
460						465						470					
ggc	gag	gcg	gga	gct	gta	gcc	ccc	tac	ggc	tac	act	cgg	ccc	cct	cag		1794
Gly	Glu	Ala	Gly	Ala	Val	Ala	Pro	Tyr	Gly	Tyr	Thr	Arg	Pro	Pro	Gln		
475						480						485					
ggg	ctg	gcg	ggc	cag	gaa	agc	gac	ttc	acc	gca	cct	gat	gtg	tgg	tac		1842
Gly	Leu	Ala	Gly	Gln	Glu	Ser	Asp	Phe	Thr	Ala	Pro	Asp	Val	Trp	Tyr		
490						495						500				505	
cct	ggc	ggc	atg	gtg	agc	aga	gtg	ccc	tat	ccc	agt	ccc	act	tgt	gtc		1890
Pro	Gly	Gly	Met	Val	Ser	Arg	Val	Pro	Tyr	Pro	Ser	Pro	Thr	Cys	Val		
				510						515				520			
aaa	agc	gaa	atg	ggc	ccc	tgg	atg	gat	agc	tac	tcc	gga	cct	tac	ggg		1938
Lys	Ser	Glu	Met	Gly	Pro	Trp	Met	Asp	Ser	Tyr	Ser	Gly	Pro	Tyr	Gly		
				525				530				535					
gac	atg	cgt	ttg	gag	act	gcc	agg	gac	cat	gtt	ttg	ccc	att	gac	tat		1986
Asp	Met	Arg	Leu	Glu	Thr	Ala	Arg	Asp	His	Val	Leu	Pro	Ile	Asp	Tyr		
		540				545						550					
tac	ttt	cca	ccc	cag	aag	acc	tgc	ctg	atc	tgt	gga	gac	gaa	gct	tct		2034
Tyr	Phe	Pro	Pro	Gln	Lys	Thr	Cys	Leu	Ile	Cys	Gly	Asp	Glu	Ala	Ser		
555						560						565					
ggg	tgt	cac	tat	gga	gct	ctc	aca	tgt	gga	agc	tgc	aag	gtc	ttc	ttc		2082
Gly	Cys	His	Tyr	Gly	Ala	Leu	Thr	Cys	Gly	Ser	Cys	Lys	Val	Phe	Phe		
570						575				580				585			
aaa	aga	gcc	gct	gaa	gga	ttt	ttc	aga	atg	aac	aaa	tta	aaa	gaa	tca		2130
Lys	Arg	Ala	Ala	Glu	Gly	Phe	Phe	Arg	Met	Asn	Lys	Leu	Lys	Glu	Ser		
				590				595				600					
tca	gac	act	aac	ccc	aag	cca	tac	tgc	atg	gca	gca	cca	atg	gga	ctg		2178
Ser	Asp	Thr	Asn	Pro	Lys	Pro	Tyr	Cys	Met	Ala	Ala	Pro	Met	Gly	Leu		
		605						610				615					
aca	gaa	aac	aac	aga	aat	agg	aag	aaa	tcc	tac	aga	gaa	aca	aac	ttg		2226
Thr	Glu	Asn	Asn	Arg	Asn	Arg	Lys	Lys	Ser	Tyr	Arg	Glu	Thr	Asn	Leu		
620						625						630					
aaa	gct	gtc	tca	tgg	cct	ttg	aat	cat	act	taa	gttttat	gat	gga	agga	tac		2279
Lys	Ala	Val	Ser	Trp	Pro	Leu	Asn	His	Thr								
635						640											
gactatgaag aaagacacag agcaacatca gacagtc																	
caag aatttcagag ccagctggca																	
2339																	
tgcaagtggac ctcatgccag cccattttat gactatttag																	
ggagacagaa gtacctgtgc																	
2399																	
gccagcagaa atgattgcac tattgataaa ttccgaagga																	
aaaattgtcc atcttgtcgt																	
2459																	
cttcggaaat gttatgaagc aggggtgact ctgggagaaa																	
aattccgggt tggcaattgc																	
2519																	
aagcatctca aaatgaccag accctgaaga aaggctgact																	
tgcctcattc aaaatgaggg																	
2579																	
ctctagaggg ctctagtggga tagtctggag aaacctggcg																	
tctgaggett aggagcttag																	
2639																	
gtttttgtctc ctcaacacag actttgacgt tggggttggg																	
ggctactctc ttgattgtctg																	
2699																	
actccctcca gcggggaccaa tagtgttttc ctacctcaca																	
gggatgttgt gaggacgggc																	
2759																	
tgtagaagta atagtgtgta ccaactcatgt agttgtgagt																	
atcatgatta ttgtttcctg																	
2819																	
taatgtggct tggcaattggc aaagtgcctt ttgattgttc																	
ttgatccat atgatggggg																	
2879																	
ccaggcactg actcaggcgg atgcagtgaa gctctggctc																	
agtcgcttgc ttttcgtggt																	
2939																	
gtgctgccag gaagaaactt tgctgatggg actcaaggtg																	
tcaccttgga caagaagcaa																	
2999																	
ctgtgtctgt ctgaggttcc tgtggccatc tttatttgtg																	
tattaggcaa ttcgtatttc																	
3059																	
ccccttaggt tctagccttc tggatcccag ccagtgacct																	
agatcttagc ctacggccct																	
3119																	
gtcactgagc tgaaggtagt agctgatcca cagaagttca																	
gtaaacaagg accagatttc																	
3179																	
tgcttctcca ggagaagaag ccagccaacc cctctcttca																	
aacacactga gagactacag																	
3239																	

-continued

```

tccgactttc cctcttacat ctageccttac tgtageccaca ctecttgatt gctctctcac 3299
atcacatgct tctcttcac agttgtaagc ctctcattct tctcccaagc cagactcaaa 3359
tattgtattg atgtcaaaga agaatacatt agagtttgga atatcttggt ctctctctgc 3419
tccatagctt ccatattgac accagtttct ttctagtggga gaagtggagt ctgtgaagcc 3479
agggaaacac acatgtgaga gtcagaagga ctctccctga cttgcctggg gcctgtcttt 3539
cccaccttct ccagttctgtc taaacacaca cacacacaca cacacacaca cacacacaca 3599
cacacacgct ctctctctct ccccccccc aacacacaca cactctctct ctcacacaca 3659
cacacataca cacacacttc tttctcttct ccttgactca gcaacattct ggagaaaagc 3719
caaggaagga cttcaggagg ggagtttccc cttctcagg gcagaatttt aatctccaga 3779
ccaacaagaa gttccctaata gtggattgaa aggctaata gggttatttt taactacttt 3839
ctatttggtt gaattgttga tatttctact agtgaaattt tcccttaata aagccattaa 3899
tacacccaaa aaaaaaaaaa aaa 3922

```

```

<210> SEQ ID NO 9
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

```

```

<400> SEQUENCE: 9

```

```

tccttcacca atgtcaactc c 21

```

```

<210> SEQ ID NO 10
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

```

```

<400> SEQUENCE: 10

```

```

gagccatcca aactcttgag a 21

```

```

<210> SEQ ID NO 11
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

```

```

<400> SEQUENCE: 11

```

```

agtaccgcat gcacaagtcc cg 22

```

```

<210> SEQ ID NO 12
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

```

```

<400> SEQUENCE: 12

```

```

gcgctctgac agcctc 16

```

```

<210> SEQ ID NO 13
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

```

-continued

<400> SEQUENCE: 13

cacctgcggg aagctc

16

<210> SEQ ID NO 14

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 14

ggctgtgatg atgcgg

16

<210> SEQ ID NO 15

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 15

cttcgcgcac gctctg

16

<210> SEQ ID NO 16

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 16

atggtgctgg cctcgc

16

<210> SEQ ID NO 17

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 17

ggtcgaagtg cccct

16

<210> SEQ ID NO 18

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 18

gacaccgaca ctgcct

16

<210> SEQ ID NO 19

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 19

cccgaagctg ttcccc

16

<210> SEQ ID NO 20

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 20

cttgctgcg ctgctg 16

<210> SEQ ID NO 21
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 21

gttgtagtag tcgcga 16

<210> SEQ ID NO 22
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 22

aagttgtagt agtcgc 16

<210> SEQ ID NO 23
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 23

gcgctgccgt agtcca 16

<210> SEQ ID NO 24
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 24

aggatgagga agcggc 16

<210> SEQ ID NO 25
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 25

gctccgcct cgccgc 16

<210> SEQ ID NO 26
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 26

-continued

cgctttctctg gcccg 16

<210> SEQ ID NO 27
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 27

gccgccaggg taccac 16

<210> SEQ ID NO 28
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 28

ccaaacgcat gtcccc 16

<210> SEQ ID NO 29
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 29

agcttcatct ccacag 16

<210> SEQ ID NO 30
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 30

tcccttcagc ggctct 16

<210> SEQ ID NO 31
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 31

tttctgctgg cgcaca 16

<210> SEQ ID NO 32
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 32

gttcattcga agttca 16

<210> SEQ ID NO 33
<211> LENGTH: 16
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 33

gaggatcatc acagat 16

<210> SEQ ID NO 34
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 34

ctaaacttcc cgtggc 16

<210> SEQ ID NO 35
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 35

ttgatttaat ggttgc 16

<210> SEQ ID NO 36
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 36

gttgatttaa tggttg 16

<210> SEQ ID NO 37
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 37

atggttgatt taatgg 16

<210> SEQ ID NO 38
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 38

tggttgattt aatggttgca 20

<210> SEQ ID NO 39
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 39

tgatttaatg gttgca 16

-continued

<210> SEQ ID NO 40
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 40

ggttgattta atgggt 16

<210> SEQ ID NO 41
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 41

tggttgattt aatggt 16

<210> SEQ ID NO 42
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 42

agttgtagta gtcgcg 16

<210> SEQ ID NO 43
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 43

gatttaatgg ttgcaa 16

<210> SEQ ID NO 44
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 44

acagcactgg agcggc 16

<210> SEQ ID NO 45
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 45

aacttcaccg aagagg 16

<210> SEQ ID NO 46
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 46

agtccttagc agcttt 16

<210> SEQ ID NO 47

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 47

gcttctctcg agcttt 16

<210> SEQ ID NO 48

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 48

ccttgcttcc tccgag 16

<210> SEQ ID NO 49

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 49

gcactttct tgettc 16

<210> SEQ ID NO 50

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 50

tcagtcctac caggca 16

<210> SEQ ID NO 51

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 51

gactgaggca gctgcg 16

<210> SEQ ID NO 52

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 52

ccgactgagg cagctg 16

-continued

<210> SEQ ID NO 53
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 53

gctagctcgc ccgctc 16

<210> SEQ ID NO 54
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 54

cagctagctc gcccg 16

<210> SEQ ID NO 55
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 55

gcaatgtgca gctagc 16

<210> SEQ ID NO 56
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 56

gtcgctggc tcctaa 16

<210> SEQ ID NO 57
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 57

ctggctccgc actcgg 16

<210> SEQ ID NO 58
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 58

atctctggct ccgcac 16

<210> SEQ ID NO 59
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

-continued

<400> SEQUENCE: 59

tgatctctgg ctccgc

16

<210> SEQ ID NO 60

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 60

agtggtccact gaagta

16

<210> SEQ ID NO 61

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 61

aggctcacag tctgtc

16

<210> SEQ ID NO 62

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 62

gacacacggt ggacaa

16

<210> SEQ ID NO 63

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 63

agaagacaca cggtag

16

<210> SEQ ID NO 64

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 64

cgctctgaca gcctca

16

<210> SEQ ID NO 65

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 65

gtcgtgcag ctagct

16

<210> SEQ ID NO 66

<211> LENGTH: 16

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 66

ggtagtcgct gcagct 16

<210> SEQ ID NO 67
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 67

gcggtagtcg ctgcag 16

<210> SEQ ID NO 68
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 68

atgcggtagt cgctgc 16

<210> SEQ ID NO 69
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 69

gtgatgatgc ggtagt 16

<210> SEQ ID NO 70
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 70

ctgtgatgat gcggtta 16

<210> SEQ ID NO 71
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 71

gaagagttca acaggc 16

<210> SEQ ID NO 72
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 72

-continued

gcttggtga atcttc 16

<210> SEQ ID NO 73
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 73

ccttgagctt ggctga 16

<210> SEQ ID NO 74
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 74

atccttgagc ttggct 16

<210> SEQ ID NO 75
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 75

tccatccttg agcttg 16

<210> SEQ ID NO 76
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 76

gtaggtcttg gacggc 16

<210> SEQ ID NO 77
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 77

gattctggaa agctcc 16

<210> SEQ ID NO 78
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 78

gctctggaac agattc 16

<210> SEQ ID NO 79
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 79

cgcgcacgct ctggaa 16

<210> SEQ ID NO 80
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 80

tcacttcgcg cagct 16

<210> SEQ ID NO 81
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 81

tggatcactt cgcgca 16

<210> SEQ ID NO 82
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 82

gttctggatc acttcg 16

<210> SEQ ID NO 83
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 83

cgctcgcggc ctctgg 16

<210> SEQ ID NO 84
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 84

tgcgctcgcg gcctct 16

<210> SEQ ID NO 85
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 85

gtgcgctcg cggcct 16

-continued

<210> SEQ ID NO 86
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 86

aggtgctgcg ctgcg 16

<210> SEQ ID NO 87
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 87

gctgttcttc atccag 16

<210> SEQ ID NO 88
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 88

tgctgcgga gccct 16

<210> SEQ ID NO 89
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 89

ggtgctggcc tcgctc 16

<210> SEQ ID NO 90
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 90

tgcatggtgc tggcct 16

<210> SEQ ID NO 91
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 91

gttgcattgt gctggc 16

<210> SEQ ID NO 92
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

-continued

<400> SEQUENCE: 92

tgctgttgct gaagga

16

<210> SEQ ID NO 93

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 93

ggatactgct tcctgc

16

<210> SEQ ID NO 94

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 94

tcggatactg cttcct

16

<210> SEQ ID NO 95

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 95

tgccttcgga tactgc

16

<210> SEQ ID NO 96

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 96

ctcgctctcc cgctgc

16

<210> SEQ ID NO 97

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 97

tgtccttgga ggaagt

16

<210> SEQ ID NO 98

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 98

tggtcgaagt gcccc

16

<210> SEQ ID NO 99

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 99

cagaaatggt cgaagt 16

<210> SEQ ID NO 100
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 100

tgttccccctg gactca 16

<210> SEQ ID NO 101
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 101

agctgttccc ctggac 16

<210> SEQ ID NO 102
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 102

gaagctgttc ccctgg 16

<210> SEQ ID NO 103
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 103

ccgaagctgt tcccct 16

<210> SEQ ID NO 104
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 104

gtacatgcaa tcccc 16

<210> SEQ ID NO 105
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 105

-continued

acagcgggtg gaactc 16

<210> SEQ ID NO 106
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 106

ggacgcacag cgggtg 16

<210> SEQ ID NO 107
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 107

gtgggacgca cagcgg 16

<210> SEQ ID NO 108
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 108

tgcattcggc caatgg 16

<210> SEQ ID NO 109
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 109

cctttgcatt cggcca 16

<210> SEQ ID NO 110
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 110

aacctttgca ttcggc 16

<210> SEQ ID NO 111
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 111

gctcttgcct gcgctg 16

<210> SEQ ID NO 112
<211> LENGTH: 16
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 112

cagtgcctctt gcctgc 16

<210> SEQ ID NO 113
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 113

ttcagtgctc ttgcct 16

<210> SEQ ID NO 114
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 114

tcttcagtgctc tcttgc 16

<210> SEQ ID NO 115
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 115

actcagcagt atcttc 16

<210> SEQ ID NO 116
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 116

atactcagca gtatct 16

<210> SEQ ID NO 117
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 117

tttgggtgtaa cctccc 16

<210> SEQ ID NO 118
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 118

cctttggtgt aacctc 16

-continued

<210> SEQ ID NO 119
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 119

ctaggctctc gccttc 16

<210> SEQ ID NO 120
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 120

cagcctaggc tctcgc 16

<210> SEQ ID NO 121
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 121

agcagcctag gctctc 16

<210> SEQ ID NO 122
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 122

ctgccagagc agccta 16

<210> SEQ ID NO 123
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 123

tcgcgactct ggtacg 16

<210> SEQ ID NO 124
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 124

agtcgcgact ctggta 16

<210> SEQ ID NO 125
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:

-continued

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 125

gtagtcgcga ctctgg 16

<210> SEQ ID NO 126

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 126

tagtagtcgc gactct 16

<210> SEQ ID NO 127

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 127

tctccagctt gatgcg 16

<210> SEQ ID NO 128

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 128

cagcgggttc tccagc 16

<210> SEQ ID NO 129

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 129

cctttctcgg ctgtga 16

<210> SEQ ID NO 130

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 130

ggtccataca actggc 16

<210> SEQ ID NO 131

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 131

acacatcagg tgcggt 16

-continued

<210> SEQ ID NO 132
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 132

cgccagggtta ccacac 16

<210> SEQ ID NO 133
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 133

catgccgccca gggtac 16

<210> SEQ ID NO 134
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 134

accatgccgc cagggt 16

<210> SEQ ID NO 135
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 135

ctgctcacca tgccgc 16

<210> SEQ ID NO 136
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 136

acacaagtgg gactgg 16

<210> SEQ ID NO 137
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 137

cccttcagcg gctctt 16

<210> SEQ ID NO 138
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

-continued

<400> SEQUENCE: 138

cagagtcac cctgct

16

<210> SEQ ID NO 139

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 139

caccctcaag attctt

16

<210> SEQ ID NO 140

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 140

aaggtagtct ttaagg

16

<210> SEQ ID NO 141

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 141

gttttcaaat gcagcc

16

<210> SEQ ID NO 142

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 142

gccatgagac agcttt

16

<210> SEQ ID NO 143

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 143

attcttgact gtctga

16

<210> SEQ ID NO 144

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 144

gcattgccagc tggctc

16

<210> SEQ ID NO 145

<211> LENGTH: 16

-continued

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 145

cgcgcaggta ggagcc 16

<210> SEQ ID NO 146
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 146

tctaaacatg acggtt 16

<210> SEQ ID NO 147
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 147

atgcaattgc ctgcc 16

<210> SEQ ID NO 148
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 148

atgggagtaa cttttg 16

<210> SEQ ID NO 149
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 149

catattattg tgctgc 16

<210> SEQ ID NO 150
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 150

gtcaatatca aagcac 16

<210> SEQ ID NO 151
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 151

-continued

gagttgtgat ttcagg 16

<210> SEQ ID NO 152
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 152

ttgatggaat gctgat 16

<210> SEQ ID NO 153
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 153

ggtaaacttt ctctga 16

<210> SEQ ID NO 154
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 154

tggattgtaa attacg 16

<210> SEQ ID NO 155
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 155

gaacattatt aggcta 16

<210> SEQ ID NO 156
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 156

tcaatctaga taccat 16

<210> SEQ ID NO 157
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 157

cacatcagaa ggagta 16

<210> SEQ ID NO 158
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 158

gagtgttaat gaagac 16

<210> SEQ ID NO 159
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 159

ctgattagct atgacc 16

<210> SEQ ID NO 160
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 160

atgagtcctc agaatc 16

<210> SEQ ID NO 161
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 161

gtagattcta gctttg 16

<210> SEQ ID NO 162
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 162

acaggctctg actagg 16

<210> SEQ ID NO 163
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 163

tgtgtgaccc ttggac 16

<210> SEQ ID NO 164
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 164

aagtatgagc atgggt 16

-continued

<210> SEQ ID NO 165
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 165

ggattctcta cacaca 16

<210> SEQ ID NO 166
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 166

ccatttgtgc caaacc 16

<210> SEQ ID NO 167
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 167

aggttaggga gtaggc 16

<210> SEQ ID NO 168
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 168

tagggtttgg tcagaa 16

<210> SEQ ID NO 169
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 169

ccttatggat gctgct 16

<210> SEQ ID NO 170
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 170

gttatcttac tctccc 16

<210> SEQ ID NO 171
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

-continued

<400> SEQUENCE: 171

gattgtgtat agctgc

16

<210> SEQ ID NO 172

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 172

ggttatgggt ctgtct

16

<210> SEQ ID NO 173

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 173

cttcattgca ggtctg

16

<210> SEQ ID NO 174

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 174

tagccaactt tcttta

16

<210> SEQ ID NO 175

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 175

cattgtacta tgccag

16

<210> SEQ ID NO 176

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 176

tttggttaaca ttaggc

16

<210> SEQ ID NO 177

<211> LENGTH: 16

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 177

atggttgtcc tgtaca

16

<210> SEQ ID NO 178

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 178

accaagtttc ttcagc 16

<210> SEQ ID NO 179
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Oligonucleotide

<400> SEQUENCE: 179

tcttatgttt ccgaaccggt 20

<210> SEQ ID NO 180
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 180

gccctggat ggatagctac t 21

<210> SEQ ID NO 181
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 181

ccacagatca ggcaggtott c 21

<210> SEQ ID NO 182
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Probe

<400> SEQUENCE: 182

actgccaggg accatgtttt gcc 24

<210> SEQ ID NO 183
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 183

cttgcccc aggagtct 18

<210> SEQ ID NO 184
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer

<400> SEQUENCE: 184

-continued

ctcagagtaa gctctagcac acatgtc	27
<210> SEQ ID NO 185 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Probe <400> SEQUENCE: 185	
agtggtgtgag cctccatctc ctgtccaa	28
<210> SEQ ID NO 186 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer <400> SEQUENCE: 186	
gccaaaggagg gagggctctt	19
<210> SEQ ID NO 187 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Primer <400> SEQUENCE: 187	
ccccccatag tgaatcagct t	21
<210> SEQ ID NO 188 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <223> OTHER INFORMATION: Probe <400> SEQUENCE: 188	
atgaagtaag gagagggact ggaccccc	28
<210> SEQ ID NO 189 <211> LENGTH: 174000 <212> TYPE: DNA <213> ORGANISM: Macaca mulatta <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: (1) ... (174000) <223> OTHER INFORMATION: n = A,T,C or G <400> SEQUENCE: 189	
aagttgtggt gggattaaat gttgcaatga gtattcaaat aaggttgaag tatctatgca	60
ttctacttac atatggttga ggtatatcca aggaagcctg tagccattaa aatctcaggg	120
aacaattttt cacctectca ggtgaaaggg tcttcaggcc tttgtgttct ggaaggttca	180
tttatagcca tttcccaaata aacattgaga cggatgagtc tagagtctag ctcaaattggc	240
aattgggctgg aagactagtt tagtttttac taatgtggaa catagaacaa aattatgtcc	300
ttgtttcagc ctgctcatct gtgaagtaga gcctatcata tccagtctcc cttgccttta	360
ggttttgagtt accttctttg gtcaaggtaa gtaaatgcct atgatgtttt gctgtgcaca	420
agataaagct acaacaaagc tacaacctgt cttttctctg tagaagacgg caaaaagcaa	480

-continued

aagagaccca	ggcaaaaatc	tcggaatgac	ttttgaaaca	gacagcctcc	ctagaatcag	540
aagtcaaagg	aatttaaaac	atagggaggc	ccagggtctc	tactgacata	aaagaaagct	600
gttttcgtta	taggtttact	tttacathtt	ctctctcttt	ccattcccac	ctgcctctcc	660
acctttacac	agggcttatg	ggacctctc	cacaaaagag	cagttgcaat	aaccacatc	720
atcctccacg	cctggctgtc	catcaagagg	cgaaaagcag	ccctatatag	gttctatcct	780
tggatagttc	cggttggaaa	gtttaaaata	tgcaaaagca	acttggaana	gcaagcggct	840
gcatacaaca	caaacctttg	caaagctctg	cacaaaattg	agggcctatg	cgtacatggc	900
aagtgttttt	agtgtttgag	tgtttacctg	cttgtctggg	tggttttgcc	tttgcaagtc	960
tggatgagaa	atgcatgggt	aaaggcaatt	ccagacagga	agaaaggcag	agaagagggt	1020
agaaatgacc	tctgattctt	ggggctgagg	gttcctagag	caaatggcac	aatgccagga	1080
ggccccgatc	atccctatga	cggaatctaa	ggtttcagct	agtatctgct	ggcttggtca	1140
tggcttgctc	ctcagtttgt	aggagactct	cccgtctgca	cgtctctatc	agtctgaaa	1200
agaacccctg	gcagccatta	ggagcaggta	ctcctatcgt	ccttttctct	cctcctctc	1260
tacaccccg	tggtttttta	gattgggctt	tggaaccaa	tttggtgagt	gctggcctcc	1320
aggaaatctg	gatctctggc	gcttaagct	tggtttagca	aagcaggagc	tattcaggaa	1380
gcaggggctc	tccagggcta	cagctagcct	ctcctgccct	cgcccacgct	gcgccagcac	1440
ttgtttctcc	aaagccacta	ggcaggcggt	agcgcgcgat	gaggggaggg	gagaaaaaga	1500
aaggggaggg	gagggaaaag	gaggtgggaa	ggcaaggagg	ccggcccggc	gggggcggga	1560
cccgaactcg	aaactgttgc	atttgctctc	cacctcccag	cgccccctcc	gagatcccgg	1620
ggagccagct	tgctgggaga	gcgggacggt	ccggagcaag	cccagaggca	gaggaggcga	1680
cagagggaaa	aacggccgag	ctagccgctc	cagtgtctga	caggagccga	agggacgcac	1740
cacgacagcc	ccagcccggc	tccagcgaca	gccaaagcct	tttgacgcgc	ggcgacttcg	1800
aagccgcgcg	cccggagctg	ccctttctct	ttcggtgaag	tttttaaaag	ctgctaaaga	1860
ctcgagggaa	gcaaggaaa	tgcttggtag	gactgacggc	tgcttttgct	ctcctctct	1920
ccaccccgcc	tcccccaacc	ctgctcccc	ccccgccccg	cgtcttctct	cccgcagctg	1980
cctcagtcgg	ctactctccg	ccaaccccc	ttaactgccc	tctccccacc	ctcctcccc	2040
cgtcgcccca	gcgtgcccag	cccgagtgtg	cagagaggta	actccctttg	gctgcgagcg	2100
ggcgagctag	ctgcacattg	caaagaaggc	tcttaggagc	caggcgactg	gggagcggct	2160
tcagcactgc	agccacgacc	tgcttggtta	ggctgcacgc	ggagagaacc	ctccgtttcc	2220
ccccactctc	tctctacttc	ctcctgcttt	ccccaccccg	agtgccgagc	cagagatcaa	2280
aagatgaaaa	gacagtcagg	gcttcagtag	ccaaaaata	aaacaaaca	aaacaaaca	2340
aaacaaaaaa	acgaataaaa	agaaaaagat	aataactcag	ttcttatattg	cacctacttc	2400
agtggacact	gaatttgga	ggtggaggat	ttgtttttt	cttttaagat	tcgggcatct	2460
tttgaatcta	cccttcaagt	gttaagagac	agactgtgag	cctagcaggg	cagatcttgt	2520
ccaccgtgtg	tcttctctct	caggagactt	tgagctgtc	agagcgcttt	ttgctgggtt	2580
gtccccgcaa	gtttccttct	ctggagcttc	ccgcagggtg	gcagctagct	gcagcgacta	2640
ccgcacatc	acagcctggt	gaactcttct	gagcaagaga	aggggaggcg	gggtaaggga	2700
agtaggtgga	agattcagcc	aagctcaagg	atggagggtc	agttagggtt	ggggagggtc	2760
tacctcggc	cgccgtccaa	gacctaccga	ggagctttcc	agaatctggt	ccagagcgtg	2820
cggaagtga	tccagaaccc	gggccccagg	caccagagg	ccgcgagcgc	agcacctccc	2880

-continued

ggcgccagtt tgcagcagca gcagcagcag cagcaagaaa ctagcccccg gcaacagcag	2940
cagcagcagc aggggtgagga tggttctccc caagcccatc gtagaggccc cacaggctac	3000
ctggtcctgg atgaggaaca gcagccttca cagcctcagt cagccccgga gtgccacccc	3060
gagagaggtt gcgtcccaga gcctggagcc gccgtggccg ccggcaaggg gctgccgcag	3120
cagctgccag cacctccgga cgaggatgac tcagctgccc catccacgtt gtctctgctg	3180
ggccccactt tccccggtt aagcagctgc tccgcgcacc ttaaagacat cctgagcgag	3240
gccagcacca tgcaactcct tcagcaacag cagcaggaag cagtatccga aggcagcagc	3300
agcgggagag cgaggagggc ctccgggggt cccacttcct ccaaggacaa ttacttaggg	3360
ggcacttcga ccatttttga cagcgccaag gagctgtgta aggcagtgtc ggtgtccatg	3420
ggcttgggtg tggaggcgtt ggagcatctg agtccagggg aacagcttcg gggggattgc	3480
atgtacgccc cagttttggg agttccaccc gctgtgcgtc cactccgtg tgccccattg	3540
gccgaatgca aaggttctct gctagacgac agcgcaggca agagcactga agatactgct	3600
gagtattccc ctttcaaggg aggttacacc aaagggctag aaggcgagag cctaggctgc	3660
tctggcagcg ctgcagcagg gagctccggg acacttgaac tgccgtccac cctgtctctc	3720
tacaagtccg gagcactgga cgaggcagct gcgtaccaga gtgcgcacta ctacaacttt	3780
ccactggctc tggcggggcc gccgccccct ccacgcctc cccatcccca cgtctgcac	3840
aagctggaga acccgctgga ctatggcagc gcctggggcg ctgcggcggc gcagtgcgc	3900
tatggggacc tggcgagcct gcattggcgc ggtgcagcgg gaccggctc tgggtcaccc	3960
tcagcggcgg cttcctcatc ctggcacact ctcttcacag ccgaagaagg ccagtgtgat	4020
ggaccgtgtg gtggtggggg cggcgcgcggt ggcggcggcg gcggcggcgc aggcgagggc	4080
ggagctgtag cccctacagg ctacactcgg ccacctcagg ggctggcggg ccagggaaggc	4140
gacttcacgg cacctgatgt gtggtaccct ggcggcatgg tgagcagagt gccctatccc	4200
agtcccactt gtgtcaaaag cgagatgggc ccctggatgg atagctactc cggaccttac	4260
ggggacatgc ggtaagtctc tcttccaga aatgtcgctt ttcggcccag ggcacagagt	4320
cgtctgcatc tctgggtgtg ctagtggctc ctacctgcgc gaacctcag actgccccg	4380
ggagagctca gcagggtaaa cctagagctc tcccgtgga ctcccgccct gccagagggt	4440
taacctgagc tctcctaatt tctgtgcgt gtctgggtg ctgattcctg ccctcccaga	4500
ttcttcaact cccccaacgg ccccaaatc tcgctacctc ctggtaccgg agtcccaaac	4560
ttaaatccta ttgtacgggc caccttcaga gacaaagctc ataagccctc cactcttctt	4620
tttctcctgt cctcgaagtc tgagaacctc aatcagaaat ttgggcaatt tcttctcttc	4680
gggtctgtta ggaacttcct ttcagcctgt gcagattaga gtcaaaaaga ctggcccaag	4740
agcttctcag cggatctcct ccaagagggt aaatgaaat tctcgggttag ggaaagaaag	4800
tggctctctg gtgctgaggt ctgctatgtg aaggagtga cttctttccc ggaagcaact	4860
ggggacttgc tccaggcgtg gaggtcagta gagataatct gaaccgtcat gtttagagta	4920
ggcagagggg caactttctt ggtaaagact ccacaggatt tgcattcaca gtttctcaac	4980
gttggttgac tatgttgaaa gtatgtgctt gggtcggttt tctcttataa agtgtttatt	5040
ttctctgtgg attttaacag atccacaacc ccctacttca ggtttgcac agatctataa	5100
agaggagaat attcttttaa tgtacaattt aattaggctt cagtctgact tacaaaagt	5160
ttggaaaaca tatttttgtg aaacatttcc tgctatttca gtgtgcccc aaatctccac	5220

-continued

tggggagggga	ggagtggaggt	ttttcttatt	atatctcttc	atttttagga	catgttggca	5280
ttttaagaata	catgctgtta	gctctaacaa	attgagtaag	aactcttagt	gacctatgag	5340
ccataatctt	accccagagt	tttaattagc	atatgagaaa	agtggcaggc	aattgcatcg	5400
tgcttattaa	aaattattcc	tcaccgcaat	tgttgagctt	cttgagagacc	atgctgaaga	5460
ttttctcccc	cagcaaatta	agatattagt	ttatctagtg	agggaggaca	tactgaattg	5520
gggaattcac	tcctcaggta	gaccagggtc	tgatgtccct	gtggacttat	gtcttattct	5580
ttgtttctat	ggctgttttc	ttttatctgt	gacttctccg	aaatttcttt	gttagcctta	5640
acatcttcgt	ttggggactt	aaatccagca	atttgccctc	tttcactgat	gctttccttg	5700
ttacaaggta	gagatagcac	gctattagt	aagaaagaaa	gaggagggtta	ggatttcata	5760
ttattttgtg	ggctgttgaa	gaaacagctt	cttaccaggc	tttacattcc	attaggtttt	5820
taatgtttgg	cttacaagat	tttgaaagg	ttcatttgat	atcgtcaaa	tattttccag	5880
ttaattttaga	ctctttat	ttgtaatgg	tttacctat	gggacaaaa	aagtattctt	5940
cattttataa	gaataaattt	tcttggcagg	gttaattttt	tttctaagcc	tgctactaga	6000
cgggtggagcc	cttctcttac	tgtaaaactt	tcttggtgga	aaatgtctaa	ggtgcatttt	6060
gacctgccat	gataactaac	ccagactctg	gaaccttcca	tcttctgcat	gcctccccc	6120
caacttactt	acttagcagg	gaaaaaactg	atggttccac	atatttctta	aaaaatgtgt	6180
gccttcaaag	gcaaaaccaa	aatttttagg	gaataactat	agagagcaaa	agttactccc	6240
atcaggtaga	caatgagctt	ggtgatttta	tttcaggctt	taatgaaaa	agcttcttta	6300
tgaggaagat	tatcatatct	tggtgcctcc	ttgacagtct	gcttaaatta	atgacataaa	6360
ctaagagaa	tttagcagtt	cctgcagaaa	gtacaagatt	ttttttctg	gtttttgatt	6420
gctgcactga	ttatgaggag	tctagttaaa	aggaaaactg	gtgttctctg	ctcgtaagtt	6480
gacgaagact	ttccatttct	aggatagaga	aaatccttaa	gtcagtttat	tgaaaattaa	6540
tcaatttaat	cagaatgcaa	tcaattocaa	tccaaaagtt	gatattttct	tactttctct	6600
ttttttcccc	tcactttgta	ggggtgcaat	ttggtgaaag	gcaagagatt	tcttaagcca	6660
aatcaagagt	gtcttccctt	tctgtattgc	atgcattatg	tgccattttt	tagctaaaaa	6720
tctcaaaatt	gtgcaggctt	ccagtgcact	gttgggttcc	tctcttttcc	attcatgtgt	6780
gtgtttatgc	acattagtta	attttttgaa	gggatttttt	taaaccttag	taacatctgc	6840
actcactctg	tgttcttaca	catttacaat	gtttctgctg	agaggatggg	agatgcaaag	6900
gtggtctctt	ttacttaatt	tagcatgtga	tttaaacaga	aggaaaaata	aaaagtgatg	6960
ggacttgtgt	gcaacctga	tgatattttg	tggagtgtgc	tgtcttctct	ctgagatcaa	7020
acaggactac	aactttgtta	attgaccact	ggctcccttg	gcagaggtag	ggcttcttag	7080
attccagcag	gcagcacaa	aatatgacaa	aaatttatct	ttgggagtgt	ggttctaaga	7140
gagtctgcat	gccagaatta	gagtttgggg	tttagagaaa	ttatccagat	gcaaaaagaa	7200
cattttaatt	tttctcttgg	taatttggtc	tggtctccat	agtaggtagt	acttttagcag	7260
tgctttgata	ttgacaagtc	ttgttccctt	tttctattag	attttacaaa	ataaggcatt	7320
ttattaatct	ctctttccct	ctcctctctc	ctctcagtta	ccaagcattt	ttatgactat	7380
cttacaaggg	acagtttgtc	ttgtaaagca	gaattttcct	ttgaaaccaa	gacagactat	7440
ttctccccat	aggcttcaag	aaccaatatt	ttggcaagaa	gcactctttc	cttggtgtca	7500
gcaaataggt	agtgagttct	gtctggattc	caacaatcaa	cacctgagga	ccaaatagcc	7560
acactgggtg	gcaccccatc	tggaagtata	cacaggatgt	agccctcttt	cttgtccaca	7620

-continued

gctcaagtca	gccaagatt	aacactggtg	agagatattt	tcgaagaagt	ttgcaggctt	7680
ccaattgcag	ggctgtttg	gggtgctttc	ttgcctgtgc	taattttatc	tcacaggct	7740
tccattcttt	gagctgtaaa	ctttgaaata	atatattaga	ttcgtggta	cgtttaattt	7800
tctttgtcaa	gtgtttttca	ttccaatagt	aatttttcat	ctggtgtaca	tatatgcatt	7860
taaaacaaaa	aattcttttg	tctcctttcg	cgtacatgca	ctgtggcttg	tacgtgtgca	7920
agccacttgg	tgggattatg	tgaattgggg	ttagaaatgt	ggacaatttt	attatgatta	7980
tttttaatgg	tgatatcaag	atcaccagtt	tcattcagaa	ccttgcataa	gcaggagca	8040
gaatgtggac	tgggtgtggc	aaagcaaggg	cttattttat	agccaaacct	gaaatcacia	8100
ctctgaaata	taaaaaaaaa	agcaaacaaa	aaaatcaagt	tttgtgagct	tggtcagaga	8160
aggaaaagaa	aatctctccc	cacccccac	ctccaccatt	ttctctttgt	ctgcagcttc	8220
ctcaagtgtc	gcctgtcccc	gattttcttt	tattccactc	ctttcatgtt	ttgacattg	8280
aaatacagac	tcttctttcc	acttctcagg	gcatttttct	cattacacct	gtggcatgct	8340
cctaataaat	ttcttaaaaa	aaaaaatct	gtaaagtagc	cgattagatc	aacccagca	8400
tctctccctt	aagacctaga	tgacatgagg	ggattgcaaa	atgaatagct	gggttttttt	8460
taccttgagg	ttaaagcctg	gttcaacagt	tgctgaggga	gttaactaga	tggcttgagg	8520
acttggcaat	ttcataaagt	attttgtctt	atgctgtcgc	tgtctctgtc	tctgtcttga	8580
tctctgtctc	tctctgtgta	ctgtaatgtt	ggccaccttc	tctcagaacc	tgagagagag	8640
ctctgagacc	cttcccagg	cggttcgggt	cagacctcgg	tagcctggtc	acaagcagta	8700
cctaatatgc	atatgtgggt	gcattgtgta	agtgtcctgc	tgggctaate	tgtttaagct	8760
acataaaaat	taatcatatg	aaaacaaaga	aagatattaa	agaaattatt	ctacctccga	8820
cttctcatat	cagcattcca	tcaagttctg	ggatgttaaa	ttcagagaaa	gttaacctca	8880
tcttaaacac	aaagttgact	tttaaacaaa	attgcttata	aagttccgta	cagttaccag	8940
cattgggtgc	cctttgtcat	acggaagaga	attatgaaat	ctcatattta	catagcattc	9000
ttaaaaaaaa	aaaaagaca	cagtgttttc	cagttttatc	actgcattca	tgttagtttg	9060
agtagggcag	gaggggtgct	tagtgattac	ccttttgcta	ggtaagaag	tagaaagata	9120
gattttctat	gatgtttgtt	taccatgtag	gggaatctct	ttagagcaac	actcccaggc	9180
tttttctctc	tgaattttcc	cacctgacaa	atactttaga	ttgttactcc	taaggacttc	9240
tctcagtagc	tgtcatatag	agacgatagt	ctatgaatta	ttgcttgcac	actcatgggt	9300
gatgccacac	gctctctctc	ctggcagttc	ttgctgccaa	cctgcaggcc	acaccaggac	9360
tgaaggcagc	tcacttagat	aagtttatag	cattaaagtg	ctgggtcact	tgagaatgtt	9420
gtcaatttag	gttacttagt	acctaatgtg	tattttttta	ataatagctt	tattgagacg	9480
taatttacaa	tccatacaat	tcactcttct	aaagtgtaca	gttccatgct	tttcagtata	9540
ttcagagttg	tgcaaccatt	attgcaatca	attttagaac	attttaatca	cccccaaagg	9600
aaacgctatg	cacctttttg	ttcaatgcct	tatgttcctt	cagtccttag	caaccaataa	9660
tctacttcta	tctatggatg	tgttattctt	aatattttgt	atgaatgaaa	tcattgaata	9720
tgtggtcttt	tgtgactagc	ttctttcaca	cagaatatgt	tttcaaggtc	atccatgctg	9780
aagcacgtat	cagtacttcg	ctatttttta	tagcctaata	atgttccact	gtatgactat	9840
acaacatttt	atctatccgt	ttatcaggag	atgagcatta	gggttggttc	caccttttga	9900
ctattatgaa	taatactgct	gtgaacattc	atgtacaagt	ttattgtgga	catattcagt	9960

-continued

ccacatatgtg	tggaacatttt	caattctttt	ggatacatatc	ataggattga	aatctctgag	10020
tcatatggta	cctctatggt	tatcctttga	agaactgtca	aactgttttc	gaaaagtgtct	10080
gcactgtttt	acaateccat	cagcaacgta	tgaggggtcc	atttcttcca	catccttgca	10140
aacacttgta	attctctttt	ttattacagc	tatattagtg	ggtgtgaagt	ggtacctcat	10200
tgtgggtttt	atttctattt	ccctaataac	gaataatggt	cagtatctat	tcatgttctt	10260
attggccatt	tgtatatctt	cttttttgag	aaatatctat	ttggattctt	tgccattttt	10320
ttagttgggt	tttttattat	tgagttttaa	gagttttaaa	aaatatattc	tgatgcatg	10380
tcctttaata	gattgtgatt	tgtggatatt	ttttcacatt	ctgtgggttg	tcttttttac	10440
tttctttttt	tttctttttg	tgtctttaat	ggtatctaga	ttgaagcaca	aaaaaagttt	10500
ttaagtttga	tgaagtccaa	ttcatctggt	tttttttttc	tgttttggtg	tatgattttg	10560
gcatacatatc	taagaaggct	ttgcctaatac	caagattaca	aagatttaca	catatgtttc	10620
cttctaagag	ttttatagtt	ttcgtctgtt	acacttaggt	ctttcatcag	ttttgatgta	10680
atgtttatat	atgattgagg	taggggtccg	acttcattct	tttacacata	gatactcatt	10740
tcttacaata	ttcttgttga	atttttcttc	acttaactgt	cttggcacc	tttgtgtaaa	10800
atcagttgac	tgtaaatgtg	agggtttatt	tgtggactct	caactgtatt	cagttgatct	10860
atatgtttat	tcctatgcca	gtaccacatt	atcttgatta	ttgtagggtt	ttagttagtt	10920
tgaaatttag	gaattttgtg	ctctttgact	ttggctctgt	ttttcaagg	tgttttggt	10980
cttgtgggtc	ccttgagttt	tcatatgaat	tggtataagt	ttgtcaattt	ctacaaagaa	11040
gtcagctggg	attctcacag	gaactatatt	acatctgtaa	atcaatttgg	ggagcattgc	11100
catctcaaca	acgttaagtt	ttttcatcca	taaataatgag	atgtcttccc	atttatttag	11160
atcttctctt	tgtcaacaat	tttttattgt	tttcagatga	taagttttgc	agttcttttt	11220
aaaatttagt	cttaagtgat	ttattttttg	atactattat	aaattgaact	gttttgttga	11280
ttttcttttc	agattattca	ctgccaatgt	atgaaaacat	aattgttttg	tgtattgatc	11340
ttgcacctg	caaccttgc	gaaaatacct	gagttttgaa	tacttctggg	acttatgggg	11400
aagagggctt	ctgctgtttc	actgaacgtt	aaagcttatt	tcatttcac	ctgtatgaag	11460
gctgcataca	agccttctgt	atgaagggga	cactgttgtc	atttttactc	agctataaat	11520
ttgaactgg	aatcccatcc	cctttcagga	tgaataggag	agtgttttta	aatgttcac	11580
tcttttagaga	acagcgggaa	agaagcctaa	taaggtttgg	gtcgtttata	atcccttttt	11640
cagaatttgg	atttgggaac	tattagcaag	ggagtgaata	ataataataa	tttctacata	11700
gaaaactaac	atgtagaggt	gacaaatgaa	atcactagct	atatttgggt	tatgtttagg	11760
tttttataag	cagctaaaat	cataattttg	tgtttttatc	tcttgtcctt	tggaacagag	11820
aaattccaat	actcctctctg	atgtgcattt	ctagatggg	aaaggattcc	tttactctca	11880
tataatttaa	gcttcttttt	agagatgtac	tccatagcca	tgaagcaaa	ataaaattca	11940
tctatgtaga	gattgaactt	tgtcttcatt	aacactctag	gctaaagggtc	atagctaatac	12000
agctacaact	gtcatgtcct	gataattgtg	agttaactgc	aggccaccca	gcaaagggtt	12060
tagttataat	ctgatagctg	tctgtagaga	ttaccctaata	aaagggaatt	ttttaaaaaa	12120
gaatctggca	gggtagtaga	gctcactcct	gtaatcccag	cactttggga	ggccgaggtg	12180
ggcgatcat	ctgaggtcag	gagttcaaga	ccagcctggc	caacatgggtg	aaaccccatg	12240
tctactaaaa	atacaaaaat	tatccaggcg	ttttgggtggg	caccataaat	cccagctact	12300
tgggaggctg	aggcaggagg	atcacttgag	cctaggaggc	agatgttgca	gcgagccgag	12360

-continued

atcatgccac	tgactccag	gatccgtcaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	12420
aaaagactct	atcaatcaac	cacttttcat	taagcacctg	ctatgtgtcc	agcatgtact	12480
aggaagagat	aagataaaag	gggacacaat	tcagacagaa	tcttcttgag	gtaattgctt	12540
acaaggagct	tatagccact	gaaaacaaaa	acaaacaaaa	acaaataacc	aaaacccaaa	12600
cagaaatgca	gcaccatcat	gccataatgc	ctgtatgaga	tcctggattg	tacgggtgtg	12660
atctttttaa	atgtagatat	ttaaaaaaaa	aaaaaaagag	agagagagag	agagaaatga	12720
atcaatagag	gctgaagtgg	tcaacaatgt	tacctgtggc	tgcttttaat	cctttgtggc	12780
agtaagtagg	agcatgtcta	aactcaagca	atagattaaa	gatcctgatg	tatattttaa	12840
ataacagaag	ttggtacctc	tggaaagaat	taactggagg	catgggttga	aatctatttc	12900
tgcttattaa	atagtgcacc	ccagtcaagt	tagttgccaa	ttttttttca	gtttcttttg	12960
ctatatcatc	gcacttgttg	ggtacatgtt	tttgatgtat	ttatctgaac	aagtccgcaa	13020
taatatgagt	aataaattag	aatagaaggt	gattaatagc	tctgaatttg	atataagatg	13080
cccagtgtgg	tggtcagatc	aagagttgtt	tttcggccgg	gcgcggtggc	tcaagcctgt	13140
aatcccagca	ctttgggagg	ccgaggcggg	tggtacacga	ggtcaggaga	tcgagaccat	13200
cctggctaac	atggtgaaac	cccgtctcta	ctaaaaatc	aaaaaactag	ccgggcgtgg	13260
tggcggggcg	ctgtagtccc	agctactcgg	aggctgaggc	gggagaatgg	cgtgaacccg	13320
ggaggcggag	cttgcaagtga	gccgagatcg	cgccactgca	ctccagcctg	ggcgacacag	13380
cgagactccg	tctcaaaaaa	aaaaaaaaaa	gagttgtttt	tctgccttct	aagtttccat	13440
tgatcctgat	ggattgcaca	aatagaacaa	ttcggggagt	atgggggcac	atgacgatct	13500
tataagagct	ttgctgtaat	agacaacgta	acattctgaa	acggcctacc	acctaacatg	13560
ggctctgggt	ctctgcagggt	tgagtgaagt	ccttgcctgt	ggaactgtag	tcccgcctatc	13620
tggccgctag	ggggactgca	agtgcctcgt	ggcaggattt	ccctgggaat	ggtgagcctc	13680
cattgacggt	ttcaacacac	agccaaggcc	ctatcgagg	ataacttcaa	ccagaactgc	13740
ttagcaccag	acaataaata	agctactatg	gtacttactg	tttcatttgg	gatgttcttt	13800
ctcgaagtgt	caagcatttt	aaagtaatat	tttgactttt	taatacctct	ctttgcataat	13860
ggagcaggac	acagcaaata	tattcaagta	gcactgtcca	gtttatagag	aagtttcata	13920
ttccattatt	gcatttcatt	cttgtttcta	ccctgtacaa	gtaactagag	ttgggagtat	13980
tataatagta	ttcatactat	tacaatactt	ttattcccat	tataaaaatt	atgctaagag	14040
tggttaagtt	acatgtttac	aatcaaacag	catcaaagtg	acagatctgg	gatttcagtc	14100
tcattctttc	ttctccagat	catgtgttcc	ctgcttttat	ctcacagctc	tttttacctt	14160
atagatagga	aacatgagag	tcagagaggc	aaaagaacca	caagtgggtg	caataactaga	14220
aatttatgaa	gttcttaagg	cttctagggt	tgttacccat	ccaccagact	gatggatttg	14280
gttgtgtgag	agttctgggt	gtcaataaac	ttgccattct	actttacaga	ctgcatacat	14340
tcaataaatg	cctattaagc	atctactatg	tgccaaattc	tgtactaggc	accaatgatg	14400
tagcagcgaa	cagaacacac	aaaaatatct	gaatggagct	gacagtttaa	tgagaggaga	14460
catgtagtat	acatctgagc	atgaatagtg	tcatgcagaa	taacttcaga	gtatagggtg	14520
tagagattca	tggtgagagg	gaatatttta	tatctgctgg	ccagggaata	ccttactgga	14580
aaggtaaatt	ttgagcagtg	acctgaagga	aattaggaaa	tgagctgcta	tttgacatc	14640
tggagttaga	atattccagg	cccagggaac	cacaggcaca	aagggcctga	ggcaggagag	14700

-continued

catgcttgct	ttgatggagg	acaaaaaggc	tcatatggct	ggtttaaata	agtgaaggat	14760
ggtagacaat	gagatcagag	ttaatgaggt	tgcattgtag	gtcttcttta	agacttttga	14820
ttttactcct	aagcaggggtg	tattggaagg	ttttgagcaa	agtaacatga	cctgacttac	14880
actttaacag	gctccctcct	cttcataaca	tctgtcactc	tgatatatta	tacgtttgtt	14940
tgtttactta	ctgtatgtgt	ggagaagaga	ctgtgggagc	aaggagggaa	gcagggagac	15000
aaggccactg	cagtgatctg	ggtagagaggt	aaccatgtct	cagactaagg	tagtattggt	15060
ggagaagata	ggaagtggct	gaattctaga	tgagttttga	tggtagagcc	aacagcattt	15120
actgacaggt	tggatattca	ctgtgaaaaa	aatagaggag	atgaggatga	ttgccaaatt	15180
tttggtctga	gtaactggaa	aaatgagatt	gccatttact	aaaattgtga	agactgtatg	15240
tagagcaggt	gcattggcag	gatagaaatc	aagagtttga	ttttttactt	ataaagtttg	15300
agttatctga	tgagcatcct	gatggcttct	cagttttcat	tcagtgcctc	cagctttgct	15360
gttcttcaag	aagattaaaa	aggaccttag	agatcaccta	ggctgtaggt	acctctctcc	15420
ttctttcctt	ttactttata	gaggtctata	gaagggtagg	gacttatcca	aggtaaaaca	15480
gtgagctggt	gacagaacta	gggcacaaac	ccagttctct	tcgattctga	ttcagtagat	15540
ttttgtgtgt	gtgtgtgtga	ttctgaggac	tcatttgggc	aagagttagt	tttttgtttg	15600
tttgtttgtt	tgcgcaaac	taaaaccagg	tgattaaact	aaatagtac	taaaactgga	15660
aaactataca	aattggttgc	tctccccaat	caaactgaaa	tattattatt	aggtttttac	15720
tgaactacat	acccaaatat	ttttttctg	taaaaacaca	gtaagtgggc	ttttaaggc	15780
aattgagctt	ttatcaaagc	tagaatctac	agggcacctg	gacaaaaatg	gcctaaaatc	15840
ctaagaaatt	agagtctcatg	gaacctggaa	gaccatcttg	tccagctagc	tcattttatt	15900
ggtagagtgc	ctgaggcacc	gagatggaaa	gggacttggc	taagctcata	cagcaagcta	15960
gtgcctgacc	tagtcagagc	ctgttctaag	tattagtgtg	atgttgtttt	cttgaaaaaa	16020
gtctatattg	gaaaaatgaa	aattctttgt	tccatactga	gaacaaagaa	ttatatataa	16080
tcatatataa	taataatgat	agcacttact	gaatgtttgc	tgtgtaaact	tccgcacctt	16140
gcattgaactg	attcatttaa	ttctcatgtc	aacttttaga	agcaggccta	gagacgttaa	16200
ataacttgct	caagggtcac	acagcttaga	agtagcagaa	cttgtgtgca	ctcccaggaa	16260
gtctggcttc	taaccacaag	gttctaacta	ctgtgcaata	tcagcagctt	ctcagattac	16320
tcttcacctt	caccatccca	aaagactggc	gacataggtg	acttcattat	gcactgcccc	16380
tattatagtc	cactgatcct	caccaaatag	ctgggtggcc	tagagggtta	agtaggggca	16440
cagtgatgga	aaggggtggt	tagaagaggt	tgataactta	tgatagggat	tggaaaaacg	16500
aactctagga	attattgaaa	agggcctaga	gatcccaagg	aggttgatct	cagactgcta	16560
caaaccaggg	caattcgatg	cctgcttaaa	taggagaggt	aagataagaa	aaataaaatt	16620
gccagttttt	acagtcaggc	attgttttat	ttctttttaca	tgtattaatt	cgtttaatcc	16680
tcaaaataat	ccatgaggta	gctacaatta	tcatttctat	gttatagatg	aagaaacagg	16740
cacagagcaa	ttaagtaacc	tgcccaagat	tagagaacaa	gtaagtgaag	gtgccaatat	16800
tagaatctag	gtgattcagc	tccacaactt	atgttatttt	ccaatacatt	tatggaacga	16860
ggtaattttc	atataacaga	aagtgtttta	agtgcaaaaa	cattgtgcct	gaacttcaaa	16920
cattgaacaa	ctcatatcct	taatatcac	cagctgcttt	taaggactct	tagaagtaag	16980
gatacttacc	taaagtcata	tgttgaacaa	gtagcagaac	cggaaactga	atttgagact	17040
ccagactgoc	agacctcttt	ccactctatc	acttgggctc	ccttctaacg	ttgatttgtc	17100

-continued

tctctccatt	cttctccgt	attgtctgc	ccttcacctt	ttaattacct	gtctccatca	17160
acaagattgg	acagagaatt	gggggagtga	gcagagtcca	tttccttcca	gagactggac	17220
aaaaggaaca	aatgttggg	aaaaaagtca	gcatgtggat	tttgtgggat	ttacactaaa	17280
taagaacgga	cacttgccag	gactgacaag	atgtacctc	aatccctcta	ggccccaatg	17340
tgttatgcag	gatcccataa	gaagtcatga	atgtagtgtg	cagataatct	ttttgttact	17400
gtggaaatgg	aagcaggata	ctgcaaaaat	ctgtctctcc	aggttttctt	ttaaagaagg	17460
tacagtcttg	ctaaatgata	actgtttgga	catttatttg	aaaatgggca	gtgcaggaga	17520
gaaagaattt	ttccaagctt	gtcacattgg	gccatctctc	tgaagcattg	tccaacctct	17580
aattagatga	ggagactgca	ttaaccaaga	gttgagagta	aagatggaaa	cacttgatgt	17640
ttggtgtttg	gggtgcagaaa	ggattccaaa	acatgttctg	agtttcttta	ctctgcccat	17700
cctccttcc	ctttcatctt	tgtttaaaaa	ccatggttag	caaatgtgtg	tagtctgttt	17760
gcaattgttc	atctgaaaaa	ttgtttgat	cagccttttg	aaaaaagat	caaaatagac	17820
tgagatattt	tagtcaccaa	ctatctaata	atagaccaa	aatttaaacc	atgctcatac	17880
tttcatatgg	tatgtggttt	gttttagacg	ctttctgggc	ttcgtgagg	tgctagattg	17940
actcaaagta	tggcaggta	gatgtggaat	tgagtagggt	ggactcttct	ctatgcctcc	18000
agattcagaa	ttcccatca	gagatgatct	catagtgttt	ggaaaaacca	agctgaaggc	18060
tttggaatt	agggtggtga	agggatatgt	tgtttccaa	agccttctca	gtcattcctt	18120
ctccccaat	tcagattctt	aacacctctt	gccgggatta	gtgcagtgat	cccacatcct	18180
ttctctctag	ctctctctgc	tactctctaa	tccctattgt	atttgtgcca	ccagatcttt	18240
ccaaagtta	gtccaaccg	tttctgtata	ctgctttaa	tgtctattag	tctttaagct	18300
ccataagggc	aggagtctg	tcttattttt	tccctattct	tcagtcttaa	tacaaaggaa	18360
gctttgtatg	attaaaattt	cagcttctcg	ccattggctt	atgggtaagt	ccaaattatt	18420
taaatctggt	gttcaagtcc	ttttatgac	tgcttatttt	tccagcctga	attcctggag	18480
ttcccttaca	aaactcttaa	aaccagcca	aatggatcta	gtcacctga	ctttaaacca	18540
tccctactct	cttgtttttt	gaacatgta	cttttattat	tatccctttg	accttgaagg	18600
ctatcccaat	ttcaacta	tccattcttc	tataacagtc	ccctacaaa	tgaatattat	18660
caacccccca	accaaggag	aagtgatcta	tatgacacaa	catgggtgaa	agaatgttgg	18720
tttactact	ttatctgtaa	accaggggct	agaaatctct	agtttataag	attttgtgga	18780
gaggggatca	catgtgatta	tgatgttag	gctcgagtca	agagtgcata	agactttttg	18840
gatttatccc	tttcttctt	ctccatcaat	atgggtactta	gtcccttaag	tactcgtggt	18900
acttgtgtta	atgactgata	gcatccttct	aaatatactt	ctaaacatct	gtctcttttt	18960
agggcaagg	ttggatatat	ctgcaagat	tctctttgga	tataagatat	ccacagcaca	19020
taacttaaca	gtgtgtgaca	tagtagatat	tccataagta	tttctttatt	aaatgattca	19080
gagtcaatag	tagtaagtga	ctgccgaaga	caactgatag	attgtaagtt	ccattaacag	19140
aaatacagtt	agccctccac	atccataggt	tccatatcca	cagatttaag	caacagcaga	19200
tggaaaaat	attttagaga	cacagtaaaa	ataacaattc	aacagtaaaa	aaaaaagtta	19260
tgtaaaacaa	ctatttacat	aacacattgt	attggtatt	acaagtaatc	tagatataaa	19320
tgaatatat	gggggatgtg	tatagggtta	atacaaatgt	gacaccattt	tatatgtttt	19380
aggtgaaggaa	catgaatatt	tttggtttt	ggtattcctg	ggagtggggg	aatggaacca	19440

-continued

agccccctca	aataccaagg	gactattata	tgggatacag	aataaaggaa	ttgattgtct	19500
tgctctgtta	aattctggtc	agacacattt	gcaatgtggt	gttcagcccc	aatattcatg	19560
gagcatctcc	ttttgtaaag	catggaggag	ctatgagaga	gacatggagc	agtgaacata	19620
actattgttt	caatgaacct	gaaggattat	catggaataa	agaagttaga	tgtttttctg	19680
tagcacccca	aaggggcaaac	gcaatgagga	cagattacaa	ttcagtaaaa	gaaagagttt	19740
tttttttttt	gtttggtttg	ttttgttttt	gggttttttt	gggttttttt	tgtttggttg	19800
tttggttttg	tttttttttt	tttagatgga	gtcttcactc	ttgttgccca	ggctggagtg	19860
caatggcgca	atcttggtct	actgcaacct	ctgcctccct	ggttcaagtg	attctcctgc	19920
ctcacccctc	ggagtagctg	ggattacagg	tgacacaccac	caatcctggg	caattttttt	19980
tttttttttt	ttttagtaga	gatggggatt	tcaccatgtt	ggccaagctg	gtctcaaact	20040
cctgactgca	ggtgatccgc	ctgcctcggc	ctcccaaagt	gttgggatta	caggcgtgaa	20100
tcaacgagac	cagcctgaaa	gatattttct	tagaagggct	tctttcatcc	ttcatcagaa	20160
gttggttaaca	tggaccatat	gagttttgtt	tggtctatat	gggtgtgtgtg	tgtgtgtttg	20220
tgtgtgtgtg	tgtgtgtgtg	tgtgtgtgtg	tgtattgaat	tacttgctaa	catttttactt	20280
caaaattcag	atttccaccg	tagggaatga	agatctgaca	atacagaact	ttcattctta	20340
catggtaatg	accagctgca	ggtgaaaagc	agctgatact	ctggatgggc	catgcacttt	20400
gcagtttgcc	caggcaccag	tgacccactt	tattcattta	agttacctgc	ttgactcttc	20460
tagtcattcg	agtatgtcat	cctgttcaga	tcagagacct	aagcaaatct	tgagtccctt	20520
gcttactcca	aggcctttca	ctcctcgtat	aggaggggct	aaagaaatgt	acaagcagca	20580
ccacaatagg	atcagacctg	actttcaatt	ctagcacagc	catgtaacat	agttggatga	20640
cctcaggtea	gtaatataac	cctctgagc	ctctagatct	tcattatctg	tagaacactc	20700
tccttacaga	gttattgtaa	gaatgaaata	aaacaactag	gataaagggc	attacactta	20760
gtagtgctg	aaatatgggt	tcctctcttc	ttattcatca	caccatttct	gtctgtctat	20820
tggctgaatt	acataaatag	taaattcaca	ttcactgaag	acatttaaga	agagtctgga	20880
ccctttggga	accatgtata	ggacaaagat	ttggactcat	agattatttt	tacagtcact	20940
ttctaacaat	ttaaaagcct	atggatgact	ccaaaatgcc	catttggaatg	atttgaggca	21000
tactttgtgt	agttaaggat	tttaaataca	taacagagag	actgaagggc	ctttgggaaa	21060
caagctgggg	taagagtcaa	aatgtaatat	gttgactgat	gttcaggaat	aggctttggc	21120
atctgataga	ttttgttttc	agtactgcc	ctgggtctta	ctagcttcca	gttctggggc	21180
acttcacctc	tcttgagttt	tagtttcttt	atttctaaaa	tgaagatact	aatgcttctt	21240
ttgttggtt	tttgtaaga	taagtgaat	aataaatgta	aaacatgtag	cccagggcct	21300
ggtgcatagt	aaaagcttca	taaattgtac	ctattattat	tagtagtagt	agtagtccag	21360
acaaacagag	cttgggaaaa	tgctagactc	tggctgacat	acatggactt	ttccccaggc	21420
cactgctgcc	tggcttcccc	ttccacaaag	ctttgagtct	ccaaaatgct	ttggctggaa	21480
tgtaagcgtg	aggctattgc	agataacagg	ggagcatgat	ttgcttcggg	aatgcaagtt	21540
attaagttac	ttccctcagc	ccagctaaaa	tctcttattg	gttgatgttt	gcttcaaagt	21600
gtgagactga	gctagtttga	ggagagaggg	agagtaagaa	gattcctctt	cttggccaga	21660
ggtcatggtc	ttccacaagg	aacagaatga	ctcaacgcaa	attatgggac	ctctttgagt	21720
ttggggcccc	tacattttaa	ccagtcactc	cattgcacaa	attggtagcc	ttcccccaac	21780
aaaattactg	ggcaggaatt	ttcttgactc	cttccatggc	ctggaatgat	ctcccttctc	21840

-continued

atccttgtga	tccacacagc	tggcaaatgg	caggcagcag	aacaaaaaca	agcctcttag	21900
catagagaga	gagagaaaga	gtcacagcag	tactgaattt	gcttgggaac	ctaatgttaa	21960
caaaggatct	tcctctcaac	accccaaca	gattaaaaca	tttttttta	acagcaagtt	22020
gtgtctcaga	gcagctcttt	gcttgggtat	atttaaagat	ctgctgagtc	atttaagagc	22080
aggctggcag	atcgtaagag	gcaaggacta	tacccagtc	tatgggggag	taagttgaga	22140
ggtgaaatct	gtttggcttt	ctcccatgtg	aaacaaacaa	ggtgatccac	ttccatctcc	22200
cacaactctg	gagagcatct	actaaggctt	cttattctat	caactttgaa	ctctcagag	22260
tataatagag	taagggtgag	agggaaggag	cagttgtacc	agtggtctg	ctgtctgaaa	22320
ttgtaatgcc	cctgcattgg	tagctgagag	tagcatggaa	gtgtcagggt	gatgggttca	22380
tttcattctt	ttcttttcag	tttctggtca	catgcattgt	taccatggca	tatgacagtt	22440
gctagaaagt	gaaataattt	tttctacttt	attcttaatt	gcacttctaa	atttattaaa	22500
ggagaaatta	gcagtttagc	actgttaact	ataggtagac	attgggggtt	ccttagagcc	22560
aattttcccc	ctagttttca	actgttaaat	ctgatagatt	ttgtcctaaa	agttggcaaa	22620
acctggagct	tctctttggt	cctggccttt	ttgaaccctg	ttccacagag	ccaatcttc	22680
tttcttggtt	gagacaacta	tccttctctt	tgcccactgc	cattttcctt	catctacttt	22740
tcccatctct	agcacctcag	actgtcttcc	cacagtggca	cagactccca	ctccactttc	22800
actgtgccat	cttcttgcta	tcaaaacat	cctcacagac	ccttactttg	ctgaaaccac	22860
ttctaggaag	ggaaatcaca	gtggatccat	gaaggatgct	ttctggatga	ctttaaaaga	22920
ttggtattaa	gatatatttt	tagtggtggc	aacactgact	tactcaggca	gccatgccca	22980
ggatctataa	gaaatcagat	aagctaaaag	ttgcttgagc	tggcaggaga	cctagttctc	23040
tgttttcctt	tcctctatgc	attttgttta	tcaatgggtt	tcagagggtt	tagaggctgg	23100
ctttgttata	gttagttggt	aagagaaatg	gtggaggact	ggaaaatggg	agtggaaacca	23160
ttgagcatgt	tattacaatt	cctaggatgt	ataaatcgct	tgaaagtcta	ccaagtactt	23220
tcagacacat	tatctttttt	actcttcaaa	atcaacttgg	aggtaggcac	aacagggatc	23280
aaatccttag	ttcacagatg	agtaaaacga	gactggaggga	aattaaagga	cattccaagg	23340
taactcagac	aataagcaac	agaactagga	tttgattagt	tttttggggg	gtggggagga	23400
cagagtctca	ctcaggctgg	agtgcagtgg	caaggtctcg	tctcactgca	acctctgcct	23460
cctgagttca	agtgattctc	atgcctcagc	ctcctgagta	gctgggatta	cagacatacg	23520
ccacaatgcc	tggcaaattt	ttgtcttttt	agtagagatg	gggttttgtc	atgttgccca	23580
ggctggctct	gaattcttgg	tctcaagtga	tccaccccca	ttggccttcc	aaagtgcgtg	23640
gaaccactgc	tcccgcccc	ggaccattaa	tttttgatgg	taggtccacg	ttttttcaag	23700
ttcacagctc	ggattttgta	tataatgaat	gaatgagtat	atatgtcatt	tggaacatt	23760
attccaactt	tcggttggaag	atttgtttta	tcagttgtgg	aacttttttt	catttttagc	23820
attatcagtt	tagttaaatg	aacatttcgt	tcatgaattc	actaattaat	tattttattc	23880
atcaatacat	ttcctgagta	ccaaactttc	tatcaaatgc	tgtgctggat	tctgaggcta	23940
caaaaagaaa	tacgacacca	tctcatgact	ctaaaaatc	acagactggg	gactgacatc	24000
tcagtagtaa	acatatgaat	agcaacttat	gaaatgccat	tagaaaaatc	tcaagttata	24060
ttcctcagtg	agtatggcca	tcctaaaaat	gagaagtctt	ttattttggg	tacatgaaaa	24120
tgaagcgttg	tgagaaattg	cattttaatc	taatcttgtc	ttactaagaa	cagaagtgaa	24180

-continued

atgtttcagc	ctctgtgtgt	gtatttgtgt	gagtgaaggt	tgagtgtgtg	atgatggatg	24240
gggctgcgag	attgctaagt	aggatctatg	gggggcctta	gatggtcctg	gtgagtccca	24300
actttctggt	tatgtatttg	ggtgcagtat	gggagtgaca	aagattgttg	tttaagagtt	24360
gattttagat	ttttccaag	taaatagtca	gcagacttgg	agcatcatca	ttccacttgc	24420
tttgaaaacc	taccacttaa	ggctccttct	tgatcatagg	taactctttc	tggtcaagta	24480
ttactctttt	tgagcatttg	cctgtcagtg	acaggtgcaa	tgtagatgtg	tgtctctctg	24540
ttttcttggt	taatctttac	tttgatccta	ggtagctctt	attagttcca	ctttataggt	24600
aagaaactga	atttcagaga	ctttaatgac	ttgttcaaga	tcacatagta	agtaacttgg	24660
tagtttggga	cttgaatttt	gattgttcaa	ttttttttcg	tttctgggcc	tcactgctgt	24720
tttactattt	ccacaccact	tcagctttat	ttttcacaga	ggccgttaaa	tgtaccctcc	24780
atcagccaaa	gcctcttgcc	tccttcaaac	gtaactcttc	tctagcgtgt	tcctaataat	24840
cttctgaaaa	gggttttacag	cctttctggg	tactgggacc	cagagtctta	atccaggctc	24900
ttaagtgcct	tagttaactg	taatatggat	aatcaaagtc	acagctaatt	caggaaaaat	24960
gagtttggga	tgtgaatttc	ctgggcaaca	tgatcatctt	ttttactccc	cttagcttca	25020
taaacttacc	cacaatgttc	cctgaggact	aacagtaatg	gaggggtgatg	aggaaaggct	25080
ttctctcctt	cctggtttcc	aagagtcctt	tagccaaatg	ccacacctcc	tcctgtttcc	25140
ctagtctctg	tgcagagatg	gaggtgggag	atagacatgg	gttcttttca	gccctgagtt	25200
catgccagag	tttttttttt	cctctagct	ggagtgaagt	aggaagagag	gttcaatgtc	25260
caccaagaag	accatgagtg	aagaagacta	aagtaactga	aagaacatca	gacctatgct	25320
taaaaatacca	gggtttgtgt	ccagactttg	tgggttacta	tctgtataat	tttgggcaag	25380
tcaacagtcc	tgagtccagag	tttcttatac	agcagattgg	aagataaatt	ctaattatat	25440
ggatgaaaca	ttaagtctag	aagtattttg	taaattcaga	aagggttat	agatttaaag	25500
tgtagctggt	ttatcacata	ctaaatccta	tacttcaggg	ataaaacctt	ctcctgtttt	25560
ttctaaaagc	ctgtgcattg	gtgggtgaag	ggatgggttt	tgccctgta	ccagccactt	25620
agcaattgta	gtaactgggg	gctgagggca	gtggcctgct	tctgcactga	gcaagtgtga	25680
aaagagggta	atgcattcag	gggtcagcag	atgacaggca	gagtagcccc	tccaaatctc	25740
cctcccatcc	cgcaaagccc	cttattttatt	caaacttaac	attggaaact	catttcaagt	25800
aggtagctct	gtgtctgggc	gtctattttc	tttctttgta	tatagcaggc	atttgtcaac	25860
ttggtgaaaa	gcattaccct	tctttccatt	tctgaggact	aattgtgctt	attcgctaga	25920
catgagttca	aaacagtggg	ttgaaagagg	gcaagtttat	gccaagaagt	cagaagtagt	25980
cataatttag	agagaattct	agaggtoagt	tccctttcgt	gtggattggg	caactgaaac	26040
ccagatagaa	aagcggatta	gaccaagtcc	acaagcaca	acacgttact	ggcacattca	26100
gattggaagt	tgagggtctc	tgtctccagg	tcagaactaa	atgccctttc	cagctagggc	26160
gttctttgat	ctcagtgatt	tggactcttt	ctactacact	ctggggacag	tgggttctga	26220
gataccaact	ccaattaaag	taggaatatg	taccagctcc	tccccttggg	ttttttctag	26280
aggcctggca	ttcagaggca	gtgtgatctc	tatatgtaat	attttcacac	tattgttctt	26340
atttaaatca	catttgaatt	ttggcaatta	acaaggcagt	aattggcatc	aggaagggtat	26400
gttagtttgc	ttatctgccc	catccccctt	cttcccgacc	cactgtgcat	tgcagaatgt	26460
tttatcagct	ctgatttgcc	aagttgctct	cttctccagt	aggtgctgca	agcagagagg	26520
gattcctcgg	aggtcatctg	ctccatcttc	ttgcctatgc	aaatgcctgc	ctgaagctgc	26580

-continued

tggaggctgg	ctttgtacca	gactttgtac	agggaaaccag	ggaaatgaat	gcagagtgc	26640
cctgacattg	cctatcaett	tttcccatga	tactctggct	tcacacgtgg	gaggtcttc	26700
agctgaaaac	ttagaactca	ttttctaggg	tagtgagtgt	tgtaaggttt	ggactgtgac	26760
ctaataattat	gcagccatga	cattatctat	taggcatact	gaccagcttg	cttgaatatc	26820
ttagcatgtt	gactaatttg	gggcagacta	cagtgtgggt	ggaggattgt	gtgtgtgtgt	26880
gtgtgtgtgt	gtgtgtgtgt	gtgtatgggg	ttgagcaatt	cattattatt	aatatgcaaa	26940
aagcacttat	ttcgctatga	caaggttgcc	tttttcatgc	atattggcct	acctgcaaga	27000
cccctagaga	cagtaagcaa	catacatgg	gtcttcacgt	tttcagcctt	tgtgcaagga	27060
acaactgtgg	gtttttgcat	gtgtgtgtgt	gtttgatgtt	tgtgtgtgat	tgtgtaccag	27120
ggatgtgtgt	tctgttactg	tgagttcact	tctgagcagt	tgtgacacac	agagatccag	27180
aaacagtgtc	ttactctgtg	tgtctctgta	gtgggaacgt	gtcttctctt	ttgtgctcgt	27240
atctctgtgt	aatcaagtgt	cttgctaagt	cagtgtgcct	ctgtctcttt	ttaccagttc	27300
ttccgtcttt	gtgtctctat	gccttcttgc	gtttctttcc	cctgagtttg	cacatgtctc	27360
tgtctatgtg	gatatctctc	actccaggcc	actgtgtcac	tgtgtctgta	ttacagctg	27420
tttctttctg	tcggtgtgtg	gattctttct	gtcgggtgtg	ggatttctat	gtctgttttc	27480
atcttaattt	gtgtgtctaa	gcaagaagac	tgttttgggg	tcactatttc	cgtttatgtc	27540
atagccccga	ttgtcccat	ctccatgtct	ctctgtgtgt	atatgttcta	atgtatctgc	27600
ctacttatct	ttattcgat	ttctctgggc	atatatccct	ctcttgacgt	tcttggcctt	27660
tgcagttttt	ggcttatgtt	tttgtatata	tcgactagaa	ttggcctcct	tatgtttttt	27720
gtgcatgttt	tagttttttg	tatatatcca	ctagaattga	cctccctatc	atttttgtgc	27780
atgtatgagt	gagcatatcc	aactctgtct	ttgagaagca	gaactgtcta	tgtttgcagt	27840
caattgtgtt	ggctgtccct	gtgtttgtcc	ctgtgtgtgc	atttcattgt	atgtgcaccc	27900
attcatgtat	ctttctgctt	ctgtatgacc	atatacttct	gtgtagctgt	ctatgtatat	27960
tggcttctat	ctgtgtctgt	gttggtggct	acatgtctgt	gcatatgcac	ccactgagtt	28020
cataaaaagc	tcacctgtct	tctaaggaat	ctaccagatt	gttttgtgaa	ataactcaca	28080
tctcgttttt	tacttgctta	gttatcttct	ggcttgccag	atgctttggg	acttaaaagt	28140
gtgttggtac	gtaggggtgc	ataatttatt	catgtaggat	gtcaaaagag	tcagttaaaa	28200
attatacaca	gtgtgtcttt	attaacagga	cagttgtgtg	tagagaatcc	ttgagaaatg	28260
agcggtaga	tgataaatct	tttcatatta	atttcatgat	ttgagtgaag	taaatttgaa	28320
aggtacaggc	tgcataagag	ctatgtgctt	tttaaaactc	attgtattga	tggtggagaa	28380
agcatttatt	tgtactgcaa	agtcttattt	gtgatgttca	ttactgggtt	agaaggtgtt	28440
acttttctga	ttttgtttgg	ctttttgaag	agttactaca	aatgacatct	tagagacaaa	28500
gagctctgaa	gggtacttag	aacacatgga	gtacagacaa	aaaggagaat	ggaaaataac	28560
agagagatgg	gcatattcct	catttgaatg	gagtcagcca	ggggctcagg	atggggtgca	28620
caggaaatgg	agaggtgacg	gtcatagaga	gaagcttagc	aggaccagat	ctttccttgt	28680
cctgggctgc	tgtgaccata	taaggaaggc	agtaagggga	ggggtaggga	tgaggaagag	28740
accagctctc	cctttctttc	tgatggaagg	ttaccacctc	tatttaaaac	ttctgttctt	28800
ttggttctct	ttctttgttt	gatttatatta	ttttctggtc	ttgttctgcc	atagcaagaa	28860
ggaaattcca	catgtggctc	actcatttat	tatacttggt	tctttgcatg	atattataga	28920

-continued

gagcttggtta	agtgctcactg	cgaacatcac	acacactgat	ccactgatat	gggcagggtg	28980
gtctttatgc	cagctctgct	cccttcccag	tgtatctgtg	gtgcttaatg	gggacaacca	29040
tgatttttct	gatgtcagtc	tgtgatgtca	gttgccagtc	gtgtatgcag	actgcttaaa	29100
agtacataca	gttcctttgt	aattatggta	gtccctgaga	aggaagtgtc	cactaataaa	29160
agactagggt	cagtagaaac	atgtaagttg	tctagggtgt	ggaaattaat	atagtactct	29220
gctaagggaa	tatatatcta	gaagttaact	ggattatgct	caataaaaag	attacaaaag	29280
tttcataaat	atttttaact	aattctataa	gattaggaga	gggatatttc	agatattcaa	29340
ataatttttt	taattgcaa	acaccttaga	catattattt	acatacaatt	gacataataa	29400
ttaaatacatt	atgtctgttt	tatgataaaa	caggatcttt	tggttagttg	tgaattattg	29460
aatgtaaaat	aatgaaaatt	taaaaaaac	agaggaggaa	tctatcctat	tttataattc	29520
agaccgttga	attgaatttt	tcttttggtg	tattgatctc	aatgtagaga	agtctgtggt	29580
gctggattcc	agtcaaaaga	taaacatttg	tatgtgggct	ctacattgca	gccaatcttg	29640
ataatttcaa	accttgatgt	tctcatctgt	ataatggtaa	taataaagac	tgtctcagct	29700
accaaagatg	tgcataatgc	aaacctctca	cttatgtaag	ggaaaaaaga	aaaagaagga	29760
caatgggggtg	gatttttctg	atagtaaaat	ttattcagtt	agggtaatat	tctgagcttg	29820
tcttctgaag	caaacctctg	aaactctggc	cattctgttt	tgtttaggaa	agagttaatc	29880
agttctgatt	ctgcgttttc	tggggaagga	ggctgagtat	ggattgaaga	ggagtcaact	29940
cttttctgag	atgatatact	tgtgctaaaa	attagtaatg	ctttgcacat	gcaacataca	30000
gtgttcaatt	ttgttagtca	acagatattt	aagtggcagc	tggtatgacc	tcaggggtgt	30060
agtgacttcc	ttatataatg	tcctttaatt	attgaaaaag	aaatctacat	cagaatatca	30120
ggtaaaatct	tattacatca	aatattataa	caaagatact	ttttatatct	tctaaaaaaa	30180
gtggagatct	cagatgttgg	ttcattttat	aatataatat	tggtattgaa	aattccagta	30240
tacaaaggga	aaaagacagc	ttcttaaaag	ttatagtgat	tttctatgaa	ctttcaattc	30300
aggatttttt	ctgttttact	ggatgatag	agctaaattt	cgaattgtaa	gtagtagatc	30360
attagactgc	agggtaaagc	ttgagattgc	ttcttttcag	gtaggaaact	ctactgtgta	30420
tttggtcagt	tcaacatact	atgggttagc	aaaaatagtt	acatatccaa	gtcagcattt	30480
tttaagttgt	tcagtgtgtc	ttaaagattg	gtcctttcca	ggaccaatcc	agctttatca	30540
aaaagttatt	atgtacatct	aaagtgttct	gacattttta	tgctcacagt	agccgaatga	30600
tgtgagtagg	aatctttgtc	ttcattttat	agatgaagag	acacagagaa	ataaactaac	30660
tgggccaggg	tcctaccact	agaatgtgac	agatgacaat	ttgagcccag	catatagttg	30720
tttccctata	atattcgttt	tatgattgta	tagatatctg	ctgaccaacc	ttaatctctg	30780
ctccctgaga	ttaacctgtc	tacaaagcag	aaactggagg	tcgttcaaat	gaaaactcta	30840
cactttttaga	ggggcattaa	caatgtctca	gttaaagaaa	agcaatcaaa	gacaactgaa	30900
atactggtac	cttcagacag	tacatatgga	tttttttttt	tttttttgta	ttatacttta	30960
agttctaggg	tacatgtgca	caacatgcag	gtttgttaca	tatgccatgt	tggtgtgctg	31020
caccatttaa	ctcgtcattt	acaataggta	tgtctcctaa	tgctatccct	cccccttccc	31080
cctgccccaa	aacaggccct	gggtgtgcat	gtttcccttc	ctgtgtccaa	gtgttctcat	31140
tgttcaattc	ccacctgtga	gtgagaacag	gcgggtgttg	gtttttttgt	cettgcgata	31200
ttttgctgag	aatgatgggt	tccagctgca	tccatgtccc	tacaaaggac	atgaactcag	31260
ccttttttat	ggctgcatag	tattccatgg	tgtatatgtg	ccacattttc	ttaatccagt	31320

-continued

ctatcattga	tgtacatttg	ggttggttcc	aagtcttggc	tattgtgaat	actgccgcag	31380
taaacatacg	tgtgcatgtg	tctttatagc	agcatgattt	ataatccttt	gggtatatac	31440
ccagtaatgg	gatggctggg	tcaaacggga	tttctagttc	tagatccttg	aggaattgcc	31500
acactatctt	ccacaatggt	tgaactagtt	tacactctga	ccaacagtgt	aaaagtgttc	31560
ctatttctcc	acatcctctc	cagcacctgt	tgtttctga	ctttttaatg	attgccattc	31620
taactggtgt	gagatggtat	ctcattgtgg	ttttgatttg	catttctctg	atggccagtg	31680
atgatgagca	tgttttcatg	tatctgttgg	ctgcataaat	gtcttatttt	gagaagtgtc	31740
tgttcatac	ctttgccc	at	ttttgatgg	ggttgtttgt	tttttcttg	31800
tgagttcttt	gtagattctt	gatattagcc	ctttgtcaga	tgagcagatt	gcaaaaaatt	31860
tctcccattc	tgtaggttgc	ctgttctactc	tgatggtagt	ttcttttgct	atacagaagc	31920
tcttttagtt	aattagatcc	catttgccag	ttttggcttt	tgttaccatt	gcttttggtg	31980
ttttagacat	gaagtccctg	cccagccta	tgctctgaat	ggatttgcc	aggttttctt	32040
ctcgggtttt	tatggtttta	ggtcttcat	ttaagtctct	aatccatctt	gaattaattt	32100
ttgtataagg	tgtaaggaag	ggatccagtt	tcagctttct	acatatggct	agccagtttt	32160
cccagcacca	tttattaat	aggaaatcct	ttcccaattt	cttgtttttg	tcagggtttgt	32220
caaagatcgg	atggtttag	atatgtgga	ctgtttctga	gggtctgtgt	ctgttccatt	32280
ggcttatatc	tctgttttgg	taccagtacc	atgctgtttt	ggttactgta	gccttgtagt	32340
atagtttgaa	gtcaggtagc	acgatgcctc	cagctttgtt	cttttggtt	aggattgtct	32400
tggcaatcgg	ggctctgtgt	tggttccata	tgaacttta	agcaattttt	tccaattctg	32460
tgaagaaact	cattggtagc	ttgatggga	tggcattgaa	tctataaatt	accttgggca	32520
gtatggccgt	tctcattata	ttgatacttc	ctatccatga	gcattggaatg	ttcttgtttg	32580
tttgtgtcct	cttttatttt	gttgagcagt	ggttttagt	tctccttgaa	gagggtccttc	32640
acatccattg	taggttggat	tcctaggtat	tttattctct	ttgaagcaat	tgtgaatggg	32700
cgttctactc	tgatttggct	ctctgtttgt	ctcttactgg	tgtataagaa	tgcttgtggg	32760
ttttgcacat	tcattttgta	tcctgagact	ttgctgaagt	ttcttatcag	cttaaggaga	32820
ttttgggctg	agacaatggg	gttttctaaa	tatacaatca	tgctatctgc	aaacagggac	32880
aatttgactt	catcttttcc	taactgaata	ccctttaatg	aattatttaa	ccttagataa	32940
tttggtttg	agctagaaag	gtagagaaag	atggaggaac	caattcttcc	ctgggttggg	33000
acttatttat	cttgctcttt	tgaagtctag	gtcaatcgtc	ctatttggtc	tgaatggccc	33060
attcatgttt	atccatttag	ggacagcagg	tttggcaca	atggattggg	tttctgaggt	33120
ctcatgtaga	gggtctgact	gactgacttc	tgaagtccc	ctctaaccct	tcaaattctg	33180
ggatcatttg	atctcaagcc	ttcatcattg	catacatttc	tatttccttt	ttgagtacca	33240
gcacaacact	gcaggctgac	ccactggatg	gatagaatgg	ggctcttgcc	ctaccaccct	33300
ttggcaaaca	atttgagggt	ggcattgtca	ctatctcatt	gatatagggt	ctcttgaggc	33360
ccagaatgac	aaagtaattt	tccactctc	acacagctag	ttattgtcag	agtaaatagc	33420
aattttgaat	ttgtagaaca	cgtggtttta	cctctatcat	ttctgtttat	tatgaaaatt	33480
ttagaagtaa	taattaatta	gaagtagaaa	tgatgattaa	aataaatgcg	taactactaa	33540
aaagtagttc	attgcagcac	cacctaaatt	catctcacca	ttctaccagt	agtacacatt	33600
tcgccattgg	gttaacattg	ttttggatct	tatagctgtt	gaagaagaca	aaattctttc	33660

-continued

cattctctag attatat	tttt ccccat	tttgt aaaacataat	ggaagtgtat	ggaaaatagg	33720
agttgataat ttttaaggcc	cctgtcagca	tattggcaca	taggattctt	gtaagtgggtg	33780
gtttacttca cttcagctat	ggaaggccta	tgcgacacca	cccatagagg	atagtttgaa	33840
agaaactgct agtgactgcg	tgtgtttcct	tcctgacata	tttgetagaa	ggtgatgagt	33900
tccagctttt tttcagactt	ggatctggct	ttcatteccc	ttctctctcc	accctcttaa	33960
acaacagagg cagcaacct	ttatacactt	tccagaagta	agtaagactc	tattccagaa	34020
acaccctatt tcaaaatgga	aataactca	gtgcccacat	gacccattgg	gcgagtttga	34080
acgtgtgcat tctctgtgct	ccccgtttta	gcttaggcct	actccctaac	ctgtcatatg	34140
tcaccagcgg atggagccta	gggcaatgag	tgccatcata	tctgactttg	tgccctctca	34200
gctttcaatg actagctttg	tagcagaagt	ttagcctctc	atccccagac	ctttggaagt	34260
agtgttgaga taaagagagg	ttgaattgaa	ggttgtgttt	tctagatttc	tttcaattgc	34320
tccttaggct ttagaagaca	aattctctta	aaagacaggt	gctacaatta	atccaagcaa	34380
agggaaagat gtcaatagag	ctgccccttt	tcgtagaggt	gtggcaactg	ctgggaagga	34440
agaaattagc tggaggccgt	gtgatcacta	ataaaactca	aagcgggtgt	tttttacttc	34500
tcaatatgag gttgaaacta	taagcttaaa	ttgctgactt	tctggcagca	ccaaacagta	34560
aggaaccac aaagataaac	ccaaataata	gagccaattt	tctttttttg	tgggggtggg	34620
ggatgacttc taactggtga	tatgaggaag	gataagaaaa	tgtttat	ttt aatctaaaaa	34680
aatggatag cacatatgat	ctttgctaag	tgactgaat	gtatgtagag	gagacaagtc	34740
tgctaaaggt atgagaattg	ggccgagatt	taacacattt	tcaaagctcc	atgaagaaac	34800
ctactgaaca gtgggagtg	agcaggttg	ggatagttaa	gtatttgtaa	tttattttta	34860
aaaaggagag ggagagagag	aaaaggaaaa	actgggccac	ccatcctttg	aaaagaaacc	34920
ttgaaagagg tccaaatata	cttagaaata	cttgacttct	taaaagtgat	aagagtttgt	34980
tttttcccc tgacaattat	agaggtcaga	gagttttctt	ttctattgca	aaacattgag	35040
agtgtgtaga aataattgta	ggtagcttag	ccttggtgtg	agtcagaact	tttgactgtg	35100
gactttagga tctgtataga	attgtatgat	atgaggatac	accaaaaact	ctatgggcta	35160
tcaaaatggg atagcattaa	aagaaatagt	gcttttg	ttt agaagaagaa	atgaaatgct	35220
tgtgtccagg tgcttaaagg	aaggcagtg	agactttcag	aaactagact	ttaagagcta	35280
tactcagata ctgagaagg	ctgatggctg	aaggaggaac	aatttaaaag	aatagccatc	35340
tctcccttcc ctgtaaatta	gacataaaag	aatatcccat	tcctctcaga	aatgtaatac	35400
aacatttttag cttgctagta	actttacatg	ctatttctct	tacctcttat	atttgagggtg	35460
tctatttggg gtgggctgtg	tttctagcta	ttctgtttat	ctggtttgtt	tttgtttgca	35520
taggaaactg gtgtacattt	tatttgggta	aatatccct	caattttcaa	ataaagcttt	35580
atttaagttt cacatgaaaa	agacaaatga	gacaaagaag	agaataattg	cattgtcaga	35640
attataagaa aaaaatcaaa	taaacatatt	tgaaatgtcc	agaaaaccta	gagttttatg	35700
tatattatac aggagagata	ttctgtcatc	tggttgccaa	actatggagg	gtgggagact	35760
tagaattttt gtccaaaagt	attgcttcat	tagaaagata	catgggtgtg	cttcacatc	35820
agcaacatga ctgcagaccg	ggaagtctc	acggagagct	ggaatatggg	tattttggac	35880
tctctggtaa gatgggctt	ttacttcaact	tcctcagtgg	tactactgta	aattttcatt	35940
ttctatgga ataccctatt	tggttccatt	gtatatagtt	gacaactaga	attcgttcgc	36000
tggtgcttga actcaactgt	aacttcttgg	cactatacat	atcttctgat	gcgcctgtgg	36060

-continued

```

aagagctacc ataatgactg tgtacatgga caaaaaaaaa aaaaagagag agagagagag 36120
aattaaatca tgagtttgtg ccttggggagc tacagtttaa acatttgctg gttttctcaa 36180
ttaatgaaaa atttatttga aaataacagc acagaaagga agaaagacag gccggcaagc 36240
atcctcctcc taatatactt atccactttt ggataccttg atctcagtct cagaggtcat 36300
atttttagta aaatggccac cagaagtaaa ggattttatt ttccagactt tgggtgtttgg 36360
agctgggtgtg ctgagagctg gtagagaaaag cgctactcag gtagatgtac caaaggagga 36420
tgggtgctgg tggatatggc agagtacctt ttatgtggtt atctctctct tgtaactctt 36480
ggctgcataa ctcttatttt cttttctatt tttgttctct ctcttgaaa aaatttggtg 36540
gtaaattttc atatgagcca tattgtcttt ttaaatagtt ttattaatat aaaatgtaca 36600
taccataaag cataccattt taaactgtaa aattcaatgg gtctctctct ctctctctct 36660
ctcttttttt tttgtatact cagagttgtg caacaattat caaaatcaat ttgaaacat 36720
tttcattgcc ccaaaaggaa accctctgcc cattagcagt tactcccat ttccccacc 36780
cccagtcctc ttcaacccta ggcaaccaca aatctacttt ctgtctctat agatttagct 36840
gttctggaca tttcatgtaa acggaatcat gcagcatgtc accctttgta tctggcttct 36900
ttcacttagc atgatgttcc caaggttcag ccgcattgta gcatctgcc atacttcatt 36960
ccttatttat gactgaataa tattccattg tattaatgta tcatattgt tttttccat 37020
catcagttga tggacacttg ggtgtttttc atcctttgtt ttttcttg ctattttaaa 37080
taatgctgct atgaatgttc atgtacaaat tttttaatga acatctgttt ttatttctcc 37140
ttggtataca cctaggagtg gaattgctgg gtaatatggg agcttaacat ttaacctttt 37200
gaggaaactgc cagatttttc caaagcagca caatcatttt acattttgac cagaagtata 37260
tgggagtttt agtttctcca catcctcaac aacactcatt attgtcattg tccttttcag 37320
ctcttttgat aatagtaatc tcaatgggtg tgaattggga cccattatg gttttaattt 37380
gcatttcctt gaagactaag gatattgatc atcttttcat gtgcttattg gccgtttgta 37440
tattttttga tcttttgctc atttccaaat tgtgttgtct tttcattatt gagttgtaag 37500
attttaaaat atattttgga tatgtttgtc attttaggga tgatacttca cagttacatg 37560
atgttttcta gcaagcattt gtgttggtct actggtgtta catatcttag ctgcattagc 37620
cacttcgttg ggtatgaatg ccagcagaat ctaaatgacc ttggcttcac tgctgagaat 37680
gcaacccaag aacagaaatt tgtcagaaat ttaacactta agccccccac ttcccaaact 37740
catctgggac aaggagaatc tacatttaaa gttctatatt ttgtgttget gtggtttttt 37800
tttttttttt tttttacttt agcttggttg ggtttaggat cttttctttt tgttttgcct 37860
taggcatacc taagcagagg caagggagga aagggatatg aaactgatag aaaagtgagt 37920
aagctttatt cagatcagca tattcatctt aatatgggtc aattggctga agaaatatct 37980
caactaaaac tctggaatac tttgaagtac caataaaatg tacctaattg acattttatt 38040
tatgttttgt ctctatgtac ttgtgtgtga aacaatgagc acaataaatt cctcctttt 38100
ttttaagcaa tttatatttg tgatttaaaa ataaaaataa tgcaagtggg aagtcatgaa 38160
accccatgta aaacgaataa gagcatatat taaaatccca cagactttag tttcaaatag 38220
tgggttttget gtttcttagc tgtgtgtcac tgtgcaagtt actttgcttc tctgagtctt 38280
tatttcttta ttggtgatgt atgtaaaaac ccaccttctc gaattattgt gaggacaaaa 38340
tgaattaatt aacataaagt tcttggtgta taataagtg tcatattttg tatttgagca 38400

```

-continued

cagggcaact	gagtttttga	aactgcacat	taatgttgca	gtcaaatccg	gcatgaaatt	38460
agagagtga	tagacagagt	gggctgggaa	aatgaaagga	ctttgaacat	ttatatctctg	38520
ctttatttag	gcatcagtg	ttaataatta	ttgatagttt	cttctgggta	tctgacattt	38580
tgaagagact	attacctagc	agaaatttct	tgtaataata	atctcttaca	cttatatagt	38640
gttttgtgcc	tttagaagta	cttaatgctc	tttatctcac	tatccataaa	tattctctga	38700
agcaagcata	cagtcagtat	caattccatt	tttcagatga	gactgcaaga	catagagtta	38760
cttgtttcaa	ttcacatagt	aaagtgcag	tttgaaccag	agcccagggtc	ttctctctga	38820
acatagctct	ttttctcctt	cattatatca	ggcatagcgg	caatgtatta	ttttactagc	38880
tttttatctt	gaatatcctt	ttagtgcct	gcctttgggtg	ttagtgtgcc	tataacattg	38940
tcgttgaata	tcttaataca	tttagtggtc	ttagcaagca	gttttgtctt	cagaaggaca	39000
ctgaaatctg	tggaaaggac	tgcaagaagat	tgggtgggca	gatacctatc	actttctggg	39060
ctggtagact	ttctgttgaa	gctatttgca	aggctagttt	gtattatcga	aaagcactac	39120
ttcagaagag	ggttgtgatg	tcaaagtagg	cactttgagt	gaagaaaggg	ctgtaagcat	39180
gggtggaaaa	tgtggtagat	gattgtcttg	agttattttc	tttaatgtca	agcaggcagt	39240
ccttggaatg	ctattttcaa	aagtgttgta	taatgttgaa	gacacagtta	cagattttcca	39300
acacgaagct	cataaatctg	caattccctg	tcctcctagg	cacatgaagg	aaaatttatg	39360
agcttcaggt	ttctatgcag	ctattaagc	atatttaatc	tgctttgagc	tcaagctccc	39420
tctcatttgc	tctcttcgtt	tgttctctt	acatgagcaa	actgcctttc	ttttctttta	39480
aaagtagtaa	gtagatttgt	tttcctccag	gtgtcatgaa	tgcaaacatt	gtaatacttc	39540
atctgttagt	tcagtctttt	gcaaaacaaa	atggcagcac	ccaggagggtt	gaaagagtta	39600
aattgtttcc	ttctctgagt	ggtaaccata	gttgttagtc	tgctactctt	tctcccagtt	39660
ggcacatgac	gctaacatcc	aatcgctagt	gatgtggcca	ttttttgcct	tattttggcc	39720
tttctcagc	caccagtcct	cagttttcat	gcataattgt	cagaccctgc	ttctcctaact	39780
ccacagttct	tagttcatct	taagcaaatc	gctgtctttt	ctctaaagat	cctcaaggaa	39840
aataaaaagc	atctccaggg	ggaatttact	gcctcatagc	cctgacagag	atttctgacc	39900
aaaccctaac	caaaaaat	cttccctcca	tttgtctttt	attgttttta	cagggggagat	39960
atgtaacata	ataacaatta	tattgtacat	aataattact	tttacaata	ataatatctg	40020
tcatcaaaaa	tatacagagc	tttgatttc	cttagtatgg	cacttcatta	agttgtgggt	40080
taagaatagc	tatgattatt	acttttgtga	taattacgtt	ccataaatatg	gaaacttata	40140
aaattacctt	taaaatgtta	ctcttattct	ggccacagga	tggaaagatg	ttcgctagtt	40200
actcatttat	aacctgaatg	tactttttac	tgaatctaaa	ggatcatctt	ttgcttggca	40260
attcccatga	cttgtctttc	tgactcttca	gatctcagct	taaaagctca	ctcttcaaag	40320
aagccttccc	ctgaccactc	tggttttgtc	ttctnnnnnn	nnnnnnnnnn	nnnnnnnnnn	40380
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	40440
nnnnnnnnnn	nnnnnnnnnn	nnnnnnnnnn	nnnnngagtt	tatattttaa	ctcttagttg	40500
aataatctaa	gccagaat	atcaaccttg	ggttgccat	gagaatcacc	aatgaagctt	40560
taaaacagtg	acaaggctat	cccaatctat	tcattaatta	tctccagggtc	taaactttag	40620
catgtatata	cattttttaa	agtcataag	tgattcttat	gtatagccag	tgctatctgt	40680
ctcttctcct	gttctttccc	ctcctctcct	tactccttcc	tcatagtttt	aagataagca	40740
tggccccaca	acaagccttt	aattcgcatg	gcagtttcta	gggtttatca	tggaaaaatga	40800

-continued

```

gccaaattgc cttcaagaag tttttacgta cctcttatat agagtgtgac atttttatatg 40860
tacctcttat aaaatgtgag cttttaagag tcatacttta ttgcaagaaa tttcaatgtc 40920
gaaaaaagta ttgaatatatt ataaagtcac aaatacaaac ttttatatga ttctcaaacc 40980
tgtgaagtta tgtcatgttc aggccttctt taaagcatgt ggctctcage cctgggtactg 41040
tccttaacca taaacctcat ctttgccctc tatagggaga ggattgtgat tataattact 41100
cattttaaat aatgtatatatt agtaatgtac cttattcata tatttgttga gcacctccta 41160
tgtgccaaacc actatgctag aaatttttta atattcttca aaatcttcaa gatattaaca 41220
tatccccatt ttacaaatga ggaaactgct ctcaaagagc ttagtttaca cagccagtaa 41280
gctgctaagc ctagattgga tggagggtgt gtgagaaaaa aagcagcatc cataaggttt 41340
tcattctcct accctgtatg atagaggtag tagaaattat taaagaaaca atagaatttt 41400
acaagacttt aggaaggagg aatgtgaagg gtacagttcc cagttgctgg aatgagtact 41460
ggagtaccaa tacatggctt gccatggggt ttggactacc tatcttaact cctttgctcc 41520
tcccaatctt gatctcattt gtttgaaaga tcactctgcc aacataaaaa tgcatttcta 41580
attctgtaat ttaagtcagt ggcaagatca gattcagtta aagtttactt tcctgacaac 41640
tatttaggat gatattctatt ttgcaaaact ctagtataa atgtatgcac acttacacat 41700
catacagcgt ctctctgat tctgactaag atgtgatgga gctgtgcaga tgtgatgggc 41760
tctttggaag aaaggtttga tatactacta atctaaggac tgaattttct ctctcatctt 41820
tgtttttgtc ccttttgaat gatgatgaga gcagcagcac ataacattct tttgtgctaa 41880
cagtatctct gcacacatt gatcaggaga attggccctg gaatggtagt ttctcagttg 41940
attttcagga aagattaggt gattattttc tccataggaa gaggatgttt gatgtgtctt 42000
ggccttggca aaaggaagct tgtcgactca actgtaagta gatagaattg cctttgactt 42060
catctgttct agtcgttgtt catactcagg tcctccagaa ggcccttaag catttttatt 42120
gactttgtgg tctattacac aaaactaaag atactgattc tcagtcgtga gtctgcttca 42180
aaattgccta gagaatcaaa aataattgta ccagttcctg tcctggaca ttgtgattca 42240
tttggctctg tatgaaggcc aggaatctgt atttttaaaa ttcactcaag taatttttgt 42300
atatagctat agttatgaaa ttataacaat aatgaaataa taataatgaa taatgaaata 42360
ataatgaaaa tctgtggctg aacttgacca ctcccctatc ccctgcaata cttccccaag 42420
gtggcattta agatgggctc agaaggttat ataagatttg aatattaaaa catggattga 42480
cagtgaggac tttttgagag gtgacaatgt gctagcagcc ctggcttget cttggcacct 42540
cctcgacctt ggctgccact ctggccacac ttgaggagcc cttcagccta ccgctgcact 42600
gtgggagccc ctctctgggc tggctgaggc cagagccagc tcctctgct tgcagggagg 42660
tgtggaggga gaggcattgc tgggaaccgg ggcacggggc tcatgggcca gctcgagttc 42720
ctggtgggca caggctccac cgccctgca ctcgagcag ctgactggcg ccgtggggcc 42780
tgggcagtga ggggcttagc acccgggcca ataactgcgg agggtagcac aggtccccc 42840
gcagtgtctg cacaccaatg ccacgcttga attcttgag ggctcagct gccttcccgc 42900
ggggcagggc tcaggacctg cagcccgtca tgcccaagcc atccccctgt gggatcctgt 42960
gtgtgccaa cctccccaac gggcaccatc ccctgctcca cagtgcctgg tcccactac 43020
tgcccaaggg ctgaggagtg tgggcacgta gtgcgggact ggtgggcagc tccaccaca 43080
gccgcagtgc cagatccact aggtgaagcc agctgagctc ctgagtaggg tggggacttg 43140

```

-continued

gagaactttt atgtctagct ggaggattgt aaatgtacca atcagcactc tgtgtctagc	43200
tccgggttcg tggatgcacc aatcagcact ctgtatctag ctaatctggg ggggacttgg	43260
agaactttta tgtctagctg gagaattgtaaatgcaccaa tcagcacttt gtgtctagct	43320
caagtttgtaaatgcaccaa taagcactct gtgtctagct caaggtttgt aaatgcacca	43380
atcagtgcctc tgtgtctagc taatctatgg gaacttgagg aacttttggt tctagctaaa	43440
ggattgtaaa tgcaccaatc agcactctgt gtctggctca aggtttgtaa atgcaccaat	43500
cagcaccctg tcaaacacaga ccaatcagtt ctctgtaaaa tggaccaatc agcaggatgt	43560
gggcagggtc agataaggta ataaaagcag gctgcctgag ccagcagctg caaccactct	43620
ggtccacttc cacacagtgg aaggctctgt ctttggctct ttgcagtaaa tcttgcctgc	43680
gctcactctt tgggtccaca atgccttcat gagctgtaac actcaccgtg aagatctgca	43740
acctcactcc tgaatcagtg gagaccacga acccactggg agggatgaac aactccaaac	43800
gcgccacctt aagagctgta acactcactg caaaggctctg cagcttccct cctgaagcca	43860
gtgagaccac aaactcacca gaaggaagaa actctggaca tgtatgaaca tctgaaggaa	43920
caaactctgg agataaccatc gttaagaact gtaaacaccta ccacaagcgt ctgcagcttt	43980
attcttgaag tcagtggagc caagaacca ccaattccgg acacgttttc acatggagat	44040
aatttggaag aaaaacttgt aaaaatgtga gaacattgag aacttttatt ttccaaggaa	44100
agaagtggca gcttcatttt tggtcattgc aaacagcagt gccatacatg aaaggaaagt	44160
ggtggtgctc atcaacttag aacacttgag actcttttct gcttataaag aaaaagtgtc	44220
aactgtaaag ttgatttatt tatgaacctat aggtactat gaaatctctg ttcacagcta	44280
gaggcctggg agagtaagat aactacttgt ttattccatg aagccactta ctgtttcttt	44340
tctattgcac atacctcaaa tgaagcattt caatagaaga accacattct attcacttgc	44400
ttcattttat tctgatttct gtaaaaactc aaaaattcct caagcagtggt ttctttgcaa	44460
ggcaacaatc ttcagttctg ttgcaaaggt caggagtgat agaataaaaa tggtagtaga	44520
ttcaacagaa ctttgggtatt tgcattggta taacattgcc atggggctgc aagacttggtg	44580
agagcttgat attttgcttg ttgatgaatg agtctgtgtt ggtgctgggtg gagtgatttg	44640
agaggtagtt ttccactgtc aatcaagagg ttggttttga aagctgattg ccagtagtca	44700
ttctgctaac cactctgggt ctccctttaga tagagaccta ctcagattca agtctcatgt	44760
actttgtggc ataaacattg tacacaccag atgtattgaa caaccacaaa gaaaactatt	44820
aggactcaag tagtatgtca gagagtagtc actgatgatg tataattctc cacttccaag	44880
aagatgtaag cgcactgttg agtggctaca tccatcatat gttggccaga atttaggaat	44940
acacatgtgc tctatacatt ttgaggtact gcctgacccc tagagaatcc tggtagaagt	45000
tttctggtgt cagtttgggt ttaatgttta ggaaatgccc acagacgact cctgctttct	45060
gcttactcat gtagtaaaac caaagcacag gactagtttg tcttctggat caaggagaaa	45120
tgagttagca gatataaaac aaatcagaaa ggaagtagtt ctcacatatt taaccataaa	45180
tagttgctgg atgttcatta actctatagc aatatttact acttattggg gatcctggaa	45240
agaaaatata ctgtccatgt ccactgttca ctgagggtccc ccgcccacag agaaactccc	45300
tgtcttcac actcactctc cacattcatt gacctagagg aacagttcat ggatgagtga	45360
gagcttgagc tatactctaa aggatggagt tggatttcaa ggcaagaggt ataagagaaa	45420
attcagagac aatattgacc atggtctttg cgaagaaaag tactttggga gataagggtg	45480
aggaaaagta cgtttgaatc ttcattccaga ggtagccctc aaatatgttg actctgttga	45540

-continued

```

aagagtactt gacttgatt cagacagatc tgcatttgac tctgttttg ccatttataa 45600
gaacttgagt aattattgtt tctgaataag agtttattta gccaaagcact cagtaaatgc 45660
ttgaatgtga aaatttactg cctgtttttt ctattgtcag atgggtccct tccttgata 45720
actttgtaat cgttgataac cttttctcag gaatcagaag gtagaaggat tgggaaaata 45780
taagaaacaa aaaggcatat tcttattttt attttcatat tgtcttccaa ctctccaagg 45840
catcttcggt tgcaaggctg acttatctaa tactgtgttg gtagagcagg tctttctttg 45900
gttttccctt gtttgggtt aaactctgag taacgttatt ttctaggtct cagccaactt 45960
tgaagcgcac gaactcacag tagcctcacg agggtcactt cagcagttag aagttacctt 46020
tcccataaa aagtgaaga gtcgatggcg gccaggcgca atggctcatg cctgtaatcc 46080
cagcatttta ggaggccgag acgggtggat catctgaggt caggagtcca agaccagcct 46140
gaccaacatg gtgaaactct gtgtctacta aaaatactaa aattagttgg gcgtggtggc 46200
acacacctgt aatcccagct actcagaagg ctgagacagg agaattgctt gaacccggaa 46260
ggcagaagtt ggagggtgca gtgagccgag actgcaccac tgcactccag cctgggtgac 46320
agaatgagac tctgtcaaaa aataataata ataataagag ttgatagcaa aataactatc 46380
tgtagcgtaa acctcagtat tctttatcat tcagtatcaa cattattacc aaaaaacga 46440
taagcaatag ggactgagtt tctgtgggtt ggaaatgtga agtggatctt ggcatgatat 46500
aacttgatgat ttggttctt ttataaacat tatcaactac ctcagctcta tcaatcactt 46560
ggcagtcctt agtgaacatt ataactcaaa tgactagtcg agtctgttca ttgtccatgt 46620
aaaggcgtat acctgaagtg agaagtctga ggtaacttag caataagttt gcagtacagt 46680
gtttagttaa gtctgaaaat tcaaggcttc gagtcatgcc agattgctcc ataaccatag 46740
cctatctctg tcacaagtaa gaaggtttaa aaatcacata ccattattgg tcacaatgtt 46800
tggagatggg gaagagtttg tggatggatc atggcagtg atggacagtg attagccac 46860
agcacagcca gtgagcactg ttgtacccaa agcacgtaaa tcaccacata tactatcaat 46920
atatttatgg atgacaacag acactatagt tttatgtcag tgctttctgc tgctgaaac 46980
aaagttagtt aagggtacct tttgtatatt tgcaacatat ctccacacct gttcctttgt 47040
ctccttcttg caagttcttt ctttcagctg actatccgct gttcctacta tggtcccag 47100
tggcttttca agagggtgat tgttttttaa gagaagatcc ttgaaggaca gagaaagcct 47160
gaatcgttca aaataatgaa ttactcagga tgaaatttca ataatttga agtttgtgga 47220
gacagatatt ttggggaagc ataattttct atgtaccctt caaatcatgg ctggagatga 47280
cagcctcttc cacctccata taagaccatt tcatttcttt ctactttttt ctccctcctt 47340
cccccaaaa cacaacata cacatatcct gtgcttcagc caccagaac ttcttactat 47400
gtcttttcaa ttctctgttg ctttgcaggt tctgctcctt ctgcctagaa tgctccttc 47460
cttttcttac ctggaaacac cccaattcaa atgtcacctt ccttatttat accaactttg 47520
tcataaactc ctttatcaca cttctcttg tgattagtct attcacttgt ctgctgttac 47580
acctgtatga gagatgaaaa ttctctcttc atctctggaa ctcacgcctt tagcatatag 47640
tagacaatct gtaaatgttt gaagggtgag tgaattaatg aatgacctt aacctttcag 47700
gcttccaatt ttctctctga aaaggacagc taaatgaaaa ctcataattt tagaagatga 47760
ggtagacagg ttggtaggtg catgcagaga ccaattatta tttaggcatt atagaagtgt 47820
atagttcttg tatgttgagt gcagtgtgag agtggcccca aatatagtta atgcccactc 47880

```

-continued

cagaccagct	tattatagag	ttggccccag	ctgtattgct	tctatttaag	actgagataa	47940
gaaatgacac	tttccatatt	ttttacctta	ttgaaagggg	aggggctggc	tggtatcaat	48000
ctcagttcac	ttgttgattg	cattggcttg	ccaagtgaga	atattagcac	cctgcacat	48060
ttctatagtt	ctgccactta	tgagatcctt	ccttcccatt	gtcatattta	ataatcagga	48120
tagccctata	aaatatgcat	tcttatttcc	cagatgagga	tactaaggct	caagtaggag	48180
aacttacttg	tttagtaaga	tctgacaact	aggaagtggg	agaggcaaga	gttgaaccca	48240
gatcttccta	gctcccggta	catcgctctg	tctactgagt	cacactggag	cagccaggag	48300
gcaggaaaat	catctgggga	atgtggtgcc	aacgtgtgat	gtttgcctaa	atgtgtgcat	48360
ccttgctgga	agccagccat	gattccatgc	tgcataagta	ttcattaatg	ttcatttcat	48420
ttatttggtc	atccatatgc	tttccagggc	gaaggcaagc	taggacaagg	gcagacaagc	48480
agccttaaag	tttgggtgct	ttccttcaaa	gctgggctgc	ctgtttgaaa	atcaaacatt	48540
tttgtgata	gaagatgggt	ccagtacaga	ttttattcat	tactgcatct	acatggacag	48600
acattttcca	aagcatagct	gaaaatatgt	gtaagtccca	gaatatttcc	tgatttagac	48660
acagactttg	agcatgataa	ccacatttag	catgttagga	aattctgtca	gaatgcttct	48720
ggaaaggcta	cctttccaga	atgaaatgaa	aaaaaaaaaa	aaaaaaagga	tggaactttga	48780
aactgattag	atttgggtta	tactccctca	cagtgtgacc	ctggcaaatg	atttaactta	48840
tccgagtttc	actttttcta	ttctttgaag	tgaaatttta	aaatgtcatc	ttgcctgatt	48900
tttgtgagaa	tgaaaatgag	atcccacacc	aggaatttag	aagctactca	gtaaatattg	48960
cttctctcct	ttccccttcc	cgagtcctgt	cccccaagtc	attcattagt	tattcagagg	49020
catgcattct	gaaatctgcc	tactgtccca	cgttgaaatg	cactgctctt	gcaaagactg	49080
attatctatt	tttttgtctt	ccaaggcccc	ctgtgttcca	ctccaccctc	ccaattctgg	49140
gggcttccaa	agtgggcagg	tacagaatgt	tctgtggagc	atcggagggt	gttactcaat	49200
atcctggcca	gcactctcaa	ctgctctttg	cacatactcc	atatgaaggc	aaactccaga	49260
acttggaatc	catgtttgtg	tcattgcattg	cactgctctt	tttaccctaa	tccatctcaa	49320
gggtgagtag	accaagctca	gacttgtctt	tggagcagat	ttctcaagct	gcccatgtcc	49380
ccacactgct	tgattaaaag	gaggtgcttc	aaactctttg	gctttatata	gactagaagc	49440
agaatgattg	gtggtgcctc	tgtttctcaag	gtatccctaa	gcactttgta	aggaaatatg	49500
acaagcgctg	aggccacgca	ggctagtaca	acagccgcca	cccagcactt	cacaattagt	49560
catgcccagc	ctgggatcat	caagcctgtt	tttgttgaaa	gagcaagaga	gggaggggaat	49620
gctagctggc	aatttccccc	ggtacccttt	atgaaagtgc	ccttggtctt	tccaatttca	49680
cctgaataac	cagctcaggc	aaattttcct	ctatcaaaaa	gcagaacgtt	atagtgacaa	49740
gctgatgcct	ggctgatgcc	ccaggacatt	gaccaaatag	gcttggcctc	acaattgggt	49800
tttattcccc	atattccttc	ttcccttttg	ttctttttct	atgtttcttt	cccccatcgc	49860
catctgcaga	gtgtcctcag	tcagaagtca	gctgtggggg	ggacagtttg	tcatttaaaa	49920
tcattccctat	tctgtctacc	cttcttatcc	ctcacataat	tgcttttaga	gcaaggacaa	49980
ttctggaagt	gaaactacaa	taacaccctg	ggctcctttc	cctctagtag	tactcagcac	50040
acttgcaatt	acatgttcaa	atttgtcttt	cttattttctg	tttaggttca	tgaaggcaag	50100
ggacatgcct	gtgttgctta	ctttctcttg	gcaggcacat	atagcaagtc	ttcaaaaaat	50160
gcttgtaaac	tataaattaa	gtgtttaaga	agcccatcgt	tagtatcttt	gcccctgcct	50220
tatttgtaaa	caaccggccc	cttctatttg	taagttacct	tgttttgatt	tccatatccc	50280

-continued

```

ccaaagcaaa ctttagctca tggccttaca gagtgtgtat attagtatgt taaaatgaaa 50340
tcaactctcc tcccccaagc cttctaattg acatgaattt gggagttgac ttgcattggc 50400
ctttgtcctg acagccaaca gagtctctct ctggtgtatt cactggtggc ttccatgaag 50460
atgctatgga gaaagtttgc cattgacata cattttgagg gcagactcaa cctgagtaga 50520
ccggattgag ctttccccat ctgcctgcca gagatcacta cctgtgtgtt gctaaaaaga 50580
gaattatagg agtcctctca aggcagaaaag acctaaaatt agacatggca gccatgcctt 50640
tggtgtgtat ggggggtggga tacaggcagc cagtttcccc tctgttttct ccettgctta 50700
cacagccaag gagtggagcc aagcctcaaa gggaagagct gtatactgga gcatgccagt 50760
atacaggttc ctggccctgg ctgagttact attttatata ttccaataga gaagcataga 50820
agacttctag gttgccactg tcatttgaaa ttgggtattt taaaagaga aacttgaaga 50880
ctcaaagaaa gctttctttt gcctccctt acagttgatt tttagcttc ataaagctac 50940
ctagtccaaa gtaccacac tcttattatt tttgtcttct ctaccggtt tttttttttt 51000
tttttttttc atcttccag gtgtttgatg atcactaaga gcttcaacat tgctcacctt 51060
gaccaggtat gaaaccaaga gttttgttta aggcataaaa gaatgtagga actcaaggat 51120
taggttgaga tggggaagg ggtgaaggc ttcttttttc ttgggttaa cagaaatgac 51180
ttagatctca gagtgaaggc ctgaattgt cacatatatc actggcaaag actagttctt 51240
tgctatgata agaattgttc atcatctcgc ccctgaggat ttagggtaa gccctggcta 51300
caccttttga tgatctcagt catatgactt aacctcttta aagttaacct ttggtgagca 51360
ctgtgcccc tgcaacccca gtaaggccca acagggtctt ccaaggaggc aaaattctga 51420
tgatacattt ctgttttagtg aaaatgggta gggaaaatta tgtcttagaa tcaattaacc 51480
aaacataaaa tcctccaagg ggcttggtag gatgcctagg gaagagcaac gagataaaaa 51540
ctccaggctg gaagggcatt gttgcagcac tgctattctc cagtttctct tggagttgtc 51600
actacctct cctttgttct cactgctgac atcatttgta aaataatttc ttccataaa 51660
taaacaaaac gtacaatcct ctaaatgact aaagaacagt tatctagaag aacagtggaa 51720
agtattttct tcacctagg gatgattctc ttacagagg tggagtaaag gatgtgcgag 51780
gaggcataat caagctaaga gatgcatgct gacttaaaag gcatgacatg tgtgaaacta 51840
agataatgtg ttcaagagtg atgccttgtt gatgcagaac ccactgaatt ccttactgtt 51900
atgtttgact gactatcagc ttattaataa agaaattgtg gtttgagtgt tcattgaaat 51960
tagccatgtt aggtttatgt ggggatgtga ggatctatgt ctaccaattg cagcttctga 52020
tgcagattgg aggcagaaat ctggcctgaa caataagtaa gagtgtcagc tctacagata 52080
tctcacatgc taagcaagca caatataggg caatccaggt ttacacaaag gattaatttg 52140
ggaacaatta tcctcatttt cactttctta aacgattttg aataaggtct tttaagtaag 52200
aagctccctg aatgcattta aaatatggtt tgattatgta catttaagat ttttctacct 52260
ttgtaggagt atctctgttg tataaaaaa caaaattccg gaacttttga aaggaagatg 52320
tgctctctt catacatttg tcattcttga aagattgtaa aatgaagtga ctgcatatca 52380
tgctgtgttc cctattgatt tcttttctca ttttaggaat attcccagaa taaaaaaaaa 52440
ttttttttaa tctactaagc atgctaggta agactgaaga tgaatctatt taagttatgt 52500
caatatctat ttataaagat ttttgtgata ttctttttac tgtagaactt gaagcatatc 52560
ctaaagggaa tgggttagcta tgtctgcaaa ctgtggcaat gacttactga gtaattgcta 52620

```

-continued

```

gcaactgatt tttggtgctt cttgttttga tagtatagca gtgcgagtag gttttagaaa 52680
agcaaaacta agaaaatcca gggaaatgcc atttgagaat ttctaacttt aaaaaacaaa 52740
taaaatagtg tcaagaaaaa atattatcca actaacccca aagtctacaa tgtaactctt 52800
ttattttgat aatgctgttc taactctatc tacttcagtc cattgccatc cagctgggtt 52860
aggaatcaaa ttcccaatgt ttcactactg ttaacattac tgttttactc ttcagtttag 52920
ttcttaaatg gcatagtgtc ttaaatccc cagcctctt tcacgtttga tttctttgga 52980
aactttttac cttttcattg aagcccatat gatcttttct gaaacagacc cttatcttta 53040
ccttctctct tggagtcttt ctctactctg aatttctgaa cttcttaaaa tggccgcttt 53100
ggattgggtg aataaatttt cttttcttct tttctttcct tttttttttt tttttttttt 53160
tttttttgag aaggagtctt gctttgtcac caggctgcag cctgtagtgc tgtggagcaa 53220
tcttggctca ctgcaacctc cacttcccag gttcaagcga ttctcctgcc tcagcctccc 53280
aagtagctgg tactacagga gtgcagcacc atgccagct aatgtttgta tttttagtag 53340
agttgggggt ttaccatggt gcccaggatg gtctcgatct cttgacctca tgatctgcca 53400
ggctcgccct cccaaagtgc tgggattaca ggcgcgtgcc actatgcctg gccagtaata 53460
agttttctta agtgctttct taatgtctg atattttaaa aaagatctgg actattttgt 53520
catacaggca acagaatggt aaaccatttc ataaagcaat gacaaatata catgattttt 53580
catcagttat aaatgctttt cttttataac attgaacatg tttttgcaac tgaataaagt 53640
gtgattttca tttttagaag gtacatgata aagttaaggc agtgggtaat taattttttc 53700
agattaattt ttcagaaaag tgactgttct tgtctgttca cttaacccca ggcacaaaac 53760
gactttaatc agaaaagaact gaagagtaat ttggttattt tagtgccctt ttttgaggca 53820
aagtcttatt ctgtcaccca ggtcggattg cagtagtgtg ctcatggttc actatagcct 53880
cgatctcctg ggttcaagt atcctccaac ttcagtttcc cagataactg ggaccacagg 53940
tgggccccac actctctgct attttttttt ttttaatttt tcatagaaat ggggtctcac 54000
tatgttgctt tggtgtgtct caaaatccta ggttcaagca atccttcac ctcagcctcc 54060
taaatgtctg tgattacagg cgtaaagcac tacacttgcc ctattttaga gatttgtcaa 54120
gctttgaaa gagaaccatt tacaatataa taggtaaatt atggatattt gaggcagttt 54180
ttatcatagt attttagta aactacagcc cccctttat aatatgtgta ttttaataaaa 54240
atgaaaatat tacttttctc ttgaacaaca aacataagtt ttaacaaagc aagcatattt 54300
agattagcac taataaccaa acgaaaacct ttataatgat agctgttttt aacatgatta 54360
caaaaaatc gctacacaaa tttttatcct aatcagtgtg aaaaacggaa aatattagct 54420
tatagggcc aactagtctt cagagtcctc ttcctacct ctactgctaa taagccaatg 54480
aaaaactccc tgatgtgtgt ggtggctcag gcctgtaatc ccagcacttt gggaggccaa 54540
ggtgggtgga ttgcttgcat tcaggagttt aagaccaacc tgggcaacat ggtgaaactt 54600
tgtctctact aaaaatacaa aaaattagct aggtgttgtg gttcacacct gtagtctcag 54660
ctactcagga ggttgagggt gggggatcgt ttgagcccag gtggtcgagg ttgcagttag 54720
ccgagatcac aggactgcac tccagcctaa gctacaaagt gaaacctgt caaaaagaaa 54780
gaaagagaga gaaaaaaga gagagagaaa gagagagagg caggcttctc cgctttttca 54840
gttctgaat aattttccaa tctagaatgc aaaagattct gaaggaagac agttaccatt 54900
tcagattggc agaagtgtg actttaatct ggacttgaat atgttttaca tcaaagggtt 54960
gectcaacag tgctcaaac tgctctctg aaaacatgct gagcgcaag gttacttgaa 55020

```

-continued

gtcttagctt	gagtacttaa	gagaatgcta	tgaggaggatt	gttgaagaga	gctgtgtcac	55080
agctaattct	tctttagtaa	ttaaagggtt	agaaaactct	tacactgcat	attgacaaat	55140
ttagcaacaa	aatgagcttg	agaaaaaat	caaggcctgc	tgtggaatct	ttttttttt	55200
tctctaaaa	aaacaaacaa	acaaacgaaa	ccttttttaga	aagattatgc	aactgtatta	55260
tctgtacta	ctgcaatagt	gtaaattctg	atagtataat	ttgcttttta	aagctatctt	55320
tacttcagtg	caacttagat	taaatttatt	ttaaatttaa	acgatatatt	tctctttgtt	55380
tattatttta	tagtaagttt	cccatagaat	tcacaaaatt	cattagaaag	attttctttt	55440
ttttacttcc	ttaggtcatt	aagtttctga	tttgtcagtg	gatttcacag	aaacctgtc	55500
tttccaaaa	tatacaaaaa	aaaaaaaaa	aaaaaaagcc	aggtgtgatg	gtgtgtgcct	55560
gtagtcccag	ctactcagaa	agccgagttg	ggaggactgc	ttgagcccag	aagttgtggc	55620
tgcagtgagc	tatggtcaca	ccacttcact	ccagcctggg	caacaaagcg	agaccccatc	55680
tccaataaat	aaataaacaa	ataagtaaaa	agttttttcac	cttgaaaagc	ttataaacat	55740
atgaaacacc	attaggttct	ctgatatagt	ttggatgtgt	gtccccgccc	aaatttggtt	55800
ttgaattgta	atccccagtg	ttggaggtgg	ggcctgcggg	gaagtaattg	gatcatgagg	55860
gcagtttttt	catgaatggg	ttagcaccat	ccccttggtg	ctgttgtcgt	gatagtgagt	55920
aagttctcat	gagatctggt	tgtatagcac	ctctccctt	gctctcttgt	tctgtcttcc	55980
accatgtgac	atgcctgtct	ccccttcacc	ttctgccata	attttaagtt	gcctgaggcc	56040
tcccagaag	ccgagcagat	gccagcacca	tgccttttgt	acagcttgca	taacctgag	56100
ccaattaaac	ctcattttta	atataaatta	cacagtctca	ggatttcttt	atagcaaggc	56160
aagaatggac	ttacacagtc	tcttttgtat	cagggagaag	gtctcctggg	tgactccact	56220
tcttttcttg	tttatgtatc	cttcacagtg	atgtatttat	ttcctttgtt	tttcaattga	56280
tatttactct	taaattaaac	taatttatta	ataaaaagca	ttttaaagtc	tcatttttaga	56340
ttattttgac	tatctgattt	tttaaattga	gtaaaaaaa	tctaccttgg	cctccatatg	56400
caatcaagca	agaaacacat	tttaagcata	ttatttgcc	tgtggattct	gccttcctcg	56460
atgtgttcag	tctgtatata	ttcattttct	ccacactgta	agaagctagt	cagatgtata	56520
attggattat	catgctacat	gatcttagca	cactcatttt	aagcttacat	agactagtga	56580
gcaccactca	ttacatgtca	ttctcttaga	gaaactagtt	gggccgtggc	tgaggactc	56640
tcacttgaag	agacacatgt	ggatgatgtt	tctcaggcag	ttaagcaata	aagtgtacct	56700
tgatttgcac	tgaaaataaa	gattccttta	aaggagcag	ttctagtatt	ctctctcttt	56760
agataccata	tgctaaacgt	ttttctatgc	actaaaacaa	taactagggt	ttatactctg	56820
ccttacagcc	tacttcacac	ccatttcaca	gggagaggaa	cagagaggta	agtgatttgc	56880
cccaacttac	ataactagga	agttatttac	tcagtgtgga	aacttggtca	gacggtcatt	56940
tcattgaaat	gtaggaagag	ttctctggc	ttctcttgag	caggagtcaa	aaactctctt	57000
tttgactag	cccagatagt	aaatatatta	ggctttctgg	gccatatggt	ctctgtcaaa	57060
actcctctac	ttgtttgttg	tagtgcataa	gcagctatac	acaatcctga	aatgaatggg	57120
tgtggccgtg	ttccagtaca	accttacaga	aaaggcaata	ggctggattt	ggctctgaga	57180
ctgtagtttg	ctgacctcag	ctcttgaa	gagctcttta	actgacctca	gctctcgaa	57240
tatggtccaa	gateccgtgg	tctgttttgg	tacctccatt	tgcctcctt	ttactctct	57300
gggagcatag	ctaagttcaa	aattgaatta	ggtacttgta	gtaagagtac	acttataatc	57360

-continued

ctgggatctt	catgttgcca	gatattaacc	tcttgaagtt	tatcaccaca	gcctgggcac	57420
ttttctgatt	tgctcacttc	tagccccacg	tttgggcccc	ttcacaagca	aacatgcaga	57480
ttttccagag	agctgtatgc	tactgaatgt	agaaaatttg	gctcatactg	gcctatggac	57540
tatctgctca	ctgccctgat	aactattttc	caagggagtg	ggtgccctac	ctttcctaca	57600
cagagttttt	ttgctagtct	cgccttaaaa	attctaggtg	tcccttgctt	ttaggataaa	57660
tatgtttcac	taggaccagc	cgaataatga	aaaatagagt	tatccaacta	ccactttaaa	57720
actggacaag	gatttttggt	gctgtgtgtg	gaggggggtg	taaacatcat	tttggcagac	57780
caaatatact	tttgggtgaa	ggcagccttt	tgcaagaca	gaacacttgg	acaagatttt	57840
gaagtctctg	ttgcctttac	tactgattta	actacagtat	ttgtggactt	gggcaagtca	57900
cttccttctt	gtgagcctca	ggttattcat	ctttgaaatg	agtataatac	ctgtgattat	57960
aattacttct	ctggattctg	cagagaactg	aaggagataa	tggatgtaaa	agtactttag	58020
tgcccagcac	tgctccttat	gaaaaatgag	aaataattga	gatgagtggg	ccattgagac	58080
aaccgtacaa	aaagtgtcga	aaactcactg	cttaaataag	cacctcttac	tgcttttgtg	58140
gcactttgta	gcaatgtggt	tttattctga	ttagaaagta	atgtttgggt	ttgtttggct	58200
ctttgctcag	taaaccata	ataaggatac	ctatttgccc	tggaaccatc	agttcaaata	58260
ttattttact	aatatggaat	tatttggtct	cagaagccac	agttttctta	gctgctcccc	58320
atccccactc	tcacctcaaa	tttttttttc	actttatttt	ttttttcttc	tcagggaag	58380
gtttgaggca	aaaaaatgcc	ttcttatgat	ccaaaaccaa	gcatgggtgt	gatttattca	58440
ccaagcgatt	cctgagtacc	tgtgtgatgg	acatggtaga	atctttgtcc	tgatccatgc	58500
cttctgatat	gcagccagta	gccacttgtg	gtaatggagc	aacagaaaca	tcactagttc	58560
aagtggaaat	gtgagatgag	aagtaggagg	tggagagaac	taaccagaag	aggggtaccca	58620
aataaaccag	aaataggat	ttgttagaga	aggggcctat	tgagtgggtg	gcagtgggat	58680
gtgtggcatt	acttgcctct	gtattctctg	ctttttactt	agttgtggct	ttggtgggat	58740
agtctcagat	ctctaagtta	tgcaggtaat	attgttatgt	atcatgtttt	ggcaatgtag	58800
actgaatact	tgctcataag	agtacaggac	aatgaagata	gtttgggttt	atttactgca	58860
tggaaagtac	aggatgttta	gtaaacagat	ccatggcata	gtgagttcac	cactaaaatc	58920
agactctgag	aatgggtttg	atttagatgg	ctagttaga	atactggatt	caggccactt	58980
gattaagaaa	ggccattttg	gctaattata	agccaccaac	attgtgtttt	caatgttaaa	59040
gcttatattt	gtcttccagt	taccagaatg	taagcttctt	gaggaagaaa	agaggagttt	59100
tcttaatctc	tgaacctata	cctgtctttc	ttctgtgtct	agcccagtgc	ctggcaccaa	59160
acaggtgctc	aatcaatggt	gattctatgc	taccaacaaa	aatgagttca	tgatgtttac	59220
tattcgataa	atgaatgcaa	ttttagagtc	aatttttact	acttacacta	catgtagatt	59280
ttctttttag	agatttcaca	atgctgattt	ttttcaaaat	aagcttgaag	ctaagtgaca	59340
aagctgaatg	atgatttggt	ttttattttt	aattctaaac	ttacaatttt	ccatgtcatt	59400
gccagaaaaa	tcattaaata	aattatgata	tactcatatg	gaatactttg	caaccattaa	59460
atcaaccatt	aaatactatg	caaccattaa	atcagccatt	aacgtattta	atggctgatt	59520
taatgggtgc	atagtattta	atgggttgatt	tgcacatttg	catataccaa	catattatat	59580
agttgagtga	gaaaagttag	tttcaaatga	ctatgttaat	atccccgtac	tcttgcaaaa	59640
agaaaaccat	acatttgaat	gtacgtatac	gcgtatgttt	atacgtgcac	agaaaaagct	59700
atggggggat	atacctcaag	ttgctaaaag	tggctccacc	tggagaggga	catggaaagg	59760

-continued

```

agctgggctaa aaactgaggt ttgttacgtt atacaccctt gcacagtttg atttcttaaa 59820
agcgatgatt ataaattcct tttgttattt ataaaaatat tatttaaaac tttggtacta 59880
aaaacagagc tccatcaaca gatcaatgga taaagaaaat gtggtacgta tatacagtg 59940
agtactattc ggccataaaa aatgagatcc tgtcattttt acaacaaaat ggatggaact 60000
ggaaattatt atattaagtg aaataaggca ggcacagaaa ggcagacatt gcatgttctc 60060
atttaatctg tggaatctaa aaatcaaaac aattgaactc atggatatag agagtagaat 60120
gatggttaacc aaaggctagg aaggatagtt ggtggggcag gggagggtga ggtgaggatg 60180
ttaaatgggc acaaaaaaat agaaagaatg ccattctaac tgggtgtgaga tcaggaaaca 60240
acaggtgctg gagagaatgt ggagaaatag gaacactgtt tacactgttg gagggattgt 60300
aaactagttc aaccattatg gaaaacagta tggcaattcc tcaacgattt agaactagat 60360
gtaccatatg acccagccat ccattattg gggatatacc caaaggatta taagtcatgc 60420
tgctataaag acacatgcac acatatgttt attgtggcac tattcataat agcaaagact 60480
tggaatcaag ccaaatgtcc atcagtgaca gactggatta agaaaatgtg gcacatatac 60540
accatggaat actatgcagc cataaaaaag gatgagtttg tgcctttgt agggacatgg 60600
atgcagctgg aaaccatcat tctcagcaaa ctatcactag aacagaaaac caaacaccgc 60660
atgttctcac tcataggtgg gaactgaaca atgagatcac ttggactcgg gaaggggaac 60720
atcatacact ggggcctatc acggggagag gggagagggg agggattgca ttgggagtta 60780
tacctgatgt aaatgacgag ttgatgggtg ctgacgagtt gatgggtgca gcacgccaac 60840
atgacacaag tatacatatg taacaaacct gcacgttacc cactgtacc ctagaactta 60900
aagtataata ataaaaaaaa attaaaaaaaa tagaaagaat gaataagacc tactatgtga 60960
taacacaata aggtgactat agttataatg atttaattgt acatttttaa ataactaaag 61020
gggtacaata ggattgattg taacacaaag aataaatgct tgagggatgt atacctcatt 61080
ctctataatg tgattagtac acattgcatg cttctatcaa aacatttcat ataccata 61140
aatatataca cctattgtgt actcacaaaa atttaaaaaa aaactgtaca ttaagaaaaa 61200
acaaaaataa aaactgtagt tcaagttata aacaaaaata aagtaatttg gagggaaaact 61260
atcttcagtt atattggata tttgggggac atttttgtat gttagttagc aaaaatcact 61320
tgaaaaaaag gattcttctt tccatgattc aaaggagcat agcaaaaaat aaatgaaata 61380
aaataaaata ataaaaagag aaaaagaaaa ttattccata aattctactt acttatttct 61440
ggcaaaactg ttgacagcac atgtgacctt tttggtaaaa agacatatat ttatatattt 61500
agttaagttt caaatataaa ttgtttgtgt ttttaaaata aattaaatgg atgacttcag 61560
ccaggtcatc atgaaaacac atgagatatt gggttatgca atgactaaca gtgtgtacgt 61620
tttcttggtt ttattcataa aactggggaa taaaaaact ttttggtcga ttactcccc 61680
aaataatttt atgtctccca aggagaattg taagtgttt gatagtaaat gctatgtatt 61740
ttgtatctta gtgtatgtat gggatttcag cgtagaaga gctcttaaat gccgtcttca 61800
tagtccaacc tgtcttctga tgettgaag ccccttgcaa taggaaatgc aaagtagaga 61860
gtagatactc aataatgtgg ttattgaatt atttagaaag aggcattttg agcccataat 61920
gtacaatagg tacttctaga ttattgttt tattctttgc agagctgcag aaaactaaga 61980
aaaaagttta ttcagattc atgtgtttat ttgattaatc tcttcataag ttctattttt 62040
cagctcctgt cagaaaaatac agattcttat aaggttcacc tttaccata agaataatag 62100

```

-continued

tataaaaggg	ttaatgtgaa	atacaatcac	ttcacagact	gtttcaatta	aataagagct	62160
cgtagataat	tcagtcacc	cccccatt	ttacagatgt	tgaaattgaa	gccccacca	62220
aaagtaaaag	acttgctcaa	agtcacacag	caagtcagtg	gtgagcctaa	ttaggcccc	62280
tgcttccat	tttggtgaga	ttcctgtgct	gatagtcata	cccggtcaa	atcctcttcg	62340
gcagttatgg	cttgcccaca	gtaatgtgtc	ctgaaaaata	tgacaataaa	ttaagttgga	62400
gacagaacca	taacctcttt	ataaaaatgt	tctggaaagt	ttacatgaca	gtacgtaata	62460
tataattaga	aaggataatt	cttatttcat	atttatcttt	ttgtttcaga	ataataaact	62520
aagctatctc	tactcagtc	attttaatac	aaaaatattt	ttaaccagat	tgagttttta	62580
tgctttttag	gaactttttg	tctacctcac	ttaattaaaa	tactagctgc	actaatcact	62640
tactgtggta	ggcagaattc	tagaatgacc	ctgattacct	tgctcctgta	tgattccttc	62700
ctctttaagt	aaggatagaa	actgtgaata	tgatatcact	cccatgatta	agctttgtta	62760
catggcgag	ttaacttta	gaaaggacca	gtcacacaag	ccatttgaaa	gcagagagtt	62820
tgggattttt	ttaactgggtg	acagaaagcc	acgcagagat	ttgaacattg	agggttaatt	62880
gaatttgata	tgccagtact	aacttgaaga	tagaggaggc	tgacagaaa	gtggccttta	62940
ggaatgatcc	ctggctgaca	gccatctaga	aaatgagggc	ctcagacctc	cggccataaa	63000
gaattctgtc	aacgaacttg	aacttgaag	tggattcttt	ctccagaact	tccatataag	63060
agtccagcct	gattgacact	gtgattttgg	ccttggtcga	ccctgagtag	agaatccagt	63120
tgacttctga	cttaaaaaaa	aagtaagata	ataaatgagt	attgttttaa	actgctaatt	63180
ttgtgataat	ttgttacgca	gcaataaaaa	ctaataatatt	taccatacaa	gtcaaggcat	63240
ttatccttct	atgattcagt	ttctttttac	ctgacataat	ggaattaatt	tatactgttg	63300
tgaaattgta	gttgagaaac	acgacttcca	aagtaataaa	atacatgtat	tattaatttt	63360
aatagtatta	atagtaatga	tactgattct	ccgaggccta	tacaaatcct	ttgatacaca	63420
aatgaatagt	aaaggaacat	aagttgtctc	taggtaggct	ttcccacaat	gcaattttac	63480
gatacagaag	tcatatgctt	attattctac	tatggcagag	aaaataagga	gcctggaaaa	63540
ctgttcattt	gcatcacata	catcttaaga	gctcactctg	aacctggtac	cttaataagc	63600
tctgtagaca	gtataaagaa	gaaaggaatc	agacatggtg	tctgacctca	ggtgtctcat	63660
aatggagtag	aagaggtaaa	atatgggtca	cactaactct	actgctaaat	agggaagtgt	63720
cgttgccctg	agattgacaa	aatttgataa	gagttcagag	gacattttct	gtgaactggg	63780
ccttgaaaaa	taggatatga	gtaggagaag	atgaagaagg	aaggcattcc	agctagagag	63840
aagagcacia	gcaaaagaat	agataacctt	gaaagtcac	atatgggata	attcaagagt	63900
tcagtataat	ggaagtataa	gatgcataaa	aataagtgtg	gtaggaaacg	agtttgaaag	63960
tacagattgg	ggtttgcct	agaaggcctt	gaatttcagg	ctgaggaggt	ttaatatata	64020
catttgtttt	tgaacaaagg	ggtttaactga	tcacatctgt	gatttagaaa	gaaaattcta	64080
gcaatagtgt	agataagggt	tgatggtaaa	gtttggaggg	tggtgaggca	gagactggag	64140
acagggaggg	catttaggat	agaaagatga	tgaagagatg	atttagaaga	gttggttttg	64200
aaaaggagga	gagagaaaat	gttttagatg	gtgcacagag	ataaaatggg	catggcatgg	64260
tgcaaggagg	taaagcccaa	tagctttgta	aggtgctgag	atagattgaa	atcacagagt	64320
taagaagttt	tagaatcagg	attagtagca	agacagcttg	gctctagatc	tcatacttaa	64380
ccattatggg	ataatcctga	gaggggtggg	aacagcaata	gtcagaggaa	agaacccttt	64440
tatacatgat	ggtacaggaa	cagcactgtc	ttccaacccc	acagctgctc	tttaacagaa	64500

-continued

```

ggtcagaaac tggggagaaa ttgtgtgtgt gtgtgtgtgt gtgtgtgtgt ctgtgtgtgt 64560
gtgtgtgtgc catttctgga actaaggatg ggaagtagat tagatgaggc cactgcagtg 64620
gagtctgcaa gttactagca ctcaccogtt ccaagaggcc ttaaggggtg tgacctgttc 64680
cctgggcac accacattct acaaatat tatctctga gagaataggg tgattcaatt 64740
tcaactgtgt tgaagggtac ttttgggggt catgtttgtt tgttctaact ctatgctaatt 64800
gatctgccaa ctgtttgtca ctttctctaa cccttaggat gtctaaactg atctgttggg 64860
aatgtgttag catttacagg atggtaggat ttgtaacatg cgatcacagg gctgtctata 64920
tagagtcctt ggggaagggga gagaagagta tttctgttac aaatgcagat tcctagggcc 64980
ctcctcaaac ttactgaggt tcaaggattg atatttataa taagcacata tccattttca 65040
ataagcatga aagtttcata cctctttta atgtttgaaa tctcaataa aattagtcatt 65100
tgatgccaga gtattacata attatggtag agaatgtgtt tctctgaatg acactttctc 65160
ccagagattc tgatatatat tctctgcac tcacctgtt tgataattac cagtatatgg 65220
accatttacc tgaagaataa gtagtaggtt ttctactatt gttgaaaatg ttctcgactc 65280
ttaacaactt gtgtgtgact gtaacaagat cacacagggt aaacagtatt agcttattca 65340
accactggct gaagaaatgt aggaaagtga acacattttt ctttacattt ctctttgttc 65400
tgtgagcctt ttatgtgga atagttttca ctgcaggctg ttattgtctg ccccgagagg 65460
agggagttga cctagcgatg gtaactggag agtggttttt gaaacctctt tcctaggttg 65520
gttgccaatg gcattcttgg aacagtgtcc ttcactttag tccctcaggg accagtgtga 65580
gaatgggaac tttatgatct ggagctgggt aagtgaagtc caaaaataat taggaaagtg 65640
tttcttccc tgggaatgag ttcagtagga atctcaatat attgtagagc acgaaggact 65700
cagcatcagg catttgcaa ggattcttcc agttgcctgt gttacagagg acacagttag 65760
aatctcttt tagtgttag gggagatgtg tacatgattg tgagatgact caccctttt 65820
gcttagatgg ttccactttc attgtggaca gactcttgg agggccaggt tggoatgcac 65880
gtgtgtgttc attcatcct ggagcattct ttatgagaaa gccatttgtt gagtggtttg 65940
ccattttgtt ttacagccac tctgtgggt atgaaatggt catctggccg ctttatttgt 66000
ccctaaaaa gcagtttttt ctttcttat cttcaaggct gccaaagcag agaaagagta 66060
actcagggaa gccatgtgat agccttttat ctgtctgttc agaaactgat gatgtatcgg 66120
atttgataat tcatgaaatg tgaggtttac tggtttgcatt tgccctcaa atgggcattg 66180
aatattttgt caggtaacat aatagataat tggcattgct ttattgaagt gaattaattc 66240
aataagccta taagtgcctg acatgtgcca ggcactgtgc taggcattct gttaatagat 66300
gagacaaatc tctgtctttt aggtgttttt agtcaaccag gggagacaaa acacctttaa 66360
aaagacaaaa acacttttta aattgctatt ttaaaaaaa ttcatagtgt acgtgaatat 66420
aaggtgctga atatgtgatt gattctgagg gaaaagagt ataagggaaa attctcagag 66480
aaactcaagc tgagggaaga aaaggacccc agacagaggg actaggctag agctatgcta 66540
ctacattgca ttaaggggaa tggcacatac ttcactgttg cttcagcaga gagcaggcct 66600
gtgttaggtt acaaggggcc ttggatgaca tctgtgggg ttttaaaatt ttatttaatt 66660
tttaattgac aaaatataat tatatatctc agtggggtag aatgtgatgt tatgatgtag 66720
gtatgcaatg tagaatgatt aaatcaagct aatttgcata tttatcatt cacatactta 66780
tgggttggtt acaacattta aaatttatc ttaacaattt tgaaatagac aacacattat 66840

```

-continued

tatcaactat	agtcaccatg	tgtgacagat	ttcaaaaact	tctaacaaaa	actttttgcc	66900
cttcgaagat	attgaacttt	gtcttatgaa	catagtctta	gaaggattta	aaaaataatt	66960
tgctattcac	tgagtacttc	ttatgtacac	tgtgcatgaa	atgagtatta	ctttttctaa	67020
tattagtttt	cttgattgag	gcttggaat	tattagtttg	tatgectgta	gaaggattat	67080
aaacagaggt	gtatcccagt	aggatttgca	ttttagaatg	atgactgcga	gtaaaataca	67140
gagaagtaaa	accaaagata	gtgggatcat	tcaggagtct	gtttcctaca	ctgaacagta	67200
gttgagcaaa	aaaaggatgg	gcagaatgtg	ttgcttctgg	gtactgcaaa	ttcatggcac	67260
ttgaatgaac	aagtttaagc	cttttattgg	ctctttgtgc	atatcttcaa	catgtatgac	67320
tacaaagaga	ccacacgggt	ttgttgttgt	tggttgttgt	gttgtgttgt	ttgttttate	67380
tgaggtggag	tttactctt	cttgcccagg	ctggagtgca	atggctcgaa	tttggtcac	67440
tgcaacctcc	gcctcctggg	ttcaagcgat	tctcctgcct	aagcctcccg	agtagctgga	67500
attagaatca	tgtgccacca	ctcccagcta	attttgattt	tttagtagag	acagggtttc	67560
catgttggtc	gggctggtct	tgaactccca	acttcaggtg	atcctccgcg	ctcagcctcc	67620
caaagtactg	ggattacagg	tatgagccac	cacggccggc	ccacacggta	tttttgaaag	67680
aacagtgagc	ttggaattag	aacactagtg	tctgggccct	ggtgctactg	cataagtaat	67740
tatgaatcca	tagccatctt	gttgctcttc	ttctctaagc	cttggtttct	ttagctataa	67800
aatggaaagt	tgaacttttc	tagctacttc	tttgagttat	gagtaacaag	ttaggtaata	67860
cacttgaagg	agaatgtgct	atacaaatc	tggttcttaa	gacagctggt	gttaatgtac	67920
tgagtattat	gcttacctca	cagggttggt	gtgagcatca	aatgggataa	tggatttgaa	67980
agcattttgt	ttaagtgtg	attcaaatgt	taagaattag	taaaaatagt	aaaagagaac	68040
aattcattct	ccatccagat	gttcctgccc	cacttatgtg	ctcattcaga	gttgtagaca	68100
aaaacctcca	cgtaattttc	acagactgga	gttccacatg	taacagaatc	atatgggacc	68160
aaaaaagctc	tctattgact	tctttcctgc	catattttgg	ctctgggacc	aacaagacac	68220
ctatttttca	tgagctgctt	gccaccaact	ttgggctcac	atctagtctt	gttgcccatg	68280
tgcattgctga	atttgggccc	atgtccccag	atctaactg	aaactcaagt	ttccttctgt	68340
tcaaaactgtc	caggcataat	agtcttgaag	tgtgatgccc	aggagagctg	tagatttttc	68400
actgtccaaa	aatcaacatg	aaaccagatg	tatctgtaaa	tctagtttca	tgccactttg	68460
tagtcaatgg	aaatacacta	gcaggcagac	aagaccagag	tttactatct	ccagcggaat	68520
taatagccac	atggaaaact	tgcccttggg	atctgtgaga	tggagataa	aggtgagaaa	68580
tcaaagcagt	tcccactcca	tctctaaat	tccaacataa	agaggccttg	aatatccttc	68640
tatcttattg	tatatttcat	taacagaagt	atgttcctaa	ttacttagtc	attctatctc	68700
cattctcctt	tgttttaact	tcagtgggtg	cagggttaaga	tgtctgtggt	ttcagctttc	68760
atggagcatg	gcattgtttt	aaacttatct	ttaaggacag	gtatgttggg	aagatcctag	68820
ttcctcatct	ctttgctcct	ggcaaggaaa	tttagaattg	cctaaagaaa	agctgtattg	68880
gccaacataa	taataaatca	gtattagtga	atctaaagcg	tattggagaa	ctttgtaaca	68940
tgagttgaaa	ttcagacctg	caatgaagtt	tttttaaaag	attttaaatt	gaaataataa	69000
aaaaaaagtt	aaaaacaagt	aaaacatctc	agtagttaat	cattctacca	aaatttggtt	69060
ttacgtttgc	atattttaacc	atttttatct	tctgtatttg	tccatgaaca	tgtgtttttg	69120
tatattgttt	atattaaaca	tggttttaat	catggcttat	ttcttttatg	ttttacttct	69180
tttcttttga	cataaaatat	tgtattttta	aaattttaac	tgcttcttgg	tataccattc	69240

-continued

caatataggt	ggctacatag	attgaagtta	aaactaatta	caatcagaga	aaattaacaa	69300
ttcatccctt	cagtcctcatt	agtcacaagt	taaatactca	atagccacat	gtatctagtt	69360
gctaccgttt	tgaatagaac	agatataaga	catttttcac	aacacagaaa	attcagttgg	69420
aaagtattgc	cctggagtaa	atgtgccata	ctgtactaaa	tcatttttct	ctgtgtggac	69480
atctaagtta	tttcttattt	ttttaatatt	ttatataact	tgacggtgaa	tatacatag	69540
tacatagcta	tttgctttgc	tgaattattt	cttagaatca	atttcaaaa	tgaggttatc	69600
aggctcaaaga	gcctgagaag	attttttgga	acctgtagtg	tattgccata	gtcctttcac	69660
aaaagtttat	gtcaacttaa	agtacttcta	gcagcaaatg	attgtactaa	ttcctgtgca	69720
atctcaacaa	cactggacat	tataagtttt	tattctaccc	tattttccat	taaaagataa	69780
cttatgcttg	attgactttg	cattttattt	tattattaat	aatgttggtg	tttccctttt	69840
ctgattttat	ttttagttaa	ggatccctt	aattttaacc	tgatattttt	ctctaaaaat	69900
tattctaaga	aaagacaaag	gtgatgtcaa	atatatcctg	agttttcatt	ttttcttgca	69960
tggaatttgt	atattttgac	ctttgccc	ttatattatg	atttcttagt	gtcttcctca	70020
tcaattttta	tgaagatttc	atatatatca	atttttccac	aaatataatc	tttttaaaaa	70080
tatatttttt	ccacgatata	attctaattg	attctccgaa	atgttgga	aaacttaagta	70140
gtcatcaaag	catttgaa	ttttttaag	gttgttttta	taccagtctt	aaatgtta	70200
ttaagggctg	taaaaagagg	tgaatttaa	atcatttttc	agtaaggggt	aagaccattt	70260
aactcttgga	aaatacagga	aacatgtaga	tttctagagg	ccaagaagga	ggtagggatt	70320
aattattttg	taactgccc	caaccttcta	acctataatg	aaagaaccac	tgaaggccct	70380
taaatatttt	taggctta	tggtgtcct	tgtacttagg	gcacatctaa	aaatcctgag	70440
gcaaccactt	aagagaacat	gcttttggtta	attcacaggg	agctgtccta	agagtgtcca	70500
gaatcctctg	tagtctggg	cctgggtgctt	gagagaccca	aaggaaaggt	caatggaatt	70560
gcagcttagt	gttagagttt	tcattggatca	cactaattag	ttaatgtcat	aaaggctctt	70620
ctcctgttat	gggaaaaagc	agcaaatagg	aacttctggt	aggggtgctta	aagttgggtt	70680
gatatttttc	ttagtaattt	taactaataa	aagtaataca	tgcttatggt	agaatgataa	70740
acctgaacga	aaaggtaga	aaatgtagaa	gttctctctac	ttatgacctc	acctcttctt	70800
tgcactccca	gtttcactcc	tcagagggta	accatagtaga	ctagtttctt	gtgtttgggt	70860
cctgagattt	tctgtgcata	tatatgtgta	gatatatgca	tattatattt	tcaaaattcc	70920
tatcacatga	caactactgt	tctgtaactt	aatttcttca	cttaattaat	agacctata	70980
tatgcttttc	catatcaata	tatatagatc	tatataagtt	ttcctaaagg	ttgcacaatt	71040
ttcaactgta	tggtgtctt	gtaatttact	ttttgtttcg	cctactaatg	gatatttcat	71100
gttttcataa	ctcttttgat	attaaaagta	gtgctgcaat	taacatcctt	gagaggcagt	71160
atatatgggtg	tttaaggtaga	atggctctgg	agccagacta	ctttggactg	aatattgatg	71220
ccactaattc	cttgctgtat	gaccttaggc	aagttgctta	atttctttgc	ctcagtgctc	71280
ttgtgtgaaa	aaatggaggc	aataatggtc	actatccagt	agagttttta	tgaggattta	71340
ataagttaat	aatgcacatt	aagaacttag	ttatttttag	attaagtagt	gaaggactat	71400
ataattgtta	gtataattgt	atacctttat	tagcatactt	ttgcatgtat	agcaataaga	71460
caaattctta	gatgtttaac	agttggacat	aaggagtgtga	cacattttca	gtactggtag	71520
atgttacctt	ttcctgcca	aaaattgcaa	atatttgata	ttaactttta	aaatcttagt	71580

-continued

aaatctgata agtataaata acaatttatg atcattttta gttgectttc ttaattttgt	71640
gtgaaaatga gtatcttttc acatgttttt tggccattta tgtttctttc catgtgaact	71700
aactgttctt ggccgttgcc tattttttgt tctgttact atatggcttt tcatctgttt	71760
ctcgttgggt tatggagctc tttgtatata aaaggattta gcctcttggt atatgtgtga	71820
caaatacttt ttccaattta tatttcaact ttgcttatgt ttccctattc atcagctata	71880
aattatgtag ttaaattcat cattgttttt tcttacggct tggagtttg gagatcatgc	71940
ttcaaaggtc tttctagggt gggttgattt aaatcaagta ctggaagtat ttttgccaaa	72000
aagactcatg aattatagat gtttagagta aaagggaact tagagatttg ctagtccaac	72060
ctccttttct tcataccttt ttaatttttc tctgcagatg aaaagaagtt tagtcccaaa	72120
gaaagaaagg actctaaagg ttctccagta agctaattgc aaaaatgtag actggaactt	72180
ctagctcctg atgggtattt cagtgatcat tcaatttaac cagatgggtt cacaagaaga	72240
gctttctact aaaaaataaa atacatattt aagcaactca gataaatatt ttttatttat	72300
cagattaatt tttacttaga gattcatcag catatgtact atatatgtac aaatcaccta	72360
tgtgttttgg atattttagt gaacaaatgt gcaaatattt taaccaaagg agcatatcta	72420
ttttcatttt actttcttaa tggttttagt tatgaatgtg aaatgtgtac ttacctaac	72480
agaaattaag tagatttttg gtctgacata tatgagaact gaaaagcatt ggcttggctg	72540
ctaactgcat tctcatcttt ctttcctgc tttggcaag tctgggatta aatctaatac	72600
cttttaaaact gtttgggact tcagccagag tgacctgtct tgaattcaga actgtgcaga	72660
tcattcccca ttctaagggt cctcatggc tctcattgc ctgtaggatg agatccaagt	72720
accttagcat agcttacgca ctgcagtcac ttgacctcta gcacctatgc agtcttcag	72780
tcttatttcc acattctttt gcacatgtg tttcccatg tggggcaact tttttcttgc	72840
ctgtctgcct gcctaagcca acttaataa acatgatttc tgtaacttct gtgaagcctt	72900
ttccaatctc tccattccaa gacgaagggt tttctatagg catgacttct ggaatggcag	72960
atcaaggatc tgggtgaacc tctactcagt gaaacaacca ttttaactggt aaaaatgatt	73020
taactggtaa aaatgatcaa tcaaccattt aaaatcttca gaaaatatcc taagggcaca	73080
tagcaaaaag agaaatgttt attcaagaaa agctattaag cctcagtaaa aacagcaaga	73140
gtctatggca tttgagtcac gacctgttc tattccttcc cttagctcca ttctacaggc	73200
aagtgcacc aagaagcgt aggtctctc tctttcaaaa tcttactcca tagttataat	73260
ttcaccctac aatggggcag gccacaagca tctctttccc ccccccaccc agccctatat	73320
tacagaagca ctgttctagg aaggcatagc tgagaggatt ggagattcct tctcaccga	73380
ctttctacat atgagggctt tgcccagggt atggtaaac aagaatacag gggtcctgct	73440
tgtgcctgcc tcagctcatc tataaggtaa aactccaca ctaggaaagg ctaattaaga	73500
ggactaggga acataccatt atccccagggt tccacttgta gaacaggga gttattctgg	73560
gagaagcagg tcaactgccc acttgtgaa caggggagtc actctgggag aagcagatca	73620
ccgtccctgc tccaattct attgcagtga cagaagttct gtcccaggga aaggcattag	73680
gatggagaac tctatagttc tccctgaggt gactgacttt atttggaaca gagcatgaag	73740
aagcttatgc ctaagggcac tgtcaaaaat aatgcagatc ttggtggtaa gcaattaaga	73800
gtggatttgt agtccatga taactagtag caacaagcaa aacagcagac caacatggag	73860
gataccagag aaccagacaa aggaatcact aagaagcgc cttgtggaac tacactcact	73920
gctgggtgtg tggaaagtta tgcattgtgt ctttactgta ccctctcaaa agcaacctaa	73980

-continued

acaggatgtg	gcgtaggctc	taaagcattc	ctcaagccac	acatggatcc	atcagtaaaa	74040
tatggagggc	ttaagggttaa	aaaggcttaa	gtacaatgtc	tggccctaca	ttttctacat	74100
gttatgccac	cctgaccaag	gggcaactcc	tacaaagcca	ggcataataa	taaaatcata	74160
tttgtctctt	ttggaatgga	tgactgtgcc	taaaactgtg	ccctttgaaa	agcaactaga	74220
gagataatth	ctgaagtgtt	tgccctacc	tgaatgcggg	caaaattcta	aactccctga	74280
agtgtgaaag	tgttttccaa	gtcacatgca	catccagtag	tggtaaagg	taaaatcta	74340
actgactaag	agggcttcac	agcaacatta	acccaaaagt	ggtttatgta	atctttgcct	74400
acctcataat	tccttaggca	ttctatgcta	ttctgtactc	agaaggctta	aaagtcaggt	74460
tagggaaagg	aggcctttga	ggttactgtg	cagaggcagt	gctgggaaag	gaatgaagtt	74520
caataaatth	aggccatcat	ggtttaaaga	atggattatg	tagataggaa	ggataaagga	74580
aaccagagt	caagaaaagt	aaagcttttc	attggtgcta	tgccaacca	tatctgagcc	74640
tgaggcaaaa	ggaaaaatgt	gctccccaat	atacatttat	acaaaatata	aactaattht	74700
atttgttgaa	ctgaatthta	aaagtcaaca	aaaattaaaa	ataaaaaaat	cgtgactata	74760
ttcttaataa	gtggtttatg	taaaccaga	gttgaccaat	gggatgccag	tctcaaccat	74820
aaaaacaac	aaataatgtg	agtagcaaca	ccagaagtht	caaagtgtca	gggaaaccag	74880
tttcacagaa	gtggttcagc	caagtcacta	aacaagaaa	tgactaagca	aaaaacaaaa	74940
tgagtctcag	agagggtcag	gtcaatatcc	agagttgtta	caatatagta	actaaaaat	75000
tgttttgaa	taaaaattht	gaggcatgca	aagaatgagg	aaagtgtaac	tcatacatgg	75060
tattatatga	aaaaatcaac	aaaaactat	ccatgaggaa	acaaggatgt	tgaacttaac	75120
taggcacaaa	ctttaaaaat	cagctattta	aacatattca	agaactgaa	ggaactatgt	75180
ctaaaaatct	aaaataaagc	gtaataacaa	tttctcatca	agtagagaat	gctaataaag	75240
agatagaagt	tatagaaaaa	gaagaaaatg	gaaaatctgg	agttgaaaag	tataactgaa	75300
atgaaaaata	cactagaaaa	ggtcacaaga	agatataact	tggcagaaga	aacaatcagc	75360
aatttagaac	atagatcaat	atagattatt	catttttaaa	gatagaagga	aaaaaagaat	75420
gaaccaaact	gaagattccc	aaagaaatgt	aggacatctt	aaaggcacat	cattaggaga	75480
agaaaagaag	aaaaagaaaa	gagcagaaag	aatatttttt	aaaaatggat	aaaatcttcc	75540
caaatttaat	gaaaaacatc	aatctacaca	tcaaagaaga	ttttttttta	atttcaagga	75600
ggaaaatgta	aagatattga	tacttagata	catcatagtc	aaaatattgg	agccaaatat	75660
aaagagaaaa	ttttgaaatt	agcaagagaa	aatgaaacg	gaaccacaat	aagattaaca	75720
actgattctc	atcagaaata	gcagagagca	gaaggcagtg	caatgccata	ttctaaccat	75780
tgaaagaatg	aaaaaactgt	cagccaagaa	tcatatattc	aacaaaagta	tctttaaggg	75840
taaaaatgaa	atgaagacat	tcctaggtaa	acaaaggctg	agaaaattht	tggttagctg	75900
acatgccttg	aaagaaatc	taaaagcttc	ctagacagta	gcttgaatct	gcatgaaaaa	75960
agcaattcca	ataaagggaa	atttgtaaat	aataaaaagg	tatcattata	tattatttht	76020
cacttaactt	acttaaaatc	aatttcttaa	agcactatct	gtaaaaatgt	attgttattt	76080
gataataaaa	tgtaaaagag	gggagtggga	attaagctaa	attggagtaa	ggaaatggta	76140
tcatatggta	aattgaatth	acagaaagaa	atgaaaaaaa	ttaagtggca	aatatgaaga	76200
ttaacaaaaa	cttctataaa	ttaattgtgt	tctctttccc	ttagcttctg	taaaagacat	76260
aagactatct	aaaatgacaa	tagcttaaac	gcattgttht	attggtaaca	aatatagaca	76320

-continued

aattatgtac	aacaattatt	attatacaag	gagagagaat	ggagctatag	aggattaaag	76380
tttttataac	ctattggaac	taagtacagta	taaactctgat	gtggattctg	ttaatttaag	76440
atatatgtta	gaagcccca	agtaatcact	gagaaaaatga	tgcaaaaata	cagtttttaa	76500
aagttaaaaa	catagttag	cttatgtatg	cctagtattc	cattatTTTT	ttttttatac	76560
tttaagttct	gggttacatg	tgacagaacgt	gcaggtttgt	tacataagta	tacaagtgcc	76620
atggtagttt	gcagatccca	tcaacacgtc	atctacatta	ggtatttctc	ctaagtctat	76680
ccctcccaca	gtcccccacc	cccctcgaca	ggccctagt	gtgatattc	ccctccctgt	76740
gtccatgtgt	tctcattgtt	caactcccac	ttacgagtga	gaacatgcgg	tattccgttt	76800
tctgttctgt	gttagtttgc	tgagaatgat	ggtttccagc	ttcatccatg	tccctgcaga	76860
ggacatgaac	tcaccccttt	ttatggctgc	atagtattcc	atggtgtata	tgtgccacat	76920
tttctttctg	cttgttccca	ggagaaagt	gctgaagctt	ccagagagaa	gctgagagta	76980
gtttaattct	ttttgccata	aacacggcaa	cccagtttct	tgcaagctgt	gttagtttgc	77040
tctctccttg	gttcatccat	tcatttattc	atagcttcca	taaagtgtta	acaaacatta	77100
attaggggcc	aagccatgtg	ctaggcgag	gggataaaac	tgtggacaaa	acaagcccca	77160
gctactctta	aggaactgat	agacaaatgg	accagcaaac	aggtctgtcc	tgttttgaa	77220
gcaaagtgcc	tggtgctcct	gatctcatga	gcacaaagca	tttagcctaa	atctcatcct	77280
cctaaggcct	cagaacaacg	gccttatttt	aataactgca	agtcagtcct	ttgaagacta	77340
aatcatagaa	tcctagaaaa	ctagtactgg	gagcaaaaca	aaagaatggg	atgagcatga	77400
aacatataatt	cagaagtgtg	ggtgtgtagg	tgtataagcc	aagctctttt	cttcacttgc	77460
ttgctaagtc	acttagcttt	tctgcctttt	tctttgctct	gtctggaaat	tgagttaattg	77520
aaatatatct	acatgataga	gatattgaga	tgattaaata	agatgctgct	gtcaccctgt	77580
atgcccttac	ctgctgtact	tagaagtatc	tgtaattcat	tttctaaact	ttttgtatga	77640
gtgcttcacg	catgccacc	accatggaag	ctaccttaag	acagtgaagg	cctttgttta	77700
acttgtttgt	actgtatcct	cagtctaatg	gtgtctggct	tatagtaggc	accgaataga	77760
attttattga	cagaatggat	tataatgaat	gtgaaggcat	ttttaaattt	atgaagtgtt	77820
gtgcatattg	ttgttaattt	taagctgttc	agttaaagaa	cccctaattc	aactctcttg	77880
agttttatag	atatcataga	agatatatct	tcccttgaca	cagaagcttt	ccttgaagct	77940
tcccttgact	catctatttg	cctcacagag	tgattgtgca	gatccacaaa	gataaattta	78000
tgtgaatgtg	ctttatgtgt	ttgaagcgct	ccacaaatcc	gggttttata	agttgagaaa	78060
atagagtcag	ggagaaagg	gactgatcca	aggtcatgca	gcgagttagt	atcagaattt	78120
atgatggaat	ttcaggctcc	caatttccag	tccagtatac	taaggcagat	tccagagaag	78180
aaacagtggg	gagcaggcac	tgacgaggga	cgaagaaaag	caggctccgt	ctggctgcaa	78240
cttgtctctt	catggcaaa	agaaactagg	acagtactat	gccagagacc	acatgataac	78300
tttgcagaat	ggaaagagct	tgtttaccac	attgaacact	ttatctgtgt	ttatctaaca	78360
atgacagtcc	caccagctcc	ttaccagctc	tcttttgcct	agtttaacaa	tataccaact	78420
atgacacatt	ttccttctca	gtttttattc	tagattacat	tttgttcaac	ttcatcttaa	78480
tgtgtagtat	agaaagagta	aggtaagagt	ataacaagtg	gttattttcc	atttctactg	78540
aggacagaga	aataatctaa	gggatttgta	ttagatatga	agaagttcat	ggccgggaca	78600
tgagagatac	tgtgatagaa	tgatatttgt	taagtctttg	gtagtttttg	aggggaaaaa	78660
agagaaattt	tttatttgct	tgataatagt	ttagcaatgt	cttaatttag	gattcaaaag	78720

-continued

ttgttcagg	gccatcttgg	ccttcaaatt	aagatgcctg	ttgagagata	acgttgttgt	78780
tttcaaactc	cattctgtga	cttaagaatg	agagaaggag	gaagaaaaga	ggagaaaatt	78840
ggagggaaaa	gtgccaggc	agtgtcaagg	ctagacactg	gaaatttatt	aatgaaagcc	78900
acatggtgga	tgggaatcag	atatgtgcat	caattatttg	tgttctaate	catagagaag	78960
taccgtataa	tgaccaaga	tatgagatgc	tttgaaagaa	gaccatataa	gtggagatgt	79020
gttcctattc	tatctaggga	tagagtcaga	aagggttcca	ttgaataagt	ggcagcctct	79080
tgggctgaga	cctgagttat	gagatgatgt	ggcaaaggag	acagatgatt	gggggcaagg	79140
tggggtcatt	gaagttggag	gcagtgacaa	tataagcaaa	gctacagggg	catgaaacag	79200
caagggttaga	ttaggggaatt	gcaacagggt	ggtactgctg	gaaggtcaca	tggaaaagat	79260
tatgagagta	ttgagataag	aagctagaaa	taagctttga	atgccatcct	agtgccttga	79320
atttgtatcc	tgcaagccaa	gtgggtttca	cttggtcatt	taataaaatt	gcagattctc	79380
aggtctcacc	tgtaacttca	gattcagaag	agtctgtgct	aactgaaggt	ggaatcagtt	79440
tccatattgc	taattagctc	ctcagaggat	tctaataatat	cagtgaagta	caaccactgc	79500
tgtaaagcat	aggtagttat	tgaagctgc	tagggagagg	agccacagaa	gcagatgttt	79560
tagataggat	ccctctgggg	tctgtgttaa	tttatggact	ggactggaga	ggatcagaca	79620
ggaaacagaa	agacttgaat	aaggcagttg	cagttagttt	ggaggcaaa	attctctctc	79680
tctctctctc	tctctctctc	tctctctctc	tctctgtgtg	tgtgtgtgtg	tgtgtgtgtg	79740
tgtgtgtaat	tgtaggaact	atttaggcag	taaaattaac	agatattagt	caactgattga	79800
ctgattggat	ggcagtgata	ggtgggggtg	attgagggaa	ttgtattaca	ttaagtccag	79860
gatgactcat	ggttttctaa	gttgagtcac	tggggattgc	cagccaatgt	gagaaactat	79920
atcgctcaat	agttgatcct	ggagtttagc	ttgaattaaa	atcttgaagc	catcaattgc	79980
tgtatgtggt	cttgggcaga	acacttaagg	tttctagacc	tcagctcttt	cttctataaa	80040
ataaggataa	taatgcatac	ctcatgcatt	tgttgtaaag	actaaatgag	gttaaattat	80100
gtagagtgtg	gtatagtaac	tagcacatac	agtggcccag	taaacgtcag	ctgttattat	80160
tgtgtctatat	gttggtgatg	gtactggagt	gagatggggg	aggggatttt	ttagtctctg	80220
acaatgactc	ctctcccat	gatcaaaac	agaaaatcag	tctcttatgt	gctgagaaga	80280
gagacacttc	tccaagtgt	ttaaggctaa	taccttgcc	tgttttgcct	tgggcccagc	80340
ctcactacac	atctgtttta	gagataagg	taagctctgt	tcttggtgag	tatctcagtg	80400
gggctgtttt	tctagttctt	gtagtttctt	tgggccaaca	tgaatgtct	aacctggct	80460
tcttggttgt	ggattctcgt	caacatttca	ctgctaccca	agttgtgtct	gctcacatga	80520
tgtctatctc	cttcttttgg	gtttccgaag	ccctcagaca	cttggtgtaa	cacttttttc	80580
acatttctta	agctatatca	tctgtgtttt	ccctgccaca	gacaaagtca	caaaaggact	80640
ttaagatagg	gtctttttcc	ccccagggtt	tttatacatt	ttgagtaagg	gcaagtggta	80700
aatgtgctt	ttctgcctta	accagtagtg	tctgacagag	gaggcagcat	gatgattgca	80760
gagctcactg	aactgaaagt	cagatgcctt	acccacctgg	actctagtac	caaggggaag	80820
atggagtggg	atggggaaaa	tggggataaa	ttatcattta	ttttgagtgt	gccaggccct	80880
ttcccatgta	ttgtctgatg	catttgtcac	aattctcttt	gggtttgaaa	tgtgattttc	80940
ttcattttat	agataaggaa	acttatggga	aggagagatta	ggttcatctc	gtgcccact	81000
ttacatggct	agtgatcaat	aatagtgaga	ttcaaactca	ggtttctctg	ttccaaaacc	81060

-continued

tttgcttttt	catcttttga	cactgtaact	tattagaaga	tgtctttgac	tctgagtctc	81120
atttgcccca	actgtaaaat	ggagctctgt	aacccttgct	ctgtatgaca	gtaaatctcc	81180
tgagaccaga	tttatgatag	gggacaagga	tatttgtatc	tttgggcccc	taatgtattg	81240
aaagtgcctc	tcagtgcctg	gcacagagaa	gggcactcaa	taaatattta	ctaatacattt	81300
tccagaaaaga	gggtagctcc	ataatgagcg	agattcattt	tgatggctgc	tgtagtgttt	81360
aatgttttta	ccacctgtta	aaatgatttt	ggagtataga	tggataactg	atgatggttg	81420
ttatatagat	tttttcatag	gttgccctgtt	ccaaattcta	tgccctggaa	gaagctaaat	81480
atccagaatt	tgacaggaaa	tattattcta	caacagatcc	ctggcataag	aacagtaaca	81540
cctctgttct	attctcagac	ttgcctctga	ataactgttt	ctcctggtea	attctctgtc	81600
tctatctggg	attgaaactt	ccccctggac	aatgagggag	ttgaactagt	ttagtggggg	81660
tcagccttga	gtggccatta	caattatttg	gggattgttg	aaaaaaattg	gatgccccaga	81720
tttttgtcgt	tgttgttgtt	gtttgttttt	taattatact	ttaagttctg	ggatacatat	81780
gcagaatgtg	caggttggct	acataggtat	acacgtgcca	tgggtggttg	ctgcacccat	81840
caaccctgca	tctatattag	gtatttctcc	tgatgctatc	cctccctagc	cccctagccc	81900
cagacaggcc	atagtgtgtg	atgttcccct	ccttgagtct	atctgttctc	attgttcaac	81960
tcccacttat	gagtgagaac	atgtgtgtgt	tggttttctg	ttcctgtgtt	agtttgcgtg	82020
gaatgatggg	ttccagcttc	atctgtgttc	ctgcaaagga	catgaactca	tccttttata	82080
tgggtgccta	atatttcatg	gtgtattgaa	ctgcttacc	cagttcaate	aaataagaat	82140
acagaatgtt	gagaggagca	tcagtatttt	aagaaggcca	cctagtgagt	tcaatgtgca	82200
accaaggatg	agaaacactg	aactagatga	ttggtaaggg	ccatccaact	ttgatagtcg	82260
acaagagaca	atgctataga	gtatggtgga	cagagcatgg	gcttttagagt	tagccaggca	82320
tgcattcaga	ccctggctct	gttacttact	agttgtgtga	tcttgaagaa	atcaaaatgg	82380
agatacacct	tgtccctggc	agtaatatgt	gtgggggatta	agcacctttg	ccagtgcctta	82440
ggacataata	aacccccagt	aaatagcttc	tttagtatca	gaagttcaga	tgggaagatg	82500
gagaaaaata	tgggttcagt	aagatttaac	atgtagatta	aaatcaagta	tttaaaaaaa	82560
ttttcctgtt	tctttagcaa	tggattccag	aaacataatg	tggaaatagc	tctgagtcct	82620
aagatttgat	gacattgcag	aaagaaatct	ggctagtgtg	cccatggctg	attggctatg	82680
atggctaaga	agccattgga	aaaaaaaatt	ggctcacaga	agacagcaga	tgtggcttgg	82740
gaaatgcaag	gacatgactc	taataaggat	ttgtcccat	tatgagagtg	attccaggag	82800
aaaaggacag	atttgtattg	tcagtgggat	atgctgttaa	aaaacacttt	tgtaccacc	82860
actccagctg	tcttggcatg	tttgttgggt	atgtaagcta	cagaaaatgg	aaatcaccaa	82920
aagggtata	gcagcctgat	gcatagtgac	aagtaattgt	tctattcatg	gttatgtgtt	82980
gtacagagca	cttgcctgat	gtcaggtttg	aggtttgagt	atgcattagg	gccatggata	83040
cccccatctt	ctctctaagt	agatttcaaa	gtaaatattt	gatgagtatg	taaaatattt	83100
agtttggtea	gtcataggac	tgagaacgtg	gtgggggtta	cctcctagta	tctgcaggca	83160
aaaaaacttt	tttcttccta	tagcaattgc	catctcagcc	ccttttgtag	cgtttctctt	83220
gctacacttt	gcattaacca	tctgtgcact	tgtcttagcc	tcaaacaggc	catgaaagct	83280
ccttgaggat	aggggctatg	tctttttcat	ctttatatat	gcatcattta	gcagagctgc	83340
tcctttataa	tgtactaatt	actgaatgaa	gggatccata	gatgaataaa	tgaatgcaaa	83400
gtaggagtga	cctctcttct	gtctttcttc	atgatgggga	ttagtgtgtg	tgtataaggg	83460

-continued

aataatcgtg	tcacataaaa	tataacctta	cttagaaggc	aagacttcca	gaatggtgga	83520
atgagaacca	acccccgcc	ccataaatc	accctttcat	gaaagcaatg	aaaacactag	83580
gaaacgttgt	gaaaattaac	ttttccagaa	ctctgggaag	gaaacaaagg	ttccaacaa	83640
tctgagaaga	atgtattcaa	gaaaaacttc	ggtaagttct	ctgatcacag	tggaataat	83700
aaacaattag	taatagaagg	atatttgga	aattcaccat	ttgtagaaca	taaacagtgg	83760
atcaaagaag	aatcataag	ggaatgaga	aaatactttg	agattaatga	aaatgaaaat	83820
acattatacc	gaaacttaca	ggatacagcc	aagctaaagc	agtacttaaa	gggtaattta	83880
taactgtgaa	tgctacatc	aacaaagaca	aatgatctca	aatcaagaac	ctaactttcc	83940
accttaggaa	actaggaaag	gaacagcaaa	ctacaaagaa	agaaggaaga	aagattaata	84000
aagactagaa	gggaaataaa	tgaatatag	aatagaaaa	cactagaatc	aatgaaatta	84060
aaaattgttt	cttgaagag	atcaacaaaa	ttgaaaaaac	tttagtcaga	ttgaataaga	84120
aaaaaaagag	agaagattca	aattatcaaa	atgagcagtg	aaactggggc	catcactacg	84180
taccttaaaa	agaattctca	aaggattaaa	aggaaatacc	attgcattag	tttattctca	84240
tacagctata	aaaacaacta	cctgagactg	ggtgtttatg	aagaaaagcg	ctttaattga	84300
ctcatagttc	cacaggctgt	acaggaggca	tggtgggtga	agcctcaaga	aacttacaat	84360
cagggtggaag	gctaaggggc	atgaaagaca	tgtcttcaca	caatggcagg	agagagagag	84420
agagcaaagg	gggaagtgcc	acaaaacttt	aaaccatcag	atcttatgac	aactcactca	84480
ctacaatgag	aacagcaagg	agaaaatctg	cccacgtgat	ccagttacct	cctacgaggt	84540
cccttcccca	acactggaaa	ttacaattca	acgtgagatt	tgggtgggga	cacagagcaa	84600
aaccatatca	accatactgt	atgccaaaa	cttagatgat	ctagatgaaa	tggaacaaata	84660
ctcagagaaa	cacaaactat	ctgaagtgtc	tgaagtgacc	agtgaagaaa	cagaaaaatct	84720
gagtagtctc	gtaacaagtc	ttgtaacaaa	actggattaa	taattaagaa	acttcccaca	84780
aataaaaacc	cagggttcaga	tgtcttccact	ggtgaatatt	atcaaattatt	taaggaaaat	84840
ttaatccctc	acaaattctt	tcaaaaattg	gaagaggctg	gaacccttcc	cttcccact	84900
aattctgcac	agtcagcatt	accctgatgc	caaaaccaa	gatatgacac	aaaaataaaa	84960
ctgcaggcta	atatcacatt	tgaatataga	taactttcta	aaaatcttaa	caaatgcta	85020
gcaaactgaa	ttcaacaaca	aataaaaagg	tttataaagg	gtgaccagg	aggatttatc	85080
tctgcaatgt	aaattaatat	tcaaaaagct	aagaatagga	ggaaactttc	ttaactttgt	85140
aatggacatc	tctgaaaaac	acacagctaa	catcatactt	agtagtgaaa	gactgaaatt	85200
tttcttgta	agatcaggaa	caagacaagg	atgactgctg	tcaccatttc	aatttaccat	85260
tgtattgtag	gtttattgta	ggtcaagtc	aagcaaaaa	aaaaaaaaa	gtaaaagaca	85320
cccatattgg	aaaggaagag	gtgaaattat	ctatatccac	agatgacatg	atcttataca	85380
aagaaaacc	ctaagaatc	catgacaaac	tattaaaatg	agtaaacgag	ttcagcaagg	85440
tttcagaata	caagattaat	gtgcaaaaat	caattgtatt	tctgtgcact	agcaatgaac	85500
aatctgaaaa	tgaaattaag	agaacagttc	actcacaata	tcatcaaat	accagaatac	85560
ttaaaaaata	atttaacaaa	agaagtgtaa	gacttgatg	ctacaaaccg	taaaacactg	85620
tggaaagtaa	ttaaaaatct	aaataaatag	aaaaacattc	cttgttcatg	tgccagagga	85680
ctcaatattg	tcaagatgga	aatactcccc	aaaggttgaa	ggaaatccct	gtcaaatcc	85740
tggctgtttt	cttagcagaa	aatgaaaatc	tgaccctaaa	attaatat	aaatacatag	85800

-continued

aatctaggat	agccaaaata	atattgagaa	agaaaaacaa	agtcagtgta	cccacgcttc	85860
ctgattccaa	accttactac	aaagcagtg	taatcaagag	cgtatgggtat	tgccatcacgt	85920
acaaacagat	caataaatgg	aatactattg	agaatccaaa	aattaactct	tacatttaag	85980
ggcaattgat	cttcaaaagt	gttgtaaga	caatttaatg	aggaaagaat	agtcttttca	86040
ataaattgta	ctggaaaaat	tgatatcca	catgaaaata	aaagatgttg	gaccacttca	86100
aacctgcaaa	aaaaaaaaaa	aatgatctaa	tggtgtatca	tgatctaaa	tgctatagag	86160
ctaagatgat	aaatctcaga	agaaaatata	agagtaaata	tttatgacct	tgaagtaggc	86220
aatgtttttt	tggtgtgaac	accagaagca	caagtagtaa	gagaaaaaaa	aaatggactt	86280
catcagattt	gaaatttttg	tgctgcaaat	gatgccatca	agaaagtga	aatctcacc	86340
acagaatgag	agaaagtatt	tgcaaatcat	atatctgata	agggtattga	atttagaata	86400
tataaagaac	tcttgcaact	caatataaaa	agacaaccca	attttaaaat	gggcaaagta	86460
tttgaatata	aattttctga	tagaagatat	acaaatttaa	aactgctcaa	cttcattagt	86520
cattagggaa	atgcagatca	aaaccaaatt	gagataccgg	tttacaccta	ttaggatggc	86580
tatagtga	aagaacaaat	aacaagtatt	ggctttaatg	tgagggaacc	ttatacattg	86640
gtggtaaaa	gtaaagtcgt	gcagcccttt	ggaaaacagt	ctgaaagtct	ttaaaaattt	86700
actatttggt	atttggtttt	tcttcacttt	taatttaggt	tcagaggtac	atatgcaggt	86760
ttgctatata	gctaaattat	gtgtcacagg	ggttttagtg	acacattatt	tcacaccca	86820
ggtaataaag	atggtaccca	ataggtagtt	tttggtatct	cacctctctc	ctaacctcca	86880
ccatcaagta	ggccctgggtg	cctcttgctc	tcttctttgt	gttcatatgt	actcaatatt	86940
tagcttccac	ttatcagtg	gaatatgcgg	tatttggttt	tctgttcctg	ctttagtttg	87000
cttaggat	tggtctccag	atcctccac	gttgctgcaa	aggacatgat	ctcattcttt	87060
ttgcatagtg	tactatgggtg	tacatgtatc	aaaaatgtta	ctgtttgacc	tagtaattct	87120
attccaatat	aactactcaa	gagaaatgaa	aacatgtcca	cacaaaaact	tgtaacacaa	87180
tggtcattgc	agcattattt	ataatagcca	aagagtggaa	gacaaatgct	ttccaaatgt	87240
gggtcccaaa	tgtccaccaa	ctgataaatg	gaaaaacaaa	atgtggtata	tccacgccat	87300
ggtttatctg	tcaataataa	gaaatgaagt	aatgatacat	gctacaatga	accttgaaaa	87360
tattatgcta	gggtgagagaa	gcaactcaca	aaagaccaca	ctgtatgatt	ttattttatat	87420
taaatgtcca	taaaagaaaa	atatttagag	atagaaagga	aattagtgtt	tccagggctc	87480
gggaggagat	gggtataagca	atggctgcta	atgggtacag	gatttctttt	tggttggtgata	87540
taattgctct	aaaattagtt	tgaggtaata	gatgtgaata	tgctaaaatg	ggtgaatttt	87600
ataatatgtg	aatataaact	cagtaagccc	attaaaaaca	acctaattaa	attaaaagca	87660
agctataaca	gaaatattat	atagccttgg	cagtttagaa	tagtgggaaa	atatggagtt	87720
ggggcaggg	aatagtcgca	agtataattc	tggttttgct	actactagtg	tatggacttg	87780
gatgagtc	ttcctttctc	taagtctcag	tttgcataata	tgcaaaatag	aggtaatgat	87840
acctacctca	gtggtagctt	ttcaaaacct	tggtctccct	catctctcct	ctacaacttt	87900
ctcgtagat	tattacagta	ataaccattt	attaagcact	gtgtcagcaa	tggtgtggga	87960
ccacaacttc	actgaatcct	cattgcaatc	ttgtggggct	tgtatttctt	tgctgttttt	88020
acatgtaaag	aaattgacgt	caaaaagagt	gttcaaggct	attctgttag	caagtggcag	88080
agatggacat	gaaaactaga	tgttctacct	atatgtcttt	ccacttcaac	taaagaattt	88140
attaaagaga	attaaaaagc	tatgaactac	ttttaatagt	aaacattgct	gtcctcgtga	88200

-continued

atgaacacac	actaaatttc	aaatctcacg	atggcagggg	ataaagatgc	tacctgtctt	88260
aagccattac	ttcaccaact	tctccaccaa	aatattcctt	gtaaccacaa	ataagtaagt	88320
acaatagatc	tataaggaga	gaataattga	gaactctctg	attttatctt	aaaagtcatt	88380
tagggatgtc	atgttcacac	atgtaattaa	taaaatatat	tttgttacta	aacataagga	88440
aaaattttat	gttcaacata	aagatgtttg	gtggttgcct	caacctcttt	tagtttgaaa	88500
agtaggtatg	tatgagaaag	atacgtgttt	acatgtctac	ccttgccctc	tctgtctctt	88560
ccctctcttc	tctctctctc	cctccctccc	cacccctctc	gccctacacc	ccccaacccc	88620
cacatgtatt	tacctttctc	taaaagctct	gcataaccaa	gaaaaatggg	cttttttatt	88680
tttaggatgt	tagatatttc	attttcttat	ggtaagacaa	aagattaagg	caaccaagac	88740
ttacaatgta	tctaccgtgt	ggcaggcacg	gaggcaaggg	cttttacatg	tgttatttaa	88800
tgtaattgta	attctcacia	aagccgtcta	gagttgaaaa	tatttcacgc	tctaattgag	88860
gcaaatggag	cacagagagc	cttaattatt	tcacccaaag	ttcagtggta	gaggcaggat	88920
tccaaccacg	gtctgtgtgg	ctccaaagcc	ttgttggttt	gccattcctc	tcgctaacaa	88980
atgaaactgg	tctgtgactt	ttgcatttca	ccccacttcc	acagtcactg	gtgggactta	89040
tttaaatata	tcagatcctt	caaagtatcc	ccaagtcctc	ctttaaaaag	aaagttaggg	89100
ggcaggggga	ggagcagagg	agaggagata	aaaaggaaag	gagtcagaga	gagagagaga	89160
gagagagaga	gagagagaga	gagagagaga	cctggtgggc	tcagctgggt	gccaagggtt	89220
cctaagccca	agttcccat	ggttgagcct	gcattagcag	gccgacagct	tctagtaatt	89280
cacttttatt	taattaatag	tgaactgttt	gaagaattgc	aagtgggtgt	ctagttcaga	89340
aaccttccat	tctatggggc	attgcttttg	cctcagactc	ataaaaccaa	atgccctgcc	89400
tcaggataat	aagtgaacat	gtaaccacag	agaggtaaga	aaaaacacaa	tgtcacgtgc	89460
aaattctgca	cttggtctca	aagcaaacct	ctcctgtgtt	tgcaattagg	atgttatcta	89520
ggagcatatt	caaaactttt	gaggttttta	tttttagttt	tcttttatta	tgtgctgttt	89580
tagtaatatc	aaagaatata	tgtaatatat	gttatatggc	ataacaataa	aattaatgtt	89640
tatgagccct	gattaaagaa	tcaacaacat	taacatcctc	attgcaacaa	ccctattaga	89700
atggaagctc	tgtgaaggca	aggatttttt	tctgttttgt	tcactgctat	atcccagga	89760
cctagaggag	tgtcagccac	ataataggag	cttagtcaat	attttttaaa	taagagcata	89820
aatctactta	tatcctcttt	cctcttatca	tcactcccag	cctcccctca	gaggtagcca	89880
ctatcctatt	ttagggtttt	aatattccct	tgcattttgt	taacttttca	catgtgtatt	89940
cccaataaat	atattgtttg	cttttgcttc	tttttgaact	ttatataatg	gaatcatatt	90000
gtatgtatcc	aattgtgagt	tatgaacttt	acgcaacatt	agtatttgag	attcaactat	90060
gtgtagctcg	attccattcc	ttttcattgc	tgaattgtat	tttattggat	atgtgtgcca	90120
taaattattt	ttctcctgtc	agttgatgtt	tatcttttat	gcttttataa	acaaaacggc	90180
tatgactgtt	cctgcattgt	cctcctggta	catatgtgcc	caactttctc	taggatataa	90240
gcctcagagg	gggactgcac	ttggaatttt	catttccaga	gcccacaggt	tagctcatga	90300
gtcagagctg	caatgtgcc	ttgtccaca	ctaggtcagg	atcagtggga	gtgctaccca	90360
aaatattttc	ctagtggggg	aatcagggag	aggcagagac	tgacctagtg	aggccaggag	90420
ttactatctc	aggctctctg	tcaaaatggg	ttgcaattag	taaaagtcca	gattctgaat	90480
cccttcatt	atttatcttc	ttcttcctcc	tttacagtta	ttttgttcca	aggtgcactt	90540

-continued

tattaaactc	atacctaaca	aacaaaactc	taatgaatat	tttgtcttcc	attgattgta	90600
aattcaatta	gattctttga	aaaaatttta	actgtatttt	cacttttagca	tggatgaaaa	90660
tttcgatttc	tttaaaaaac	atttttaata	ataacacaat	aaggtctacc	ctcataacaa	90720
aatttaaggg	cacaacacca	tattgttaac	tataggcaca	atgttgtaca	gcagatgtct	90780
agaatttttt	tcttcatgct	taactgaaac	tttatagcca	tgaaacggca	acagtccatt	90840
tctatttctt	aaaagtcott	tacaaaatga	gctttctaca	tgtttcatt	ttgtttatct	90900
gataattttt	tttcgttttt	tattatactt	taagttctgg	gatacatgtg	cagaatgtgc	90960
agggttggtta	cataggtata	cacgtgccag	ggtggcttgc	cacaccctac	aaccctgcat	91020
ctacattaga	tattactcct	aaagctatcc	cctccgcttg	ccctcacccc	atcactggcc	91080
ccagtgtgtg	atgttccctg	tctgtgtgcc	aagtgttctc	attgttcaac	tcccacttat	91140
gagtgagaac	atgtagtgtt	tggttttctt	ttcttgtgtc	agtttgctga	gaatgatggt	91200
ttccagcttc	atccatgccc	ctgcaaagga	catgaactca	tctttttata	tggctgcata	91260
gtattccatg	gtgtatatgt	gccacatttt	ctttatccag	tctatcattg	atgggcattt	91320
gggttggttc	caagtctttg	ctattgtgaa	tagtgccctc	gtaaacatac	gtgtgcatgt	91380
gtctttatag	caccatgatt	tataatcctt	tgggtatata	cccagtattg	ggatggctag	91440
gtcaaatggt	atttctagtt	ctagatcctt	gaggaattgc	cacactgtct	tccacaatgg	91500
tgaaactaag	ttacaacccc	accaacaatg	taaaagcatt	cctatttctc	cacatcctct	91560
ccagcatctg	ttgtattctg	actttttaat	gatcatgatt	ctaactggca	tgtgatagtc	91620
tctcattatg	gttttgattt	gcatttctct	aatgaccagt	gttgatgacc	ttttttttat	91680
atgtttgttg	gttgcataaa	tgtcttcttt	tgagaagtg	ctgttaattt	ccttcaccca	91740
ctttttgatg	gggttggttt	ttctctgtaa	atttgtttaa	gttccttgta	cattctggat	91800
attagccttt	tgtcagatgg	atacattgca	aaaattttct	ctcattctgt	aggttttctg	91860
ttcactctga	tgataattta	ttttgcccgt	cagaagctct	ttagtttaat	tagattccat	91920
ttgtcaattt	tggcttttgt	tgcggttgc	tttgggtgtt	tagtcatgaa	gtctttgacc	91980
atacttatgt	cttgaatagt	attacctagg	ttttcttcta	gggatttaat	ggttttaggt	92040
cttacgttta	agactcatct	tgtatttaatt	tttgtataag	gtgtaaggaa	ggggccaggg	92100
ttcagttttc	tgcataatgg	tagccagttt	tcccaacacc	atttattaaa	gaggggaatcc	92160
tttccccatt	gcttgctttt	gtcaggtttg	tcaaagatca	gatgggtgta	gatgtgtggt	92220
gttatttatg	agacctctgt	tctgttccat	tggctctgtat	atctggtttg	gtaccagtat	92280
catgtgtgtt	tggttactgt	agccttgtag	tatagtgtga	agtcaggtag	cgtgatgcct	92340
ccagttttgc	tctttttgct	tagaattgtc	ttggctatgg	gggctcttta	ttggttccat	92400
atgaaattta	aagtagtttt	ttctaattct	gtgaggaaag	tcattggtag	cttgatggga	92460
ttagcattga	atctgtaaat	tactttgggc	agtatggcca	tttctatgat	aatgattctt	92520
cctagccttc	agcatggaat	ggttttccag	ttatttttgt	cctctcttat	ttacttgagc	92580
agtggtttgc	aattctccat	gaagaggtcc	ttcacatccc	ttgtaagttg	tattcctaca	92640
tattttatct	tgttttagtc	aattgtgaat	gggagttcac	tcatgatttg	gttctctgtt	92700
tgtctgttat	tgggtgatag	gaatgcttgt	gattttcaca	cactgatttt	gtatcctgag	92760
actttgctga	agttgctgat	aagcttaagg	tgatttttga	ctgagacgat	ggggttttct	92820
gaatatacag	tcatgtcatc	tgcaaacaga	gacaatttga	cttcctgttt	tcctatttga	92880
atacccttta	ttgatttctc	ttgcctgatt	gccctggctg	gaacttccaa	tgctatgttg	92940

-continued

```

aataggagtg gtgagagacg gcatccttgt cttgtgctgg ttttcaaagg gaatgcttcc 93000
agtttttgcc cattcagtat gatattgggt ctgagtttgt cataaatagc tcttattttg 93060
agatatatct cattaatacc tagtttattg agagttttag catgaagggg tgttgaatct 93120
tgtcaaaggc cttttctgca tctattgaga taatcatatg gtttttgtca ttggttctgt 93180
tgatgtgatg gattatgttt actgatttgc gtatgttgaa ccagccttgc attccaggga 93240
tgaaaccac ttgatcatgg tggataagct ttttgatgtg ctgctggatt cggtttgcca 93300
gtattttatt gaggattttc gcattgatgt tcatcagggt tattgtcctg acattttctt 93360
tttttgttgt gtctctgcca ggttttggtg tcaggatgat gctggcccat aaaatgagtt 93420
agggaggatt ccttcttttt ctattgattg gaatagtctc agaaggaata gtaccagctc 93480
ctctttgtac ctctggtaga attcggctgt gaatccatct ggtcctggac attttctggt 93540
tggtaggcta ttaattactg cctcaatttc agaacttggt attggtctat tcagggattt 93600
ggaggtctat ttaggcttgg gagggatata gtgttcagga atttttctat ttcttctaga 93660
ttttctatct tatgtgcccc agagggtgtt atagtattct ctgatggtaa tttatatctc 93720
tatgggatga gtggtgatat actctttatc attttttatt gcactctatga ttcttctctc 93780
tcttcttttt tattagtctg gctagtgggc tatctacaaa atagatagac tgtttatctg 93840
atattttatt tgtaattatc taataataat catcattatc atcagcatca tcattgtcat 93900
ctcctttacc catacataca tttgtgtctt tcaaataata atcccatctt tgaagtacat 93960
cctcatctgt agcagtcttc actctgcttt cttatatcat ttactatctt attttataat 94020
tatttacttc ccgtctttct tctctaacag atagtatttt tttagggcca aggaaatctc 94080
tcgatcacca ctatatcccc agcatctacc cctgtgctg gtccataggg ctagatgcta 94140
agagttgagt tgaaccaatc tacctaactc taaccttcag tagcacaaca tggtttgtca 94200
gtggttaaga atctacactt tggagtcaga ctcaaccagg atggaatcct ggcattacca 94260
cttattatta atagatacat gaccttgaa aagttcactt aattgttctt agcatcagtt 94320
tcctcttctg tgatataggg atgatacaga gctacctggt aggttggttg aataattaaa 94380
tgagatgata tgtatgaaat ggctggcac atagagtgc taaatacacg ttgttctgat 94440
tttatttggc ctgtttgtgt tagtaacaga aatcaaaaag gtggagaaa gagaaaggta 94500
cttgggaaaa ttttctatct cttctccatg ttctattcaa gactgaggaa gggggcacag 94560
tttttaccac aggaacgac atttttagcc aaaggaatta tgatcttagc atttagctga 94620
attgtatatt ggaagtaagc tccttccttg tggaaactat ggccttgcta gccttggttt 94680
gttgggaagt ctcttgctgg ctttctagtt agggtaggga aaggaaggct tgtggggagt 94740
gaagataggc catgatatca agccactgag tgtgcaaac agtagaactt ttcgattgct 94800
ttctgttgta cttgggactt gaataaaggc tgatatttgt gtcttgctgg taaagtgctt 94860
gtaaagtgag tgaaagtctt ctttgttctt gtcctgccag agctgttcac ttggggctga 94920
ggggaggata acctttcatg tttttatctt tttttattct gatgactgtg ctgagcattt 94980
gaacgaaatg gccattgggt gaaagtaaag gtgaatgggt agaagacaat aggataatgg 95040
aaactgtgat ggacttgagg tcaaatctt ctgaacttct cctctccaag tcttacttct 95100
ttcatctgta caatgaatat taaaatgaga aaataagctt gtcttcacag agttattgtt 95160
aggtgttgaa atcaccgac acagcaaca ggctcccat agggctcatt ttccttcatt 95220
ccttagtaag gaagaagtac ttataaaaata cagcagttgt gctcttgatga atgatagcat 95280

```

-continued

gggcagtgtg	catctctctg	aggcagatta	accagaaatg	ccacttgagt	ttgtttaat	95340
gcttaggcat	aagacatagg	aaagacaaaa	gttgacctt	gggtagtaag	aacaatgttc	95400
cattttgttc	aaacttgaat	ttttttacta	taggagactg	agaattaacc	ttccatgaag	95460
gttttaggat	ttgctttctg	actcttctct	ttcatatcca	cctgaaagag	cttgggcaca	95520
gatgttcttg	gagaaaggta	gttaaacaag	gtgacttctg	aagctccatc	cttgcccaaa	95580
gaacttatga	gtcccttagt	ggccaagtat	tttgatggta	gtagcctaaa	agatgtccag	95640
gatcaccgtg	catcattttt	tcaacagaag	cctcaggcat	agggattatg	cttggtactt	95700
tatgttggtg	aatggaatcc	ggcagatgtc	catgtgatct	agagaaacac	ctaaggaaa	95760
tgaagaaatg	ggggaaaaaa	taacaagact	tgtatgataa	tactaatcac	tatccttggtg	95820
tatttatcc	aaggacattt	tctccattat	ctgatttata	ttaccactca	cagcagcagc	95880
tcaataggat	gggagatatt	atccctattt	tatagatgag	atttgaggct	cgaggagcta	95940
aaacaagaaa	catcaaattc	ctttgatatt	tggtctgatt	ttgttatagt	tctcccttg	96000
gatgaggtaa	agtcacaaaa	ctgggttcat	atcatttaat	tagtctgaaa	atgttgectg	96060
aacaccacct	taagttagat	atcttaacct	caggtttcct	actttcattg	ctgcctctta	96120
tagacataga	ctatgagatt	ggctaatacc	agagaacttc	cctaatacct	tggcaagatc	96180
caaaaaggct	cagtcacacc	ctactaccac	catctttagg	agaagtctca	gaaaattcag	96240
cttcacacta	actcacttga	gcatacaata	atagtagttt	atgcatgcag	gttaatcctg	96300
aagacctcag	acttcacttg	cctattttctg	ccattctatg	acatgtgttg	cattggtttt	96360
ttgtgtcttt	ccagtttgga	gactgccagg	gaccatgttt	tgccaattga	ctattacttt	96420
ccaccccgag	agacctgcct	gatctgtgga	gatgaagctt	ctgggtgtca	ctatggagct	96480
ctcacatgtg	gaagctgcaa	ggctctcttc	aaaagagccg	ctgaaggtaa	agggacatgc	96540
acatgcactt	ctgtttccct	ttctccttta	ccttccagag	agagacacta	acctttcagg	96600
gcccaggatt	ttatcatctc	agaaacagag	tcattggcaa	ggccctatca	aataacttag	96660
gagcctaagg	aagcaaat	ttgcacttgc	tagttccctg	gtttcagcag	ccttgtttgt	96720
acaggcaatg	taggcagtga	aggtgggtcc	agctggggct	tggggctcag	tgggtcctag	96780
aatgaagga	aaaattaatg	atttgaaaag	atttaatttc	ctccctctct	gttttctact	96840
ctgctggcta	gtaaaggaaa	aatttgtcct	tattagagag	gttagaagtg	gagaaacccc	96900
aactgagtcc	ccagcctgtt	ccttgggatg	aatatgagac	tgtttcttag	caaaggcttc	96960
ctggcctcgg	cccagaaaag	agagtgttct	cactcttcag	cagactatca	gtctctgcac	97020
ctgtccctc	ctgttgctgc	ctccttggga	cctgtctttg	cgttaatagt	tcctaggtag	97080
gtaagaactc	agagtgaaga	aacacattta	ttctcctctc	cagagacctg	acctcaaagc	97140
ctgtccatta	gtccctaacc	ttaatctaag	gtagcatctt	atatctggct	aaattgggtc	97200
aagccctagc	tccttagttt	tatttagctt	agaacaactc	atgtctgctc	aacccctaaa	97260
ggtgctcagc	ctacattctg	cagtagaaac	tcccattttc	aggcctctta	tatatgataa	97320
tgtctcttcc	tctaaccacc	cagggcttaa	gcttctgct	tatccacttc	actctccacc	97380
ctgtatcgag	ggctttcttc	tcaaaaggac	attgatgagg	agccctaga	gagagatttt	97440
gtgctctggg	accagaccgg	ttgttaaacy	ccagtattca	cctctgcccc	gactttcccc	97500
aaagaggtag	ttcccgccaa	ggcctttctc	tttctctctc	ctggctggaa	gtgttgagtt	97560
ccatgtcaga	accagaatag	agaacctttc	cttctataag	ggctataaac	cttgagaaca	97620
gtcttaaga	taggtatgta	ggccacacca	ttcaccacaa	atgtactgat	actcatcaga	97680

-continued

```

ggatggaaga agcaccagag agtttgaagc atctagagaa aaggtagaaa gagaatgcc 97740
tttaactgac ctctcgtatg atagtcaatc acaatgatga gtgttgattc atcattttgg 97800
ctgggtggca gaaatatcta taaaacagaa gctgccgtgt tgtttacttc cagtcctcgg 97860
ggcccacaag aaggcagcta tcatttggtta ttactaaaaa catgccccat gttcagctca 97920
tcccccaaaa tgaccactg ctactgttta tgctgggcta gcatgaagcc cagggcccta 97980
gtgtctaggt ctggtcagtg aggcctagag cagagcctaa agagcctgag agcagtgcct 98040
tcctttcttc agagtactca tgaaggatg gctgtcagaa aaggaagtga ggaggggctc 98100
cagagacttc agaccacccc aacttcccc aatgagaccct ggcacttccc cataacctct 98160
cactcagcgg gccctgtcta tagagcagaa aatgaaacag agcagtcatc tagaggtagt 98220
gtatcagcaa gcccaggcac cacagtaata gcaaccatat cagatgggaa aggagttcaa 98280
gtgaacaaac aagcaaattc aatagtcaga taggttagat tatacttgat gctgtttctg 98340
ggttttacaa atctgggtta ccaattgtt attttcagaa aacagaggaa atgctctatc 98400
acattgtgaa agggaagatt ttactgtcgt atcatatata ctacatggga gctttctgca 98460
gaagttagag ctgaaggagg gagacaggca gaagggcagc tggcagggtc gcctgggagg 98520
agctctgcta taagggtgat cctgtgccat ttgagaacag ggaagaaagc aatgaagtgt 98580
tggggaggga atcactcaac tcacagaaca tacagaaatc cagcaagggt tcaaatgct 98640
ctacacccta gagtctctta agttaggga actctctgag ctcatggggc caaatgctct 98700
tgcctgcttg aaatatgaaa aatcaacaat ggattccttg caaaaccagg aaaaggggaa 98760
cttctgagcc ccttggttat ttgaaatac ggaccataaa tttcagtcct gagcccttg 98820
aaggtaggag aaggtggttt agaaaacaca gacacagaca catacacaca cccccccaa 98880
aataaagcaa aaaaaaaaaat actggtgttt tctttctccc cacatctgta aagttgttg 98940
attgatttta ctgccatgt tatccctatt tgaaggcagg gggctgtctt attacccaaa 99000
gaggacattt attgatttga ttatcttttt ccatttttac agtgcacat ctttttcacc 99060
catatggcct ttctggaggt ggttctcaat ctggcttggt gaagcatcaa attacacctg 99120
tcttagagag agtagaaaca caaatcttct tcttctctcat ttacttggtg tagtcagtta 99180
actcagactg tgtattcaga ctcttgatta tcacttaatt catagtttca gaaatctctg 99240
gaatgggcac aagtacagga cttaaagcc tggaaatcca gacagaaata tatttctagc 99300
tttgatggtt tataacacat gggactttta ggctgtcatt gatgcagggc tcagcacaga 99360
gtcagttgta atctggccag gttttgttgt tgaggaagag tgggaagggg gagtccctaca 99420
ttttctcctt gtcagtaata ttggagaatt ggggtgagag tgaagctggg caggggaaag 99480
tctgcataga aaaaagggtc tggcgagaaa aaatcatgct actaagccat gagggtaaaa 99540
tgaccaagtt atggttgaca gaaacttggc catagtgtgt ggggggaggg taggggggtga 99600
gggcagagag aaagtgtgtc taagtctgtg ttgggggaca gtgcttggtg ggatgaactc 99660
tgggttagaa acaggcatgt agggaaatag ttggtttatg gtgtgggtag gatgaatggg 99720
gcggtgaaag ggaaggcatt ttgaatgcta agagaccagg aagtcaaagc aaagcaatac 99780
ccataaacag aggttaagggc tcagagaggt tttagtgtga tagtcttggg taagaaattt 99840
ccccctttga acctcagttt tccttgactg taaaacaacg gacttgaact agatatttca 99900
aaatgtgctt ccaacttaga cattttgtga tcgttctaca aattacaaac ataactcatca 99960
tcatttcagc aaactcacgt gtatttatac ctgcatatgt ttttggctct gctttcctag 100020

```

-continued

```

aagatgacta atccaagatc ctaatcaatt aaagaagcaa tcttcagatg gggatagagc 100080
cagctgagag agtgactatc gtatggagtg ggtaaaact caggactctg agatttttac 100140
cttgtgatca ttgctgggta acttccttcc ttttctattt ctcatctgga aaatcaggat 100200
atgaatcccc atctctacct cattatgttt caaagagggt taattaatcc atcatgtgca 100260
ttatgtgctc aagaatttac tatttttcag atattttcta gtaaaacgtt ggagattata 100320
tgtccatttg tttgtacac atggagtgtc gtttggtaca catcataaaa ttgaaactgt 100380
agtttacatt ctgaactcaa agaattacac catcctcact gatgtttaca ataggtecca 100440
atttagtttc tttggcaaat tttatgtaag tatggctttg attctctctc tcaccccagg 100500
tttttgtagg ggaagaaatg caagtgaacc ctcatgaac tctttctgtc ctttaaatcc 100560
attctttccc acctcaactc atgtggaatt gaatgttacc tctagtttgg agtctagcag 100620
agagtttttg gtgcataatc gtgtcccttc cactccctga ctttttgagt aacatttccc 100680
agaggcaaat taactctgct aagaggatct gcttgacgtc tcaacagagc cttcatcagg 100740
tatctttggc caaggagtgt actgatectg actttgcgag tcctagagat cttttcacia 100800
aactcctctc atgtttctgt ctctggtttt cttaaaagtc gcagacagac tttagattta 100860
ggggttggtt aactttttgt aaagggccat gtagtaata ttttaggctt tgtagatcat 100920
atggtctctg tgtcaactac tcagctctgc ctttgcagga tgaaagcagc catggataat 100980
acttgaacta atgggagtag ctgtgttcca ataaaacttt atgggcactg aaatttgaat 101040
ttcacttaat tttcacatat catttaatat tatttttctt ttttaaccatt taaaaattta 101100
gaaatcattc ttatctcggt gggcctcaca aaaacagatg gtagagtaga tttggtttat 101160
gggctgcagt ttgttgacct ctgctttaga taatcacttc tgtacttata aatctgcaaa 101220
ggttttatgt tttcccatct ctgggtattt tagtagctct ctagattatc taatttaaaa 101280
attttttctc agtaggccc aaagttgcaca tcttgtagc acagaatgcc tggcctagt 101340
gcttcttggc cctgagcctt ttactaaaca ggagaaaaac taaatgtcta gaaatgctag 101400
aagaggatcc tattttgttt taatgatcta gtagatcact cctccttgca ataccagag 101460
gagaaactga aaatatttca agcattttct agacttctgt gttgtaaatg tgtggataac 101520
tatgaactat acatgaaagc acttttctgg atgacacata tattccagat ggcaaaaagg 101580
aagcactttg gggactctct ggtaccaagt atcatggaaa aattgtgtgt ctcatagaaa 101640
gtagatccca ggaagccagc tgagtgtgg atctgccata tattacctca tgattctgtc 101700
ttcgcacact cactggctta attctgggcc tccccataac acgactagac cacaggcttg 101760
cagaagaaat aatttagctc tgtaactcat tgcagttggt gccacccaa gtctctgtca 101820
gtgccaatt cgaggacct gccagaatt tgccattgct gcttcgtagt ggccctgtgc 101880
ctgcttattt atagcctgtg cattttatga aacagagatt aataagaagt tgccatagta 101940
cttgaccat tatgtaata tctgcaatgc ttacatagcc tttgtcactt gcaagatctt 102000
ttgagtccac tgccttctgc taccatgct taccatttc ctagtcctt attattattt 102060
tttaatttat tataattaac tttgtgata catgttcaga atgtgcagg ttcttatata 102120
ggatatacag tgctgtggtg gtgtgtgaa accaacaacc cgtcatctgc attagttatt 102180
tattctaag ctatccctcc cctagcccag tgtgtgagt tccccctct gtgtccatgt 102240
tttctcattg ttcaactccc acttatgagt gagaacatgc agtgtttggt tttctgttcc 102300
tgtgtttgtt ttctgagaat gatggtttcc agcttcatct atgtccctgg aaaggacatg 102360
aactcatcct ttttgatggc tgtatagtat tccatggtgt atatgtgcca cattttcttt 102420

```

-continued

atccagtcta tcattgatgg gcatttcggg tgattccaag tctgtgctat tgtgaatagt 102480
gctgcaataa acatacgtat gcatgtatct ttatagaaga atgatttata atcctttggg 102540
tgtataccca gtaatgggat tgctgggtca aatgatattt caggttctag atccttaagg 102600
aatctccaca ctgtctttca taatggttga actaatttac acccccacca ccaatgtaaa 102660
agcattccta tttcttcaca tctctccat catctgttgt ttctgactt cttaatgatc 102720
accattctaa ctggcatgac atgggatctc attgtgggtt tgatttgcat ttctctaatt 102780
accagtgatg atgagctttt ttcatatgt ttgctggcgg cataaatgac ttcttttgag 102840
aagtgcctgt tcatatcctt caccattttt ctgatgtggg tgtttttttc ttgtaaatat 102900
gtttaagtgc ctgttagatt ctggatatta gccctttgtc agatggatgg attgcaaaaa 102960
tttctctcat tctgtagctt ggtgtttcac tctgatgcta gtttcttttg ctatgtagaa 103020
gctctttagt ttaattagat ttcatttgtc atttttggct tttgttgcca ttacttttgg 103080
tatttttagtc atgaagactt tgcccattca ctattgtac aaagagaaca aaatacctag 103140
gaatacaact tacaagggat gtgaaggacc tcttcgagga gaactacaaa ccactgctca 103200
aggcaataag agaggacaca aacaaatgga aaaacattcc atgctcatgg ataggaagaa 103260
tcaatatcgt gacaattgcc atactgcca aagtaaatta tagattcggg gctatcccca 103320
ttaagctacc attgactttc ttcacagaat tagaaaatac tactttaagt ttcatatgga 103380
acaaaaaaga gcccatatac cctagacaat tctaagcaaa aagaataaag ctagaggat 103440
caagttacct gacttcaaac tacagtacaa ggctacagta acccttatca attttgtatt 103500
gctgtccat tttctgcagc cagaagcttc ttcagtcctt taagggaatt tctgggtgac 103560
tatcaaaactc tggtagttca tttttgcagt tgactgctat tgtgaggata agtgtcagac 103620
tcactctctc ttcagagata gaaattatgt attaattatc tggattctag acccagca 103680
aggagcaaac tgctctcaa aataactgaa ttcttcgaga agtcacatt gtaaaacaat 103740
atcttcagtt atagtagcca tgtgtgcatg cttctggaaa ctgtttttca gattttcatc 103800
ttccttcctt gtctctctat agcaaggcag ctgctttcag ccttgtagag atgctagtga 103860
gctttgtacc tacaacctg agaaaattga actgagattt ggagggtgaat gactcttgat 103920
aaagggaaca aggttttaga ttatcagtcc ctttgcctcc aggtgtgtgt gtgactactt 103980
aggcactcca gtgaatcac tattctcctt atctagacta atgcctgtcc ctgcagagca 104040
cctcatgaga acaggcctgg tagtaatac ctcatgcatt cagtcagtaa atatttacgg 104100
agtgttact acatgtagga tattgggctg acatactcaa ggtacagggc ttgcttcag 104160
gaggttatag tttattaatc ataaaagtgg catttttttt gagacggagt cttgctctgc 104220
ctgtgcacca gactggagtg cagtggcatg atctcggtc actgcaagct ccgctccca 104280
ggttcatgag attctctgc ctcacctcc cgaacagctg ggactacagg ggtgcaaccac 104340
cacacctagc tattttttct tttatatata tatatatata tatatatata 104400
tatatttttt tttttttttt tttttcagta gagacagagt ttcaccatat aggccaggct 104460
ggtctcgaa ccttgacttc gtgatccacc cacctcagcg tcccaaagtg ctgagattac 104520
agggtgaaa atgtgacaat ctttaaagct cttcagtgga tgaaaggcca ccctatctac 104580
tgtccatttg aactttgcaa ctatcttggg acagagtgag aagttattct cttggttttc 104640
catatgagta aactgaggct ttgccagtc atcagcagg aataaataat gtatctggaa 104700
tttgaaccca ggtcttctgg ggtcaaaggc agcattcact ctgttccatc acagcagctc 104760

-continued

ctcaataag ccaacataga aaccaagtac tatgcctagg caacaagaaa ggcagcaatg 104820
aagagcaaca gcagagtga atagtagaga aggaagttaa gaaagatgtt aagtactgtg 104880
gggagtaacc aagaaccac caagtatgc taacatcaca gggagcttgt cttoctaaga 104940
aaactccaag cacttaaac agctggtagt tcatcagcaa ctctctttat tagatgtatg 105000
agggacatgt gggccatagt ccttctacca acttatatgc ttcaggggga agttctgatt 105060
ctgatgagac ccagcatggt cgcttttaac tcaactgtgt cacacaacta tagaacagga 105120
agcacaactt aacacctgtg tcatgagaa ttttgcctct tatgaccaag ctaaagaaag 105180
agcttagaca ggatgtgagg atataaatgt agattcatgg ttccttggtc ctttggtttg 105240
agccttctca gcagagcatg ccacagagt ttttccatgg ggcagtagc aagagaaatc 105300
catttccctc ctctcgtatg tcagaaaaca gagaatattg tctttcagga tagaattaaa 105360
aagtcataga ggcagcaact tgttttcta tattagggtt taaaattct gtttttctt 105420
cctctcctga gtcacatcat tgtgtggatg gaccttgatt tcaactgtgt atctggatgt 105480
gggacctgaa ggccatggac ttctaacagt tccttaagtt acagaagcac attcctatag 105540
gtcacaagct catttactta caggatggtt gattcagtc caggttattt catgaaaata 105600
cttaaaagat ttgcagtgtt caaaactgca ggatctttaa aactaaaac ttgaagggaag 105660
ggaatttgga aatcaaaaaa tctggtcaaa ccgtttcatg gaaaagtaa gtgaggetca 105720
gagagaggaa attactttcc tgggtttcta tagcatataa atggcagaag tgagagcctc 105780
cctgccattt atagttttct gctgagaga cctcctgct tcaagctaa ttagcagagt 105840
tacagaggtc attacctgac aattctcaag aattatgtga ggcagtatag taagcattta 105900
tggcccttgg tcccagaag gagcttagtc cctgatatgc ctctctgctc ttgctgcat 105960
tgtgtgagac catcttctgt aactgtatgt ctccccct agtaagttaa tgagtaataa 106020
aggattccg tagtgagagg actctgtaag agaattcttg gtgtaaggat tgttgcaagg 106080
tgttttctgt tgtatgtgca tgtataaact tttttaggga gtgtattcat agcttttaca 106140
tggatctcag aggtctgtga acagaaaatt acagaatact ggtcttgtct ttggtaaggga 106200
ttttatagac ccataaggga gtattctgac tacagtgata tccaacatgg ctatttaatg 106260
cctggcattt tccccacata acatacgttt attcaacagt cagtgcctac tgtgtacatg 106320
agacctatac caggcactgg gataagagac atgaaataac agctaaaact gtttattgag 106380
cagtcaatat gcattagatg cttttagtagc attttcttat tcaatctgta taccctcaat 106440
ttacaaatga gggaaaccgag acacaaaaga gttgagtgtat ttgcccagg tcatacaaat 106500
agtcagtggc tatgtgtgta atagttacca acatgaaaga gtgagattac tgctgtacta 106560
aaagtaggca cataattccc tgagcagata gtatgagaga atgatttatt ttacctggaa 106620
agtttaggaa ggcttcacag aggagttaag ggttgatctg gatcttgagg gatggataag 106680
aatttgccag atacaaaaag gtgaaaagag aacttcagga ggaggggaaca ggttgagcaa 106740
agacaagggt atatgaaagc gggaggcttg ttgggggagc attatggaat ctggaagtca 106800
ttgtggggaa tctcatcaga tgcagcaagc tgcttgacag gccttcaatt ggctctttgt 106860
accttgctcc ctccccatgc tgagctgtcc atagctgcct taggctggtg tctgggattt 106920
tcggaagggt actatccagg tagtgaaca agatgcagtg taagagcacc agatcggggc 106980
tctggctctg ctactgaact aacacctggc attaagcatg tctagttccc tctttgtaca 107040
ttaaaatctc cattggagca gtaacatggt tgtattaaat gatcttgaag attttaaaaa 107100
taaatatata acaatataaa tcgttaacaa taatttttagt agtaaatctc taaaatttta 107160

-continued

cagataatcc agattcatcc attggccaat ggttcacttt gtatgcataa ttttttggga 107220
aacaggcaga ccgaatttca atcccttagtt gtaagactta atacatatgt gacctcaagc 107280
aaatttatatt gaatgcctct ataaggataa taatatctta cagaactatt gtaagaacta 107340
aatgatgtgt aataaagctc ctgggtactca gtcagttttg gatccctttc cttagtgtag 107400
tcttggtcat aggcacgcac atacttgtag gggccctga gtaggcagaa agaacaaatg 107460
agagatggta tctgtggtat tccccaggta aaggaggcct tgggttggtg taagatttca 107520
cttcacttta gagttactta attagggacc agaaaggcca tcgcatctgt atgagaatat 107580
aacaaggtc aatttcttcc tctttacttt ttacgctgtg agtaacattc cccagccagc 107640
ccagccggca cgtgttcttt gcctctcctg acttcagac tttggtcttg aagggtgcag 107700
agctctctgt gtatctttgc ccccaacagg ataagtctga cctcccagc aaattcaact 107760
cctaagccac tgtccaggag aagagctagc aaggtcataa attattctcc atattttcca 107820
gccattggtt tcccttgctc agccagaggt gtgtcttaaa gtatgctgag gctagattca 107880
atagaaacct gagccagcac ctgtgttaact aatttttaaa actcccttc ctgaagctgg 107940
atgaatatTT tttaaaacta agctggatta tcttttatct agcatgccgt ttcctacatt 108000
cctagtgtc tggacctctt ggaggaatgt agtttggtta tagtggtatt gtcttgcttg 108060
tctgttggtg gggaggagga catttcttc aaaaacaagg taatacttcg gtctggacta 108120
tgactatTTT gtttaaaatg aaactatggc actgtactgg tactcattct gcttcctata 108180
ggtagcttt acatccctct gtcttcaccc actctacagt tctgatcctt ttaaaaagca 108240
gccaacaaaa accagcaagt acatactgct tatctctgac ttctacctga atcaacttca 108300
gatcttgctc aaagctccat ctgaagagag ggggataaca cctgccaag agccctcagg 108360
gcccacagt aagtagacat cctgtccttg aggtctctta actctgctca gcttcagaat 108420
acagaagggg ttggttcttc atttggttg tttataacta aaagcctcct acttcccgt 108480
ttttttgcat agcttcttct gccatccac ctgtgtagcc tcttcaactc ccctaaaact 108540
cctctgtagc cctgtcact tggaaagagt tttctttgtc tcttttgcaa cttgacaatg 108600
actagccagc aagtttaagt tcaattatt gttccatggg aacagagata gatataggaa 108660
acaaaaaag ggatatggag gtatggagta atttcccacc tacctagtga gcactactga 108720
gatattcaaa tgctctctac tcaagaatc tattgatata aacgtaaaaa acttgatctt 108780
aggtctaata tccattagta gtgtgacctt gggaaaacga taccactccc aaaggcttag 108840
tttttttaac tataaaatag gaataatgat gaccaccccc agaggattca taaggataac 108900
atgagataag gcaacttgaa atttccctagc atggcgatag acttttgaaa ataaaatgaa 108960
ccaaacactg ataacagtac ttccctagtgc acaaatgaga aatcagtcct tcatcaaatt 109020
acagcacatt tccaatgctc cgattatgtc actgtagaaa tgctaagtgt gattaaataa 109080
tttgtctgtt gctatttata tggataattt gatagtaatt atttttggac atggatagtt 109140
ttgaagcctt acagatgagt ccatccccaa gtacccaaaa ttaaagaaag ttggctagag 109200
tgatggcaag gtggcagcac agagctccct gggttctggg ccctgtcccc tagctaggga 109260
gaactccagg ctataagcat ttgtattctc atagtccaat ggcagggaaa aggggtgaag 109320
gtgagtactt ttcactcatt tattttttca acaagcatgt atgggtgcag gccttgtagt 109380
catccacaga caaatgtgag ctagccctga cctcaaggag atttcagttg cagcttttagc 109440
actgcaaaga gtatctacct gcggcagata caatgtgatg ggacatggcg gagaaaaaat 109500

-continued

ctataaacag agcctcccca tccccaggca tggaaacaat cctaaccag gctggcatag 109560
tacaatgggc ctgtctctat cagcagggtt ggaagcttta acaacaaca aaaaaacaat 109620
aataatgatg atgataatca tagtgccata tgttaccaaa cattttccgt gtgttaagta 109680
ctataactaag tgcatactta atcctcacag caactctata aggtagtaga tactcttact 109740
actaccctga ttttacaat atggaaactg aggcacagaa gactgagaga acaggaatac 109800
acctaattca cctcagtcca acaaacacca agcatctgtt ttatgtcagg cctcgtgctg 109860
gggtgccagg agagagaaat gagtaaagca tagtttcagt ccagtgggag caaatgacag 109920
cacacagtgg acacatatat tgcagccctt ctgctttatg ctaagaactc attgtcagt 109980
atgaatcaaa cacagtccct ctctcaaaga tcttcaagct tagtaggaga tatctgtgtg 110040
aaaacaaaaa ttaagactg ctgtgataag tgtcataaga gataagtga aaatgagaga 110100
gagatcactg tagcagtga ttgggtttaa tcaaagcccc ccaaaaaaca gtgttattga 110160
gaattataga acaactaatt gatttaaatc aaagcccaaa cagaacagtg tttgctaatt 110220
ttatttcagg ttggttgata gattttcatt ttttattcca tcccgacaat ggaagattag 110280
tgcttggttc ccaccaagg ataccaggat atttcaggga ctgtattaca atatagttaa 110340
attattccct tatctcaaag cacaccaca ctttctccta tctttccct tactcaggct 110400
atctctctg cctcagggtc ttttctcca catttccata ttcttaagtc ctacctcct 110460
tcaaggcctc actcgaatgc ctctcctcc atgaagcatc caccatcg aaaggtaacct 110520
cgccatctcc tgtactccca catcacttca tgggtgtctc tctgtggttc ttaccacttc 110580
ctgctttatc tttcagtaat gcacttacag ttctctttcc tccactagac agagctcttc 110640
agacaaagat tcacttggtc gaaacatga ttttacttta aacacattga aaacctctac 110700
cggaatgcat tgtgtctggt gggcttcaac cttaattctt aagtatgtga aaatacatta 110760
cctatctgga gggttacact ttctgcta atgacttttt ttaagtccac caccctaaca 110820
caacaaatgc ttaaaacatg tcttcatttc ctttaggtct ggccctcatg catgcatata 110880
atztatagag tcaactgttt gctcggttgt cctcatgcct ctatattatt ggagggttag 110940
attgtttcca cacacttagg ttgtattcat gtacattttt tttcttttt aaatttcct 111000
agcatccatt cccaccattg gaaattcagg gtcaaacag ggggtgggaa ttggagcatg 111060
tgtatcacag ataaccaatc atgtgttatg acttaagaat ttatgaaagg gccctctacc 111120
tgaagatata ttgtactga tctgtctca cagtgtctga aactccatc atatgtggaa 111180
ttgttttgga agattttgcc tctggggca cattcagcca taatcaggaa atagtattga 111240
gcattagact gtcagtatgt ccattagcaa gactgtggaa gaatggaatc accaatatta 111300
tattttatag gggatacaga attcaagaga agttctgaag agaaaatgct tatctagaat 111360
aggaaggctt agatacagca tgaagctgc aggccttgag gagccagagg tcaaatgaaa 111420
gcactgagta tttgtttata tgaagaaca gaaagggaaa agagaagcag aggaagggat 111480
agtagagaga aatgaataag ttttatccat ttaacttgga attgtgttg gctatgggca 111540
caacagaagc agtgagatca ctttatttta ttttattct catagacagg gtcttgetat 111600
gttgcgcagg ctggagtgtg cagctcttca cagggtgat catagtgtac tacaccctcg 111660
aactcctgaa ctcaagcaat cctccaacct cagcctcctg agtagctggg acaagtgcac 111720
accaccacac ccaatgagat cacttaaaaa ctaggagag atgtgtgagt tctgggcaac 111780
cagtagttag aaaaccagga ggggtttgga aatcagaaaa ccagcagagg caggaaaact 111840
cagggcagca tggcagatgt agtatataca agtaggttca caccagtcag cagacagaat 111900

-continued

tgtaactgct gatgtggagt agaggctagc tttgtctgct gtgtgatacc caaaccttta 111960
agaatagtag gtgtatacgg ggaattggag ggagataggt ggctgtatth actaattggt 112020
tgatttcact gagatggtht gggatattgtg gcttccagat gctcatatth tctthttttg 112080
gtagagactc caacatcatt acagaactat aaattacata tggaaaagaa aggcctccta 112140
tgtagaata gaaaatagaa tgcgtggtggg ttgagggaca gagggctctgt ctaggaagtc 112200
agatagcatt ttcccgthtct gtccctcaga gttccttgct cccattgaga ctcaatthtct 112260
cttactthtg tthctagtgt taccaccac tgttctthtct catctcaacc ctgagtataa 112320
gtacagatca cttccttggt gttcttagaa cataatagaa atgaactctc attcatcaaa 112380
atgccatta gtaaaactg agggagaaca aactagaaat ccagtataga aagtaaaat 112440
aggattatat tcttgcaat ctcaaaaaa acaatgaaga gctthtcttg ggcattagac 112500
accttccat aagggtgctg actctcttht agtcatgtca acttgacca atcttctct 112560
ggtagcatt tthtcttggt cattaacca tctgctatgc tctatgggt tcttagagaa 112620
atgccgtca tgtacacga tatcaataa cacaagatc actctgact ggcaagcct 112680
thtatgatgc tgtgagcatt tgatacctt gttgctagta atatcagtga gtgacctgac 112740
ccatathtg aacagaatat gatcagtata ttgctcaaa gaggcctca ctgttctaaa 112800
aaatataatt ccagagthtg ctgactcaca ccgtggaata tgtgcaaaa tgaatcctgc 112860
agataagcct thctctgact agthtcagaa thttthtctg ggtaathtta aaattathth 112920
thtaththtg taggtacaaa gtagggtgat atatgtatga ggtacctgag gcaththgat 112980
acaagtatac agtgtgtaat aatcaccagc gtcaatgggt tatcccttac cacaagtatt 113040
tatcctthtct ttgtgatata aacaatccaa ttatathctt ttagtththt taagatggac 113100
aatgtthtg ttgactgcag tcacctgtt gagctatcaa atactagatc tcattcatc 113160
taactatatt thtgatccca gtgacctcc cacttctctc cctccacta cctthtccag 113220
cctctgataa ccatcattcc actctctatg tctatgagct caattgttht aagththtagc 113280
tcccacaaat atgtgagaaa atgccaagt tgtctthtctg tgctggctt atttcacgta 113340
atataatgct thctagtgc atccatgta ttgcaaatga caggatctct thtthththta 113400
tggtgaata gtactthatt gtacgtatgt accacathth ctcatccat ttgctgttg 113460
atggacaaga gttgcttcca aatattggct attgtgaata gtgctgcaat aaatgtggga 113520
atgcagatat ctcttcaata tgetgathth ctthtthtag ggtgtatacc cagcagthgg 113580
attgtgggt catatgatag ctctaththt agtaththgt ggaacctcaa atctathctc 113640
cataatggtt thactgactt acatatccac caacagtgta tgaggatact ctthtctcca 113700
catctcacc agcattcatt acttctgtt ctthggatga aagccathth aaccgtggtg 113760
aaatgagatc ccattgttgt thtgatgtgc acttctctga tgatcagtga ggttgaggac 113820
cttgtcatat atctgtthgt caththgatg ththththtg agagatatct accagatct 113880
thtgccatt ttgtaatcag attgttatat ththththtcc tatagagtha cttagctcc 113940
thtatataccc tagththta thcttggtca gatgggtagt ttgcaaatag thtctctcat 114000
tctgtgcatt gtctcttcc thtggtgact gaatcctthg ctgtgcagaa gctththaac 114060
thgatgtgac ctcatthgtc caththtagt tgctgtgct ggtatggtat tatcaagaa 114120
aththtgcc agattaatgt thtgagagt thcccaatg ththtthgaa gtctthtcat 114180
ggattgatgt cttagathth agtctthaat atgtthtgat ththththt gtaththgctg 114240

-continued

agagataggg ctctagtttc cttctgcata tggatatcca gttttccag caccatcttt 114300
tgaagagact atccattctt taatatacat ccttggtacc tttgttgaaa ataagttcac 114360
tgtagatgta tggacttggt tctgggttct ctgttctggt tcattcgtct atgtgtttgc 114420
tttcatatga ataccatggt gttttggta caatagctct gtattataat ttgaagtcag 114480
ataatgtgat tcttcaggt ttgcttggt ctttttctc aagatagctt tgcctatcct 114540
gggtctcttg tggttctata tacatttttag gattattttt tctatttatg tgaagaatgt 114600
cattgatatt ttgatataaa ttgcattgaa tctgtagata gcttcaggta gtgtggacat 114660
ttaacaata tcaattcttg aaattcacga gcatggaata tcattctatt atttggaagt 114720
cttcaatttc ttatatatgt attatatata tattagtttt cattgtagag atatttaatt 114780
tatttaacta aatttattgc taggtatttt attttatttt tacctattgt caatgggatt 114840
gttgtcttga tttctttttt agattgttca ctgttggcat acagaaaagc tactgatttt 114900
tatatgttga ttttgtatcc tgcacttta ctgaatttgt ttatcagttc taataggctt 114960
ttggtgcagt ctttaggttt ttccaaatat aagatcatat cgtctgcaa caagaataat 115020
ttgacttctt tcttttcaat ttggatgcc ttcatttctt tctctgtct gattgctcta 115080
gctaggactt ccagtactct gttgaataac agtggggaaa gttaacatcc ttgttttgtt 115140
tcagatctta tagccaatgc cttcagtttt tccaaattta gtatgatgct agctatgggt 115200
ctgtcatata tggcttttgt tatgctgaag tatgctccct agtttttga aagtttttgt 115260
cttttaagga agataaaaat tgaatgttat caaatgcttt tcatgtaaca attgaaatga 115320
tcaagtgtt tttgtccttc attctgttga tatgatatat cacattgatt gacttagatg 115380
tattttgagc catccttgca gcccttggt aatcccactt agtcatggtg aatgaacttt 115440
ttaatgtgtt gttgaattca gtttctagt attttcttga ggatttttgc atcaatgttt 115500
atcagggata ttggcctata gttttccttt ttgtgtgtgt atattttgga ttttgttatc 115560
aggttaatc tggccttgta gattgagttt ggaatgatcc tctcctctat tttttgaaat 115620
actttgaata ggattgatgt tactttttct taaaatgttt ggtaaaattc tgcactgaag 115680
ccactgggtc ctggactttt tactgctgag aagacttttt gttacagctt caatcttatt 115740
atttgttatt ggtctgttca agtttttagat tttttctgtg gttcaatctt cccaagttgt 115800
ctgtttctcg aaatttatca atttattcta ggttttccaa tgtattgtca tatagttgct 115860
catagtagcc tctaataatc ccttgaattt ttgcagtaac cattgtaata ttctcttttt 115920
ttaaatctct gattttattt gagcattctc ttttttctt agtctagcta aatatttgtc 115980
aatgttggtt cttcatccac aaaaccaact tttcgtttca ctgatgtttt ttgtattttt 116040
tccttttaat ttattttatt tctactctga tctttatcat ttcatttatt ccagttattt 116100
gagtttggtt tgctcttgc tttctagtcc tttaatatgc attgttaggt tattttattg 116160
aactttttga tgtagggtca tattgctata aactttcgtt ataatttgc ttttgcgtga 116220
tcccataggt tttagtatgc tgtttagtat gttttcaatt tggtagattt caataaattt 116280
ttaaattttc ttctttattt attgacatag tcattccaga gtatactgtt taatttccat 116340
gtggttggt tagtttccaa aattcctcgt gtttttgatt tctagtttta ttctattgtg 116400
gtcagagaat aagcttgata tgattgcaat ttttaatact tttttaaaaa cttgttttgt 116460
ggcctaagat atgatctgtc attgagaatg atctatatgc tgaggaaaga atgtatatcc 116520
tgcagccatt ggataaaaat gtcttttaaa atctattatg tccatttaag acataatgca 116580
ggccaggcgc ggtggctcaa gcctgtaatc ccagcacttt gggaggccga gacgggcgga 116640

-continued

tcacgaggtc aagagatoga gaccatcctg gccgacacgg tgaaccccg tctctactaa 116700
aaaatacaga aaactagccg ggcgaggtgg cgggcgcctg tagtcccagc tactcgggag 116760
gctgaggcag gagaatggcg taaacccggg aggcggagct tgcagtgagc cgagatcccg 116820
ccactgcact ccagcctggg cgacagagcg agactccgct tcaaaaaaa aaaaaaaaag 116880
acataatgcg gattaaggcc aatgtttcat tgttcatttt tctgtctgga taatcttttc 116940
aatgctgaaa gtgggggtgtt aaaatctcca aatgttattg tattgggagc tttctcttct 117000
ttcaactctg ataataattg ctttagatat ctgggtgctc cagtgttggg tgcatatata 117060
cttaaaattg ttgtatctc ctgatgaatt gaccctttta tcattatata atgaccttct 117120
ttttctcttt gtgtagtgtt ggtcttgaaa tctattttgt ctgatattag tatagctgct 117180
aatttttttg gtttccattt gcatgaaata tctttttcat tcttttattt tcaatcaatg 117240
tgtttcttta tatttaatat gtgaaatatg tttcttgtaa ataaaaatta ttattttaac 117300
atatttttaa aataatactt tttaaataat aacagttatt attatttttt aaattttcat 117360
tagttttggg agcccagggt gattttgatt acatgagtga gttctttagt agtggatttt 117420
gagattttag tggagcagtc acctgagaag tgtacattac ccaacatgta gttgtatgta 117480
tattatatat acagtatata tataaagcat atatacacac tatatatagt atatatgtac 117540
atatagtata aatatatata gtatatatgc tttatatata gtgtatatat gctttataat 117600
tgtatatata tgctttatat atgttggtga tatctagtat atattgtata tatagtatat 117660
ataatatata atgctttatg tattgtattt atatatgta taatatataa agcatatata 117720
gtatatatac tatatatata gcatatattt tgtatatata ttatatatgt tgtgtatata 117780
tattatatat ataattaaat tctgggatac atgtgcagaa cttgcagttt tcttacatag 117840
gtatacatgt gccatgggtg tttgctgcac ccatcaacct gccatatata ttaggtattt 117900
ctcctaagtc tatccctccc ctagccccc cctactccct gacaggcccc agtgtgtgat 117960
gtccccctcc ctgtgtccat gtgatctcat tgttcaactg ccacttatga gtgagaatat 118020
gcggtgtttg gttttctgtt ctgtgttca ctgagaatga tggtttccag cttcatccat 118080
gtccctgcaa aggacatgaa ctcatccttt tttatggcta catagtattc catgggtgat 118140
agggtccaca ttttctatat ccagtctatc actgatgggc atttcggttg gttccaagtc 118200
catgctattg tgaatagtgc tgcaataaac atatcgctgc atttgccttt atagaagaat 118260
ggtttataat cctttgggta tatacccagt aatgggattg ctgagtcaaa tgggtatttct 118320
ggttctagat ccttaaggaa ttgccacact gtcttcaca atggttgaac taatttatgc 118380
tcccaccaac aatgtaaaaa cgttcctatt tcttcaaatc ctactaaca tctgttattt 118440
cctgactttt taatgatcac cattctaaat ggcagagat ggtatgtcat tgtggttttg 118500
ctttgcattt ctctaataac cagtgatgat gagctttttt tcatgtgtgt tggcagcata 118560
aatgtcaaga agtgtctgtt catattcttc acccactttt ggatgggggt gtttggtttt 118620
ttttttcttg taaatttgtt taagttcctt gtagattctg gatattaccc ctttgcaga 118680
tggtatagatt gcaaaaaatt tctcccatc tgtagggtgc ctcttcattc tgcgtatagt 118740
ttctctgct gtgcagaagc tttttagttt aattagatcc catttgtcaa ttttggtttt 118800
tgttgccatt gcttttgggtg ttttagtcat gaagtcttg cccatgccc tgcctgaat 118860
ggtattgcct tggttttctt ctatggtttt tatggtttta ggtcttgcac ttaagctttt 118920
aatccatctt gagttaattt ttgtataaca tgtaagggaag ggttcagtt tcaagttctt 118980

-continued

gcgtgaggtt agccagtttt cccaacacca ttattataat agagaatcct tccccattg 119040
 cttgtttttg tcaagtttgt caaagatcag gtggtttag atgtgtggtg ttatttctga 119100
 ggctctctct gtgttccact tgtctatata tctgttttgg taccagtacc atgtgggttt 119160
 gggtaatgta ccctttagt atggtttgaa gtcaggtagc gtgatgcctt cggttttgg 119220
 ctttttgttt aggattgtct tgactatatg agctcttttt tggttccata tgaaatttga 119280
 aaagtaaaca gtacaataag atgtaaatag aaacaacaaa gtgataacaa gcagagagat 119340
 gaattagaaa aaaatatatt ttttctaatt ctgtgaagaa agtcaatgat agcttattgg 119400
 ggatagcatt gaatctataa gttgctttgg gcagtgtggc cattttcatg ataatgattc 119460
 ttcctatcca tgagtatgga atgtttttcc atttgttgt gtctctctt atttcttga 119520
 gcaatgggtt gtagttctcc ttaaagaggt atttcacatc cttgtgaatt gtattcctag 119580
 gtattttatt ctcttttag caatttgaa tggcgggtca ttcattgatt gattctctgt 119640
 ctgttattgc tgtataggaa tgctttagt ttttgcaaat tgattttgta tactgagatt 119700
 ttgataaagt tgcttatcag ctttaaggat atttttggg gaggtgatgg ggttttctaa 119760
 atatatggtc atgtcatctg caaacggaga caatttgact tcctctcttc ctatttgaat 119820
 acctttattt ctttctcttg cttgattgcc ctactgtaa ctttcaatac tatgttgaat 119880
 aggattggtg aaagagagct tccttgtctt gcaactgggt tcaaagggaa tgcttcagct 119940
 tttgccatt cagtatgacc aatatgtagt cttttattcc tcacctctc tcaaccctca 120000
 cccaacgga gtctcaagt cttttacatc actgtgtgtt attgcatcct catagcttag 120060
 ctccactta taaatgagaa aatgcagtat ttggttttct attctttgct tacttaatta 120120
 gaataatggc ctccagctcc atccaggtgt cttgttttcc attcattcag ccagtctaca 120180
 tgttttgctt ggagagtttc gtccatttag attcagtgtt atgactgata actaaggact 120240
 tactcctgcc atttggttgt tttctggtg ttctgtggtc ttctctctc ttttccctc 120300
 ctctctgtct gccttttagt gaaagtgatt ttctctggtg gtgtatttta ttttattttc 120360
 ttccttttta ttttattttt ttgtgtgtgt atttgttga cgttattgat ttgaggttac 120420
 cgtgaggctt gcgcataata ttttctaact cattatttta aactgatgac aacttaacac 120480
 tctatttgtt aaaaaatcat ggaagagaa aactaataaa aactgtacat ttttaacttta 120540
 tcgctctgct tgttatcact ttgtcatttc tatttacatc ttactgtact gtttatgtct 120600
 tgaaaagtag tttcagttat tattttttat tggcccatct catagtcttt ctactcaaga 120660
 tatgagtagt tcacatacca caattacagt gttacaatat tctgtgtttt tctctgtact 120720
 ttttaattacc agtgagtttt gtattttcag ataatttgtt attgctcact aacattctat 120780
 tctttcagat taaagaggtc ccttttagcat tacttatagg aaaagtctgg tgtaaatgaa 120840
 ttccttcagc ttttgtttgt ctgtgaaagt ctttattttt ccttcattgt tcataggat 120900
 tttcactgga tattctattc tattctaagg taaaagggtt ttttgtttgt ttgtttgttt 120960
 gttttcttca gcccttttag tatgtcatgc cactctctcc tgacctataa ggctaccact 121020
 gaaaagtctg ctgccagaca tatatgagct ccattttatg ttacttggtt cttttctctt 121080
 gttactttta ggatcccttc tttatccttg gacctttggg agtttgatta ttaaagcct 121140
 tgagggtggtc ttttttggat taaatcttct tgggtgtctg taactttctt gtacttggat 121200
 gttaatatct ttctctaggt ttgggaagtt ctctgttatt atccctttga ataaactttc 121260
 taccaagatg tctctctctc tctctccctc tctctctcat tcttaaggcc aataactctt 121320
 agatttgccc ttttgaggct attttctaga tctcgtaggt gtgtctcatt gtttgttatt 121380

-continued

cttttttgtc tcttctgact acattttcaa atagcctggt ttaaaactca ctaattcttt 121440
cttctgcttg atcaattatg ttgttaagag actctgagge attcttcagt gtgtcagttg 121500
catttttcag caccagaatg tctgcttatt tttcttaatt atttccatct ctttggttaa 121560
tatactgac agaattttga attctttctg tgttatcttt aatttccttg aatttcctca 121620
acacatctat tttgaattat ctgtctgaaa ggtcacatat ctctattttt ccaggatggg 121680
tatctggtgc tttatttagt tcattttgtg aggtcatggt ttcttgatg gtgttaatgc 121740
cagatgtttt tcagtgtctg agcattcaaa agttagggtt ttattgtagt cttcacagtc 121800
tgggcttggt catacctgcc cttcttgga gactttccaa gtattccaag ggatttggt 121860
tctgtgact tagtcttgg tcactacagc catatctgct ttatggagca tcccatgctc 121920
agtaatgctg tggtcttttc agactcatag agttactgcc tgcagtctct tgggtaagag 121980
ccaggaaaat tccctggatt accaagcaga gactcttggt ctcttccctt acttcccccc 122040
aaacagagta tctgtcgcat tctcttttct tctcttctct tctctctctc 122100
gtcattctc tgccgacctg cctggatctg gggtagggat gacataatca catttgtagt 122160
caccaccaat gggactgtgc taggtcagac ccaaagccag cacagcactg agtctcgccc 122220
aaagcccaca gagaccctc cctgggtact gtccgtgctt gctcaaggcc caagggctgt 122280
acaagctggt gaggccagcc tgtcttatgt ccttcccttc agggtgatga gttcttcaag 122340
caggtaagg gatggtgtcc aggagccaag gcctcgagct gtgactgagc tggcacccaa 122400
tccataagac aacgattttt tccacacttt ccttcccttt tctcaagcaa aggagtctct 122460
cctgtggcc accaccaccc ccatgttcat ggcaagtatt gtctggctac caccaatctt 122520
cactcaaggc ccaagcgttc tttagtcaac ttaagggtgaa tgctaccagg gctgggtctc 122580
taccttcagg gaagtgggct cctctctggc ccagggcagg tccagaaata ccatccaaga 122640
gccaaggcct gaaatcaggt tccccagag cccatttggt gctctacccc cactgtggca 122700
gaaccagtac ccaagctgca agacaaagtc ctctttactc ttcttctctc ttacagaga 122760
ctctccctat agccaccaca gctaggaata tgctgggtca ctcttgagc aagaacagct 122820
ctgagtctca ctcaaaactc ctggcaagtg ctgctggct accacactga ttattcaggg 122880
cccaagggt ctttagtcag caggagtgc atcctgccag tactggttcc ttccctcaa 122940
ggcagccgat taccttctgg ccagtggtgt atctagaaat atcgtttggg agctagggcc 123000
tggcatggtg acctcaggac tctgctggt gccctttct actgtggctg atgtagtgtc 123060
caaattgtaa gacaaagtcc tctgtactct cccctctccc atctttaagc agaaggaaag 123120
agtccacct ggagtggga catgcattgc ctgagattgg aggaggggtg gcacaagcac 123180
tctcttggtc acctcagctg gtgtttcact aggtcacatg ttcccaagt ccactggctc 123240
tgagcccagc acaacaccag gaggtagcca agaattgcaa ttcttggtgt ttagactgcc 123300
tttcaagttt atttgggact gcagaccact ttagccaca gtgacagggc ttgccagaat 123360
ttagtttctg actgtgaga tgggcaattt gcctctgatt aggacggatc taagtgtctc 123420
ttctgtgggc actggctgag ttctgtctca tgttgccttc tgctgtgaca gggcaacatt 123480
gagtgcctat gcaagtccca caatcactgt aatcttctc tcccaagcct actctgaaca 123540
ccatgtggtt gctgctggga gattggcgag ggatgttgta ggcaattcaa gaatgtcttt 123600
cctacccttt tcagtgtctc ttcccttagt atgatgttaa aaccagtac tgtgattgct 123660
catctgattt ttggttctta ggaagggtct ttttgtgtgg atcactgttc aattgttgtt 123720

-continued

gcctgcaggc aggggtgggg gacaattgct ggaggettct ctttagccat cttgctccac 123780
ctcttcoccta gtattagaaa ttccaagca gttaggatga gggtagaagg aaagggtgct 123840
tggaatcaga aaatccatgt cttagctttg agccttagga aattcatttg acccttgtaa 123900
gcctctgttg cttcatctgt aaaagagaaa taatatagtg actgaaaata tcaaagggtga 123960
taatgctgtt gaaagcacta tagaaaatga tgaaatatca catgagtatt attttctagt 124020
ttctaggagt ctctttaacca ttgtacagga caaccatgtc tatttttaaa taaattatta 124080
tttgccctcg agcaccctcg caaagagttg cctataggag aaacagctta acttgcaaatt 124140
cactccactg ttttctttgt gtacagttta ttaatacata aggcacatgt cctccagtct 124200
gtagtaacat tggaatgatt acctctttgg agtacctacc agagcttctc aaagtgaatt 124260
ttgtatatca ccacaaaaa tagtctgttg cagagataac ctccaaattc aatgacaata 124320
tttccaatca cttttgcatg atacagaaat agacaaatat ataattttgg ttatacagat 124380
aattattgtc tcccaacaag tgattagtag tcagaaaatg gccaaagaaat accatggggg 124440
gtgccttccc ataacaactt atctttgggt tttagttgca aggttactaa aagcctgtgt 124500
agggttcatg gcaaaagtaa aacttgctcc aagagcaagc ccttgtttca ttgtctaatt 124560
ttcttaatcc ccagcagaca tgatttggtat ctggcatttg gcaacaggac agtttccaaa 124620
gttgctgtat gcaactgag gaagagaggt gatattattg gaatgaattt atttgttgta 124680
agttataaat atatgggctt ttccaatccc atcaccctta aaaatttttc tgcagtaagg 124740
gtgtctctct tgtctttaat atgcttgctt tgagttcatg gatgaacatt cttgcttggc 124800
tgacatgtgg actctctgaa attgttctaa ggtctttttc tttgtttttt tcttgattcc 124860
caagctgccca agggtagtac tggtagtggt gggcagacaa ggagggtgata gcaagctgaa 124920
ctttgtctc tggettccct tgaccattg cattcattat ctaagggact ccaagtcagc 124980
attccacaga atggccttac caaactcact gagactgaaa gagaaccaag attccaaaca 125040
gccaatatga aaggaaagag agagagactt agggtttgca gaatgggata ctctgttgat 125100
tatttttatt ccatacagat actaatatc tttaggaaaa cattaaaaac acatgatctt 125160
ccaggacctg ggctgcttct ttaagaagca tgttacagag agctctcttg gccaaacaaca 125220
tattgaaaga taaattaatc aatcattcat tcaaataagg tatattcaga attgagggtat 125280
attgtagcca gacagtgaga ctataaaaat gaatgcacct tacccttgtc tcttgacaaa 125340
tctaagagg gagataacca ctcttccaat ttatagtgac ctataacatt tcatacgtcg 125400
ctgaatatct ttacatgata atgacacaat agaaagattg caaaatagac agaggctggg 125460
ggaagaagga ttgagtgtga atatagctc tcataaatcg agggggaatg gtctgcatct 125520
cctgatcatg cagaggtaat aaatacagaa atgatttcaa actaacaac caaatgtgca 125580
gaaaatactg agaatatagt gggcaggata cctgagtttt agttctatct ctgttattga 125640
ctcattgtgt aatctgggtc aggtctgttc tgcctctctg atctcaccct ttcttatctg 125700
taaaatgaga ttattgaatt agacgatatc tatagaggtt ctgcctatt ctgacattca 125760
aggagttttt ctttaagtaa taatatatgt gatctgtata gtgctttaca cttgacatga 125820
tatttttgca tctattatct catgtgagaa aatcactgga ctgctggact gggaaatgagg 125880
acacctggat tcttgtccct attttgacac tgattcatgg tgtgacctt aagcaaattc 125940
tctgagtttc agtttctcaa tctgtaaaat agggaggtat gaggattgga ctaaatcagt 126000
aggtctctaa aatgttccac aaagccctgg ggttggggac tcctacagag tttcactaag 126060
gcaaaccaca aggctaggcc tgcatagaag aggagaaaaa gagtgcctg gcaagagaag 126120

-continued

ttccaagttt cctatgcoaa ccccaggcag attaggttta attttatctg ttttataaac 126180
agagcttcta tgtaatgttt tatttgtaaa aagactttac tataaaaaac tcaactagtt 126240
tgatttttta aaattgcaca tttaagttag atcatacagt cagtatttgt ctttctgttg 126300
ctggcttatt tcacttagca taatgtctc cagcatcatc tatgttgctg caaatgacac 126360
actcttcttt tcattaaagg cgatatagca ttccattgtg tatgcacacc acattttctg 126420
ttttgtaact ttcatttttag gtccaggggt tcatgagcat gtttgataca taggtaaact 126480
gcatgtcaga gaggtttctt gtacagatta tttcatcacc caggtataaa gcatggtagc 126540
atagtaccta atggattttt tttttctgat cctctccctt ctcccacct ccaacctcag 126600
gtaagccctg gtgtctgttg tccccctctt tgtgtccatt acaccagatt ttctttatcc 126660
acttatccat ccattggacac ttagtgtgct tccatatggt ggctattgtg aataatgacg 126720
aaaaaagtca aactcataga agcagagagt agaattgttg ttaccaggga ctgggaggca 126780
gttcagttag ctaggaaaag agagctataa aaagggtaca atgtgtgagt tatatagaag 126840
gaataagtta tattgatcta ttgccagca tcgtgacct agttaaaaat aatgtattat 126900
atgtcttagt attgctaaaa gagtagattt taaatattct aaccacaaaa aattataagt 126960
aggtaggtg atggatatgt taatttactt gatttaactt ttctacaatg catacatata 127020
tcaaaatata ccactgtatc ccataaatat atactattat ttttgtcaa ttaaaaaatt 127080
taaaaacttg atttagatga gctctaaggc cttaagtatt aaaatattat taaagtata 127140
tgtaaccaag tatattgctt ggtaacttca tttttgtgtg tgttttaaca aaccaatata 127200
ttgtgaatat acttccaagt gaaaagaaaa aaagacatta cagtcacat taattactgc 127260
aaaatattcc tttgcatgaa tatggaataa ttcatttaat cattccctta atgttagaca 127320
ttcaaatgtt tccaactttt tctgtttaa taatgtcata ataaacttct attttgtgct 127380
tattgtatta ttttcttata acacatccct agaagtggaa tttctagaag tttatagaca 127440
tttccaattt ttttccaaat atgtgggaaa atttctctct aaagtattta tgttcctacc 127500
agaaatacct ctttccaac acacagtgtt taatctgtac caatctggct tgagaaaatg 127560
atatttactt tgtatttctg tgatttctag cttaaataaa taatcttcac atgcttattg 127620
gtcattttta tttctttgaa ttgcctcttc ctgtctgttg cccatttttc tattgtgctg 127680
tttattttta tatatcaaat atattgacca ttgattttac atacttgatg ctaataatta 127740
gtnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 127800
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 127860
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnntttt gattttaact agtaatttaa 127920
ctttattttc ttctccaaat gattcactag ttgttctgac attatttagt gaataattca 127980
tccttttttc actgaattgg aatggcatat tccatatact gtgtctgggt ttggcttttc 128040
tgttctcttc cactgatcaa cctaagctgg agccagtatc aaactgttat aatcattatg 128100
gcttttagata ctttaaatgt acagcaggga atgtcttatt actcttattt ttcacaaata 128160
tcttgacact gtctcatgtt ttattccttc gataaatttt gggattcatt tgtgatgatt 128220
ttgtctgagt tgttttaaat ttttagattt cactggggaa gaactgaaat ccttgaaata 128280
ctgcttctta ttaggcagga atatggtaca actttgcatt taattcagggt ctttccttaa 128340
ataccacaat gaagtttttt gttttgttca tataggctct gcattaacac tgtttatata 128400
aagtgaaga aagactatag tctcaggct tctctatagg ttaacaatga agatgatgac 128460

-continued

```

tcaacctttt ctttatttgc ataattgtgat gccactaata gtgggcaact tccctgtctt 128520
acctcctctg ttccaaacag gatttttttg aatgaacaag ttaaaagaat cgtaatcaga 128580
cactaaccoc aagccatact gcatggcagc accaacggga ctgacagaaa acaacagaaa 128640
taggaagga gctgcagaa aaacaaactt gaaagctgtc tcatggcctt tgttcctgct 128700
ggagctttga gtcatactta agttttatga tggagaata ggagtgtgaa gaaagataca 128760
gagcaccatc agacagtcaa gaatttcaga gccagctggc atgcagtgga cctcatgcca 128820
gcccattttg ttactattta ggtagtcaag gatttaagat tcttctaata agacagtttt 128880
tatgcattta aatgagtgtc tcttttgag ctctagcgtg tggccttacc tacttcaaca 128940
tgagaagatt tttgtatttt gtcactcatt tcacaatgac ttatagttag ccttcatta 129000
tacactgtgg atacaacttt gctgttgga attaacagtg tcaaaaaact ggggtataatg 129060
ttttagtagt ctgaggaggg agagctgcct aggaagtgtt attccctgtg ttaatttttc 129120
agtctcttag gttatagaag accttctaga accaccttac agcaggccta gatctcattt 129180
acacacttct tctgtcactt gaatacagag aagggatcca caaggcata tacttcctag 129240
acaaagagca aagatttcta ccactcag aagactttgt cttcagactg taatcaccca 129300
caccatattt cctttggatc cagtttccag atttttgtgc tggcactaac accaacttgc 129360
tgtggcttgg ggcagtgaat ttcaatattt tgtgcccatt ttcttaactg aagagtcagg 129420
catcacactg ggcattttta gattctttac agcccaatga ttctgtgttt ctaattaggc 129480
ccaatgggtt agagctataa ggaacagtg agtttctctg aaggaaagga cacataacac 129540
agtccagaga taaacgggc tgcattcaag aaaagattgg gcaatacttt gcagggatgc 129600
tacagagaca attcaagcct tgtatggagg aatggatgtg atacaacca aaagtcttta 129660
aaaattcttt ccaactaatc tgggattcat aaccttatgg actgtgattt gcagcaaacc 129720
aaggatgtga tgccaggcag aacaatatct ctgatcaaca tcaatgcaag gttcctcaac 129780
aaaagactag tattgtttct ggaatgcaag gatggttcaa catatgcaa tcaataatat 129840
taacagaatg aaggacaaaa actatatgat catctcaata gatgcagaaa aataatttga 129900
caaaattcaa catcatttta tgatgaaatc ttccaagaaa ttgggtatta gaaggaatgt 129960
ttctcaacac aataaaggcc atatcagaca agcccacagc taacattata ttcaatgacc 130020
aggaatgaga taaggatgct cactctcacc acttctattt aacatagtac tggagtcct 130080
agccaatttc atattaatga gtctcatttt cttcatcata gaatgaagta tgtaataatc 130140
cctattatac ttactttgca caattattat tattttatta ttattttgag acagggtctc 130200
actctgtcac ccaggctgga gtgcagtacc acaatcacag cttacttaaa ccacgacctc 130260
ccaggcacia aggatccagc ccctcagcct cctgagtagc tgggacttca ggtgcacacc 130320
accatgccta actaattttc tttttttcat ttttttatag agacggagtc tcaactatgtt 130380
acccaggctg gtctcaaaact cctgtgtctc agcaatcttt ccaccttggc ctcccaaagt 130440
gctggtatta caggagttag ccactgcacc tggccttgca gattattatt aaactttgta 130500
aactaatcaa atgagagtga ttattgttac tgtaagaac tctaatagcc tcattcatat 130560
at ttggagaa attgaataaa taggaagaa ataatagcag accaatgatt ttaccttggc 130620
tctatcatca tttggggaag tgataattca gataggagaa gtgacttgta agcagcttgg 130680
agagattacc tgttccatcc cctatatattg tccttaaac aaattgtaca gataaataag 130740
gtcttatttt taggacttac agaaaaaag attcctttca tatccatctt tggaatcctc 130800
agccacttct gtcactatta aatgtcattt taaacgttaa attcatcatt ctgctttgaa 130860

```

-continued

ggaacacatg tgtcatgtgt acctatattgt atgttttgggt gtgttttatg ctttatatga 130920
tcacccacat atgcacagat aattagtgtg cagggtgtgt attccctgtg ttaattattc 130980
agtcacacac tctcacacac ctatgcactc acacatacat gaatacacac atgttcatta 131040
gaatgtttat gcttatgttg catgtgactg gcaacatcag tgcctttcta aggcaatatt 131100
aaccactttg agttttggga gagctttaga aaacaaagac aagagactaa atgattctag 131160
atgtaagaga caatgttgca ataagttact atcctaaaaa gacagaatac aaggacaaga 131220
gattattatt ttggataatt tcttgcttac cagtaatact taagtccttt acattaaaaa 131280
aaaaaaaaa actctaaata tattacagaa gacatccaga tgtccttcaa gattctttaga 131340
gttggaagg attttaata ctttccagtc caatctattt catgtaatca gtgggatcag 131400
agaggcaaaa ggacttgctc aaggtcatat agtgagttag tgataaggct gaacaaggat 131460
tcagatgttg gggcttccag cccactgatc tgtctctcat ctgggacttg tatatttttg 131520
ttcattagag attttctctc gtaacctcaa tatccaatgc agggccttgc acataataga 131580
ttaccagtaa atgttaaatt aatatgtcat ggctttgggt ttactgggct ttgcacttac 131640
tcttgagtaa attgtaaata atatctatgt tttaggtctc cttgttttag accaagatgt 131700
acccagagaa aaggtatgaa ctatgctaag aaaattatct gagtcccaa ttgaaaaaa 131760
aaaaaaaaa tcattgcttt ccactatgac ctctctcatt cacagagtga ttctctttca 131820
aaagggaat gtagaacct tctggcattc tgggagccat attccattgg ctgtgcaatc 131880
atattattgc aaactggggt ccaggaaagt attttctcgg ggaagatgag atttctcaa 131940
gaagtcatgc actttctaac ctaagcttat ttcagtaatc agtgtagcaa actggctctg 132000
aggattgcag cagtaccaat actgtgggag tgtaccagtt ctagaacagc tacagcattg 132060
gaattgaacg cactagaatt ggatacagga cctgtttttg aggagctaac acccaaggc 132120
tgaaagcact cgtagcactg tctttctgtg gcacatatcg tagtctcag ttgagcag 132180
aaaaaaaaa tgtagcaaa ttatgtgctc tgtttatgca aataaaatcc tgtggtatac 132240
tagaaagagc accggcctag aggccttagt tttctcatat gttaaaaaa cctaacacag 132300
gcctgggtta tagtaggcac ccaataaata ctagagtttt tctttgggg gcctctgatt 132360
cagtgtgctt cttcaggtaa ttcacttccc tggaaactct ccttgtaatg agagttgttc 132420
tggtgtgatt tttaacagtt ccttcaagcc aagcattttg gaatccttc ataaaggag 132480
aaaggaaaga aaggagaaag gaaaattaaa ggaaaaaaa ggaaataaaa agttaaaaag 132540
gaggaaaga aaaagaatcc ttactacaa taaatcta atctatgctc tgcaagtagc 132600
actttaagta aaagaagttc ttgtctgacc tgggttactac tgaacctact acataaaata 132660
gcctactgta acacatgcat ttctgtgctt aatcttcacc ttttagcctt agtaaatgta 132720
gaggaatgct gatgtatagt taaatttatg tttttagttg cttttttttt ctactctcaa 132780
atgtcaatca ctcttttagt tctctttctt ttccgacgg caagtattct tctctgcct 132840
aaagaagctt ccctaaaatc ccagtctatc cagtaaatca aagcacagca ataaatttga 132900
ggaaacaata ccagagacaa aaaggagtga ggggatgcag aagctcaagc tggagcagga 132960
ttgtaagcat gagaagtctc gcgtgcttca gagcagcgaa ggatgtattt ttgcttattc 133020
ctgctggtga ctctttgtct atgcatccat ctgctgcaat tgcagtgtta gtcagtcaat 133080
ccacgtttgt tgagagactg ctgtgtgcca ggattgtgct agcataaagg agcgaagtat 133140
tgagcaaaat atgtttgagc agctgtaatt ctgaggatct ctaggctga gcatgtgat 133200

-continued

gtgtatgcac ttctgtgtat ctgtgacaaac tccagggtgtg catgacagtg atctttgtta 133260
 ctctgttggc ttcataaac ttcttttag ttgctgtgat tcaactacata gagtgggctt 133320
 tatctctgat tttataaac tgcagtacta ggggtatgat caccagaaat ctaaaaacag 133380
 ttagaaatcc catggagtta tcttttag aagttttcct gtactaatat tatgaaaaat 133440
 aagcatcttg ttaacttgag tgtaattcta tgcagtatta cagggtgtcaa taggaagaaa 133500
 cattgactga gttcagatct ctctacgcc atgctaaagg ggtgacaagt tccacaatgg 133560
 atcattttct catgggcatt tctggctttt ggtaaaagta gggcatctta tttaaaaaac 133620
 cagtgagtag tcctaataat ggagatatca tcaggatctg aattgttcat ccctaaaaaa 133680
 aaacaaaaaa aacaaaaaaa caaaaacaaa acaaaaaaaa aaaaaccaat ggaaatcaaa 133740
 taatatagtg ccaaatataa ctgctttaat atttaggttc tgtaggatca aattgtttgg 133800
 tgccatactc tgtccacttt tctgtccact tttctcatgt gataggatat aattttatat 133860
 cttttctgtt ctagaaatac ccaagaaaag agactctgga aactcattaa caggctctgtc 133920
 cactcttgta tttgttatcc cagggaaaca gaagtacctg tgtgccagca gaaatgattg 133980
 cactattgat aaattccgaa ggaataattg tccatcttgc cgtcttcgga aatgttatga 134040
 agcagggatg actctgggag gtaagatact tttctttctc ttcttctcc tcttctctgt 134100
 ctcccccttt cctccctcat tttctagtct ctctttaaac cagattttct tctttgatgc 134160
 ttccaagggg accagccatg ctccagacac aggcggaccc tttcatagcc aacgtggcca 134220
 tcagccagct ggtgcctttt tttttttaat ccttaactat accaatcccc attctggggc 134280
 tcagcattag agcaggaggt gtgaagcagg gataaggagc caacagaggg tgagtgagga 134340
 tgcagtgtgac tgggcagggt cccagggga cttaattgga ctgacctgat gttgttcaat 134400
 ggtagctagg atgagagaac taagaaatcc agaacagtca cagggtgcagg atgacctcagg 134460
 cataggatca ggatgaccca ggcacagtct gacctgaac acctgggaat atccctcagc 134520
 taactgctgc ctatgttgta gggccagcca cctggaatga gaagctgctt ctctttggag 134580
 cctgtgacta ggctgacaaa cagtggcaat ttcctatcct atctctccca aagatgaaca 134640
 ggtgttttaa tcatttccct tcttttgcaa agctattgat catttccaaa agcatttttt 134700
 tttcagtagg acagtaacat tacagaagga agatacagct ctttcaaggg tgttctctca 134760
 tcataaggct ctctgtccca tgaacctgtc tgccatgagt gttgtcatca ttccagaaag 134820
 gcttgacatc agttgattga catttatatt ttccctctcc aaactcccc atctctccat 134880
 gtttcatctc gccaatgcc agggcatca ctgcagcctg ctgcttccaa aaatatgtgt 134940
 ctttcttag aaaaaaaga tcattaatct acttcaattt ggaaatggaa tttgaagaaa 135000
 ggcaagccta tttctgagtg cctgcaactg tagcctcata tccgattatt cattattagc 135060
 ctggaaaacc caagtgccta gaatccaacc ctttcccta tctcttaag gctaatttag 135120
 accagtgtgc tatcactggc tttctgtgag ttgttcaata ccttgtctgc ctatgtgcac 135180
 atctatagac aacaactagt gctcttatcc tggaaacagg ccatgtgtga atctatatgt 135240
 agataactat atccttccca tctcacagg gcagtggat tatttaaaac gaacaaagta 135300
 cctcaaatga attgaccag gctggatgag agacaatttc aaaagaatca tctcaagtag 135360
 catccagtac tcccaaacat cacaggtaga tattctgtga gtggctttcc aagcatccct 135420
 atcaaatgag aatcagatat ctgagaaaac tcaaccttgt tttggtttgc ttagtgtacc 135480
 ccaaagaaat ccaacaattg aggtctacag tggagaagaa gtaggactgg ggtcaggagg 135540
 tacagaggca aaggcaggaa gggtgacaaa gtgattgaca agagaaaatg ttctccatat 135600

-continued

gaatgttgca gccccatggt gagggttctt atacactcag ctttcaatta tttagccttc 135660
tgcgaaattat gtatagtata agagatagag actctcaggt agggaaacctc ttggctgggc 135720
atctggcaat atgaattgca agtccacttt gatgcaggt aagtttaatg gtaacaaaag 135780
tcctcataat atttggtatc aaatcttaac attaatcca tgtctcagcc aacattctcc 135840
attataaatc aggcgtgtgat atgattacag tgacccactt ttgaaaagga gcctgtgtat 135900
aacagataat ttcactatac tatatagtac tcagatgcag gtttgtaaat taattttattg 135960
gtgagaatgg ttcagtacat tttcaaattg atttattagt agagtactca aatttgagtg 136020
ggcttggtga acacaatgaa gacaagctga gaagtgtgt gactggcctt catttcagtt 136080
gcaggcccat gatattttga gcactctcca tgtacaaggc accatgctag tcattagagc 136140
ttgaggctgg caaacttcag gaaatgttca caagatacca gcattcttga tgttgtgtaa 136200
atggccttgc ctttagagtc aggcagatct agtttaaagg ctcagctcct ttatttaatg 136260
tgtgccccctc tgagcttcaa gatctctgc tgtgatttag aaataccatc ctcatagaat 136320
tataatgaag atcagatgac atgatgaatg tgaacatcct tgataaatag caaaatgcta 136380
gacaaatgtg ggggcttaat atgtcattga ggtcactagt aatttagctg gaaaggctgt 136440
aacacagcac tccccgatgg cttttaccct aagtaacttg gtatgccata taatatgtaa 136500
cagatccaac aggcagagca tcgccagaaa acagtcttga ttacctcaa caaaaagtt 136560
ccaccaggat cctgttcaga agctaatttt agtaattaag ggaatcatat gctatgttca 136620
agtaccatgc cagtaaaaac ccaattgtgt acctctctaa atcactgctt gaagagcaaa 136680
tctttccact ttggtgaatg aacttatctc cacattccct gccctactga cacaactccc 136740
tcccacgttt attgttaact tacacattca atgcacagca cacctttact caaacaacgg 136800
aaaagaaaagt gtcaatacaa agtggccctt gtctattcct taaggagtag acttccattt 136860
tcatgagatg tggatttagc atagacatat tgattacct gaagaagaat tcatataatt 136920
ttatcttctg attctcatca ctcaaatcaa aattatataa tatatccaa aatgacaact 136980
agaaatgtgg ccttgggcaa gtccctctc ttctctgatg cttgggtttc ccatcataga 137040
attggaattg tgggcttcac caaggacctt tctggtgcta acattttgtg attctgtgta 137100
aaaagccacg cagaaaggat tgtttttcag cctttctta gattgtctgt tccctgctcc 137160
cagaagtata gataatgaga cttgagtgct ttgatacatc gtaattgtat ctacctccat 137220
tcatacctac ttaagatata tgtctaaaag tagactagac agattattga gagagtggag 137280
ggcagaaggg ctgtctctgt atcttaaaga agctggcact tttcagctga tggtgcttg 137340
gtcttgaggc ctcaagatct ctaatctggc tttctctata gtgtttcatt cactgtttgg 137400
tgatggaatc tcttcagctc agagataact aatagatata gctttttatt tctgcttcc 137460
aggcctacct acctgttcc tgcctttttt ttttttttt tttttttat actagttgct 137520
gttgtttctg aaagaatcct gaggggtggt ggagtctcag aatggcttcc ttaaagacta 137580
ccttcaggct ctcagctgct catccacaac aaagataagc ctttatttgt agatgattca 137640
ttcttggtg catttgaaaa ccacatattg ctaattgctt gaagaattta aatcccttga 137700
ctacttttca tttcagaaaa cccttacaaa aaaagtccaa atgaggacct tccctccagt 137760
gaattagctg tggctttctc acagtccata gttaggatta atgtaaagcc atctctcatt 137820
tttctggaca ctteccaagg atacactcct tgtttccaaa atggaatgag aaagaaagaa 137880
gtgcccttcc tgccatcttc tcccatgacc cttttctcct tcccacttcc cctcctattc 137940

-continued

```

ctctctcaaac atgatttatt tctgtgtttt gcaactcttg agttctcatc atttagtaaa 138000
tgggtgttggc ccctattgat tcttctctgt cctggaccat ggagagtagt aggcctttca 138060
gaaatttcag gtagcagcca aaccttgga gaagagaagg aacacggagt cctagaccat 138120
gtgagaacct gaggtgtgca gcatttctt cacagattcg tctagcatat ttgagaagta 138180
tctttcccac taggagactg aactctgcat ctgagaaaaa aaaaaactta acatatctac 138240
aggttttgac aacctctatg aattacctag ttgagaggat ggctcaagga gcctatggcc 138300
atggtctgat gtcattatgg acactatgaa catccttgag gtttccattg ttgaagacag 138360
ccctgatgcc agctgtctca tcattcccca tgttcaagag catcccagca tcgctacctc 138420
aggatcccat gtctgaatg caacagagtg atttcgtgc tgaattacta ttcattggcac 138480
ggctcttcac agcatttatt catccatgtc catccgtcct tccagccagc caagaagctc 138540
atgctttcat cttttcatcc tgagtaccaa ctatgtgcc aacactctgc taggcatttt 138600
ggggaagcag aactgaataa gatatcattc ctttctgaa aaatttaagc aagaggagaa 138660
aggtagtgat aaggaatata ccttagccat aaaggaaaaa taataaatca cttagaagaa 138720
gttgagttag atggaaggaa aaggacatcc aaagcaaagg gtacagttag aataaaggca 138780
gagagacatg aacaaaatgc attgaggggt tgaggaacag caattggttt aacatggcca 138840
gagctgggga aatggtaaag gcaagctgaa agcacattga aagcaaactt cgttactata 138900
ctaggtagtt tagacttcaa agagtgtgaa atctatgacc atgggacagg tatgatgaca 138960
tattattttg tttattttct tttttttttt tttttttttt tgagacggag tctcgtctg 139020
tcgcccaggc tggagtgcag tggccggatc tcagctcact gcaagctctg cctcccgggt 139080
ttacgccatt ctcttgctc agcctcccg atagctggga ctacaggcgc ctgccacctc 139140
gcccggctaa tttttttttt tgtatttttt agtagagacg gggtttctact gtgttagcca 139200
ggatgggtctc aatctcccg cctcgtgatc cgcccgctc ggcctccaa agtgctggga 139260
ttacaggctt gagccaccgc gccgggcctt taatttgttt attttcatgt ttctttaag 139320
aaaactggca gcagcacaaa tgttttggtg atgagggctt aaattttaga aagttagaca 139380
attttagaaa ggccagctag agagaaattt ttagcatcaa gttttgctaa acacctagaa 139440
tttattctcg gagctagtta cctccatttg ggttgttacc tgcaagtact gaccacgtat 139500
atgaagaaat actggttag accaaggcaa ttggtgtat aagaggccta cctcatacc 139560
aaaagccagt ttccttggtc taggccagt tttaccagta tgtgttctga gaaaactagt 139620
tccatgacat gttccatgaa aaatacgatt tctatttca aataagttag agaaacttgc 139680
atattatggt cctgctcagg aagatttaca gtccttatta gcatatcgca ggtcctggtg 139740
aatactgcaa taaagtaacc tgaggagctt tgtaactcag gattcccaa gttgattcaa 139800
ccacagaacc tcatttatc acataacacc tgttatccta caaaaccact gttctctaga 139860
atacacttct gaaaacttgg gtagagataa aaactctatc ctataggcag agaataacctc 139920
tagctcaggc catcattttg cagatgtgtg tgctattaag aatcaatcca taatgcatta 139980
atgatcaaaa gcagaccatc cttaccacat ggtgcataag attatgctat tagctactaa 140040
agccactgaa gttaatcatg ttgggtctgt aatattgttg ttatgcaca aggataggct 140100
gcaaaagtgt cctaggccaa agcatggcta ttgcccaagt tatctaagt ctgcaggtag 140160
atattctga cctaaggatt gtgctaaaga agttatttct aagaaatata gtgacttcca 140220
gcatcatgca gaatgatcat ttaatatatt gaatatctag acattttgct gtagaattta 140280
atagtccttt tatactgt ctgaccaaca ttttgacatt tactcagaat cccatcacag 140340

```

-continued

tgctaccaca taacctcatt actaaagtag gaggcctaga aatcacagat ttgtagaaac 140400
catccaatga ttgaatcccc tctacctcct gttcagcagg cagcagagtg tcataaataa 140460
ttaacaatgt ggaactcagt tactgggatt tcttccattc tcctttggct ctctagacta 140520
gattctaaag acctcaggc tggtaatgca agtggttaagt ctcatctctg agaaatgctg 140580
cttctacac acagttctct gatactgag tgctttgact gatctgcata actgaggcat 140640
gcaccaagga gcagaattac tctataaatt ttggcatcaa tatgtacaac gtgtgactca 140700
gcactttgaa actctgggga tttttttgtt cggttggttt ttgttttaag aggtcctgtg 140760
gtatagtggg aatcgtagg tagactcaga tacagagagg ccttgtttct agtcttggtt 140820
ctgtcactta ctatcttgat gaccttgggc aatgactag aactctctga gcctcagttt 140880
ctccaaccac actgtaggaa taataaaatc ttgtttacgg catttttgta aatacgtaga 140940
gaaactggta cacagtaggc acacagtaaa tgtcaccata cccttcagtc cttcttttgt 141000
ggatgaaaaa tggctcttct ttgtgctccc agtaaccact ggggtctggt ctctctctct 141060
gctggacagt gtggctctct gttcttggtt ctttgttctt tggctcttaa attacccttg 141120
aaacaaccct tgaaatttcc actcgatgac ctaaattgtc atccctaagt tggttacatg 141180
catatttggt gaccttttg aggggaaaag ctttatgtct ctctaactgt agttcttaag 141240
ggaatttgca tatggaaaaa caagagactc catctcttaa tctctccaaa ccaaattatc 141300
tgggatagta catatatgtt gtactctgtc tcttagcatt tgctcttaga gaaatatggt 141360
tagagagaag taattttttc taatcataaa aattaatgat actgcatatc tgatacttga 141420
atgagtacct ccttgtaaaa tttctactta aatccttgag tttttaaggt gtaatagcaa 141480
tagaaagatt ttattattgt ttacttttgc tatgagtgtc ccaaaatccc tcagtagctc 141540
ttgagagagc aagatgatgt cataggcaat attttccaaa ggtagtaggc agaaaactaa 141600
gtacacagca cacaataggc catatataca aaggcaagta ttttacaat atagtaattc 141660
aagaaaaaag tttcattttc actggttaacc tgactgtttg tttaaaaaca ttttattatt 141720
tattatttaa aaagagtgtc acttggtaca gattgtggga tgtgttcctt aagatcacia 141780
aaatgtaaaa tattttcttt ttatattgaa cacatacata gacaactaac ctgagcaagc 141840
tgctttttag agacatttgc acatcttttg ggatcacgtt gttaagaagt agaactaagg 141900
gaaaaagaca cagccacca gaaaccggtg gagctttcag ttcatctggt attaatattt 141960
ccatgacaca gatatttagg aagtaaacag aaaatagcat cgctatcctg cgtcaccttt 142020
tttggaatca ggttccattc ttctcagtc agttcatcct tctgatactt ttaagatctc 142080
aaccaagaca tagaaatatc atattttccc ttgcttaata ccccatggaa ccaatgcccc 142140
tgtggctgaa gtaaaaatta attggttagg gacatttcag ccctctagca gtcaacaatt 142200
aaaaacatgt aagcaccgag cacctgcaga aaacttgcac tggcatttgg atctaagaag 142260
aaaatctgca tcttaaaaa catgaaaagt cgccagccca agcttgtgca gtgaagtgtc 142320
atgctggcca caatgaaacc gaaagagact gatgactctc ctgagggtgg aaacgaggc 142380
atggaagctt tgattagtga gctgttaggc acacagacat taatttcaaa gcattctcat 142440
ctccagtctg agtaataatt ctgttagtat tatgcaattg tttggctgct gcaagaaatt 142500
cagcagactc caacaagtag tctttcttgg tctctgagtg actgtaactt aaattctacc 142560
tcccttctct tctctacat cttccactc cccacccgac ctcacccac acacacacac 142620
aattcttgta cactgtgttc agagagatgc acacacacat atatatgtat atatatagta 142680

-continued

tatttgtcaa taaagcagaa aagaagaaag aactccaatt aacaattttc catttcccca 142740
tctcacctct gtcttacaag tagataggaa aagagaaaac ccagtaaaa aatggcaacc 142800
acccgcctcc ccaactttac atgctgcttc ctatgttaga ggacttggt taggcatctg 142860
attgtggagc ctgctagata caagccata tttagactgc tacattcaac aatgtctctc 142920
tttcatatta gaaaaattcc gggttggcaa ttacaagcat ctcaaatga ccagaacctg 142980
aagaaaggct gacttgcttc gttcaaaatg agggctctgc tctagtggat agtcggaga 143040
aacctggagt ctgaggctta ggagcttagg tttttgctcc tcaacacaga ctttgacgtt 143100
ggggttgggg gctactctct tggttgctga ctccctccaa cgggaccaat agtggtttcc 143160
tacctcacag ggatgtgtg aggacgggct atagaagtaa tagtggttac cattcatgta 143220
gttatgagta tcatgattat tgtttcctgt aatgcggctt ggcatggca aagtgtttt 143280
tgattgttct tgatcatata tgatgtggc caggcactga ctcaggcaga tgcagtgaag 143340
ctctggctca gtcacttget tttcgtgta tgttctggg aagaaacttt gctgatggga 143400
ctcaagggtg caccttggac aagaacaac tgtgtctgtc tgaggttctt gtggccatct 143460
ttttttgttt attaggcaat tcgtatttcc cccttcggtt ctacccctcc agatccctgc 143520
caaggaccta gatcttagcc tcaggcccca tcaactgagct gaaggtagta gctgatccac 143580
agaagttcag taaacaagga ccagatttct gcttctcccg gagaagaagc cagccaacc 143640
ctctcttcaa acacactggg atactagagt cagactttcc ctcttacatc tagccttact 143700
gtageccacac tccttgattg ctctttcaca tcacatgett ctcttcgtca gttgtgaggc 143760
cctctcattc ttctccaag ccagactcaa acattatatt gatgtcaaag aagaatcact 143820
tagagttagg aataccttgt tctctctctg ctccatagct tccatattga aaccagtttc 143880
tttctctggt agaagtggag tctgtgaagc cagagacagg cacatacgag agtcagaagc 143940
actctccctg acttgctggt ggctgtctt tcccaccttc ttctccagtt tgtctaaact 144000
ctctctctct ctctctctct ctctctctct ctctctcttt ctctccccc cctacacaca 144060
cacacacaca cacacacaca cacttttttc tctttccctt gactcagcaa cattctggag 144120
aaaagccaag gaaggacttc aggaggggag tttctcctt ctcagggcag aattttaatc 144180
tccagaccaa caagaaatc cctaattgtg attgaaaggc taatgaggtt tatttttaac 144240
tgctttctat ttgtttgaat gttgcatatt tctgctagtg aaattttccc ttaataaagc 144300
cattaataca ccaatcgtat tttcttattt acaacagact gagagaatta atgctgttaa 144360
cattggacct tttttctttt tttctgtttt cctttttttt ttttttctt tttttctctc 144420
ttgtttgett tccaggteat gctgacctgt tcagettgga ctgtttcaca tttgttttta 144480
atgtcagttt aaatgtaatt gtaaaagcat gtatgctcta aatcattgta gttacttttt 144540
tcagtggaaa agcctggtat tcgaaagcat ttccaggctc cgcaatttca tatgagcagg 144600
ttttcggtaa aatcttttgt ccctcactca ggatggtatc tggacagtga gcccctttct 144660
tctggctcag tagtcagaga gaggagactt ggagacagtt tctgccgat cctgtgcttt 144720
ggcaaggatg tgcagcattg catatcattc tatcattaat tacgtttact cctccatgaa 144780
ctaaaaacca ttagactaaa tagtccaaca taaacctga aagataaaat ttgatattct 144840
ttcgctggc catttctctg acccagaatt ggggctggga ggggaatgga gacttggggg 144900
agagaatcaa ggaggcttct tgctggggg aatttggcat gcacttatta atccatttg 144960
gttgactcc ctactaatcc ctactccat acctgccaa gattggcttt gctccctgct 145020
tctcatcccg gtcctagttc ttctcaacc atctccattt cccaccactg atcctctctt 145080

-continued

ccagtaagat gctattcaac ctgatgaaat ataaagagta gcaccacct ggaagtcagg 145140
ataccttagt tttagctcct gctctaccat tatctaactg tgtgaacttg ggtatgagtt 145200
aacctttgcc ctttaactcg aacagtcctt aagaattggt ttataggaga aaggaaggga 145260
tagacaagat ccaaggcctt tgaacccttt ttgggaaatg aatccttttc ttcaaacaaa 145320
atttgactca gagtcccaaa tataggtaga gaataaaatg ctgctgttct tgtttgaaag 145380
gtggtggggg gcttgaggcc acatgctcag gccactttg ccacctctca ggaaccctcg 145440
aaaaaactta taggactcct ggggctctac cattgtacta gactgatgct tggggagtct 145500
tctaactcca attttctctt ctgttacatt tcagtccttg tgaaaactct atatgtttca 145560
tcagttcact ttttcagaaa gttcacctgc ttggggtaaa gggcatgcag tggagaatgt 145620
ggggctcagt aactagcaat agtaaaaaac atcattggct ggcttacata atttactctg 145680
ttctaagcat cttaaacaca tactcatctg aaaaatcaca acaaccttgt gaggtagatc 145740
ctgttattat cttaggattc tgaacctgc cagcttgact ctcaaccttt gacttgagac 145800
cagtcgcccc agatggaaag ttatactttt cacagtttac caccgtaagc agtttttcag 145860
agtgacttct agctagagat ccattcttag aaaaagtcag aacctgcccc ttagcatgca 145920
ctatcacccg gcgcagagta ccttcactgg gttcatccca tttcctccta aaaatagtcc 145980
tatgcagtag tcaagtcata tcatcaccat tatatagggt agaaagctga ggtgtaggag 146040
aaatcaagag atctgttcaa gggtacacat ccataagac tctgaatacc accatcaaga 146100
ataataagcc ttttatgtga aaagcatttt agaacttcag tgtcattatt gcattctgcc 146160
tcttgagggt cagtgcactt tttcaccatg ctttaactct ggagtcctgg tggtagacaa 146220
tctgccttct actctcaggc aacaccatag tgtctttatc cctcataaca aacatatgat 146280
ttaagtaatg atattatccc cattttacaa attagttaac tgagataccg agaggctaag 146340
tcttgcccaa agtcacaaag ctagtccagc atagagccgg agttacaaat gaggcagcct 146400
gactccagaa tatttgctct taactactac tctttataca tatgtaagga aactaaaagc 146460
caaagaggga aagacgtccc tgaggtocca cattgagttc cccgactcat ccagtattct 146520
tctgaccttc taatcctaaa gttatacagt aagatccctt gactctaate ctgtagatg 146580
gaaagatggc tggcatgatt taagctacag gccacaaact ggctttcccg gagccagaaa 146640
tcacctgcag aattctgttt gtcacgcaca gtgtttgttt agaaaattga catagactgc 146700
ccctaggcag ggcatacaat actgtcactg tcccagccc tccctattta tgtttgccaa 146760
gctttttttt ttttttctca tttatgtgtc tgccctgact gtgaaggat ttgagtttat 146820
gacttttaga ttttaagcatt ggaatatata agcactgcac atacacacat actcacatgc 146880
attcacaaaa gtatagccta gtctagcttc acaaagaatt tgtagcccta caccaaacac 146940
acctttatgt ttacttaaca tttagaatta gatttaagat ctgaatttag ttccacaggc 147000
attcaagtgt ggaagaatct cggttattat tttttgttcc atactgttcc actcttgctt 147060
tccctgctgt gtctggaccc ctgtcagtc tcttttctgc cattctccat gectgagtta 147120
gggccccctg aagccactca ctcatataat tttaggaata gatggagagt ggaaaccagt 147180
ttggagggtt caccatgtgc caggcatcct ctcathtagt tctcataagt gtcctaagag 147240
acaggtggca gcacattcgt tttataaatg aggaaactaa atcttagaga agctcaacaa 147300
agacctcaaa gtcattaagg tactaattaa cggagctggg atttgaatgc aagattgtcg 147360
gactccagag cctattcttt tgccctatac cacagttcct tacaaggaag atgtattcgt 147420

-continued

tttctattac tgcataacac attgccacaa atttagcagc ttcaaacatt tatcagctca 147480
gtttttgtaag tcagaagtct ggccacagcat ggctagattc tcagttcagg gtctctgaag 147540
gatgaagggtg tttaccagga tgcattctaa tctgaagctc agggttctct tccaaactca 147600
tgtaattatt gcaggattca gttatttgtg gttgtaggac taagggtccc acttcctttc 147660
tggctaccag ccaagggcca ttcttagctc ctggaggctg ccctctttcc ttttcatgtg 147720
gacccaaca ccttcaaagc cagcaacaga gactcttcct tgtgttgaat gtttctcact 147780
ctacggatgt ctttccagga gaatcccagt cctgtgaggg ctacactgac gaggtcagg 147840
acatcaagaa taaccacact tcaaattcaa ctgaattagc accttaatta catctgccta 147900
gttttttcaa cagcacctag gttagtgtt gactgaatga ctggaaggaa ggatgtgtat 147960
gctcaggcct cagaatcttg ggggccatct tagaagtcag cctaccacag acgttgattg 148020
ctttcatgtg tcaaatcca tagtgagaca gggagaacag aaatatcctt gaccttagat 148080
agagcgattc aaactttcta agactttgga aacttcacat cactttcacc tttcccttga 148140
tcatggttga gaaggcctat gtcttggagt ggcaaggagt gagactggaa cagtaccta 148200
aggttaagga gactaaagaa gttacagatt ggtcacatct gtcctccct aggaatgagc 148260
catggaacct gatttgaatt tttttttct ctggtgtctat agagatagct cccacagggg 148320
tctaataccc caaggctgaa aagttcgtc cccataggat ccaggcatga tatcagacca 148380
gggtgttcaa tctcctaaag aggaggtatg gacaggaaag ccccttgcca atgaccttt 148440
cttgtcactg ctctgactca agactaatag ggcagagata gtgagcaact cacatactac 148500
taaaactatc cacttatact gcccccttc tcttgcttt atcactccat ttaagtaagc 148560
cagtgaagtct ctgccttgac acagtggcaa gctgatctgt atcttatatg gaagaattag 148620
atttgactct ggggctcagg tgcagagggc aggaggggca taggggtggc cctcatggaa 148680
gaaaacaagt ccttgatatac tgagtaacag ctgagactag caagccttat tgtccaggat 148740
tccaagtcgt ctagcaacat ccttgctct gctgcagaga gaacagagga tccccggca 148800
gaatgaatgg agtctgattt caattacgtt cagtnnnnnn nnnnnnnnnn nnnnnnnnnn 148860
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 148920
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 148980
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 149040
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn ngggtcctgg 149100
aggcaagtgg gaatgcagct tctcttctt aagcagatgc catataggcc tggggaggag 149160
aatgtgagaa taccagccaa gttctcattg gcactatacg gagaaagggg aattatttca 149220
tcttgatgga ttctccccc agtctctgca catattgatc ttacttgtaa tgagtttgtt 149280
cagattcacg agtcatcatc ccagggagat ctgagtcatt ggtgggaaa tcgaggtgac 149340
agattatatac tcgctgatct cactgtcacc aattgctctg tgtgtccctc cacttttga 149400
aaaagcccat ggaatcattt gtgtataatt aatttgatt tatttcttat ttatcaatag 149460
ctttagtggg gtattgtaaa tgggaaagct accccagaga acagtgtaca ttcacagtat 149520
tattcaatag aactttctga gatgatgaaa atcttctata tcttatgttg tccagtataa 149580
tacagccgct aactacatgt agcttttgaa cactgaacat gtggctagtg agactgaggg 149640
attctatttt taatttttta atgttgtaat taatttaatt ttttaaaagt tttgctttct 149700
attttatagc ttaataatta aactaaactt acatagccca catgtggcta gttggccact 149760
atactggaca gtacaagtct agaaagatct cagagagaca catgctgaga tacagcagga 149820

-continued

ataggttagt cagaaagaga gccaatgtaa cataggggaat tctggattgg gaattagagc 149880
cctggctcta atctcagetc tgccactagg tgaccttgcc ctctctgggt tcagttctcc 149940
catctttaac ttgaaagggt aaactaacta acgtcaaaag tcccaaaatc gtggctatgg 150000
actgaattca atttgggata cataagtttc aggaattttt ttaaaaatct attaatgcct 150060
tctaggtgtg tgtatgcacg cttacaggca tgtacctatg cacaagcatg ggacggcagt 150120
aaggcattca ttccagttca ccagtgctact aaccattcac acatacacac acacacacac 150180
acacagacac atacacacac acgcatgcat acacacccta ctgtattgcc tatgtagacc 150240
ctgaaggctc ttgaatctgt caccattgga taagataatt tctaacgacc ctteccgctt 150300
tgtctgctg aaaatcttta agccactata gtgtcccaa tctatttcaa ttggggcaga 150360
tgactggagt attctcatag ctctctgtct ctteccctct gaatttgata ctagtattga 150420
agtttggcgt caaggatgaa gaaggaggc agggaggata taaccacgc cccactcctt 150480
aactccgctt ttggattaga agtagcgttc agggcttcag attccttggg gaggaagtag 150540
agataaatatg ggctttgtta tcagaagatg ggggtcagat gattgggttc tcaacttttc 150600
gatagctgtg ttacctcagt ttattcattt gtaaaatagg gataagaaat atctttaacc 150660
tcctaagatc atgtggaatt aagtgatgta acgtgatgaa gcgaggcatg cagaaggccc 150720
tgaaaaaata atagttaacc ttaagggaac taaatggtct ggcaactgt gagctcaaag 150780
ctagaaaggc ccggtgatgg ggaagatggg gtctttctgc aggaactaca gcaggggagc 150840
agaacctgta agccaccagt ctgtggagct gtgtccaaga actcatgttt gcaacaagtt 150900
caccaaatta caagatactg tgggttccag gcctctaact caagaagatg gtcttggccc 150960
agatcatacc ttgcagcctg tgcctttggt gggatgtgag tgttggcagt ggctatgcat 151020
atctccttat tactggctgt gcccaagccc tgcagaaatg attgttggac aaggctcatct 151080
tgactcagg gttggttttc caggcttctt tgttattttc cccttagttc ttctgtgctc 151140
ctcttgcaac accaaccoca ccatttcctt ctccctacc ttagttgttg gtccaaacat 151200
gtaatccatt cttgcagtga ttatttgagt gataccgtaa ctggagttag cattgaagga 151260
cttatttttc taattagaac taaaagtcag ttccaggctg ggtgtagtgg ctcacgctg 151320
taatccagc actttgggag gccgagatgg aaggattgct taaggccagg agtttgagtc 151380
cagctgggc aacatagtga gatcccatct ctacaaaaa acatgttagc caggagtggg 151440
agtgtacacc tctgggtcca gctactggg agactgagga gggagaattg cttgagccca 151500
ggaagttag gctacagtga gcttttatca tgccactgcc ctccagcttg ggtgacagag 151560
ggagatcctc cctcaaaaaa taaataaaaa ctacaaaaa aaatgtcact tccaggttgt 151620
atcttttttc acaggggcca gacacagatg aggagtaggt tttgttgtat ttatccattt 151680
aaattgagca atcagcttct ctctttggtt tataccttc ttatttatta ttattatttt 151740
aaaaggatta gagataaagt gctttatggt ctttctcagt gcaactgctt atgctagacc 151800
tcagaattat gacctcttca attatttata ttctcgtctt tataaatact ggaaaaaata 151860
gtacaaagta aacatcggga tgccaaagga cctctaaatt gtgtgtgagc acctggggaa 151920
gatggttctt aagggttgag ttttgatta ttgtggtgt cttaaataat gttatttcta 151980
tcattccttc caatggctgt ctctagcat ggttccatt ttacagactg atggtagagg 152040
cagaaagatt ctctcacttc tttgatagta ttgaggattt cagccttca ccgctcctct 152100
ccccttgct aaaaaagaaa aaaatcaata tgtatgttat agtgtatgtt caactatgag 152160

-continued

caactatgtg tattcaatga gaaatggaat accataaaat taccatagtt gaacccaaat 152220
 gataggatag aattogatag tctgaggatg gaagggaact tcaaggccac tttaaaaaac 152280
 cccattccta tataatgctt gaattcttaa ccaactgtgca tctagtattt gatcatttcc 152340
 agtgatatgt gtgcctggca acttttccat ctcccagcgc tttaactatc aaaatgtatg 152400
 tatgtgtgtg tgtgcatgta tgtgtgtgtg tttagagaca gagagagaca gaaagagaaa 152460
 gagagattaa aatccaagtc actgttcttt ctgggaccca aaaaacaagt ctagtcatte 152520
 tccatttcta gtctctttcc ctagcaatcg gctagacatg ctagacatag acacatgtac 152580
 atcactcctt tgattttacag cattcagtat ttgtctatca cttataagat aaaaccata 152640
 cttacttttt atttttattt ttttagagac agtgttttac tatgtcaccc aggctagagc 152700
 atcagtggca caatcatagc tcaactgcgc ctagaactgc tgggctcaag caatccttcc 152760
 acctctgcct cctgagtagc agagactaca gatgtgcacc accagacctg gctaatttag 152820
 ttttttacta attttgtgga gatggtgtag tgtcttctta tgttgcctag gctgatattg 152880
 aggtcctggc ctcaagcact cctcccatct cagccttcca aaatgctggg attacaggta 152940
 tgaaccacct tactcagcca gatttcttaa tatgatatac atgctccttt aaaatcaagc 153000
 accatctttg ctttcaaccc cattattaac cactttccca tatacgcaac atatgcttca 153060
 gtcatactag tctctggttg tccccaaac actcctcagt gcttttgttt atgcccttcc 153120
 tgcccacctt tgcttggtga aatcctcacc aatcttcaaa ttctaggtea aatactatct 153180
 ttcatataaa gcattttcta aaccacctg tgtaaaaaga ttagtggttt cctattttgt 153240
 tgatgcctcc attgcagcat tttccagtct gactttttct agaattgact gtggcaaggc 153300
 taccagctg ggccagggcc tgtgtctttt ctgtcaccca gaagcaaagg tctaacaatg 153360
 gatatctgct gaatgaatga atgaaaatga atcattaata tagtagtaaa tgagttaatt 153420
 aaaggttcca ggtatgaata ctgaagcctg cattgaggca gagctgaatc caagactatg 153480
 ttaggttggt ctggcacaag aatcagagtt ttcctctgca agctatgaaa aatttggtt 153540
 tagcacggat ttgggatgac gaattataca ttcaaccagt gttgaatgag cacttgctct 153600
 taaggagttt agagtctgtg accagggaga atgatgattt tcttagctcg ggcagttttt 153660
 ctaacaaggt agttgcattg tgtgtttttg aacactgatg ataaattcaa gtttctcttc 153720
 ctgcccata gcccggaagc tgaagaaact tggtaatctg aaactacagg aggaaggaga 153780
 ggcttccagc accaccagcc ccaactgagga gacagcccag aagctgacag tgccacacat 153840
 tgaaggctat gaatgtcagc ccatctttct gaatgtcctg gaggccattg agccagggtg 153900
 ggtgtgtgct ggacatgaca acaaccagcc cgactccttc gcagccttgc tctctagcct 153960
 caatgaactg ggagagagac agcttgtaga tgtggtcaag tgggccaagg ccttgccctg 154020
 taaggaaaag ggaagtggga gcatgagata agggggatca tatttagtga acgctcctat 154080
 gggccagcca ccagctctgg tgtttttctg cccattaact caggtagtct tcgtcgtaac 154140
 cctatgggag agggattgtt ataaatctca ctttaaacat acagggattg agactcagaa 154200
 agcaaagaga aagataatat tataagggtg cctatgtggc ccacattgat gcacagcagt 154260
 catgctttca catttaactc acagaaatgg tcagcaaaat ttcccttaac cacaaaatca 154320
 catagacata tccatatatg ccttaggata ctctctata tttgcacaca caggctcacc 154380
 ccaaagataa tctccagcct gactgacatt ctgtcttcag tgtcaccttt aggaactata 154440
 tcatgggaac tctcataata tgatatggtg gaaagaacat gaggttggga atcagaacac 154500
 ttcagatcta cttttagttc tgctagtaac ttattgtgtg attccttccc cttctgggtc 154560

-continued

tcagtttctc tatctgtata atgtataagg catggtttgt accaaattga tggttttcaa 154620
atattgcttc gagaaatgct ttgtgcactt taaactacct aaggaatcat aataggagga 154680
aagattaggt gatagtgaag gaattatcaa ctggttggtct aacagaagtt ggataacaga 154740
agttccccag tgatggggaa ctcaacttctt tcttatgtca tctgttgctt aaacaagtct 154800
ggttattaaa atattacagc ttaaggaatt cttagagatc ctctatccaa tgattcacia 154860
actttcatth aacagccaag tgctttatth ctcaaaagaa ttgtacacag atatgagtgg 154920
agctagttht tttaaagcca gagtctgtgg ctgggcctc accagttcag cctctttctc 154980
tctatcccag ggaagcccc aggtcactct tgcaaaatct tagggctccg aggaacacag 155040
tttgaacc agtgaagtat atgctcttht aaggttctcc taatcttgca attatgattt 155100
aaagactctt ttggaataat aacaactaaa cctctcttg tgagtcata gattaaccg 155160
cctttcaata ataactgcca ttcaggtaga aatgtatagt gaacagagca attttgtata 155220
tattacctga attgattctt ataggaatcc tataaatga gattcttctt cctgttttac 155280
agaccaaata ggaagctgtg gagaataatg tgattgacct atagttacat agtcagaaaa 155340
tagcaggacc agaacttgag ccaggttct ctctgattc caaatctcc cttattcca 155400
ctccacctgt aggtgcagc accactgcag ttctgtaact ctgggcttht cagtggggg 155460
ccaaggtct actgaaggc actgggtca tactgtggg tgctgcatt tgaagacatt 155520
gcatgtggc tgtcaagtct tagatttga tttccaactc acaggttagg cctggtcaca 155580
gccctaacca tctctgcac ctctcagct tgggaagctg aggttgacta ggcaataaga 155640
tcaactggga ggaacccaa ggactctgat tggatatgt ctgtgcaaa gcagagggt 155700
cacacagaga ggaataat aaaaagaaa aaggagaaa ctgcttht tcttact 155760
ttttcatctg gatatttga tatcatgtgt ttgacaaa ttcaaagttt aatcttccca 155820
agcagtttc aaacacttat ctactttat aagttacaga gcttttcat atatatgac 155880
ccagttatc ctcaacaa ttctatgat catagagact attattcca ttccacatgc 155940
caaggctcaa agaggataac taactgtct catttggtca cttaacacat ggaaccagaa 156000
cttgacctag acctcaggt ttctaaattg gttatcttga caataacct gtgcaaaact 156060
ctatagcaga atttgtatga cttgggatca ctgggcttt ccttgccca gccaccagga 156120
tggaagtcc cctccctta cattaacaaa tctgcaacc aatatcagtt caccatctag 156180
cttgccagac taagtgtct ctgactccga atcttttaa agaatagctt caaaagaaa 156240
ccaattacca cattcataag aactgttct catattatc ataattacct acaagttcaa 156300
gtaattcact aattcaatag attgagttct tgacctgaa aatgaactgt gctaggcctc 156360
taataagata aattttgtg taagtttct acgacagtaa tgatgtatg aaattgcta 156420
gtagagtacc tggcacatta ataaatgata actattaatt tagagtggg gagtagactg 156480
ggtgtgcaca gtatatttag aatctaattt atctgggttg gaactctagc tatggactat 156540
ttctgtgacc ttgagtaaat cacatgtct ctctgtgct ctgtgtctc atttgaaga 156600
tgatagaata atcgtacct ttcaaattgt cgtcaacaaa gagattatgt ataaagagca 156660
cctagtaagg tagcctgaaa catagtaaat gctctgtaa tgggtggtta ttattatgag 156720
acttgagtgc taagccactg ctttaatgaa actcaattt agctaccact tgccttgct 156780
gctcatgcat ggaccacaag gtgaaattgt cttctctgaa gacctggca ggcagatgca 156840
ctacagcagc aaagatttc aaactggcct ttctttgagc ctattctccc agaccagaca 156900

-continued

tgagactaca agtttctgct gcacatgaaa aaaatatgat gtcagttgga ttctagttag 156960
 aaaacagagt gtctaataaa ctgcttctgc tccctagcct gtttaatgtg tttcaaaacc 157020
 tgagaatgac tcctctctgt ttctccagaa cagcctaaca caatggcaaa tgggcattga 157080
 gtgaatgcat acttaaggaa atctgtaggg ctgcggctac tctttctca agtaatccct 157140
 tgatagtcac gcaggctact tcagagattg ggcattagag aacagagtca ggtattataa 157200
 tcagattaga ctctaggag attagccagc catattgctg atatgtgcac agttactggg 157260
 cttccgtgct aagcagctct cattaagcac agttaattaa tattatggcc aacttaagct 157320
 tcccccttct tctcctgttt gttagtctcg cagcatttta gggagaaaa aataagcatc 157380
 agtatggaca atttgettca tacctgtacg atttaattct catccttcca tgggccttca 157440
 cattcacaca ctccactaga agaccaaggt tcaccagcca aagacttttc ttgctcccca 157500
 ctgcctccta cccaagatat tcagggttca acctcccagg cctcttctct aagagatccc 157560
 tgggtgctac atgcctagac cctgettctt atttctact gagaagggtc agtccaaggc 157620
 attctgtgct acagaagggt tccagacagg aactactctg ggatctgagg ctccagccag 157680
 tctgtcagtg tgtcattacg gtgaagggtg gaagcacagg cctgggagct aagactgccca 157740
 agatgaggta ctctagaatc cctgatctc ggaaggctta ggatctaaag gaaaagaaca 157800
 gtgaaatggg gctatatgag tggacaggga ccaaccaagc agaacaatgt atctggataa 157860
 tgtagacttc agacctgac ctatggctga caaaagttgg tgaccttggg gggtcctgag 157920
 ctgtaacctt cagcagtgga gtgaaaaaa cactggagaa cagaatcaga acacctgggt 157980
 tctagtatta gttcagccac atataacca tatgacctg ggcaagtcaa tttatttctc 158040
 tggccctcat gttccttgtt ggtaaaataa gtgtcacatc acctaacctc tgggattatt 158100
 gtgagagtta aattagggtca tcaacaggaa agtgagaagt ttggtctaca tttggggaag 158160
 cattcctaata gaggtatgat gacaaaattt cagataattc tggatttgtt agtgagaaga 158220
 gagagtgttg gtaggatga gctctgaggt gatgcctta taactttaag catccaactg 158280
 tttcagaacc tccaggagaa catggccatg tctgtactac ctgtgtgtta ttgtagagg 158340
 agcatctggg agcctctgct ctctgagctt aagggaggtta atttgagat catttaattc 158400
 tcattttata aaaggaaaac aaattgagga tctttaggcc atttgtttag gtttcttaag 158460
 tgccactca aatacgtgga ctgtactaag tactaggag gttaacttga atatgaagat 158520
 atggtccctg tcttcaagaa gctctaagtc ttgtggggga gacagacatg tatgtacata 158580
 gatttcaatg ctgtgtaatg agtgctataa ctgtgtgagg ctacacaagg agcaatgaga 158640
 atgtaaaata agaactctta agccttcttc ttggatgagt tggaaaagcc ttcacagaag 158700
 aggtagcctt tgagtgaaga cttgaaagat gagtaggtgt ttaaccggat gaaagacctg 158760
 agaaggagga atgcattcta ggcaaaagca actgcctgtg cagagataac agagatatag 158820
 aggcattgta gagggcaagt ggcaacagat cagtctaggc agcaggtcat aaagggcctg 158880
 ttcatatata atgatggcag taagatgggg atggcagtaa ggtgggaaac tagtagggcc 158940
 aggctaccta ttgagtagaa aagaatggag aggaactgcc aggcagaaa tggtatggac 159000
 gcaagaaagg gaacatgaaa gtgggtcaaca ggaggcagtg gctgtcaaga catctctcca 159060
 tacactgtac actgtatgta atatccgtct cccagggttg ttagaagggt caaacagct 159120
 catagctgga aaagagcttt gtgaagtga aactgtttat gtgggagaaa tgatgttate 159180
 ctgcacttc ggaaaggtag agtgatcaag agcacagacc ttggaatctg actgctttgc 159240
 tttggaactt ggtctaccaa ttactagctg tatgatctg gacaagtcc ttaatctctc 159300

-continued

```

tctgactcac ttgtactggt tcacagaatg gagataataa tagtacctac tttactaatt 159360
gttgtgaata ttaaatgaga taatataagt aaagtgtta gaaaagagtt aaatgtgccc 159420
cataaataca tacaactatc atatacccaa aatatttttt aagttttttt aaaaaagcaa 159480
tccaatggaa atcaaaagaa aaaaagtgtg ctctatatatg cagtcaataa gtgtagatt 159540
atTTTTctct tacaactgac aatgcccttt ttttctccat catcatctca tttgagcagc 159600
tcagtgatgt agggaggaca acgaatatta tcctcaccat atagttttgtg cttttcccca 159660
ccaccctca gtggccagtc tggatggtcc ctggggatcc ttaggggatg tccaaatgcc 159720
agagcatctc taccagcagc gggctcagac ttagctcagc ccgtcagtac ccagattgac 159780
cactgcctct gcctctctct ctccaggctt ccgcaactta cactggagc accagatggc 159840
tgtcattcag tactcctgga tggggtctcat ggtgtttgcc atgggctggc gatccttcac 159900
caatgtcaac tccaggatgc tctactttgc cctgatctg gttttcaatg agtaagtgt 159960
cctggggccc agacctcact aaaatacagc agcttgcca gaccagttg gtggtgatgg 160020
tgatggagtg acagtgaagc ttacctcatt tgacctgagc gtgtggcatt ggatgcccc 160080
gccagccaac tcggtatgag gcagctttgc cctggcttc agccaactgg taggagctga 160140
ggagatggt gctgagacta cccctttcac acccaagaac caatcctggt cgtgtttctg 160200
gtctccttta cagcttatct cagaaccaca tggaaagatt cctcccttc acttttagca 160260
acataaaaa gaggcagaaa gactctggct ttaagggctg aagtttcttg ggttctgttg 160320
ctaccaccaa aggtactgc tagtcaccac ttgctgagca attagtttgt gccaagaata 160380
tgctagatac tttctaaatc ctatctcatt gagtctcat ggtgacctga cctcccttt 160440
ttatagataa ctctattttt tttatggacg gggaaagtca ggctcagcaa agtaagtga 160500
ctcaccctca gtcacagagc tagtgctgt tggagagaag attcaaatgt atttccgtgt 160560
gaatccagc tctctcggt catggtggt actgatggg aggagtacct ctaccactct 160620
ctgtctgtgt gaccttggt ctgccattt ctttctctta aacagcttta attaatacct 160680
gccctgccac tagctctata taacatcatg aatttgcca gtggctcaga ttttgaatt 160740
acattttct cactaaaat ctcaattcta ttattttctt aatcagctc tttgggaaag 160800
acccttaact tttctgacc ccaatttct catcaattaa tgataataga accttcataa 160860
gtaatttct atgataacta aatgggaact gacagatgt gaatgtctgg cccatagtgg 160920
gcaagaagaa aaaaaaaaaa gtccctttct gatccaccat tccctaagag tgatattttt 160980
ttcccccaa gatggagtgt ggcgtgcca cccaggtgg aggggtgtgg tgcaatgatc 161040
tcggccact gcaacctcca cctctctggt tcaagcaatt ctctgcctc agcttccca 161100
gtagctgggc ttatagatgc cagccagcaa tgtccagcta atttttgtat ttttggtaga 161160
gatgggattt caccatgtta gccaggtgg tcttgaactc ctgacctcat tatctgcca 161220
cctcagccag gcatgataat cttttctatg tctgtgtat gaggtccctc gatggcataa 161280
tgaatggagc tggccagaga aatcttccca aggacctga gctagtctcc ccacagagaa 161340
tccttcagc caggacagga attgacctc cccctcttc agccctctaa cccagaagag 161400
tcttaaaata aaatctacag gccagtgtt ccttcagta cagcactgca atgtgagga 161460
gagtgagcgt cccagctgc cctctccaa cctgccagc ctggtagcca gaagctaaga 161520
ataaccacta ggcttttggc aaaaactgct ttgtggtttt cagacctcca aaaagttgcc 161580
tatgatgcca tctctgggg caggccttga aaagccctt aactgttcat ctccatcct 161640

```

-continued

```

caaaccctg ctgcccttaa gcaattgaat caactccatg agcacctgct ctaccttccc 161700
cagagctctg agacctttgg agctttgaaa agtgataatt ggctgttctc taaatcctca 161760
tttcttttc tacctctgag taagcatgtg gcatcccacc tcagcttctt ggtccagtct 161820
tgctcagctt ataaaaaggc cccccacag ggtcagaggc ctagacccat caaatcccag 161880
ggctcctgaa acaataggac cctatttctt cctgtaggaa gccactatgt tagaactctc 161940
aggggtgtcta caaacatcta gataagtgtt tctcaacatg gattattttg acatattggg 162000
aaaaataatt ttgtcaatat gtagaatatg gttgacatac ctggcaccag cctactttat 162060
accaaagagg attccagtca ttctgacagc ccaaactgct cccacgcatt tctaacaccc 162120
actgaagaag cagtactctc cagttgagag tgactaattg ctgccagcct cctaagggtg 162180
ctaattggga gcctcagacc caaagaggga gataagaact tgttcaaagt aggtcaaccc 162240
atttgctgat ctcttcaaca ccaactcta ttatcagccc tgttttttcc tttccttctg 162300
tctttgtaga gatcacatgt tgtgaggata atgagcctga actttagctg tgtgaccttg 162360
ggcaaattac tgaacttcta tatgcctcaa attttatctg gagactgctg aagagtatta 162420
taatagcacc tttctacatg tcatttatgg aacacctgct atgtgtcagg cactgtgctt 162480
agtgttttcc aatcttcatt tctcatctta ttttctctct tgcactccca ccaacctgc 162540
tctctccta aattccattc ctgcctcatt tttataccct ccattctcct ctctcttctt 162600
tcctttaact gtctccctag tattttttcc ctttttcccc ctttcttgct ccttccccct 162660
atgaatttcc tccttttctt tcccccttct ctttctccca tccccactt tttctgcccc 162720
gaggcctgca gcaatgttaa aggaatctc attccagcat tgtgatttca atggtaaaaa 162780
aagattgcag cactgtcatc aacagagggtg ggaaagtaca ttggagactg gagcagggcc 162840
agacctcagg gtcagccaat ctactaaaa aattctctat agtgaaagag cttggagcaa 162900
cactgttctg ctcaattgat ttgtgatacc atctaaacac ttcctcttct cagttgggct 162960
tcagcctgag ttgaataatt ctacaccatc tgcccccttc tctctttctc caggacagcc 163020
aagatctctc tgagatagga tgetgagttt ccaccagac aataccaggc cttctcatcc 163080
tgtggagtag gctagtggct tggaaccaca aatgtcaaac catagccttt aggetccatc 163140
tgggagggtc ttgtcctcac cacttaagtg ggtgtcagat ttccttccct ttctgcacat 163200
gctgcacaat caatttctgt cttacacaca cacacacaca cacacacaca 163260
caatttttga agtgctgaaa actagaaagc ctactagcat gaggatgctg tgtcttctct 163320
tagaggatg ccatggctcag ccatggaacc aagagggtgc tcttctctga aaagtgggc 163380
aagcattggc cacctccccg tataatttat aggtgataat gtgtgatctt gttcagaagt 163440
aactataata aatgcagctc acatatgtct acagtttcca aactgtggta aggagcagcc 163500
agcatatgag ggaatgggct ccccttcagc aggggacatt taaattagac attcaaaaac 163560
actccctggc agatttaaca ttgaaactca ttttgaaaga acaatgtgga atctccttca 163620
ctggaagttt ttgaagaaat attaaatttc tagtattcca ggccagaggc aaaggggtca 163680
acaggatgac caaacacttc gggtcacttg caaatcctgg tgcctgatg ttaagagctg 163740
actactgggg cttctcctaa aaatccttca tgttgagctg cctgggaggc aggttcttgt 163800
tctggctgta gatgggatat tagaactgta gtcagggaga ccatgtgcct gccccattgt 163860
gttcatttgg ttaggcttct ttgtccccga ctcagaaaac agaaggggca cagagacctg 163920
gaaattccat gtgctaacc atactctggc cagggaagat agtagtaatc aggatgtcag 163980
gattttggaa aagagagaga taaaaaaaaa acaaaaaaaaa aaaaaaaaaa acagaccaac 164040

```

-continued

aaacaaacaa aaacctcatc ctgatccctg aagcaccagc aggagaaaca gcaagctctt 164100
cttgagaaac ctggggagga agggcaatca gagacattcc ctctgggctt attgcaagcc 164160
tccccctatt cctttttcct ctatgtatct ccttcccagg taccgcatgc acaaateccc 164220
gatgtacagc cagtgtgtcc gaatgaggca cctctctcaa gagtttggat ggctccaaat 164280
cacccccag gaattcctgt gcatgaaagc gctgctactc ttcagcatta gtaagtgcct 164340
agaggtgcag ggaatgcccc tgagggcaca gagactcaga gaggaccact tttgacatta 164400
aaacgttatt agggagaagc cagctccttg acatttcctt tcttcatttc cctcccccat 164460
ccccactgta ctctccctca gtatcattct tctaacaaga aacaatttca tgactagaag 164520
ccaatgtatt tgctagaagt cagcttccat cagattcccc acctatccct agtctatctt 164580
tgggacaagg cctttttgac tggttatagc aggtctgtga atttctccac agcttctgct 164640
atagaaacaa acatgggcca ccttgtattc ctgacagggc agtaaagcag gaggcatttc 164700
ctcctggaag gatttcctct tctgccaaac ggaggaggtc tatgtaagca actcaggtag 164760
gatttatttg gcagccaagg aacttttctt taatatcttt tctaacaaga gccctttctt 164820
agcctctgtt gagggagaaa ggcaaaattt gatattcaaa gctatgtgtt ttagttgtct 164880
aatcagggt ttgactgtaa atgacataaa agcttaggtc ctaaaaaatg agtatatgag 164940
aagagtagaa aaagaaaaga ttcaggaaat ttgatttact tgactccctt cagattggat 165000
ccagctatcc tttcccctga gatctccctg acagactgaa gtccccaagc ccacagactt 165060
caactaacag gaagccaagt agatgggtcc ctgtgggggt gggggtcaag tttgtggtca 165120
gaaaacttgg tgctttgtct aatgttccct cgtgggcatg cttcccctcc ccattctgtc 165180
ttcatccac atcagttcca gtggatgggc tgaaaaatca aaaattcttt gatgaacttc 165240
gaatgaacta catcaaggaa ctgcgatgta tcattgcatg caaaagaaaa aatcccacat 165300
cctgtcaag gcgtttctac cagctcacca agctcctgga ctccgtgcag cctgtaagca 165360
aacgatggag ggtgctttat caggagaaac agcctgatag agccaatgat aatatgcttc 165420
tctagggctc ggcaccacct gttgggaggt gcttccattc ccctctggct ttgagtgtgg 165480
tccaggaaga aaatgtggtg aagaaaggaa cacgggtcac agtgtcccag ctggatattg 165540
tgaaaggggt ggaggagtgt agaacagagc agttgggact cagggaaggg acttacagca 165600
gatgaattct ctaggcagac aaaacagacc tggatgttcc tcccctcttc tttgagtcac 165660
gttcatgtga gtttgtgtgt gtgtgtgcgc gcgcgtgtgt gtgtgtgtgt gtgtgtgaca 165720
gagagagaga ggagagaggg agagagagag agagagagag agatggagtg cagaggctgg 165780
ggtgagagca caagctggag aagtcttgag tcagaaagct tacaatggta taagacatcg 165840
cttgggagcc ctcaagtact cnnnnnnnnn nnnnnnnnn nctctctctc tctctctctc 165900
tctctctctc tcactcacac acacacacac acacacacac acacacacac acacacacac 165960
gacctcatgg gggaggacca aggaaggaca gggaaggggg aggaacaaa agactgaaag 166020
acaaaaatc aaaggtagg gaagagtcta gcagagccca cctcctgtgc aaccctgttt 166080
ttctctctct tattgttccc tacagattgc gagagagctg catcagttca cttttgacct 166140
gctaataaag tcacacatgg tgagcgtgga ctttccggaa atgatggcag agatcatctc 166200
tgtgcaagtg cccaagatcc tttctgggaa agtcaagccc atctatttcc acaccagtg 166260
aagcattgga aateccctatt tcctcaccac agctcatgcc cccttccaga tgtctctctc 166320
ctgttataac tctgcactac tcctctgcag tgccttgggg aatttcctct attgatgtac 166380

-continued

agtctgtcat gaacatgttc ctgagttcta tttgctgggc ttttttttc tctttctctc 166440
ctttcgtttt cttcttcctt ccttatctaa tcttcccatg gcaacttcag actttgtctc 166500
ccattgtgac tcctatctgt gttttgaatg gtgttgatg cctttaaatc tgtgatgac 166560
ctcatgtggc ccagtatcaa gttgtgcttg ttacagcac tactctctgc cagccacaca 166620
aacgtttact tatcttatgc cacgggaagt ttagagagct aagattatct ggggaaatca 166680
aaacaaaagc aagcaaaaaa aaaaaaaaag gcaaaaacaa aacgaaaaat aagccaaaaa 166740
accttgctag tgttttttcc tcaaaaaata ataaataaat aaataattac acacatacaa 166800
acaaatatat agaaatcccc aaagaggcca atagtgacta gaagggtgaa attgcaggcc 166860
cctgggaagt tactgatttt tctatctctt ccttccatgg gagactttat tttctgcca 166920
tggctgttgc cattagaggg cagagtgacc ccagagctga gttgggcagg gggctggaca 166980
gagagagagg agaggacaag gagggcagat ggaacatcag tacctgcca cagccttggc 167040
cctggggggc tagactgtc aactgtagag caattcatta tactgaaat gtgctgttg 167100
ttgaaaattt gtctgcatgt taatgcctca ccccaaac cttttcttct tctctctctg 167160
cctccaacct caaattgact ttcaatagtt tttctaagac ctttgaactg aatgttctct 167220
ttagccaaaa cttggtgact tccacagaaa agtcagacca ctgagaagaa ggggagcaga 167280
gatttaacct tttgtaaggc cccatttga tccaggctctg ctttctcatg tgtgagtcag 167340
agaggagctg gagccagagg agaagaaagt gatagcttga ctgttctctt gcttaggaca 167400
ctgactgaat agttaaacct tctctgccac tacattttcc ccacctttaa aagacctgaa 167460
tgaagttttc tgccaaactc cgtgaagcca caagcacctt atgtctcca ttcagtgttt 167520
tgtaggcccg aacttcatca cactgcattt cagccatggt ggtcaagcct gtttcttct 167580
tttgggcatg ttcacagatt ctctgctaag agctcccc atcaagaagg ttagcaggcc 167640
aacagctctg acatctatct gtagatgcca gtagtcacaa agatttctta ccaactgtca 167700
gatcgtgga gcccttagac aaactggaaa gaaggcatca aagggatcag acaaactggg 167760
tgtcttgtcc ttgtcccca gagatgacac ccttccagca agtggagaag ttctcacttc 167820
cttctttaga gcagctaaag gggctgcca gatcagggtt gaagagaaaa ctcaattacc 167880
agggtgggaa gaatgaaggc actagaacca gaaaccctgc aaatgtctct cttgccacct 167940
agcatatcca cctgcagaag tcatgagaag agagaaggaa caaagaggag actttgacta 168000
ctgaattaaa atcttcagcg gcaaaacctt aagtcagatg aacaccatct ggtgagttca 168060
ctcatcatcc tctctgctg ctgattctgg gctctgacat tgcccatact cactcagatt 168120
ccccacctt gttgtgctt cttagtcaag gggaggccaa accattgaga ctttctatag 168180
aaccatggtt tcttccggaa aggtctggtt ggtgtggctc caatacattg ccacctga 168240
actcaagggt tgccctggga cactggttct atctagtctt ttggcacgcc tgtgttctgt 168300
tgacttcatt ctccaacccc aagtgaagg caaaatgtcc acctacttct tcatcttggc 168360
cactgcctcc ttacttagct cttaatctca tctgtgaac tcaagaaatc aagggccagt 168420
catcaagctg ccatttttaa ttggttcaact ctgtttgttg agaggatagt ttctgagtga 168480
catgatatga tccacaaggg tttccttccc tgatttctgc attgatatta atagccaaac 168540
gaacttgcaa aacagcttct ttaataaaca agggagaggg gaacctaaag tgagtaatat 168600
gccaatccaa gactgtgga caaaactaaa gctaacaggt tccctttctg ggatgggata 168660
gacacattct ggttttcttt attactacac catctggctc atgtacagga tcaacttttag 168720
ctgttttaaa cagaaaaaaa ttccaccact ctttctagtt acactagggt acattttaat 168780

-continued

```

aggtccttta catctgtttt ggaatgattt tcatcttttg tgatacatgg attgaattat 168840
atcattctca tatctctect tgtaaatact agaagctctc ctttacattt ctctatcaaa 168900
tgtttcatct ttatgggtttt cccagttgtg actcttgtct ctatgaatat atgtttttca 168960
tttgcaaaag ccaaaaatca gtgaaacagc agtgtaatta aaagcaacaa ctggattact 169020
ccaaatttcc aatgacaag actagggaaa aatagcctac acaaggcttt aggccctctc 169080
tttctgtgct tggatttgag tgaacaaagg aggttttagc ttggctctgt tctcccatgg 169140
atgaaaggag gaggattatt ttttttttct ttggccatt gatgttctag ccaatgtaat 169200
tgacagaagt ctcattttgc atgcactctg ctctacaaac agagttagga tggttgggat 169260
actgtactca cctgtgaagg actggccact cagaccact taactggcga gctagaagat 169320
gaggatcact caccggaaaa gtcacgagga ccatctcaa acaagttggc agtgcttgat 169380
gtggatgaag agtgaggaag agaaaaagaa ggagcaccag ggaaaagacc tcgtctgtgc 169440
caggcagcag actgctgccg ggatcacgaa ctctgtagtc aaagaaaaga gtcgtgtggc 169500
ggtttcagct ctgcttcatt gggcagctcg cctgggccca gcctctgtgt tgacatggga 169560
gttgttgat tctttgttct atagcttttt ctatgccaca ggcaatgttg ttgttcttgg 169620
aaagtttatt atttttttta attcccttac tctgagaaag ggatattttg aaggactgtc 169680
atatatcttt gaaaaaagaa aatctgtaat acatatattt ttatgtatgt tcaactggcag 169740
taaaaaata tagagagctt cattctgtcc tttgggtagt tgctgagga attgtccagg 169800
ttgaaaaaca atgtgctgat gctagagtcc ctctctgtcc atactctact tccaaatgga 169860
tataggcata cataataagt ttattctgac ttgtacttta agagaaaata tgtccaccat 169920
ccacatgata ctgacacaaa tgagctaaca ttgagcttca agtagcttct aagtgttcat 169980
ttcactaggg acagcacaga tgtggccttt cccccctct ctcccttgat atctggcagg 170040
gcataaaggc ccaggccact tctctgccc ctcccagcc ctgcacaaa gctgcatttc 170100
aggagactct ctgagacag tccagtaact accggagcat ggccctgca tagccctgga 170160
aaaaataagag gctggctgtc tacgaatcat cttgtgccag ttgccagggt gagagggcac 170220
tggggccaagg gagtggtttt catgtttgac ccactacaag gggtcatggg aatcaggaat 170280
gccaaagtac cagatcaaat ccaaaactta aagtcaaat aagccattca gcatgttcag 170340
tttcttgaa aaggaagttt ctaccctga tgcctttgta ggcagatctg ttctcaccat 170400
taatcttttt gaaaatcttt taaagcagtt tttaaaaaga aagatgaaag catcacatta 170460
tgtaacccaa gattacattg tatctgctaa gataccaaaa ttcacaaggg cagggaggga 170520
gcaagcatta gtgcctcttt gataagctgt ccaaagacag actaaaggac ttgctgggtg 170580
actgacttat aagagttttg tggggttttt tttccctaata aatatacatg ttggaagag 170640
ttgaaaaaa ttttgggaaa atgggtttat gggtccttca ctaagtgatt ttataagtag 170700
aactggcttt ccttttcttt agtagttgct gagcaaattc ttgaagctcc atcattgcat 170760
ggttggaaat ggagctattc ttagecactg tgtttgctag tgcccatggt agcttatctg 170820
aagatgtgaa acccttgctg ataaggaatc atttaaagta ctagattttg cactagaggg 170880
acagcaggca gaaatcctta tttctgccca ctttggtatg cacaagaagt tatctgcagt 170940
tgaaggcaga aagtgaaat atattgtaa tgaatatttg tattcatgtt tcaaaattga 171000
aatatatata tatatatttt atatatatat atatacacac acacacatat atagtgtgtg 171060
tgtgtgtgtg tgcgcgcgcg cgcgcgtgtg tgtgttctga tagctttacc tttctctgga 171120

```

-continued

tctttatact tgggtccaga tcacacctga tgccatgtac ttgtgagaga ggatgcagtt 171180
atggttatga agctctctca gaacagacaa gacatgtaga ttaatcagat aactgaaagt 171240
tttctccctt attgggtctg acccacaggt cctgtgaagg agcagagggg taaaaagagt 171300
agaggacatg atacattgta ctttactagt tcaagacaga tgaatgtgga aagtgtaaaa 171360
actcaatgga actgattgag atttaccaca ggggaaggccc aaacttgggg ccaaaagcct 171420
actcaagtga ttgaccagtg gcgccctaata gggacctgag ctattgggag aagagaactg 171480
ttctttggtc ttcaccatcc ttgtgagaga aggacagttt cctgcattgg aacctggagc 171540
aagcgctcca tctttcacac aaattccctc acctgagatt gaggtgctcc tgttaatggg 171600
tgtctgtgtg ctgtaattct ggttttggat atgttctgta aagattttga caaatgaaaa 171660
tatgttttta tctgttaaaa cttgtcagag tactagaagt tgtatctctg taggtgcagg 171720
tccattttctg cccacgggta ggggtgtttt ctttgactaa gagattgaca ccgggatctg 171780
ttgccagggg cctcccaact caaccatttc taggtgaagg cagaaaaate cacattagtc 171840
actcctcttc agacatttca gctgagataa caaatcattt ggaatttctt caccataga 171900
aagagtggta gatatttgaa tttagtaggt ggagttttat agaaaaaca gcttttgcct 171960
cagttttgat ttatcctcat ttgatttggc cagaacgtag gtaatatgca tcgattggct 172020
tctgattcca attcagtata gcagggtgct gggtttttcc ttttcccac cgtctctta 172080
gcctagggaa ttaataaga agccttagaa tgggtggccc ttgtgacctg aaacacttcc 172140
tacataagct acttaacaag attgtcatgt agctgcagat tcctttgccc accaaagact 172200
agaacacacg catatccata aaccaaagga aagacaactc tgaaatgctg tttctctggt 172260
ggttccctct ctggctgttg cttcacagta tgggaacctg tactctcat aggtgacagg 172320
ccagatttgc attctcttac aaccttagcc cttggtgtta actgtcctac agtgaagtgc 172380
ctgtggagtt gtcctatccc agaagccact tggatgctga gagcagccac catcagaacg 172440
acccacgca aaaaaaaaa attaaaaagt cccctcaca cccagtga cctttctgct 172500
ttcctctaga ctggaacatt gattagggag tgcctcagac atgacattct tgtgtgttcc 172560
ttggaattaa tctgacagca ggaggggcga gactatgtaa acagagataa gaattaattt 172620
tcaaagtga aggggaaaaa aagaaagaaa aaagaagaga gagagaaaga aagcatcgta 172680
caaagatttt cttaaaaaaa acaattttgc ttgaaatttc tttagatggg gctcagttgt 172740
cacagtggca cttggcctcc actgggcagc aggaccagct ccaagcgcta gtgttctgtt 172800
ctctttttgt aatcttgga tcttttgttg ctctaaatac aattaaaaat ggtagaaact 172860
tgtttgttgg actaaatgtg tgactttggg tctgtctctg cctctgcttt cagaaatgtc 172920
atccattgtg taaaatatgt gcttgctggc ctgccagcta aaacttggcc acatccctg 172980
ttgtggctgc aggatcgagt tattgttaac aaagagacct aagaaaagct gctaattgtc 173040
tcttatcatt gttgttaatt tgttaaaaca taaagaaate taaaatttca gatgaatgtc 173100
atcagagttc ttttaattag ctctttttat tggctgtttt tattgaagtc aagagttggg 173160
atcatgccca gttgtgtttt atgctatttt gattttcata tattttttaa agtctttgca 173220
caaggcttac aaatttgccc tgtggtggcc ttagcataag ctgacctggg accaccaaaa 173280
taacaaggaa tttgggctag aaagcacaga tggacactgg cggcccatca caacttctct 173340
tgaaaaacac caaacttgtc agctggggaa aagccacaca aagcccagtt gcctacttct 173400
acaaccttat ccatgtggga gcataaaatg gtggcatcac tgcccagttc taaccaagct 173460
tcagttaaag aatgggtacc ttcacatcct cactattttt caggggcctt accatcctca 173520

-continued

accacccaag taaaatctaa atcagccttc ttttgggttc ttcagttcaa gtaaggcctc 173580
ttcttgtggc ctctcagtgt gaatacttac gaggttccag attgaatttt tgggcctgag 173640
atacaaggca tcaatgaggt gtgacaaaac atgtcaacga ataataagaa aattctctat 173700
tcttccatat cctccctgt aataagggtt gtcagaatgc cttctttctc ggctgagttg 173760
aagattcagt gagaacatat gtgacacagc tgggtgggcta ttaagctctg gctttgctcc 173820
ctgttaaaat gccagaacct ttgagaggga tccacattc agccatgttt atcattgacc 173880
accttagaat ggatggattt ctcagatttt tcttgagatc agtgcttgat ggagaggaga 173940
ggagaacaat agattcttgg gatgtgtgct ttgcatgtgt ttaagtaaga gacagagagt 174000

<210> SEQ ID NO 190
<211> LENGTH: 27
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 190

gcggttgctc ttcttcttgc gtttttt 27

<210> SEQ ID NO 191
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 191

tctggaacag attctg 16

<210> SEQ ID NO 192
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 192

gcttcattctc cacaga 16

<210> SEQ ID NO 193
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 193

ggctactacg ccgtca 16

<210> SEQ ID NO 194
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 194

gagaaccatc ctcacc 16

<210> SEQ ID NO 195

-continued

<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 195

ggaccaggta gcctgt 16

<210> SEQ ID NO 196
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 196

cccctggact cagatg 16

<210> SEQ ID NO 197
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 197

gcacaaggag tgggac 16

<210> SEQ ID NO 198
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 198

gctgtgaaga gagtgt 16

<210> SEQ ID NO 199
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 199

tttgacacaa gtggga 16

<210> SEQ ID NO 200
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 200

gtgacacca gaagct 16

<210> SEQ ID NO 201
<211> LENGTH: 16
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 201

-continued

catccttgct tcataa 16

<210> SEQ ID NO 202
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 202

tggggagaac catcttcacc ctgc 24

<210> SEQ ID NO 203
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 203

tccaggacca ggtagcctgt gggg 24

<210> SEQ ID NO 204
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 204

tgttcccctg gactcagatg ctcc 24

<210> SEQ ID NO 205
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 205

tggggcacaa ggagtgggac gcac 24

<210> SEQ ID NO 206
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 206

ttcggctgtg aagagagtgt gccac 24

<210> SEQ ID NO 207
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 207

cgcttttgac acaagtggga ctgg 24

<210> SEQ ID NO 208
<211> LENGTH: 24
<212> TYPE: DNA

-continued

<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 208

catagtgaca cccagaagct tcat 24

<210> SEQ ID NO 209
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 209

gagtcacccc tgcttcataa catt 24

<210> SEQ ID NO 210
<211> LENGTH: 14
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 210

ctgtgaagag agtg 14

<210> SEQ ID NO 211
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 211

tgtgaagaga gt 12

<210> SEQ ID NO 212
<211> LENGTH: 14
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 212

ttgacacaag tggg 14

<210> SEQ ID NO 213
<211> LENGTH: 12
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 213

tgacacaagt gg 12

<210> SEQ ID NO 214
<211> LENGTH: 14
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 214

tgacaccag aagc 14

<210> SEQ ID NO 215
 <211> LENGTH: 12
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: Synthetic oligonucleotide

<400> SEQUENCE: 215

gacacccaga ag

12

What is claimed:

1. A single-stranded modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase sequence comprising an at least [12] // contiguous nucleobase portion of SEQ ID NO: 12 or 175, wherein the modified oligonucleotide is at least 90% complementary to SEQ ID NO: 1 and comprises:

a gap segment consisting of linked deoxynucleosides;
 a 5' wing segment consisting of linked nucleosides;
 a 3' wing segment consisting of linked nucleosides;
 wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

2. The single-stranded modified oligonucleotide of claim 1, wherein each internucleoside linkage is a phosphorothioate linkage.

3. The single-stranded modified oligonucleotide of claim 1, wherein the modified sugar comprises a 2'-O-methoxyethyl sugar.

4. The single-stranded modified oligonucleotide of claim 1, wherein the modified sugar comprises a bicyclic sugar.

5. The single-stranded modified oligonucleotide of claim 4, wherein the bicyclic sugar comprises a group selected from: [4'-CH(CH₃)-O-2'] 4'-CH(CH₃)-O-2', [4'-CH₂-O-2'] 4'-CH₂-O-2', and [4'-(CH₂)₂-O-2'] 4'-(CH₂)₂-O-2'.

6. The single-stranded modified oligonucleotide of claim 1, wherein each cytosine is a 5-methylcytosine.

7. The single-stranded modified oligonucleotide of claim 1, wherein the modified oligonucleotide is 100% complementary to SEQ ID NO: 1.

8. The single-stranded modified oligonucleotide of claim 1, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;
 a 5' wing segment consisting of linked nucleosides;
 a 3' wing segment consisting of linked nucleosides;
 wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, each nucleoside of each wing segment comprises a modified sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine is a 5-methylcytosine.

9. The single-stranded modified oligonucleotide of claim 8, wherein the modified sugar comprises a 2'-O-methoxyethyl sugar.

10. The single-stranded modified oligonucleotide of claim 8, wherein the modified sugar comprises a bicyclic sugar.

11. The single-stranded modified oligonucleotide of claim 10, wherein the bicyclic sugar comprises a group selected from: [4'-CH(CH₃)-O-2'] 4'-CH(CH₃)-O-2', [4'-CH₂-O-2'] 4'-CH₂-O-2', and [4'-(CH₂)₂-O-2'] 4'-(CH₂)₂-O-2'.

12. A single-stranded modified oligonucleotide consisting of 16 to 30 linked nucleosides having a nucleobase sequence

comprising the nucleobase sequence of any one of SEQ ID NOs: 12, 13, 35, 39, 43, 124, 150, 155, 169, or 175, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;
 a 5' wing segment consisting of linked nucleosides;
 a 3' wing segment consisting of linked nucleosides;
 wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.

13. The single-stranded modified oligonucleotide of claim 12, wherein each internucleoside linkage is a phosphorothioate linkage.

14. The single-stranded modified oligonucleotide of claim 12, wherein the modified sugar comprises a 2'-O-methoxyethyl sugar.

15. The single-stranded modified oligonucleotide of claim 12, wherein the modified sugar comprises a bicyclic sugar.

16. The single-stranded modified oligonucleotide of claim 15, wherein the bicyclic sugar comprises a group selected from: [4'-CH(CH₃)-O-2'] 4'-CH(CH₃)-O-2', [4'-CH₂-O-2'] 4'-CH₂-O-2', and [4'-(CH₂)₂-O-2'] 4'-(CH₂)₂-O-2'.

17. The single-stranded modified oligonucleotide of claim 12, wherein each cytosine is a 5-methylcytosine.

18. The single-stranded modified oligonucleotide of claim 12, wherein the modified oligonucleotide is 100% complementary to SEQ ID NO: 1.

19. The single-stranded modified oligonucleotide of claim 12, wherein the modified oligonucleotide comprises:

a gap segment consisting of linked deoxynucleosides;
 a 5' wing segment consisting of linked nucleosides;
 a 3' wing segment consisting of linked nucleosides;
 wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, each nucleoside of each wing segment comprises a modified sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine is a 5-methylcytosine.

20. The single-stranded modified oligonucleotide of claim 12, wherein the modified oligonucleotide consists of 16 linked nucleosides having a nucleobase sequence consisting of the nucleobase sequence of any one of SEQ ID NOs: 12, 13, 35, 39, 43, 124, 150, 155, 169, or 175.

21. The single-stranded modified oligonucleotide of claim 20, wherein each internucleoside linkage is a phosphorothioate linkage.

22. The single-stranded modified oligonucleotide of claim 20, wherein the modified sugar comprises a 2'-O-methoxyethyl sugar.

23. The single-stranded modified oligonucleotide of claim 20, wherein the modified sugar comprises a bicyclic sugar.

24. The single-stranded modified oligonucleotide of claim 23, wherein the bicyclic sugar comprises a group selected

575

from: $[4' \text{-CH(CH}_3\text{)-O-2'}]$ $4' \text{-CH(CH}_3\text{)-O-2'}$, $[4' \text{-CH}_2\text{-O-2'}]$ $4' \text{-CH}_2\text{-O-2'}$, and $[4' \text{-(CH}_2\text{)}_2\text{-O-2'}]$ $4' \text{-(CH}_2\text{)}_2\text{-O-2'}$.

25. The single-stranded modified oligonucleotide of claim 20, wherein each cytosine is a 5-methylcytosine.

26. The single-stranded modified oligonucleotide of claim 20, wherein the modified oligonucleotide has a nucleobase sequence consisting of the nucleobase sequence of any one of SEQ ID NOs: 43, 124, 150, 155, 169, or 175, and wherein the modified oligonucleotide comprises:

- a gap segment consisting of ten linked deoxynucleosides;
- a 5' wing segment consisting of 3 linked nucleosides; and
- a 3' wing segment consisting of 3 linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein each nucleoside of each wing segment comprises a constrained ethyl nucleoside; wherein each internucleoside linkage of the modified oligonucleotide is a phosphorothioate linkage; and wherein each cytosine of the modified oligonucleotide is a 5-methylcytosine.

27. A method of treating cancer in a subject comprising administering to the subject the compound of claim 26, thereby treating cancer in the subject.

28. The method of claim 27, wherein the cancer is prostate cancer, breast cancer, ovarian cancer, gastric cancer, or bladder cancer.

29. The method of claim 27, wherein the cancer is castrate-resistant prostate cancer.

30. The method of claim 29, wherein the castrate-resistant prostate cancer is resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700, and VT464.

31. A compound comprising a single-stranded modified oligonucleotide consisting of 16 linked nucleosides, wherein the modified oligonucleotide has a nucleobase sequence consisting of the sequence of SEQ ID NO: 35, and is a pharmaceutically acceptable salt selected from the group consisting of sodium and potassium salts, wherein the modified oligonucleotide comprises:

- a gap segment consisting of 9 linked deoxynucleosides;
- a 5' wing segment consisting of three linked nucleosides; and

a 3' wing segment consisting of four linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein the sugars of the three linked nucleosides of the 5' wing segment are each a constrained ethyl (cEt) sugar; wherein the sugars of the four linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

32. A compound comprising a single-stranded modified oligonucleotide consisting of 16 linked nucleosides, wherein the modified oligonucleotide has a nucleobase sequence consisting of the sequence of SEQ ID NO: 39 and is a pharmaceutically acceptable salt selected from the group consisting of sodium and potassium salts, wherein the modified oligonucleotide comprises:

- a gap segment consisting of 7 linked deoxynucleosides;
- a 5' wing segment consisting of four linked nucleosides; and

a 3' wing segment consisting of five linked nucleosides;

wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment; wherein the sugars of the four linked nucleosides of the 5' wing segment are

576

a 2'-O-methoxyethyl sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, and a constrained ethyl (cEt) sugar in the 5' to 3' direction; wherein the sugars of the five linked nucleosides of the 3' wing segment are a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a constrained ethyl (cEt) sugar, a 2'-O-methoxyethyl sugar, and a 2'-O-methoxyethyl sugar in the 5' to 3' direction; wherein each internucleoside linkage is a phosphorothioate linkage; and wherein each cytosine is a 5-methylcytosine.

33. A composition comprising the compound of claim 31 or claim 32, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier.

34. A combination comprising the compound of claim 31 or claim 32, or a pharmaceutically acceptable salt thereof, and an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464.

35. The combination of claim 34, wherein the anti-androgenic agent is MDV3100.

36. A method of treating cancer comprising administering to a subject having cancer a compound or salt of claim 31 or claim 32, thereby treating cancer in the subject.

37. The method of claim 36, wherein the cancer is prostate cancer, breast cancer, ovarian cancer, gastric cancer or bladder cancer.

38. The method of claim 36, wherein the cancer is castrate-resistant prostate cancer.

39. The method of claim 38, wherein the castrate-resistant prostate cancer is resistant to an anti-androgenic agent selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464.

40. A method of treating prostate cancer in a patient in need thereof, comprising administering to the patient a compound or salt of claim 31 or claim 32 and an anti-androgenic agent.

41. The method of claim 40, wherein the anti-androgenic agent is selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464.

42. The method of claim 40, wherein the compound and the anti-androgenic agent synergize in combination to inhibit the growth or proliferation of the prostate cancer cell.

43. The method of claim 40, wherein the patient is administered an amount of the compound and an amount of anti-androgenic agent that are each or both less in combination than the amount of either the compound or anti-androgenic agent alone effective in inhibiting the growth or proliferation of said prostate cancer cell.

44. A method of inhibiting growth or proliferation of an androgen receptor (AR)-positive breast cancer cell comprising contacting the breast cancer cell with a compound or salt of claim 31 or claim 32 wherein the growth or proliferation of the breast cancer cell is inhibited.

45. A method of treating prostate cancer in a patient in need thereof, comprising administering to the patient a composition of claim 33 and an anti-androgenic agent.

46. The method of claim 45, wherein the anti-androgenic agent is selected from: MDV3100, ARN-059, ODM-201, abiraterone, TOK001, TAK700 and VT464.

47. The method of claim 41, wherein the anti-androgenic agent is MDV3100.

48. The method of claim 47, wherein the compound and the anti-androgenic agent synergize in combination to inhibit the growth or proliferation of the prostate cancer cell.

577

578

49. The method of claim 46, wherein the anti-androgenic agent is MDV3100.

50. The method of claim 49, wherein the compound and the anti-androgenic agent synergize in combination to inhibit the growth or proliferation of the prostate cancer cell.

* * * * *